ticker,rpa_date_utc,rpa_time_utc,rp_entity_id,entity_name,relevance,event_sentiment_score,group,sub_type,event_text,news_type,source_name,headline
BIIB,2024-01-11,13:23:37,CEDFD5,Biogen Inc.,100,-0.46,partnerships,terminated,Acorda Therapeutics: Biogen Ending Fampyra Collaboration,FULL-ARTICLE,Dow Jones Newswires,Acorda Therapeutics: Biogen Ending Fampyra Collaboration
BIIB,2024-01-24,11:49:50,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Neutral From Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Neutral From Buy by UBS
BIIB,2024-01-24,11:49:50,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $276.00/Share by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $276.00/Share by UBS
BIIB,2024-01-25,10:01:12,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Neutral From Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Neutral From Buy by UBS
BIIB,2024-01-25,10:01:12,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $276.00/Share From $311.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $276.00/Share From $311.00 by UBS
BIIB,2024-01-31,12:30:00,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:00,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda accelerated approval of ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda accelerated approval of ADUHELM,FULL-ARTICLE,Dow Jones Newswires,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:54:26,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen halts development of controversial Alzheimer's drug,FULL-ARTICLE,MarketWatch,MW Biogen halts development of controversial Alzheimer's drug
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda accelerated approval of ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,PRESS-RELEASE,GlobeNewswire,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda accelerated approval of ADUHELM,PRESS-RELEASE,GlobeNewswire,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda accelerated approval of ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:36:02,CEDFD5,Biogen Inc.,100,0.34,products-services,,Biogen Licensed Aducanumab From Neurimmune,NEWS-FLASH,Dow Jones Newswires,"Biogen Licensed Aducanumab From Neurimmune and Has Terminated That License, the Rights to Aducanumab Will Revert to Neurimmune >BIIB"
BIIB,2024-01-31,12:54:26,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen Halts Development Of Controversial Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Halts Development Of Controversial Alzheimer's Drug -- MarketWatch
BIIB,2024-01-31,13:55:53,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen Ends Development of Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Ends Development of Alzheimer's Drug Aduhelm -- Barrons.com
BIIB,2024-01-31,13:55:53,CEDFD5,Biogen Inc.,100,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen Ends Development of Alzheimer's Drug Aduhelm -- Barrons.com
BIIB,2024-01-31,14:00:03,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda granted Aduhelm accelerated approval,FULL-ARTICLE,MarketWatch,MW Biogen drops controversial Alzheimer's drug
BIIB,2024-01-31,16:02:19,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen is pulling the plug on its ill-fated Alzheimer's disease drug Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Quits Controversial Alzheimer's Drug Aduhelm -- WSJ
BIIB,2024-02-01,07:03:43,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen is pulling the plug on its ill-fated Alzheimer's disease drug Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Quits Controversial Alzheimer's Drug Aduhelm ---- By Jennifer Calfas and Colin Kellaher
BIIB,2024-02-01,07:32:09,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen is pulling the plug on its ill-fated Alzheimer's disease drug Aduhelm,FULL-ARTICLE,Wall Street Journal,Biogen Quits Controversial Alzheimer's Drug Aduhelm -- WSJ
BIIB,2024-02-02,15:48:31,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 634 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 634 Of Biogen Inc >BIIB
BIIB,2024-02-05,23:40:33,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 634 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 634 Of Biogen Inc >BIIB
BIIB,2024-02-09,15:00:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Aptar Signs Enterprise Agreement with Biogen,PRESS-RELEASE,Business Wire,Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
BIIB,2024-02-09,15:00:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Aptar will further collaborate to potentially develop and bring to market new digital,PRESS-RELEASE,Business Wire,Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
BIIB,2024-02-09,15:00:24,CEDFD5,Biogen Inc.,100,0.39,products-services,,Aptar Signs Enterprise Agreement With Biogen,NEWS-FLASH,Dow Jones Newswires,Aptar Signs Enterprise Agreement With Biogen to Operate and Develop Digital Health Solutions
BIIB,2024-02-09,15:00:35,CEDFD5,Biogen Inc.,100,0.39,products-services,,Aptar Signs Enterprise Agreement with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
BIIB,2024-02-09,15:00:35,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Aptar will further collaborate to potentially develop and bring to market new digital,PRESS-RELEASE,Dow Jones Newswires,Press Release: Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
BIIB,2024-02-10,01:02:12,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Murphy Acquires 1,463 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Murphy Acquires 1,463 Of Biogen Inc >BIIB"
BIIB,2024-02-10,01:04:35,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 1,570 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 1,570 Of Biogen Inc >BIIB"
BIIB,2024-02-10,01:07:29,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 535 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 535 Of Biogen Inc >BIIB
BIIB,2024-02-10,01:12:05,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Izzar Acquires 1,422 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Acquires 1,422 Of Biogen Inc >BIIB"
BIIB,2024-02-10,01:16:00,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Gregory Acquires 1,137 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Acquires 1,137 Of Biogen Inc >BIIB"
BIIB,2024-02-10,01:17:47,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Alexander Acquires 1,535 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Alexander Acquires 1,535 Of Biogen Inc >BIIB"
BIIB,2024-02-12,16:12:32,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 419 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 419 Of Biogen Inc >BIIB
BIIB,2024-02-12,21:06:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,GlobeNewswire,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: SKYCLARYS is also approved for use in the United States,PRESS-RELEASE,GlobeNewswire,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: SKYCLARYS is also approved for use in the United States,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: SKYCLARYS is also approved for use in the United States,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: SKYCLARYS is also approved for use in the United States,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",FULL-ARTICLE,Dow Jones Newswires,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Skyclarys is also approved for use in the United States,FULL-ARTICLE,Dow Jones Newswires,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:16,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS (omaveloxolone), the First",NEWS-FLASH,Dow Jones Newswires,"Biogen Received European Commission Approval for SKYCLARYS (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:31:52,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission,FULL-ARTICLE,Dow Jones Newswires,Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission
BIIB,2024-02-12,21:46:52,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission,FULL-ARTICLE,Dow Jones Newswires,Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission
BIIB,2024-02-13,12:08:18,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Adj EPS $2.95,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Adj EPS $2.95 >BIIB
BIIB,2024-02-13,12:09:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.4B >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 4Q Rev $2.4B >BIIB
BIIB,2024-02-13,12:09:55,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $1.71 >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 4Q EPS $1.71 >BIIB
BIIB,2024-02-13,12:10:21,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY24 Adj EPS $15,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY24 Adj EPS $15-Adj EPS $16 >BIIB
BIIB,2024-02-13,12:11:00,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Skyclarys Revenue $56M >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 4Q Skyclarys Revenue $56M >BIIB
BIIB,2024-02-13,12:21:57,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen's quarterly results miss expectations,FULL-ARTICLE,MarketWatch,MW Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,12:21:57,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen expects adjusted earnings per share of $15.00 to $16.00,FULL-ARTICLE,MarketWatch,MW Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,12:21:57,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,"Biogen Inc.: the company said Tuesday, and anticipates total revenue to decline",FULL-ARTICLE,MarketWatch,MW Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,12:36:31,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Biogen's Revenue Stung By Softening,FULL-ARTICLE,Dow Jones Newswires,Biogen's Revenue Stung By Softening Sales Of Multiple Sclerosis Products -- Market Talk
BIIB,2024-02-13,12:36:32,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Biogen's Revenue Stung By Softening,FULL-ARTICLE,Dow Jones Newswires,Biogen's Revenue Stung By Softening Sales Of Multiple Sclerosis Products -- Market Talk
BIIB,2024-02-13,12:37:02,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen Inc.: the company reported fourth-quarter results that fell short of Wall Street expectations,FULL-ARTICLE,MarketWatch,MW Biogen's stock slides as quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,12:37:02,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen expects adjusted earnings per share of $15.00 to $16.00,FULL-ARTICLE,MarketWatch,MW Biogen's stock slides as quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,12:37:02,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,"Biogen Inc.: the company said Tuesday, and anticipates total revenue to decline",FULL-ARTICLE,MarketWatch,MW Biogen's stock slides as quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,13:46:45,CEDFD5,Biogen Inc.,100,0.0,earnings,,Factset expected Biogen to earn $3.18 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit -- IBD
BIIB,2024-02-13,13:46:45,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen earned $4.05 a share,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit -- IBD
BIIB,2024-02-13,13:46:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.: The company also expects revenue to fall,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit -- IBD
BIIB,2024-02-13,15:15:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's soft 2024 guidance,FULL-ARTICLE,Dow Jones Newswires,"Despite New Alzheimer's Therapy, Biogen Is a Show-Me Story for Wall Street -- WSJ"
BIIB,2024-02-13,15:28:44,CEDFD5,Biogen Inc.,99,-0.75,revenues,down,Biogen now expects full-year sales to decline,FULL-ARTICLE,Dow Jones Newswires,Biogen's Turnaround Is Still Waiting In The Wings As Aduhelm Pressures Continue -- IBD
BIIB,2024-02-13,15:28:44,CEDFD5,Biogen Inc.,99,-0.36,revenues,down,Tecfidera sales fell nearly 18%,FULL-ARTICLE,Dow Jones Newswires,Biogen's Turnaround Is Still Waiting In The Wings As Aduhelm Pressures Continue -- IBD
BIIB,2024-02-13,15:28:44,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: The company also expects sales to fall,FULL-ARTICLE,Dow Jones Newswires,Biogen's Turnaround Is Still Waiting In The Wings As Aduhelm Pressures Continue -- IBD
BIIB,2024-02-13,15:50:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen said Tuesday that its non-GAAP diluted earnings,FULL-ARTICLE,Dow Jones Newswires,Biogen Promised a Return to Growth. Why the Stock Is Dropping. -- Barrons.com
BIIB,2024-02-13,15:50:50,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen Inc.: The company reported fourth-quarter non-GAAP diluted earnings of $2.95 a share,FULL-ARTICLE,Dow Jones Newswires,Biogen Promised a Return to Growth. Why the Stock Is Dropping. -- Barrons.com
BIIB,2024-02-13,15:50:50,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen developed in partnership with Eisai,FULL-ARTICLE,Dow Jones Newswires,Biogen Promised a Return to Growth. Why the Stock Is Dropping. -- Barrons.com
BIIB,2024-02-13,23:02:00,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Alexander Acquires 1,637 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Alexander Acquires 1,637 Of Biogen Inc >BIIB"
BIIB,2024-02-13,23:04:58,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 588 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 588 Of Biogen Inc >BIIB
BIIB,2024-02-13,23:06:01,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Izzar Acquires 1,070 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Acquires 1,070 Of Biogen Inc >BIIB"
BIIB,2024-02-13,23:06:13,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Murphy Acquires 1,511 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Murphy Acquires 1,511 Of Biogen Inc >BIIB"
BIIB,2024-02-13,23:06:18,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 1,826 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 1,826 Of Biogen Inc >BIIB"
BIIB,2024-02-13,23:08:05,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 419 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 419 Of Biogen Inc >BIIB
BIIB,2024-02-13,23:15:08,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Gregory Acquires 1,524 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Acquires 1,524 Of Biogen Inc >BIIB"
BIIB,2024-02-14,07:03:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's soft 2024 guidance,FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street: Despite New Alzheimer's Therapy, Biogen Is a Show-Me Story for Wall Street ---- By David Wainer"
BIIB,2024-02-14,11:06:40,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2024-02-14,11:06:40,CEDFD5,Biogen Inc.,100,-0.32,price-targets,downgrade,Biogen Price Target Cut to $300.00/Share From $305.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $300.00/Share From $305.00 by Needham
BIIB,2024-02-14,12:10:20,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Equal-Weight From Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Equal-Weight From Overweight by Wells Fargo
BIIB,2024-02-14,12:10:20,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $240.00/Share From $315.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $240.00/Share From $315.00 by Wells Fargo
BIIB,2024-02-14,14:55:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2024-02-14,14:55:01,CEDFD5,Biogen Inc.,100,-0.52,price-targets,downgrade,Biogen Price Target Cut to $364.00/Share From $379.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $364.00/Share From $379.00 by RBC Capital
BIIB,2024-02-14,16:14:41,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2024-02-14,16:14:41,CEDFD5,Biogen Inc.,100,-0.32,price-targets,downgrade,Biogen Price Target Cut to $290.00/Share From $295.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $290.00/Share From $295.00 by Oppenheimer
BIIB,2024-02-14,16:59:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by BMO Capital
BIIB,2024-02-14,16:59:01,CEDFD5,Biogen Inc.,100,-0.48,price-targets,downgrade,Biogen Price Target Cut to $285.00/Share From $295.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $285.00/Share From $295.00 by BMO Capital
BIIB,2024-02-14,17:36:21,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Piper Sandler
BIIB,2024-02-14,17:36:21,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $325.00/Share From $350.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $325.00/Share From $350.00 by Piper Sandler
BIIB,2024-02-14,19:13:41,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Baird
BIIB,2024-02-14,19:13:41,CEDFD5,Biogen Inc.,100,-0.6,price-targets,downgrade,Biogen Price Target Cut to $316.00/Share From $333.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $316.00/Share From $333.00 by Baird
BIIB,2024-02-16,18:36:45,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by UBS
BIIB,2024-02-16,18:36:45,CEDFD5,Biogen Inc.,100,-0.78,price-targets,downgrade,Biogen Price Target Cut to $250.00/Share From $276.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $250.00/Share From $276.00 by UBS
BIIB,2024-02-19,08:05:46,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Reata Pharmaceuticals Inc Cl, Inst Holders, 4Q 2023 (RETA)",RNS-SEC13F,Dow Jones Newswires,"Reata Pharmaceuticals  Inc Cl, Inst Holders, 4Q 2023 (RETA)"
BIIB,2024-02-19,08:08:08,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2023 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2023 (BIIB)"
BIIB,2024-02-20,15:05:34,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2024-02-20,15:05:34,CEDFD5,Biogen Inc.,100,-0.32,price-targets,downgrade,Biogen Price Target Cut to $305.00/Share From $310.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $305.00/Share From $310.00 by Canaccord Genuity
BIIB,2024-02-21,02:15:46,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Dir Rowinsky Buys 455 Of Biogen Inc >BIIB,TABULAR-MATERIAL,Dow Jones Newswires,Dir Rowinsky Buys 455 Of Biogen Inc >BIIB
BIIB,2024-02-21,15:27:32,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 108 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 108 Of Biogen Inc >BIIB
BIIB,2024-02-22,02:28:49,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 108 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 108 Of Biogen Inc >BIIB
BIIB,2024-02-22,02:29:38,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 650 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 650 Of Biogen Inc >BIIB
BIIB,2024-02-22,02:30:57,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 3,282 Of Biogen Inc >BIIB",TABULAR-MATERIAL,Dow Jones Newswires,"CFO McDonnell Acquires 3,282 Of Biogen Inc >BIIB"
BIIB,2024-02-22,02:32:36,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 949 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 949 Of Biogen Inc >BIIB
BIIB,2024-02-22,02:36:09,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Izzar Acquires 1,065 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Acquires 1,065 Of Biogen Inc >BIIB"
BIIB,2024-02-22,02:37:23,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Gregory Acquires 2,440 Of Biogen Inc >BIIB",TABULAR-MATERIAL,Dow Jones Newswires,"VP Gregory Acquires 2,440 Of Biogen Inc >BIIB"
BIIB,2024-02-22,02:41:21,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Alexander Acquires 2,600 Of Biogen Inc >BIIB",TABULAR-MATERIAL,Dow Jones Newswires,"VP Alexander Acquires 2,600 Of Biogen Inc >BIIB"
BIIB,2024-02-22,15:18:35,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 262 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 262 Of Biogen Inc >BIIB
BIIB,2024-02-22,16:35:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Mizuho
BIIB,2024-02-22,16:35:29,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $277.00/Share From $355.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $277.00/Share From $355.00 by Mizuho
BIIB,2024-02-22,20:04:29,CEDFD5,Biogen Inc.,93,0.52,products-services,,The debut of Aduhelm from Biogen,PRESS-RELEASE,GlobeNewswire,"Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen's Leqembi, According to Spherix Global Insights Neurologist Survey"
BIIB,2024-02-23,12:00:26,CEDFD5,Biogen Inc.,100,0.52,products-services,,"Biogen Inc.: Press Release: Biogen's QALSODY(R)(tofersen), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen's QALSODY(R)(tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP"
BIIB,2024-02-23,12:00:26,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration granted accelerated approval for QALSODY,FULL-ARTICLE,Dow Jones Newswires,"Biogen's QALSODY(R)(tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP"
BIIB,2024-02-23,12:00:27,CEDFD5,Biogen Inc.,100,0.52,products-services,,"Biogen Inc.: Press Release: Biogen's QALSODY(R) (tofersen), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen's QALSODY(R) (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP"
BIIB,2024-02-23,12:00:59,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen's Qalsody Gets Positive Opinion From CHMP,NEWS-FLASH,Dow Jones Newswires,Biogen's Qalsody Gets Positive Opinion From CHMP >BIIB
BIIB,2024-02-23,12:02:36,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Gets CHMP Positive Opinion for Qalsody,NEWS-FLASH,Dow Jones Newswires,Biogen Gets CHMP Positive Opinion for Qalsody in Adults With ALS Associated With Mutation in SOD1 Gene >BIIB
BIIB,2024-02-23,12:27:22,CEDFD5,Biogen Inc.,93,0.71,products-services,,The U.S. Food and Drug Administration granted accelerated approval to Qalsody,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets CHMP Backing for ALS Treatment Qalsody
BIIB,2024-02-24,07:30:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-02-27,00:55:53,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 262 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 262 Of Biogen Inc >BIIB
BIIB,2024-03-04,18:44:27,CEDFD5,Biogen Inc.,100,0.01,credit-ratings,affirmation,Moody's Affirms Biogen's Baa2 Ratings,NEWS-FLASH,Dow Jones Newswires,Moody's Affirms Biogen's Baa2 Ratings; Revises Outlook To Stable From Negative
BIIB,2024-03-08,15:20:48,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,"Rbc's Abrahams, who has an outperform rating on Biogen",FULL-ARTICLE,Dow Jones Newswires,Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's Treatment -- IBD
BIIB,2024-03-08,16:56:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,"Rbc's Abrahams, who has an outperform rating on Biogen",FULL-ARTICLE,Dow Jones Newswires,Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's Treatment -- IBD
BIIB,2024-03-08,21:05:10,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,"Rbc's Abrahams, who has an outperform rating on Biogen",FULL-ARTICLE,Dow Jones Newswires,Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's Treatment -- IBD
BIIB,2024-03-11,13:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Abcellera to Collaborate with Biogen to Discover Therapeutic Antibodies,PRESS-RELEASE,Business Wire,AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
BIIB,2024-03-11,13:01:20,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Abcellera to Collaborate with Biogen to Discover Therapeutic Antibodies,PRESS-RELEASE,Dow Jones Newswires,Press Release: AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
BIIB,2024-03-26,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: Indivi to Collaborate with Biogen to,PRESS-RELEASE,Business Wire,Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease
BIIB,2024-04-02,14:12:30,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 93 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 93 Of Biogen Inc >BIIB
BIIB,2024-04-04,00:12:25,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 123 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 123 Of Biogen Inc >BIIB
BIIB,2024-04-04,00:26:01,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 93 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 93 Of Biogen Inc >BIIB
BIIB,2024-04-04,13:46:35,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2024-04-04,13:46:35,CEDFD5,Biogen Inc.,100,-0.66,price-targets,downgrade,Biogen Price Target Cut to $215.00/Share From $230.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $215.00/Share From $230.00 by Barclays
BIIB,2024-04-11,12:59:31,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by JP Morgan
BIIB,2024-04-11,12:59:31,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $240.00/Share From $270.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $240.00/Share From $270.00 by JP Morgan
BIIB,2024-04-12,12:10:33,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by B of A Securities
BIIB,2024-04-12,12:10:33,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $260.00/Share From $280.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $260.00/Share From $280.00 by B of A Securities
BIIB,2024-04-17,17:06:24,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2024-04-17,17:06:24,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $213.00/Share From $245.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $213.00/Share From $245.00 by Wedbush
BIIB,2024-04-18,11:40:25,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by UBS
BIIB,2024-04-18,11:40:26,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $214.00/Share From $250.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $214.00/Share From $250.00 by UBS
BIIB,2024-04-19,15:03:28,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2024-04-19,15:03:28,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $290.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $290.00 by Oppenheimer
BIIB,2024-04-24,10:46:36,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen's sales declined 7% to $2.29 billion,FULL-ARTICLE,Dow Jones Newswires,Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? -- IBD
BIIB,2024-04-24,10:46:36,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Tysabri sales fell close to 9%,FULL-ARTICLE,Dow Jones Newswires,Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? -- IBD
BIIB,2024-04-24,10:46:36,CEDFD5,Biogen Inc.,100,0.41,revenues,up,Spinraza sales grew 1%,FULL-ARTICLE,Dow Jones Newswires,Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? -- IBD
BIIB,2024-04-24,10:49:50,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc. (BIIB) on Wednesday reported first-quarter profit that beat analysts' expectations,FULL-ARTICLE,Dow Jones Newswires,Biogen First-Quarter Profit Tops Estimates As Alzheimer's Drug Uptake Improves -- MarketWatch
BIIB,2024-04-24,10:49:50,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc. (BIIB) on Wednesday reported first-quarter profit that beat analysts' expectations,FULL-ARTICLE,MarketWatch,MW Biogen first-quarter profit tops estimates as Alzheimer's drug uptake improves
BIIB,2024-04-24,10:56:02,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.3B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.3B >BIIB
BIIB,2024-04-24,10:56:13,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $2.70 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $2.70 >BIIB
BIIB,2024-04-24,10:56:25,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $3.67,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Adj EPS $3.67 >BIIB
BIIB,2024-04-24,10:57:19,CEDFD5,Biogen Inc.,100,0.0,earnings,unchanged,Biogen Backs 2024 Adj EPS $15,NEWS-FLASH,Dow Jones Newswires,Biogen Backs 2024 Adj EPS $15-Adj EPS $16 >BIIB
BIIB,2024-04-24,11:04:02,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $2.70 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $2.70 >BIIB
BIIB,2024-04-24,11:04:02,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $3.67,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Adj EPS $3.67 >BIIB
BIIB,2024-04-24,11:04:02,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Net $393.4M,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Net $393.4M >BIIB
BIIB,2024-04-24,11:04:02,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.29B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.29B >BIIB
BIIB,2024-04-24,12:08:31,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen's stock climbs as first-quarter profit tops estimates,FULL-ARTICLE,MarketWatch,"MW Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves"
BIIB,2024-04-24,12:08:31,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,"Biogen says, but total sales fall",FULL-ARTICLE,MarketWatch,"MW Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves"
BIIB,2024-04-24,12:08:31,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: the company reported first-quarter profit,FULL-ARTICLE,MarketWatch,"MW Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves"
BIIB,2024-04-24,12:08:31,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,Its 2023 acquisition of Reata Pharmaceuticals,FULL-ARTICLE,MarketWatch,"MW Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves"
BIIB,2024-04-24,12:08:31,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen's total sales in the quarter fell short of analysts' estimates,FULL-ARTICLE,MarketWatch,"MW Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves"
BIIB,2024-04-24,12:51:25,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported first-quarter adjusted earnings of $3.67 a share,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Rises After Earnings and on Jump in Alzheimer's Drug Sales -- Barrons.com
BIIB,2024-04-24,20:20:02,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Raffat reiterated his outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Surges After Two Notable Products Walloped Sales Expectations -- IBD
BIIB,2024-04-24,20:20:02,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen's sales declined 7% to $2.29 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Surges After Two Notable Products Walloped Sales Expectations -- IBD
BIIB,2024-04-24,20:20:02,CEDFD5,Biogen Inc.,100,-0.42,revenues,down,Spinraza sales plunged 23%,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Surges After Two Notable Products Walloped Sales Expectations -- IBD
BIIB,2024-04-24,20:20:02,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Tysabri sales fell nearly 9%,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Surges After Two Notable Products Walloped Sales Expectations -- IBD
BIIB,2024-04-25,12:03:11,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2024-04-25,12:03:11,CEDFD5,Biogen Inc.,100,-0.7,price-targets,downgrade,Biogen Price Target Cut to $300.00/Share From $325.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $300.00/Share From $325.00 by HC Wainwright & Co.
BIIB,2024-04-25,12:42:11,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2024-04-25,12:42:11,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $215.00/Share From $213.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $215.00/Share From $213.00 by Wedbush
BIIB,2024-04-25,18:12:52,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2024-04-25,18:12:52,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $200.00/Share From $215.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $200.00/Share From $215.00 by Barclays
BIIB,2024-04-25,20:05:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab),PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab), a Biosimilar Referencing ROACTEMRA(R)"
BIIB,2024-04-25,20:05:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab), a Biosimilar Referencing ROACTEMRA(R)"
BIIB,2024-04-25,20:05:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab),FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab), a Biosimilar Referencing ROACTEMRA(R)"
BIIB,2024-04-26,06:01:48,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Regulators approved Skyclarys for Friedreich's ataxia,FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street: For Biogen, Good Enough Will Do ---- By David Wainer"
BIIB,2024-04-26,06:32:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Regulators approved Skyclarys for Friedreich's ataxia,FULL-ARTICLE,Wall Street Journal,"Heard on the Street: For Biogen, Good Enough Will Do -- WSJ"
BIIB,2024-04-29,16:59:51,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2024-05-03,18:50:40,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HSBC,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HSBC
BIIB,2024-05-03,18:50:40,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $342.00/Share From $339.00 by HSBC,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $342.00/Share From $339.00 by HSBC
BIIB,2024-05-04,00:03:22,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Keeney Acquires 662 Of Biogen Inc >BIIB,TABULAR-MATERIAL,Dow Jones Newswires,Officer Keeney Acquires 662 Of Biogen Inc >BIIB
BIIB,2024-05-15,14:21:09,CEDFD5,Biogen Inc.,97,0.34,analyst-ratings,neutral,William Blair analyst Myles Minter kept his outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment -- IBD
BIIB,2024-05-15,20:05:41,CEDFD5,Biogen Inc.,97,0.34,analyst-ratings,neutral,William Blair analyst Myles Minter kept his outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Continues Its 24% Sprint On A Twist In Alzheimer's Treatment -- IBD
BIIB,2024-05-16,11:30:09,CEDFD5,Biogen Inc.,99,0.0,products-services,,Ionis and Biogen Announce Topline Phase 1/2 Study,PRESS-RELEASE,PR Newswire,Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
BIIB,2024-05-16,11:30:10,CEDFD5,Biogen Inc.,99,0.0,products-services,,Ionis and Biogen Announce Topline Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
BIIB,2024-05-16,11:30:14,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen and Ionis Announce Topline Phase 1/2 Study,PRESS-RELEASE,GlobeNewswire,Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
BIIB,2024-05-16,11:30:14,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen and Ionis Announce Topline Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
BIIB,2024-05-16,11:33:32,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen to Terminate Development of BIIB105,NEWS-FLASH,Dow Jones Newswires,"Ionis, Biogen to Terminate Development of BIIB105 Based on Topline Results From Phase 1/2 ALSpire Study >IONS"
BIIB,2024-05-16,12:05:22,CEDFD5,Biogen Inc.,98,-0.52,products-services,,Biogen have canned development of an investigational therapy,FULL-ARTICLE,Dow Jones Newswires,"Biogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis"
BIIB,2024-05-16,17:24:48,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2024-05-16,18:07:45,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen won accelerated Food and Drug Administration approval for tofersen,FULL-ARTICLE,MarketWatch,MW Biogen and Ionis Pharma shares slide as they end development of ALS treatment
BIIB,2024-05-19,07:07:54,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 1Q 2024 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 1Q 2024 (BIIB)"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen has agreed to acquire HI-Bio for $1.15 billion,FULL-ARTICLE,Dow Jones Newswires,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's previously issued 2024 guidance,FULL-ARTICLE,Dow Jones Newswires,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen has agreed to acquire HI-Bio for $1.15 billion,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's previously issued 2024 guidance,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen has agreed to acquire HI-Bio for $1.15 billion,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's previously issued 2024 guidance,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen has agreed to acquire HI-Bio for $1.15 billion,PRESS-RELEASE,GlobeNewswire,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's previously issued 2024 guidance,PRESS-RELEASE,GlobeNewswire,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen has agreed to acquire HI-Bio for $1.15 billion,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's previously issued 2024 guidance,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:49,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen To Acquire Human Immunology Biosciences >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen To Acquire Human Immunology Biosciences >BIIB
BIIB,2024-05-22,11:33:35,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen: Agreed to Acquire HI-Bio for $1.15 B,NEWS-FLASH,Dow Jones Newswires,Biogen: Agreed to Acquire HI-Bio for $1.15 B Upfront and Up to $650 M in Potential Milestone Payments >BIIB
BIIB,2024-05-22,11:42:05,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in milestone payments
BIIB,2024-05-22,11:42:05,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen To Acquire Privately Held Human Immunology Biosciences For $1.15 Billion,FULL-ARTICLE,Dow Jones Newswires,Biogen To Acquire Privately Held Human Immunology Biosciences For $1.15 Billion Upfront And Up To $650 Million In Milestone Payments -- MarketWatch
BIIB,2024-05-22,12:03:26,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,12:03:26,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's guidance for 2024,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,12:03:26,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen's stock climbs as first-quarter profit tops estimates,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,12:31:27,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Human Immunology Biosciences for Up to $1.8 Bln,FULL-ARTICLE,Dow Jones Newswires,Biogen to Buy Human Immunology Biosciences for Up to $1.8 Bln
BIIB,2024-05-22,12:36:56,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,12:36:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's guidance for 2024,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,12:36:56,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen's stock climbs as first-quarter profit tops estimates,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,23:30:03,CEDFD5,Biogen Inc.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Against Biogen Inc.,PRESS-RELEASE,PR Newswire,Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
BIIB,2024-05-22,23:30:03,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
BIIB,2024-05-22,23:30:03,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
BIIB,2024-05-22,23:30:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
BIIB,2024-05-22,23:30:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
BIIB,2024-05-22,23:50:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead the Biogen Class Action Lawsuit"
BIIB,2024-05-22,23:50:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead the Biogen Class Action Lawsuit"
BIIB,2024-05-23,10:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,BIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
BIIB,2024-05-23,10:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,Business Wire,BIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
BIIB,2024-05-23,16:36:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB)",PRESS-RELEASE,GlobeNewswire,"Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB)"
BIIB,2024-05-23,16:36:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB)"
BIIB,2024-05-23,16:36:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB)"
BIIB,2024-05-23,20:56:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,PR Newswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-23,20:56:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-23,20:56:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-23,22:23:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-23,22:23:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-23,22:25:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-23,22:25:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-23,23:28:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,Business Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-23,23:28:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-23,23:32:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for fiscal year 2023,PRESS-RELEASE,Business Wire,Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-23,23:32:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai, Biogen's development partner",PRESS-RELEASE,Business Wire,Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-23,23:32:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,Business Wire,Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-23,23:32:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,Business Wire,Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-24,03:28:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,PR Newswire,"(PR) BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-24,03:28:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"(PR) BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-24,10:11:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-24,10:11:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-24,14:15:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-24,14:15:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-24,14:15:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-24,14:31:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-24,14:31:04,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-24,14:31:04,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-24,14:31:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-24,14:31:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-24,16:30:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-05-24,16:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-05-24,20:06:10,CEDFD5,Biogen Inc.,100,0.03,credit-ratings,affirmation,S&PGR Affirms Biogen's 'BBB+,NEWS-FLASH,Dow Jones Newswires,S&PGR Affirms Biogen's 'BBB+' ICR; Outlook Stable
BIIB,2024-05-24,20:06:10,CEDFD5,Biogen Inc.,100,0.03,credit-ratings,affirmation,S&PGR Affirms Biogen's 'BBB+,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Affirms Biogen's 'BBB+' ICR; Outlook Stable
BIIB,2024-05-24,20:06:10,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Inc. agreed to buy Human Immunology Biosciences for $1.15 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Affirms Biogen's 'BBB+' ICR; Outlook Stable
BIIB,2024-05-24,20:06:10,CEDFD5,Biogen Inc.,100,0.65,revenues,up,Biogen's revenue will eventually improve,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Affirms Biogen's 'BBB+' ICR; Outlook Stable
BIIB,2024-05-24,20:06:20,CEDFD5,Biogen Inc.,100,0.03,credit-ratings,affirmation,S&PGR Affirms Biogen's 'BBB+,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Affirms Biogen's 'BBB+' ICR; -2-
BIIB,2024-05-25,00:18:09,CEDFD5,Biogen Inc.,100,-0.52,legal,,Has Filed a Class Action Against Biogen Inc. (BIIB),PRESS-RELEASE,GlobeNewswire,Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
BIIB,2024-05-25,00:18:09,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
BIIB,2024-05-25,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-25,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-25,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-25,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-25,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-25,12:35:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-25,12:35:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-26,09:53:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-05-26,09:53:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-05-26,11:36:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-26,11:36:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-26,11:36:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-26,13:18:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-26,13:18:25,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-26,13:18:25,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-26,13:18:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-26,13:18:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-27,09:03:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-27,09:03:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-28,09:04:41,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-28,09:04:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-28,14:26:44,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-05-28,14:26:44,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-05-28,14:26:44,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-05-28,14:26:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-05-28,14:26:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-05-28,18:01:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-05-28,18:01:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-05-28,18:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-05-28,19:16:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-05-28,19:16:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-05-28,19:50:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-05-28,19:50:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-05-28,20:02:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR NOTICE: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-28,20:02:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR NOTICE: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-29,00:35:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,Biogen Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Against BIIB
BIIB,2024-05-29,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-29,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-29,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-29,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-29,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-29,01:16:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.( BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-05-29,01:16:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.( BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-05-29,09:02:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-29,09:02:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-29,09:31:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-05-29,09:31:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-05-29,11:06:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-05-29,11:17:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-29,11:17:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-29,15:31:30,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-05-29,15:31:30,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-05-29,17:04:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-29,17:04:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-29,19:16:00,CEDFD5,Biogen Inc.,100,-0.64,legal,,Biogen Inc. (Nasdaq: BIIB) Sued for Securities Fraud after,PRESS-RELEASE,GlobeNewswire,BIOGEN ALERT: BFA Law Announces Biogen Inc. (Nasdaq: BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact the Firm if You Suffered Losses
BIIB,2024-05-29,19:16:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,BIOGEN ALERT: BFA Law Announces Biogen Inc. (Nasdaq: BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact the Firm if You Suffered Losses
BIIB,2024-05-29,19:16:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,BIOGEN ALERT: BFA Law Announces Biogen Inc. (Nasdaq: BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact the Firm if You Suffered Losses
BIIB,2024-05-29,19:31:45,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-05-29,19:31:45,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-05-29,20:46:19,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,Biogen Inc. (Nasdaq: BIIB) Investors Notice: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
BIIB,2024-05-29,21:01:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-29,21:01:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-29,21:47:14,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-29,21:47:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-29,21:47:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-30,07:06:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-05-30,07:06:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-05-30,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,Business Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:00:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:00:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,PR Newswire,"(PR) BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"(PR) BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:01:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-30,08:01:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-30,08:42:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-05-30,08:42:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-05-30,08:50:41,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,08:50:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,09:02:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-30,09:02:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-30,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-05-30,10:36:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,10:36:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,12:19:10,CEDFD5,Biogen Inc.,100,-0.64,legal,,Biogen Inc. (BIIB) Sued for Securities Fraud after,PRESS-RELEASE,DJ Global Press Release Wire,FRAUD ALERT: Biogen Inc. (BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact BFA Law if You Suffered Losses
BIIB,2024-05-30,12:19:10,CEDFD5,Biogen Inc.,100,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,FRAUD ALERT: Biogen Inc. (BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact BFA Law if You Suffered Losses
BIIB,2024-05-30,12:19:10,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,FRAUD ALERT: Biogen Inc. (BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact BFA Law if You Suffered Losses
BIIB,2024-05-30,15:30:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,15:30:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,16:07:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,"Biogen Inc.: On November 8, 2023, Biogen released its third quarter 2023 financial results",PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,16:07:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,16:07:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,16:07:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,17:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,"Biogen Inc.: On November 8, 2023, Biogen released its third quarter 2023 financial results",PRESS-RELEASE,Business Wire,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,17:08:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,17:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,17:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,19:31:37,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN LEGAL DEADLINE NOTICE: BFA Law Reminds BIIB Investors About Approaching Deadline in Securities Fraud Case After Significant Stock Drops
BIIB,2024-05-30,19:31:37,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN LEGAL DEADLINE NOTICE: BFA Law Reminds BIIB Investors About Approaching Deadline in Securities Fraud Case After Significant Stock Drops
BIIB,2024-05-30,20:15:46,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-05-30,20:15:46,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-05-30,20:51:04,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for QALSODY(R) (tofersen), the First",PRESS-RELEASE,GlobeNewswire,"Biogen Receives European Commission Approval for QALSODY(R) (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:04,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for QALSODY(R) (tofersen), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for QALSODY(R) (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First",FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Qalsody is also approved for use in the United States,FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:05,CEDFD5,Biogen Inc.,100,0.71,products-services,,The U.S. Food and Drug Administration granted accelerated approval for QALSODY,FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,21:00:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-30,21:00:03,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-30,21:00:03,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-30,21:00:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-30,21:00:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-30,21:00:55,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen: Receives European Commission Approval for QALSODY,NEWS-FLASH,Dow Jones Newswires,"Biogen: Receives European Commission Approval for QALSODY Therapy to Treat Rare, Genetic Form of ALS"
BIIB,2024-05-30,21:35:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-05-30,21:35:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-05-30,23:03:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors"
BIIB,2024-05-30,23:03:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors"
BIIB,2024-05-30,23:03:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors"
BIIB,2024-05-30,23:03:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors"
BIIB,2024-05-31,09:01:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-31,09:01:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-31,09:31:39,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-31,09:31:39,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-31,09:33:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-05-31,09:33:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-05-31,12:24:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,LEGAL DEADLINE NOTICE: Biogen Inc. Investors are Reminded About Upcoming Deadline in Securities Action and are Encouraged to Submit Their Information
BIIB,2024-05-31,12:24:09,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,LEGAL DEADLINE NOTICE: Biogen Inc. Investors are Reminded About Upcoming Deadline in Securities Action and are Encouraged to Submit Their Information
BIIB,2024-05-31,15:42:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Biogen Inc. Sued for Securities Law Violations -- Investors Should Contact Levi & Korsinsky for More Information -- BIIB
BIIB,2024-05-31,15:46:36,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-05-31,15:46:36,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-05-31,16:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-05-31,16:31:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-31,16:31:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-31,19:34:46,CEDFD5,Biogen Inc.,100,-0.52,legal,,Biogen INVESTOR ALERT: Biogen Inc. (BIIB) Sued for,PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN INVESTOR ALERT: Biogen Inc. (BIIB) Sued for Securities Fraud, Contact BFA Law if You Suffered Losses"
BIIB,2024-05-31,19:34:46,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN INVESTOR ALERT: Biogen Inc. (BIIB) Sued for Securities Fraud, Contact BFA Law if You Suffered Losses"
BIIB,2024-05-31,22:03:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,Business Wire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-05-31,22:03:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-01,00:59:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIIB Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Biogen Inc. Class Action
BIIB,2024-06-01,09:33:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline
BIIB,2024-06-01,09:33:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline
BIIB,2024-06-01,11:32:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-01,11:32:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-01,11:32:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-01,16:08:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-01,16:08:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-01,16:08:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-01,16:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-01,16:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-01,16:16:03,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-01,16:16:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-01,23:04:38,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-01,23:04:38,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-02,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-06-02,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-06-02,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-06-02,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-06-02,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-06-02,01:57:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-02,01:57:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-02,13:51:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-02,13:51:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-02,14:00:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-02,14:00:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-02,16:24:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-02,16:24:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-02,18:25:11,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-02,18:25:11,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-03,09:02:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-03,09:02:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-03,09:22:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-03,09:22:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-03,11:33:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIIB DEADLINE ALERT: Biogen Inc. Investors who Lost Money are Reminded to Contact BFA Law before Upcoming Legal Deadline
BIIB,2024-06-03,11:33:59,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIIB DEADLINE ALERT: Biogen Inc. Investors who Lost Money are Reminded to Contact BFA Law before Upcoming Legal Deadline
BIIB,2024-06-03,12:02:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-03,12:02:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-03,15:56:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-03,15:56:12,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-03,15:56:12,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-03,15:56:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-03,15:56:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-03,18:46:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-03,18:46:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-03,20:04:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,BIOGEN 50 DAY NOTICE: Investors of Biogen Inc. (Nasdaq: BIIB) are Encouraged to Contact BFA Law Before July 2024 Deadline in Securities Fraud Class Action
BIIB,2024-06-03,18:49:29,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-03,18:49:29,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-03,19:00:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-03,19:00:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-03,19:06:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,"Biogen Inc.: On November 8, 2023, Biogen released its third quarter 2023 financial results",PRESS-RELEASE,Business Wire,Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-03,19:06:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-03,19:06:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-03,19:06:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-03,19:38:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Biogen Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
BIIB,2024-06-03,20:04:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,BIOGEN 50 DAY NOTICE: Investors of Biogen Inc. (Nasdaq: BIIB) are Encouraged to Contact BFA Law Before July 2024 Deadline in Securities Fraud Class Action
BIIB,2024-06-03,20:31:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-03,20:31:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-04,02:32:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,Robbins LLP Urges BIIB Investors With Large Losses to Contact the Firm for Information About the Biogen Inc. Class Action
BIIB,2024-06-04,05:42:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Lifshitz Law PLLC Announces Investigations of Ventyx Biosciences, Inc. (NASDAQ:VTYX), Biogen, Inc. (NASDAQ:BIIB), Enphase Energy, Inc. (NASDAQ:ENPH), and Fastly, Inc. (NYSE:FSLY)"
BIIB,2024-06-04,05:45:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-04,05:45:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-04,06:33:16,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-04,06:33:16,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-04,09:02:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-04,09:02:23,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-04,09:17:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-04,09:17:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-04,09:45:06,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,PR Newswire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-04,09:45:06,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-04,11:33:42,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,DEADLINE NOTICE BIOGEN (BIIB): Investors Who Lost Money are Encouraged to Contact BFA Law Before July 2024 Deadline in Securities Fraud Class Action
BIIB,2024-06-04,11:33:42,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,DEADLINE NOTICE BIOGEN (BIIB): Investors Who Lost Money are Encouraged to Contact BFA Law Before July 2024 Deadline in Securities Fraud Class Action
BIIB,2024-06-04,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,Business Wire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-04,15:00:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-04,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-04,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-04,15:36:17,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-04,15:36:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-04,16:24:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-04,16:24:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-04,16:24:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-04,17:46:26,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-04,17:46:26,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-04,18:01:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-04,18:01:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-04,19:28:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INVESTOR NOTICE: Biogen Inc. (BIIB) Shareholders are Reminded of July 2024 Deadline in Securities Action and Are Encouraged to Contact BFA Law
BIIB,2024-06-04,19:28:09,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INVESTOR NOTICE: Biogen Inc. (BIIB) Shareholders are Reminded of July 2024 Deadline in Securities Action and Are Encouraged to Contact BFA Law
BIIB,2024-06-05,09:02:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-05,09:02:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-05,09:20:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-05,09:20:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-05,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class Action - BIIB
BIIB,2024-06-05,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class Action - BIIB
BIIB,2024-06-05,11:14:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN SHAREHOLDER ALERT: Biogen Inc. (BIIB) Investors are Reminded of July 2024 Deadline in Securities Action and are Encouraged to Contact BFA Law
BIIB,2024-06-05,11:14:16,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN SHAREHOLDER ALERT: Biogen Inc. (BIIB) Investors are Reminded of July 2024 Deadline in Securities Action and are Encouraged to Contact BFA Law
BIIB,2024-06-05,11:31:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-05,11:31:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-05,14:37:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-05,14:37:19,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-05,14:37:19,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-05,14:37:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-05,14:37:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-05,15:07:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-05,15:07:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-05,15:33:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-05,15:33:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-05,15:52:34,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR DEADLINE: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-05,15:52:34,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR DEADLINE: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-05,16:02:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-05,16:02:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-05,18:05:09,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-05,18:05:09,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-05,19:26:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,UPCOMING DEADLINE ALERT: Biogen Inc. (Nasdaq: BIIB) Investors are Encouraged to Contact BFA Law About Approaching July 2024 Deadline in Securities Class Action
BIIB,2024-06-05,19:26:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,UPCOMING DEADLINE ALERT: Biogen Inc. (Nasdaq: BIIB) Investors are Encouraged to Contact BFA Law About Approaching July 2024 Deadline in Securities Class Action
BIIB,2024-06-05,19:45:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-05,19:45:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-06,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Class Action Lawsuits Have Been Filed Against Biogen,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-06,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-06,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-06,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-06,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-06,01:10:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-06,01:10:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-06,05:47:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-06-06,06:13:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-06,06:13:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-06,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-06,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-06,08:22:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-06,08:22:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-06,08:51:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Shareholders
BIIB,2024-06-06,08:51:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Shareholders
BIIB,2024-06-06,09:01:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-06,09:01:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-06,09:17:02,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-06,09:17:02,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-06,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-06,11:33:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,UPCOMING LEGAL DEADLINE: Biogen Inc. (BIIB) Investors that Suffered Losses are Encouraged to Contact BFA Law About Approaching July 2024 Court Deadline
BIIB,2024-06-06,11:33:52,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,UPCOMING LEGAL DEADLINE: Biogen Inc. (BIIB) Investors that Suffered Losses are Encouraged to Contact BFA Law About Approaching July 2024 Court Deadline
BIIB,2024-06-06,12:01:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-06,12:01:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-06,15:32:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-06,15:32:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-06,16:33:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-06,16:33:53,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-06,16:33:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-06,16:33:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-06,17:01:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-06,17:01:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-06,18:42:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,GlobeNewswire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join -- Contact The Gross Law Firm"
BIIB,2024-06-06,18:42:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join -- Contact The Gross Law Firm"
BIIB,2024-06-06,19:24:14,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN APPROACHING DEADLINE: Biogen Inc. (BIIB) Investors are Reminded of Upcoming July 2024 Court Deadline and Urged to Contact BFA Law
BIIB,2024-06-06,19:24:14,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN APPROACHING DEADLINE: Biogen Inc. (BIIB) Investors are Reminded of Upcoming July 2024 Court Deadline and Urged to Contact BFA Law
BIIB,2024-06-06,20:32:00,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-06,20:32:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-06,20:46:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-06,20:46:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-06,20:46:37,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-06,20:46:37,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-07,09:02:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-07,09:02:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-07,09:19:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-07,09:19:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-07,10:46:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-07,10:46:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-07,10:46:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-07,11:11:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,APPROACHING LEGAL DEADLINE: Biogen Inc. (BIIB) Investors that Suffered Losses are Urged to Contact BFA Law About Upcoming July 2024 Legal Deadline
BIIB,2024-06-07,11:11:43,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,APPROACHING LEGAL DEADLINE: Biogen Inc. (BIIB) Investors that Suffered Losses are Urged to Contact BFA Law About Upcoming July 2024 Legal Deadline
BIIB,2024-06-07,11:21:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-07,11:21:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-07,16:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-07,16:31:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-07,16:31:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-07,17:27:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Shareholders
BIIB,2024-06-07,19:32:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN UPCOMING DEADLINE: Biogen Inc. (BIIB) Investors are Urged to Contact BFA Law About Approaching July 2024 Deadline in Securities Class Action
BIIB,2024-06-07,19:32:13,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN UPCOMING DEADLINE: Biogen Inc. (BIIB) Investors are Urged to Contact BFA Law About Approaching July 2024 Deadline in Securities Class Action
BIIB,2024-06-07,21:12:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIIB Class Action Reminder: Contact Robbins LLP for Information About Your Rights Against Biogen Inc.
BIIB,2024-06-07,21:37:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-07,21:37:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-07,22:13:03,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"Biogen Inc. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-07,22:13:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-08,22:22:17,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-08,09:11:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,BIOGEN CASE DEADLINE: Biogen Inc. (Nasdaq: BIIB) Investors are Reminded of Upcoming July 2024 Legal Deadline and Encouraged to Contact BFA Law
BIIB,2024-06-08,09:11:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,BIOGEN CASE DEADLINE: Biogen Inc. (Nasdaq: BIIB) Investors are Reminded of Upcoming July 2024 Legal Deadline and Encouraged to Contact BFA Law
BIIB,2024-06-08,14:46:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-08,14:46:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-08,22:22:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-08,22:25:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-08,22:25:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-09,09:54:44,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-09,09:54:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-09,11:54:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-09,11:54:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-09,11:54:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-09,15:18:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-09,15:18:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-09,16:07:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-09,16:07:24,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-09,16:07:24,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-09,16:07:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-09,16:07:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-10,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Class Action Lawsuits Have Been Filed Against Biogen,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-10,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-10,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-10,21:32:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-10,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-10,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-10,09:02:34,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-10,09:02:34,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-10,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
BIIB,2024-06-10,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
BIIB,2024-06-10,11:19:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN CASE ALERT: Biogen Inc. (BIIB) Investors that Suffered Losses are Encouraged to Contact BFA Law About Approaching July 2024 Legal Deadline
BIIB,2024-06-10,11:19:56,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN CASE ALERT: Biogen Inc. (BIIB) Investors that Suffered Losses are Encouraged to Contact BFA Law About Approaching July 2024 Legal Deadline
BIIB,2024-06-10,14:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-10,14:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-10,14:27:12,CEDFD5,Biogen Inc.,95,0.34,analyst-ratings,neutral,Minter has an outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,"Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug -- IBD"
BIIB,2024-06-10,15:01:41,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-10,15:01:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-10,15:36:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-10,15:36:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-10,16:43:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-10,16:43:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-10,17:01:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-10,17:01:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-10,19:37:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN REMINDER: If You Suffered Losses on Your Biogen Inc. (BIIB) Investment, You are Encouraged to Contact BFA Law Before Approaching July 2024 Legal Deadline"
BIIB,2024-06-10,19:37:12,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN REMINDER: If You Suffered Losses on Your Biogen Inc. (BIIB) Investment, You are Encouraged to Contact BFA Law Before Approaching July 2024 Legal Deadline"
BIIB,2024-06-10,21:32:03,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-10,21:32:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-10,21:32:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-10,21:48:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-10,21:48:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-11,09:02:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-11,09:02:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-11,09:20:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-11,09:20:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-11,10:43:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,"BIOGEN NOTICE: If You Suffered Losses on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to Contact BFA Law Before Approaching July 2024 Legal Deadline"
BIIB,2024-06-11,10:43:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,"BIOGEN NOTICE: If You Suffered Losses on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to Contact BFA Law Before Approaching July 2024 Legal Deadline"
BIIB,2024-06-11,10:55:42,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-11,10:55:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-11,14:39:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-11,14:39:13,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-11,14:39:13,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-11,14:39:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-11,14:39:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-11,16:46:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-11,16:46:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-11,18:16:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-11,18:16:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-11,19:22:43,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-11,19:22:43,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-11,19:31:47,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION NOTICE: If You Lost Money on Your Biogen Inc. (Nasdaq:BIIB) Investment, You are Reminded to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-11,19:31:47,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION NOTICE: If You Lost Money on Your Biogen Inc. (Nasdaq:BIIB) Investment, You are Reminded to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-11,19:46:34,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-11,19:46:34,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-11,22:04:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-11,22:04:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-11,22:04:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-12,09:01:44,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-12,09:01:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-12,09:15:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-12,09:15:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-12,10:08:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION REMINDER: If You Lost Money on Your Biogen Inc. (BIIB) Investment, You are Encouraged to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-12,10:08:09,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION REMINDER: If You Lost Money on Your Biogen Inc. (BIIB) Investment, You are Encouraged to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-12,11:07:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-06-12,11:20:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-12,11:20:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-12,11:22:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-12,11:22:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-12,16:00:03,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-12,16:00:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-12,16:00:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-12,16:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-12,16:16:42,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-12,16:16:42,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-12,20:04:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB COURT DEADLINE: If You Lost Money on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to Contact BFA Law Before July 2024 Legal Deadline"
BIIB,2024-06-12,20:04:08,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB COURT DEADLINE: If You Lost Money on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to Contact BFA Law Before July 2024 Legal Deadline"
BIIB,2024-06-12,20:05:28,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-12,20:05:28,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-12,20:20:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-12,20:20:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-13,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-13,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-13,08:21:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-13,08:21:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-13,08:21:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-13,08:21:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-13,09:01:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-13,09:01:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-13,09:41:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,09:41:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,11:31:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,"BIOGEN LEGAL DEADLINE: If You Lost Money on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Encouraged to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-13,11:31:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,"BIOGEN LEGAL DEADLINE: If You Lost Money on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Encouraged to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-13,11:50:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-13,11:50:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-13,14:30:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-13,14:30:20,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-13,14:30:20,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-13,14:30:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-13,14:30:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-13,14:46:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,14:46:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,15:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for BIIB, DRCT, FSLY, CRGE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-13,15:16:53,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-13,15:16:53,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-13,15:17:47,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-13,15:17:47,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-13,19:03:00,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-13,19:03:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-13,20:06:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BFA Law Notice: Biogen Inc. (Nasdaq: BIIB) Investors that Lost Money on Investment Have the Opportunity to Lead Securities Fraud Lawsuit and are Urged to Contact the Firm
BIIB,2024-06-13,20:06:18,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BFA Law Notice: Biogen Inc. (Nasdaq: BIIB) Investors that Lost Money on Investment Have the Opportunity to Lead Securities Fraud Lawsuit and are Urged to Contact the Firm
BIIB,2024-06-13,20:30:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,20:30:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,21:20:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for fiscal year 2023,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-06-13,21:20:42,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai, Biogen's development partner",PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-06-13,21:20:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-06-13,21:20:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-06-13,21:41:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-13,21:41:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-14,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Class Action Lawsuits Have Been Filed Against Biogen,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-14,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-14,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-14,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-14,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-14,01:17:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-14,01:17:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-14,01:17:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-14,01:17:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-14,09:03:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-14,09:03:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-14,09:36:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-14,09:36:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-14,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-14,11:03:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BFA Law Alert: Biogen Inc. (BIIB) Investors that Lost Money on Investment Have the Opportunity to Lead Securities Fraud Lawsuit and are Urged to Contact the Firm
BIIB,2024-06-14,11:03:07,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BFA Law Alert: Biogen Inc. (BIIB) Investors that Lost Money on Investment Have the Opportunity to Lead Securities Fraud Lawsuit and are Urged to Contact the Firm
BIIB,2024-06-14,13:45:47,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-14,13:45:47,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-14,14:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-14,14:15:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-14,14:00:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-14,14:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-14,14:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-14,14:01:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-14,14:01:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-14,14:02:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-14,14:02:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-14,14:02:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-14,14:15:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-14,16:10:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-14,16:31:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-14,16:31:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-14,20:06:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN INVESTOR ALERT: Lose Money on your Biogen Inc. (Nasdaq:BIIB) Investment? BFA Law Reminds You to Contact the Firm before July 22, 2024 Legal Deadline"
BIIB,2024-06-14,20:06:57,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN INVESTOR ALERT: Lose Money on your Biogen Inc. (Nasdaq:BIIB) Investment? BFA Law Reminds You to Contact the Firm before July 22, 2024 Legal Deadline"
BIIB,2024-06-14,20:30:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-14,20:30:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-15,10:04:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,"BIOGEN STOCK NOTICE: Lose Money on your Biogen Inc. (Nasdaq: BIIB) Investment? BFA Law Encourages You to Contact the Firm before July 22, 2024 Court Deadline"
BIIB,2024-06-15,10:04:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,"BIOGEN STOCK NOTICE: Lose Money on your Biogen Inc. (Nasdaq: BIIB) Investment? BFA Law Encourages You to Contact the Firm before July 22, 2024 Court Deadline"
BIIB,2024-06-15,13:31:12,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-15,13:31:12,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-15,14:45:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-15,14:45:04,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-15,14:45:04,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-15,14:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-15,14:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-15,22:09:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-15,22:09:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-15,22:20:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-15,22:20:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-16,11:06:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-16,11:06:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-16,11:57:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-16,11:57:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-16,11:57:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-16,12:01:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-16,12:01:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-16,12:02:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-16,12:02:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-17,09:02:39,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-17,09:02:39,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-17,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Shareholders of Biogen Inc. Should Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Shareholders of Biogen Inc. Should Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,09:51:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,09:51:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,09:56:39,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-17,09:56:39,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-17,10:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,"BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case"
BIIB,2024-06-17,10:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,Business Wire,"BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case"
BIIB,2024-06-17,10:35:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN SHAREHOLDER DEADLINE: Lose Money on your Biogen Inc. (Nasdaq:BIIB) Investment? BFA Law Reminds You to Contact the Firm before July 22, 2024 Cutoff Date"
BIIB,2024-06-17,10:35:43,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN SHAREHOLDER DEADLINE: Lose Money on your Biogen Inc. (Nasdaq:BIIB) Investment? BFA Law Reminds You to Contact the Firm before July 22, 2024 Cutoff Date"
BIIB,2024-06-17,11:10:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,11:10:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,11:11:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-17,11:11:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-17,11:15:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-17,11:15:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-17,11:48:15,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-17,11:48:15,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-17,15:46:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-17,15:46:22,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-17,15:46:22,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-17,15:46:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-17,15:46:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-17,16:05:01,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-17,16:05:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-17,16:05:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-17,16:05:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-17,16:36:03,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"BIIB: Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-17,16:36:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"BIIB: Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-17,16:36:04,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,"Press Release: BIIB: Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-17,16:36:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: BIIB: Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-17,17:02:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-17,17:02:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-18,01:03:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,01:03:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,09:01:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-18,09:01:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-18,09:21:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-18,09:21:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-18,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-18,09:46:38,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-18,09:46:38,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-18,15:41:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-18,15:41:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-18,15:46:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-18,15:46:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-18,16:10:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-18,16:46:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-18,16:46:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-18,16:46:48,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-18,16:46:48,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-18,17:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Biogen Inc. Sued for Securities Law Violations -- Investors Should Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights -- BIIB"
BIIB,2024-06-18,21:15:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,21:15:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,21:24:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-18,21:24:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-18,21:36:03,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-18,21:36:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-18,21:36:03,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-18,21:36:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-18,21:49:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-18,21:49:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-18,21:49:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,21:49:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,22:00:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-18,22:00:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-18,22:00:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-19,09:01:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-19,09:01:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-19,09:15:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-19,09:15:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-19,09:30:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-19,09:30:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-19,11:17:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-06-19,11:41:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-19,11:41:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-19,14:01:13,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities Fraud Class Action Lawsuit Against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against Biogen Inc."
BIIB,2024-06-19,14:01:13,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against Biogen Inc."
BIIB,2024-06-19,15:08:41,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-19,15:08:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-20,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Class Action Lawsuits Have Been Filed Against Biogen,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-20,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-20,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-20,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-20,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-20,01:30:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-20,01:30:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-20,01:31:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-20,01:31:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-20,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-20,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-20,08:31:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,08:31:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,08:31:37,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-20,08:31:37,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-20,09:01:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-20,09:01:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-20,09:31:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-20,09:31:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-20,09:32:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-20,09:32:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-20,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-20,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-20,15:08:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-20,15:08:21,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-20,15:08:21,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-20,15:08:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-20,15:08:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-20,15:31:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-20,15:31:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-20,15:34:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,15:34:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,16:01:54,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities Fraud Class Action Lawsuit Against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against Biogen Inc."
BIIB,2024-06-20,16:01:54,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against Biogen Inc."
BIIB,2024-06-20,16:21:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,16:21:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,16:32:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-20,16:32:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-20,17:03:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for BIIB, DRCT, FSLY, CRGE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-20,17:30:58,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-20,17:30:58,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-20,17:45:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-20,17:45:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-20,22:30:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-20,22:30:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-20,22:30:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-21,09:01:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-21,09:01:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-21,09:31:41,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-21,09:31:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-21,09:41:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,09:41:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-21,15:31:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,15:31:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,15:32:55,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against - BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-06-21,15:32:55,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-06-21,16:02:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-21,16:02:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-21,16:02:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-21,16:02:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-21,16:16:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-21,16:16:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-21,17:00:03,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-21,17:00:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-21,17:00:03,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-21,17:00:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-21,19:49:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,19:49:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,19:50:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,19:50:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,20:02:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-21,20:02:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-22,12:29:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-22,12:29:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-22,12:29:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-22,14:47:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-22,14:47:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-22,14:47:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-22,14:47:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-22,14:47:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-22,15:30:00,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) -- Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-22,15:30:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) -- Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-22,22:16:29,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-22,22:16:29,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-22,22:20:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-22,22:20:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-23,09:43:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-23,09:43:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-23,10:15:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-23,10:15:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-23,15:35:07,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-23,15:35:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-23,15:38:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-23,15:38:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-23,16:18:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Reminder for NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-06-23,16:18:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Reminder for NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-06-23,17:00:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-23,17:00:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-23,17:01:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-23,17:01:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-24,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Class Action Lawsuits Have Been Filed Against Biogen,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-24,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-24,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-24,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-24,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-24,01:17:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-24,01:17:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-24,01:17:17,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-24,01:17:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-24,09:01:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-24,09:01:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-24,09:16:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-24,09:16:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-24,09:18:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-24,09:18:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-24,13:31:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Reminder for NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-06-24,13:31:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Reminder for NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-06-24,18:06:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-24,18:06:04,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-24,18:06:04,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-24,18:06:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-24,18:06:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-24,18:31:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-24,18:31:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-24,18:31:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-24,18:31:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-24,19:46:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-06-24,20:21:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-24,20:21:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-24,20:46:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-24,20:46:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-24,22:18:30,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Biogen Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
BIIB,2024-06-24,23:46:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-24,23:46:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-24,23:46:54,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-24,23:46:54,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-25,09:01:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-25,09:01:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-25,09:16:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-25,09:16:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-25,09:22:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-25,09:22:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-25,09:45:03,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,PR Newswire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm
BIIB,2024-06-25,09:45:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm
BIIB,2024-06-25,09:45:04,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,Dow Jones Newswires,Press Release: Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm
BIIB,2024-06-25,09:45:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm
BIIB,2024-06-25,15:31:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-25,15:31:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-25,15:47:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-25,15:47:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-25,16:16:27,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against - BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-06-25,16:16:27,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-06-25,19:47:52,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-25,19:47:52,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-25,20:15:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-25,20:15:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-25,21:52:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-25,21:52:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-25,21:52:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-26,02:53:08,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,02:53:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,02:53:10,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,02:53:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,03:05:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,03:05:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,09:01:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-26,09:01:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-26,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-26,13:35:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,PR Newswire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-26,13:35:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-26,13:35:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-26,14:01:31,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-26,14:01:31,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-26,14:02:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-26,14:02:57,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-26,14:02:57,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-26,14:02:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-26,14:02:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-26,15:06:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,15:06:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,15:16:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,15:16:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,16:00:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,16:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,16:00:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,16:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,16:17:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-26,16:17:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-26,16:31:14,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-26,16:31:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-26,16:33:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-26,17:01:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-26,17:01:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-26,17:02:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-26,17:02:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-27,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-27,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-27,08:21:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-27,08:21:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-27,08:21:34,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-27,08:21:34,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-27,09:01:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-27,09:01:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-27,09:26:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-27,09:26:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-27,09:27:14,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-27,09:27:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-27,11:16:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-27,11:31:28,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-27,11:31:28,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-27,11:46:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-27,11:46:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-27,15:24:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-27,15:24:02,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-27,15:24:02,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-27,15:24:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-27,15:24:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-27,20:21:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-27,20:21:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-27,20:23:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for BIIB, DRCT, FSLY, CRGE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-27,20:31:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-27,20:31:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,-0.48,legal,,"Biogen, Charge, Fastly, and NIKE",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,-0.48,legal,,"Biogen, Charge, Fastly, and NIKE",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:15:37,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-28,01:15:37,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-28,09:03:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-28,09:03:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-28,09:13:15,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-28,09:13:15,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-28,09:15:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-28,09:15:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-28,09:45:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB LAWSUIT ALERT: The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-28,09:45:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB LAWSUIT ALERT: The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-28,13:40:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-28,13:40:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-28,13:40:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-28,14:02:30,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-28,14:02:30,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-28,14:02:39,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-28,14:02:39,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-28,15:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-28,15:00:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-28,15:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-28,15:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-28,15:17:45,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-28,15:17:45,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-28,15:18:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-28,15:18:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-28,22:00:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-28,22:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-28,22:00:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-28,22:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-28,22:01:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for fiscal year 2023,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Kirby McInerney LLP Notifies Biogen, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit"
BIIB,2024-06-28,22:01:20,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai, Biogen's development partner",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Kirby McInerney LLP Notifies Biogen, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit"
BIIB,2024-06-28,22:01:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Kirby McInerney LLP Notifies Biogen, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit"
BIIB,2024-06-28,22:01:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Kirby McInerney LLP Notifies Biogen, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit"
BIIB,2024-06-28,22:17:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-28,22:17:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-28,22:31:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-28,22:31:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-29,03:45:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-29,03:45:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-29,12:14:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-29,12:14:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-29,12:14:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-29,13:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Biogen Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
BIIB,2024-06-29,14:45:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-29,14:45:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-30,01:18:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-30,01:18:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-30,01:26:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-30,01:26:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-30,09:54:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-30,09:54:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-30,10:11:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-30,10:11:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-30,10:12:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-30,10:12:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-30,13:47:11,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-30,13:47:11,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-30,13:58:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-30,13:58:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-30,15:14:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-30,15:14:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-30,15:21:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-30,15:21:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-30,15:21:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-30,15:21:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-30,15:21:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-30,15:27:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-30,15:27:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-30,15:37:56,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-30,15:37:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-30,17:06:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-30,17:06:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-01,09:02:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-01,09:02:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-01,09:21:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-01,09:21:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-01,09:31:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-01,09:31:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-01,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-01,11:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-07-01,11:19:45,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-01,11:19:45,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-01,11:20:42,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-01,11:20:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-01,14:16:07,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-07-01,14:16:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-07-01,16:33:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Contact The Gross Law Firm by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,-0.48,legal,,"Biogen, Charge, Fastly, and NIKE",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,-0.48,legal,,"Biogen, Charge, Fastly, and NIKE",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:15:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,01:15:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,01:31:18,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-02,01:31:18,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-02,09:01:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-02,09:01:23,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-02,09:16:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,09:16:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,09:16:40,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-02,09:16:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-02,13:16:51,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition Of Human Immunology Biosciences >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Completes Acquisition Of Human Immunology Biosciences >BIIB
BIIB,2024-07-02,13:16:51,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology Biosciences,PRESS-RELEASE,GlobeNewswire,Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:51,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: we will begin working together with our,PRESS-RELEASE,GlobeNewswire,Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:51,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology -2,PRESS-RELEASE,GlobeNewswire,Biogen Completes Acquisition of Human Immunology -2-
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology Biosciences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: we will begin working together with our,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology Biosciences,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: we will begin working together with our,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of -2-
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology -2,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Completes Acquisition of Human Immunology -2-
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology Biosciences,FULL-ARTICLE,Dow Jones Newswires,Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology -2,FULL-ARTICLE,Dow Jones Newswires,Biogen Completes Acquisition of Human Immunology -2-
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology Biosciences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: we will begin working together with our,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of -2-
BIIB,2024-07-02,13:47:20,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-07-02,13:47:20,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-07-02,14:00:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-02,14:00:08,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-02,14:00:08,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-02,14:00:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-02,14:00:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-02,14:07:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-02,14:16:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,14:16:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,14:16:10,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against - BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-07-02,14:16:10,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-07-02,15:32:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-02,15:32:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-02,15:46:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,15:46:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,16:35:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-02,20:02:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIIB STOCKHOLDERS: Lead Plaintiff Deadline Approaching in Biogen Inc. Class Action; Contact Robbins LLP
BIIB,2024-07-02,20:14:42,CEDFD5,Biogen Inc.,97,0.34,analyst-ratings,neutral,He has an outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug -- IBD
BIIB,2024-07-02,20:31:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-02,20:31:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-02,20:36:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,20:36:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,21:04:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-02,21:04:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-02,21:12:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,21:12:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,21:25:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-02,21:25:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-02,21:25:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-03,03:05:07,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-03,03:05:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-03,03:05:10,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-03,03:05:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-03,03:19:45,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-03,03:19:45,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-03,03:31:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-03,03:31:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-03,09:02:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-03,09:02:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-03,09:31:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-03,09:31:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-03,09:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"July 22, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against BIIB"
BIIB,2024-07-03,09:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: July 22, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against BIIB"
BIIB,2024-07-03,13:40:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,PR Newswire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-03,13:40:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-03,13:40:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-03,14:02:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-03,14:02:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-03,14:03:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-03,14:03:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-03,15:30:48,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-03,15:30:48,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-03,15:32:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-03,15:32:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-03,18:46:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Securities Fraud Class Action Lawsuit - Kessler Topaz Meltzer & Check, LLP Announces That a Lawsuit Has Been Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-03,18:46:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Securities Fraud Class Action Lawsuit - Kessler Topaz Meltzer & Check, LLP Announces That a Lawsuit Has Been Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-03,19:10:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for BIIB, DRCT, FSLY, CRGE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-03,19:31:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-03,19:31:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-03,19:32:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Shareholders
BIIB,2024-07-03,19:32:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Shareholders
BIIB,2024-07-04,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-04,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-04,08:21:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-04,08:21:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-04,08:21:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,08:21:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,09:00:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-04,09:00:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-04,09:31:35,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-04,09:31:35,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-04,09:32:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-04,09:32:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-04,14:20:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-04,14:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-04,14:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-04,14:30:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,14:30:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,15:31:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,15:31:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,15:33:48,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,15:33:48,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,19:30:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"BIIB SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of Securities Fraud Class Action Lawsuit Filed On the Behalf"
BIIB,2024-07-04,19:30:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"BIIB SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of Securities Fraud Class Action Lawsuit Filed On the Behalf"
BIIB,2024-07-04,19:45:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-04,19:45:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-04,19:45:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-04,19:45:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-05,09:01:14,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-05,09:01:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-05,09:31:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-05,09:31:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-05,09:32:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-05,09:32:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-05,15:02:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Biogen Inc. Securities Fraud Class Action Lawsuit"
BIIB,2024-07-05,16:01:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-05,16:01:51,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-05,16:01:51,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-05,16:01:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-05,16:01:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-05,16:17:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that Lost Money on Biogen Inc.(BIIB) Should Contact Levi & Korsinsky About Pending Class Action - BIIB
BIIB,2024-07-05,16:17:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that Lost Money on Biogen Inc.(BIIB) Should Contact Levi & Korsinsky About Pending Class Action - BIIB
BIIB,2024-07-05,16:30:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-05,16:30:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-06,18:49:07,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-07-06,18:49:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-07-07,01:22:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-07,01:22:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-07,01:28:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-07,01:28:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-07,09:56:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-07,09:56:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-07,11:10:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-07,11:10:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-07,11:12:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-07,11:12:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-07,12:05:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-07,12:05:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-07,12:05:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-07,14:16:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-07,14:16:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-07,14:16:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-07,14:16:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-07,14:16:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-07,15:08:30,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-07,15:08:30,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-07,15:08:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-07,15:08:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-07,16:04:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-07,16:04:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-07,16:05:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-07,16:05:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-07,16:16:09,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc"
BIIB,2024-07-07,16:16:09,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc"
BIIB,2024-07-08,09:01:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-08,09:01:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-08,09:31:21,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-08,09:31:21,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-08,09:32:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-08,09:32:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-08,09:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-07-08,14:49:47,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-07-08,15:16:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-08,15:16:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-08,15:16:42,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-08,15:16:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-08,15:25:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-08,15:25:20,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-08,15:25:20,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-08,15:25:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-08,15:25:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-08,16:00:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-08,16:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-08,16:00:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-08,16:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-08,16:19:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-08,16:19:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-08,16:34:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-08,16:34:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-08,18:05:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"Kessler Topaz Meltzer & Check, LLP Encourages Biogen Inc. Investors with Substantial Loss to Contact the Firm in Regards to Securities Class Action Lawsuit Filed against Biogen Inc."
BIIB,2024-07-08,18:05:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Kessler Topaz Meltzer & Check, LLP Encourages Biogen Inc. Investors with Substantial Loss to Contact the Firm in Regards to Securities Class Action Lawsuit Filed against Biogen Inc."
BIIB,2024-07-08,18:45:58,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-08,18:45:58,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-08,21:27:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-08,21:27:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-08,21:27:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-08,22:32:47,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-08,22:32:47,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-08,22:33:44,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-08,22:33:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-09,09:00:45,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-09,09:00:45,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-09,09:16:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-09,09:16:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-09,09:16:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-09,09:16:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-09,13:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Biogen Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
BIIB,2024-07-09,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-09,15:00:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-09,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-09,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-09,15:17:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-09,15:17:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-09,15:32:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-09,15:32:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-09,16:28:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-09,16:46:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-09,16:46:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-09,17:00:56,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-09,17:00:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-09,17:16:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"Important July 22, 2024 Deadline Reminder for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-07-09,17:16:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Important July 22, 2024 Deadline Reminder for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-07-09,17:32:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-09,17:32:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-09,17:45:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-09,17:45:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-09,18:51:54,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,GlobeNewswire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors -- Contact The Gross Law Firm
BIIB,2024-07-09,18:51:54,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors -- Contact The Gross Law Firm
BIIB,2024-07-09,21:47:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-09,21:47:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-09,21:47:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-09,23:51:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,09:01:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-10,09:01:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-10,09:21:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-10,09:21:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-10,09:21:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,09:21:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,13:25:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,PR Newswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-10,13:25:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-10,13:25:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-10,15:34:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-10,13:46:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-10,13:46:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-10,14:15:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-10,14:15:03,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-10,14:15:03,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-10,14:15:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-10,14:15:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-10,14:33:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,14:33:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,14:50:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-10,14:50:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-10,15:17:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-10,15:17:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-10,15:34:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-10,16:00:02,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-10,16:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-10,16:00:02,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-10,16:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-10,16:04:25,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Notification: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-10,16:04:25,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Notification: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-10,16:32:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,16:32:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,16:34:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that Lost Money on Biogen Inc.(BIIB) Should Contact Levi & Korsinsky About Pending Class Action - BIIB
BIIB,2024-07-10,16:34:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that Lost Money on Biogen Inc.(BIIB) Should Contact Levi & Korsinsky About Pending Class Action - BIIB
BIIB,2024-07-10,17:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights -- BIIB"
BIIB,2024-07-10,23:45:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,23:45:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,23:45:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-10,23:45:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-11,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-11,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-11,08:31:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-11,08:31:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-11,09:01:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-11,09:01:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-11,09:16:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-11,09:16:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-11,09:16:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-11,09:16:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-11,15:15:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-11,15:15:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-11,16:48:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for BIIB, DRCT, FSLY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-11,17:16:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-11,17:16:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-11,20:01:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf"
BIIB,2024-07-11,22:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for fiscal year 2023,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-07-11,22:00:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai, Biogen's development partner",PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-07-11,22:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-07-11,22:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-07-11,22:11:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-11,22:11:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-12,09:01:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-12,09:01:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-12,09:16:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-12,09:16:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-12,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB
BIIB,2024-07-12,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB
BIIB,2024-07-12,12:33:47,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Piper Sandler
BIIB,2024-07-12,12:33:47,CEDFD5,Biogen Inc.,100,-0.66,price-targets,downgrade,Biogen Price Target Cut to $313.00/Share From $335.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $313.00/Share From $335.00 by Piper Sandler
BIIB,2024-07-12,14:15:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-12,14:15:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-12,14:15:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-12,14:31:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-12,14:31:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-12,15:15:41,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-12,15:15:41,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-12,15:30:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-12,15:30:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-12,18:15:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-12,18:15:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-12,18:15:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-12,18:15:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-12,18:15:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-12,18:30:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-12,18:30:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-13,14:01:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB NOTICE: Kessler Topaz Meltzer & Check, LLP Notifies Biogen Inc. (BIIB) Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-07-13,15:15:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case"
BIIB,2024-07-13,15:15:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case"
BIIB,2024-07-14,01:22:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-14,01:22:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-14,09:56:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-14,09:56:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-14,11:30:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-14,11:30:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-14,11:35:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-14,11:35:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-14,11:35:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-14,13:15:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"BIIB Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Deadline in Securities Fraud Class Action Lawsuit"
BIIB,2024-07-14,13:15:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Deadline in Securities Fraud Class Action Lawsuit"
BIIB,2024-07-14,13:31:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-14,13:31:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-14,16:00:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-14,16:00:51,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-14,16:00:51,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-14,16:00:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-14,16:00:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-14,17:02:33,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-14,17:02:33,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-15,09:01:17,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-15,09:01:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-15,09:15:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-15,09:15:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-15,09:45:07,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,PR Newswire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-15,09:45:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-15,13:30:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"Final Deadline Approaching for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Lead Plaintiff Deadline"
BIIB,2024-07-15,13:30:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Final Deadline Approaching for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Lead Plaintiff Deadline"
BIIB,2024-07-15,13:30:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Final Deadline Approaching for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Lead Plaintiff Deadline"
BIIB,2024-07-15,13:30:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Final Deadline Approaching for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Lead Plaintiff Deadline"
BIIB,2024-07-15,13:47:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-15,13:47:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-15,15:21:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit -- BIIB"
BIIB,2024-07-15,18:48:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-15,18:48:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-15,19:46:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-15,19:46:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-15,22:11:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-15,22:11:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-15,22:11:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-16,08:31:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-16,08:31:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-16,09:01:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-16,09:01:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-16,09:31:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-16,09:31:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-16,09:45:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-16,09:45:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-16,10:00:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-16,10:00:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-16,14:14:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-16,14:14:33,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-16,14:14:33,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-16,14:14:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-16,14:14:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-16,16:45:39,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights -- BIIB"
BIIB,2024-07-16,14:46:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-07-16,14:46:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-07-16,15:01:17,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-16,15:01:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-16,15:55:39,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: analysts expect the company's sales to decline,FULL-ARTICLE,Dow Jones Newswires,Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense -- IBD
BIIB,2024-07-16,16:06:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-16,16:33:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-16,16:33:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-16,18:02:07,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Deadline Alert - Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-16,18:02:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Deadline Alert - Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-16,19:18:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-16,19:18:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-16,20:02:40,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: analysts expect the company's sales to decline,FULL-ARTICLE,Dow Jones Newswires,Three Surprising Names That Could Be On Biogen's Buyout Shortlist -- IBD
BIIB,2024-07-16,22:19:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-16,22:19:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-16,22:19:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-17,09:00:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-17,09:00:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-17,09:20:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-17,09:20:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-17,09:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-17,09:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-17,15:31:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-17,15:31:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-17,18:39:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-17,18:39:41,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-17,18:39:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-17,18:39:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-17,19:02:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-17,19:02:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-17,20:31:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Lead Plaintiff Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of Deadline in Securities Fraud Class Action Lawsuit"
BIIB,2024-07-17,22:35:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-17,22:35:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-17,22:35:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-18,00:30:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,00:30:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-18,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-18,08:10:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,08:10:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,09:00:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-18,09:00:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-18,09:15:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-18,09:15:23,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-18,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-18,11:36:30,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-18,11:36:30,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-18,12:15:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE MONDAY: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-18,12:15:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE MONDAY: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-18,12:45:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-18,12:45:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-18,14:05:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-18,14:05:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-18,14:05:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-18,14:16:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,14:16:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,16:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, FSLY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-18,16:31:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-18,16:31:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-18,19:01:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-18,19:01:03,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-18,19:01:03,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-18,19:01:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-18,19:01:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-18,20:52:22,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Deadline - Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-18,20:52:22,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Deadline - Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-18,20:52:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,20:52:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,23:02:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-18,23:02:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-19,09:00:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-19,09:00:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-19,09:30:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-07-19,09:30:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-07-19,13:31:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-19,13:31:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-19,13:47:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Lead Plaintiff Deadline Approaching - Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Shareholders of Deadline in Securities Fraud Class Action Lawsuit"
BIIB,2024-07-19,14:02:27,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-19,14:02:27,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-19,14:05:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,PR Newswire,"Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-19,14:05:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-19,14:05:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,"Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-19,14:30:56,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-19,14:30:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-19,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,"Biogen Inc.: On November 8, 2023, Biogen released its third quarter 2023 financial results",PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-19,15:00:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-19,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-19,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-20,12:25:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-20,12:25:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-20,12:25:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-20,14:04:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"BIIB DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Biogen Inc. (BIIB) Securities Fraud Class Action Lawsuit"
BIIB,2024-07-20,14:04:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Biogen Inc. (BIIB) Securities Fraud Class Action Lawsuit"
BIIB,2024-07-20,14:20:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-20,14:20:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-20,14:20:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-20,14:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-20,14:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-21,01:12:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-21,01:12:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-21,08:01:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-07-21,08:01:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-07-21,09:35:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-21,09:35:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-21,09:36:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-21,09:36:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-21,10:43:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-21,10:43:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-21,12:53:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi, LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-21,12:53:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi, LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-21,12:53:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi, LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-21,13:30:49,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"FINAL DEADLINE REMINDER FOR BIIB INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-21,13:30:49,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL DEADLINE REMINDER FOR BIIB INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-21,14:34:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-21,14:34:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-22,08:01:17,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-07-22,08:01:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-07-22,09:00:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-22,09:00:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-22,09:01:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-22,09:01:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-22,09:31:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-22,09:31:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-22,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-22,15:01:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-22,15:23:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-22,15:23:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-22,15:24:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-22,15:24:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-22,15:24:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-22,15:45:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-22,15:45:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-22,15:54:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery -- Contact The Gross Law Firm
BIIB,2024-07-23,17:50:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-23,17:50:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-24,03:05:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Lifshitz Law PLLC Announces Investigations of Biogen, Inc. (NASDAQ: BIIB), Direct Digital Holdings, Inc. (NASDAQ: DRCT), AST SpaceMobile, Inc. (NASDAQ: ASTS), and Perion Network Ltd. (NASDAQ: PERI)"
BIIB,2024-07-24,10:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124),PRESS-RELEASE,Business Wire,Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
BIIB,2024-07-24,10:31:15,CEDFD5,Biogen Inc.,100,-0.65,products-services,negative,"Sage, Biogen: SAGE-324 Fails in Phase 2 Study",NEWS-FLASH,Dow Jones Newswires,"Sage, Biogen: SAGE-324 Fails in Phase 2 Study in Essential Tremor >SAGE BIIB"
BIIB,2024-07-24,10:34:46,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124),PRESS-RELEASE,Dow Jones Newswires,Press Release: Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
BIIB,2024-07-24,10:58:03,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen End Development of SAGE-324 in Essential Tremor,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen End Development of SAGE-324 in Essential Tremor"
BIIB,2024-07-24,10:58:03,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen are ending development of a proposed treatment,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen End Development of SAGE-324 in Essential Tremor"
BIIB,2024-07-24,12:44:24,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Sage Therapeutics Inc.: the company's collaboration with Biogen Inc.,FULL-ARTICLE,MarketWatch,MW Sage Therapeutics' stock dives as failed trial hits Biogen collaboration
BIIB,2024-07-24,13:02:06,CEDFD5,Biogen Inc.,93,-0.65,products-services,negative,Biogen-partnered treatment for essential tremor failed in a Phase 2 study,FULL-ARTICLE,Dow Jones Newswires,Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails -- IBD
BIIB,2024-07-24,20:08:11,CEDFD5,Biogen Inc.,93,-0.65,products-services,negative,Biogen-partnered treatment for essential tremor failed in a Phase 2 study,FULL-ARTICLE,Dow Jones Newswires,Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails -- IBD
BIIB,2024-07-26,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc. (NASDAQ: BIIB)",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-07-26,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-07-26,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-07-26,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-07-26,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-07-26,11:21:44,CEDFD5,Biogen Inc.,100,-0.61,products-services,negative,Biogen Gets Negative CHMP Opinion for the Humanized Anti-Soluble Aggregated Amyloid-Beta Monoclonal,NEWS-FLASH,Dow Jones Newswires,Biogen Gets Negative CHMP Opinion for the Humanized Anti-Soluble Aggregated Amyloid-Beta Monoclonal Antibody Lecanemab >BIIB
BIIB,2024-07-26,14:48:23,CEDFD5,Biogen Inc.,98,0.44,products-services,,"Biogen, which is looking to Leqembi to revive",FULL-ARTICLE,Dow Jones Newswires,EU Rejection of Alzheimer's Drug Is Another Disappointment for Biogen -- Barrons.com
BIIB,2024-07-26,15:16:10,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Raffat maintained his outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug -- IBD
BIIB,2024-07-26,20:16:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Raffat maintained his outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug -- IBD
BIIB,2024-07-29,11:29:55,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Baird
BIIB,2024-07-29,11:29:55,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $294.00/Share From $316.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $294.00/Share From $316.00 by Baird
BIIB,2024-07-30,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",PRESS-RELEASE,Business Wire,"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-07-30,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-07-30,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-07-30,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",PRESS-RELEASE,GlobeNewswire,"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-07-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-07-30,11:30:10,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",NEWS-FLASH,Dow Jones Newswires,"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-08-01,10:55:54,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $4.00 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q EPS $4.00 >BIIB
BIIB,2024-08-01,10:55:54,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Adj EPS $5.28,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Adj EPS $5.28 >BIIB
BIIB,2024-08-01,10:55:54,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Net $583.6M,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Net $583.6M >BIIB
BIIB,2024-08-01,10:55:54,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 2Q Rev $2.46B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Rev $2.46B >BIIB
BIIB,2024-08-01,10:58:09,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY24 Adj EPS $15.75,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY24 Adj EPS $15.75-Adj EPS $16.25 >BIIB
BIIB,2024-08-01,10:59:33,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Expects 2024 Revenue to Decline,RNS-SEC8K,Dow Jones Newswires,Biogen Expects 2024 Revenue to Decline By a Low-Single Digit Percentage >BIIB
BIIB,2024-08-01,11:19:05,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen boosts profit outlook,FULL-ARTICLE,MarketWatch,MW Drug maker Biogen boosts profit outlook and tops Q2 profit estimate
BIIB,2024-08-01,11:19:05,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen said its second-quarter profit fell,FULL-ARTICLE,MarketWatch,MW Drug maker Biogen boosts profit outlook and tops Q2 profit estimate
BIIB,2024-08-01,11:19:05,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Boosts Profit Outlook,FULL-ARTICLE,Dow Jones Newswires,Drug Maker Biogen Boosts Profit Outlook And Tops Q2 Profit Estimate -- MarketWatch
BIIB,2024-08-01,11:19:05,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen said its second-quarter profit fell,FULL-ARTICLE,Dow Jones Newswires,Drug Maker Biogen Boosts Profit Outlook And Tops Q2 Profit Estimate -- MarketWatch
BIIB,2024-08-01,11:29:10,CEDFD5,Biogen Inc.,97,0.61,earnings,positive,Biogen to earn $4.02 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Earnings Flat; Biotech Giant Raises Guidance -- IBD
BIIB,2024-08-01,11:43:34,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Lifts Earnings Guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Earnings Guidance After Revenue Beats Forecasts -- WSJ
BIIB,2024-08-01,12:43:25,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen boosts profit outlook,FULL-ARTICLE,MarketWatch,MW Drugmaker Biogen boosts profit outlook on 'momentum' for new drugs
BIIB,2024-08-01,12:43:25,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen (BIIB) said its second-quarter profit fell,FULL-ARTICLE,MarketWatch,MW Drugmaker Biogen boosts profit outlook on 'momentum' for new drugs
BIIB,2024-08-01,14:48:41,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen boosts profit outlook,FULL-ARTICLE,MarketWatch,"MW Biogen boosts profit outlook on 'momentum' for new drugs, but stock dips"
BIIB,2024-08-01,14:48:41,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen's second-quarter profit fell to $583.6 million,FULL-ARTICLE,MarketWatch,"MW Biogen boosts profit outlook on 'momentum' for new drugs, but stock dips"
BIIB,2024-08-01,14:48:41,CEDFD5,Biogen Inc.,100,0.64,earnings,up,Biogen boosted its earnings,FULL-ARTICLE,MarketWatch,"MW Biogen boosts profit outlook on 'momentum' for new drugs, but stock dips"
BIIB,2024-08-01,15:03:09,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Raymond has an overweight rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Slips As Alzheimer's Drug Looks Abroad For Quarterly Beat -- IBD
BIIB,2024-08-01,15:03:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Spinraza beat sales expectations at,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Slips As Alzheimer's Drug Looks Abroad For Quarterly Beat -- IBD
BIIB,2024-08-01,20:01:41,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Raymond has an overweight rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Slips As Alzheimer's Drug Looks Abroad For Quarterly Beat -- IBD
BIIB,2024-08-01,20:01:41,CEDFD5,Biogen Inc.,100,0.0,revenues,,Spinraza beat sales expectations at,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Slips As Alzheimer's Drug Looks Abroad For Quarterly Beat -- IBD
BIIB,2024-08-02,13:58:44,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2024-08-02,13:58:44,CEDFD5,Biogen Inc.,100,-0.4,price-targets,downgrade,Biogen Price Target Cut to $210.00/Share From $215.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $210.00/Share From $215.00 by Wedbush
BIIB,2024-08-02,14:41:44,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2024-08-02,14:41:44,CEDFD5,Biogen Inc.,100,-0.6,price-targets,downgrade,Biogen Price Target Cut to $190.00/Share From $200.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $190.00/Share From $200.00 by Barclays
BIIB,2024-08-02,16:41:54,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Sector Outperform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Outperform by Scotiabank
BIIB,2024-08-02,16:41:54,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $244.00/Share From $275.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $244.00/Share From $275.00 by Scotiabank
BIIB,2024-08-02,18:39:24,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Wells Fargo
BIIB,2024-08-02,18:39:24,CEDFD5,Biogen Inc.,100,-0.66,price-targets,downgrade,Biogen Price Target Cut to $225.00/Share From $240.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $225.00/Share From $240.00 by Wells Fargo
BIIB,2024-08-02,19:57:05,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2024-08-02,19:57:05,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $292.00/Share From $282.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $292.00/Share From $282.00 by RBC Capital
BIIB,2024-08-05,10:23:11,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2024-08-05,10:23:11,CEDFD5,Biogen Inc.,100,-0.2,price-targets,downgrade,Biogen Price Target Cut to $285.00/Share From $288.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $285.00/Share From $288.00 by Needham
BIIB,2024-08-05,13:54:51,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $302.00/Share From $340.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $302.00/Share From $340.00 by Truist Securities
BIIB,2024-08-06,11:29:53,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Mizuho
BIIB,2024-08-06,11:29:53,CEDFD5,Biogen Inc.,100,-0.78,price-targets,downgrade,Biogen Price Target Cut to $251.00/Share From $277.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $251.00/Share From $277.00 by Mizuho
BIIB,2024-08-14,20:32:39,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen Inc.: the ""Company"") entered into a credit agreement with Bank of America, N.A.",RNS-SEC8K,Dow Jones Newswires,Biogen Files 8K - Entry Into Definitive Agreement >BIIB
BIIB,2024-08-19,07:07:33,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 2Q 2024 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 2Q 2024 (BIIB)"
BIIB,2024-08-22,09:59:48,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Score U.K. Nod for Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,"Eisai, Biogen Score U.K. Nod for Alzheimer's Drug -- market Talk"
BIIB,2024-09-03,17:03:29,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 431 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 431 Of Biogen Inc >BIIB
BIIB,2024-09-05,11:54:20,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 431 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 431 Of Biogen Inc >BIIB
BIIB,2024-09-11,12:00:11,CEDFD5,Biogen Inc.,100,0.0,products-services,,Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial,PRESS-RELEASE,PR Newswire,"Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE(TM) (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy"
BIIB,2024-09-11,12:00:11,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Bio-Thera Solutions, Ltd. today announced, in collaboration with Biogen",PRESS-RELEASE,PR Newswire,"Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE(TM) (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy"
BIIB,2024-09-11,12:00:11,CEDFD5,Biogen Inc.,100,0.39,products-services,,"Bio-Thera Solutions, Ltd. and Biogen entered into a commercialization and license agreement",PRESS-RELEASE,PR Newswire,"Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE(TM) (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy"
BIIB,2024-09-11,12:00:52,CEDFD5,Biogen Inc.,100,0.0,products-services,,Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial,NEWS-FLASH,Dow Jones Newswires,"Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE (BAT1806/BIIB800), Approved Biosimilar Referencing Tocilizumab in Arthritis Research & Therapy"
BIIB,2024-09-12,11:30:00,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Board Appoints Two New Independent Directors,PRESS-RELEASE,GlobeNewswire,Biogen Board Appoints Two New Independent Directors
BIIB,2024-09-12,11:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Board Appoints Two New Independent Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Board Appoints Two New Independent Directors
BIIB,2024-09-12,11:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Board Appoints Two New Independent Directors,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Board Appoints Two New Independent Directors
BIIB,2024-09-12,11:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Board Appoints Two New Independent Directors,FULL-ARTICLE,Dow Jones Newswires,Biogen Board Appoints Two New Independent Directors
BIIB,2024-09-12,11:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Board Appoints Two New Independent Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Board Appoints Two New Independent Directors
BIIB,2024-09-12,11:30:11,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Two New Independent Directors,NEWS-FLASH,Dow Jones Newswires,Biogen Appoints Two New Independent Directors >BIIB
BIIB,2024-09-12,11:31:13,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,"Biogen Names Lloyd Minor, Menelas Pangalos to Board",NEWS-FLASH,Dow Jones Newswires,"Biogen Names Lloyd Minor, Menelas Pangalos to Board >BIIB"
BIIB,2024-09-12,20:36:20,CEDFD5,Biogen Inc.,94,0.84,products-services,positive,Biogen's litifilimab has shown promise in its Phase II clinical trial,PRESS-RELEASE,GlobeNewswire,US Rheumatologists Believe Biogen's Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
BIIB,2024-09-17,13:38:24,CEDFD5,Biogen Inc.,99,0.65,products-services,,Health Canada has accepted for priority review its New Drug Submission (NDS) for omaveloxolone,PRESS-RELEASE,Canadian News Wire,Biogen's New Drug Submission for Omaveloxolone Accepted for Priority Review by Health Canada for the Treatment of Friedreich's Ataxia
BIIB,2024-09-17,13:38:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,Canadian News Wire,Biogen's New Drug Submission for Omaveloxolone Accepted for Priority Review by Health Canada for the Treatment of Friedreich's Ataxia
BIIB,2024-09-20,12:00:02,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Aflibercept,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-09-20,12:00:02,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-09-20,12:00:02,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Aflibercept,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-09-20,12:00:02,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-09-23,14:04:32,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2024-09-23,14:04:32,CEDFD5,Biogen Inc.,100,-0.4,price-targets,downgrade,Biogen Price Target Cut to $205.00/Share From $210.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $205.00/Share From $210.00 by Wedbush
BIIB,2024-09-24,05:00:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Ucb and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,GlobeNewswire,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between UCB and Biogen,PRESS-RELEASE,GlobeNewswire,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Ucb and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,Dow Jones Newswires,Press Release: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between UCB and Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Ucb and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,Dow Jones Newswires,Press Release: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between UCB and Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Ucb and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,DJ Global Press Release Wire,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between UCB and Biogen,PRESS-RELEASE,DJ Global Press Release Wire,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Ucb and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol,FULL-ARTICLE,Dow Jones Newswires,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between UCB and Biogen,FULL-ARTICLE,Dow Jones Newswires,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:08:27,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus,NEWS-FLASH,Dow Jones Newswires,"UCB, Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus"
BIIB,2024-09-24,10:41:49,CEDFD5,Biogen Inc.,93,0.49,partnerships,,Biogen and Belgium's UCB have been working together since,FULL-ARTICLE,Dow Jones Newswires,"Biogen, UCB Post Positive Phase 3 Study Results in Systemic Lupus Erythematosus"
BIIB,2024-09-24,11:18:55,CEDFD5,Biogen Inc.,95,0.41,products-services,start,Biogen (BIIB) said they would initiate a second Phase 3 trial,FULL-ARTICLE,MarketWatch,MW Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
BIIB,2024-09-24,15:04:22,CEDFD5,Biogen Inc.,95,0.41,products-services,start,Biogen (BIIB) said they would initiate a second Phase 3 trial,FULL-ARTICLE,MarketWatch,MW Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
BIIB,2024-09-26,11:01:12,CEDFD5,Biogen Inc.,100,0.49,partnerships,,The Collaboration With Biogen on,NEWS-FLASH,Dow Jones Newswires,Sage Therapeutics Announces Discontinuation of the Collaboration With Biogen on the SAGE-324 Program
BIIB,2024-09-26,11:28:08,CEDFD5,Biogen Inc.,100,-0.43,products-services,terminated,"Sage Therapeutics, Biogen End Licensing Agreement",FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen End Licensing Agreement for Tremor Drug"
BIIB,2024-10-03,19:00:53,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by UBS
BIIB,2024-10-03,19:00:53,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $202.00/Share From $234.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $202.00/Share From $234.00 by UBS
BIIB,2024-10-04,14:57:45,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2024-10-04,14:57:45,CEDFD5,Biogen Inc.,100,-0.72,price-targets,downgrade,Biogen Price Target Cut to $269.00/Share From $292.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $269.00/Share From $292.00 by RBC Capital
BIIB,2024-10-07,21:31:04,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen reported encouraging topline findings from the Phase III,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:04,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen are launching a second Phase 3 trial of dapirolizumab pegol,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:04,CEDFD5,Biogen Inc.,100,0.65,revenues,up,Biogen Inc.: Peak Sales,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:25,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen reported encouraging topline findings from the Phase III,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:25,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen are launching a second Phase 3 trial of dapirolizumab pegol,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:25,CEDFD5,Biogen Inc.,100,0.65,revenues,up,Biogen Inc.: Peak Sales,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:25,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: The Positive Topline Results From Phase III Study,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight -2-
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Data from the clinical development program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen plans to initiate Phase 3 trials for felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired Human Immunology Biosciences (HI-Bio) in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Data from the clinical development program,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen plans to initiate Phase 3 trials for felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired Human Immunology Biosciences (HI-Bio) in July 2024,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen plans to initiate Phase 3 trials for felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired Human Immunology Biosciences (HI-Bio) in July 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Data from the clinical development program,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen plans to initiate Phase 3 trials for felzartamab,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired Human Immunology Biosciences (HI-Bio) in July 2024,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Data from the clinical development program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen plans to initiate Phase 3 trials for felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired Human Immunology Biosciences (HI-Bio) in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:07,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,NEWS-FLASH,Dow Jones Newswires,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients >BIIB
BIIB,2024-10-09,11:32:18,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Gets FDA Breakthrough Therapy Designation for Felzartamab,NEWS-FLASH,Dow Jones Newswires,Biogen Gets FDA Breakthrough Therapy Designation for Felzartamab for Antibody-Mediated Rejection in Kidney Transplant Recipients >BIIB
BIIB,2024-10-09,11:50:21,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen is planning to initiate Phase 3 trials in 2025,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Bounces After Treatment For Kidney-Transplant Rejection Gets FDA Boost -- MarketWatch
BIIB,2024-10-09,11:50:21,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen is planning to initiate Phase 3 trials in 2025,FULL-ARTICLE,MarketWatch,MW Biogen's stock bounces after treatment for kidney-transplant rejection gets FDA boost
BIIB,2024-10-09,11:59:22,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Gets FDA Breakthrough Designation,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,11:59:22,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen said it won Food and Drug Administration breakthrough-therapy designation,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,11:59:22,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen's July acquisition of Human Immunology Biosciences,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,11:59:22,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen said it plans to initiate Phase 3 studies for felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,12:14:22,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Gets FDA Breakthrough Designation,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,12:14:22,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen said it won Food and Drug Administration breakthrough-therapy designation,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,12:14:22,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen's July acquisition of Human Immunology Biosciences,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,12:14:22,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen said it plans to initiate Phase 3 studies for felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,12:32:17,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen is planning to initiate Phase 3 trials for felzartamab in 2025,FULL-ARTICLE,MarketWatch,MW Biogen's stock bounces after FDA boost on kidney-transplant rejection treatment
BIIB,2024-10-09,12:32:17,CEDFD5,Biogen Inc.,100,-0.58,products-services,denied,Regulators reject Biogen's treatment for Alzheimer's disease,FULL-ARTICLE,MarketWatch,MW Biogen's stock bounces after FDA boost on kidney-transplant rejection treatment
BIIB,2024-10-17,14:04:04,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by BMO Capital
BIIB,2024-10-17,14:04:04,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $230.00/Share From $260.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $230.00/Share From $260.00 by BMO Capital
BIIB,2024-10-22,11:30:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-22,11:30:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,GlobeNewswire,Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-22,11:30:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-22,11:30:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-27,00:15:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy,PRESS-RELEASE,GlobeNewswire,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,GlobeNewswire,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy,FULL-ARTICLE,Dow Jones Newswires,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-28,12:30:30,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,Biogen Chief Fincl Officer Michael McDonnell to Retire in February,NEWS-FLASH,Dow Jones Newswires,Biogen Chief Fincl Officer Michael McDonnell to Retire in February >BIIB
BIIB,2024-10-28,12:31:17,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen: Robin Kramer to Succeed McDonnell as Chief Financial Officer,NEWS-FLASH,Dow Jones Newswires,Biogen: Robin Kramer to Succeed McDonnell as Chief Financial Officer >BIIB
BIIB,2024-10-28,12:42:42,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,Biogen Chief Financial Officer Michael McDonnell to Retire in February,FULL-ARTICLE,Dow Jones Newswires,Biogen Chief Financial Officer Michael McDonnell to Retire in February
BIIB,2024-10-28,12:42:42,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,"Biogen's top finance executive, Michael McDonnell, plans to retire",FULL-ARTICLE,Dow Jones Newswires,Biogen Chief Financial Officer Michael McDonnell to Retire in February
BIIB,2024-10-29,12:00:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer"
BIIB,2024-10-29,12:00:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer",FULL-ARTICLE,Dow Jones Newswires,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer"
BIIB,2024-10-29,12:00:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer"
BIIB,2024-10-29,12:00:04,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer"
BIIB,2024-10-29,12:00:04,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer",PRESS-RELEASE,GlobeNewswire,"(PMZN) Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer"
BIIB,2024-10-29,12:01:28,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Daniel Quirk Chief Medical Officer >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Names Daniel Quirk Chief Medical Officer >BIIB
BIIB,2024-10-29,22:00:23,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: This collaboration with Neomorph reflects the approach we want to,PRESS-RELEASE,GlobeNewswire,"Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases"
BIIB,2024-10-29,22:00:24,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: This collaboration with Neomorph reflects the approach we want to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases"
BIIB,2024-10-29,22:00:24,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: This collaboration with Neomorph reflects the approach we want to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Neomorph Announce Multi-Target Research Collaborationto Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases"
BIIB,2024-10-29,22:00:24,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: This collaboration with Neomorph reflects the approach we want to,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Neomorph Announce Multi-Target Research Collaborationto Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases"
BIIB,2024-10-30,01:00:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc. (NASDAQ: BIIB)",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-10-30,01:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-10-30,10:56:14,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,3Q EPS $2.66 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q EPS $2.66 >BIIB
BIIB,2024-10-30,10:56:14,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $4.08,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $4.08 >BIIB
BIIB,2024-10-30,10:56:14,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Net $388.5M,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Net $388.5M >BIIB
BIIB,2024-10-30,10:56:14,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.47B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.47B >BIIB
BIIB,2024-10-30,10:59:00,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises Full-Year 2024 Financial Guidance >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Raises Full-Year 2024 Financial Guidance >BIIB
BIIB,2024-10-30,11:00:02,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises 2024 View To Adj EPS $16.10,NEWS-FLASH,Dow Jones Newswires,Biogen Raises 2024 View To Adj EPS $16.10-Adj EPS $16.60 >BIIB
BIIB,2024-10-30,11:01:23,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Still Sees 2024 Total Revenue Down,NEWS-FLASH,Dow Jones Newswires,Biogen Still Sees 2024 Total Revenue Down Low-Single Digits >BIIB
BIIB,2024-10-30,11:10:21,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen had EPS of $4.08,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Pops After Earnings Top Estimates And Company Raises Guidance -- MarketWatch
BIIB,2024-10-30,11:10:21,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raised its full-year guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Pops After Earnings Top Estimates And Company Raises Guidance -- MarketWatch
BIIB,2024-10-30,11:10:21,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen had EPS of $4.08,FULL-ARTICLE,MarketWatch,MW Biogen's stock pops after earnings top estimates and company raises guidance
BIIB,2024-10-30,11:10:21,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raised its full-year guidance,FULL-ARTICLE,MarketWatch,MW Biogen's stock pops after earnings top estimates and company raises guidance
BIIB,2024-10-30,11:28:36,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Earnings Top Views,FULL-ARTICLE,Dow Jones Newswires,Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum -- IBD
BIIB,2024-10-30,11:28:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen to earn $3.77 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum -- IBD
BIIB,2024-10-30,11:28:36,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.: the company reported $2.53 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum -- IBD
BIIB,2024-10-30,11:47:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen had EPS of $4.08,FULL-ARTICLE,MarketWatch,MW Biogen's stock pops after earnings top estimates and company raises guidance
BIIB,2024-10-30,11:47:36,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raised its full-year guidance,FULL-ARTICLE,MarketWatch,MW Biogen's stock pops after earnings top estimates and company raises guidance
BIIB,2024-10-30,14:15:09,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen earned $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough. -- IBD
BIIB,2024-10-30,15:34:27,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen had EPS of $4.08,FULL-ARTICLE,MarketWatch,MW Biogen's stock hit by soft sales of Alzheimer's treatment
BIIB,2024-10-30,15:34:27,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raised its full-year guidance,FULL-ARTICLE,MarketWatch,MW Biogen's stock hit by soft sales of Alzheimer's treatment
BIIB,2024-10-30,20:28:07,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen earned $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough. -- IBD
BIIB,2024-10-30,20:46:45,CEDFD5,Biogen Inc.,99,0.0,labor-issues,,Biogen Inc.: the Company's annual bonus plan,RNS-SEC8K,Dow Jones Newswires,"Biogen Files 8K - Director, Officer or Compensation Filing >BIIB"
BIIB,2024-10-30,20:46:45,CEDFD5,Biogen Inc.,94,-0.49,labor-issues,,"Biogen Inc.: Mr. McDonnell will retire from the Company on February 28, 2025",RNS-SEC8K,Dow Jones Newswires,Biogen Files 8K - Regulation FD >BIIB
BIIB,2024-10-31,10:24:26,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Equal-Weight From Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Equal-Weight From Overweight by Morgan Stanley
BIIB,2024-10-31,10:24:26,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $204.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $204.00/Share From $285.00 by Morgan Stanley
BIIB,2024-10-31,17:07:17,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by TD Cowen
BIIB,2024-10-31,17:07:17,CEDFD5,Biogen Inc.,100,-0.74,price-targets,downgrade,Biogen Price Target Cut to $275.00/Share From $300.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $275.00/Share From $300.00 by TD Cowen
BIIB,2024-10-31,18:11:47,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2024-10-31,18:11:47,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $180.00/Share From $190.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $180.00/Share From $190.00 by Barclays
BIIB,2024-10-31,18:19:47,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2024-10-31,18:19:47,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $255.00/Share From $270.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $255.00/Share From $270.00 by Oppenheimer
BIIB,2024-11-04,14:47:16,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by JP Morgan
BIIB,2024-11-04,14:47:16,CEDFD5,Biogen Inc.,100,-0.56,price-targets,downgrade,Biogen Price Target Cut to $210.00/Share From $220.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $210.00/Share From $220.00 by JP Morgan
BIIB,2024-11-04,21:40:07,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Grogan Acquires 491 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Grogan Acquires 491 Of Biogen Inc >BIIB
BIIB,2024-11-14,13:04:54,CEDFD5,Biogen Inc.,100,0.01,analyst-ratings,neutral,Biogen Initiated at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Neutral by Citigroup
BIIB,2024-11-14,13:04:54,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $190.00/Share by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $190.00/Share by Citigroup
BIIB,2024-11-15,10:25:25,CEDFD5,Biogen Inc.,100,0.01,analyst-ratings,neutral,Biogen Initiated at Peer Perform by Wolfe Research,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Peer Perform by Wolfe Research
BIIB,2024-11-15,12:28:16,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Baird
BIIB,2024-11-15,12:28:16,CEDFD5,Biogen Inc.,100,0.38,price-targets,upgrade,Biogen Price Target Raised to $300.00/Share From $294.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $300.00/Share From $294.00 by Baird
BIIB,2024-11-18,10:19:02,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Hold From Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Hold From Buy by Needham
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc.: our partnership with Samsung Bioepis, with",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc.: our partnership with Samsung Bioepis, with",PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-19,08:07:14,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 3Q 2024 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 3Q 2024 (BIIB)"
BIIB,2024-11-21,13:18:59,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Mizuho
BIIB,2024-11-21,13:18:59,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $207.00/Share From $251.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $207.00/Share From $251.00 by Mizuho
BIIB,2024-12-04,23:34:38,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen: Mexico Approves Leqembi,NEWS-FLASH,Dow Jones Newswires,"Eisai, Biogen: Mexico Approves Leqembi for Treatment of Early Alzheimer's Disease"
BIIB,2024-12-05,13:00:05,CEDFD5,Biogen Inc.,99,0.0,products-services,,Partner Biogen is conducting the global Phase 2b LUMA study of BIIB122,PRESS-RELEASE,GlobeNewswire,"Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease"
BIIB,2024-12-05,13:00:05,CEDFD5,Biogen Inc.,99,0.0,products-services,,Partner Biogen is conducting the global Phase 2b LUMA study of BIIB122,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease"
BIIB,2024-12-09,11:51:55,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Hold From Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Hold From Buy by Jefferies
BIIB,2024-12-09,11:51:55,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $180.00/Share From $250.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $180.00/Share From $250.00 by Jefferies
BIIB,2024-12-09,15:39:24,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 110 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 110 Of Biogen Inc >BIIB
BIIB,2024-12-09,21:57:28,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 181 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 181 Of Biogen Inc >BIIB
BIIB,2024-12-09,22:00:13,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 110 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 110 Of Biogen Inc >BIIB
BIIB,2024-12-10,12:49:07,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $178.00/Share by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $178.00/Share by B of A Securities
BIIB,2024-12-20,10:16:03,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Market Perform From Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Market Perform From Outperform by BMO Capital
BIIB,2024-12-20,10:16:03,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $164.00/Share From $230.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $164.00/Share From $230.00 by BMO Capital
BIIB,2024-01-11,13:23:37,CEDFD5,Biogen Inc.,100,-0.46,partnerships,terminated,Acorda Therapeutics: Biogen Ending Fampyra Collaboration,FULL-ARTICLE,Dow Jones Newswires,Acorda Therapeutics: Biogen Ending Fampyra Collaboration
BIIB,2024-01-24,11:49:50,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Neutral From Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Neutral From Buy by UBS
BIIB,2024-01-24,11:49:50,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $276.00/Share by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $276.00/Share by UBS
BIIB,2024-01-25,10:01:12,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Neutral From Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Neutral From Buy by UBS
BIIB,2024-01-25,10:01:12,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $276.00/Share From $311.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $276.00/Share From $311.00 by UBS
BIIB,2024-01-31,12:30:00,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:00,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda accelerated approval of ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda accelerated approval of ADUHELM,FULL-ARTICLE,Dow Jones Newswires,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:54:26,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen halts development of controversial Alzheimer's drug,FULL-ARTICLE,MarketWatch,MW Biogen halts development of controversial Alzheimer's drug
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda accelerated approval of ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,PRESS-RELEASE,GlobeNewswire,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda accelerated approval of ADUHELM,PRESS-RELEASE,GlobeNewswire,Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:30:01,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda accelerated approval of ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Realign Resources for Alzheimer's Disease Franchise
BIIB,2024-01-31,12:36:02,CEDFD5,Biogen Inc.,100,0.34,products-services,,Biogen Licensed Aducanumab From Neurimmune,NEWS-FLASH,Dow Jones Newswires,"Biogen Licensed Aducanumab From Neurimmune and Has Terminated That License, the Rights to Aducanumab Will Revert to Neurimmune >BIIB"
BIIB,2024-01-31,12:54:26,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen Halts Development Of Controversial Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Halts Development Of Controversial Alzheimer's Drug -- MarketWatch
BIIB,2024-01-31,13:55:53,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen Ends Development of Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Ends Development of Alzheimer's Drug Aduhelm -- Barrons.com
BIIB,2024-01-31,13:55:53,CEDFD5,Biogen Inc.,100,0.71,products-services,,Aduhelm received accelerated approval from the U.S. Food and Drug Administration in June 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen Ends Development of Alzheimer's Drug Aduhelm -- Barrons.com
BIIB,2024-01-31,14:00:03,CEDFD5,Biogen Inc.,99,0.71,products-services,,Fda granted Aduhelm accelerated approval,FULL-ARTICLE,MarketWatch,MW Biogen drops controversial Alzheimer's drug
BIIB,2024-01-31,16:02:19,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen is pulling the plug on its ill-fated Alzheimer's disease drug Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Quits Controversial Alzheimer's Drug Aduhelm -- WSJ
BIIB,2024-02-01,07:03:43,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen is pulling the plug on its ill-fated Alzheimer's disease drug Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Quits Controversial Alzheimer's Drug Aduhelm ---- By Jennifer Calfas and Colin Kellaher
BIIB,2024-02-01,07:32:09,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen is pulling the plug on its ill-fated Alzheimer's disease drug Aduhelm,FULL-ARTICLE,Wall Street Journal,Biogen Quits Controversial Alzheimer's Drug Aduhelm -- WSJ
BIIB,2024-02-02,15:48:31,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 634 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 634 Of Biogen Inc >BIIB
BIIB,2024-02-05,23:40:33,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 634 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 634 Of Biogen Inc >BIIB
BIIB,2024-02-09,15:00:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Aptar Signs Enterprise Agreement with Biogen,PRESS-RELEASE,Business Wire,Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
BIIB,2024-02-09,15:00:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Aptar will further collaborate to potentially develop and bring to market new digital,PRESS-RELEASE,Business Wire,Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
BIIB,2024-02-09,15:00:24,CEDFD5,Biogen Inc.,100,0.39,products-services,,Aptar Signs Enterprise Agreement With Biogen,NEWS-FLASH,Dow Jones Newswires,Aptar Signs Enterprise Agreement With Biogen to Operate and Develop Digital Health Solutions
BIIB,2024-02-09,15:00:35,CEDFD5,Biogen Inc.,100,0.39,products-services,,Aptar Signs Enterprise Agreement with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
BIIB,2024-02-09,15:00:35,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Aptar will further collaborate to potentially develop and bring to market new digital,PRESS-RELEASE,Dow Jones Newswires,Press Release: Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
BIIB,2024-02-10,01:02:12,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Murphy Acquires 1,463 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Murphy Acquires 1,463 Of Biogen Inc >BIIB"
BIIB,2024-02-10,01:04:35,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 1,570 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 1,570 Of Biogen Inc >BIIB"
BIIB,2024-02-10,01:07:29,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 535 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 535 Of Biogen Inc >BIIB
BIIB,2024-02-10,01:12:05,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Izzar Acquires 1,422 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Acquires 1,422 Of Biogen Inc >BIIB"
BIIB,2024-02-10,01:16:00,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Gregory Acquires 1,137 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Acquires 1,137 Of Biogen Inc >BIIB"
BIIB,2024-02-10,01:17:47,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Alexander Acquires 1,535 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Alexander Acquires 1,535 Of Biogen Inc >BIIB"
BIIB,2024-02-12,16:12:32,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 419 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 419 Of Biogen Inc >BIIB
BIIB,2024-02-12,21:06:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,GlobeNewswire,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: SKYCLARYS is also approved for use in the United States,PRESS-RELEASE,GlobeNewswire,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: SKYCLARYS is also approved for use in the United States,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: SKYCLARYS is also approved for use in the United States,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: SKYCLARYS is also approved for use in the United States,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",FULL-ARTICLE,Dow Jones Newswires,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Skyclarys is also approved for use in the United States,FULL-ARTICLE,Dow Jones Newswires,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:06:16,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS (omaveloxolone), the First",NEWS-FLASH,Dow Jones Newswires,"Biogen Received European Commission Approval for SKYCLARYS (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia"
BIIB,2024-02-12,21:31:52,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission,FULL-ARTICLE,Dow Jones Newswires,Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission
BIIB,2024-02-12,21:46:52,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission,FULL-ARTICLE,Dow Jones Newswires,Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission
BIIB,2024-02-13,12:08:18,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Adj EPS $2.95,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Adj EPS $2.95 >BIIB
BIIB,2024-02-13,12:09:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.4B >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 4Q Rev $2.4B >BIIB
BIIB,2024-02-13,12:09:55,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $1.71 >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 4Q EPS $1.71 >BIIB
BIIB,2024-02-13,12:10:21,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY24 Adj EPS $15,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY24 Adj EPS $15-Adj EPS $16 >BIIB
BIIB,2024-02-13,12:11:00,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Skyclarys Revenue $56M >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 4Q Skyclarys Revenue $56M >BIIB
BIIB,2024-02-13,12:21:57,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen's quarterly results miss expectations,FULL-ARTICLE,MarketWatch,MW Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,12:21:57,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen expects adjusted earnings per share of $15.00 to $16.00,FULL-ARTICLE,MarketWatch,MW Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,12:21:57,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,"Biogen Inc.: the company said Tuesday, and anticipates total revenue to decline",FULL-ARTICLE,MarketWatch,MW Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,12:36:31,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Biogen's Revenue Stung By Softening,FULL-ARTICLE,Dow Jones Newswires,Biogen's Revenue Stung By Softening Sales Of Multiple Sclerosis Products -- Market Talk
BIIB,2024-02-13,12:36:32,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Biogen's Revenue Stung By Softening,FULL-ARTICLE,Dow Jones Newswires,Biogen's Revenue Stung By Softening Sales Of Multiple Sclerosis Products -- Market Talk
BIIB,2024-02-13,12:37:02,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen Inc.: the company reported fourth-quarter results that fell short of Wall Street expectations,FULL-ARTICLE,MarketWatch,MW Biogen's stock slides as quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,12:37:02,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen expects adjusted earnings per share of $15.00 to $16.00,FULL-ARTICLE,MarketWatch,MW Biogen's stock slides as quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,12:37:02,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,"Biogen Inc.: the company said Tuesday, and anticipates total revenue to decline",FULL-ARTICLE,MarketWatch,MW Biogen's stock slides as quarterly results miss expectations amid slow launch of Alzheimer's treatment
BIIB,2024-02-13,13:46:45,CEDFD5,Biogen Inc.,100,0.0,earnings,,Factset expected Biogen to earn $3.18 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit -- IBD
BIIB,2024-02-13,13:46:45,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen earned $4.05 a share,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit -- IBD
BIIB,2024-02-13,13:46:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.: The company also expects revenue to fall,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit -- IBD
BIIB,2024-02-13,15:15:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's soft 2024 guidance,FULL-ARTICLE,Dow Jones Newswires,"Despite New Alzheimer's Therapy, Biogen Is a Show-Me Story for Wall Street -- WSJ"
BIIB,2024-02-13,15:28:44,CEDFD5,Biogen Inc.,99,-0.75,revenues,down,Biogen now expects full-year sales to decline,FULL-ARTICLE,Dow Jones Newswires,Biogen's Turnaround Is Still Waiting In The Wings As Aduhelm Pressures Continue -- IBD
BIIB,2024-02-13,15:28:44,CEDFD5,Biogen Inc.,99,-0.36,revenues,down,Tecfidera sales fell nearly 18%,FULL-ARTICLE,Dow Jones Newswires,Biogen's Turnaround Is Still Waiting In The Wings As Aduhelm Pressures Continue -- IBD
BIIB,2024-02-13,15:28:44,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: The company also expects sales to fall,FULL-ARTICLE,Dow Jones Newswires,Biogen's Turnaround Is Still Waiting In The Wings As Aduhelm Pressures Continue -- IBD
BIIB,2024-02-13,15:50:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen said Tuesday that its non-GAAP diluted earnings,FULL-ARTICLE,Dow Jones Newswires,Biogen Promised a Return to Growth. Why the Stock Is Dropping. -- Barrons.com
BIIB,2024-02-13,15:50:50,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen Inc.: The company reported fourth-quarter non-GAAP diluted earnings of $2.95 a share,FULL-ARTICLE,Dow Jones Newswires,Biogen Promised a Return to Growth. Why the Stock Is Dropping. -- Barrons.com
BIIB,2024-02-13,15:50:50,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen developed in partnership with Eisai,FULL-ARTICLE,Dow Jones Newswires,Biogen Promised a Return to Growth. Why the Stock Is Dropping. -- Barrons.com
BIIB,2024-02-13,23:02:00,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Alexander Acquires 1,637 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Alexander Acquires 1,637 Of Biogen Inc >BIIB"
BIIB,2024-02-13,23:04:58,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 588 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 588 Of Biogen Inc >BIIB
BIIB,2024-02-13,23:06:01,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Izzar Acquires 1,070 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Acquires 1,070 Of Biogen Inc >BIIB"
BIIB,2024-02-13,23:06:13,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Murphy Acquires 1,511 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Murphy Acquires 1,511 Of Biogen Inc >BIIB"
BIIB,2024-02-13,23:06:18,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 1,826 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 1,826 Of Biogen Inc >BIIB"
BIIB,2024-02-13,23:08:05,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 419 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 419 Of Biogen Inc >BIIB
BIIB,2024-02-13,23:15:08,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Gregory Acquires 1,524 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Acquires 1,524 Of Biogen Inc >BIIB"
BIIB,2024-02-14,07:03:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's soft 2024 guidance,FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street: Despite New Alzheimer's Therapy, Biogen Is a Show-Me Story for Wall Street ---- By David Wainer"
BIIB,2024-02-14,11:06:40,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2024-02-14,11:06:40,CEDFD5,Biogen Inc.,100,-0.32,price-targets,downgrade,Biogen Price Target Cut to $300.00/Share From $305.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $300.00/Share From $305.00 by Needham
BIIB,2024-02-14,12:10:20,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Equal-Weight From Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Equal-Weight From Overweight by Wells Fargo
BIIB,2024-02-14,12:10:20,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $240.00/Share From $315.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $240.00/Share From $315.00 by Wells Fargo
BIIB,2024-02-14,14:55:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2024-02-14,14:55:01,CEDFD5,Biogen Inc.,100,-0.52,price-targets,downgrade,Biogen Price Target Cut to $364.00/Share From $379.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $364.00/Share From $379.00 by RBC Capital
BIIB,2024-02-14,16:14:41,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2024-02-14,16:14:41,CEDFD5,Biogen Inc.,100,-0.32,price-targets,downgrade,Biogen Price Target Cut to $290.00/Share From $295.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $290.00/Share From $295.00 by Oppenheimer
BIIB,2024-02-14,16:59:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by BMO Capital
BIIB,2024-02-14,16:59:01,CEDFD5,Biogen Inc.,100,-0.48,price-targets,downgrade,Biogen Price Target Cut to $285.00/Share From $295.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $285.00/Share From $295.00 by BMO Capital
BIIB,2024-02-14,17:36:21,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Piper Sandler
BIIB,2024-02-14,17:36:21,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $325.00/Share From $350.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $325.00/Share From $350.00 by Piper Sandler
BIIB,2024-02-14,19:13:41,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Baird
BIIB,2024-02-14,19:13:41,CEDFD5,Biogen Inc.,100,-0.6,price-targets,downgrade,Biogen Price Target Cut to $316.00/Share From $333.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $316.00/Share From $333.00 by Baird
BIIB,2024-02-16,18:36:45,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by UBS
BIIB,2024-02-16,18:36:45,CEDFD5,Biogen Inc.,100,-0.78,price-targets,downgrade,Biogen Price Target Cut to $250.00/Share From $276.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $250.00/Share From $276.00 by UBS
BIIB,2024-02-19,08:05:46,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Reata Pharmaceuticals Inc Cl, Inst Holders, 4Q 2023 (RETA)",RNS-SEC13F,Dow Jones Newswires,"Reata Pharmaceuticals  Inc Cl, Inst Holders, 4Q 2023 (RETA)"
BIIB,2024-02-19,08:08:08,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2023 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2023 (BIIB)"
BIIB,2024-02-20,15:05:34,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2024-02-20,15:05:34,CEDFD5,Biogen Inc.,100,-0.32,price-targets,downgrade,Biogen Price Target Cut to $305.00/Share From $310.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $305.00/Share From $310.00 by Canaccord Genuity
BIIB,2024-02-21,02:15:46,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Dir Rowinsky Buys 455 Of Biogen Inc >BIIB,TABULAR-MATERIAL,Dow Jones Newswires,Dir Rowinsky Buys 455 Of Biogen Inc >BIIB
BIIB,2024-02-21,15:27:32,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 108 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 108 Of Biogen Inc >BIIB
BIIB,2024-02-22,02:28:49,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 108 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 108 Of Biogen Inc >BIIB
BIIB,2024-02-22,02:29:38,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 650 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 650 Of Biogen Inc >BIIB
BIIB,2024-02-22,02:30:57,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 3,282 Of Biogen Inc >BIIB",TABULAR-MATERIAL,Dow Jones Newswires,"CFO McDonnell Acquires 3,282 Of Biogen Inc >BIIB"
BIIB,2024-02-22,02:32:36,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 949 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 949 Of Biogen Inc >BIIB
BIIB,2024-02-22,02:36:09,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Izzar Acquires 1,065 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Acquires 1,065 Of Biogen Inc >BIIB"
BIIB,2024-02-22,02:37:23,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Gregory Acquires 2,440 Of Biogen Inc >BIIB",TABULAR-MATERIAL,Dow Jones Newswires,"VP Gregory Acquires 2,440 Of Biogen Inc >BIIB"
BIIB,2024-02-22,02:41:21,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Alexander Acquires 2,600 Of Biogen Inc >BIIB",TABULAR-MATERIAL,Dow Jones Newswires,"VP Alexander Acquires 2,600 Of Biogen Inc >BIIB"
BIIB,2024-02-22,15:18:35,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 262 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 262 Of Biogen Inc >BIIB
BIIB,2024-02-22,16:35:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Mizuho
BIIB,2024-02-22,16:35:29,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $277.00/Share From $355.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $277.00/Share From $355.00 by Mizuho
BIIB,2024-02-22,20:04:29,CEDFD5,Biogen Inc.,93,0.52,products-services,,The debut of Aduhelm from Biogen,PRESS-RELEASE,GlobeNewswire,"Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen's Leqembi, According to Spherix Global Insights Neurologist Survey"
BIIB,2024-02-23,12:00:26,CEDFD5,Biogen Inc.,100,0.52,products-services,,"Biogen Inc.: Press Release: Biogen's QALSODY(R)(tofersen), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen's QALSODY(R)(tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP"
BIIB,2024-02-23,12:00:26,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration granted accelerated approval for QALSODY,FULL-ARTICLE,Dow Jones Newswires,"Biogen's QALSODY(R)(tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP"
BIIB,2024-02-23,12:00:27,CEDFD5,Biogen Inc.,100,0.52,products-services,,"Biogen Inc.: Press Release: Biogen's QALSODY(R) (tofersen), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen's QALSODY(R) (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP"
BIIB,2024-02-23,12:00:59,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen's Qalsody Gets Positive Opinion From CHMP,NEWS-FLASH,Dow Jones Newswires,Biogen's Qalsody Gets Positive Opinion From CHMP >BIIB
BIIB,2024-02-23,12:02:36,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Gets CHMP Positive Opinion for Qalsody,NEWS-FLASH,Dow Jones Newswires,Biogen Gets CHMP Positive Opinion for Qalsody in Adults With ALS Associated With Mutation in SOD1 Gene >BIIB
BIIB,2024-02-23,12:27:22,CEDFD5,Biogen Inc.,93,0.71,products-services,,The U.S. Food and Drug Administration granted accelerated approval to Qalsody,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets CHMP Backing for ALS Treatment Qalsody
BIIB,2024-02-24,07:30:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-02-27,00:55:53,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 262 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 262 Of Biogen Inc >BIIB
BIIB,2024-03-04,18:44:27,CEDFD5,Biogen Inc.,100,0.01,credit-ratings,affirmation,Moody's Affirms Biogen's Baa2 Ratings,NEWS-FLASH,Dow Jones Newswires,Moody's Affirms Biogen's Baa2 Ratings; Revises Outlook To Stable From Negative
BIIB,2024-03-08,15:20:48,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,"Rbc's Abrahams, who has an outperform rating on Biogen",FULL-ARTICLE,Dow Jones Newswires,Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's Treatment -- IBD
BIIB,2024-03-08,16:56:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,"Rbc's Abrahams, who has an outperform rating on Biogen",FULL-ARTICLE,Dow Jones Newswires,Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's Treatment -- IBD
BIIB,2024-03-08,21:05:10,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,"Rbc's Abrahams, who has an outperform rating on Biogen",FULL-ARTICLE,Dow Jones Newswires,Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's Treatment -- IBD
BIIB,2024-03-11,13:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Abcellera to Collaborate with Biogen to Discover Therapeutic Antibodies,PRESS-RELEASE,Business Wire,AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
BIIB,2024-03-11,13:01:20,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Abcellera to Collaborate with Biogen to Discover Therapeutic Antibodies,PRESS-RELEASE,Dow Jones Newswires,Press Release: AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
BIIB,2024-03-26,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: Indivi to Collaborate with Biogen to,PRESS-RELEASE,Business Wire,Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease
BIIB,2024-04-02,14:12:30,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 93 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 93 Of Biogen Inc >BIIB
BIIB,2024-04-04,00:12:25,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 123 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 123 Of Biogen Inc >BIIB
BIIB,2024-04-04,00:26:01,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 93 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 93 Of Biogen Inc >BIIB
BIIB,2024-04-04,13:46:35,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2024-04-04,13:46:35,CEDFD5,Biogen Inc.,100,-0.66,price-targets,downgrade,Biogen Price Target Cut to $215.00/Share From $230.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $215.00/Share From $230.00 by Barclays
BIIB,2024-04-11,12:59:31,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by JP Morgan
BIIB,2024-04-11,12:59:31,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $240.00/Share From $270.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $240.00/Share From $270.00 by JP Morgan
BIIB,2024-04-12,12:10:33,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by B of A Securities
BIIB,2024-04-12,12:10:33,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $260.00/Share From $280.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $260.00/Share From $280.00 by B of A Securities
BIIB,2024-04-17,17:06:24,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2024-04-17,17:06:24,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $213.00/Share From $245.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $213.00/Share From $245.00 by Wedbush
BIIB,2024-04-18,11:40:25,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by UBS
BIIB,2024-04-18,11:40:26,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $214.00/Share From $250.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $214.00/Share From $250.00 by UBS
BIIB,2024-04-19,15:03:28,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2024-04-19,15:03:28,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $290.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $290.00 by Oppenheimer
BIIB,2024-04-24,10:46:36,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen's sales declined 7% to $2.29 billion,FULL-ARTICLE,Dow Jones Newswires,Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? -- IBD
BIIB,2024-04-24,10:46:36,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Tysabri sales fell close to 9%,FULL-ARTICLE,Dow Jones Newswires,Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? -- IBD
BIIB,2024-04-24,10:46:36,CEDFD5,Biogen Inc.,100,0.41,revenues,up,Spinraza sales grew 1%,FULL-ARTICLE,Dow Jones Newswires,Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? -- IBD
BIIB,2024-04-24,10:49:50,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc. (BIIB) on Wednesday reported first-quarter profit that beat analysts' expectations,FULL-ARTICLE,Dow Jones Newswires,Biogen First-Quarter Profit Tops Estimates As Alzheimer's Drug Uptake Improves -- MarketWatch
BIIB,2024-04-24,10:49:50,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc. (BIIB) on Wednesday reported first-quarter profit that beat analysts' expectations,FULL-ARTICLE,MarketWatch,MW Biogen first-quarter profit tops estimates as Alzheimer's drug uptake improves
BIIB,2024-04-24,10:56:02,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.3B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.3B >BIIB
BIIB,2024-04-24,10:56:13,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $2.70 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $2.70 >BIIB
BIIB,2024-04-24,10:56:25,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $3.67,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Adj EPS $3.67 >BIIB
BIIB,2024-04-24,10:57:19,CEDFD5,Biogen Inc.,100,0.0,earnings,unchanged,Biogen Backs 2024 Adj EPS $15,NEWS-FLASH,Dow Jones Newswires,Biogen Backs 2024 Adj EPS $15-Adj EPS $16 >BIIB
BIIB,2024-04-24,11:04:02,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $2.70 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $2.70 >BIIB
BIIB,2024-04-24,11:04:02,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $3.67,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Adj EPS $3.67 >BIIB
BIIB,2024-04-24,11:04:02,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Net $393.4M,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Net $393.4M >BIIB
BIIB,2024-04-24,11:04:02,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.29B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.29B >BIIB
BIIB,2024-04-24,12:08:31,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen's stock climbs as first-quarter profit tops estimates,FULL-ARTICLE,MarketWatch,"MW Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves"
BIIB,2024-04-24,12:08:31,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,"Biogen says, but total sales fall",FULL-ARTICLE,MarketWatch,"MW Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves"
BIIB,2024-04-24,12:08:31,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: the company reported first-quarter profit,FULL-ARTICLE,MarketWatch,"MW Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves"
BIIB,2024-04-24,12:08:31,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,Its 2023 acquisition of Reata Pharmaceuticals,FULL-ARTICLE,MarketWatch,"MW Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves"
BIIB,2024-04-24,12:08:31,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen's total sales in the quarter fell short of analysts' estimates,FULL-ARTICLE,MarketWatch,"MW Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves"
BIIB,2024-04-24,12:51:25,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported first-quarter adjusted earnings of $3.67 a share,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Rises After Earnings and on Jump in Alzheimer's Drug Sales -- Barrons.com
BIIB,2024-04-24,20:20:02,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Raffat reiterated his outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Surges After Two Notable Products Walloped Sales Expectations -- IBD
BIIB,2024-04-24,20:20:02,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen's sales declined 7% to $2.29 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Surges After Two Notable Products Walloped Sales Expectations -- IBD
BIIB,2024-04-24,20:20:02,CEDFD5,Biogen Inc.,100,-0.42,revenues,down,Spinraza sales plunged 23%,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Surges After Two Notable Products Walloped Sales Expectations -- IBD
BIIB,2024-04-24,20:20:02,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Tysabri sales fell nearly 9%,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Surges After Two Notable Products Walloped Sales Expectations -- IBD
BIIB,2024-04-25,12:03:11,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2024-04-25,12:03:11,CEDFD5,Biogen Inc.,100,-0.7,price-targets,downgrade,Biogen Price Target Cut to $300.00/Share From $325.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $300.00/Share From $325.00 by HC Wainwright & Co.
BIIB,2024-04-25,12:42:11,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2024-04-25,12:42:11,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $215.00/Share From $213.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $215.00/Share From $213.00 by Wedbush
BIIB,2024-04-25,18:12:52,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2024-04-25,18:12:52,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $200.00/Share From $215.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $200.00/Share From $215.00 by Barclays
BIIB,2024-04-25,20:05:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab),PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab), a Biosimilar Referencing ROACTEMRA(R)"
BIIB,2024-04-25,20:05:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab), a Biosimilar Referencing ROACTEMRA(R)"
BIIB,2024-04-25,20:05:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab),FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives Positive CHMP Opinion for TOFIDENCE(TM) (tocilizumab), a Biosimilar Referencing ROACTEMRA(R)"
BIIB,2024-04-26,06:01:48,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Regulators approved Skyclarys for Friedreich's ataxia,FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street: For Biogen, Good Enough Will Do ---- By David Wainer"
BIIB,2024-04-26,06:32:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Regulators approved Skyclarys for Friedreich's ataxia,FULL-ARTICLE,Wall Street Journal,"Heard on the Street: For Biogen, Good Enough Will Do -- WSJ"
BIIB,2024-04-29,16:59:51,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2024-05-03,18:50:40,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HSBC,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HSBC
BIIB,2024-05-03,18:50:40,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $342.00/Share From $339.00 by HSBC,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $342.00/Share From $339.00 by HSBC
BIIB,2024-05-04,00:03:22,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Keeney Acquires 662 Of Biogen Inc >BIIB,TABULAR-MATERIAL,Dow Jones Newswires,Officer Keeney Acquires 662 Of Biogen Inc >BIIB
BIIB,2024-05-15,14:21:09,CEDFD5,Biogen Inc.,97,0.34,analyst-ratings,neutral,William Blair analyst Myles Minter kept his outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment -- IBD
BIIB,2024-05-15,20:05:41,CEDFD5,Biogen Inc.,97,0.34,analyst-ratings,neutral,William Blair analyst Myles Minter kept his outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Continues Its 24% Sprint On A Twist In Alzheimer's Treatment -- IBD
BIIB,2024-05-16,11:30:09,CEDFD5,Biogen Inc.,99,0.0,products-services,,Ionis and Biogen Announce Topline Phase 1/2 Study,PRESS-RELEASE,PR Newswire,Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
BIIB,2024-05-16,11:30:10,CEDFD5,Biogen Inc.,99,0.0,products-services,,Ionis and Biogen Announce Topline Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
BIIB,2024-05-16,11:30:14,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen and Ionis Announce Topline Phase 1/2 Study,PRESS-RELEASE,GlobeNewswire,Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
BIIB,2024-05-16,11:30:14,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen and Ionis Announce Topline Phase 1/2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
BIIB,2024-05-16,11:33:32,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen to Terminate Development of BIIB105,NEWS-FLASH,Dow Jones Newswires,"Ionis, Biogen to Terminate Development of BIIB105 Based on Topline Results From Phase 1/2 ALSpire Study >IONS"
BIIB,2024-05-16,12:05:22,CEDFD5,Biogen Inc.,98,-0.52,products-services,,Biogen have canned development of an investigational therapy,FULL-ARTICLE,Dow Jones Newswires,"Biogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis"
BIIB,2024-05-16,17:24:48,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2024-05-16,18:07:45,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen won accelerated Food and Drug Administration approval for tofersen,FULL-ARTICLE,MarketWatch,MW Biogen and Ionis Pharma shares slide as they end development of ALS treatment
BIIB,2024-05-19,07:07:54,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 1Q 2024 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 1Q 2024 (BIIB)"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen has agreed to acquire HI-Bio for $1.15 billion,FULL-ARTICLE,Dow Jones Newswires,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's previously issued 2024 guidance,FULL-ARTICLE,Dow Jones Newswires,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen has agreed to acquire HI-Bio for $1.15 billion,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's previously issued 2024 guidance,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen has agreed to acquire HI-Bio for $1.15 billion,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's previously issued 2024 guidance,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfoliowith Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen has agreed to acquire HI-Bio for $1.15 billion,PRESS-RELEASE,GlobeNewswire,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's previously issued 2024 guidance,PRESS-RELEASE,GlobeNewswire,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen has agreed to acquire HI-Bio for $1.15 billion,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's previously issued 2024 guidance,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences"
BIIB,2024-05-22,11:30:49,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen To Acquire Human Immunology Biosciences >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen To Acquire Human Immunology Biosciences >BIIB
BIIB,2024-05-22,11:33:35,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen: Agreed to Acquire HI-Bio for $1.15 B,NEWS-FLASH,Dow Jones Newswires,Biogen: Agreed to Acquire HI-Bio for $1.15 B Upfront and Up to $650 M in Potential Milestone Payments >BIIB
BIIB,2024-05-22,11:42:05,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in milestone payments
BIIB,2024-05-22,11:42:05,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen To Acquire Privately Held Human Immunology Biosciences For $1.15 Billion,FULL-ARTICLE,Dow Jones Newswires,Biogen To Acquire Privately Held Human Immunology Biosciences For $1.15 Billion Upfront And Up To $650 Million In Milestone Payments -- MarketWatch
BIIB,2024-05-22,12:03:26,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,12:03:26,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's guidance for 2024,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,12:03:26,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen's stock climbs as first-quarter profit tops estimates,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,12:31:27,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Human Immunology Biosciences for Up to $1.8 Bln,FULL-ARTICLE,Dow Jones Newswires,Biogen to Buy Human Immunology Biosciences for Up to $1.8 Bln
BIIB,2024-05-22,12:36:56,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,12:36:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's guidance for 2024,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,12:36:56,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen's stock climbs as first-quarter profit tops estimates,FULL-ARTICLE,MarketWatch,MW Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
BIIB,2024-05-22,23:30:03,CEDFD5,Biogen Inc.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Against Biogen Inc.,PRESS-RELEASE,PR Newswire,Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
BIIB,2024-05-22,23:30:03,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
BIIB,2024-05-22,23:30:03,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
BIIB,2024-05-22,23:30:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
BIIB,2024-05-22,23:30:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
BIIB,2024-05-22,23:50:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead the Biogen Class Action Lawsuit"
BIIB,2024-05-22,23:50:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead the Biogen Class Action Lawsuit"
BIIB,2024-05-23,10:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,BIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
BIIB,2024-05-23,10:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,Business Wire,BIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
BIIB,2024-05-23,16:36:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB)",PRESS-RELEASE,GlobeNewswire,"Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB)"
BIIB,2024-05-23,16:36:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB)"
BIIB,2024-05-23,16:36:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB)"
BIIB,2024-05-23,20:56:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,PR Newswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-23,20:56:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-23,20:56:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-23,22:23:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-23,22:23:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-23,22:25:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-23,22:25:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-23,23:28:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,Business Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-23,23:28:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-23,23:32:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for fiscal year 2023,PRESS-RELEASE,Business Wire,Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-23,23:32:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai, Biogen's development partner",PRESS-RELEASE,Business Wire,Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-23,23:32:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,Business Wire,Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-23,23:32:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,Business Wire,Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-24,03:28:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,PR Newswire,"(PR) BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-24,03:28:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"(PR) BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-24,10:11:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-24,10:11:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-24,14:15:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-24,14:15:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-24,14:15:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-24,14:31:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-24,14:31:04,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-24,14:31:04,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-24,14:31:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-24,14:31:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-24,16:30:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-05-24,16:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-05-24,20:06:10,CEDFD5,Biogen Inc.,100,0.03,credit-ratings,affirmation,S&PGR Affirms Biogen's 'BBB+,NEWS-FLASH,Dow Jones Newswires,S&PGR Affirms Biogen's 'BBB+' ICR; Outlook Stable
BIIB,2024-05-24,20:06:10,CEDFD5,Biogen Inc.,100,0.03,credit-ratings,affirmation,S&PGR Affirms Biogen's 'BBB+,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Affirms Biogen's 'BBB+' ICR; Outlook Stable
BIIB,2024-05-24,20:06:10,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Inc. agreed to buy Human Immunology Biosciences for $1.15 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Affirms Biogen's 'BBB+' ICR; Outlook Stable
BIIB,2024-05-24,20:06:10,CEDFD5,Biogen Inc.,100,0.65,revenues,up,Biogen's revenue will eventually improve,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Affirms Biogen's 'BBB+' ICR; Outlook Stable
BIIB,2024-05-24,20:06:20,CEDFD5,Biogen Inc.,100,0.03,credit-ratings,affirmation,S&PGR Affirms Biogen's 'BBB+,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Affirms Biogen's 'BBB+' ICR; -2-
BIIB,2024-05-25,00:18:09,CEDFD5,Biogen Inc.,100,-0.52,legal,,Has Filed a Class Action Against Biogen Inc. (BIIB),PRESS-RELEASE,GlobeNewswire,Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
BIIB,2024-05-25,00:18:09,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
BIIB,2024-05-25,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-25,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-25,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-25,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-25,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-25,12:35:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-25,12:35:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-26,09:53:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-05-26,09:53:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-05-26,11:36:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-26,11:36:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-26,11:36:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-26,13:18:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-26,13:18:25,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-26,13:18:25,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-26,13:18:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-26,13:18:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-27,09:03:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-27,09:03:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-28,09:04:41,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-28,09:04:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-28,14:26:44,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-05-28,14:26:44,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-05-28,14:26:44,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-05-28,14:26:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-05-28,14:26:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-05-28,18:01:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-05-28,18:01:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-05-28,18:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-05-28,19:16:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-05-28,19:16:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-05-28,19:50:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-05-28,19:50:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-05-28,20:02:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR NOTICE: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-28,20:02:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR NOTICE: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-29,00:35:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,Biogen Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Against BIIB
BIIB,2024-05-29,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-29,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-29,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-29,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-29,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-05-29,01:16:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.( BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-05-29,01:16:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.( BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-05-29,09:02:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-29,09:02:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-29,09:31:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-05-29,09:31:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-05-29,11:06:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-05-29,11:17:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-29,11:17:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-29,15:31:30,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-05-29,15:31:30,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-05-29,17:04:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-29,17:04:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-29,19:16:00,CEDFD5,Biogen Inc.,100,-0.64,legal,,Biogen Inc. (Nasdaq: BIIB) Sued for Securities Fraud after,PRESS-RELEASE,GlobeNewswire,BIOGEN ALERT: BFA Law Announces Biogen Inc. (Nasdaq: BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact the Firm if You Suffered Losses
BIIB,2024-05-29,19:16:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,BIOGEN ALERT: BFA Law Announces Biogen Inc. (Nasdaq: BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact the Firm if You Suffered Losses
BIIB,2024-05-29,19:16:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,BIOGEN ALERT: BFA Law Announces Biogen Inc. (Nasdaq: BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact the Firm if You Suffered Losses
BIIB,2024-05-29,19:31:45,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-05-29,19:31:45,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-05-29,20:46:19,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,Biogen Inc. (Nasdaq: BIIB) Investors Notice: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
BIIB,2024-05-29,21:01:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-29,21:01:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-29,21:47:14,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-29,21:47:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-29,21:47:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-05-30,07:06:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-05-30,07:06:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-05-30,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,Business Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:00:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:00:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,PR Newswire,"(PR) BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"(PR) BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-05-30,08:01:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-30,08:01:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-05-30,08:42:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-05-30,08:42:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-05-30,08:50:41,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,08:50:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,09:02:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-30,09:02:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-30,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-05-30,10:36:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,10:36:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,12:19:10,CEDFD5,Biogen Inc.,100,-0.64,legal,,Biogen Inc. (BIIB) Sued for Securities Fraud after,PRESS-RELEASE,DJ Global Press Release Wire,FRAUD ALERT: Biogen Inc. (BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact BFA Law if You Suffered Losses
BIIB,2024-05-30,12:19:10,CEDFD5,Biogen Inc.,100,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,FRAUD ALERT: Biogen Inc. (BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact BFA Law if You Suffered Losses
BIIB,2024-05-30,12:19:10,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,FRAUD ALERT: Biogen Inc. (BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact BFA Law if You Suffered Losses
BIIB,2024-05-30,15:30:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,15:30:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-30,16:07:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,"Biogen Inc.: On November 8, 2023, Biogen released its third quarter 2023 financial results",PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,16:07:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,16:07:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,16:07:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,17:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,"Biogen Inc.: On November 8, 2023, Biogen released its third quarter 2023 financial results",PRESS-RELEASE,Business Wire,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,17:08:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,17:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,17:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
BIIB,2024-05-30,19:31:37,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN LEGAL DEADLINE NOTICE: BFA Law Reminds BIIB Investors About Approaching Deadline in Securities Fraud Case After Significant Stock Drops
BIIB,2024-05-30,19:31:37,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN LEGAL DEADLINE NOTICE: BFA Law Reminds BIIB Investors About Approaching Deadline in Securities Fraud Case After Significant Stock Drops
BIIB,2024-05-30,20:15:46,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-05-30,20:15:46,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-05-30,20:51:04,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for QALSODY(R) (tofersen), the First",PRESS-RELEASE,GlobeNewswire,"Biogen Receives European Commission Approval for QALSODY(R) (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:04,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for QALSODY(R) (tofersen), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for QALSODY(R) (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First",FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Qalsody is also approved for use in the United States,FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,20:51:05,CEDFD5,Biogen Inc.,100,0.71,products-services,,The U.S. Food and Drug Administration granted accelerated approval for QALSODY,FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives European Commission Approval for QALSODY(R)(tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS"
BIIB,2024-05-30,21:00:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-30,21:00:03,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-30,21:00:03,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-30,21:00:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-30,21:00:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-05-30,21:00:55,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen: Receives European Commission Approval for QALSODY,NEWS-FLASH,Dow Jones Newswires,"Biogen: Receives European Commission Approval for QALSODY Therapy to Treat Rare, Genetic Form of ALS"
BIIB,2024-05-30,21:35:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-05-30,21:35:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-05-30,23:03:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors"
BIIB,2024-05-30,23:03:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors"
BIIB,2024-05-30,23:03:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors"
BIIB,2024-05-30,23:03:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,"Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors"
BIIB,2024-05-31,09:01:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-31,09:01:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit"
BIIB,2024-05-31,09:31:39,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-31,09:31:39,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-05-31,09:33:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-05-31,09:33:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-05-31,12:24:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,LEGAL DEADLINE NOTICE: Biogen Inc. Investors are Reminded About Upcoming Deadline in Securities Action and are Encouraged to Submit Their Information
BIIB,2024-05-31,12:24:09,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,LEGAL DEADLINE NOTICE: Biogen Inc. Investors are Reminded About Upcoming Deadline in Securities Action and are Encouraged to Submit Their Information
BIIB,2024-05-31,15:42:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Biogen Inc. Sued for Securities Law Violations -- Investors Should Contact Levi & Korsinsky for More Information -- BIIB
BIIB,2024-05-31,15:46:36,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-05-31,15:46:36,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-05-31,16:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-05-31,16:31:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-31,16:31:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-05-31,19:34:46,CEDFD5,Biogen Inc.,100,-0.52,legal,,Biogen INVESTOR ALERT: Biogen Inc. (BIIB) Sued for,PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN INVESTOR ALERT: Biogen Inc. (BIIB) Sued for Securities Fraud, Contact BFA Law if You Suffered Losses"
BIIB,2024-05-31,19:34:46,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN INVESTOR ALERT: Biogen Inc. (BIIB) Sued for Securities Fraud, Contact BFA Law if You Suffered Losses"
BIIB,2024-05-31,22:03:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,Business Wire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-05-31,22:03:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-01,00:59:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIIB Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Biogen Inc. Class Action
BIIB,2024-06-01,09:33:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline
BIIB,2024-06-01,09:33:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline
BIIB,2024-06-01,11:32:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-01,11:32:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-01,11:32:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-01,16:08:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-01,16:08:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-01,16:08:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-01,16:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-01,16:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-01,16:16:03,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-01,16:16:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-01,23:04:38,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-01,23:04:38,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-02,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-06-02,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-06-02,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-06-02,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-06-02,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm"
BIIB,2024-06-02,01:57:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-02,01:57:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-02,13:51:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-02,13:51:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-02,14:00:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-02,14:00:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-02,16:24:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-02,16:24:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-02,18:25:11,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-02,18:25:11,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-03,09:02:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-03,09:02:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-03,09:22:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-03,09:22:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-03,11:33:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIIB DEADLINE ALERT: Biogen Inc. Investors who Lost Money are Reminded to Contact BFA Law before Upcoming Legal Deadline
BIIB,2024-06-03,11:33:59,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIIB DEADLINE ALERT: Biogen Inc. Investors who Lost Money are Reminded to Contact BFA Law before Upcoming Legal Deadline
BIIB,2024-06-03,12:02:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-03,12:02:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-03,15:56:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-03,15:56:12,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-03,15:56:12,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-03,15:56:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-03,15:56:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-03,18:46:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-03,18:46:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-03,20:04:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,BIOGEN 50 DAY NOTICE: Investors of Biogen Inc. (Nasdaq: BIIB) are Encouraged to Contact BFA Law Before July 2024 Deadline in Securities Fraud Class Action
BIIB,2024-06-03,18:49:29,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-03,18:49:29,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-06-03,19:00:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-03,19:00:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-03,19:06:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,"Biogen Inc.: On November 8, 2023, Biogen released its third quarter 2023 financial results",PRESS-RELEASE,Business Wire,Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-03,19:06:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-03,19:06:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-03,19:06:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-03,19:38:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Biogen Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
BIIB,2024-06-03,20:04:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,BIOGEN 50 DAY NOTICE: Investors of Biogen Inc. (Nasdaq: BIIB) are Encouraged to Contact BFA Law Before July 2024 Deadline in Securities Fraud Class Action
BIIB,2024-06-03,20:31:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-03,20:31:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-04,02:32:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,Robbins LLP Urges BIIB Investors With Large Losses to Contact the Firm for Information About the Biogen Inc. Class Action
BIIB,2024-06-04,05:42:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Lifshitz Law PLLC Announces Investigations of Ventyx Biosciences, Inc. (NASDAQ:VTYX), Biogen, Inc. (NASDAQ:BIIB), Enphase Energy, Inc. (NASDAQ:ENPH), and Fastly, Inc. (NYSE:FSLY)"
BIIB,2024-06-04,05:45:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-04,05:45:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-04,06:33:16,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-04,06:33:16,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-04,09:02:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-04,09:02:23,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-04,09:17:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-04,09:17:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-04,09:45:06,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,PR Newswire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-04,09:45:06,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-04,11:33:42,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,DEADLINE NOTICE BIOGEN (BIIB): Investors Who Lost Money are Encouraged to Contact BFA Law Before July 2024 Deadline in Securities Fraud Class Action
BIIB,2024-06-04,11:33:42,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,DEADLINE NOTICE BIOGEN (BIIB): Investors Who Lost Money are Encouraged to Contact BFA Law Before July 2024 Deadline in Securities Fraud Class Action
BIIB,2024-06-04,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,Business Wire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-04,15:00:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-04,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-04,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-04,15:36:17,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-04,15:36:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-04,16:24:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-04,16:24:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-04,16:24:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-04,17:46:26,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-04,17:46:26,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-04,18:01:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-04,18:01:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-04,19:28:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INVESTOR NOTICE: Biogen Inc. (BIIB) Shareholders are Reminded of July 2024 Deadline in Securities Action and Are Encouraged to Contact BFA Law
BIIB,2024-06-04,19:28:09,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INVESTOR NOTICE: Biogen Inc. (BIIB) Shareholders are Reminded of July 2024 Deadline in Securities Action and Are Encouraged to Contact BFA Law
BIIB,2024-06-05,09:02:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-05,09:02:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-05,09:20:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-05,09:20:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-05,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class Action - BIIB
BIIB,2024-06-05,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class Action - BIIB
BIIB,2024-06-05,11:14:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN SHAREHOLDER ALERT: Biogen Inc. (BIIB) Investors are Reminded of July 2024 Deadline in Securities Action and are Encouraged to Contact BFA Law
BIIB,2024-06-05,11:14:16,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN SHAREHOLDER ALERT: Biogen Inc. (BIIB) Investors are Reminded of July 2024 Deadline in Securities Action and are Encouraged to Contact BFA Law
BIIB,2024-06-05,11:31:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-05,11:31:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-05,14:37:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-05,14:37:19,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-05,14:37:19,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-05,14:37:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-05,14:37:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-05,15:07:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-05,15:07:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-05,15:33:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-05,15:33:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-05,15:52:34,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR DEADLINE: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-05,15:52:34,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR DEADLINE: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-05,16:02:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-05,16:02:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-05,18:05:09,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-05,18:05:09,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-05,19:26:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,UPCOMING DEADLINE ALERT: Biogen Inc. (Nasdaq: BIIB) Investors are Encouraged to Contact BFA Law About Approaching July 2024 Deadline in Securities Class Action
BIIB,2024-06-05,19:26:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,UPCOMING DEADLINE ALERT: Biogen Inc. (Nasdaq: BIIB) Investors are Encouraged to Contact BFA Law About Approaching July 2024 Deadline in Securities Class Action
BIIB,2024-06-05,19:45:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-05,19:45:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-06,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Class Action Lawsuits Have Been Filed Against Biogen,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-06,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-06,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-06,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-06,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-06,01:10:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-06,01:10:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-06,05:47:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-06-06,06:13:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-06,06:13:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-06,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-06,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-06,08:22:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-06,08:22:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-06,08:51:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Shareholders
BIIB,2024-06-06,08:51:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Shareholders
BIIB,2024-06-06,09:01:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-06,09:01:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-06,09:17:02,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-06,09:17:02,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-06,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-06,11:33:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,UPCOMING LEGAL DEADLINE: Biogen Inc. (BIIB) Investors that Suffered Losses are Encouraged to Contact BFA Law About Approaching July 2024 Court Deadline
BIIB,2024-06-06,11:33:52,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,UPCOMING LEGAL DEADLINE: Biogen Inc. (BIIB) Investors that Suffered Losses are Encouraged to Contact BFA Law About Approaching July 2024 Court Deadline
BIIB,2024-06-06,12:01:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-06,12:01:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-06,15:32:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-06,15:32:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-06,16:33:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-06,16:33:53,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-06,16:33:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-06,16:33:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-06,17:01:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-06,17:01:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-06,18:42:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,GlobeNewswire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join -- Contact The Gross Law Firm"
BIIB,2024-06-06,18:42:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join -- Contact The Gross Law Firm"
BIIB,2024-06-06,19:24:14,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN APPROACHING DEADLINE: Biogen Inc. (BIIB) Investors are Reminded of Upcoming July 2024 Court Deadline and Urged to Contact BFA Law
BIIB,2024-06-06,19:24:14,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN APPROACHING DEADLINE: Biogen Inc. (BIIB) Investors are Reminded of Upcoming July 2024 Court Deadline and Urged to Contact BFA Law
BIIB,2024-06-06,20:32:00,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-06,20:32:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-06,20:46:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-06,20:46:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-06,20:46:37,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-06,20:46:37,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-07,09:02:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-07,09:02:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-07,09:19:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-07,09:19:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-07,10:46:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-07,10:46:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-07,10:46:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-07,11:11:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,APPROACHING LEGAL DEADLINE: Biogen Inc. (BIIB) Investors that Suffered Losses are Urged to Contact BFA Law About Upcoming July 2024 Legal Deadline
BIIB,2024-06-07,11:11:43,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,APPROACHING LEGAL DEADLINE: Biogen Inc. (BIIB) Investors that Suffered Losses are Urged to Contact BFA Law About Upcoming July 2024 Legal Deadline
BIIB,2024-06-07,11:21:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-07,11:21:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-07,16:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-07,16:31:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-07,16:31:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-07,17:27:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Shareholders
BIIB,2024-06-07,19:32:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN UPCOMING DEADLINE: Biogen Inc. (BIIB) Investors are Urged to Contact BFA Law About Approaching July 2024 Deadline in Securities Class Action
BIIB,2024-06-07,19:32:13,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN UPCOMING DEADLINE: Biogen Inc. (BIIB) Investors are Urged to Contact BFA Law About Approaching July 2024 Deadline in Securities Class Action
BIIB,2024-06-07,21:12:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIIB Class Action Reminder: Contact Robbins LLP for Information About Your Rights Against Biogen Inc.
BIIB,2024-06-07,21:37:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-07,21:37:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-07,22:13:03,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"Biogen Inc. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-07,22:13:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-08,22:22:17,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-08,09:11:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,BIOGEN CASE DEADLINE: Biogen Inc. (Nasdaq: BIIB) Investors are Reminded of Upcoming July 2024 Legal Deadline and Encouraged to Contact BFA Law
BIIB,2024-06-08,09:11:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,BIOGEN CASE DEADLINE: Biogen Inc. (Nasdaq: BIIB) Investors are Reminded of Upcoming July 2024 Legal Deadline and Encouraged to Contact BFA Law
BIIB,2024-06-08,14:46:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-08,14:46:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-08,22:22:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-08,22:25:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-08,22:25:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-09,09:54:44,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-09,09:54:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-09,11:54:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-09,11:54:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-09,11:54:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-09,15:18:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-09,15:18:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-09,16:07:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-09,16:07:24,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-09,16:07:24,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-09,16:07:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-09,16:07:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-10,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Class Action Lawsuits Have Been Filed Against Biogen,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-10,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-10,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-10,21:32:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-10,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-10,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-10,09:02:34,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-10,09:02:34,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-10,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
BIIB,2024-06-10,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
BIIB,2024-06-10,11:19:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN CASE ALERT: Biogen Inc. (BIIB) Investors that Suffered Losses are Encouraged to Contact BFA Law About Approaching July 2024 Legal Deadline
BIIB,2024-06-10,11:19:56,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN CASE ALERT: Biogen Inc. (BIIB) Investors that Suffered Losses are Encouraged to Contact BFA Law About Approaching July 2024 Legal Deadline
BIIB,2024-06-10,14:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-10,14:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to Contact the Firm"
BIIB,2024-06-10,14:27:12,CEDFD5,Biogen Inc.,95,0.34,analyst-ratings,neutral,Minter has an outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,"Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug -- IBD"
BIIB,2024-06-10,15:01:41,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-10,15:01:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-10,15:36:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-10,15:36:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-10,16:43:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-10,16:43:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-10,17:01:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-10,17:01:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-10,19:37:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN REMINDER: If You Suffered Losses on Your Biogen Inc. (BIIB) Investment, You are Encouraged to Contact BFA Law Before Approaching July 2024 Legal Deadline"
BIIB,2024-06-10,19:37:12,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN REMINDER: If You Suffered Losses on Your Biogen Inc. (BIIB) Investment, You are Encouraged to Contact BFA Law Before Approaching July 2024 Legal Deadline"
BIIB,2024-06-10,21:32:03,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-10,21:32:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-10,21:32:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-10,21:48:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-10,21:48:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-11,09:02:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-11,09:02:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors Can Join the Class Action Lawsuit!"
BIIB,2024-06-11,09:20:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-11,09:20:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-11,10:43:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,"BIOGEN NOTICE: If You Suffered Losses on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to Contact BFA Law Before Approaching July 2024 Legal Deadline"
BIIB,2024-06-11,10:43:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,"BIOGEN NOTICE: If You Suffered Losses on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to Contact BFA Law Before Approaching July 2024 Legal Deadline"
BIIB,2024-06-11,10:55:42,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-11,10:55:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-11,14:39:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-11,14:39:13,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-11,14:39:13,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-11,14:39:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-11,14:39:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-11,16:46:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-11,16:46:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-11,18:16:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-11,18:16:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-11,19:22:43,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-11,19:22:43,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-11,19:31:47,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION NOTICE: If You Lost Money on Your Biogen Inc. (Nasdaq:BIIB) Investment, You are Reminded to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-11,19:31:47,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION NOTICE: If You Lost Money on Your Biogen Inc. (Nasdaq:BIIB) Investment, You are Reminded to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-11,19:46:34,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-11,19:46:34,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-11,22:04:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-11,22:04:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-11,22:04:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-12,09:01:44,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-12,09:01:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-12,09:15:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-12,09:15:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-12,10:08:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION REMINDER: If You Lost Money on Your Biogen Inc. (BIIB) Investment, You are Encouraged to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-12,10:08:09,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION REMINDER: If You Lost Money on Your Biogen Inc. (BIIB) Investment, You are Encouraged to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-12,11:07:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-06-12,11:20:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-12,11:20:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-12,11:22:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-12,11:22:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-12,16:00:03,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-12,16:00:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-12,16:00:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-12,16:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-12,16:16:42,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-12,16:16:42,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-12,20:04:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB COURT DEADLINE: If You Lost Money on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to Contact BFA Law Before July 2024 Legal Deadline"
BIIB,2024-06-12,20:04:08,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB COURT DEADLINE: If You Lost Money on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to Contact BFA Law Before July 2024 Legal Deadline"
BIIB,2024-06-12,20:05:28,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-12,20:05:28,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-12,20:20:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-12,20:20:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-13,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-13,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-13,08:21:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-13,08:21:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-13,08:21:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-13,08:21:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-13,09:01:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-13,09:01:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-13,09:41:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,09:41:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,11:31:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,"BIOGEN LEGAL DEADLINE: If You Lost Money on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Encouraged to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-13,11:31:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,"BIOGEN LEGAL DEADLINE: If You Lost Money on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Encouraged to Contact BFA Law Before July 2024 Court Deadline"
BIIB,2024-06-13,11:50:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-13,11:50:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-13,14:30:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-13,14:30:20,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-13,14:30:20,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-13,14:30:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-13,14:30:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-13,14:46:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,14:46:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,15:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for BIIB, DRCT, FSLY, CRGE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-13,15:16:53,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-13,15:16:53,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-13,15:17:47,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-13,15:17:47,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-13,19:03:00,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-13,19:03:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-13,20:06:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BFA Law Notice: Biogen Inc. (Nasdaq: BIIB) Investors that Lost Money on Investment Have the Opportunity to Lead Securities Fraud Lawsuit and are Urged to Contact the Firm
BIIB,2024-06-13,20:06:18,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BFA Law Notice: Biogen Inc. (Nasdaq: BIIB) Investors that Lost Money on Investment Have the Opportunity to Lead Securities Fraud Lawsuit and are Urged to Contact the Firm
BIIB,2024-06-13,20:30:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,20:30:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-13,21:20:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for fiscal year 2023,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-06-13,21:20:42,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai, Biogen's development partner",PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-06-13,21:20:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-06-13,21:20:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-06-13,21:41:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-13,21:41:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-14,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Class Action Lawsuits Have Been Filed Against Biogen,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-14,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-14,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-14,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-14,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-14,01:17:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-14,01:17:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-14,01:17:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-14,01:17:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-14,09:03:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-14,09:03:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-14,09:36:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-14,09:36:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-14,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-14,11:03:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,BFA Law Alert: Biogen Inc. (BIIB) Investors that Lost Money on Investment Have the Opportunity to Lead Securities Fraud Lawsuit and are Urged to Contact the Firm
BIIB,2024-06-14,11:03:07,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,BFA Law Alert: Biogen Inc. (BIIB) Investors that Lost Money on Investment Have the Opportunity to Lead Securities Fraud Lawsuit and are Urged to Contact the Firm
BIIB,2024-06-14,13:45:47,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-14,13:45:47,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-14,14:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-14,14:15:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-14,14:00:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-14,14:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-14,14:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-14,14:01:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-14,14:01:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-14,14:02:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-14,14:02:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-14,14:02:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-14,14:15:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-14,16:10:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-14,16:31:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-14,16:31:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-14,20:06:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN INVESTOR ALERT: Lose Money on your Biogen Inc. (Nasdaq:BIIB) Investment? BFA Law Reminds You to Contact the Firm before July 22, 2024 Legal Deadline"
BIIB,2024-06-14,20:06:57,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN INVESTOR ALERT: Lose Money on your Biogen Inc. (Nasdaq:BIIB) Investment? BFA Law Reminds You to Contact the Firm before July 22, 2024 Legal Deadline"
BIIB,2024-06-14,20:30:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-14,20:30:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-15,10:04:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,GlobeNewswire,"BIOGEN STOCK NOTICE: Lose Money on your Biogen Inc. (Nasdaq: BIIB) Investment? BFA Law Encourages You to Contact the Firm before July 22, 2024 Court Deadline"
BIIB,2024-06-15,10:04:01,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,GlobeNewswire,"BIOGEN STOCK NOTICE: Lose Money on your Biogen Inc. (Nasdaq: BIIB) Investment? BFA Law Encourages You to Contact the Firm before July 22, 2024 Court Deadline"
BIIB,2024-06-15,13:31:12,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-15,13:31:12,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-15,14:45:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-15,14:45:04,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-15,14:45:04,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-15,14:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-15,14:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-15,22:09:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-15,22:09:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-15,22:20:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-15,22:20:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-16,11:06:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-16,11:06:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-16,11:57:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-16,11:57:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-16,11:57:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-16,12:01:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-16,12:01:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-16,12:02:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-16,12:02:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-17,09:02:39,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-17,09:02:39,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-17,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Shareholders of Biogen Inc. Should Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,09:45:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Shareholders of Biogen Inc. Should Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,09:51:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,09:51:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,09:56:39,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-17,09:56:39,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-17,10:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Business Wire,"BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case"
BIIB,2024-06-17,10:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,Business Wire,"BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case"
BIIB,2024-06-17,10:35:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,"May 22, 2024, Biogen was sued",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN SHAREHOLDER DEADLINE: Lose Money on your Biogen Inc. (Nasdaq:BIIB) Investment? BFA Law Reminds You to Contact the Firm before July 22, 2024 Cutoff Date"
BIIB,2024-06-17,10:35:43,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen's acquisition of Reata Pharmaceuticals, Inc. would",PRESS-RELEASE,DJ Global Press Release Wire,"BIOGEN SHAREHOLDER DEADLINE: Lose Money on your Biogen Inc. (Nasdaq:BIIB) Investment? BFA Law Reminds You to Contact the Firm before July 22, 2024 Cutoff Date"
BIIB,2024-06-17,11:10:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,11:10:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-17,11:11:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-17,11:11:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-17,11:15:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-17,11:15:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-17,11:48:15,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-17,11:48:15,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-17,15:46:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-17,15:46:22,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-17,15:46:22,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-17,15:46:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-17,15:46:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-17,16:05:01,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-17,16:05:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-17,16:05:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-17,16:05:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-17,16:36:03,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"BIIB: Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-17,16:36:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"BIIB: Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-17,16:36:04,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,"Press Release: BIIB: Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-17,16:36:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: BIIB: Biogen Inc. Investor Reminder: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-17,17:02:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-17,17:02:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-18,01:03:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,01:03:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,09:01:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-18,09:01:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-18,09:21:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-18,09:21:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-18,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-18,09:46:38,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-18,09:46:38,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-18,15:41:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-18,15:41:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-18,15:46:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-18,15:46:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-18,16:10:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-18,16:46:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-18,16:46:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-18,16:46:48,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-18,16:46:48,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-18,17:30:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Biogen Inc. Sued for Securities Law Violations -- Investors Should Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights -- BIIB"
BIIB,2024-06-18,21:15:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,21:15:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,21:24:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-18,21:24:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-18,21:36:03,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-18,21:36:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-18,21:36:03,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-18,21:36:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-18,21:49:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-18,21:49:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-18,21:49:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,21:49:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-18,22:00:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-18,22:00:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-18,22:00:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-19,09:01:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-19,09:01:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-19,09:15:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-19,09:15:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-19,09:30:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-19,09:30:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-19,11:17:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-06-19,11:41:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-19,11:41:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-19,14:01:13,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities Fraud Class Action Lawsuit Against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against Biogen Inc."
BIIB,2024-06-19,14:01:13,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against Biogen Inc."
BIIB,2024-06-19,15:08:41,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-19,15:08:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-20,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Class Action Lawsuits Have Been Filed Against Biogen,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-20,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-20,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-20,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-20,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-20,01:30:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-20,01:30:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-20,01:31:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-20,01:31:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-20,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-20,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-20,08:31:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,08:31:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,08:31:37,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-20,08:31:37,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-20,09:01:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-20,09:01:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-20,09:31:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-20,09:31:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-20,09:32:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-20,09:32:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-20,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-20,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-20,15:08:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-20,15:08:21,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-20,15:08:21,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-20,15:08:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-20,15:08:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-20,15:31:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-20,15:31:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-20,15:34:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,15:34:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,16:01:54,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities Fraud Class Action Lawsuit Against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against Biogen Inc."
BIIB,2024-06-20,16:01:54,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against Biogen Inc."
BIIB,2024-06-20,16:21:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,16:21:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-20,16:32:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-20,16:32:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-20,17:03:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for BIIB, DRCT, FSLY, CRGE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-20,17:30:58,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-20,17:30:58,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-20,17:45:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-20,17:45:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-20,22:30:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-20,22:30:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-20,22:30:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-21,09:01:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-21,09:01:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-21,09:31:41,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-21,09:31:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-21,09:41:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,09:41:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,09:45:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-21,15:31:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,15:31:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,15:32:55,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against - BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-06-21,15:32:55,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-06-21,16:02:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-21,16:02:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-21,16:02:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-21,16:02:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-21,16:16:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-21,16:16:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-06-21,17:00:03,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-21,17:00:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-21,17:00:03,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-21,17:00:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-21,19:49:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,19:49:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,19:50:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,19:50:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-21,20:02:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-21,20:02:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-22,12:29:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-22,12:29:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-22,12:29:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-22,14:47:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-22,14:47:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-22,14:47:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-22,14:47:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-22,14:47:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-22,15:30:00,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) -- Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-22,15:30:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) -- Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-22,22:16:29,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-22,22:16:29,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-22,22:20:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-22,22:20:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-23,09:43:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-23,09:43:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-23,10:15:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-23,10:15:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-23,15:35:07,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-23,15:35:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-23,15:38:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-23,15:38:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-23,16:18:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Reminder for NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-06-23,16:18:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Reminder for NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-06-23,17:00:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-23,17:00:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-23,17:01:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-23,17:01:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-06-24,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Class Action Lawsuits Have Been Filed Against Biogen,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-24,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-24,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-24,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-24,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm"
BIIB,2024-06-24,01:17:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-24,01:17:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-24,01:17:17,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-24,01:17:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-24,09:01:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-24,09:01:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-06-24,09:16:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-24,09:16:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-24,09:18:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-24,09:18:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-24,13:31:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Reminder for NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-06-24,13:31:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Reminder for NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-06-24,18:06:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-24,18:06:04,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-24,18:06:04,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-24,18:06:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-24,18:06:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-24,18:31:31,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-24,18:31:31,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc. (BIIB)"
BIIB,2024-06-24,18:31:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-24,18:31:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-24,19:46:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-06-24,20:21:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-24,20:21:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-24,20:46:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-24,20:46:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-24,22:18:30,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Biogen Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
BIIB,2024-06-24,23:46:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-24,23:46:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-24,23:46:54,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-24,23:46:54,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-25,09:01:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-25,09:01:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-25,09:16:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-25,09:16:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-25,09:22:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-25,09:22:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-25,09:45:03,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,PR Newswire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm
BIIB,2024-06-25,09:45:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm
BIIB,2024-06-25,09:45:04,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,Dow Jones Newswires,Press Release: Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm
BIIB,2024-06-25,09:45:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm
BIIB,2024-06-25,15:31:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-25,15:31:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-25,15:47:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-25,15:47:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-25,16:16:27,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against - BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-06-25,16:16:27,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-06-25,19:47:52,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-25,19:47:52,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-25,20:15:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-25,20:15:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-25,21:52:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-25,21:52:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-25,21:52:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-26,02:53:08,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,02:53:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,02:53:10,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,02:53:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,03:05:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,03:05:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,09:01:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-26,09:01:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-26,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-26,13:35:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,PR Newswire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-26,13:35:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-26,13:35:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-26,14:01:31,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-26,14:01:31,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-26,14:02:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-26,14:02:57,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-26,14:02:57,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-26,14:02:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-26,14:02:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-26,15:06:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,15:06:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,15:16:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,15:16:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-26,16:00:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,16:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,16:00:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,16:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-06-26,16:17:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-26,16:17:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-26,16:31:14,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-26,16:31:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-26,16:33:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-26,17:01:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-26,17:01:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-06-26,17:02:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-26,17:02:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-27,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-27,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-06-27,08:21:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-27,08:21:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-27,08:21:34,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-27,08:21:34,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-27,09:01:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-27,09:01:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-27,09:26:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-27,09:26:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-27,09:27:14,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-27,09:27:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-27,11:16:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
BIIB,2024-06-27,11:31:28,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-27,11:31:28,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-06-27,11:46:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-27,11:46:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-27,15:24:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-27,15:24:02,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-27,15:24:02,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-27,15:24:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-27,15:24:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-06-27,20:21:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-27,20:21:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-27,20:23:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for BIIB, DRCT, FSLY, CRGE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-06-27,20:31:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-27,20:31:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,-0.48,legal,,"Biogen, Charge, Fastly, and NIKE",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,-0.48,legal,,"Biogen, Charge, Fastly, and NIKE",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:00:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-06-28,01:15:37,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-28,01:15:37,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-28,09:03:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-28,09:03:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-28,09:13:15,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-28,09:13:15,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-06-28,09:15:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-28,09:15:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-28,09:45:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB LAWSUIT ALERT: The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-28,09:45:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB LAWSUIT ALERT: The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-06-28,13:40:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-28,13:40:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-28,13:40:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-28,14:02:30,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-28,14:02:30,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-28,14:02:39,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-28,14:02:39,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-06-28,15:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-28,15:00:00,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-28,15:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-28,15:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-06-28,15:17:45,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-28,15:17:45,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-06-28,15:18:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-28,15:18:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-06-28,22:00:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-28,22:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-28,22:00:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-28,22:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-28,22:01:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for fiscal year 2023,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Kirby McInerney LLP Notifies Biogen, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit"
BIIB,2024-06-28,22:01:20,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai, Biogen's development partner",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Kirby McInerney LLP Notifies Biogen, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit"
BIIB,2024-06-28,22:01:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Kirby McInerney LLP Notifies Biogen, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit"
BIIB,2024-06-28,22:01:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Kirby McInerney LLP Notifies Biogen, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit"
BIIB,2024-06-28,22:17:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-28,22:17:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-06-28,22:31:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-28,22:31:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-29,03:45:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-29,03:45:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-06-29,12:14:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-29,12:14:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-29,12:14:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-06-29,13:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Biogen Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
BIIB,2024-06-29,14:45:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-29,14:45:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)"
BIIB,2024-06-30,01:18:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-30,01:18:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-30,01:26:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-30,01:26:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-30,09:54:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-30,09:54:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-06-30,10:11:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-30,10:11:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-30,10:12:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-30,10:12:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-30,13:47:11,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-30,13:47:11,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-06-30,13:58:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-30,13:58:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-06-30,15:14:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-30,15:14:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-06-30,15:21:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-30,15:21:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-30,15:21:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-30,15:21:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-30,15:21:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-06-30,15:27:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-30,15:27:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-06-30,15:37:56,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-30,15:37:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-06-30,17:06:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-06-30,17:06:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-01,09:02:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-01,09:02:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-01,09:21:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-01,09:21:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-01,09:31:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-01,09:31:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-01,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-01,11:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-07-01,11:19:45,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-01,11:19:45,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-01,11:20:42,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-01,11:20:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-01,14:16:07,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-07-01,14:16:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-07-01,16:33:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Contact The Gross Law Firm by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,-0.48,legal,,"Biogen, Charge, Fastly, and NIKE",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,-0.48,legal,,"Biogen, Charge, Fastly, and NIKE",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:00:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm"
BIIB,2024-07-02,01:15:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,01:15:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,01:31:18,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-02,01:31:18,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-02,09:01:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-02,09:01:23,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-02,09:16:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,09:16:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,09:16:40,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-02,09:16:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-02,13:16:51,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition Of Human Immunology Biosciences >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Completes Acquisition Of Human Immunology Biosciences >BIIB
BIIB,2024-07-02,13:16:51,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology Biosciences,PRESS-RELEASE,GlobeNewswire,Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:51,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: we will begin working together with our,PRESS-RELEASE,GlobeNewswire,Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:51,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology -2,PRESS-RELEASE,GlobeNewswire,Biogen Completes Acquisition of Human Immunology -2-
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology Biosciences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: we will begin working together with our,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology Biosciences,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: we will begin working together with our,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of -2-
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology -2,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Completes Acquisition of Human Immunology -2-
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology Biosciences,FULL-ARTICLE,Dow Jones Newswires,Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology -2,FULL-ARTICLE,Dow Jones Newswires,Biogen Completes Acquisition of Human Immunology -2-
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Human Immunology Biosciences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: we will begin working together with our,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Human Immunology Biosciences
BIIB,2024-07-02,13:16:52,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of -2-
BIIB,2024-07-02,13:47:20,CEDFD5,Biogen Inc.,100,-0.64,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-07-02,13:47:20,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) - Contact Kessler Topaz Meltzer & Check, LLP"
BIIB,2024-07-02,14:00:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-02,14:00:08,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-02,14:00:08,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-02,14:00:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-02,14:00:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-02,14:07:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-02,14:16:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,14:16:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,14:16:10,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against - BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-07-02,14:16:10,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIIB"
BIIB,2024-07-02,15:32:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-02,15:32:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-02,15:46:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,15:46:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,16:35:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-02,20:02:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIIB STOCKHOLDERS: Lead Plaintiff Deadline Approaching in Biogen Inc. Class Action; Contact Robbins LLP
BIIB,2024-07-02,20:14:42,CEDFD5,Biogen Inc.,97,0.34,analyst-ratings,neutral,He has an outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug -- IBD
BIIB,2024-07-02,20:31:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-02,20:31:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-02,20:36:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,20:36:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-02,21:04:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-02,21:04:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-02,21:12:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,21:12:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-02,21:25:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-02,21:25:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-02,21:25:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-03,03:05:07,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-03,03:05:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-03,03:05:10,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-03,03:05:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-03,03:19:45,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-03,03:19:45,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-03,03:31:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-03,03:31:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-03,09:02:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-03,09:02:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-03,09:31:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-03,09:31:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-03,09:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"July 22, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against BIIB"
BIIB,2024-07-03,09:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: July 22, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against BIIB"
BIIB,2024-07-03,13:40:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,PR Newswire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-03,13:40:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-03,13:40:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,"INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-03,14:02:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-03,14:02:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-03,14:03:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-03,14:03:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-03,15:30:48,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-03,15:30:48,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-03,15:32:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-03,15:32:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-03,18:46:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Securities Fraud Class Action Lawsuit - Kessler Topaz Meltzer & Check, LLP Announces That a Lawsuit Has Been Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-03,18:46:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Securities Fraud Class Action Lawsuit - Kessler Topaz Meltzer & Check, LLP Announces That a Lawsuit Has Been Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-03,19:10:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for BIIB, DRCT, FSLY, CRGE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-03,19:31:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-03,19:31:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-03,19:32:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Shareholders
BIIB,2024-07-03,19:32:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Shareholders
BIIB,2024-07-04,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-04,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-04,08:21:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-04,08:21:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-04,08:21:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,08:21:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,09:00:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-04,09:00:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-04,09:31:35,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-04,09:31:35,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-04,09:32:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-04,09:32:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-04,14:20:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-04,14:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-04,14:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-04,14:30:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,14:30:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,15:31:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,15:31:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,15:33:48,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,15:33:48,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-04,19:30:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"BIIB SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of Securities Fraud Class Action Lawsuit Filed On the Behalf"
BIIB,2024-07-04,19:30:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"BIIB SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of Securities Fraud Class Action Lawsuit Filed On the Behalf"
BIIB,2024-07-04,19:45:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-04,19:45:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-04,19:45:57,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-04,19:45:57,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-05,09:01:14,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-05,09:01:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-05,09:31:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-05,09:31:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-05,09:32:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-05,09:32:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-05,15:02:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Biogen Inc. Securities Fraud Class Action Lawsuit"
BIIB,2024-07-05,16:01:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-05,16:01:51,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-05,16:01:51,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-05,16:01:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-05,16:01:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-05,16:17:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that Lost Money on Biogen Inc.(BIIB) Should Contact Levi & Korsinsky About Pending Class Action - BIIB
BIIB,2024-07-05,16:17:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that Lost Money on Biogen Inc.(BIIB) Should Contact Levi & Korsinsky About Pending Class Action - BIIB
BIIB,2024-07-05,16:30:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-05,16:30:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-06,18:49:07,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-07-06,18:49:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc."
BIIB,2024-07-07,01:22:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-07,01:22:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-07,01:28:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-07,01:28:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-07,09:56:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-07,09:56:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-07,11:10:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-07,11:10:32,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-07,11:12:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-07,11:12:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-07,12:05:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-07,12:05:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-07,12:05:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-07,14:16:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-07,14:16:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-07,14:16:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-07,14:16:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-07,14:16:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-07,15:08:30,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-07,15:08:30,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-07,15:08:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-07,15:08:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-07,16:04:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-07,16:04:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-07,16:05:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-07,16:05:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-07,16:16:09,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc"
BIIB,2024-07-07,16:16:09,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc"
BIIB,2024-07-08,09:01:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-08,09:01:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-08,09:31:21,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-08,09:31:21,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-08,09:32:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-08,09:32:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-08,09:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-07-08,14:49:47,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
BIIB,2024-07-08,15:16:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-08,15:16:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-08,15:16:42,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-08,15:16:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-08,15:25:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-08,15:25:20,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-08,15:25:20,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-08,15:25:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-08,15:25:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-08,16:00:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-08,16:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-08,16:00:04,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-08,16:00:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-08,16:19:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-08,16:19:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-08,16:34:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-08,16:34:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-08,18:05:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"Kessler Topaz Meltzer & Check, LLP Encourages Biogen Inc. Investors with Substantial Loss to Contact the Firm in Regards to Securities Class Action Lawsuit Filed against Biogen Inc."
BIIB,2024-07-08,18:05:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Kessler Topaz Meltzer & Check, LLP Encourages Biogen Inc. Investors with Substantial Loss to Contact the Firm in Regards to Securities Class Action Lawsuit Filed against Biogen Inc."
BIIB,2024-07-08,18:45:58,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-08,18:45:58,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-08,21:27:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-08,21:27:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-08,21:27:11,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-08,22:32:47,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-08,22:32:47,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-08,22:33:44,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-08,22:33:44,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-09,09:00:45,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-09,09:00:45,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-09,09:16:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-09,09:16:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-09,09:16:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-09,09:16:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-09,13:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Biogen Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
BIIB,2024-07-09,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-09,15:00:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-09,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-09,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-09,15:17:36,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-09,15:17:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-09,15:32:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-09,15:32:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-09,16:28:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-09,16:46:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-09,16:46:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-09,17:00:56,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-09,17:00:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-09,17:16:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"Important July 22, 2024 Deadline Reminder for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-07-09,17:16:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Important July 22, 2024 Deadline Reminder for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-07-09,17:32:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-09,17:32:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-09,17:45:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-09,17:45:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-09,18:51:54,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,GlobeNewswire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors -- Contact The Gross Law Firm
BIIB,2024-07-09,18:51:54,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors -- Contact The Gross Law Firm
BIIB,2024-07-09,21:47:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-09,21:47:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-09,21:47:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-09,23:51:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,09:01:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-10,09:01:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-10,09:21:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-10,09:21:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-10,09:21:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,09:21:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,13:25:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,PR Newswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-10,13:25:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-10,13:25:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-10,15:34:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-10,13:46:50,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-10,13:46:50,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-10,14:15:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-10,14:15:03,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-10,14:15:03,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-10,14:15:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-10,14:15:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-10,14:33:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,14:33:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,14:50:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-10,14:50:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-10,15:17:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-10,15:17:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-10,15:34:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-10,16:00:02,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-10,16:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-10,16:00:02,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-10,16:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-10,16:04:25,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Notification: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-10,16:04:25,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Notification: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-10,16:32:08,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,16:32:08,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,16:34:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that Lost Money on Biogen Inc.(BIIB) Should Contact Levi & Korsinsky About Pending Class Action - BIIB
BIIB,2024-07-10,16:34:24,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that Lost Money on Biogen Inc.(BIIB) Should Contact Levi & Korsinsky About Pending Class Action - BIIB
BIIB,2024-07-10,17:08:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights -- BIIB"
BIIB,2024-07-10,23:45:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,23:45:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-10,23:45:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-10,23:45:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-11,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-11,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-11,08:31:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-11,08:31:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-11,09:01:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-11,09:01:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-11,09:16:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-11,09:16:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-11,09:16:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-11,09:16:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-11,15:15:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-11,15:15:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-11,16:48:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for BIIB, DRCT, FSLY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-11,17:16:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-11,17:16:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-11,20:01:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf"
BIIB,2024-07-11,22:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for fiscal year 2023,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-07-11,22:00:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai, Biogen's development partner",PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-07-11,22:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-07-11,22:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its fourth quarter and fiscal year 2023 results,PRESS-RELEASE,GlobeNewswire,"Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm"
BIIB,2024-07-11,22:11:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-11,22:11:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-12,09:01:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-12,09:01:26,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-12,09:16:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-12,09:16:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-12,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB
BIIB,2024-07-12,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB
BIIB,2024-07-12,12:33:47,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Piper Sandler
BIIB,2024-07-12,12:33:47,CEDFD5,Biogen Inc.,100,-0.66,price-targets,downgrade,Biogen Price Target Cut to $313.00/Share From $335.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $313.00/Share From $335.00 by Piper Sandler
BIIB,2024-07-12,14:15:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-12,14:15:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-12,14:15:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-12,14:31:21,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-12,14:31:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-12,15:15:41,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-12,15:15:41,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-12,15:30:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-12,15:30:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-12,18:15:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-12,18:15:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-12,18:15:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-12,18:15:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-12,18:15:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-12,18:30:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-12,18:30:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-13,14:01:19,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB NOTICE: Kessler Topaz Meltzer & Check, LLP Notifies Biogen Inc. (BIIB) Investors of Securities Fraud Class Action Lawsuit"
BIIB,2024-07-13,15:15:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case"
BIIB,2024-07-13,15:15:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case"
BIIB,2024-07-14,01:22:28,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-14,01:22:28,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-14,09:56:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-14,09:56:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-14,11:30:55,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-14,11:30:55,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2024-07-14,11:35:10,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-14,11:35:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-14,11:35:10,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-14,13:15:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"BIIB Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Deadline in Securities Fraud Class Action Lawsuit"
BIIB,2024-07-14,13:15:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Deadline in Securities Fraud Class Action Lawsuit"
BIIB,2024-07-14,13:31:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-14,13:31:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB"
BIIB,2024-07-14,16:00:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-14,16:00:51,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-14,16:00:51,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-14,16:00:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-14,16:00:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-14,17:02:33,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-14,17:02:33,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
BIIB,2024-07-15,09:01:17,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-15,09:01:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-15,09:15:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-15,09:15:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-15,09:45:07,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,PR Newswire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-15,09:45:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-15,13:30:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,PR Newswire,"Final Deadline Approaching for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Lead Plaintiff Deadline"
BIIB,2024-07-15,13:30:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Final Deadline Approaching for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Lead Plaintiff Deadline"
BIIB,2024-07-15,13:30:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Final Deadline Approaching for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Lead Plaintiff Deadline"
BIIB,2024-07-15,13:30:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Final Deadline Approaching for Biogen Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Lead Plaintiff Deadline"
BIIB,2024-07-15,13:47:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-15,13:47:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-15,15:21:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit -- BIIB"
BIIB,2024-07-15,18:48:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-15,18:48:07,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB"
BIIB,2024-07-15,19:46:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-15,19:46:29,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-15,22:11:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-15,22:11:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-15,22:11:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-16,08:31:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-16,08:31:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-16,09:01:01,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-16,09:01:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-16,09:31:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-16,09:31:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIIB
BIIB,2024-07-16,09:45:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-16,09:45:22,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-16,10:00:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-16,10:00:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-16,14:14:33,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-16,14:14:33,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-16,14:14:33,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-16,14:14:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-16,14:14:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-16,16:45:39,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights -- BIIB"
BIIB,2024-07-16,14:46:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-07-16,14:46:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-07-16,15:01:17,CEDFD5,Biogen Inc.,99,-0.64,legal,,Securities fraud class action lawsuit against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-16,15:01:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit
BIIB,2024-07-16,15:55:39,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: analysts expect the company's sales to decline,FULL-ARTICLE,Dow Jones Newswires,Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense -- IBD
BIIB,2024-07-16,16:06:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-16,16:33:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-16,16:33:27,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-16,18:02:07,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Deadline Alert - Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-16,18:02:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Deadline Alert - Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-16,19:18:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-16,19:18:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Class Action: Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-16,20:02:40,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: analysts expect the company's sales to decline,FULL-ARTICLE,Dow Jones Newswires,Three Surprising Names That Could Be On Biogen's Buyout Shortlist -- IBD
BIIB,2024-07-16,22:19:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-16,22:19:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-16,22:19:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-17,09:00:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-17,09:00:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit!"
BIIB,2024-07-17,09:20:49,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-17,09:20:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-17,09:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-17,09:45:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,Dow Jones Newswires,Press Release: The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-17,15:31:15,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-17,15:31:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-17,18:39:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its third quarter 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-17,18:39:41,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-17,18:39:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-17,18:39:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,GlobeNewswire,Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-17,19:02:20,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-17,19:02:20,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-17,20:31:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Lead Plaintiff Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of Deadline in Securities Fraud Class Action Lawsuit"
BIIB,2024-07-17,22:35:06,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-17,22:35:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-17,22:35:06,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-18,00:30:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,00:30:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,08:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-18,08:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!"
BIIB,2024-07-18,08:10:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,08:10:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,09:00:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-18,09:00:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-18,09:15:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-18,09:15:23,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders
BIIB,2024-07-18,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,Levi & Korsinsky Notifies Shareholders of Biogen Inc.(BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-18,11:36:30,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-18,11:36:30,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-18,12:15:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE MONDAY: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-18,12:15:42,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,DJ Global Press Release Wire,"INVESTOR DEADLINE MONDAY: Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-18,12:45:52,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-18,12:45:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-18,14:05:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-18,14:05:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-18,14:05:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-18,14:16:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,14:16:40,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,16:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, FSLY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-18,16:31:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-18,16:31:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc. (BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-18,19:01:03,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-18,19:01:03,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-18,19:01:03,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-18,19:01:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-18,19:01:03,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB
BIIB,2024-07-18,20:52:22,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Deadline - Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-18,20:52:22,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Deadline - Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-18,20:52:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,20:52:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB"
BIIB,2024-07-18,23:02:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-18,23:02:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
BIIB,2024-07-19,09:00:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-19,09:00:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-19,09:30:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-07-19,09:30:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Shareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
BIIB,2024-07-19,13:31:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-19,13:31:36,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen negatively revised non-GAAP diluted EPS guidance for FY 2023,PRESS-RELEASE,GlobeNewswire,"MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB"
BIIB,2024-07-19,13:47:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Lead Plaintiff Deadline Approaching - Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Shareholders of Deadline in Securities Fraud Class Action Lawsuit"
BIIB,2024-07-19,14:02:27,CEDFD5,Biogen Inc.,100,-0.52,legal,,Class Action Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-19,14:02:27,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join - Contact Levi & Korsinsky"
BIIB,2024-07-19,14:05:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,PR Newswire,"Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-19,14:05:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-19,14:05:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,PR Newswire,"Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-19,14:30:56,CEDFD5,Biogen Inc.,100,-0.52,legal,,Levi & Korsinsky to Join Class Action Suit Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-19,14:30:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"July 22, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIIB"
BIIB,2024-07-19,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,"Biogen Inc.: On November 8, 2023, Biogen released its third quarter 2023 financial results",PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-19,15:00:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the Company's launch of its Alzheimer's disease treatment, Leqembi",PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-19,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-19,15:00:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen released its fourth quarter and full year 2023 financial results,PRESS-RELEASE,Business Wire,The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
BIIB,2024-07-20,12:25:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-20,12:25:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-20,12:25:09,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-20,14:04:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,Securities class action lawsuit has been filed in the United States District Court for the District of Colorado against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"BIIB DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Biogen Inc. (BIIB) Securities Fraud Class Action Lawsuit"
BIIB,2024-07-20,14:04:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIIB DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Biogen Inc. (BIIB) Securities Fraud Class Action Lawsuit"
BIIB,2024-07-20,14:20:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-20,14:20:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-20,14:20:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-20,14:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-20,14:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines -- BIIB
BIIB,2024-07-21,01:12:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-21,01:12:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-21,08:01:35,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-07-21,08:01:35,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-07-21,09:35:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-21,09:35:43,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-21,09:36:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-21,09:36:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-21,10:43:59,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-21,10:43:59,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-21,12:53:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi, LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-21,12:53:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi, LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-21,12:53:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Faruqi & Faruqi, LLP Reminds Shareholders of a Lead Plaintiff Deadline on July 22, 2024 in Biogen Lawsuit"
BIIB,2024-07-21,13:30:49,CEDFD5,Biogen Inc.,100,-0.52,legal,,Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB),PRESS-RELEASE,DJ Global Press Release Wire,"FINAL DEADLINE REMINDER FOR BIIB INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-21,13:30:49,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL DEADLINE REMINDER FOR BIIB INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Biogen Inc. (BIIB)"
BIIB,2024-07-21,14:34:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-21,14:34:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-22,08:01:17,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-07-22,08:01:17,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"
BIIB,2024-07-22,09:00:58,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-22,09:00:58,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-22,09:01:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-22,09:01:04,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit"
BIIB,2024-07-22,09:31:13,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-22,09:31:13,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
BIIB,2024-07-22,09:45:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,PR Newswire,"Levi & Korsinsky Reminds Biogen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB"
BIIB,2024-07-22,15:01:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2024-07-22,15:23:56,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-22,15:23:56,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)"
BIIB,2024-07-22,15:24:16,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc.",PRESS-RELEASE,DJ Global Press Release Wire,"FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-22,15:24:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-22,15:24:16,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen"
BIIB,2024-07-22,15:45:53,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-22,15:45:53,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
BIIB,2024-07-22,15:54:46,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery -- Contact The Gross Law Firm
BIIB,2024-07-23,17:50:12,CEDFD5,Biogen Inc.,99,-0.52,legal,,Lawsuit was filed against Biogen Inc.,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-23,17:50:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
BIIB,2024-07-24,03:05:41,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,DJ Global Press Release Wire,"Lifshitz Law PLLC Announces Investigations of Biogen, Inc. (NASDAQ: BIIB), Direct Digital Holdings, Inc. (NASDAQ: DRCT), AST SpaceMobile, Inc. (NASDAQ: ASTS), and Perion Network Ltd. (NASDAQ: PERI)"
BIIB,2024-07-24,10:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124),PRESS-RELEASE,Business Wire,Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
BIIB,2024-07-24,10:31:15,CEDFD5,Biogen Inc.,100,-0.65,products-services,negative,"Sage, Biogen: SAGE-324 Fails in Phase 2 Study",NEWS-FLASH,Dow Jones Newswires,"Sage, Biogen: SAGE-324 Fails in Phase 2 Study in Essential Tremor >SAGE BIIB"
BIIB,2024-07-24,10:34:46,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124),PRESS-RELEASE,Dow Jones Newswires,Press Release: Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
BIIB,2024-07-24,10:58:03,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen End Development of SAGE-324 in Essential Tremor,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen End Development of SAGE-324 in Essential Tremor"
BIIB,2024-07-24,10:58:03,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen are ending development of a proposed treatment,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen End Development of SAGE-324 in Essential Tremor"
BIIB,2024-07-24,12:44:24,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Sage Therapeutics Inc.: the company's collaboration with Biogen Inc.,FULL-ARTICLE,MarketWatch,MW Sage Therapeutics' stock dives as failed trial hits Biogen collaboration
BIIB,2024-07-24,13:02:06,CEDFD5,Biogen Inc.,93,-0.65,products-services,negative,Biogen-partnered treatment for essential tremor failed in a Phase 2 study,FULL-ARTICLE,Dow Jones Newswires,Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails -- IBD
BIIB,2024-07-24,20:08:11,CEDFD5,Biogen Inc.,93,-0.65,products-services,negative,Biogen-partnered treatment for essential tremor failed in a Phase 2 study,FULL-ARTICLE,Dow Jones Newswires,Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails -- IBD
BIIB,2024-07-26,01:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc. (NASDAQ: BIIB)",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-07-26,01:00:00,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen had agreed to pay $900 million to settle allegations,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-07-26,01:00:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Biogen announced that it would acquire Reata Pharmaceuticals, Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-07-26,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-07-26,01:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-07-26,11:21:44,CEDFD5,Biogen Inc.,100,-0.61,products-services,negative,Biogen Gets Negative CHMP Opinion for the Humanized Anti-Soluble Aggregated Amyloid-Beta Monoclonal,NEWS-FLASH,Dow Jones Newswires,Biogen Gets Negative CHMP Opinion for the Humanized Anti-Soluble Aggregated Amyloid-Beta Monoclonal Antibody Lecanemab >BIIB
BIIB,2024-07-26,14:48:23,CEDFD5,Biogen Inc.,98,0.44,products-services,,"Biogen, which is looking to Leqembi to revive",FULL-ARTICLE,Dow Jones Newswires,EU Rejection of Alzheimer's Drug Is Another Disappointment for Biogen -- Barrons.com
BIIB,2024-07-26,15:16:10,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Raffat maintained his outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug -- IBD
BIIB,2024-07-26,20:16:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Raffat maintained his outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug -- IBD
BIIB,2024-07-29,11:29:55,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Baird
BIIB,2024-07-29,11:29:55,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $294.00/Share From $316.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $294.00/Share From $316.00 by Baird
BIIB,2024-07-30,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",PRESS-RELEASE,Business Wire,"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-07-30,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-07-30,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-07-30,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",PRESS-RELEASE,GlobeNewswire,"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-07-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-07-30,11:30:10,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Beckman Coulter and Fujirebio to Collaborate on",NEWS-FLASH,Dow Jones Newswires,"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease"
BIIB,2024-08-01,10:55:54,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $4.00 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q EPS $4.00 >BIIB
BIIB,2024-08-01,10:55:54,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Adj EPS $5.28,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Adj EPS $5.28 >BIIB
BIIB,2024-08-01,10:55:54,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Net $583.6M,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Net $583.6M >BIIB
BIIB,2024-08-01,10:55:54,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 2Q Rev $2.46B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Rev $2.46B >BIIB
BIIB,2024-08-01,10:58:09,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY24 Adj EPS $15.75,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY24 Adj EPS $15.75-Adj EPS $16.25 >BIIB
BIIB,2024-08-01,10:59:33,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Expects 2024 Revenue to Decline,RNS-SEC8K,Dow Jones Newswires,Biogen Expects 2024 Revenue to Decline By a Low-Single Digit Percentage >BIIB
BIIB,2024-08-01,11:19:05,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen boosts profit outlook,FULL-ARTICLE,MarketWatch,MW Drug maker Biogen boosts profit outlook and tops Q2 profit estimate
BIIB,2024-08-01,11:19:05,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen said its second-quarter profit fell,FULL-ARTICLE,MarketWatch,MW Drug maker Biogen boosts profit outlook and tops Q2 profit estimate
BIIB,2024-08-01,11:19:05,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Boosts Profit Outlook,FULL-ARTICLE,Dow Jones Newswires,Drug Maker Biogen Boosts Profit Outlook And Tops Q2 Profit Estimate -- MarketWatch
BIIB,2024-08-01,11:19:05,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen said its second-quarter profit fell,FULL-ARTICLE,Dow Jones Newswires,Drug Maker Biogen Boosts Profit Outlook And Tops Q2 Profit Estimate -- MarketWatch
BIIB,2024-08-01,11:29:10,CEDFD5,Biogen Inc.,97,0.61,earnings,positive,Biogen to earn $4.02 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Earnings Flat; Biotech Giant Raises Guidance -- IBD
BIIB,2024-08-01,11:43:34,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Lifts Earnings Guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Earnings Guidance After Revenue Beats Forecasts -- WSJ
BIIB,2024-08-01,12:43:25,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen boosts profit outlook,FULL-ARTICLE,MarketWatch,MW Drugmaker Biogen boosts profit outlook on 'momentum' for new drugs
BIIB,2024-08-01,12:43:25,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen (BIIB) said its second-quarter profit fell,FULL-ARTICLE,MarketWatch,MW Drugmaker Biogen boosts profit outlook on 'momentum' for new drugs
BIIB,2024-08-01,14:48:41,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen boosts profit outlook,FULL-ARTICLE,MarketWatch,"MW Biogen boosts profit outlook on 'momentum' for new drugs, but stock dips"
BIIB,2024-08-01,14:48:41,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen's second-quarter profit fell to $583.6 million,FULL-ARTICLE,MarketWatch,"MW Biogen boosts profit outlook on 'momentum' for new drugs, but stock dips"
BIIB,2024-08-01,14:48:41,CEDFD5,Biogen Inc.,100,0.64,earnings,up,Biogen boosted its earnings,FULL-ARTICLE,MarketWatch,"MW Biogen boosts profit outlook on 'momentum' for new drugs, but stock dips"
BIIB,2024-08-01,15:03:09,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Raymond has an overweight rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Slips As Alzheimer's Drug Looks Abroad For Quarterly Beat -- IBD
BIIB,2024-08-01,15:03:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Spinraza beat sales expectations at,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Slips As Alzheimer's Drug Looks Abroad For Quarterly Beat -- IBD
BIIB,2024-08-01,20:01:41,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Raymond has an overweight rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Slips As Alzheimer's Drug Looks Abroad For Quarterly Beat -- IBD
BIIB,2024-08-01,20:01:41,CEDFD5,Biogen Inc.,100,0.0,revenues,,Spinraza beat sales expectations at,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Slips As Alzheimer's Drug Looks Abroad For Quarterly Beat -- IBD
BIIB,2024-08-02,13:58:44,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2024-08-02,13:58:44,CEDFD5,Biogen Inc.,100,-0.4,price-targets,downgrade,Biogen Price Target Cut to $210.00/Share From $215.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $210.00/Share From $215.00 by Wedbush
BIIB,2024-08-02,14:41:44,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2024-08-02,14:41:44,CEDFD5,Biogen Inc.,100,-0.6,price-targets,downgrade,Biogen Price Target Cut to $190.00/Share From $200.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $190.00/Share From $200.00 by Barclays
BIIB,2024-08-02,16:41:54,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Sector Outperform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Outperform by Scotiabank
BIIB,2024-08-02,16:41:54,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $244.00/Share From $275.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $244.00/Share From $275.00 by Scotiabank
BIIB,2024-08-02,18:39:24,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Wells Fargo
BIIB,2024-08-02,18:39:24,CEDFD5,Biogen Inc.,100,-0.66,price-targets,downgrade,Biogen Price Target Cut to $225.00/Share From $240.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $225.00/Share From $240.00 by Wells Fargo
BIIB,2024-08-02,19:57:05,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2024-08-02,19:57:05,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $292.00/Share From $282.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $292.00/Share From $282.00 by RBC Capital
BIIB,2024-08-05,10:23:11,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2024-08-05,10:23:11,CEDFD5,Biogen Inc.,100,-0.2,price-targets,downgrade,Biogen Price Target Cut to $285.00/Share From $288.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $285.00/Share From $288.00 by Needham
BIIB,2024-08-05,13:54:51,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $302.00/Share From $340.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $302.00/Share From $340.00 by Truist Securities
BIIB,2024-08-06,11:29:53,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Mizuho
BIIB,2024-08-06,11:29:53,CEDFD5,Biogen Inc.,100,-0.78,price-targets,downgrade,Biogen Price Target Cut to $251.00/Share From $277.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $251.00/Share From $277.00 by Mizuho
BIIB,2024-08-14,20:32:39,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen Inc.: the ""Company"") entered into a credit agreement with Bank of America, N.A.",RNS-SEC8K,Dow Jones Newswires,Biogen Files 8K - Entry Into Definitive Agreement >BIIB
BIIB,2024-08-19,07:07:33,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 2Q 2024 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 2Q 2024 (BIIB)"
BIIB,2024-08-22,09:59:48,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Score U.K. Nod for Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,"Eisai, Biogen Score U.K. Nod for Alzheimer's Drug -- market Talk"
BIIB,2024-09-03,17:03:29,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 431 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 431 Of Biogen Inc >BIIB
BIIB,2024-09-05,11:54:20,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 431 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 431 Of Biogen Inc >BIIB
BIIB,2024-09-11,12:00:11,CEDFD5,Biogen Inc.,100,0.0,products-services,,Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial,PRESS-RELEASE,PR Newswire,"Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE(TM) (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy"
BIIB,2024-09-11,12:00:11,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Bio-Thera Solutions, Ltd. today announced, in collaboration with Biogen",PRESS-RELEASE,PR Newswire,"Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE(TM) (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy"
BIIB,2024-09-11,12:00:11,CEDFD5,Biogen Inc.,100,0.39,products-services,,"Bio-Thera Solutions, Ltd. and Biogen entered into a commercialization and license agreement",PRESS-RELEASE,PR Newswire,"Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE(TM) (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy"
BIIB,2024-09-11,12:00:52,CEDFD5,Biogen Inc.,100,0.0,products-services,,Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial,NEWS-FLASH,Dow Jones Newswires,"Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE (BAT1806/BIIB800), Approved Biosimilar Referencing Tocilizumab in Arthritis Research & Therapy"
BIIB,2024-09-12,11:30:00,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Board Appoints Two New Independent Directors,PRESS-RELEASE,GlobeNewswire,Biogen Board Appoints Two New Independent Directors
BIIB,2024-09-12,11:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Board Appoints Two New Independent Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Board Appoints Two New Independent Directors
BIIB,2024-09-12,11:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Board Appoints Two New Independent Directors,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Board Appoints Two New Independent Directors
BIIB,2024-09-12,11:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Board Appoints Two New Independent Directors,FULL-ARTICLE,Dow Jones Newswires,Biogen Board Appoints Two New Independent Directors
BIIB,2024-09-12,11:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Board Appoints Two New Independent Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Board Appoints Two New Independent Directors
BIIB,2024-09-12,11:30:11,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Two New Independent Directors,NEWS-FLASH,Dow Jones Newswires,Biogen Appoints Two New Independent Directors >BIIB
BIIB,2024-09-12,11:31:13,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,"Biogen Names Lloyd Minor, Menelas Pangalos to Board",NEWS-FLASH,Dow Jones Newswires,"Biogen Names Lloyd Minor, Menelas Pangalos to Board >BIIB"
BIIB,2024-09-12,20:36:20,CEDFD5,Biogen Inc.,94,0.84,products-services,positive,Biogen's litifilimab has shown promise in its Phase II clinical trial,PRESS-RELEASE,GlobeNewswire,US Rheumatologists Believe Biogen's Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
BIIB,2024-09-17,13:38:24,CEDFD5,Biogen Inc.,99,0.65,products-services,,Health Canada has accepted for priority review its New Drug Submission (NDS) for omaveloxolone,PRESS-RELEASE,Canadian News Wire,Biogen's New Drug Submission for Omaveloxolone Accepted for Priority Review by Health Canada for the Treatment of Friedreich's Ataxia
BIIB,2024-09-17,13:38:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,Canadian News Wire,Biogen's New Drug Submission for Omaveloxolone Accepted for Priority Review by Health Canada for the Treatment of Friedreich's Ataxia
BIIB,2024-09-20,12:00:02,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Aflibercept,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-09-20,12:00:02,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-09-20,12:00:02,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Aflibercept,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-09-20,12:00:02,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-09-23,14:04:32,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2024-09-23,14:04:32,CEDFD5,Biogen Inc.,100,-0.4,price-targets,downgrade,Biogen Price Target Cut to $205.00/Share From $210.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $205.00/Share From $210.00 by Wedbush
BIIB,2024-09-24,05:00:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Ucb and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,GlobeNewswire,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between UCB and Biogen,PRESS-RELEASE,GlobeNewswire,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Ucb and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,Dow Jones Newswires,Press Release: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between UCB and Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Ucb and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,Dow Jones Newswires,Press Release: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between UCB and Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Ucb and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,DJ Global Press Release Wire,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between UCB and Biogen,PRESS-RELEASE,DJ Global Press Release Wire,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Ucb and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol,FULL-ARTICLE,Dow Jones Newswires,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between UCB and Biogen,FULL-ARTICLE,Dow Jones Newswires,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
BIIB,2024-09-24,05:08:27,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus,NEWS-FLASH,Dow Jones Newswires,"UCB, Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus"
BIIB,2024-09-24,10:41:49,CEDFD5,Biogen Inc.,93,0.49,partnerships,,Biogen and Belgium's UCB have been working together since,FULL-ARTICLE,Dow Jones Newswires,"Biogen, UCB Post Positive Phase 3 Study Results in Systemic Lupus Erythematosus"
BIIB,2024-09-24,11:18:55,CEDFD5,Biogen Inc.,95,0.41,products-services,start,Biogen (BIIB) said they would initiate a second Phase 3 trial,FULL-ARTICLE,MarketWatch,MW Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
BIIB,2024-09-24,15:04:22,CEDFD5,Biogen Inc.,95,0.41,products-services,start,Biogen (BIIB) said they would initiate a second Phase 3 trial,FULL-ARTICLE,MarketWatch,MW Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
BIIB,2024-09-26,11:01:12,CEDFD5,Biogen Inc.,100,0.49,partnerships,,The Collaboration With Biogen on,NEWS-FLASH,Dow Jones Newswires,Sage Therapeutics Announces Discontinuation of the Collaboration With Biogen on the SAGE-324 Program
BIIB,2024-09-26,11:28:08,CEDFD5,Biogen Inc.,100,-0.43,products-services,terminated,"Sage Therapeutics, Biogen End Licensing Agreement",FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen End Licensing Agreement for Tremor Drug"
BIIB,2024-10-03,19:00:53,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by UBS
BIIB,2024-10-03,19:00:53,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $202.00/Share From $234.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $202.00/Share From $234.00 by UBS
BIIB,2024-10-04,14:57:45,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2024-10-04,14:57:45,CEDFD5,Biogen Inc.,100,-0.72,price-targets,downgrade,Biogen Price Target Cut to $269.00/Share From $292.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $269.00/Share From $292.00 by RBC Capital
BIIB,2024-10-07,21:31:04,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen reported encouraging topline findings from the Phase III,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:04,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen are launching a second Phase 3 trial of dapirolizumab pegol,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:04,CEDFD5,Biogen Inc.,100,0.65,revenues,up,Biogen Inc.: Peak Sales,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:25,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen reported encouraging topline findings from the Phase III,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:25,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen are launching a second Phase 3 trial of dapirolizumab pegol,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:25,CEDFD5,Biogen Inc.,100,0.65,revenues,up,Biogen Inc.: Peak Sales,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
BIIB,2024-10-07,21:31:25,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: The Positive Topline Results From Phase III Study,PRESS-RELEASE,PR Newswire,The Positive Topline Results From Phase III Study of UCB/Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight -2-
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Data from the clinical development program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen plans to initiate Phase 3 trials for felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired Human Immunology Biosciences (HI-Bio) in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Data from the clinical development program,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen plans to initiate Phase 3 trials for felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired Human Immunology Biosciences (HI-Bio) in July 2024,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen plans to initiate Phase 3 trials for felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired Human Immunology Biosciences (HI-Bio) in July 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Data from the clinical development program,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen plans to initiate Phase 3 trials for felzartamab,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired Human Immunology Biosciences (HI-Bio) in July 2024,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Data from the clinical development program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen plans to initiate Phase 3 trials for felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired Human Immunology Biosciences (HI-Bio) in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
BIIB,2024-10-09,11:30:07,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab,NEWS-FLASH,Dow Jones Newswires,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients >BIIB
BIIB,2024-10-09,11:32:18,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Gets FDA Breakthrough Therapy Designation for Felzartamab,NEWS-FLASH,Dow Jones Newswires,Biogen Gets FDA Breakthrough Therapy Designation for Felzartamab for Antibody-Mediated Rejection in Kidney Transplant Recipients >BIIB
BIIB,2024-10-09,11:50:21,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen is planning to initiate Phase 3 trials in 2025,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Bounces After Treatment For Kidney-Transplant Rejection Gets FDA Boost -- MarketWatch
BIIB,2024-10-09,11:50:21,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen is planning to initiate Phase 3 trials in 2025,FULL-ARTICLE,MarketWatch,MW Biogen's stock bounces after treatment for kidney-transplant rejection gets FDA boost
BIIB,2024-10-09,11:59:22,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Gets FDA Breakthrough Designation,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,11:59:22,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen said it won Food and Drug Administration breakthrough-therapy designation,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,11:59:22,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen's July acquisition of Human Immunology Biosciences,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,11:59:22,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen said it plans to initiate Phase 3 studies for felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,12:14:22,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen Gets FDA Breakthrough Designation,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,12:14:22,CEDFD5,Biogen Inc.,100,0.7,products-services,,Biogen said it won Food and Drug Administration breakthrough-therapy designation,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,12:14:22,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen's July acquisition of Human Immunology Biosciences,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,12:14:22,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen said it plans to initiate Phase 3 studies for felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Breakthrough Designation for Kidney-Transplant Drug
BIIB,2024-10-09,12:32:17,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen is planning to initiate Phase 3 trials for felzartamab in 2025,FULL-ARTICLE,MarketWatch,MW Biogen's stock bounces after FDA boost on kidney-transplant rejection treatment
BIIB,2024-10-09,12:32:17,CEDFD5,Biogen Inc.,100,-0.58,products-services,denied,Regulators reject Biogen's treatment for Alzheimer's disease,FULL-ARTICLE,MarketWatch,MW Biogen's stock bounces after FDA boost on kidney-transplant rejection treatment
BIIB,2024-10-17,14:04:04,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by BMO Capital
BIIB,2024-10-17,14:04:04,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $230.00/Share From $260.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $230.00/Share From $260.00 by BMO Capital
BIIB,2024-10-22,11:30:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-22,11:30:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,GlobeNewswire,Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-22,11:30:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-22,11:30:00,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-24,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
BIIB,2024-10-27,00:15:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy,PRESS-RELEASE,GlobeNewswire,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,GlobeNewswire,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy,FULL-ARTICLE,Dow Jones Newswires,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-27,00:15:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
BIIB,2024-10-28,12:30:30,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,Biogen Chief Fincl Officer Michael McDonnell to Retire in February,NEWS-FLASH,Dow Jones Newswires,Biogen Chief Fincl Officer Michael McDonnell to Retire in February >BIIB
BIIB,2024-10-28,12:31:17,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen: Robin Kramer to Succeed McDonnell as Chief Financial Officer,NEWS-FLASH,Dow Jones Newswires,Biogen: Robin Kramer to Succeed McDonnell as Chief Financial Officer >BIIB
BIIB,2024-10-28,12:42:42,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,Biogen Chief Financial Officer Michael McDonnell to Retire in February,FULL-ARTICLE,Dow Jones Newswires,Biogen Chief Financial Officer Michael McDonnell to Retire in February
BIIB,2024-10-28,12:42:42,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,"Biogen's top finance executive, Michael McDonnell, plans to retire",FULL-ARTICLE,Dow Jones Newswires,Biogen Chief Financial Officer Michael McDonnell to Retire in February
BIIB,2024-10-29,12:00:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer"
BIIB,2024-10-29,12:00:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer",FULL-ARTICLE,Dow Jones Newswires,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer"
BIIB,2024-10-29,12:00:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer"
BIIB,2024-10-29,12:00:04,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer"
BIIB,2024-10-29,12:00:04,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer",PRESS-RELEASE,GlobeNewswire,"(PMZN) Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer"
BIIB,2024-10-29,12:01:28,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Daniel Quirk Chief Medical Officer >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Names Daniel Quirk Chief Medical Officer >BIIB
BIIB,2024-10-29,22:00:23,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: This collaboration with Neomorph reflects the approach we want to,PRESS-RELEASE,GlobeNewswire,"Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases"
BIIB,2024-10-29,22:00:24,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: This collaboration with Neomorph reflects the approach we want to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases"
BIIB,2024-10-29,22:00:24,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: This collaboration with Neomorph reflects the approach we want to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Neomorph Announce Multi-Target Research Collaborationto Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases"
BIIB,2024-10-29,22:00:24,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: This collaboration with Neomorph reflects the approach we want to,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Neomorph Announce Multi-Target Research Collaborationto Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases"
BIIB,2024-10-30,01:00:02,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc. (NASDAQ: BIIB)",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-10-30,01:00:02,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2024-10-30,10:56:14,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,3Q EPS $2.66 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q EPS $2.66 >BIIB
BIIB,2024-10-30,10:56:14,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $4.08,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $4.08 >BIIB
BIIB,2024-10-30,10:56:14,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Net $388.5M,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Net $388.5M >BIIB
BIIB,2024-10-30,10:56:14,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.47B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.47B >BIIB
BIIB,2024-10-30,10:59:00,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises Full-Year 2024 Financial Guidance >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Raises Full-Year 2024 Financial Guidance >BIIB
BIIB,2024-10-30,11:00:02,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises 2024 View To Adj EPS $16.10,NEWS-FLASH,Dow Jones Newswires,Biogen Raises 2024 View To Adj EPS $16.10-Adj EPS $16.60 >BIIB
BIIB,2024-10-30,11:01:23,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Still Sees 2024 Total Revenue Down,NEWS-FLASH,Dow Jones Newswires,Biogen Still Sees 2024 Total Revenue Down Low-Single Digits >BIIB
BIIB,2024-10-30,11:10:21,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen had EPS of $4.08,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Pops After Earnings Top Estimates And Company Raises Guidance -- MarketWatch
BIIB,2024-10-30,11:10:21,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raised its full-year guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Pops After Earnings Top Estimates And Company Raises Guidance -- MarketWatch
BIIB,2024-10-30,11:10:21,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen had EPS of $4.08,FULL-ARTICLE,MarketWatch,MW Biogen's stock pops after earnings top estimates and company raises guidance
BIIB,2024-10-30,11:10:21,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raised its full-year guidance,FULL-ARTICLE,MarketWatch,MW Biogen's stock pops after earnings top estimates and company raises guidance
BIIB,2024-10-30,11:28:36,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Earnings Top Views,FULL-ARTICLE,Dow Jones Newswires,Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum -- IBD
BIIB,2024-10-30,11:28:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen to earn $3.77 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum -- IBD
BIIB,2024-10-30,11:28:36,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.: the company reported $2.53 billion in sales,FULL-ARTICLE,Dow Jones Newswires,Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum -- IBD
BIIB,2024-10-30,11:47:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen had EPS of $4.08,FULL-ARTICLE,MarketWatch,MW Biogen's stock pops after earnings top estimates and company raises guidance
BIIB,2024-10-30,11:47:36,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raised its full-year guidance,FULL-ARTICLE,MarketWatch,MW Biogen's stock pops after earnings top estimates and company raises guidance
BIIB,2024-10-30,14:15:09,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen earned $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough. -- IBD
BIIB,2024-10-30,15:34:27,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen had EPS of $4.08,FULL-ARTICLE,MarketWatch,MW Biogen's stock hit by soft sales of Alzheimer's treatment
BIIB,2024-10-30,15:34:27,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raised its full-year guidance,FULL-ARTICLE,MarketWatch,MW Biogen's stock hit by soft sales of Alzheimer's treatment
BIIB,2024-10-30,20:28:07,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen earned $4.08 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough. -- IBD
BIIB,2024-10-30,20:46:45,CEDFD5,Biogen Inc.,99,0.0,labor-issues,,Biogen Inc.: the Company's annual bonus plan,RNS-SEC8K,Dow Jones Newswires,"Biogen Files 8K - Director, Officer or Compensation Filing >BIIB"
BIIB,2024-10-30,20:46:45,CEDFD5,Biogen Inc.,94,-0.49,labor-issues,,"Biogen Inc.: Mr. McDonnell will retire from the Company on February 28, 2025",RNS-SEC8K,Dow Jones Newswires,Biogen Files 8K - Regulation FD >BIIB
BIIB,2024-10-31,10:24:26,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Equal-Weight From Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Equal-Weight From Overweight by Morgan Stanley
BIIB,2024-10-31,10:24:26,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $204.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $204.00/Share From $285.00 by Morgan Stanley
BIIB,2024-10-31,17:07:17,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by TD Cowen
BIIB,2024-10-31,17:07:17,CEDFD5,Biogen Inc.,100,-0.74,price-targets,downgrade,Biogen Price Target Cut to $275.00/Share From $300.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $275.00/Share From $300.00 by TD Cowen
BIIB,2024-10-31,18:11:47,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2024-10-31,18:11:47,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $180.00/Share From $190.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $180.00/Share From $190.00 by Barclays
BIIB,2024-10-31,18:19:47,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2024-10-31,18:19:47,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $255.00/Share From $270.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $255.00/Share From $270.00 by Oppenheimer
BIIB,2024-11-04,14:47:16,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by JP Morgan
BIIB,2024-11-04,14:47:16,CEDFD5,Biogen Inc.,100,-0.56,price-targets,downgrade,Biogen Price Target Cut to $210.00/Share From $220.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $210.00/Share From $220.00 by JP Morgan
BIIB,2024-11-04,21:40:07,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Grogan Acquires 491 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Grogan Acquires 491 Of Biogen Inc >BIIB
BIIB,2024-11-14,13:04:54,CEDFD5,Biogen Inc.,100,0.01,analyst-ratings,neutral,Biogen Initiated at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Neutral by Citigroup
BIIB,2024-11-14,13:04:54,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $190.00/Share by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $190.00/Share by Citigroup
BIIB,2024-11-15,10:25:25,CEDFD5,Biogen Inc.,100,0.01,analyst-ratings,neutral,Biogen Initiated at Peer Perform by Wolfe Research,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Peer Perform by Wolfe Research
BIIB,2024-11-15,12:28:16,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Baird
BIIB,2024-11-15,12:28:16,CEDFD5,Biogen Inc.,100,0.38,price-targets,upgrade,Biogen Price Target Raised to $300.00/Share From $294.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $300.00/Share From $294.00 by Baird
BIIB,2024-11-18,10:19:02,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Hold From Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Hold From Buy by Needham
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc.: our partnership with Samsung Bioepis, with",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc.: our partnership with Samsung Bioepis, with",PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-18,12:00:21,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ(TM)"
BIIB,2024-11-19,08:07:14,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 3Q 2024 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 3Q 2024 (BIIB)"
BIIB,2024-11-21,13:18:59,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Mizuho
BIIB,2024-11-21,13:18:59,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $207.00/Share From $251.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $207.00/Share From $251.00 by Mizuho
BIIB,2024-12-04,23:34:38,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen: Mexico Approves Leqembi,NEWS-FLASH,Dow Jones Newswires,"Eisai, Biogen: Mexico Approves Leqembi for Treatment of Early Alzheimer's Disease"
BIIB,2024-12-05,13:00:05,CEDFD5,Biogen Inc.,99,0.0,products-services,,Partner Biogen is conducting the global Phase 2b LUMA study of BIIB122,PRESS-RELEASE,GlobeNewswire,"Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease"
BIIB,2024-12-05,13:00:05,CEDFD5,Biogen Inc.,99,0.0,products-services,,Partner Biogen is conducting the global Phase 2b LUMA study of BIIB122,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease"
BIIB,2024-12-09,11:51:55,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Hold From Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Hold From Buy by Jefferies
BIIB,2024-12-09,11:51:55,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $180.00/Share From $250.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $180.00/Share From $250.00 by Jefferies
BIIB,2024-12-09,15:39:24,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 110 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 110 Of Biogen Inc >BIIB
BIIB,2024-12-09,21:57:28,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 181 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 181 Of Biogen Inc >BIIB
BIIB,2024-12-09,22:00:13,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 110 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 110 Of Biogen Inc >BIIB
BIIB,2024-12-10,12:49:07,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $178.00/Share by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $178.00/Share by B of A Securities
BIIB,2024-12-20,10:16:03,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Market Perform From Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Market Perform From Outperform by BMO Capital
BIIB,2024-12-20,10:16:03,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $164.00/Share From $230.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $164.00/Share From $230.00 by BMO Capital
BIIB,2021-01-05,04:43:29,CEDFD5,Biogen Inc.,99,-0.69,equity-actions,delisting,"Biogen stock was halted on November 6, 2020",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
BIIB,2021-01-05,15:16:30,CEDFD5,Biogen Inc.,100,-0.52,legal,,Lawsuits FILED AGAINST BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST BIIB, YY and SPLK - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2021-01-06,00:37:21,CEDFD5,Biogen Inc.,100,-0.52,legal,,C. Files Securities Class Action Lawsuit Against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: Lowey Dannenberg, P.C. Files Securities Class Action Lawsuit Against Biogen Inc. on Behalf of Investors Who Acquired Shares from October 22, 2019 to November 6, 2020 and Encourages Investors to Inquire About the Lead Plaintiff Position Before the January 12, 2021 Lead Plaintiff Deadline"
BIIB,2021-01-06,16:30:51,CEDFD5,Biogen Inc.,100,-0.52,legal,,Lawsuits Filed Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"Lawsuits Filed Against BIIB, BABA and TRIT - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2021-01-07,02:00:15,CEDFD5,Biogen Inc.,96,-0.65,equity-actions,halt,Biogen shares were halted,PRESS-RELEASE,Business Wire,"DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm"
BIIB,2021-01-07,11:22:20,CEDFD5,Biogen Inc.,100,-0.52,legal,,Lawsuits FILED AGAINST BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST BIIB, BRY and NERV - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2021-01-08,16:00:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,Business Wire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 12, 2021"
BIIB,2021-01-09,02:00:00,CEDFD5,Biogen Inc.,97,-0.52,legal,,"Class Action Lawsuit Has Been Filed Against Biogen, Inc.",PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm"
BIIB,2021-01-09,02:00:00,CEDFD5,Biogen Inc.,97,-0.65,equity-actions,halt,Biogen shares were halted,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm"
BIIB,2021-01-10,15:26:12,CEDFD5,Biogen Inc.,100,-0.52,legal,,Lawsuits FILED AGAINST BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST BIIB, SPLK and QSR - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS"
BIIB,2021-01-11,16:02:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 12, 2021"
BIIB,2021-01-12,14:14:59,CEDFD5,Biogen Inc.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc.,PRESS-RELEASE,PR Newswire,"DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BIIB,2021-01-12,14:14:59,CEDFD5,Biogen Inc.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,"Press Release: DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BIIB,2021-01-19,14:17:26,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-01-19,14:17:26,CEDFD5,Biogen Inc.,100,-0.28,price-targets,downgrade,Biogen Price Target Cut to $352.00/Share From $357.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $352.00/Share From $357.00 by Morgan Stanley
BIIB,2021-01-20,09:00:45,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2020 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2020 (BIIB)"
BIIB,2021-01-29,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
BIIB,2021-01-29,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
BIIB,2021-01-29,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
BIIB,2021-01-29,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,GlobeNewswire,Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
BIIB,2021-01-29,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
BIIB,2021-01-29,12:48:07,CEDFD5,Biogen Inc.,100,-0.47,regulatory,,Fda Extends Review of Biogen,FULL-ARTICLE,Dow Jones Newswires,"FDA Extends Review of Biogen, Eisai Alzheimer's Drug Candidate"
BIIB,2021-01-29,15:50:17,CEDFD5,Biogen Inc.,100,-0.47,regulatory,,Fda Extends Review of Biogen,FULL-ARTICLE,Dow Jones Newswires,"FDA Extends Review of Biogen, Eisai's Alzheimer's Drug"
BIIB,2021-01-29,16:00:03,CEDFD5,Biogen Inc.,100,-0.47,regulatory,,Fda Extends Review of Biogen,FULL-ARTICLE,Dow Jones Newswires,"FDA Extends Review of Biogen, Eisai's Alzheimer's Drug"
BIIB,2021-02-01,12:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Plegridy was first approved by the FDA,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces FDA Approval of PLEGRIDY(R) (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
BIIB,2021-02-03,12:04:46,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $2.32 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q EPS $2.32 >BIIB
BIIB,2021-02-03,12:04:46,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Adj EPS $4.58,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Adj EPS $4.58 >BIIB
BIIB,2021-02-03,12:04:46,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Net $357.9M,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Net $357.9M >BIIB
BIIB,2021-02-03,12:04:46,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.85B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Rev $2.85B >BIIB
BIIB,2021-02-03,12:20:58,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Net Product Revenue $2.3B,RNS-SEC8K,Dow Jones Newswires,Biogen 4Q Net Product Revenue $2.3B
BIIB,2021-02-03,12:22:58,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen 4Q Profit Falls on,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q Profit Falls on Lower Revenue, Higher R&D Costs"
BIIB,2021-02-03,12:24:05,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees FY21 Rev $10.45B-$10.75B,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY21 Rev $10.45B-$10.75B
BIIB,2021-02-03,12:24:06,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY21 Adj EPS $17,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY21 Adj EPS $17-Adj EPS $18.50
BIIB,2021-02-03,12:24:38,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Expects FY21 Capex Between $375M,RNS-SEC8K,Dow Jones Newswires,Biogen Expects FY21 Capex Between $375M and $425M >BIIB
BIIB,2021-02-03,12:37:58,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen 4Q Profit Falls on,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q Profit Falls on Lower Revenue, Higher R&D Costs"
BIIB,2021-02-03,12:47:20,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Expects Revenue to Fall,FULL-ARTICLE,Dow Jones Newswires,Biogen Expects Revenue to Fall by as Much as 22.3% in 2021
BIIB,2021-02-03,12:47:20,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc. said it expects revenue to fall,FULL-ARTICLE,Dow Jones Newswires,Biogen Expects Revenue to Fall by as Much as 22.3% in 2021
BIIB,2021-02-03,12:47:20,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.: The company said it forecasts 2021 revenue of $10.45 billion to $10.75 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Expects Revenue to Fall by as Much as 22.3% in 2021
BIIB,2021-02-03,15:04:55,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen also said it expects a sharp decline in sales,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Because Earnings Guidance Came Up Short -- Barrons.com
BIIB,2021-02-03,15:04:55,CEDFD5,Biogen Inc.,100,0.01,analyst-ratings,neutral,He rates Biogen at Neutral,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Because Earnings Guidance Came Up Short -- Barrons.com
BIIB,2021-02-03,15:04:55,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Aducanumab receives FDA approval,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Because Earnings Guidance Came Up Short -- Barrons.com
BIIB,2021-02-03,15:04:55,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Yee rates Biogen at Buy,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Because Earnings Guidance Came Up Short -- Barrons.com
BIIB,2021-02-03,15:49:57,CEDFD5,Biogen Inc.,95,-0.52,products-services,,Biogen ends development of another drug candidate,FULL-ARTICLE,Dow Jones Newswires,Biogen Pulls Plug on Parkinson's Drug Candidate -- Market Talk
BIIB,2021-02-03,18:30:20,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q4 2020 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q4 2020 Results -- Earnings Call Transcript >BIIB
BIIB,2021-02-03,18:30:20,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen-inc-biib-ceo-michel-vounatsos-on-q4-2020-results-earnings,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q4 2020 Results -- Earnings Call Transcript >BIIB
BIIB,2021-02-04,10:29:11,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2021-02-04,10:29:11,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $380.00/Share From $430.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $380.00/Share From $430.00 by SVB Leerink
BIIB,2021-02-04,11:25:51,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2021-02-04,11:25:51,CEDFD5,Biogen Inc.,100,0.6,price-targets,upgrade,Biogen Price Target Raised to $305.00/Share From $289.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $305.00/Share From $289.00 by HC Wainwright & Co.
BIIB,2021-02-04,13:07:21,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-02-04,13:07:21,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $351.00/Share From $352.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $351.00/Share From $352.00 by Morgan Stanley
BIIB,2021-02-04,14:02:00,CEDFD5,Biogen Inc.,100,0.0,credit,,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045,PRESS-RELEASE,GlobeNewswire,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
BIIB,2021-02-04,14:02:01,CEDFD5,Biogen Inc.,100,0.0,credit,,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
BIIB,2021-02-04,14:03:06,CEDFD5,Biogen Inc.,100,0.0,credit,,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045,NEWS-FLASH,Dow Jones Newswires,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
BIIB,2021-02-04,15:09:52,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Credit Suisse
BIIB,2021-02-04,15:09:52,CEDFD5,Biogen Inc.,100,-0.48,price-targets,downgrade,Biogen Price Target Cut to $338.00/Share From $350.00 by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $338.00/Share From $350.00 by Credit Suisse
BIIB,2021-02-04,16:08:12,CEDFD5,Biogen Inc.,100,0.06,credit-ratings,set,Moody's Assign's Baa1 To Biogen's Notes,NEWS-FLASH,Dow Jones Newswires,Moody's Assign's Baa1 To Biogen's Notes; On Review For Downgrade
BIIB,2021-02-04,16:08:52,CEDFD5,Biogen Inc.,100,0.06,credit-ratings,set,Moody's Assign's Baa1 to Biogen's Notes,NEWS-FLASH,Dow Jones Newswires,Moody's Assign's Baa1 to Biogen's Notes; On Review for Downgrade
BIIB,2021-02-05,12:01:10,CEDFD5,Biogen Inc.,99,0.59,equity-actions,approved,"Aducanumab, even authorizing two separate $5 billion share repurchases",FULL-ARTICLE,Dow Jones Newswires,Biogen Bet Big on Its Alzheimer's Drug. The Stock Will Soar or Dive on the FDA's Decision. -- Barrons.com
BIIB,2021-02-05,12:01:10,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: The company issued 2021 sales guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Bet Big on Its Alzheimer's Drug. The Stock Will Soar or Dive on the FDA's Decision. -- Barrons.com
BIIB,2021-02-05,12:01:10,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Fda's collaboration with Biogen as,FULL-ARTICLE,Dow Jones Newswires,Biogen Bet Big on Its Alzheimer's Drug. The Stock Will Soar or Dive on the FDA's Decision. -- Barrons.com
BIIB,2021-02-05,13:00:05,CEDFD5,Biogen Inc.,99,0.49,partnerships,,New partnership with Biogen,PRESS-RELEASE,PR Newswire,Biogen Offers Arcadia's Home Renewable Energy Program to Employees
BIIB,2021-02-05,13:00:05,CEDFD5,Biogen Inc.,99,0.22,acquisitions-mergers,,Biogen Inc.: our commitment to purchase 100% of our,PRESS-RELEASE,PR Newswire,Biogen Offers Arcadia's Home Renewable Energy Program to Employees
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.59,equity-actions,approved,"Aducanumab, even authorizing two separate $5 billion share repurchases",FULL-ARTICLE,Dow Jones Newswires,Biogen Goes All-In On Alzheimer's Drug
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: The company issued 2021 sales guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Goes All-In On Alzheimer's Drug
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Fda's collaboration with Biogen as,FULL-ARTICLE,Dow Jones Newswires,Biogen Goes All-In On Alzheimer's Drug
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.59,equity-actions,approved,"Aducanumab, even authorizing two separate $5 billion share repurchases",FULL-ARTICLE,Barrons,Biogen Goes All-In On Alzheimer's Drug -- Barron's
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: The company issued 2021 sales guidance,FULL-ARTICLE,Barrons,Biogen Goes All-In On Alzheimer's Drug -- Barron's
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Fda's collaboration with Biogen as,FULL-ARTICLE,Barrons,Biogen Goes All-In On Alzheimer's Drug -- Barron's
BIIB,2021-02-09,21:18:45,CEDFD5,Biogen Inc.,100,0.0,insider-trading,,Dir Posner Gifts 125 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Dir Posner Gifts 125 Of Biogen Inc >BIIB
BIIB,2021-02-10,21:32:37,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Dir Mantas Buys 898 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Dir Mantas Buys 898 Of Biogen Inc >BIIB
BIIB,2021-02-17,17:02:53,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Cantor Fitzgerald
BIIB,2021-02-17,17:02:53,CEDFD5,Biogen Inc.,100,-0.48,price-targets,downgrade,Biogen Price Target Cut to $268.00/Share From $278.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $268.00/Share From $278.00 by Cantor Fitzgerald
BIIB,2021-02-17,22:01:38,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Alexander Acquires 459 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Acquires 459 Of Biogen Inc >BIIB
BIIB,2021-02-17,22:03:58,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Galdes Acquires 858 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Galdes Acquires 858 Of Biogen Inc >BIIB
BIIB,2021-02-17,22:04:28,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Gregory Acquires 741 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Gregory Acquires 741 Of Biogen Inc >BIIB
BIIB,2021-02-17,22:04:48,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Guindo Acquires 2,216 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Guindo Acquires 2,216 Of Biogen Inc >BIIB"
BIIB,2021-02-17,22:05:48,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 218 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 218 Of Biogen Inc >BIIB
BIIB,2021-02-17,22:05:58,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Sandrock Acquires 944 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Sandrock Acquires 944 Of Biogen Inc >BIIB
BIIB,2021-02-17,22:06:28,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Ceo Vounatsos Acquires 1,816 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CEO Vounatsos Acquires 1,816 Of Biogen Inc >BIIB"
BIIB,2021-03-04,12:47:36,CEDFD5,Biogen Inc.,99,0.41,assets,open,Biogen Inc.: The new facility,PRESS-RELEASE,GlobeNewswire,"Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina"
BIIB,2021-03-04,12:47:36,CEDFD5,Biogen Inc.,99,0.41,assets,open,Biogen Inc.: The new facility,PRESS-RELEASE,DJ Global Press Release Wire,"Press Release: Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina"
BIIB,2021-03-04,12:47:37,CEDFD5,Biogen Inc.,99,0.41,assets,open,Biogen Inc.: The new facility,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina"
BIIB,2021-03-04,12:47:51,CEDFD5,Biogen Inc.,99,0.41,assets,open,Biogen Inc.: The new facility,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina"
BIIB,2021-03-18,13:39:28,CEDFD5,Biogen Inc.,97,0.49,partnerships,,Biogen (ticker: BIIB) is developing in partnership with Sage Therapeutics (SAGE),FULL-ARTICLE,Dow Jones Newswires,Don't Lose Sight of Biogen's Depression Drug Amid Focus on Alzheimer's Disease -- Barrons.com
BIIB,2021-03-25,12:16:53,CEDFD5,Biogen Inc.,99,-0.62,legal,,Biogen Inc.: the company lost a patent suit,FULL-ARTICLE,Dow Jones Newswires,Biogen Investors Want News on Alzheimer's Therapy. 2 More Key Points to Watch. -- Barrons.com
BIIB,2021-03-25,12:16:53,CEDFD5,Biogen Inc.,99,0.0,revenues,,Analysts expect only $1.6 billion in Tecfidera sales in 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen Investors Want News on Alzheimer's Therapy. 2 More Key Points to Watch. -- Barrons.com
BIIB,2021-04-08,11:00:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,PRESS-RELEASE,GlobeNewswire,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,11:00:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,11:00:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,11:00:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,11:00:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,11:00:53,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,NEWS-FLASH,Dow Jones Newswires,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,13:09:09,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Licenses Actemra,FULL-ARTICLE,Dow Jones Newswires,Biogen Licenses Actemra Biosimilar Candidate From Bio-Thera Solutions
BIIB,2021-04-08,13:24:08,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Licenses Actemra,FULL-ARTICLE,Dow Jones Newswires,Biogen Licenses Actemra Biosimilar Candidate From Bio-Thera Solutions
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's board of directors at its 2021 annual meeting,PRESS-RELEASE,GlobeNewswire,Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,-0.43,labor-issues,,Biogen Inc.: will retire from the company's board,PRESS-RELEASE,GlobeNewswire,Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's board of directors at its 2021 annual meeting,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,-0.43,labor-issues,,Biogen Inc.: will retire from the company's board,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's board of directors at its 2021 annual meeting,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,-0.43,labor-issues,,Biogen Inc.: will retire from the company's board,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Annual Report on Form 10-K for the fiscal year ended December,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees -2-
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's board of directors at its 2021 annual meeting,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,-0.43,labor-issues,,Biogen Inc.: will retire from the company's board,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Annual Report on Form 10-K for the fiscal year ended December,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Announces Two New Nominees -2-
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Annual Report on Form 10-K for the fiscal year ended December,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees -2-
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's board of directors at its 2021 annual meeting,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,-0.43,labor-issues,,Biogen Inc.: will retire from the company's board,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-12,11:23:41,CEDFD5,Biogen Inc.,91,0.0,products-services,,Biogen Inc. said they saw positive topline results from a Phase 2 study,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen Sees Positive Results for Essential Tremors Treatment"
BIIB,2021-04-12,11:38:41,CEDFD5,Biogen Inc.,91,0.0,products-services,,Biogen Inc. said they saw positive topline results from a Phase 2 study,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen Sees Positive Results for Essential Tremors Treatment"
BIIB,2021-04-12,12:28:37,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2021-04-12,12:28:37,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $245.00/Share From $236.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $245.00/Share From $236.00 by Wedbush
BIIB,2021-04-12,20:30:05,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Sage's partnership with Biogen is,FULL-ARTICLE,Dow Jones Newswires,"Neurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogen -- Barrons.com"
BIIB,2021-04-14,20:06:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,GlobeNewswire,"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021"
BIIB,2021-04-14,20:06:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,DJ Global Press Release Wire,"Press Release: Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021"
BIIB,2021-04-14,20:06:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021"
BIIB,2021-04-14,20:06:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,FULL-ARTICLE,Dow Jones Newswires,"Press Release: Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021"
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen's expansion in China,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,China's National Medical Products Administration (NMPA) has approved TECFIDERA(R) (dimethyl fumarate) for the treatment,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results from clinical trials,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen's expansion in China,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,China's National Medical Products Administration (NMPA) has approved TECFIDERA(R) (dimethyl fumarate) for the treatment,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen's expansion in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,China's National Medical Products Administration (NMPA) has approved TECFIDERA(R) (dimethyl fumarate) for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results from clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen's expansion in China,PRESS-RELEASE,GlobeNewswire,Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,China's National Medical Products Administration (NMPA) has approved TECFIDERA(R) (dimethyl fumarate) for the treatment,PRESS-RELEASE,GlobeNewswire,Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results from clinical trials,PRESS-RELEASE,GlobeNewswire,Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen's expansion in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,China's National Medical Products Administration (NMPA) has approved TECFIDERA(R) (dimethyl fumarate) for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results from clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:31:24,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Tecfidera Received Approval in China,NEWS-FLASH,Dow Jones Newswires,Biogen: TECFIDERA Received Approval in China for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:31:35,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen Expansion in China,NEWS-FLASH,Dow Jones Newswires,Biogen Expansion in China Now Includes Treatment Options Approved for Relapsing MS and Spinal Muscular Atrophy >BIIB
BIIB,2021-04-15,21:22:27,CEDFD5,Biogen Inc.,94,0.57,products-services,granted,Biogen Inc. on Thursday said its Tecfidera received approval from China's National Medical Products Administration for the treatment,FULL-ARTICLE,Dow Jones Newswires,Biogen Says Tecfidera Approved in China to Treat Relapsing Multiple Sclerosis
BIIB,2021-04-15,21:37:27,CEDFD5,Biogen Inc.,94,0.57,products-services,granted,Biogen Inc. on Thursday said its Tecfidera received approval from China's National Medical Products Administration for the treatment,FULL-ARTICLE,Dow Jones Newswires,Biogen Says Tecfidera Approved in China to Treat Relapsing Multiple Sclerosis
BIIB,2021-04-19,13:35:15,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-04-19,13:35:15,CEDFD5,Biogen Inc.,100,-0.4,price-targets,downgrade,Biogen Price Target Cut to $343.00/Share From $351.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $343.00/Share From $351.00 by Morgan Stanley
BIIB,2021-04-19,14:03:38,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen is developing in partnership with Sage Therapeutics (SAGE),FULL-ARTICLE,Dow Jones Newswires,How Biogen Stock Could Rise 85%. Two Drugs Are Critical. -- Barrons.com
BIIB,2021-04-19,14:03:38,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen is set to report its first-quarter earnings on Thursday,FULL-ARTICLE,Dow Jones Newswires,How Biogen Stock Could Rise 85%. Two Drugs Are Critical. -- Barrons.com
BIIB,2021-04-19,14:03:38,CEDFD5,Biogen Inc.,100,0.0,revenues,,Analysts expect Tecfidera sales to plummet,FULL-ARTICLE,Dow Jones Newswires,How Biogen Stock Could Rise 85%. Two Drugs Are Critical. -- Barrons.com
BIIB,2021-04-19,14:03:38,CEDFD5,Biogen Inc.,100,0.61,acquisitions-mergers,rumor,Biogen could be an acquisition target,FULL-ARTICLE,Dow Jones Newswires,How Biogen Stock Could Rise 85%. Two Drugs Are Critical. -- Barrons.com
BIIB,2021-04-21,07:25:11,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 1Q 2021 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 1Q 2021 (BIIB)"
BIIB,2021-04-22,11:09:00,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $2.69 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $2.69 >BIIB
BIIB,2021-04-22,11:09:00,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Net $410.2M,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Net $410.2M >BIIB
BIIB,2021-04-22,11:10:25,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.69B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.69B >BIIB
BIIB,2021-04-22,11:10:40,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $5.34,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Adj EPS $5.34 >BIIB
BIIB,2021-04-22,11:11:44,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees FY Rev $10.45B-$10.75B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Sees FY Rev $10.45B-$10.75B >BIIB
BIIB,2021-04-22,11:12:22,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises FY View To Adj EPS $17.50,NEWS-FLASH,Dow Jones Newswires,Biogen Raises FY View To Adj EPS $17.50-Adj EPS $19 >BIIB
BIIB,2021-04-22,11:16:03,CEDFD5,Biogen Inc.,100,-0.68,earnings,down,Biogen Q1 EPS $2.69 vs. $8.08 a year ago,NEWS-FLASH,MarketWatch,Biogen Q1 EPS $2.69 vs. $8.08 a year ago
BIIB,2021-04-22,11:16:54,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Q1 adj. EPS $5.34,NEWS-FLASH,MarketWatch,Biogen Q1 adj. EPS $5.34; FactSet EPS consensus $4.97
BIIB,2021-04-22,11:17:20,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q1 revenue $2.69 bln vs. $3.53 bln a year ago; FactSet consensus $2.65 bln,NEWS-FLASH,MarketWatch,Biogen Q1 revenue $2.69 bln vs. $3.53 bln a year ago; FactSet consensus $2.65 bln
BIIB,2021-04-22,11:17:55,CEDFD5,Biogen Inc.,100,0.46,earnings,up,Biogen raises 2021 adj. EPS outlook to $17.50-$19.00 from $17.00-$18.50,NEWS-FLASH,MarketWatch,Biogen raises 2021 adj. EPS outlook to $17.50-$19.00 from $17.00-$18.50
BIIB,2021-04-22,11:41:56,CEDFD5,Biogen Inc.,93,0.0,revenues,unchanged,Biogen continues to expect revenue of $10.45 billion to $10.75 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts 2021 Adj Earnings Guidance
BIIB,2021-04-22,11:47:05,CEDFD5,Biogen Inc.,100,-0.44,revenues,down,"Biogen's stock is up, though revenue fell 25% for the quarter",FULL-ARTICLE,MarketWatch,"Biogen's stock is up, though revenue fell 25% for the quarter"
BIIB,2021-04-22,11:47:05,CEDFD5,Biogen Inc.,100,-0.44,revenues,down,"Biogen's Stock Is Up, Though Revenue Fell 25% For The Quarter",FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Is Up, Though Revenue Fell 25% For The Quarter -- MarketWatch"
BIIB,2021-04-22,11:56:56,CEDFD5,Biogen Inc.,93,0.0,revenues,unchanged,Biogen continues to expect revenue of $10.45 billion to $10.75 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts 2021 Adjusted Earnings Guidance
BIIB,2021-04-22,12:14:43,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen's Earnings Beat Forecasts,FULL-ARTICLE,Dow Jones Newswires,Biogen's Earnings Beat Forecasts. The Stock Is Rising. -- Barrons.com
BIIB,2021-04-22,12:14:43,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported non-GAAP diluted earnings of $5.34 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen's Earnings Beat Forecasts. The Stock Is Rising. -- Barrons.com
BIIB,2021-04-22,17:45:02,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q1 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q1 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2021-04-22,17:45:02,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen-inc-biib-ceo-michel-vounatsos-on-q1-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q1 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2021-04-28,22:20:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Tysabri was approved by the European Commission in March 2021,PRESS-RELEASE,GlobeNewswire,Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI(R) (natalizumab)
BIIB,2021-04-28,22:20:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Tysabri was approved by the European Commission in March 2021,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI(R) (natalizumab)
BIIB,2021-04-28,22:20:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Tysabri was approved by the European Commission in March 2021,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI(R) (natalizumab)
BIIB,2021-04-28,22:20:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Tysabri was approved by the European Commission in March 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI(R) (natalizumab)
BIIB,2021-04-28,22:20:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Tysabri was approved by the European Commission in March 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI(R) (natalizumab)
BIIB,2021-05-10,20:06:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,PRESS-RELEASE,GlobeNewswire,Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-10,20:06:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-10,20:06:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-10,20:06:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-10,20:06:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-10,20:06:54,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,NEWS-FLASH,Dow Jones Newswires,Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-12,12:00:49,CEDFD5,Biogen Inc.,95,0.51,products-services,,"Tms Co. Ltd. to acquire TMS-007, an investigational drug",FULL-ARTICLE,Dow Jones Newswires,Biogen Exercises Option to Acquire Investigational Drug TMS-007
BIIB,2021-05-12,12:15:49,CEDFD5,Biogen Inc.,95,0.51,products-services,,"Tms Co. Ltd. to acquire TMS-007, an investigational drug",FULL-ARTICLE,Dow Jones Newswires,Biogen Exercises Option to Acquire Investigational Drug TMS-007
BIIB,2021-05-13,20:06:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,PRESS-RELEASE,GlobeNewswire,Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,20:06:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,20:06:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,20:06:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,20:06:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,20:06:48,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,NEWS-FLASH,Dow Jones Newswires,Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,21:01:14,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics: Announce Collaboration to Advance,NEWS-FLASH,Dow Jones Newswires,Biogen and Envisagenics: Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-14,11:30:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Inc.: the company also entered into an agreement with Catalyst Biosciences to,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:18,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,NEWS-FLASH,Dow Jones Newswires,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:53,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen: Announces Topline Results From Phase 2/3 Gene Therapy Study,NEWS-FLASH,Dow Jones Newswires,Biogen: Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP>BIIB
BIIB,2021-05-14,14:33:51,CEDFD5,Biogen Inc.,96,0.62,acquisitions-mergers,,"Biogen acquired the drug, BIIB",FULL-ARTICLE,Dow Jones Newswires,Biogen Gene Therapy Hits Setback In Study -- Market Talk
BIIB,2021-05-14,14:33:52,CEDFD5,Biogen Inc.,96,0.62,acquisitions-mergers,,"Biogen acquired the drug, BIIB",FULL-ARTICLE,Dow Jones Newswires,Biogen Gene Therapy Hits Setback In Study -- Market Talk
BIIB,2021-05-18,13:46:48,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2021-05-18,13:46:48,CEDFD5,Biogen Inc.,100,0.72,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $300.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $300.00 by Oppenheimer
BIIB,2021-05-20,20:06:00,CEDFD5,Biogen Inc.,99,0.22,products-services,,Biogen Inc.: our state-of-the-art manufacturing site in,PRESS-RELEASE,GlobeNewswire,"Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland"
BIIB,2021-05-20,20:06:00,CEDFD5,Biogen Inc.,99,0.22,products-services,,Biogen Inc.: our state-of-the-art manufacturing site in,PRESS-RELEASE,DJ Global Press Release Wire,"Press Release: Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland"
BIIB,2021-05-20,20:06:01,CEDFD5,Biogen Inc.,99,0.22,products-services,,Biogen Inc.: our state-of-the-art manufacturing site in,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland"
BIIB,2021-05-20,20:06:01,CEDFD5,Biogen Inc.,99,0.22,products-services,,Biogen Inc.: our state-of-the-art manufacturing site in,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland"
BIIB,2021-05-21,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,PRESS-RELEASE,GlobeNewswire,Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:07,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,NEWS-FLASH,Dow Jones Newswires,Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:36,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Biogen, Ginkgo Bioworks to Develop Novel Gene-Therapy",NEWS-FLASH,Dow Jones Newswires,"Biogen, Ginkgo Bioworks to Develop Novel Gene-Therapy Manufacturing Platform"
BIIB,2021-05-21,11:49:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration"
BIIB,2021-05-21,11:49:52,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Inc. Friday said it signed a collaboration and licensing agreement,FULL-ARTICLE,Dow Jones Newswires,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration"
BIIB,2021-05-21,12:04:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration"
BIIB,2021-05-21,12:04:52,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Inc. Friday said it signed a collaboration and licensing agreement,FULL-ARTICLE,Dow Jones Newswires,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration"
BIIB,2021-06-01,11:30:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen and Bio-Thera Announce Positive Results From Phase 3 Study,FULL-ARTICLE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera announced a commercialization and license agreement,FULL-ARTICLE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen and Bio-Thera Announce Positive Results From Phase 3 Study,PRESS-RELEASE,DJ Global Press Release Wire,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera announced a commercialization and license agreement,PRESS-RELEASE,DJ Global Press Release Wire,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen and Bio-Thera Announce Positive Results From Phase 3 Study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera announced a commercialization and license agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen and Bio-Thera Announce Positive Results From Phase 3 Study,PRESS-RELEASE,GlobeNewswire,"Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera announced a commercialization and license agreement,PRESS-RELEASE,GlobeNewswire,"Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen and Bio-Thera Announce Positive Results From Phase 3 Study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera announced a commercialization and license agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-07,14:44:15,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2021-06-07,15:12:37,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2021-06-07,15:49:56,CEDFD5,Biogen Inc.,92,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,FULL-ARTICLE,Dow Jones Newswires,Subscribers: Disregard Biogen Headline
BIIB,2021-06-07,15:59:30,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) today approved aducanumab,PRESS-RELEASE,PR Newswire,FDA APPROVES ADUCANUMAB FOR ALZHEIMER'S DISEASE
BIIB,2021-06-07,16:04:56,CEDFD5,Biogen Inc.,92,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,FULL-ARTICLE,Dow Jones Newswires,Subscribers: Disregard Biogen Headline
BIIB,2021-06-07,17:01:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,GlobeNewswire,Biogen and Eisai launch multiple initiatives to -2-
BIIB,2021-06-07,17:01:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Eisai launch multiple -2-
BIIB,2021-06-07,17:01:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Eisai launch multiple -2-
BIIB,2021-06-07,17:01:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai launch multiple -2-
BIIB,2021-06-07,17:01:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai launch multiple -2-
BIIB,2021-06-07,17:25:02,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2021-06-07,17:30:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2021-06-07,17:37:03,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Paused due to volatility,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Paused due to volatility
BIIB,2021-06-07,17:42:03,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2021-06-07,17:43:34,CEDFD5,Biogen Inc.,92,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,FULL-ARTICLE,Dow Jones Newswires,Subscribers: Disregard Biogen Headline
BIIB,2021-06-07,17:58:34,CEDFD5,Biogen Inc.,92,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,FULL-ARTICLE,Dow Jones Newswires,Subscribers: Disregard Biogen Headline
BIIB,2021-06-07,19:05:47,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Fda cleared Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Drug Approval Bodes Well For Lilly -- Market Talk
BIIB,2021-06-07,19:05:47,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Fda cleared Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Drug Approval Bodes Well For Lilly -- Market Talk
BIIB,2021-06-07,19:18:33,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Fda cleared Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Focus Turns to Insurer Coverage for Alzheimer's Drug -- Market Talk
BIIB,2021-06-07,19:32:22,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Fda's approval of Biogen's Alzheimer's drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Will Market Aduhelm Based on Patients Treated in Studies -- Market Talk
BIIB,2021-06-07,19:32:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda cleared Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Will Market Aduhelm Based on Patients Treated in Studies -- Market Talk
BIIB,2021-06-07,23:05:52,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Dir Posner Sells 360 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,Dir Posner Sells 360 Of Biogen Inc >BIIB
BIIB,2021-06-08,11:19:36,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2021-06-08,11:19:36,CEDFD5,Biogen Inc.,100,0.84,price-targets,upgrade,Biogen Price Target Raised to $452.00/Share From $305.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $452.00/Share From $305.00 by HC Wainwright & Co.
BIIB,2021-06-08,11:29:16,CEDFD5,Biogen Inc.,100,0.62,analyst-ratings,positive,Biogen Raised to Neutral From Underperform by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Neutral From Underperform by Baird
BIIB,2021-06-08,11:29:16,CEDFD5,Biogen Inc.,100,0.9,price-targets,upgrade,Biogen Price Target Raised to $382.00/Share From $216.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $382.00/Share From $216.00 by Baird
BIIB,2021-06-08,11:55:36,CEDFD5,Biogen Inc.,100,0.62,analyst-ratings,positive,Biogen Raised to Neutral From Sell by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Neutral From Sell by Citigroup
BIIB,2021-06-08,11:55:36,CEDFD5,Biogen Inc.,100,0.94,price-targets,upgrade,Biogen Price Target Raised to $440.00/Share From $200.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $440.00/Share From $200.00 by Citigroup
BIIB,2021-06-08,12:08:56,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-06-08,12:08:56,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $455.00/Share From $343.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $455.00/Share From $343.00 by Morgan Stanley
BIIB,2021-06-08,12:27:44,CEDFD5,Biogen Inc.,100,0.82,price-targets,upgrade,Biogen stock price target raised to $450 from $325 at Oppenheimer,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $450 from $325 at Oppenheimer
BIIB,2021-06-08,13:31:47,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2021-06-08,13:31:47,CEDFD5,Biogen Inc.,100,0.84,price-targets,upgrade,Biogen Price Target Raised to $395.00/Share From $265.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $395.00/Share From $265.00 by Barclays
BIIB,2021-06-08,13:35:17,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Jefferies
BIIB,2021-06-08,13:35:17,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $500.00/Share From $450.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $500.00/Share From $450.00 by Jefferies
BIIB,2021-06-08,13:52:27,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-06-08,13:52:27,CEDFD5,Biogen Inc.,100,0.84,price-targets,upgrade,Biogen Price Target Raised to $400.00/Share From $259.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $400.00/Share From $259.00 by RBC Capital
BIIB,2021-06-08,14:54:46,CEDFD5,Biogen Inc.,100,0.88,price-targets,upgrade,Biogen stock price target raised to $400 from $235 at BofA Securities,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $400 from $235 at BofA Securities
BIIB,2021-06-08,14:56:02,CEDFD5,Biogen Inc.,100,0.62,analyst-ratings,positive,Biogen upgraded to neutral from underperform at BofA Securities,NEWS-FLASH,MarketWatch,MW Biogen upgraded to neutral from underperform at BofA Securities
BIIB,2021-06-08,16:36:47,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Outperform From Market Perform by William Blair,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Market Perform by William Blair
BIIB,2021-06-08,17:02:04,CEDFD5,Biogen Inc.,91,0.57,products-services,granted,Fda approval of Biogen's Alzheimer drug,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Approval Means Upside Potential for Roche -- Market Talk
BIIB,2021-06-08,18:27:49,CEDFD5,Biogen Inc.,94,0.0,investor-relations,,Biogen Inc.: the company's conference call with,FULL-ARTICLE,MarketWatch,"MW Biogen expects its $56,000 Alzheimer's drug to be covered by Medicare for 'most' patients"
BIIB,2021-06-08,18:27:49,CEDFD5,Biogen Inc.,94,0.62,analyst-ratings,positive,Bofa Securities analyst Geoff Meacham upgraded Biogen to neutral from underperform,FULL-ARTICLE,MarketWatch,"MW Biogen expects its $56,000 Alzheimer's drug to be covered by Medicare for 'most' patients"
BIIB,2021-06-08,18:27:49,CEDFD5,Biogen Inc.,94,0.0,investor-relations,,Biogen Inc.: the company's conference call with,FULL-ARTICLE,Dow Jones Newswires,"Biogen Expects Its $56,000 Alzheimer's Drug To Be Covered By Medicare For 'most' Patients -- MarketWatch"
BIIB,2021-06-08,18:27:49,CEDFD5,Biogen Inc.,94,0.62,analyst-ratings,positive,Bofa Securities analyst Geoff Meacham upgraded Biogen to neutral from underperform,FULL-ARTICLE,Dow Jones Newswires,"Biogen Expects Its $56,000 Alzheimer's Drug To Be Covered By Medicare For 'most' Patients -- MarketWatch"
BIIB,2021-06-08,20:33:59,CEDFD5,Biogen Inc.,100,-0.45,credit-ratings,negative,S&PGR Afrms Biogen 'A-' Rating; Outlook Negative,NEWS-FLASH,Dow Jones Newswires,S&PGR Afrms Biogen 'A-' Rating; Outlook Negative
BIIB,2021-06-08,20:34:04,CEDFD5,Biogen Inc.,100,-0.45,credit-ratings,negative,S&PGR Afrms Biogen 'A-' Rating; Outlook Negative,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Afrms Biogen 'A-' Rating; Outlook Negative
BIIB,2021-06-08,20:34:04,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Inc.: we expect the multibillion-dollar revenue opportunity to reverse recent revenue declines in 2020 and 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Afrms Biogen 'A-' Rating; Outlook Negative
BIIB,2021-06-08,20:34:04,CEDFD5,Biogen Inc.,100,0.52,products-services,,Vumerity (launched in October 2019,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Afrms Biogen 'A-' Rating; Outlook Negative
BIIB,2021-06-08,20:34:14,CEDFD5,Biogen Inc.,100,0.09,credit-ratings,affirmation,S&PGR Afrms Biogen 'A-' Rating,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Afrms Biogen 'A-' Rating; -2-
BIIB,2021-06-08,20:34:34,CEDFD5,Biogen Inc.,100,-0.57,credit-ratings,negative,S&P Takes Biogen Inc. Off Watch; Outlk Neg,NEWS-FLASH,Dow Jones Newswires,S&P Takes Biogen Inc. Off Watch; Outlk Neg
BIIB,2021-06-09,23:06:23,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Guindo Sells 3,087 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Guindo Sells 3,087 Of Biogen Inc >BIIB"
BIIB,2021-06-09,23:06:48,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Sandrock Sells 7,672 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Sandrock Sells 7,672 Of Biogen Inc >BIIB"
BIIB,2021-06-10,13:04:38,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2021-06-10,13:04:38,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $475.00/Share From $380.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $475.00/Share From $380.00 by SVB Leerink
BIIB,2021-06-10,16:14:49,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Neutral by UBS
BIIB,2021-06-10,16:14:49,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $463.00/Share by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $463.00/Share by UBS
BIIB,2021-06-10,22:40:10,CEDFD5,Biogen Inc.,100,0.05,credit-ratings,confirmation,Moody's Confirms Biogen At Baa1,NEWS-FLASH,Dow Jones Newswires,Moody's Confirms Biogen At Baa1; Stable Outlook
BIIB,2021-06-11,10:58:03,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Outperform From Market Perform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Market Perform by Bernstein
BIIB,2021-06-11,10:58:03,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $500.00/Share by Bernstein,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $500.00/Share by Bernstein
BIIB,2021-06-11,11:22:29,CEDFD5,Biogen Inc.,100,0.86,price-targets,upgrade,Biogen stock price target raised to $435 from $269 at J.P. Morgan,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $435 from $269 at J.P. Morgan
BIIB,2021-06-11,16:14:46,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen upgraded to buy from neutral at UBS,NEWS-FLASH,MarketWatch,MW Biogen upgraded to buy from neutral at UBS
BIIB,2021-06-11,16:15:06,CEDFD5,Biogen Inc.,100,0.84,price-targets,upgrade,Biogen stock price target raised to $463 from $311 at UBS,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $463 from $311 at UBS
BIIB,2021-06-11,16:29:54,CEDFD5,Biogen Inc.,94,0.57,products-services,granted,The FDA gave the green light to Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,A Third Expert Quits FDA Panel Over Approval of Biogen Alzheimer's Drug -- Barrons.com
BIIB,2021-06-11,18:27:30,CEDFD5,Biogen Inc.,93,0.94,analyst-ratings,positive,Bristow upgraded Biogen to buy from neutral,FULL-ARTICLE,MarketWatch,"MW Biogen stock heads for biggest weekly rally in more than 2 decades, UBS analyst targets more gains"
BIIB,2021-06-11,18:27:30,CEDFD5,Biogen Inc.,93,0.94,analyst-ratings,positive,Bristow upgraded Biogen to buy from neutral,FULL-ARTICLE,Dow Jones Newswires,"Biogen Stock Heads For Biggest Weekly Rally In More Than 2 Decades, UBS Analyst Targets More Gains -- MarketWatch"
BIIB,2021-06-14,13:57:31,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2021-06-14,13:57:31,CEDFD5,Biogen Inc.,100,0.82,price-targets,upgrade,Biogen Price Target Raised to $647.00/Share From $458.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $647.00/Share From $458.00 by Truist Securities
BIIB,2021-06-14,14:18:01,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Goldman Sachs
BIIB,2021-06-14,14:18:01,CEDFD5,Biogen Inc.,100,0.9,price-targets,upgrade,Biogen Price Target Raised to $436.00/Share From $246.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $436.00/Share From $246.00 by Goldman Sachs
BIIB,2021-06-14,20:06:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from Phase 3 Gene Therapy Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-14,20:06:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from Phase 3 Gene Therapy Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-14,20:06:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from Phase 3 Gene Therapy Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-14,20:06:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from Phase 3 Gene Therapy Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-14,20:06:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from Phase 3 Gene Therapy Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-14,20:06:07,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 3 Gene Therapy Study,NEWS-FLASH,Dow Jones Newswires,Biogen Announces Topline Results From Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-15,10:30:00,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,Business Wire,"Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:01,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,GlobeNewswire,"Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:01,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:01,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,DJ Global Press Release Wire,"Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:01,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:01,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:07,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,NEWS-FLASH,Dow Jones Newswires,"Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:23,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,NEWS-FLASH,Dow Jones Newswires,Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone
BIIB,2021-06-15,10:30:30,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,12:41:10,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen depressive disorder treatment meets primary endpoint in Phase 3 study,NEWS-FLASH,MarketWatch,"MW Sage Therapeutics, Biogen depressive disorder treatment meets primary endpoint in Phase 3 study"
BIIB,2021-06-15,12:41:15,CEDFD5,Biogen Inc.,95,0.0,products-services,,Partner Biogen Inc. (BIIB) said a Phase 3 study of,FULL-ARTICLE,MarketWatch,"MW Sage, Biogen MDD treatment meets primary endpoint"
BIIB,2021-06-15,12:41:15,CEDFD5,Biogen Inc.,95,0.0,products-services,,Partner Biogen Inc. (BIIB) said a Phase 3 study of,FULL-ARTICLE,Dow Jones Newswires,"Sage, Biogen MDD Treatment Meets Primary Endpoint -- MarketWatch"
BIIB,2021-06-16,13:00:02,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approval of Aducanumab for Alzheimer's Disease,PRESS-RELEASE,GlobeNewswire,Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer's Disease
BIIB,2021-06-16,13:00:02,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen with its efforts to obtain FDA accelerated approval,PRESS-RELEASE,GlobeNewswire,Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer's Disease
BIIB,2021-06-16,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Teams partner with Biogen in,PRESS-RELEASE,GlobeNewswire,Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer's Disease
BIIB,2021-06-16,20:30:00,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen will discontinue clinical development of,FULL-ARTICLE,Dow Jones Newswires,"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:30:00,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen will discontinue clinical development of,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:30:00,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen will discontinue clinical development of,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:30:00,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen will discontinue clinical development of,PRESS-RELEASE,GlobeNewswire,"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:30:01,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen will discontinue clinical development of,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:30:06,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2 Study,NEWS-FLASH,Dow Jones Newswires,"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:32:34,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2 Study,NEWS-FLASH,Dow Jones Newswires,"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:32:40,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen Will Discontinue Clinical Development,NEWS-FLASH,Dow Jones Newswires,Biogen Will Discontinue Clinical Development of Gosuranemab >BIIB
BIIB,2021-06-16,20:33:14,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen: Will Discontinue Clinical Development,NEWS-FLASH,Dow Jones Newswires,Biogen: Will Discontinue Clinical Development of Gosuranemab >BIIB
BIIB,2021-06-16,20:59:18,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen halts development of antibody drug,FULL-ARTICLE,MarketWatch,MW Biogen halts development of antibody drug aimed at Alzheimer's
BIIB,2021-06-16,20:59:18,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval of another Biogen drug,FULL-ARTICLE,MarketWatch,MW Biogen halts development of antibody drug aimed at Alzheimer's
BIIB,2021-06-16,21:01:38,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen to Discontinue Clinical Development of Potential Treatment for Alzheimer,FULL-ARTICLE,Dow Jones Newswires,Biogen to Discontinue Clinical Development of Potential Treatment for Alzheimer's
BIIB,2021-06-16,21:16:38,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen to Discontinue Clinical Development of Potential Treatment for Alzheimer,FULL-ARTICLE,Dow Jones Newswires,Biogen to Discontinue Clinical Development of Potential Treatment for Alzheimer's
BIIB,2021-06-17,11:29:54,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen halts development of antibody drug,FULL-ARTICLE,MarketWatch,MW Biogen halts development of antibody drug aimed at Alzheimer's
BIIB,2021-06-17,11:29:54,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval of another Biogen drug,FULL-ARTICLE,MarketWatch,MW Biogen halts development of antibody drug aimed at Alzheimer's
BIIB,2021-06-17,11:30:01,CEDFD5,Biogen Inc.,99,0.62,products-services,positive,Biogen Inc.: Positive Phase 2 LILAC study efficacy results,PRESS-RELEASE,GlobeNewswire,Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
BIIB,2021-06-17,11:30:01,CEDFD5,Biogen Inc.,99,0.62,products-services,positive,Biogen Inc.: Positive Phase 2 LILAC study efficacy results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
BIIB,2021-06-17,11:30:01,CEDFD5,Biogen Inc.,99,0.62,products-services,positive,Biogen Inc.: Positive Phase 2 LILAC study efficacy results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
BIIB,2021-06-17,11:30:01,CEDFD5,Biogen Inc.,99,0.62,products-services,positive,Biogen Inc.: Positive Phase 2 LILAC study efficacy results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
BIIB,2021-06-18,11:15:33,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Overweight From Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Overweight From Neutral by Piper Sandler
BIIB,2021-06-18,11:15:33,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $450.00/Share From $384.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $450.00/Share From $384.00 by Piper Sandler
BIIB,2021-06-18,12:30:36,CEDFD5,Biogen Inc.,94,0.94,analyst-ratings,positive,"He upgrade Biogen (ticker: BIIB) shares to Overweight, from Neutral",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Can Go 'Decisively Higher' on Sales of Alzheimer's Drug -- Barrons.com
BIIB,2021-06-22,20:30:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approved Biogen Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,FDA Approved Biogen Alzheimer's Drug Despite Some Staff Concerns
BIIB,2021-06-22,20:49:50,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approved Biogen Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,FDA Approved Biogen Alzheimer's Drug Despite Some Staff Concerns -- Update
BIIB,2021-06-22,22:21:31,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approved Biogen Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,FDA Approved Biogen Alzheimer's Drug Despite Some Staff Concerns -- 2nd Update
BIIB,2021-06-23,20:06:03,CEDFD5,Biogen Inc.,99,0.51,products-services,complete,Eisai and Biogen completed enrollment,PRESS-RELEASE,PR Newswire,"Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-23,20:06:03,CEDFD5,Biogen Inc.,99,0.39,products-services,,Eisai and Biogen entered into a joint development and commercialization agreement,PRESS-RELEASE,PR Newswire,"Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-23,20:06:03,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen are collaborating on the joint development,PRESS-RELEASE,PR Newswire,"Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-23,20:06:04,CEDFD5,Biogen Inc.,99,0.51,products-services,complete,Eisai and Biogen completed enrollment,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-23,20:06:04,CEDFD5,Biogen Inc.,99,0.39,products-services,,Eisai and Biogen entered into a joint development and commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-23,20:06:04,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen are collaborating on the joint development,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-24,11:25:51,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda gave its stamp of approval for an Alzheimer's drug from Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Drops Premarket
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Ranibizumab,FULL-ARTICLE,Dow Jones Newswires,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,FULL-ARTICLE,Dow Jones Newswires,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Ranibizumab,PRESS-RELEASE,DJ Global Press Release Wire,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,DJ Global Press Release Wire,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Ranibizumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Ranibizumab,PRESS-RELEASE,GlobeNewswire,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,GlobeNewswire,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Ranibizumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,12:15:14,CEDFD5,Biogen Inc.,100,0.57,products-services,positive,Biogen Gets Positive Opinion in Europe for Eye Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Positive Opinion in Europe for Eye Drug
BIIB,2021-06-25,12:30:14,CEDFD5,Biogen Inc.,100,0.57,products-services,positive,Biogen Gets Positive Opinion in Europe for Eye Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Positive Opinion in Europe for Eye Drug
BIIB,2021-06-28,11:27:38,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-06-28,11:27:38,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $354.00/Share From $400.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $354.00/Share From $400.00 by RBC Capital
BIIB,2021-06-28,14:00:18,CEDFD5,Biogen Inc.,100,-0.52,legal,,Committees announced an investigation of Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Sliding. House Committees Will Investigate Its $56K Alzheimer's Drug. -- Barrons.com
BIIB,2021-06-29,12:53:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Enel S.p.A.: Our relationship with Biogen,PRESS-RELEASE,PR Newswire,Enel X Collaborates With Biogen To Electrify Take-home Vehicle Fleet In North America
BIIB,2021-06-29,12:53:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Enel S.p.A.: Our relationship with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Enel X Collaborates With Biogen To Electrify Take-home Vehicle Fleet In North America
BIIB,2021-06-29,12:53:14,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Enel X Collaborates With Biogen to,NEWS-FLASH,Dow Jones Newswires,Enel X Collaborates With Biogen to Electrify Take-home Vehicle Fleet in N Amer
BIIB,2021-07-02,21:23:24,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 177 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 177 Of Biogen Inc >BIIB
BIIB,2021-07-09,18:02:10,CEDFD5,Biogen Inc.,98,0.49,partnerships,,Biogen Inc.: They collaborated with the company to,FULL-ARTICLE,Dow Jones Newswires,"FDA Seeks Probe of Talks Between Staff, Biogen on Alzheimer's Drug -- Update"
BIIB,2021-07-09,18:34:41,CEDFD5,Biogen Inc.,99,-0.52,products-services,,Biogen scrapped development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW FDA calls for investigation into its own approval of Biogen's Alzheimer's drug
BIIB,2021-07-09,18:37:28,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: They collaborated with the company to,FULL-ARTICLE,Dow Jones Newswires,"FDA Seeks Probe of Talks Between Staff, Biogen on Alzheimer's Drug -- Update 2"
BIIB,2021-07-09,18:57:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration's approval last month of Biogen's Alzheimer's disease therapy,FULL-ARTICLE,Dow Jones Newswires,FDA Commissioner Asks for Investigation Into Approval Process for Biogen's Alzheimer's Drug -- Barrons.com
BIIB,2021-07-09,19:33:32,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration last month approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,"Biogen Alzheimer's Drug Will Exceed the $56,000 List Price for Many, Analysis Says"
BIIB,2021-07-09,19:50:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration last month approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,"Biogen Alzheimer's Drug Will Exceed the $56,000 List Price for Many, Analysis Says"
BIIB,2021-07-09,23:15:49,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: They collaborated with the company to,FULL-ARTICLE,Dow Jones Newswires,"FDA Seeks Probe of Talks Between Staff, Biogen on Alzheimer's Drug -- 3rd Update"
BIIB,2021-07-10,06:14:14,CEDFD5,Biogen Inc.,98,0.49,partnerships,,Biogen Inc.: They collaborated with the company to,FULL-ARTICLE,Dow Jones Newswires,U.S. News:  FDA Seeks Probe of Talks  Between Staff and Biogen  ---  Agency chief requests  review of interactions  before recent approval  of Alzheimer's drug  ----  By Thomas M. Burton
BIIB,2021-07-10,06:32:21,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: They collaborated with the company to,FULL-ARTICLE,Wall Street Journal,FDA Seeks Probe of Talks Between Staff and Biogen -- WSJ
BIIB,2021-07-10,12:52:49,CEDFD5,Biogen Inc.,99,-0.52,products-services,,Biogen scrapped development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW FDA calls for investigation into its own approval of Biogen's Alzheimer's drug
BIIB,2021-07-11,13:14:38,CEDFD5,Biogen Inc.,99,-0.52,products-services,,Biogen scrapped development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW FDA calls for investigation into its own approval of Biogen's Alzheimer's drug
BIIB,2021-07-12,14:10:40,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda's approval of Biogen's Alzheimer's drug,FULL-ARTICLE,Dow Jones Newswires,Wall Street Shrugs Off FDA's Call for Probe of Approval of Biogen Alzheimer's Drug -- Barrons.com
BIIB,2021-07-12,14:10:40,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda announced its approval of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Wall Street Shrugs Off FDA's Call for Probe of Approval of Biogen Alzheimer's Drug -- Barrons.com
BIIB,2021-07-12,23:00:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,PRESS-RELEASE,GlobeNewswire,"Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:00:44,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,NEWS-FLASH,Dow Jones Newswires,"Biogen and Innocare Announce License and Collaboration Agreement for Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor for the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:02:20,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare: Announce License and Collaboration,NEWS-FLASH,Dow Jones Newswires,"Biogen and Innocare: Announce License and Collaboration Agreement for Orelabrutinib, a CNS Penetrant BTK Inhibitor for Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:14:54,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen in Rights Agreement With InnoCare,FULL-ARTICLE,Dow Jones Newswires,Biogen in Rights Agreement With InnoCare for Orelabrutinib Drug
BIIB,2021-07-12,23:29:54,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen in Rights Agreement With InnoCare,FULL-ARTICLE,Dow Jones Newswires,Biogen in Rights Agreement With InnoCare for Orelabrutinib Drug
BIIB,2021-07-14,12:17:13,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency approved Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,Top FDA Staffers Defend Approval of Biogen's Alzheimer's Drug in Medical Journal -- Barrons.com
BIIB,2021-07-16,12:45:37,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-07-16,12:45:37,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $453.00/Share From $455.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $453.00/Share From $455.00 by Morgan Stanley
BIIB,2021-07-21,07:34:54,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 2Q 2021 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 2Q 2021 (BIIB)"
BIIB,2021-07-21,12:03:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc.: Mirimus, Inc. Forms Strategic Collaboration with Biogen",PRESS-RELEASE,PR Newswire,"Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications"
BIIB,2021-07-21,12:03:04,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Forms Strategic Collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications"
BIIB,2021-07-21,12:04:06,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Forms Strategic Collaboration With Biogen to,NEWS-FLASH,Dow Jones Newswires,Mirimus Forms Strategic Collaboration With Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications
BIIB,2021-07-22,11:09:33,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $2.99 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q EPS $2.99 >BIIB
BIIB,2021-07-22,11:09:33,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Net $448.5M,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Net $448.5M >BIIB
BIIB,2021-07-22,11:19:44,CEDFD5,Biogen Inc.,100,-0.7,earnings,down,Biogen Q2 EPS $2.99 vs. $9.59 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q2 EPS $2.99 vs. $9.59 a year ago
BIIB,2021-07-22,11:20:08,CEDFD5,Biogen Inc.,100,-0.44,revenues,down,Biogen Q2 revenue $2.775 bln vs. $3.681 bln a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q2 revenue $2.775 bln vs. $3.681 bln a year ago
BIIB,2021-07-22,11:20:27,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Q2 FactSet EPS consensus $4.55,NEWS-FLASH,MarketWatch,MW Biogen Q2 FactSet EPS consensus $4.55; revenue $2.609 bln
BIIB,2021-07-22,11:22:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Q2 adj. EPS $5.68,NEWS-FLASH,MarketWatch,MW Biogen Q2 adj. EPS $5.68
BIIB,2021-07-22,11:22:59,CEDFD5,Biogen Inc.,100,-0.42,revenues,down,Biogen Q2 MS revenue fell 24% to $1.786 bln,NEWS-FLASH,MarketWatch,MW Biogen Q2 MS revenue fell 24% to $1.786 bln
BIIB,2021-07-22,11:23:15,CEDFD5,Biogen Inc.,100,0.41,revenues,up,Biogen Q2 Spinraza revenue up 1% at $500 mln,NEWS-FLASH,MarketWatch,MW Biogen Q2 Spinraza revenue up 1% at $500 mln
BIIB,2021-07-22,11:23:33,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Q2 Aduhelm revenue $2 mln,NEWS-FLASH,MarketWatch,MW Biogen Q2 Aduhelm revenue $2 mln
BIIB,2021-07-22,11:23:42,CEDFD5,Biogen Inc.,100,0.41,revenues,up,Biogen Q2 biosimilars revenue up 18% to $202 mln,NEWS-FLASH,MarketWatch,MW Biogen Q2 biosimilars revenue up 18% to $202 mln
BIIB,2021-07-22,11:24:39,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees full-year adj. EPS $17.50 to $19.00,NEWS-FLASH,MarketWatch,"MW Biogen now sees full-year adj. EPS $17.50 to $19.00, unchanged vs. prior guidance"
BIIB,2021-07-22,11:25:04,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen now sees full-year revenue $10.65 bln to $10.85 bln,NEWS-FLASH,MarketWatch,MW Biogen now sees full-year revenue $10.65 bln to $10.85 bln vs. prior $10.45 bln to $10.75 bln
BIIB,2021-07-22,11:31:14,CEDFD5,Biogen Inc.,100,-0.7,earnings,down,"Biogen Inc.: Net income attributable to the company was $448.5 million, compared with $1.54 billion",FULL-ARTICLE,Dow Jones Newswires,"Biogen Posts 2Q Sales, Earnings Declines on Lower Multiple-Sclerosis Drug Revenue"
BIIB,2021-07-22,11:31:14,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.'s reported second-quarter revenue,FULL-ARTICLE,Dow Jones Newswires,"Biogen Posts 2Q Sales, Earnings Declines on Lower Multiple-Sclerosis Drug Revenue"
BIIB,2021-07-22,11:46:14,CEDFD5,Biogen Inc.,100,-0.7,earnings,down,"Biogen Inc.: Net income attributable to the company was $448.5 million, compared with $1.54 billion",FULL-ARTICLE,Dow Jones Newswires,"Biogen Posts 2Q Sales, Earnings Declines on Lower Multiple-Sclerosis Drug Revenue"
BIIB,2021-07-22,11:46:14,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.'s reported second-quarter revenue,FULL-ARTICLE,Dow Jones Newswires,"Biogen Posts 2Q Sales, Earnings Declines on Lower Multiple-Sclerosis Drug Revenue"
BIIB,2021-07-22,11:46:19,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Raises Rev Guidance,FULL-ARTICLE,Dow Jones Newswires,"Biogen Raises Rev Guidance, Reiterates Earnings Guidance"
BIIB,2021-07-22,11:54:47,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the second quarter,FULL-ARTICLE,MarketWatch,"MW Biogen's beats on earnings, says it's also brought in $2 million in sales of Alzheimer's drug"
BIIB,2021-07-22,11:54:47,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the second quarter,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Beats On Earnings, Says It's Also Brought In $2 Million In Sales Of Alzheimer's Drug -- MarketWatch"
BIIB,2021-07-22,11:55:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen's Aduhelm Posts 2Q Sales of $1.6M,FULL-ARTICLE,Dow Jones Newswires,Biogen's Aduhelm Posts 2Q Sales of $1.6M -- Market Talk
BIIB,2021-07-22,11:55:45,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen raised its full-year 2021 revenue guidance to a range of $10.65B to $10.85B,FULL-ARTICLE,Dow Jones Newswires,Biogen's Aduhelm Posts 2Q Sales of $1.6M -- Market Talk
BIIB,2021-07-22,11:55:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen's Aduhelm Posts 2Q Sales of $1.6M,FULL-ARTICLE,Dow Jones Newswires,Biogen's Aduhelm Posts 2Q Sales of $1.6M -- Market Talk
BIIB,2021-07-22,11:55:45,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen raised its full-year 2021 revenue guidance to a range of $10.65B to $10.85B,FULL-ARTICLE,Dow Jones Newswires,Biogen's Aduhelm Posts 2Q Sales of $1.6M -- Market Talk
BIIB,2021-07-22,12:01:19,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Raises Revenue Guidance,FULL-ARTICLE,Dow Jones Newswires,"Biogen Raises Revenue Guidance, Reiterates Earnings Guidance"
BIIB,2021-07-22,13:40:36,CEDFD5,Biogen Inc.,97,0.0,revenues,,Biogen reported $1.6 million in revenues,FULL-ARTICLE,Dow Jones Newswires,Biogen Sold $1.6M of Aduhelm in Weeks After Approval. Earnings Were Strong. -- Barrons.com
BIIB,2021-07-22,17:06:54,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q2 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q2 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2021-07-22,17:06:54,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen-inc-biib-ceo-michel-vounatsos-on-q2-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q2 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2021-07-22,18:11:51,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the second quarter,FULL-ARTICLE,MarketWatch,"MW Biogen beats on earnings, says it's brought in $2 million in sales of Alzheimer's drug"
BIIB,2021-07-22,18:11:51,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the second quarter,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen Beats On Earnings, Says It's Brought In $2 Million In Sales Of Alzheimer's Drug -- MarketWatch"
BIIB,2021-07-22,19:07:16,CEDFD5,Biogen Inc.,99,-0.47,regulatory,,Aduhelm is currently being reviewed by regulators,FULL-ARTICLE,MarketWatch,"MW Biogen, under pressure, tells investors it 'stands by' the FDA review process for its Alzheimer's drug"
BIIB,2021-07-23,11:00:00,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-07-23,11:00:00,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $341.00/Share From $361.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $341.00/Share From $361.00 by RBC Capital
BIIB,2021-07-23,11:33:07,CEDFD5,Biogen Inc.,99,-0.47,regulatory,,Aduhelm is currently being reviewed by regulators,FULL-ARTICLE,MarketWatch,"MW Biogen, under pressure, tells investors it 'stands by' the FDA review process for its Alzheimer's drug"
BIIB,2021-07-23,13:36:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-07-23,13:36:01,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $455.00/Share From $453.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $455.00/Share From $453.00 by Morgan Stanley
BIIB,2021-07-23,16:16:02,CEDFD5,Biogen Inc.,99,-0.47,regulatory,,Aduhelm is currently being reviewed by regulators,FULL-ARTICLE,MarketWatch,"MW Biogen, under pressure, tells investors it 'stands by' the FDA review process for its Alzheimer's drug"
BIIB,2021-07-23,20:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results in early-stage clinical trials,PRESS-RELEASE,GlobeNewswire,Biogen to Present Data from ADUHELM and -2-
BIIB,2021-07-23,20:34:22,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results in early-stage clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present Data from -2-
BIIB,2021-07-27,14:39:46,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2021-07-27,14:39:46,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $423.00/Share From $359.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $423.00/Share From $359.00 by Canaccord Genuity
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,Nasdaq: BIIB) today announced results from the two-year,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,Nasdaq: BIIB) today announced results from the two-year,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Results from Phase 3b NOVA Study -2-
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Results from Phase 3b NOVA Study -2-
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,Nasdaq: BIIB) today announced results from the two-year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc. (Nasdaq: BIIB) today announced results from the two-year,PRESS-RELEASE,GlobeNewswire,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces Results from Phase 3b NOVA Study -2-
BIIB,2021-08-02,11:30:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc. (Nasdaq: BIIB) today announced results from the two-year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:31:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results From Phase 3b NOVA Study,NEWS-FLASH,Dow Jones Newswires,Biogen Announces Results From Phase 3b NOVA Study Evaluating Every Six-Week Dosing With Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,12:28:34,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Mizuho
BIIB,2021-08-02,12:28:34,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $300.00/Share From $244.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $300.00/Share From $244.00 by Mizuho
BIIB,2021-08-23,15:00:04,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,The U.S. Food & Drug Administration granted approval of Aduhelm,PRESS-RELEASE,PR Newswire,First Patient in West Michigan Receives Biogen Alzheimer's Drug at Infusion Associates Outpatient Infusion Center
BIIB,2021-08-26,15:48:44,CEDFD5,Biogen Inc.,97,0.0,revenues,,Now expects $13 million in Aduhelm sales in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Early Sales of Biogen's Alzheimer Drug Remain Unclear -- Barrons.com
BIIB,2021-08-26,15:48:44,CEDFD5,Biogen Inc.,97,0.0,investor-relations,,Biogen Inc.: the company's earnings call in July,FULL-ARTICLE,Dow Jones Newswires,Early Sales of Biogen's Alzheimer Drug Remain Unclear -- Barrons.com
BIIB,2021-08-27,15:22:21,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's second-quarter earnings call,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Beyond Reach for Many Patients
BIIB,2021-08-27,15:40:04,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's second-quarter earnings call,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Beyond Reach for Many Patients
BIIB,2021-08-28,06:14:15,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's second-quarter earnings call,FULL-ARTICLE,Dow Jones Newswires,U.S. News:  Biogen Alzheimer's Drug Sits Unused  ----  By Joseph Walker
BIIB,2021-08-28,06:32:36,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's second-quarter earnings call,FULL-ARTICLE,Wall Street Journal,Biogen Alzheimer's Drug Sits Unused -- WSJ
BIIB,2021-09-03,20:13:05,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 3,423 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 3,423 Of Biogen Inc >BIIB"
BIIB,2021-09-13,11:05:28,CEDFD5,Biogen Inc.,92,0.52,products-services,,Biogen Inc.: the company said the launch of its Alzheimer's drug,FULL-ARTICLE,Dow Jones Newswires,"Airbnb, Apache, Biogen: What to Watch When the Stock Market Opens Today"
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Plans to Initiate Phase 3b Study -2-
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Plans to Initiate Phase 3b Study -2-
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,GlobeNewswire,Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,GlobeNewswire,Biogen Plans to Initiate Phase 3b Study -2-
BIIB,2021-09-15,11:30:02,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)
BIIB,2021-09-15,11:30:23,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,NEWS-FLASH,Dow Jones Newswires,Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of Higher Dose of Nusinersen in Patients Previously Treated With Evrysdi
BIIB,2021-09-15,11:45:28,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Plans Phase 3b Trial of,FULL-ARTICLE,Dow Jones Newswires,Biogen Plans Phase 3b Trial of Spinal Muscular Atrophy Drug
BIIB,2021-09-15,12:00:28,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Plans Phase 3b Trial of,FULL-ARTICLE,Dow Jones Newswires,Biogen Plans Phase 3b Trial of Spinal Muscular Atrophy Drug
BIIB,2021-09-15,18:14:18,CEDFD5,Biogen Inc.,92,0.0,products-services,,Biogen Plans Phase 3b Trial of,FULL-ARTICLE,Dow Jones Newswires,Correction to Biogen Plans Phase 3b Trial Article
BIIB,2021-09-15,18:29:18,CEDFD5,Biogen Inc.,92,0.0,products-services,,Biogen Plans Phase 3b Trial of,FULL-ARTICLE,Dow Jones Newswires,Correction to Biogen Plans Phase 3b Trial Article
BIIB,2021-09-16,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:30:02,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:30:37,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results From Phase 2 CONVEY Study,NEWS-FLASH,Dow Jones Newswires,Biogen Announces Positive Topline Results From Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:50:55,CEDFD5,Biogen Inc.,93,0.0,products-services,,Biogen Inc. said its Phase 2 study of,FULL-ARTICLE,Dow Jones Newswires,Biogen Drug Candidate for Small Fiber Neuropathy Meets Primary Endpoint for 200 Milligram Dose
BIIB,2021-09-16,12:05:56,CEDFD5,Biogen Inc.,93,0.0,products-services,,Biogen Inc. said its Phase 2 study of,FULL-ARTICLE,Dow Jones Newswires,Biogen Drug Candidate for Small Fiber Neuropathy Meets Primary Endpoint for 200 Milligram Dose
BIIB,2021-09-16,12:51:33,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by UBS
BIIB,2021-09-16,12:51:33,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $442.00/Share From $475.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $442.00/Share From $475.00 by UBS
BIIB,2021-09-20,11:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,DJ Global Press Release Wire,"FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,FULL-ARTICLE,Dow Jones Newswires,"FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:30:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,GlobeNewswire,"FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:30:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,GlobeNewswire,"FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:30:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:32:23,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda-approved ADUHELM,FULL-ARTICLE,Dow Jones Newswires,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai in collaboration with Biogen, and BIIB",FULL-ARTICLE,Dow Jones Newswires,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.7,products-services,,Lecanemab received Breakthrough Therapy designation from the FDA,FULL-ARTICLE,Dow Jones Newswires,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda-approved ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai in collaboration with Biogen, and BIIB",PRESS-RELEASE,DJ Global Press Release Wire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.7,products-services,,Lecanemab received Breakthrough Therapy designation from the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: A Phase 1b study of,PRESS-RELEASE,DJ Global Press Release Wire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",FULL-ARTICLE,Dow Jones Newswires,Biogen R&D Day to Provide Overview of Diversified -2-
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,DJ Global Press Release Wire,Biogen R&D Day to Provide Overview of Diversified -2-
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda-approved ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai in collaboration with Biogen, and BIIB",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.7,products-services,,Lecanemab received Breakthrough Therapy designation from the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: A Phase 1b study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview -2-
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda-approved ADUHELM,PRESS-RELEASE,GlobeNewswire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai in collaboration with Biogen, and BIIB",PRESS-RELEASE,GlobeNewswire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.7,products-services,,Lecanemab received Breakthrough Therapy designation from the FDA,PRESS-RELEASE,GlobeNewswire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: A Phase 1b study of,PRESS-RELEASE,GlobeNewswire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,GlobeNewswire,Biogen R&D Day to Provide Overview of Diversified -2-
BIIB,2021-09-21,12:30:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda-approved ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai in collaboration with Biogen, and BIIB",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:02,CEDFD5,Biogen Inc.,99,0.7,products-services,,Lecanemab received Breakthrough Therapy designation from the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:02,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: A Phase 1b study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview -2-
BIIB,2021-09-22,14:04:34,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Goodman has an Outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Down on a Report That Few Have Received Its New Alzheimer's Therapy -- Barrons.com
BIIB,2021-09-23,08:48:58,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Biogen Initiated at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Buy by Needham
BIIB,2021-09-23,08:48:58,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $400.00/Share by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $400.00/Share by Needham
BIIB,2021-09-24,15:47:21,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Committee to approve Aduhelm,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Aduhelm Struggles Don't Hurt Lilly's Outlook, Says Analyst -- Barrons.com"
BIIB,2021-09-29,11:34:39,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-09-29,11:34:39,CEDFD5,Biogen Inc.,100,-0.54,price-targets,downgrade,Biogen Price Target Cut to $326.00/Share From $341.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $326.00/Share From $341.00 by RBC Capital
BIIB,2021-10-08,10:58:24,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2021-10-08,10:58:24,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $290.00/Share From $395.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $290.00/Share From $395.00 by Barclays
BIIB,2021-10-08,13:13:54,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Jefferies
BIIB,2021-10-08,13:13:54,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $400.00/Share From $500.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $400.00/Share From $500.00 by Jefferies
BIIB,2021-10-12,12:19:38,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-10-12,12:19:38,CEDFD5,Biogen Inc.,100,-0.34,price-targets,downgrade,Biogen Price Target Cut to $447.00/Share From $455.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $447.00/Share From $455.00 by Morgan Stanley
BIIB,2021-10-13,10:05:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Combined post-marketing data based on prescriptions and clinical trials,PRESS-RELEASE,GlobeNewswire,New Data at ECTRIMS 2021 Highlight Biogen's Focus -2-
BIIB,2021-10-13,10:05:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Combined post-marketing data based on prescriptions and clinical trials,PRESS-RELEASE,DJ Global Press Release Wire,New Data at ECTRIMS 2021 Highlight Biogen's Focus -3-
BIIB,2021-10-15,10:52:39,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen stock price target cut to $344 from $430 at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $344 from $430 at Stifel Nicolaus
BIIB,2021-10-15,13:26:56,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Cantor Fitzgerald
BIIB,2021-10-15,13:26:56,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $327.00/Share From $427.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $327.00/Share From $427.00 by Cantor Fitzgerald
BIIB,2021-10-15,13:32:36,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Stifel
BIIB,2021-10-15,13:32:36,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $344.00/Share From $430.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $344.00/Share From $430.00 by Stifel
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from the Tofersen Phase 3 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen will expand its ongoing early access program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Data from the tofersen Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen will expand its ongoing early access program,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen will expand its ongoing early access program,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Data from the tofersen Phase 3 study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The open-label extension study is an ongoing Phase 3 study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen will expand its ongoing early access program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Data from the tofersen Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The open-label extension study is an ongoing Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:03,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen will expand its ongoing early access program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
BIIB,2021-10-18,12:09:08,CEDFD5,Biogen Inc.,100,-0.65,products-services,negative,Biogen says ALS drug did not meet primary endpoint in Phase 3 clinical trial,FULL-ARTICLE,MarketWatch,MW Biogen says ALS drug did not meet primary endpoint in Phase 3 clinical trial
BIIB,2021-10-18,12:09:08,CEDFD5,Biogen Inc.,100,-0.65,products-services,negative,Biogen Says ALS Drug Did Not Meet Primary Endpoint In Phase 3 Clinical Trial,FULL-ARTICLE,Dow Jones Newswires,Biogen Says ALS Drug Did Not Meet Primary Endpoint In Phase 3 Clinical Trial -- MarketWatch
BIIB,2021-10-18,13:32:24,CEDFD5,Biogen Inc.,97,-0.65,products-services,negative,Experimental drug tofersen failed in a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Biogen Suffers Pipeline Setback in ALS Study -- Market Talk
BIIB,2021-10-18,13:32:24,CEDFD5,Biogen Inc.,97,-0.65,products-services,negative,Experimental drug tofersen failed in a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Biogen Suffers Pipeline Setback in ALS Study -- Market Talk
BIIB,2021-10-19,10:14:30,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2021-10-19,10:14:30,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $398.00/Share From $400.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $398.00/Share From $400.00 by Needham
BIIB,2021-10-19,10:30:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Sage Therapeutics And Biogen Announce Plans To Submit A New Drug Application (NDA) For Zuranolone To The U.S. Food & Drug Administration In,NEWS-FLASH,Dow Jones Newswires,Sage Therapeutics And Biogen Announce Plans To Submit A New Drug Application (NDA) For Zuranolone To The U.S. Food & Drug Administration In The Second Half Of 2022 With Rolling Submission Expected To Start In Early 2022 >SAGE
BIIB,2021-10-19,10:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in,PRESS-RELEASE,Business Wire,Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
BIIB,2021-10-19,10:30:54,CEDFD5,Biogen Inc.,100,0.0,products-services,,Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
BIIB,2021-10-19,10:31:08,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone",NEWS-FLASH,Dow Jones Newswires,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone in 2nd Half of 2022"
BIIB,2021-10-19,11:10:35,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone",FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone in 2nd Half of 2022"
BIIB,2021-10-19,11:25:35,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone",FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone in 2nd Half of 2022"
BIIB,2021-10-20,11:10:34,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,3Q EPS $2.22 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q EPS $2.22 >BIIB
BIIB,2021-10-20,11:10:34,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $4.77,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $4.77 >BIIB
BIIB,2021-10-20,11:10:34,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Net $329.2M,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Net $329.2M >BIIB
BIIB,2021-10-20,11:10:34,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.78B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.78B >BIIB
BIIB,2021-10-20,11:16:39,CEDFD5,Biogen Inc.,100,-0.38,revenues,down,"Biogen 3Q Multiple Sclerosis Rev Including Royalties on OCREVUS Sales $1.82B, Down 19%",NEWS-FLASH,Dow Jones Newswires,"Biogen 3Q Multiple Sclerosis Rev Including Royalties on OCREVUS Sales $1.82B, Down 19% >BIIB"
BIIB,2021-10-20,11:17:07,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen 3Q SPINRAZA Rev $444M, Down 10%",NEWS-FLASH,Dow Jones Newswires,"Biogen 3Q SPINRAZA Rev $444M, Down 10% >BIIB"
BIIB,2021-10-20,11:18:28,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees FY Rev $10.8B-$10.9B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Sees FY Rev $10.8B-$10.9B >BIIB
BIIB,2021-10-20,11:18:28,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY Adj EPS $18.85,NEWS-FLASH,Dow Jones Newswires,Biogen Sees FY Adj EPS $18.85-Adj EPS $19.35 >BIIB
BIIB,2021-10-20,11:18:54,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Sees FY CapEx $250M-$300M >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Sees FY CapEx $250M-$300M >BIIB
BIIB,2021-10-20,11:23:37,CEDFD5,Biogen Inc.,100,-0.62,earnings,down,Biogen Q3 EPS $2.22 vs. $4.46 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q3 EPS $2.22 vs. $4.46 a year ago
BIIB,2021-10-20,11:23:55,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q3 adj. EPS $4.77; FactSet consensus $4.09,NEWS-FLASH,MarketWatch,MW Biogen Q3 adj. EPS $4.77; FactSet consensus $4.09
BIIB,2021-10-20,11:24:20,CEDFD5,Biogen Inc.,100,-0.34,revenues,down,Biogen Q3 revenue down 17% to $2.779 bln,NEWS-FLASH,MarketWatch,MW Biogen Q3 revenue down 17% to $2.779 bln; FactSet consensus $2.669 bln
BIIB,2021-10-20,11:25:48,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raises full-year guidance,NEWS-FLASH,MarketWatch,"MW Biogen raises full-year guidance, now sees revenue of $10.8 bln to $10.9 bln vs. prior $10.65 bln to $10.85 bln"
BIIB,2021-10-20,11:26:26,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees full-year adj. EPS of $18.85 to $19.35,NEWS-FLASH,MarketWatch,MW Biogen now sees full-year adj. EPS of $18.85 to $19.35 vs. prior $17.50 to $19.00
BIIB,2021-10-20,11:28:13,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises Full-Year Guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises Full-Year Guidance
BIIB,2021-10-20,11:28:13,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Inc. raised its full-year sales and earnings guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises Full-Year Guidance
BIIB,2021-10-20,11:31:11,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen 3Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Biogen 3Q Results Beat Expectations; Alzheimer's Drug Aduhelm Posts Sales of $300,000"
BIIB,2021-10-20,11:43:13,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises Full-Year Guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises Full-Year Guidance
BIIB,2021-10-20,11:43:13,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Inc. raised its full-year sales and earnings guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises Full-Year Guidance
BIIB,2021-10-20,11:46:10,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen 3Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Biogen 3Q Results Beat Expectations; Alzheimer's Drug Aduhelm Posts Sales of $300,000"
BIIB,2021-10-20,11:49:33,CEDFD5,Biogen Inc.,95,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the third quarter,FULL-ARTICLE,MarketWatch,"MW Biogen's stock is up on strong earnings; new Alzheimer's drug had $300,000 in sales in Q3"
BIIB,2021-10-20,11:49:33,CEDFD5,Biogen Inc.,95,0.0,revenues,,Biogen's revenue was $2.7 billion in the third quarter,FULL-ARTICLE,MarketWatch,"MW Biogen's stock is up on strong earnings; new Alzheimer's drug had $300,000 in sales in Q3"
BIIB,2021-10-20,11:49:33,CEDFD5,Biogen Inc.,95,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the third quarter,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Is Up On Strong Earnings; New Alzheimer's Drug Had $300,000 In Sales In Q3 -- MarketWatch"
BIIB,2021-10-20,11:49:33,CEDFD5,Biogen Inc.,95,0.0,revenues,,Biogen's revenue was $2.7 billion in the third quarter,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Is Up On Strong Earnings; New Alzheimer's Drug Had $300,000 In Sales In Q3 -- MarketWatch"
BIIB,2021-10-20,12:17:21,CEDFD5,Biogen Inc.,99,0.64,earnings,up,Biogen increased its profit,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock. -- Barrons.com
BIIB,2021-10-20,12:17:21,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen said that third-quarter revenues,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock. -- Barrons.com
BIIB,2021-10-20,12:17:21,CEDFD5,Biogen Inc.,99,-0.11,products-services,,Spinraza are facing increasing competition,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock. -- Barrons.com
BIIB,2021-10-20,12:30:04,CEDFD5,Biogen Inc.,99,0.64,earnings,up,Biogen increased its profit,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.
BIIB,2021-10-20,12:30:04,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen said that third-quarter revenues,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.
BIIB,2021-10-20,12:30:04,CEDFD5,Biogen Inc.,99,-0.11,products-services,,Spinraza are facing increasing competition,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.
BIIB,2021-10-20,12:31:19,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,The Food and Drug Administration approved Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Meets Slow Rollout -- Update
BIIB,2021-10-20,12:31:19,CEDFD5,Biogen Inc.,96,-0.68,revenues,down,Biogen's sales declined to $2.78 billion in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Meets Slow Rollout -- Update
BIIB,2021-10-20,12:40:03,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,The Food and Drug Administration approved Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Meets Slow Rollout
BIIB,2021-10-20,12:40:03,CEDFD5,Biogen Inc.,96,-0.68,revenues,down,Biogen's sales declined to $2.78 billion in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Meets Slow Rollout
BIIB,2021-10-20,14:41:59,CEDFD5,Biogen Inc.,99,0.7,earnings,up,Biogen raised its sales and profit outlook for 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen Shareholders Face the Waiting Game -- Heard on the Street
BIIB,2021-10-20,15:52:37,CEDFD5,Biogen Inc.,99,-0.68,revenues,down,Biogen's sales declined to $2.78 billion for the third quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Meets Slow Rollout -- 2nd Update
BIIB,2021-10-20,17:41:05,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q3 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q3 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2021-10-21,06:00:56,CEDFD5,Biogen Inc.,99,0.7,earnings,up,Biogen raised its sales and profit outlook for 2021,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street:  Biogen Shareholders Face  Waiting Game on Alzheimer's Drug  ----  By Charley Grant
BIIB,2021-10-21,06:09:16,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Biogen's sales declined to $2.78 billion for the third quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Posts Weak Quarterly Sales  Of New Alzheimer's Drug Aduhelm  ----  By Joseph Walker and Matt Grossman
BIIB,2021-10-21,06:32:07,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Biogen's sales declined to $2.78 billion for the third quarter,FULL-ARTICLE,Wall Street Journal,Biogen Posts Weak Quarterly Sales Of New Alzheimer's Drug Aduhelm -- WSJ
BIIB,2021-10-21,06:32:16,CEDFD5,Biogen Inc.,99,0.7,earnings,up,Biogen raised its sales and profit outlook for 2021,FULL-ARTICLE,Wall Street Journal,Heard on the Street: Biogen Shareholders Face Waiting Game on Alzheimer's Drug -- WSJ
BIIB,2021-10-21,07:19:35,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 3Q 2021 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 3Q 2021 (BIIB)"
BIIB,2021-10-21,10:28:52,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2021-10-21,10:28:52,CEDFD5,Biogen Inc.,100,-0.44,price-targets,downgrade,Biogen Price Target Cut to $386.00/Share From $398.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $386.00/Share From $398.00 by Needham
BIIB,2021-10-21,11:26:22,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2021-10-21,11:26:22,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $390.00/Share From $450.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $390.00/Share From $450.00 by Oppenheimer
BIIB,2021-10-21,11:30:09,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen stock price target cut to $502 from $647,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $502 from $647 at Truist
BIIB,2021-10-21,11:41:56,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen stock price target cut to $390 from $450 at Oppenheimer,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $390 from $450 at Oppenheimer
BIIB,2021-10-21,12:11:52,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-10-21,12:11:52,CEDFD5,Biogen Inc.,100,-0.76,price-targets,downgrade,Biogen Price Target Cut to $295.00/Share From $325.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $295.00/Share From $325.00 by RBC Capital
BIIB,2021-10-21,13:21:23,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-10-21,13:21:23,CEDFD5,Biogen Inc.,100,-0.32,price-targets,downgrade,Biogen Price Target Cut to $440.00/Share From $447.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $440.00/Share From $447.00 by Morgan Stanley
BIIB,2021-10-21,14:28:03,CEDFD5,Biogen Inc.,100,0.2,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Cowen & Co.
BIIB,2021-10-21,14:28:03,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $375.00/Share From $450.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $375.00/Share From $450.00 by Cowen & Co.
BIIB,2021-10-21,16:00:11,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-21,16:00:11,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-21,16:00:11,CEDFD5,Biogen Inc.,99,0.46,equity-actions,,Biib's continued considerable investment in the program,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,11:36:48,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,11:36:48,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,11:36:48,CEDFD5,Biogen Inc.,99,0.46,equity-actions,,Biib's continued considerable investment in the program,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,13:00:15,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,13:00:15,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,13:00:15,CEDFD5,Biogen Inc.,99,0.46,equity-actions,,Biib's continued considerable investment in the program,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-26,11:05:03,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Mizuho
BIIB,2021-10-26,11:05:03,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $300.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $300.00 by Mizuho
BIIB,2021-10-29,11:00:16,CEDFD5,Biogen Inc.,99,0.53,labor-issues,,Biogen Inc.: New General Manager,PRESS-RELEASE,Canadian News Wire,Biogen Canada Welcomes Eric Tse as New General Manager in New Toronto Head Office
BIIB,2021-10-29,11:00:16,CEDFD5,Biogen Inc.,99,0.41,assets,open,Biogen Inc.: New head office for Biogen Canada,PRESS-RELEASE,Canadian News Wire,Biogen Canada Welcomes Eric Tse as New General Manager in New Toronto Head Office
BIIB,2021-11-03,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: With data from the largest clinical trial,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: With data from the largest clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:02,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: With data from the largest clinical trial,PRESS-RELEASE,GlobeNewswire,Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,GlobeNewswire,Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:34:29,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: With data from the largest clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:34:29,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-09,17:44:22,CEDFD5,Biogen Inc.,97,0.57,equity-actions,listing,Biogen Inc.: the company's presentation to FDA,FULL-ARTICLE,Dow Jones Newswires,Biogen Investigates Death of Aduhelm Patient
BIIB,2021-11-09,17:44:22,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,"June, the Food and Drug Administration approved Aduhelm",FULL-ARTICLE,Dow Jones Newswires,Biogen Investigates Death of Aduhelm Patient
BIIB,2021-11-09,17:50:04,CEDFD5,Biogen Inc.,97,0.57,equity-actions,listing,Biogen Inc.: the company's presentation to FDA,FULL-ARTICLE,Dow Jones Newswires,Biogen Investigates Death of Aduhelm Patient
BIIB,2021-11-09,17:50:04,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,"June, the Food and Drug Administration approved Aduhelm",FULL-ARTICLE,Dow Jones Newswires,Biogen Investigates Death of Aduhelm Patient
BIIB,2021-11-10,14:15:11,CEDFD5,Biogen Inc.,100,0.03,credit-ratings,affirmation,Moody's Affirms Biogen At Baa1,NEWS-FLASH,Dow Jones Newswires,Moody's Affirms Biogen At Baa1; Revises Outlook To Negative
BIIB,2021-11-10,17:16:32,CEDFD5,Biogen Inc.,100,0.0,credit-ratings,action,Moody's Announces Completion Of A Periodic Review Of Ratings Of Biogen Inc.,NEWS-FLASH,Dow Jones Newswires,Moody's Announces Completion Of A Periodic Review Of Ratings Of Biogen Inc.
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.56,products-services,,Biogen earns top ESG leadership,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.58,indexes,,Biogen for being included in the Dow Jones Sustainability Index,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.56,products-services,,Biogen earns top ESG leadership,FULL-ARTICLE,Dow Jones Newswires,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.58,indexes,,Biogen for being included in the Dow Jones Sustainability Index,FULL-ARTICLE,Dow Jones Newswires,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.56,products-services,,Biogen earns top ESG leadership,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.58,indexes,,Biogen for being included in the Dow Jones Sustainability Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.56,products-services,,Biogen earns top ESG leadership,PRESS-RELEASE,GlobeNewswire,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.58,indexes,,Biogen for being included in the Dow Jones Sustainability Index,PRESS-RELEASE,GlobeNewswire,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.56,products-services,,Biogen earns top ESG leadership,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.58,indexes,,Biogen for being included in the Dow Jones Sustainability Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-16,00:44:06,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research",PRESS-RELEASE,GlobeNewswire,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development"
BIIB,2021-11-16,00:44:07,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research",FULL-ARTICLE,Dow Jones Newswires,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development"
BIIB,2021-11-16,00:44:07,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development"
BIIB,2021-11-16,00:44:07,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development"
BIIB,2021-11-16,00:44:07,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development"
BIIB,2021-11-16,14:43:45,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Gets Europe OK for Vumerity,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug >BIIB
BIIB,2021-11-16,14:43:45,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The U.S. Food and Drug Administration approved Vumerity in October 2019,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug >BIIB
BIIB,2021-11-16,14:43:45,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Vumerity also is approved in the U.K.,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug >BIIB
BIIB,2021-11-16,14:58:35,CEDFD5,Biogen Inc.,100,-0.3,labor-issues,,Top Biogen Executive Announces Retirement,FULL-ARTICLE,Dow Jones Newswires,Top Biogen Executive Announces Retirement as Aduhelm Rollout Stumbles -- Barrons.com
BIIB,2021-11-16,14:58:35,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The Food and Drug Administration approved Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,Top Biogen Executive Announces Retirement as Aduhelm Rollout Stumbles -- Barrons.com
BIIB,2021-11-16,14:58:44,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Gets Europe OK for Vumerity,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug
BIIB,2021-11-16,14:58:44,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The U.S. Food and Drug Administration approved Vumerity in October 2019,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug
BIIB,2021-11-16,14:58:44,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Vumerity also is approved in the U.K.,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug
BIIB,2021-11-17,07:32:12,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,Biogen's R&D Chief to Retire,FULL-ARTICLE,Wall Street Journal,Biogen's R&D Chief to Retire at End of Year -- WSJ
BIIB,2021-11-17,12:51:42,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,MarketWatch,MW Biogen shares slide 4% after EU advisory committee says it can't agree to endorse company's Alzheimer's disease drug
BIIB,2021-11-17,12:51:42,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Slide 4% After EU Advisory Committee Says It Can't Agree To Endorse Company's Alzheimer's Disease Drug -- MarketWatch
BIIB,2021-11-19,10:43:36,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Biogen Initiated at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Outperform by BMO Capital
BIIB,2021-11-19,10:43:36,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $315.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $315.00/Share by BMO Capital
BIIB,2021-11-19,13:49:06,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-11-19,13:49:06,CEDFD5,Biogen Inc.,100,-0.64,price-targets,downgrade,Biogen Price Target Cut to $277.00/Share From $295.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $277.00/Share From $295.00 by RBC Capital
BIIB,2021-11-19,13:49:14,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen started at outperform with $315 stock price target at BMO Capital,NEWS-FLASH,MarketWatch,MW Biogen started at outperform with $315 stock price target at BMO Capital
BIIB,2021-11-30,21:22:16,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 28,884 Of Sangamo Therapeutics Inc >SGMO",FULL-ARTICLE,Dow Jones Newswires,"Holder Biogen Inc Sells 28,884 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2021-12-03,21:10:49,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 2,604 Of Sangamo Therapeutics Inc >SGMO",FULL-ARTICLE,Dow Jones Newswires,"Holder Biogen Inc Sells 2,604 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2021-12-06,11:37:34,CEDFD5,Biogen Inc.,100,0.01,analyst-ratings,neutral,Biogen Initiated at Neutral by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Neutral by Goldman Sachs
BIIB,2021-12-06,11:37:34,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $271.00/Share by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $271.00/Share by Goldman Sachs
BIIB,2021-12-06,21:16:10,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 207 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 207 Of Biogen Inc >BIIB
BIIB,2021-12-07,21:10:30,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 239 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 239 Of Biogen Inc >BIIB
BIIB,2021-12-09,13:36:03,CEDFD5,Biogen Inc.,100,0.01,analyst-ratings,neutral,Biogen Initiated at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Equal-Weight by Wells Fargo
BIIB,2021-12-09,13:36:03,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $250.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $250.00/Share by Wells Fargo
BIIB,2021-12-09,21:10:10,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 127,992 Of Sangamo Therapeutics Inc >SGMO",FULL-ARTICLE,Dow Jones Newswires,"Holder Biogen Inc Sells 127,992 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2021-12-10,14:43:00,CEDFD5,Biogen Inc.,93,0.49,partnerships,,Biogen and Ginkgo Bioworks announce collaboration,PRESS-RELEASE,Business Wire,"Global Spinal Muscular Atrophy Treatment Market (2021 to 2026) - Featuring Astellas Pharma, Biogen and Cytokinetics Among Others - ResearchAndMarkets.com"
BIIB,2021-12-10,21:09:57,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 23,660 Of Sangamo Therapeutics Inc >SGMO",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Biogen Inc Sells 23,660 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and TheraPanacea Announce New Collaboration,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen will invest up to $15 million in,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.55,equity-actions,,Biogen Inc.: Spinoff of,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and TheraPanacea Announce New Collaboration,FULL-ARTICLE,Dow Jones Newswires,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen will invest up to $15 million in,FULL-ARTICLE,Dow Jones Newswires,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and TheraPanacea Announce New Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen will invest up to $15 million in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.55,equity-actions,,Biogen Inc.: Spinoff of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:04,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and TheraPanacea Announce New Collaboration,PRESS-RELEASE,GlobeNewswire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:04,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen will invest up to $15 million in,PRESS-RELEASE,GlobeNewswire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:04,CEDFD5,Biogen Inc.,100,0.55,equity-actions,,Biogen Inc.: Spinoff of,PRESS-RELEASE,GlobeNewswire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and TheraPanacea Announce New Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:05,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen will invest up to $15 million in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:05,CEDFD5,Biogen Inc.,100,0.55,equity-actions,,Biogen Inc.: Spinoff of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:02:47,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen to Invest Up to $15 Million in,NEWS-FLASH,Dow Jones Newswires,"Biogen, TheraPanacea: Biogen to Invest Up to $15 Million in Exchange for TheraPanacea Convertible Debt >BIIB"
BIIB,2021-12-16,15:07:41,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces New Trial for Alzheimer's drug Aduhelm -- Barrons.com
BIIB,2021-12-16,15:07:41,CEDFD5,Biogen Inc.,99,-0.68,revenues,down,Aduhelm sales fell,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces New Trial for Alzheimer's drug Aduhelm -- Barrons.com
BIIB,2021-12-17,11:56:54,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Agency approving aduhelm,FULL-ARTICLE,MarketWatch,MW Biogen and Eisai say EU regulatory committee adopted negative opinion for its Alzheimer's treatment
BIIB,2021-12-17,11:56:54,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Agency approving aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen And Eisai Say EU Regulatory Committee Adopted Negative Opinion For Its Alzheimer's Treatment -- MarketWatch
BIIB,2021-12-17,12:30:20,CEDFD5,Biogen Inc.,92,0.71,products-services,,The U.S. Food and Drug Administration granted accelerated approval for Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer's Treatment Gets Negative CHMP Opinion
BIIB,2021-12-17,12:30:20,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Aduhelm is also approved in the United Arab Emirates,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer's Treatment Gets Negative CHMP Opinion
BIIB,2021-12-17,12:45:20,CEDFD5,Biogen Inc.,92,0.71,products-services,,The U.S. Food and Drug Administration granted accelerated approval for Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer's Treatment Gets Negative CHMP Opinion
BIIB,2021-12-17,12:45:20,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Aduhelm is also approved in the United Arab Emirates,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer's Treatment Gets Negative CHMP Opinion
BIIB,2021-12-20,09:59:42,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2021-12-20,09:59:42,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $325.00/Share From $450.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $325.00/Share From $450.00 by SVB Leerink
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The cost during the first,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The cost during the first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Reduced Price for ADUHELM(R) to -2-
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Reduced Price for ADUHELM(R) to -2-
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,GlobeNewswire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,GlobeNewswire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The cost during the first,PRESS-RELEASE,GlobeNewswire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,GlobeNewswire,Biogen Announces Reduced Price for ADUHELM(R) to -2-
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The cost during the first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:01:00,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Cuts Aduhelm List Price in,NEWS-FLASH,Dow Jones Newswires,Biogen Cuts Aduhelm List Price in Half
BIIB,2021-12-20,12:01:00,CEDFD5,Biogen Inc.,100,-0.72,products-services,cut,Biogen Cuts Price for Alzheimer's Drug Aduhelm by Half,FULL-ARTICLE,Dow Jones Newswires,Biogen Cuts Price for Alzheimer's Drug Aduhelm by Half
BIIB,2021-12-20,12:01:24,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Cuts Price for Aduhelm,NEWS-FLASH,Dow Jones Newswires,Biogen Cuts Price for Aduhelm to Improve Access for Patients With Early Alzheimer's Disease >BIIB
BIIB,2021-12-20,12:03:10,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen to reduce price of its Alzheimer's drug aduhelm,NEWS-FLASH,MarketWatch,MW Biogen to reduce price of its Alzheimer's drug aduhelm in U.S. by 50% effective Jan. 1
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen to lower price of Alzheimer's drug,FULL-ARTICLE,MarketWatch,"MW Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year"
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,MarketWatch,"MW Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year"
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Aduhelm, which was approved by the U.S. Food and Drug Administration",FULL-ARTICLE,MarketWatch,"MW Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year"
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen To Lower Price Of Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen To Lower Price Of Alzheimer's Drug Aduhlem By 50% Starting Jan. 1 To About $28,200 A Year -- MarketWatch"
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,Dow Jones Newswires,"Biogen To Lower Price Of Alzheimer's Drug Aduhlem By 50% Starting Jan. 1 To About $28,200 A Year -- MarketWatch"
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Aduhelm, which was approved by the U.S. Food and Drug Administration",FULL-ARTICLE,Dow Jones Newswires,"Biogen To Lower Price Of Alzheimer's Drug Aduhlem By 50% Starting Jan. 1 To About $28,200 A Year -- MarketWatch"
BIIB,2021-12-20,12:20:03,CEDFD5,Biogen Inc.,100,-0.72,products-services,cut,Biogen Cuts Price for Alzheimer's Drug Aduhelm by Half,FULL-ARTICLE,Dow Jones Newswires,Biogen Cuts Price for Alzheimer's Drug Aduhelm by Half
BIIB,2021-12-20,12:20:17,CEDFD5,Biogen Inc.,100,0.46,products-services,raise,Biogen up 3% as company cuts Alzheimer's drug price by 50%,NEWS-FLASH,MarketWatch,MW Biogen up 3% as company cuts Alzheimer's drug price by 50% starting Jan. 1
BIIB,2021-12-20,13:40:03,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Halves Price of Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen Halves Price of Alzheimer's Drug, Says It Will Slash Its Own Costs -- Barrons.com"
BIIB,2021-12-20,15:54:30,CEDFD5,Biogen Inc.,93,-0.44,products-services,cut,Biogen halves Aduhelm's list price,FULL-ARTICLE,Dow Jones Newswires,Biogen's Price Cut Could Be Too Little Too Late -- Market Talk
BIIB,2021-12-20,15:54:30,CEDFD5,Biogen Inc.,93,-0.44,products-services,cut,Biogen halves Aduhelm's list price,FULL-ARTICLE,Dow Jones Newswires,Biogen's Price Cut Could Be Too Little Too Late -- Market Talk
BIIB,2021-12-20,19:31:18,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,19:31:18,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,19:31:18,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,19:31:18,CEDFD5,Biogen Inc.,99,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,19:31:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's third-quarter earnings,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,20:58:54,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,20:58:54,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,20:58:54,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency's approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,20:58:54,CEDFD5,Biogen Inc.,99,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,20:58:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's third-quarter earnings,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,07:10:56,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Cuts Alzheimer's Drug Price,FULL-ARTICLE,Dow Jones Newswires,Biogen Cuts Alzheimer's Drug Price  ----  By Joseph Walker
BIIB,2021-12-21,07:32:11,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Cuts Alzheimer's Drug Price,FULL-ARTICLE,Wall Street Journal,Biogen Cuts Alzheimer's Drug Price -- WSJ
BIIB,2021-12-21,10:37:51,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Slashes Alzheimer's Drug Price,FULL-ARTICLE,Dow Jones Newswires,Biogen Slashes Alzheimer's Drug Price to Improve Access and Affordability -- ESG Insight
BIIB,2021-12-21,12:01:18,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Baird
BIIB,2021-12-21,12:01:18,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $258.00/Share From $296.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $258.00/Share From $296.00 by Baird
BIIB,2021-12-21,12:32:12,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,12:32:12,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,12:32:12,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency's approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,12:32:12,CEDFD5,Biogen Inc.,99,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,12:32:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's third-quarter earnings,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,13:39:37,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,13:39:37,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,13:39:37,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency's approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,13:39:37,CEDFD5,Biogen Inc.,99,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,13:39:37,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's third-quarter earnings,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,15:11:00,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by JP Morgan
BIIB,2021-12-21,15:11:00,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $276.00/Share From $324.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $276.00/Share From $324.00 by JP Morgan
BIIB,2021-12-22,12:40:18,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Agency's approving Aduhelm,FULL-ARTICLE,MarketWatch,MW Japan regulator to continue deliberations on Biogen and Eisai's Alzheimer's drug
BIIB,2021-12-22,12:40:18,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Agency's approving Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Japan Regulator To Continue Deliberations On Biogen And Eisai's Alzheimer's Drug -- MarketWatch
BIIB,2021-12-22,12:40:45,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2021-12-22,12:40:45,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $350.00/Share From $390.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $350.00/Share From $390.00 by Oppenheimer
BIIB,2021-12-28,13:12:24,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 81,787 Of Sangamo Therapeutics Inc >SGMO",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Biogen Inc Sells 81,787 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2021-12-29,19:55:13,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,interest,Samsung in Talks to Buy Biogen,FULL-ARTICLE,Dow Jones Newswires,"Samsung in Talks to Buy Biogen, Sources Say -Korea Economic Daily"
BIIB,2021-12-29,21:00:04,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: the Food and Drug Administration approved a medicine developed by the company,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Rise After Report Samsung in Talks to Buy
BIIB,2021-12-29,22:12:58,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,interest,Samsung Group was in talks to acquire the drugmaker,FULL-ARTICLE,Dow Jones Newswires,"Biogen Stock Jumped. Samsung Wants to Buy It, According to a Report. -- Barrons.com"
BIIB,2021-12-30,00:41:08,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,interest,Group in Talks to Buy US Drug Firm Biogen,NEWS-FLASH,Dow Jones Newswires,Samsung Biologics Shares Gain After Media Report Its Parent Group in Talks to Buy US Drug Firm Biogen
BIIB,2021-12-30,14:43:16,CEDFD5,Biogen Inc.,99,0.57,acquisitions-mergers,interest,Parent was looking to acquire Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Give Up Gains as Samsung Denies Takeover Rumor >BIIB
BIIB,2021-12-30,14:58:16,CEDFD5,Biogen Inc.,99,0.57,acquisitions-mergers,interest,Parent was looking to acquire Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Give Up Gains as Samsung Denies Takeover Rumor
BIIB,2021-12-30,16:40:03,CEDFD5,Biogen Inc.,99,0.57,acquisitions-mergers,interest,Parent was looking to acquire Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Give Up Gains as Samsung Denies Takeover Rumor
BIIB,2021-12-30,22:14:43,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 2,764 Of Sangamo Therapeutics Inc >SGMO",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Biogen Inc Sells 2,764 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2021-01-05,04:43:29,CEDFD5,Biogen Inc.,99,-0.69,equity-actions,delisting,"Biogen stock was halted on November 6, 2020",PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
BIIB,2021-01-05,15:16:30,CEDFD5,Biogen Inc.,100,-0.52,legal,,Lawsuits FILED AGAINST BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST BIIB, YY and SPLK - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2021-01-06,00:37:21,CEDFD5,Biogen Inc.,100,-0.52,legal,,C. Files Securities Class Action Lawsuit Against Biogen Inc.,PRESS-RELEASE,GlobeNewswire,"SHAREHOLDER ALERT: Lowey Dannenberg, P.C. Files Securities Class Action Lawsuit Against Biogen Inc. on Behalf of Investors Who Acquired Shares from October 22, 2019 to November 6, 2020 and Encourages Investors to Inquire About the Lead Plaintiff Position Before the January 12, 2021 Lead Plaintiff Deadline"
BIIB,2021-01-06,16:30:51,CEDFD5,Biogen Inc.,100,-0.52,legal,,Lawsuits Filed Against BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"Lawsuits Filed Against BIIB, BABA and TRIT - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2021-01-07,02:00:15,CEDFD5,Biogen Inc.,96,-0.65,equity-actions,halt,Biogen shares were halted,PRESS-RELEASE,Business Wire,"DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm"
BIIB,2021-01-07,11:22:20,CEDFD5,Biogen Inc.,100,-0.52,legal,,Lawsuits FILED AGAINST BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST BIIB, BRY and NERV - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2021-01-08,16:00:18,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,Business Wire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 12, 2021"
BIIB,2021-01-09,02:00:00,CEDFD5,Biogen Inc.,97,-0.52,legal,,"Class Action Lawsuit Has Been Filed Against Biogen, Inc.",PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm"
BIIB,2021-01-09,02:00:00,CEDFD5,Biogen Inc.,97,-0.65,equity-actions,halt,Biogen shares were halted,PRESS-RELEASE,GlobeNewswire,"DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm"
BIIB,2021-01-10,15:26:12,CEDFD5,Biogen Inc.,100,-0.52,legal,,Lawsuits FILED AGAINST BIIB,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST BIIB, SPLK and QSR - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS"
BIIB,2021-01-11,16:02:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen Inc. (""Biogen",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 12, 2021"
BIIB,2021-01-12,14:14:59,CEDFD5,Biogen Inc.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc.,PRESS-RELEASE,PR Newswire,"DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BIIB,2021-01-12,14:14:59,CEDFD5,Biogen Inc.,100,-0.52,legal,,Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,"Press Release: DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm"
BIIB,2021-01-19,14:17:26,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-01-19,14:17:26,CEDFD5,Biogen Inc.,100,-0.28,price-targets,downgrade,Biogen Price Target Cut to $352.00/Share From $357.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $352.00/Share From $357.00 by Morgan Stanley
BIIB,2021-01-20,09:00:45,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2020 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2020 (BIIB)"
BIIB,2021-01-29,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
BIIB,2021-01-29,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
BIIB,2021-01-29,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
BIIB,2021-01-29,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,GlobeNewswire,Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
BIIB,2021-01-29,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai Announce FDA's 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
BIIB,2021-01-29,12:48:07,CEDFD5,Biogen Inc.,100,-0.47,regulatory,,Fda Extends Review of Biogen,FULL-ARTICLE,Dow Jones Newswires,"FDA Extends Review of Biogen, Eisai Alzheimer's Drug Candidate"
BIIB,2021-01-29,15:50:17,CEDFD5,Biogen Inc.,100,-0.47,regulatory,,Fda Extends Review of Biogen,FULL-ARTICLE,Dow Jones Newswires,"FDA Extends Review of Biogen, Eisai's Alzheimer's Drug"
BIIB,2021-01-29,16:00:03,CEDFD5,Biogen Inc.,100,-0.47,regulatory,,Fda Extends Review of Biogen,FULL-ARTICLE,Dow Jones Newswires,"FDA Extends Review of Biogen, Eisai's Alzheimer's Drug"
BIIB,2021-02-01,12:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Plegridy was first approved by the FDA,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces FDA Approval of PLEGRIDY(R) (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
BIIB,2021-02-03,12:04:46,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $2.32 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q EPS $2.32 >BIIB
BIIB,2021-02-03,12:04:46,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Adj EPS $4.58,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Adj EPS $4.58 >BIIB
BIIB,2021-02-03,12:04:46,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Net $357.9M,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Net $357.9M >BIIB
BIIB,2021-02-03,12:04:46,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.85B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Rev $2.85B >BIIB
BIIB,2021-02-03,12:20:58,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Net Product Revenue $2.3B,RNS-SEC8K,Dow Jones Newswires,Biogen 4Q Net Product Revenue $2.3B
BIIB,2021-02-03,12:22:58,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen 4Q Profit Falls on,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q Profit Falls on Lower Revenue, Higher R&D Costs"
BIIB,2021-02-03,12:24:05,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees FY21 Rev $10.45B-$10.75B,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY21 Rev $10.45B-$10.75B
BIIB,2021-02-03,12:24:06,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY21 Adj EPS $17,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY21 Adj EPS $17-Adj EPS $18.50
BIIB,2021-02-03,12:24:38,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Expects FY21 Capex Between $375M,RNS-SEC8K,Dow Jones Newswires,Biogen Expects FY21 Capex Between $375M and $425M >BIIB
BIIB,2021-02-03,12:37:58,CEDFD5,Biogen Inc.,100,-0.67,earnings,down,Biogen 4Q Profit Falls on,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q Profit Falls on Lower Revenue, Higher R&D Costs"
BIIB,2021-02-03,12:47:20,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Expects Revenue to Fall,FULL-ARTICLE,Dow Jones Newswires,Biogen Expects Revenue to Fall by as Much as 22.3% in 2021
BIIB,2021-02-03,12:47:20,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc. said it expects revenue to fall,FULL-ARTICLE,Dow Jones Newswires,Biogen Expects Revenue to Fall by as Much as 22.3% in 2021
BIIB,2021-02-03,12:47:20,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.: The company said it forecasts 2021 revenue of $10.45 billion to $10.75 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Expects Revenue to Fall by as Much as 22.3% in 2021
BIIB,2021-02-03,15:04:55,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen also said it expects a sharp decline in sales,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Because Earnings Guidance Came Up Short -- Barrons.com
BIIB,2021-02-03,15:04:55,CEDFD5,Biogen Inc.,100,0.01,analyst-ratings,neutral,He rates Biogen at Neutral,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Because Earnings Guidance Came Up Short -- Barrons.com
BIIB,2021-02-03,15:04:55,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Aducanumab receives FDA approval,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Because Earnings Guidance Came Up Short -- Barrons.com
BIIB,2021-02-03,15:04:55,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Yee rates Biogen at Buy,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Because Earnings Guidance Came Up Short -- Barrons.com
BIIB,2021-02-03,15:49:57,CEDFD5,Biogen Inc.,95,-0.52,products-services,,Biogen ends development of another drug candidate,FULL-ARTICLE,Dow Jones Newswires,Biogen Pulls Plug on Parkinson's Drug Candidate -- Market Talk
BIIB,2021-02-03,18:30:20,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q4 2020 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q4 2020 Results -- Earnings Call Transcript >BIIB
BIIB,2021-02-03,18:30:20,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen-inc-biib-ceo-michel-vounatsos-on-q4-2020-results-earnings,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q4 2020 Results -- Earnings Call Transcript >BIIB
BIIB,2021-02-04,10:29:11,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2021-02-04,10:29:11,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $380.00/Share From $430.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $380.00/Share From $430.00 by SVB Leerink
BIIB,2021-02-04,11:25:51,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2021-02-04,11:25:51,CEDFD5,Biogen Inc.,100,0.6,price-targets,upgrade,Biogen Price Target Raised to $305.00/Share From $289.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $305.00/Share From $289.00 by HC Wainwright & Co.
BIIB,2021-02-04,13:07:21,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-02-04,13:07:21,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $351.00/Share From $352.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $351.00/Share From $352.00 by Morgan Stanley
BIIB,2021-02-04,14:02:00,CEDFD5,Biogen Inc.,100,0.0,credit,,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045,PRESS-RELEASE,GlobeNewswire,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
BIIB,2021-02-04,14:02:01,CEDFD5,Biogen Inc.,100,0.0,credit,,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
BIIB,2021-02-04,14:03:06,CEDFD5,Biogen Inc.,100,0.0,credit,,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045,NEWS-FLASH,Dow Jones Newswires,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
BIIB,2021-02-04,15:09:52,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Credit Suisse
BIIB,2021-02-04,15:09:52,CEDFD5,Biogen Inc.,100,-0.48,price-targets,downgrade,Biogen Price Target Cut to $338.00/Share From $350.00 by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $338.00/Share From $350.00 by Credit Suisse
BIIB,2021-02-04,16:08:12,CEDFD5,Biogen Inc.,100,0.06,credit-ratings,set,Moody's Assign's Baa1 To Biogen's Notes,NEWS-FLASH,Dow Jones Newswires,Moody's Assign's Baa1 To Biogen's Notes; On Review For Downgrade
BIIB,2021-02-04,16:08:52,CEDFD5,Biogen Inc.,100,0.06,credit-ratings,set,Moody's Assign's Baa1 to Biogen's Notes,NEWS-FLASH,Dow Jones Newswires,Moody's Assign's Baa1 to Biogen's Notes; On Review for Downgrade
BIIB,2021-02-05,12:01:10,CEDFD5,Biogen Inc.,99,0.59,equity-actions,approved,"Aducanumab, even authorizing two separate $5 billion share repurchases",FULL-ARTICLE,Dow Jones Newswires,Biogen Bet Big on Its Alzheimer's Drug. The Stock Will Soar or Dive on the FDA's Decision. -- Barrons.com
BIIB,2021-02-05,12:01:10,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: The company issued 2021 sales guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Bet Big on Its Alzheimer's Drug. The Stock Will Soar or Dive on the FDA's Decision. -- Barrons.com
BIIB,2021-02-05,12:01:10,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Fda's collaboration with Biogen as,FULL-ARTICLE,Dow Jones Newswires,Biogen Bet Big on Its Alzheimer's Drug. The Stock Will Soar or Dive on the FDA's Decision. -- Barrons.com
BIIB,2021-02-05,13:00:05,CEDFD5,Biogen Inc.,99,0.49,partnerships,,New partnership with Biogen,PRESS-RELEASE,PR Newswire,Biogen Offers Arcadia's Home Renewable Energy Program to Employees
BIIB,2021-02-05,13:00:05,CEDFD5,Biogen Inc.,99,0.22,acquisitions-mergers,,Biogen Inc.: our commitment to purchase 100% of our,PRESS-RELEASE,PR Newswire,Biogen Offers Arcadia's Home Renewable Energy Program to Employees
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.59,equity-actions,approved,"Aducanumab, even authorizing two separate $5 billion share repurchases",FULL-ARTICLE,Dow Jones Newswires,Biogen Goes All-In On Alzheimer's Drug
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: The company issued 2021 sales guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Goes All-In On Alzheimer's Drug
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Fda's collaboration with Biogen as,FULL-ARTICLE,Dow Jones Newswires,Biogen Goes All-In On Alzheimer's Drug
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.59,equity-actions,approved,"Aducanumab, even authorizing two separate $5 billion share repurchases",FULL-ARTICLE,Barrons,Biogen Goes All-In On Alzheimer's Drug -- Barron's
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: The company issued 2021 sales guidance,FULL-ARTICLE,Barrons,Biogen Goes All-In On Alzheimer's Drug -- Barron's
BIIB,2021-02-06,02:30:14,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Fda's collaboration with Biogen as,FULL-ARTICLE,Barrons,Biogen Goes All-In On Alzheimer's Drug -- Barron's
BIIB,2021-02-09,21:18:45,CEDFD5,Biogen Inc.,100,0.0,insider-trading,,Dir Posner Gifts 125 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Dir Posner Gifts 125 Of Biogen Inc >BIIB
BIIB,2021-02-10,21:32:37,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Dir Mantas Buys 898 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Dir Mantas Buys 898 Of Biogen Inc >BIIB
BIIB,2021-02-17,17:02:53,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Cantor Fitzgerald
BIIB,2021-02-17,17:02:53,CEDFD5,Biogen Inc.,100,-0.48,price-targets,downgrade,Biogen Price Target Cut to $268.00/Share From $278.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $268.00/Share From $278.00 by Cantor Fitzgerald
BIIB,2021-02-17,22:01:38,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Alexander Acquires 459 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Acquires 459 Of Biogen Inc >BIIB
BIIB,2021-02-17,22:03:58,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Galdes Acquires 858 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Galdes Acquires 858 Of Biogen Inc >BIIB
BIIB,2021-02-17,22:04:28,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Gregory Acquires 741 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Gregory Acquires 741 Of Biogen Inc >BIIB
BIIB,2021-02-17,22:04:48,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Guindo Acquires 2,216 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Guindo Acquires 2,216 Of Biogen Inc >BIIB"
BIIB,2021-02-17,22:05:48,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 218 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 218 Of Biogen Inc >BIIB
BIIB,2021-02-17,22:05:58,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Sandrock Acquires 944 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Sandrock Acquires 944 Of Biogen Inc >BIIB
BIIB,2021-02-17,22:06:28,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Ceo Vounatsos Acquires 1,816 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CEO Vounatsos Acquires 1,816 Of Biogen Inc >BIIB"
BIIB,2021-03-04,12:47:36,CEDFD5,Biogen Inc.,99,0.41,assets,open,Biogen Inc.: The new facility,PRESS-RELEASE,GlobeNewswire,"Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina"
BIIB,2021-03-04,12:47:36,CEDFD5,Biogen Inc.,99,0.41,assets,open,Biogen Inc.: The new facility,PRESS-RELEASE,DJ Global Press Release Wire,"Press Release: Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina"
BIIB,2021-03-04,12:47:37,CEDFD5,Biogen Inc.,99,0.41,assets,open,Biogen Inc.: The new facility,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina"
BIIB,2021-03-04,12:47:51,CEDFD5,Biogen Inc.,99,0.41,assets,open,Biogen Inc.: The new facility,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina"
BIIB,2021-03-18,13:39:28,CEDFD5,Biogen Inc.,97,0.49,partnerships,,Biogen (ticker: BIIB) is developing in partnership with Sage Therapeutics (SAGE),FULL-ARTICLE,Dow Jones Newswires,Don't Lose Sight of Biogen's Depression Drug Amid Focus on Alzheimer's Disease -- Barrons.com
BIIB,2021-03-25,12:16:53,CEDFD5,Biogen Inc.,99,-0.62,legal,,Biogen Inc.: the company lost a patent suit,FULL-ARTICLE,Dow Jones Newswires,Biogen Investors Want News on Alzheimer's Therapy. 2 More Key Points to Watch. -- Barrons.com
BIIB,2021-03-25,12:16:53,CEDFD5,Biogen Inc.,99,0.0,revenues,,Analysts expect only $1.6 billion in Tecfidera sales in 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen Investors Want News on Alzheimer's Therapy. 2 More Key Points to Watch. -- Barrons.com
BIIB,2021-04-08,11:00:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,PRESS-RELEASE,GlobeNewswire,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,11:00:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,11:00:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,11:00:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,11:00:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,11:00:53,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement,NEWS-FLASH,Dow Jones Newswires,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
BIIB,2021-04-08,13:09:09,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Licenses Actemra,FULL-ARTICLE,Dow Jones Newswires,Biogen Licenses Actemra Biosimilar Candidate From Bio-Thera Solutions
BIIB,2021-04-08,13:24:08,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Licenses Actemra,FULL-ARTICLE,Dow Jones Newswires,Biogen Licenses Actemra Biosimilar Candidate From Bio-Thera Solutions
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's board of directors at its 2021 annual meeting,PRESS-RELEASE,GlobeNewswire,Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,-0.43,labor-issues,,Biogen Inc.: will retire from the company's board,PRESS-RELEASE,GlobeNewswire,Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's board of directors at its 2021 annual meeting,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,-0.43,labor-issues,,Biogen Inc.: will retire from the company's board,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's board of directors at its 2021 annual meeting,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,-0.43,labor-issues,,Biogen Inc.: will retire from the company's board,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Annual Report on Form 10-K for the fiscal year ended December,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees -2-
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's board of directors at its 2021 annual meeting,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,-0.43,labor-issues,,Biogen Inc.: will retire from the company's board,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Annual Report on Form 10-K for the fiscal year ended December,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Announces Two New Nominees -2-
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Annual Report on Form 10-K for the fiscal year ended December,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees -2-
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's board of directors at its 2021 annual meeting,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-09,20:30:01,CEDFD5,Biogen Inc.,99,-0.43,labor-issues,,Biogen Inc.: will retire from the company's board,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Two New Nominees for Election to Board of Directors
BIIB,2021-04-12,11:23:41,CEDFD5,Biogen Inc.,91,0.0,products-services,,Biogen Inc. said they saw positive topline results from a Phase 2 study,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen Sees Positive Results for Essential Tremors Treatment"
BIIB,2021-04-12,11:38:41,CEDFD5,Biogen Inc.,91,0.0,products-services,,Biogen Inc. said they saw positive topline results from a Phase 2 study,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen Sees Positive Results for Essential Tremors Treatment"
BIIB,2021-04-12,12:28:37,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2021-04-12,12:28:37,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $245.00/Share From $236.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $245.00/Share From $236.00 by Wedbush
BIIB,2021-04-12,20:30:05,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Sage's partnership with Biogen is,FULL-ARTICLE,Dow Jones Newswires,"Neurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogen -- Barrons.com"
BIIB,2021-04-14,20:06:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,GlobeNewswire,"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021"
BIIB,2021-04-14,20:06:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,DJ Global Press Release Wire,"Press Release: Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021"
BIIB,2021-04-14,20:06:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021"
BIIB,2021-04-14,20:06:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,FULL-ARTICLE,Dow Jones Newswires,"Press Release: Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021"
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen's expansion in China,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,China's National Medical Products Administration (NMPA) has approved TECFIDERA(R) (dimethyl fumarate) for the treatment,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results from clinical trials,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen's expansion in China,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,China's National Medical Products Administration (NMPA) has approved TECFIDERA(R) (dimethyl fumarate) for the treatment,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen's expansion in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,China's National Medical Products Administration (NMPA) has approved TECFIDERA(R) (dimethyl fumarate) for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results from clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen's expansion in China,PRESS-RELEASE,GlobeNewswire,Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,China's National Medical Products Administration (NMPA) has approved TECFIDERA(R) (dimethyl fumarate) for the treatment,PRESS-RELEASE,GlobeNewswire,Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results from clinical trials,PRESS-RELEASE,GlobeNewswire,Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen's expansion in China,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,China's National Medical Products Administration (NMPA) has approved TECFIDERA(R) (dimethyl fumarate) for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results from clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Grows Presence in China with the Approval of TECFIDERA(R) (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:31:24,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Tecfidera Received Approval in China,NEWS-FLASH,Dow Jones Newswires,Biogen: TECFIDERA Received Approval in China for the Treatment of Relapsing Multiple Sclerosis
BIIB,2021-04-15,20:31:35,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen Expansion in China,NEWS-FLASH,Dow Jones Newswires,Biogen Expansion in China Now Includes Treatment Options Approved for Relapsing MS and Spinal Muscular Atrophy >BIIB
BIIB,2021-04-15,21:22:27,CEDFD5,Biogen Inc.,94,0.57,products-services,granted,Biogen Inc. on Thursday said its Tecfidera received approval from China's National Medical Products Administration for the treatment,FULL-ARTICLE,Dow Jones Newswires,Biogen Says Tecfidera Approved in China to Treat Relapsing Multiple Sclerosis
BIIB,2021-04-15,21:37:27,CEDFD5,Biogen Inc.,94,0.57,products-services,granted,Biogen Inc. on Thursday said its Tecfidera received approval from China's National Medical Products Administration for the treatment,FULL-ARTICLE,Dow Jones Newswires,Biogen Says Tecfidera Approved in China to Treat Relapsing Multiple Sclerosis
BIIB,2021-04-19,13:35:15,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-04-19,13:35:15,CEDFD5,Biogen Inc.,100,-0.4,price-targets,downgrade,Biogen Price Target Cut to $343.00/Share From $351.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $343.00/Share From $351.00 by Morgan Stanley
BIIB,2021-04-19,14:03:38,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen is developing in partnership with Sage Therapeutics (SAGE),FULL-ARTICLE,Dow Jones Newswires,How Biogen Stock Could Rise 85%. Two Drugs Are Critical. -- Barrons.com
BIIB,2021-04-19,14:03:38,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen is set to report its first-quarter earnings on Thursday,FULL-ARTICLE,Dow Jones Newswires,How Biogen Stock Could Rise 85%. Two Drugs Are Critical. -- Barrons.com
BIIB,2021-04-19,14:03:38,CEDFD5,Biogen Inc.,100,0.0,revenues,,Analysts expect Tecfidera sales to plummet,FULL-ARTICLE,Dow Jones Newswires,How Biogen Stock Could Rise 85%. Two Drugs Are Critical. -- Barrons.com
BIIB,2021-04-19,14:03:38,CEDFD5,Biogen Inc.,100,0.61,acquisitions-mergers,rumor,Biogen could be an acquisition target,FULL-ARTICLE,Dow Jones Newswires,How Biogen Stock Could Rise 85%. Two Drugs Are Critical. -- Barrons.com
BIIB,2021-04-21,07:25:11,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 1Q 2021 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 1Q 2021 (BIIB)"
BIIB,2021-04-22,11:09:00,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $2.69 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $2.69 >BIIB
BIIB,2021-04-22,11:09:00,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Net $410.2M,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Net $410.2M >BIIB
BIIB,2021-04-22,11:10:25,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.69B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.69B >BIIB
BIIB,2021-04-22,11:10:40,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $5.34,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Adj EPS $5.34 >BIIB
BIIB,2021-04-22,11:11:44,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees FY Rev $10.45B-$10.75B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Sees FY Rev $10.45B-$10.75B >BIIB
BIIB,2021-04-22,11:12:22,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises FY View To Adj EPS $17.50,NEWS-FLASH,Dow Jones Newswires,Biogen Raises FY View To Adj EPS $17.50-Adj EPS $19 >BIIB
BIIB,2021-04-22,11:16:03,CEDFD5,Biogen Inc.,100,-0.68,earnings,down,Biogen Q1 EPS $2.69 vs. $8.08 a year ago,NEWS-FLASH,MarketWatch,Biogen Q1 EPS $2.69 vs. $8.08 a year ago
BIIB,2021-04-22,11:16:54,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Q1 adj. EPS $5.34,NEWS-FLASH,MarketWatch,Biogen Q1 adj. EPS $5.34; FactSet EPS consensus $4.97
BIIB,2021-04-22,11:17:20,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q1 revenue $2.69 bln vs. $3.53 bln a year ago; FactSet consensus $2.65 bln,NEWS-FLASH,MarketWatch,Biogen Q1 revenue $2.69 bln vs. $3.53 bln a year ago; FactSet consensus $2.65 bln
BIIB,2021-04-22,11:17:55,CEDFD5,Biogen Inc.,100,0.46,earnings,up,Biogen raises 2021 adj. EPS outlook to $17.50-$19.00 from $17.00-$18.50,NEWS-FLASH,MarketWatch,Biogen raises 2021 adj. EPS outlook to $17.50-$19.00 from $17.00-$18.50
BIIB,2021-04-22,11:41:56,CEDFD5,Biogen Inc.,93,0.0,revenues,unchanged,Biogen continues to expect revenue of $10.45 billion to $10.75 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts 2021 Adj Earnings Guidance
BIIB,2021-04-22,11:47:05,CEDFD5,Biogen Inc.,100,-0.44,revenues,down,"Biogen's stock is up, though revenue fell 25% for the quarter",FULL-ARTICLE,MarketWatch,"Biogen's stock is up, though revenue fell 25% for the quarter"
BIIB,2021-04-22,11:47:05,CEDFD5,Biogen Inc.,100,-0.44,revenues,down,"Biogen's Stock Is Up, Though Revenue Fell 25% For The Quarter",FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Is Up, Though Revenue Fell 25% For The Quarter -- MarketWatch"
BIIB,2021-04-22,11:56:56,CEDFD5,Biogen Inc.,93,0.0,revenues,unchanged,Biogen continues to expect revenue of $10.45 billion to $10.75 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts 2021 Adjusted Earnings Guidance
BIIB,2021-04-22,12:14:43,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen's Earnings Beat Forecasts,FULL-ARTICLE,Dow Jones Newswires,Biogen's Earnings Beat Forecasts. The Stock Is Rising. -- Barrons.com
BIIB,2021-04-22,12:14:43,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported non-GAAP diluted earnings of $5.34 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen's Earnings Beat Forecasts. The Stock Is Rising. -- Barrons.com
BIIB,2021-04-22,17:45:02,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q1 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q1 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2021-04-22,17:45:02,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen-inc-biib-ceo-michel-vounatsos-on-q1-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q1 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2021-04-28,22:20:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Tysabri was approved by the European Commission in March 2021,PRESS-RELEASE,GlobeNewswire,Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI(R) (natalizumab)
BIIB,2021-04-28,22:20:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Tysabri was approved by the European Commission in March 2021,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI(R) (natalizumab)
BIIB,2021-04-28,22:20:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Tysabri was approved by the European Commission in March 2021,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI(R) (natalizumab)
BIIB,2021-04-28,22:20:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Tysabri was approved by the European Commission in March 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI(R) (natalizumab)
BIIB,2021-04-28,22:20:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Tysabri was approved by the European Commission in March 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI(R) (natalizumab)
BIIB,2021-05-10,20:06:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,PRESS-RELEASE,GlobeNewswire,Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-10,20:06:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-10,20:06:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-10,20:06:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-10,20:06:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-10,20:06:54,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Capsigen Announce Collaboration to,NEWS-FLASH,Dow Jones Newswires,Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
BIIB,2021-05-12,12:00:49,CEDFD5,Biogen Inc.,95,0.51,products-services,,"Tms Co. Ltd. to acquire TMS-007, an investigational drug",FULL-ARTICLE,Dow Jones Newswires,Biogen Exercises Option to Acquire Investigational Drug TMS-007
BIIB,2021-05-12,12:15:49,CEDFD5,Biogen Inc.,95,0.51,products-services,,"Tms Co. Ltd. to acquire TMS-007, an investigational drug",FULL-ARTICLE,Dow Jones Newswires,Biogen Exercises Option to Acquire Investigational Drug TMS-007
BIIB,2021-05-13,20:06:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,PRESS-RELEASE,GlobeNewswire,Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,20:06:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,20:06:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,20:06:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,20:06:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,20:06:48,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics Announce Collaboration to Advance,NEWS-FLASH,Dow Jones Newswires,Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-13,21:01:14,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Envisagenics: Announce Collaboration to Advance,NEWS-FLASH,Dow Jones Newswires,Biogen and Envisagenics: Announce Collaboration to Advance RNA Splicing Research
BIIB,2021-05-14,11:30:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Inc.: the company also entered into an agreement with Catalyst Biosciences to,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:18,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study,NEWS-FLASH,Dow Jones Newswires,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
BIIB,2021-05-14,11:30:53,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen: Announces Topline Results From Phase 2/3 Gene Therapy Study,NEWS-FLASH,Dow Jones Newswires,Biogen: Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP>BIIB
BIIB,2021-05-14,14:33:51,CEDFD5,Biogen Inc.,96,0.62,acquisitions-mergers,,"Biogen acquired the drug, BIIB",FULL-ARTICLE,Dow Jones Newswires,Biogen Gene Therapy Hits Setback In Study -- Market Talk
BIIB,2021-05-14,14:33:52,CEDFD5,Biogen Inc.,96,0.62,acquisitions-mergers,,"Biogen acquired the drug, BIIB",FULL-ARTICLE,Dow Jones Newswires,Biogen Gene Therapy Hits Setback In Study -- Market Talk
BIIB,2021-05-18,13:46:48,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2021-05-18,13:46:48,CEDFD5,Biogen Inc.,100,0.72,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $300.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $300.00 by Oppenheimer
BIIB,2021-05-20,20:06:00,CEDFD5,Biogen Inc.,99,0.22,products-services,,Biogen Inc.: our state-of-the-art manufacturing site in,PRESS-RELEASE,GlobeNewswire,"Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland"
BIIB,2021-05-20,20:06:00,CEDFD5,Biogen Inc.,99,0.22,products-services,,Biogen Inc.: our state-of-the-art manufacturing site in,PRESS-RELEASE,DJ Global Press Release Wire,"Press Release: Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland"
BIIB,2021-05-20,20:06:01,CEDFD5,Biogen Inc.,99,0.22,products-services,,Biogen Inc.: our state-of-the-art manufacturing site in,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland"
BIIB,2021-05-20,20:06:01,CEDFD5,Biogen Inc.,99,0.22,products-services,,Biogen Inc.: our state-of-the-art manufacturing site in,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland"
BIIB,2021-05-21,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,PRESS-RELEASE,GlobeNewswire,Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:07,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ginkgo Bioworks Announce Collaboration,NEWS-FLASH,Dow Jones Newswires,Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
BIIB,2021-05-21,11:30:36,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Biogen, Ginkgo Bioworks to Develop Novel Gene-Therapy",NEWS-FLASH,Dow Jones Newswires,"Biogen, Ginkgo Bioworks to Develop Novel Gene-Therapy Manufacturing Platform"
BIIB,2021-05-21,11:49:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration"
BIIB,2021-05-21,11:49:52,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Inc. Friday said it signed a collaboration and licensing agreement,FULL-ARTICLE,Dow Jones Newswires,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration"
BIIB,2021-05-21,12:04:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration"
BIIB,2021-05-21,12:04:52,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Inc. Friday said it signed a collaboration and licensing agreement,FULL-ARTICLE,Dow Jones Newswires,"Biogen, Ginkgo Bioworks in Gene-Therapy Manufacturing Platform Collaboration"
BIIB,2021-06-01,11:30:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen and Bio-Thera Announce Positive Results From Phase 3 Study,FULL-ARTICLE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera announced a commercialization and license agreement,FULL-ARTICLE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen and Bio-Thera Announce Positive Results From Phase 3 Study,PRESS-RELEASE,DJ Global Press Release Wire,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera announced a commercialization and license agreement,PRESS-RELEASE,DJ Global Press Release Wire,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen and Bio-Thera Announce Positive Results From Phase 3 Study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera announced a commercialization and license agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen and Bio-Thera Announce Positive Results From Phase 3 Study,PRESS-RELEASE,GlobeNewswire,"Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera announced a commercialization and license agreement,PRESS-RELEASE,GlobeNewswire,"Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen and Bio-Thera Announce Positive Results From Phase 3 Study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-01,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Bio-Thera announced a commercialization and license agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra(R) (Tocilizumab)"
BIIB,2021-06-07,14:44:15,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2021-06-07,15:12:37,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2021-06-07,15:49:56,CEDFD5,Biogen Inc.,92,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,FULL-ARTICLE,Dow Jones Newswires,Subscribers: Disregard Biogen Headline
BIIB,2021-06-07,15:59:30,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) today approved aducanumab,PRESS-RELEASE,PR Newswire,FDA APPROVES ADUCANUMAB FOR ALZHEIMER'S DISEASE
BIIB,2021-06-07,16:04:56,CEDFD5,Biogen Inc.,92,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,FULL-ARTICLE,Dow Jones Newswires,Subscribers: Disregard Biogen Headline
BIIB,2021-06-07,17:01:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,GlobeNewswire,Biogen and Eisai launch multiple initiatives to -2-
BIIB,2021-06-07,17:01:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,FULL-ARTICLE,Dow Jones Newswires,Press Release: Biogen and Eisai launch multiple -2-
BIIB,2021-06-07,17:01:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,DJ Global Press Release Wire,Press Release: Biogen and Eisai launch multiple -2-
BIIB,2021-06-07,17:01:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai launch multiple -2-
BIIB,2021-06-07,17:01:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai have collaborated on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai launch multiple -2-
BIIB,2021-06-07,17:25:02,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2021-06-07,17:30:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2021-06-07,17:37:03,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Paused due to volatility,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Paused due to volatility
BIIB,2021-06-07,17:42:03,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2021-06-07,17:43:34,CEDFD5,Biogen Inc.,92,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,FULL-ARTICLE,Dow Jones Newswires,Subscribers: Disregard Biogen Headline
BIIB,2021-06-07,17:58:34,CEDFD5,Biogen Inc.,92,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,FULL-ARTICLE,Dow Jones Newswires,Subscribers: Disregard Biogen Headline
BIIB,2021-06-07,19:05:47,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Fda cleared Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Drug Approval Bodes Well For Lilly -- Market Talk
BIIB,2021-06-07,19:05:47,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Fda cleared Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Drug Approval Bodes Well For Lilly -- Market Talk
BIIB,2021-06-07,19:18:33,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Fda cleared Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Focus Turns to Insurer Coverage for Alzheimer's Drug -- Market Talk
BIIB,2021-06-07,19:32:22,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Fda's approval of Biogen's Alzheimer's drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Will Market Aduhelm Based on Patients Treated in Studies -- Market Talk
BIIB,2021-06-07,19:32:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda cleared Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Will Market Aduhelm Based on Patients Treated in Studies -- Market Talk
BIIB,2021-06-07,23:05:52,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Dir Posner Sells 360 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,Dir Posner Sells 360 Of Biogen Inc >BIIB
BIIB,2021-06-08,11:19:36,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2021-06-08,11:19:36,CEDFD5,Biogen Inc.,100,0.84,price-targets,upgrade,Biogen Price Target Raised to $452.00/Share From $305.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $452.00/Share From $305.00 by HC Wainwright & Co.
BIIB,2021-06-08,11:29:16,CEDFD5,Biogen Inc.,100,0.62,analyst-ratings,positive,Biogen Raised to Neutral From Underperform by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Neutral From Underperform by Baird
BIIB,2021-06-08,11:29:16,CEDFD5,Biogen Inc.,100,0.9,price-targets,upgrade,Biogen Price Target Raised to $382.00/Share From $216.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $382.00/Share From $216.00 by Baird
BIIB,2021-06-08,11:55:36,CEDFD5,Biogen Inc.,100,0.62,analyst-ratings,positive,Biogen Raised to Neutral From Sell by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Neutral From Sell by Citigroup
BIIB,2021-06-08,11:55:36,CEDFD5,Biogen Inc.,100,0.94,price-targets,upgrade,Biogen Price Target Raised to $440.00/Share From $200.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $440.00/Share From $200.00 by Citigroup
BIIB,2021-06-08,12:08:56,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-06-08,12:08:56,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $455.00/Share From $343.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $455.00/Share From $343.00 by Morgan Stanley
BIIB,2021-06-08,12:27:44,CEDFD5,Biogen Inc.,100,0.82,price-targets,upgrade,Biogen stock price target raised to $450 from $325 at Oppenheimer,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $450 from $325 at Oppenheimer
BIIB,2021-06-08,13:31:47,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2021-06-08,13:31:47,CEDFD5,Biogen Inc.,100,0.84,price-targets,upgrade,Biogen Price Target Raised to $395.00/Share From $265.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $395.00/Share From $265.00 by Barclays
BIIB,2021-06-08,13:35:17,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Jefferies
BIIB,2021-06-08,13:35:17,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $500.00/Share From $450.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $500.00/Share From $450.00 by Jefferies
BIIB,2021-06-08,13:52:27,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-06-08,13:52:27,CEDFD5,Biogen Inc.,100,0.84,price-targets,upgrade,Biogen Price Target Raised to $400.00/Share From $259.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $400.00/Share From $259.00 by RBC Capital
BIIB,2021-06-08,14:54:46,CEDFD5,Biogen Inc.,100,0.88,price-targets,upgrade,Biogen stock price target raised to $400 from $235 at BofA Securities,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $400 from $235 at BofA Securities
BIIB,2021-06-08,14:56:02,CEDFD5,Biogen Inc.,100,0.62,analyst-ratings,positive,Biogen upgraded to neutral from underperform at BofA Securities,NEWS-FLASH,MarketWatch,MW Biogen upgraded to neutral from underperform at BofA Securities
BIIB,2021-06-08,16:36:47,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Outperform From Market Perform by William Blair,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Market Perform by William Blair
BIIB,2021-06-08,17:02:04,CEDFD5,Biogen Inc.,91,0.57,products-services,granted,Fda approval of Biogen's Alzheimer drug,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Approval Means Upside Potential for Roche -- Market Talk
BIIB,2021-06-08,18:27:49,CEDFD5,Biogen Inc.,94,0.0,investor-relations,,Biogen Inc.: the company's conference call with,FULL-ARTICLE,MarketWatch,"MW Biogen expects its $56,000 Alzheimer's drug to be covered by Medicare for 'most' patients"
BIIB,2021-06-08,18:27:49,CEDFD5,Biogen Inc.,94,0.62,analyst-ratings,positive,Bofa Securities analyst Geoff Meacham upgraded Biogen to neutral from underperform,FULL-ARTICLE,MarketWatch,"MW Biogen expects its $56,000 Alzheimer's drug to be covered by Medicare for 'most' patients"
BIIB,2021-06-08,18:27:49,CEDFD5,Biogen Inc.,94,0.0,investor-relations,,Biogen Inc.: the company's conference call with,FULL-ARTICLE,Dow Jones Newswires,"Biogen Expects Its $56,000 Alzheimer's Drug To Be Covered By Medicare For 'most' Patients -- MarketWatch"
BIIB,2021-06-08,18:27:49,CEDFD5,Biogen Inc.,94,0.62,analyst-ratings,positive,Bofa Securities analyst Geoff Meacham upgraded Biogen to neutral from underperform,FULL-ARTICLE,Dow Jones Newswires,"Biogen Expects Its $56,000 Alzheimer's Drug To Be Covered By Medicare For 'most' Patients -- MarketWatch"
BIIB,2021-06-08,20:33:59,CEDFD5,Biogen Inc.,100,-0.45,credit-ratings,negative,S&PGR Afrms Biogen 'A-' Rating; Outlook Negative,NEWS-FLASH,Dow Jones Newswires,S&PGR Afrms Biogen 'A-' Rating; Outlook Negative
BIIB,2021-06-08,20:34:04,CEDFD5,Biogen Inc.,100,-0.45,credit-ratings,negative,S&PGR Afrms Biogen 'A-' Rating; Outlook Negative,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Afrms Biogen 'A-' Rating; Outlook Negative
BIIB,2021-06-08,20:34:04,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Inc.: we expect the multibillion-dollar revenue opportunity to reverse recent revenue declines in 2020 and 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Afrms Biogen 'A-' Rating; Outlook Negative
BIIB,2021-06-08,20:34:04,CEDFD5,Biogen Inc.,100,0.52,products-services,,Vumerity (launched in October 2019,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Afrms Biogen 'A-' Rating; Outlook Negative
BIIB,2021-06-08,20:34:14,CEDFD5,Biogen Inc.,100,0.09,credit-ratings,affirmation,S&PGR Afrms Biogen 'A-' Rating,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Afrms Biogen 'A-' Rating; -2-
BIIB,2021-06-08,20:34:34,CEDFD5,Biogen Inc.,100,-0.57,credit-ratings,negative,S&P Takes Biogen Inc. Off Watch; Outlk Neg,NEWS-FLASH,Dow Jones Newswires,S&P Takes Biogen Inc. Off Watch; Outlk Neg
BIIB,2021-06-09,23:06:23,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Guindo Sells 3,087 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Guindo Sells 3,087 Of Biogen Inc >BIIB"
BIIB,2021-06-09,23:06:48,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Sandrock Sells 7,672 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Sandrock Sells 7,672 Of Biogen Inc >BIIB"
BIIB,2021-06-10,13:04:38,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2021-06-10,13:04:38,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $475.00/Share From $380.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $475.00/Share From $380.00 by SVB Leerink
BIIB,2021-06-10,16:14:49,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Neutral by UBS
BIIB,2021-06-10,16:14:49,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $463.00/Share by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $463.00/Share by UBS
BIIB,2021-06-10,22:40:10,CEDFD5,Biogen Inc.,100,0.05,credit-ratings,confirmation,Moody's Confirms Biogen At Baa1,NEWS-FLASH,Dow Jones Newswires,Moody's Confirms Biogen At Baa1; Stable Outlook
BIIB,2021-06-11,10:58:03,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Outperform From Market Perform by Bernstein,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Market Perform by Bernstein
BIIB,2021-06-11,10:58:03,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $500.00/Share by Bernstein,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $500.00/Share by Bernstein
BIIB,2021-06-11,11:22:29,CEDFD5,Biogen Inc.,100,0.86,price-targets,upgrade,Biogen stock price target raised to $435 from $269 at J.P. Morgan,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $435 from $269 at J.P. Morgan
BIIB,2021-06-11,16:14:46,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen upgraded to buy from neutral at UBS,NEWS-FLASH,MarketWatch,MW Biogen upgraded to buy from neutral at UBS
BIIB,2021-06-11,16:15:06,CEDFD5,Biogen Inc.,100,0.84,price-targets,upgrade,Biogen stock price target raised to $463 from $311 at UBS,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $463 from $311 at UBS
BIIB,2021-06-11,16:29:54,CEDFD5,Biogen Inc.,94,0.57,products-services,granted,The FDA gave the green light to Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,A Third Expert Quits FDA Panel Over Approval of Biogen Alzheimer's Drug -- Barrons.com
BIIB,2021-06-11,18:27:30,CEDFD5,Biogen Inc.,93,0.94,analyst-ratings,positive,Bristow upgraded Biogen to buy from neutral,FULL-ARTICLE,MarketWatch,"MW Biogen stock heads for biggest weekly rally in more than 2 decades, UBS analyst targets more gains"
BIIB,2021-06-11,18:27:30,CEDFD5,Biogen Inc.,93,0.94,analyst-ratings,positive,Bristow upgraded Biogen to buy from neutral,FULL-ARTICLE,Dow Jones Newswires,"Biogen Stock Heads For Biggest Weekly Rally In More Than 2 Decades, UBS Analyst Targets More Gains -- MarketWatch"
BIIB,2021-06-14,13:57:31,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2021-06-14,13:57:31,CEDFD5,Biogen Inc.,100,0.82,price-targets,upgrade,Biogen Price Target Raised to $647.00/Share From $458.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $647.00/Share From $458.00 by Truist Securities
BIIB,2021-06-14,14:18:01,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Goldman Sachs
BIIB,2021-06-14,14:18:01,CEDFD5,Biogen Inc.,100,0.9,price-targets,upgrade,Biogen Price Target Raised to $436.00/Share From $246.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $436.00/Share From $246.00 by Goldman Sachs
BIIB,2021-06-14,20:06:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from Phase 3 Gene Therapy Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-14,20:06:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from Phase 3 Gene Therapy Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-14,20:06:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from Phase 3 Gene Therapy Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-14,20:06:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from Phase 3 Gene Therapy Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-14,20:06:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from Phase 3 Gene Therapy Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-14,20:06:07,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 3 Gene Therapy Study,NEWS-FLASH,Dow Jones Newswires,Biogen Announces Topline Results From Phase 3 Gene Therapy Study in Choroideremia
BIIB,2021-06-15,10:30:00,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,Business Wire,"Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:01,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,GlobeNewswire,"Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:01,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:01,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,DJ Global Press Release Wire,"Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:01,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:01,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:07,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,NEWS-FLASH,Dow Jones Newswires,"Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,10:30:23,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,NEWS-FLASH,Dow Jones Newswires,Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone
BIIB,2021-06-15,10:30:30,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen Announce Positive Pivotal Phase 3 Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder"
BIIB,2021-06-15,12:41:10,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Biogen depressive disorder treatment meets primary endpoint in Phase 3 study,NEWS-FLASH,MarketWatch,"MW Sage Therapeutics, Biogen depressive disorder treatment meets primary endpoint in Phase 3 study"
BIIB,2021-06-15,12:41:15,CEDFD5,Biogen Inc.,95,0.0,products-services,,Partner Biogen Inc. (BIIB) said a Phase 3 study of,FULL-ARTICLE,MarketWatch,"MW Sage, Biogen MDD treatment meets primary endpoint"
BIIB,2021-06-15,12:41:15,CEDFD5,Biogen Inc.,95,0.0,products-services,,Partner Biogen Inc. (BIIB) said a Phase 3 study of,FULL-ARTICLE,Dow Jones Newswires,"Sage, Biogen MDD Treatment Meets Primary Endpoint -- MarketWatch"
BIIB,2021-06-16,13:00:02,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approval of Aducanumab for Alzheimer's Disease,PRESS-RELEASE,GlobeNewswire,Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer's Disease
BIIB,2021-06-16,13:00:02,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen with its efforts to obtain FDA accelerated approval,PRESS-RELEASE,GlobeNewswire,Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer's Disease
BIIB,2021-06-16,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Teams partner with Biogen in,PRESS-RELEASE,GlobeNewswire,Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer's Disease
BIIB,2021-06-16,20:30:00,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen will discontinue clinical development of,FULL-ARTICLE,Dow Jones Newswires,"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:30:00,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen will discontinue clinical development of,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:30:00,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen will discontinue clinical development of,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:30:00,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen will discontinue clinical development of,PRESS-RELEASE,GlobeNewswire,"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:30:01,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen will discontinue clinical development of,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:30:06,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2 Study,NEWS-FLASH,Dow Jones Newswires,"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:32:34,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results From Phase 2 Study,NEWS-FLASH,Dow Jones Newswires,"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease"
BIIB,2021-06-16,20:32:40,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen Will Discontinue Clinical Development,NEWS-FLASH,Dow Jones Newswires,Biogen Will Discontinue Clinical Development of Gosuranemab >BIIB
BIIB,2021-06-16,20:33:14,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen: Will Discontinue Clinical Development,NEWS-FLASH,Dow Jones Newswires,Biogen: Will Discontinue Clinical Development of Gosuranemab >BIIB
BIIB,2021-06-16,20:59:18,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen halts development of antibody drug,FULL-ARTICLE,MarketWatch,MW Biogen halts development of antibody drug aimed at Alzheimer's
BIIB,2021-06-16,20:59:18,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval of another Biogen drug,FULL-ARTICLE,MarketWatch,MW Biogen halts development of antibody drug aimed at Alzheimer's
BIIB,2021-06-16,21:01:38,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen to Discontinue Clinical Development of Potential Treatment for Alzheimer,FULL-ARTICLE,Dow Jones Newswires,Biogen to Discontinue Clinical Development of Potential Treatment for Alzheimer's
BIIB,2021-06-16,21:16:38,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen to Discontinue Clinical Development of Potential Treatment for Alzheimer,FULL-ARTICLE,Dow Jones Newswires,Biogen to Discontinue Clinical Development of Potential Treatment for Alzheimer's
BIIB,2021-06-17,11:29:54,CEDFD5,Biogen Inc.,100,-0.52,products-services,,Biogen halts development of antibody drug,FULL-ARTICLE,MarketWatch,MW Biogen halts development of antibody drug aimed at Alzheimer's
BIIB,2021-06-17,11:29:54,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval of another Biogen drug,FULL-ARTICLE,MarketWatch,MW Biogen halts development of antibody drug aimed at Alzheimer's
BIIB,2021-06-17,11:30:01,CEDFD5,Biogen Inc.,99,0.62,products-services,positive,Biogen Inc.: Positive Phase 2 LILAC study efficacy results,PRESS-RELEASE,GlobeNewswire,Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
BIIB,2021-06-17,11:30:01,CEDFD5,Biogen Inc.,99,0.62,products-services,positive,Biogen Inc.: Positive Phase 2 LILAC study efficacy results,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
BIIB,2021-06-17,11:30:01,CEDFD5,Biogen Inc.,99,0.62,products-services,positive,Biogen Inc.: Positive Phase 2 LILAC study efficacy results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
BIIB,2021-06-17,11:30:01,CEDFD5,Biogen Inc.,99,0.62,products-services,positive,Biogen Inc.: Positive Phase 2 LILAC study efficacy results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
BIIB,2021-06-18,11:15:33,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Overweight From Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Overweight From Neutral by Piper Sandler
BIIB,2021-06-18,11:15:33,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $450.00/Share From $384.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $450.00/Share From $384.00 by Piper Sandler
BIIB,2021-06-18,12:30:36,CEDFD5,Biogen Inc.,94,0.94,analyst-ratings,positive,"He upgrade Biogen (ticker: BIIB) shares to Overweight, from Neutral",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Can Go 'Decisively Higher' on Sales of Alzheimer's Drug -- Barrons.com
BIIB,2021-06-22,20:30:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approved Biogen Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,FDA Approved Biogen Alzheimer's Drug Despite Some Staff Concerns
BIIB,2021-06-22,20:49:50,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approved Biogen Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,FDA Approved Biogen Alzheimer's Drug Despite Some Staff Concerns -- Update
BIIB,2021-06-22,22:21:31,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approved Biogen Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,FDA Approved Biogen Alzheimer's Drug Despite Some Staff Concerns -- 2nd Update
BIIB,2021-06-23,20:06:03,CEDFD5,Biogen Inc.,99,0.51,products-services,complete,Eisai and Biogen completed enrollment,PRESS-RELEASE,PR Newswire,"Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-23,20:06:03,CEDFD5,Biogen Inc.,99,0.39,products-services,,Eisai and Biogen entered into a joint development and commercialization agreement,PRESS-RELEASE,PR Newswire,"Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-23,20:06:03,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen are collaborating on the joint development,PRESS-RELEASE,PR Newswire,"Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-23,20:06:04,CEDFD5,Biogen Inc.,99,0.51,products-services,complete,Eisai and Biogen completed enrollment,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-23,20:06:04,CEDFD5,Biogen Inc.,99,0.39,products-services,,Eisai and Biogen entered into a joint development and commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-23,20:06:04,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen are collaborating on the joint development,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease"
BIIB,2021-06-24,11:25:51,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda gave its stamp of approval for an Alzheimer's drug from Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Drops Premarket
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Ranibizumab,FULL-ARTICLE,Dow Jones Newswires,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,FULL-ARTICLE,Dow Jones Newswires,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Ranibizumab,PRESS-RELEASE,DJ Global Press Release Wire,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,DJ Global Press Release Wire,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Ranibizumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Ranibizumab,PRESS-RELEASE,GlobeNewswire,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,GlobeNewswire,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen Receive Positive CHMP Opinion for Ranibizumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,11:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Samsung Bioepis and Biogen announced that they had entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ(TM)"
BIIB,2021-06-25,12:15:14,CEDFD5,Biogen Inc.,100,0.57,products-services,positive,Biogen Gets Positive Opinion in Europe for Eye Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Positive Opinion in Europe for Eye Drug
BIIB,2021-06-25,12:30:14,CEDFD5,Biogen Inc.,100,0.57,products-services,positive,Biogen Gets Positive Opinion in Europe for Eye Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Positive Opinion in Europe for Eye Drug
BIIB,2021-06-28,11:27:38,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-06-28,11:27:38,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $354.00/Share From $400.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $354.00/Share From $400.00 by RBC Capital
BIIB,2021-06-28,14:00:18,CEDFD5,Biogen Inc.,100,-0.52,legal,,Committees announced an investigation of Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Sliding. House Committees Will Investigate Its $56K Alzheimer's Drug. -- Barrons.com
BIIB,2021-06-29,12:53:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Enel S.p.A.: Our relationship with Biogen,PRESS-RELEASE,PR Newswire,Enel X Collaborates With Biogen To Electrify Take-home Vehicle Fleet In North America
BIIB,2021-06-29,12:53:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Enel S.p.A.: Our relationship with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Enel X Collaborates With Biogen To Electrify Take-home Vehicle Fleet In North America
BIIB,2021-06-29,12:53:14,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Enel X Collaborates With Biogen to,NEWS-FLASH,Dow Jones Newswires,Enel X Collaborates With Biogen to Electrify Take-home Vehicle Fleet in N Amer
BIIB,2021-07-02,21:23:24,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 177 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 177 Of Biogen Inc >BIIB
BIIB,2021-07-09,18:02:10,CEDFD5,Biogen Inc.,98,0.49,partnerships,,Biogen Inc.: They collaborated with the company to,FULL-ARTICLE,Dow Jones Newswires,"FDA Seeks Probe of Talks Between Staff, Biogen on Alzheimer's Drug -- Update"
BIIB,2021-07-09,18:34:41,CEDFD5,Biogen Inc.,99,-0.52,products-services,,Biogen scrapped development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW FDA calls for investigation into its own approval of Biogen's Alzheimer's drug
BIIB,2021-07-09,18:37:28,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: They collaborated with the company to,FULL-ARTICLE,Dow Jones Newswires,"FDA Seeks Probe of Talks Between Staff, Biogen on Alzheimer's Drug -- Update 2"
BIIB,2021-07-09,18:57:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration's approval last month of Biogen's Alzheimer's disease therapy,FULL-ARTICLE,Dow Jones Newswires,FDA Commissioner Asks for Investigation Into Approval Process for Biogen's Alzheimer's Drug -- Barrons.com
BIIB,2021-07-09,19:33:32,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration last month approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,"Biogen Alzheimer's Drug Will Exceed the $56,000 List Price for Many, Analysis Says"
BIIB,2021-07-09,19:50:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The U.S. Food and Drug Administration last month approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,"Biogen Alzheimer's Drug Will Exceed the $56,000 List Price for Many, Analysis Says"
BIIB,2021-07-09,23:15:49,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: They collaborated with the company to,FULL-ARTICLE,Dow Jones Newswires,"FDA Seeks Probe of Talks Between Staff, Biogen on Alzheimer's Drug -- 3rd Update"
BIIB,2021-07-10,06:14:14,CEDFD5,Biogen Inc.,98,0.49,partnerships,,Biogen Inc.: They collaborated with the company to,FULL-ARTICLE,Dow Jones Newswires,U.S. News:  FDA Seeks Probe of Talks  Between Staff and Biogen  ---  Agency chief requests  review of interactions  before recent approval  of Alzheimer's drug  ----  By Thomas M. Burton
BIIB,2021-07-10,06:32:21,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: They collaborated with the company to,FULL-ARTICLE,Wall Street Journal,FDA Seeks Probe of Talks Between Staff and Biogen -- WSJ
BIIB,2021-07-10,12:52:49,CEDFD5,Biogen Inc.,99,-0.52,products-services,,Biogen scrapped development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW FDA calls for investigation into its own approval of Biogen's Alzheimer's drug
BIIB,2021-07-11,13:14:38,CEDFD5,Biogen Inc.,99,-0.52,products-services,,Biogen scrapped development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW FDA calls for investigation into its own approval of Biogen's Alzheimer's drug
BIIB,2021-07-12,14:10:40,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda's approval of Biogen's Alzheimer's drug,FULL-ARTICLE,Dow Jones Newswires,Wall Street Shrugs Off FDA's Call for Probe of Approval of Biogen Alzheimer's Drug -- Barrons.com
BIIB,2021-07-12,14:10:40,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda announced its approval of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Wall Street Shrugs Off FDA's Call for Probe of Approval of Biogen Alzheimer's Drug -- Barrons.com
BIIB,2021-07-12,23:00:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,PRESS-RELEASE,GlobeNewswire,"Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:00:44,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare Announce License and Collaboration,NEWS-FLASH,Dow Jones Newswires,"Biogen and Innocare Announce License and Collaboration Agreement for Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor for the Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:02:20,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Innocare: Announce License and Collaboration,NEWS-FLASH,Dow Jones Newswires,"Biogen and Innocare: Announce License and Collaboration Agreement for Orelabrutinib, a CNS Penetrant BTK Inhibitor for Potential Treatment of Multiple Sclerosis"
BIIB,2021-07-12,23:14:54,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen in Rights Agreement With InnoCare,FULL-ARTICLE,Dow Jones Newswires,Biogen in Rights Agreement With InnoCare for Orelabrutinib Drug
BIIB,2021-07-12,23:29:54,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen in Rights Agreement With InnoCare,FULL-ARTICLE,Dow Jones Newswires,Biogen in Rights Agreement With InnoCare for Orelabrutinib Drug
BIIB,2021-07-14,12:17:13,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency approved Biogen's drug,FULL-ARTICLE,Dow Jones Newswires,Top FDA Staffers Defend Approval of Biogen's Alzheimer's Drug in Medical Journal -- Barrons.com
BIIB,2021-07-16,12:45:37,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-07-16,12:45:37,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $453.00/Share From $455.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $453.00/Share From $455.00 by Morgan Stanley
BIIB,2021-07-21,07:34:54,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 2Q 2021 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 2Q 2021 (BIIB)"
BIIB,2021-07-21,12:03:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc.: Mirimus, Inc. Forms Strategic Collaboration with Biogen",PRESS-RELEASE,PR Newswire,"Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications"
BIIB,2021-07-21,12:03:04,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Forms Strategic Collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications"
BIIB,2021-07-21,12:04:06,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Forms Strategic Collaboration With Biogen to,NEWS-FLASH,Dow Jones Newswires,Mirimus Forms Strategic Collaboration With Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications
BIIB,2021-07-22,11:09:33,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $2.99 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q EPS $2.99 >BIIB
BIIB,2021-07-22,11:09:33,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Net $448.5M,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Net $448.5M >BIIB
BIIB,2021-07-22,11:19:44,CEDFD5,Biogen Inc.,100,-0.7,earnings,down,Biogen Q2 EPS $2.99 vs. $9.59 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q2 EPS $2.99 vs. $9.59 a year ago
BIIB,2021-07-22,11:20:08,CEDFD5,Biogen Inc.,100,-0.44,revenues,down,Biogen Q2 revenue $2.775 bln vs. $3.681 bln a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q2 revenue $2.775 bln vs. $3.681 bln a year ago
BIIB,2021-07-22,11:20:27,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Q2 FactSet EPS consensus $4.55,NEWS-FLASH,MarketWatch,MW Biogen Q2 FactSet EPS consensus $4.55; revenue $2.609 bln
BIIB,2021-07-22,11:22:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Q2 adj. EPS $5.68,NEWS-FLASH,MarketWatch,MW Biogen Q2 adj. EPS $5.68
BIIB,2021-07-22,11:22:59,CEDFD5,Biogen Inc.,100,-0.42,revenues,down,Biogen Q2 MS revenue fell 24% to $1.786 bln,NEWS-FLASH,MarketWatch,MW Biogen Q2 MS revenue fell 24% to $1.786 bln
BIIB,2021-07-22,11:23:15,CEDFD5,Biogen Inc.,100,0.41,revenues,up,Biogen Q2 Spinraza revenue up 1% at $500 mln,NEWS-FLASH,MarketWatch,MW Biogen Q2 Spinraza revenue up 1% at $500 mln
BIIB,2021-07-22,11:23:33,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Q2 Aduhelm revenue $2 mln,NEWS-FLASH,MarketWatch,MW Biogen Q2 Aduhelm revenue $2 mln
BIIB,2021-07-22,11:23:42,CEDFD5,Biogen Inc.,100,0.41,revenues,up,Biogen Q2 biosimilars revenue up 18% to $202 mln,NEWS-FLASH,MarketWatch,MW Biogen Q2 biosimilars revenue up 18% to $202 mln
BIIB,2021-07-22,11:24:39,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees full-year adj. EPS $17.50 to $19.00,NEWS-FLASH,MarketWatch,"MW Biogen now sees full-year adj. EPS $17.50 to $19.00, unchanged vs. prior guidance"
BIIB,2021-07-22,11:25:04,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen now sees full-year revenue $10.65 bln to $10.85 bln,NEWS-FLASH,MarketWatch,MW Biogen now sees full-year revenue $10.65 bln to $10.85 bln vs. prior $10.45 bln to $10.75 bln
BIIB,2021-07-22,11:31:14,CEDFD5,Biogen Inc.,100,-0.7,earnings,down,"Biogen Inc.: Net income attributable to the company was $448.5 million, compared with $1.54 billion",FULL-ARTICLE,Dow Jones Newswires,"Biogen Posts 2Q Sales, Earnings Declines on Lower Multiple-Sclerosis Drug Revenue"
BIIB,2021-07-22,11:31:14,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.'s reported second-quarter revenue,FULL-ARTICLE,Dow Jones Newswires,"Biogen Posts 2Q Sales, Earnings Declines on Lower Multiple-Sclerosis Drug Revenue"
BIIB,2021-07-22,11:46:14,CEDFD5,Biogen Inc.,100,-0.7,earnings,down,"Biogen Inc.: Net income attributable to the company was $448.5 million, compared with $1.54 billion",FULL-ARTICLE,Dow Jones Newswires,"Biogen Posts 2Q Sales, Earnings Declines on Lower Multiple-Sclerosis Drug Revenue"
BIIB,2021-07-22,11:46:14,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.'s reported second-quarter revenue,FULL-ARTICLE,Dow Jones Newswires,"Biogen Posts 2Q Sales, Earnings Declines on Lower Multiple-Sclerosis Drug Revenue"
BIIB,2021-07-22,11:46:19,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Raises Rev Guidance,FULL-ARTICLE,Dow Jones Newswires,"Biogen Raises Rev Guidance, Reiterates Earnings Guidance"
BIIB,2021-07-22,11:54:47,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the second quarter,FULL-ARTICLE,MarketWatch,"MW Biogen's beats on earnings, says it's also brought in $2 million in sales of Alzheimer's drug"
BIIB,2021-07-22,11:54:47,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the second quarter,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Beats On Earnings, Says It's Also Brought In $2 Million In Sales Of Alzheimer's Drug -- MarketWatch"
BIIB,2021-07-22,11:55:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen's Aduhelm Posts 2Q Sales of $1.6M,FULL-ARTICLE,Dow Jones Newswires,Biogen's Aduhelm Posts 2Q Sales of $1.6M -- Market Talk
BIIB,2021-07-22,11:55:45,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen raised its full-year 2021 revenue guidance to a range of $10.65B to $10.85B,FULL-ARTICLE,Dow Jones Newswires,Biogen's Aduhelm Posts 2Q Sales of $1.6M -- Market Talk
BIIB,2021-07-22,11:55:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen's Aduhelm Posts 2Q Sales of $1.6M,FULL-ARTICLE,Dow Jones Newswires,Biogen's Aduhelm Posts 2Q Sales of $1.6M -- Market Talk
BIIB,2021-07-22,11:55:45,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen raised its full-year 2021 revenue guidance to a range of $10.65B to $10.85B,FULL-ARTICLE,Dow Jones Newswires,Biogen's Aduhelm Posts 2Q Sales of $1.6M -- Market Talk
BIIB,2021-07-22,12:01:19,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Raises Revenue Guidance,FULL-ARTICLE,Dow Jones Newswires,"Biogen Raises Revenue Guidance, Reiterates Earnings Guidance"
BIIB,2021-07-22,13:40:36,CEDFD5,Biogen Inc.,97,0.0,revenues,,Biogen reported $1.6 million in revenues,FULL-ARTICLE,Dow Jones Newswires,Biogen Sold $1.6M of Aduhelm in Weeks After Approval. Earnings Were Strong. -- Barrons.com
BIIB,2021-07-22,17:06:54,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q2 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q2 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2021-07-22,17:06:54,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen-inc-biib-ceo-michel-vounatsos-on-q2-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q2 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2021-07-22,18:11:51,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the second quarter,FULL-ARTICLE,MarketWatch,"MW Biogen beats on earnings, says it's brought in $2 million in sales of Alzheimer's drug"
BIIB,2021-07-22,18:11:51,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the second quarter,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen Beats On Earnings, Says It's Brought In $2 Million In Sales Of Alzheimer's Drug -- MarketWatch"
BIIB,2021-07-22,19:07:16,CEDFD5,Biogen Inc.,99,-0.47,regulatory,,Aduhelm is currently being reviewed by regulators,FULL-ARTICLE,MarketWatch,"MW Biogen, under pressure, tells investors it 'stands by' the FDA review process for its Alzheimer's drug"
BIIB,2021-07-23,11:00:00,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-07-23,11:00:00,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $341.00/Share From $361.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $341.00/Share From $361.00 by RBC Capital
BIIB,2021-07-23,11:33:07,CEDFD5,Biogen Inc.,99,-0.47,regulatory,,Aduhelm is currently being reviewed by regulators,FULL-ARTICLE,MarketWatch,"MW Biogen, under pressure, tells investors it 'stands by' the FDA review process for its Alzheimer's drug"
BIIB,2021-07-23,13:36:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-07-23,13:36:01,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $455.00/Share From $453.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $455.00/Share From $453.00 by Morgan Stanley
BIIB,2021-07-23,16:16:02,CEDFD5,Biogen Inc.,99,-0.47,regulatory,,Aduhelm is currently being reviewed by regulators,FULL-ARTICLE,MarketWatch,"MW Biogen, under pressure, tells investors it 'stands by' the FDA review process for its Alzheimer's drug"
BIIB,2021-07-23,20:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results in early-stage clinical trials,PRESS-RELEASE,GlobeNewswire,Biogen to Present Data from ADUHELM and -2-
BIIB,2021-07-23,20:34:22,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results in early-stage clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present Data from -2-
BIIB,2021-07-27,14:39:46,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2021-07-27,14:39:46,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $423.00/Share From $359.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $423.00/Share From $359.00 by Canaccord Genuity
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,Nasdaq: BIIB) today announced results from the two-year,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,Nasdaq: BIIB) today announced results from the two-year,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Results from Phase 3b NOVA Study -2-
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Results from Phase 3b NOVA Study -2-
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,Nasdaq: BIIB) today announced results from the two-year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc. (Nasdaq: BIIB) today announced results from the two-year,PRESS-RELEASE,GlobeNewswire,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces Results from Phase 3b NOVA Study -2-
BIIB,2021-08-02,11:30:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results from Phase 3b NOVA Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:30:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc. (Nasdaq: BIIB) today announced results from the two-year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,11:31:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Results From Phase 3b NOVA Study,NEWS-FLASH,Dow Jones Newswires,Biogen Announces Results From Phase 3b NOVA Study Evaluating Every Six-Week Dosing With Natalizumab in Relapsing-Remitting Multiple Sclerosis
BIIB,2021-08-02,12:28:34,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Mizuho
BIIB,2021-08-02,12:28:34,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $300.00/Share From $244.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $300.00/Share From $244.00 by Mizuho
BIIB,2021-08-23,15:00:04,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,The U.S. Food & Drug Administration granted approval of Aduhelm,PRESS-RELEASE,PR Newswire,First Patient in West Michigan Receives Biogen Alzheimer's Drug at Infusion Associates Outpatient Infusion Center
BIIB,2021-08-26,15:48:44,CEDFD5,Biogen Inc.,97,0.0,revenues,,Now expects $13 million in Aduhelm sales in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Early Sales of Biogen's Alzheimer Drug Remain Unclear -- Barrons.com
BIIB,2021-08-26,15:48:44,CEDFD5,Biogen Inc.,97,0.0,investor-relations,,Biogen Inc.: the company's earnings call in July,FULL-ARTICLE,Dow Jones Newswires,Early Sales of Biogen's Alzheimer Drug Remain Unclear -- Barrons.com
BIIB,2021-08-27,15:22:21,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's second-quarter earnings call,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Beyond Reach for Many Patients
BIIB,2021-08-27,15:40:04,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's second-quarter earnings call,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Beyond Reach for Many Patients
BIIB,2021-08-28,06:14:15,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's second-quarter earnings call,FULL-ARTICLE,Dow Jones Newswires,U.S. News:  Biogen Alzheimer's Drug Sits Unused  ----  By Joseph Walker
BIIB,2021-08-28,06:32:36,CEDFD5,Biogen Inc.,99,0.0,investor-relations,,Biogen Inc.: the company's second-quarter earnings call,FULL-ARTICLE,Wall Street Journal,Biogen Alzheimer's Drug Sits Unused -- WSJ
BIIB,2021-09-03,20:13:05,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 3,423 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 3,423 Of Biogen Inc >BIIB"
BIIB,2021-09-13,11:05:28,CEDFD5,Biogen Inc.,92,0.52,products-services,,Biogen Inc.: the company said the launch of its Alzheimer's drug,FULL-ARTICLE,Dow Jones Newswires,"Airbnb, Apache, Biogen: What to Watch When the Stock Market Opens Today"
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Plans to Initiate Phase 3b Study -2-
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Plans to Initiate Phase 3b Study -2-
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,GlobeNewswire,Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)
BIIB,2021-09-15,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,GlobeNewswire,Biogen Plans to Initiate Phase 3b Study -2-
BIIB,2021-09-15,11:30:02,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)
BIIB,2021-09-15,11:30:23,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Plans to Initiate Phase 3b Study,NEWS-FLASH,Dow Jones Newswires,Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of Higher Dose of Nusinersen in Patients Previously Treated With Evrysdi
BIIB,2021-09-15,11:45:28,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Plans Phase 3b Trial of,FULL-ARTICLE,Dow Jones Newswires,Biogen Plans Phase 3b Trial of Spinal Muscular Atrophy Drug
BIIB,2021-09-15,12:00:28,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Plans Phase 3b Trial of,FULL-ARTICLE,Dow Jones Newswires,Biogen Plans Phase 3b Trial of Spinal Muscular Atrophy Drug
BIIB,2021-09-15,18:14:18,CEDFD5,Biogen Inc.,92,0.0,products-services,,Biogen Plans Phase 3b Trial of,FULL-ARTICLE,Dow Jones Newswires,Correction to Biogen Plans Phase 3b Trial Article
BIIB,2021-09-15,18:29:18,CEDFD5,Biogen Inc.,92,0.0,products-services,,Biogen Plans Phase 3b Trial of,FULL-ARTICLE,Dow Jones Newswires,Correction to Biogen Plans Phase 3b Trial Article
BIIB,2021-09-16,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:30:02,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:30:37,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Announces Positive Topline Results From Phase 2 CONVEY Study,NEWS-FLASH,Dow Jones Newswires,Biogen Announces Positive Topline Results From Phase 2 CONVEY Study in Small Fiber Neuropathy
BIIB,2021-09-16,11:50:55,CEDFD5,Biogen Inc.,93,0.0,products-services,,Biogen Inc. said its Phase 2 study of,FULL-ARTICLE,Dow Jones Newswires,Biogen Drug Candidate for Small Fiber Neuropathy Meets Primary Endpoint for 200 Milligram Dose
BIIB,2021-09-16,12:05:56,CEDFD5,Biogen Inc.,93,0.0,products-services,,Biogen Inc. said its Phase 2 study of,FULL-ARTICLE,Dow Jones Newswires,Biogen Drug Candidate for Small Fiber Neuropathy Meets Primary Endpoint for 200 Milligram Dose
BIIB,2021-09-16,12:51:33,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by UBS
BIIB,2021-09-16,12:51:33,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $442.00/Share From $475.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $442.00/Share From $475.00 by UBS
BIIB,2021-09-20,11:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,DJ Global Press Release Wire,"FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,FULL-ARTICLE,Dow Jones Newswires,"FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:30:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,GlobeNewswire,"FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:30:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,GlobeNewswire,"FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:30:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-20,11:32:23,CEDFD5,Biogen Inc.,99,0.39,products-services,,Samsung Bioepis and Biogen entered into a commercialization agreement,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab-nuna)"
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda-approved ADUHELM,FULL-ARTICLE,Dow Jones Newswires,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai in collaboration with Biogen, and BIIB",FULL-ARTICLE,Dow Jones Newswires,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.7,products-services,,Lecanemab received Breakthrough Therapy designation from the FDA,FULL-ARTICLE,Dow Jones Newswires,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda-approved ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai in collaboration with Biogen, and BIIB",PRESS-RELEASE,DJ Global Press Release Wire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.7,products-services,,Lecanemab received Breakthrough Therapy designation from the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: A Phase 1b study of,PRESS-RELEASE,DJ Global Press Release Wire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",FULL-ARTICLE,Dow Jones Newswires,Biogen R&D Day to Provide Overview of Diversified -2-
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,DJ Global Press Release Wire,Biogen R&D Day to Provide Overview of Diversified -2-
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda-approved ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai in collaboration with Biogen, and BIIB",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.7,products-services,,Lecanemab received Breakthrough Therapy designation from the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: A Phase 1b study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview -2-
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda-approved ADUHELM,PRESS-RELEASE,GlobeNewswire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai in collaboration with Biogen, and BIIB",PRESS-RELEASE,GlobeNewswire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.7,products-services,,Lecanemab received Breakthrough Therapy designation from the FDA,PRESS-RELEASE,GlobeNewswire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: A Phase 1b study of,PRESS-RELEASE,GlobeNewswire,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,GlobeNewswire,Biogen R&D Day to Provide Overview of Diversified -2-
BIIB,2021-09-21,12:30:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda-approved ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Eisai in collaboration with Biogen, and BIIB",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:02,CEDFD5,Biogen Inc.,99,0.7,products-services,,Lecanemab received Breakthrough Therapy designation from the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:02,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: A Phase 1b study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
BIIB,2021-09-21,12:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen R&D Day to Provide Overview -2-
BIIB,2021-09-22,14:04:34,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Goodman has an Outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Down on a Report That Few Have Received Its New Alzheimer's Therapy -- Barrons.com
BIIB,2021-09-23,08:48:58,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Biogen Initiated at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Buy by Needham
BIIB,2021-09-23,08:48:58,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $400.00/Share by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $400.00/Share by Needham
BIIB,2021-09-24,15:47:21,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Committee to approve Aduhelm,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Aduhelm Struggles Don't Hurt Lilly's Outlook, Says Analyst -- Barrons.com"
BIIB,2021-09-29,11:34:39,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-09-29,11:34:39,CEDFD5,Biogen Inc.,100,-0.54,price-targets,downgrade,Biogen Price Target Cut to $326.00/Share From $341.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $326.00/Share From $341.00 by RBC Capital
BIIB,2021-10-08,10:58:24,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2021-10-08,10:58:24,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $290.00/Share From $395.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $290.00/Share From $395.00 by Barclays
BIIB,2021-10-08,13:13:54,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Jefferies
BIIB,2021-10-08,13:13:54,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $400.00/Share From $500.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $400.00/Share From $500.00 by Jefferies
BIIB,2021-10-12,12:19:38,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-10-12,12:19:38,CEDFD5,Biogen Inc.,100,-0.34,price-targets,downgrade,Biogen Price Target Cut to $447.00/Share From $455.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $447.00/Share From $455.00 by Morgan Stanley
BIIB,2021-10-13,10:05:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Combined post-marketing data based on prescriptions and clinical trials,PRESS-RELEASE,GlobeNewswire,New Data at ECTRIMS 2021 Highlight Biogen's Focus -2-
BIIB,2021-10-13,10:05:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Combined post-marketing data based on prescriptions and clinical trials,PRESS-RELEASE,DJ Global Press Release Wire,New Data at ECTRIMS 2021 Highlight Biogen's Focus -3-
BIIB,2021-10-15,10:52:39,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen stock price target cut to $344 from $430 at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $344 from $430 at Stifel Nicolaus
BIIB,2021-10-15,13:26:56,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Cantor Fitzgerald
BIIB,2021-10-15,13:26:56,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $327.00/Share From $427.00 by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $327.00/Share From $427.00 by Cantor Fitzgerald
BIIB,2021-10-15,13:32:36,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Stifel
BIIB,2021-10-15,13:32:36,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $344.00/Share From $430.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $344.00/Share From $430.00 by Stifel
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Announces Topline Results from the Tofersen Phase 3 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen will expand its ongoing early access program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Data from the tofersen Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen will expand its ongoing early access program,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen will expand its ongoing early access program,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Data from the tofersen Phase 3 study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The open-label extension study is an ongoing Phase 3 study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen will expand its ongoing early access program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Data from the tofersen Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The open-label extension study is an ongoing Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Topline Results from the Tofersen Phase 3 Studyand its Open-Label Extension in SOD1-ALS
BIIB,2021-10-17,20:20:03,CEDFD5,Biogen Inc.,99,0.44,products-services,,Biogen will expand its ongoing early access program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
BIIB,2021-10-18,12:09:08,CEDFD5,Biogen Inc.,100,-0.65,products-services,negative,Biogen says ALS drug did not meet primary endpoint in Phase 3 clinical trial,FULL-ARTICLE,MarketWatch,MW Biogen says ALS drug did not meet primary endpoint in Phase 3 clinical trial
BIIB,2021-10-18,12:09:08,CEDFD5,Biogen Inc.,100,-0.65,products-services,negative,Biogen Says ALS Drug Did Not Meet Primary Endpoint In Phase 3 Clinical Trial,FULL-ARTICLE,Dow Jones Newswires,Biogen Says ALS Drug Did Not Meet Primary Endpoint In Phase 3 Clinical Trial -- MarketWatch
BIIB,2021-10-18,13:32:24,CEDFD5,Biogen Inc.,97,-0.65,products-services,negative,Experimental drug tofersen failed in a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Biogen Suffers Pipeline Setback in ALS Study -- Market Talk
BIIB,2021-10-18,13:32:24,CEDFD5,Biogen Inc.,97,-0.65,products-services,negative,Experimental drug tofersen failed in a Phase 3 study,FULL-ARTICLE,Dow Jones Newswires,Biogen Suffers Pipeline Setback in ALS Study -- Market Talk
BIIB,2021-10-19,10:14:30,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2021-10-19,10:14:30,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $398.00/Share From $400.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $398.00/Share From $400.00 by Needham
BIIB,2021-10-19,10:30:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Sage Therapeutics And Biogen Announce Plans To Submit A New Drug Application (NDA) For Zuranolone To The U.S. Food & Drug Administration In,NEWS-FLASH,Dow Jones Newswires,Sage Therapeutics And Biogen Announce Plans To Submit A New Drug Application (NDA) For Zuranolone To The U.S. Food & Drug Administration In The Second Half Of 2022 With Rolling Submission Expected To Start In Early 2022 >SAGE
BIIB,2021-10-19,10:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in,PRESS-RELEASE,Business Wire,Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
BIIB,2021-10-19,10:30:54,CEDFD5,Biogen Inc.,100,0.0,products-services,,Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
BIIB,2021-10-19,10:31:08,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone",NEWS-FLASH,Dow Jones Newswires,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone in 2nd Half of 2022"
BIIB,2021-10-19,11:10:35,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone",FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone in 2nd Half of 2022"
BIIB,2021-10-19,11:25:35,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone",FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone in 2nd Half of 2022"
BIIB,2021-10-20,11:10:34,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,3Q EPS $2.22 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q EPS $2.22 >BIIB
BIIB,2021-10-20,11:10:34,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $4.77,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $4.77 >BIIB
BIIB,2021-10-20,11:10:34,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Net $329.2M,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Net $329.2M >BIIB
BIIB,2021-10-20,11:10:34,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.78B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.78B >BIIB
BIIB,2021-10-20,11:16:39,CEDFD5,Biogen Inc.,100,-0.38,revenues,down,"Biogen 3Q Multiple Sclerosis Rev Including Royalties on OCREVUS Sales $1.82B, Down 19%",NEWS-FLASH,Dow Jones Newswires,"Biogen 3Q Multiple Sclerosis Rev Including Royalties on OCREVUS Sales $1.82B, Down 19% >BIIB"
BIIB,2021-10-20,11:17:07,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen 3Q SPINRAZA Rev $444M, Down 10%",NEWS-FLASH,Dow Jones Newswires,"Biogen 3Q SPINRAZA Rev $444M, Down 10% >BIIB"
BIIB,2021-10-20,11:18:28,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees FY Rev $10.8B-$10.9B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Sees FY Rev $10.8B-$10.9B >BIIB
BIIB,2021-10-20,11:18:28,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY Adj EPS $18.85,NEWS-FLASH,Dow Jones Newswires,Biogen Sees FY Adj EPS $18.85-Adj EPS $19.35 >BIIB
BIIB,2021-10-20,11:18:54,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Sees FY CapEx $250M-$300M >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Sees FY CapEx $250M-$300M >BIIB
BIIB,2021-10-20,11:23:37,CEDFD5,Biogen Inc.,100,-0.62,earnings,down,Biogen Q3 EPS $2.22 vs. $4.46 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q3 EPS $2.22 vs. $4.46 a year ago
BIIB,2021-10-20,11:23:55,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q3 adj. EPS $4.77; FactSet consensus $4.09,NEWS-FLASH,MarketWatch,MW Biogen Q3 adj. EPS $4.77; FactSet consensus $4.09
BIIB,2021-10-20,11:24:20,CEDFD5,Biogen Inc.,100,-0.34,revenues,down,Biogen Q3 revenue down 17% to $2.779 bln,NEWS-FLASH,MarketWatch,MW Biogen Q3 revenue down 17% to $2.779 bln; FactSet consensus $2.669 bln
BIIB,2021-10-20,11:25:48,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raises full-year guidance,NEWS-FLASH,MarketWatch,"MW Biogen raises full-year guidance, now sees revenue of $10.8 bln to $10.9 bln vs. prior $10.65 bln to $10.85 bln"
BIIB,2021-10-20,11:26:26,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees full-year adj. EPS of $18.85 to $19.35,NEWS-FLASH,MarketWatch,MW Biogen now sees full-year adj. EPS of $18.85 to $19.35 vs. prior $17.50 to $19.00
BIIB,2021-10-20,11:28:13,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises Full-Year Guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises Full-Year Guidance
BIIB,2021-10-20,11:28:13,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Inc. raised its full-year sales and earnings guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises Full-Year Guidance
BIIB,2021-10-20,11:31:11,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen 3Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Biogen 3Q Results Beat Expectations; Alzheimer's Drug Aduhelm Posts Sales of $300,000"
BIIB,2021-10-20,11:43:13,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises Full-Year Guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises Full-Year Guidance
BIIB,2021-10-20,11:43:13,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Inc. raised its full-year sales and earnings guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises Full-Year Guidance
BIIB,2021-10-20,11:46:10,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen 3Q Results Beat Expectations,FULL-ARTICLE,Dow Jones Newswires,"Biogen 3Q Results Beat Expectations; Alzheimer's Drug Aduhelm Posts Sales of $300,000"
BIIB,2021-10-20,11:49:33,CEDFD5,Biogen Inc.,95,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the third quarter,FULL-ARTICLE,MarketWatch,"MW Biogen's stock is up on strong earnings; new Alzheimer's drug had $300,000 in sales in Q3"
BIIB,2021-10-20,11:49:33,CEDFD5,Biogen Inc.,95,0.0,revenues,,Biogen's revenue was $2.7 billion in the third quarter,FULL-ARTICLE,MarketWatch,"MW Biogen's stock is up on strong earnings; new Alzheimer's drug had $300,000 in sales in Q3"
BIIB,2021-10-20,11:49:33,CEDFD5,Biogen Inc.,95,0.7,earnings,above-expectations,Biogen Inc.: the company beat expectations for the third quarter,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Is Up On Strong Earnings; New Alzheimer's Drug Had $300,000 In Sales In Q3 -- MarketWatch"
BIIB,2021-10-20,11:49:33,CEDFD5,Biogen Inc.,95,0.0,revenues,,Biogen's revenue was $2.7 billion in the third quarter,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Is Up On Strong Earnings; New Alzheimer's Drug Had $300,000 In Sales In Q3 -- MarketWatch"
BIIB,2021-10-20,12:17:21,CEDFD5,Biogen Inc.,99,0.64,earnings,up,Biogen increased its profit,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock. -- Barrons.com
BIIB,2021-10-20,12:17:21,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen said that third-quarter revenues,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock. -- Barrons.com
BIIB,2021-10-20,12:17:21,CEDFD5,Biogen Inc.,99,-0.11,products-services,,Spinraza are facing increasing competition,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock. -- Barrons.com
BIIB,2021-10-20,12:30:04,CEDFD5,Biogen Inc.,99,0.64,earnings,up,Biogen increased its profit,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.
BIIB,2021-10-20,12:30:04,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen said that third-quarter revenues,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.
BIIB,2021-10-20,12:30:04,CEDFD5,Biogen Inc.,99,-0.11,products-services,,Spinraza are facing increasing competition,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.
BIIB,2021-10-20,12:31:19,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,The Food and Drug Administration approved Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Meets Slow Rollout -- Update
BIIB,2021-10-20,12:31:19,CEDFD5,Biogen Inc.,96,-0.68,revenues,down,Biogen's sales declined to $2.78 billion in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Meets Slow Rollout -- Update
BIIB,2021-10-20,12:40:03,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,The Food and Drug Administration approved Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Meets Slow Rollout
BIIB,2021-10-20,12:40:03,CEDFD5,Biogen Inc.,96,-0.68,revenues,down,Biogen's sales declined to $2.78 billion in the third quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Meets Slow Rollout
BIIB,2021-10-20,14:41:59,CEDFD5,Biogen Inc.,99,0.7,earnings,up,Biogen raised its sales and profit outlook for 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen Shareholders Face the Waiting Game -- Heard on the Street
BIIB,2021-10-20,15:52:37,CEDFD5,Biogen Inc.,99,-0.68,revenues,down,Biogen's sales declined to $2.78 billion for the third quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen's New Alzheimer's Drug Meets Slow Rollout -- 2nd Update
BIIB,2021-10-20,17:41:05,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q3 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q3 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2021-10-21,06:00:56,CEDFD5,Biogen Inc.,99,0.7,earnings,up,Biogen raised its sales and profit outlook for 2021,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street:  Biogen Shareholders Face  Waiting Game on Alzheimer's Drug  ----  By Charley Grant
BIIB,2021-10-21,06:09:16,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Biogen's sales declined to $2.78 billion for the third quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Posts Weak Quarterly Sales  Of New Alzheimer's Drug Aduhelm  ----  By Joseph Walker and Matt Grossman
BIIB,2021-10-21,06:32:07,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Biogen's sales declined to $2.78 billion for the third quarter,FULL-ARTICLE,Wall Street Journal,Biogen Posts Weak Quarterly Sales Of New Alzheimer's Drug Aduhelm -- WSJ
BIIB,2021-10-21,06:32:16,CEDFD5,Biogen Inc.,99,0.7,earnings,up,Biogen raised its sales and profit outlook for 2021,FULL-ARTICLE,Wall Street Journal,Heard on the Street: Biogen Shareholders Face Waiting Game on Alzheimer's Drug -- WSJ
BIIB,2021-10-21,07:19:35,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 3Q 2021 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 3Q 2021 (BIIB)"
BIIB,2021-10-21,10:28:52,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2021-10-21,10:28:52,CEDFD5,Biogen Inc.,100,-0.44,price-targets,downgrade,Biogen Price Target Cut to $386.00/Share From $398.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $386.00/Share From $398.00 by Needham
BIIB,2021-10-21,11:26:22,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2021-10-21,11:26:22,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $390.00/Share From $450.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $390.00/Share From $450.00 by Oppenheimer
BIIB,2021-10-21,11:30:09,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen stock price target cut to $502 from $647,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $502 from $647 at Truist
BIIB,2021-10-21,11:41:56,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen stock price target cut to $390 from $450 at Oppenheimer,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $390 from $450 at Oppenheimer
BIIB,2021-10-21,12:11:52,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-10-21,12:11:52,CEDFD5,Biogen Inc.,100,-0.76,price-targets,downgrade,Biogen Price Target Cut to $295.00/Share From $325.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $295.00/Share From $325.00 by RBC Capital
BIIB,2021-10-21,13:21:23,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2021-10-21,13:21:23,CEDFD5,Biogen Inc.,100,-0.32,price-targets,downgrade,Biogen Price Target Cut to $440.00/Share From $447.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $440.00/Share From $447.00 by Morgan Stanley
BIIB,2021-10-21,14:28:03,CEDFD5,Biogen Inc.,100,0.2,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Cowen & Co.
BIIB,2021-10-21,14:28:03,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $375.00/Share From $450.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $375.00/Share From $450.00 by Cowen & Co.
BIIB,2021-10-21,16:00:11,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-21,16:00:11,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-21,16:00:11,CEDFD5,Biogen Inc.,99,0.46,equity-actions,,Biib's continued considerable investment in the program,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,11:36:48,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,11:36:48,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,11:36:48,CEDFD5,Biogen Inc.,99,0.46,equity-actions,,Biib's continued considerable investment in the program,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,13:00:15,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,13:00:15,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-22,13:00:15,CEDFD5,Biogen Inc.,99,0.46,equity-actions,,Biib's continued considerable investment in the program,FULL-ARTICLE,MarketWatch,"MW Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says"
BIIB,2021-10-26,11:05:03,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Mizuho
BIIB,2021-10-26,11:05:03,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $300.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $300.00 by Mizuho
BIIB,2021-10-29,11:00:16,CEDFD5,Biogen Inc.,99,0.53,labor-issues,,Biogen Inc.: New General Manager,PRESS-RELEASE,Canadian News Wire,Biogen Canada Welcomes Eric Tse as New General Manager in New Toronto Head Office
BIIB,2021-10-29,11:00:16,CEDFD5,Biogen Inc.,99,0.41,assets,open,Biogen Inc.: New head office for Biogen Canada,PRESS-RELEASE,Canadian News Wire,Biogen Canada Welcomes Eric Tse as New General Manager in New Toronto Head Office
BIIB,2021-11-03,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: With data from the largest clinical trial,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: With data from the largest clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:02,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: With data from the largest clinical trial,PRESS-RELEASE,GlobeNewswire,Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,GlobeNewswire,Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:34:29,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: With data from the largest clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-03,11:34:29,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
BIIB,2021-11-09,17:44:22,CEDFD5,Biogen Inc.,97,0.57,equity-actions,listing,Biogen Inc.: the company's presentation to FDA,FULL-ARTICLE,Dow Jones Newswires,Biogen Investigates Death of Aduhelm Patient
BIIB,2021-11-09,17:44:22,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,"June, the Food and Drug Administration approved Aduhelm",FULL-ARTICLE,Dow Jones Newswires,Biogen Investigates Death of Aduhelm Patient
BIIB,2021-11-09,17:50:04,CEDFD5,Biogen Inc.,97,0.57,equity-actions,listing,Biogen Inc.: the company's presentation to FDA,FULL-ARTICLE,Dow Jones Newswires,Biogen Investigates Death of Aduhelm Patient
BIIB,2021-11-09,17:50:04,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,"June, the Food and Drug Administration approved Aduhelm",FULL-ARTICLE,Dow Jones Newswires,Biogen Investigates Death of Aduhelm Patient
BIIB,2021-11-10,14:15:11,CEDFD5,Biogen Inc.,100,0.03,credit-ratings,affirmation,Moody's Affirms Biogen At Baa1,NEWS-FLASH,Dow Jones Newswires,Moody's Affirms Biogen At Baa1; Revises Outlook To Negative
BIIB,2021-11-10,17:16:32,CEDFD5,Biogen Inc.,100,0.0,credit-ratings,action,Moody's Announces Completion Of A Periodic Review Of Ratings Of Biogen Inc.,NEWS-FLASH,Dow Jones Newswires,Moody's Announces Completion Of A Periodic Review Of Ratings Of Biogen Inc.
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.56,products-services,,Biogen earns top ESG leadership,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.58,indexes,,Biogen for being included in the Dow Jones Sustainability Index,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.56,products-services,,Biogen earns top ESG leadership,FULL-ARTICLE,Dow Jones Newswires,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.58,indexes,,Biogen for being included in the Dow Jones Sustainability Index,FULL-ARTICLE,Dow Jones Newswires,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.56,products-services,,Biogen earns top ESG leadership,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.58,indexes,,Biogen for being included in the Dow Jones Sustainability Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.56,products-services,,Biogen earns top ESG leadership,PRESS-RELEASE,GlobeNewswire,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.58,indexes,,Biogen for being included in the Dow Jones Sustainability Index,PRESS-RELEASE,GlobeNewswire,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.56,products-services,,Biogen earns top ESG leadership,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-15,12:30:02,CEDFD5,Biogen Inc.,99,0.58,indexes,,Biogen for being included in the Dow Jones Sustainability Index,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
BIIB,2021-11-16,00:44:06,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research",PRESS-RELEASE,GlobeNewswire,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development"
BIIB,2021-11-16,00:44:07,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research",FULL-ARTICLE,Dow Jones Newswires,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development"
BIIB,2021-11-16,00:44:07,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development"
BIIB,2021-11-16,00:44:07,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development"
BIIB,2021-11-16,00:44:07,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development"
BIIB,2021-11-16,14:43:45,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Gets Europe OK for Vumerity,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug >BIIB
BIIB,2021-11-16,14:43:45,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The U.S. Food and Drug Administration approved Vumerity in October 2019,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug >BIIB
BIIB,2021-11-16,14:43:45,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Vumerity also is approved in the U.K.,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug >BIIB
BIIB,2021-11-16,14:58:35,CEDFD5,Biogen Inc.,100,-0.3,labor-issues,,Top Biogen Executive Announces Retirement,FULL-ARTICLE,Dow Jones Newswires,Top Biogen Executive Announces Retirement as Aduhelm Rollout Stumbles -- Barrons.com
BIIB,2021-11-16,14:58:35,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The Food and Drug Administration approved Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,Top Biogen Executive Announces Retirement as Aduhelm Rollout Stumbles -- Barrons.com
BIIB,2021-11-16,14:58:44,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Gets Europe OK for Vumerity,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug
BIIB,2021-11-16,14:58:44,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The U.S. Food and Drug Administration approved Vumerity in October 2019,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug
BIIB,2021-11-16,14:58:44,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Vumerity also is approved in the U.K.,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug
BIIB,2021-11-17,07:32:12,CEDFD5,Biogen Inc.,100,-0.49,labor-issues,,Biogen's R&D Chief to Retire,FULL-ARTICLE,Wall Street Journal,Biogen's R&D Chief to Retire at End of Year -- WSJ
BIIB,2021-11-17,12:51:42,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,MarketWatch,MW Biogen shares slide 4% after EU advisory committee says it can't agree to endorse company's Alzheimer's disease drug
BIIB,2021-11-17,12:51:42,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Slide 4% After EU Advisory Committee Says It Can't Agree To Endorse Company's Alzheimer's Disease Drug -- MarketWatch
BIIB,2021-11-19,10:43:36,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Biogen Initiated at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Outperform by BMO Capital
BIIB,2021-11-19,10:43:36,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $315.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $315.00/Share by BMO Capital
BIIB,2021-11-19,13:49:06,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Perform by RBC Capital
BIIB,2021-11-19,13:49:06,CEDFD5,Biogen Inc.,100,-0.64,price-targets,downgrade,Biogen Price Target Cut to $277.00/Share From $295.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $277.00/Share From $295.00 by RBC Capital
BIIB,2021-11-19,13:49:14,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen started at outperform with $315 stock price target at BMO Capital,NEWS-FLASH,MarketWatch,MW Biogen started at outperform with $315 stock price target at BMO Capital
BIIB,2021-11-30,21:22:16,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 28,884 Of Sangamo Therapeutics Inc >SGMO",FULL-ARTICLE,Dow Jones Newswires,"Holder Biogen Inc Sells 28,884 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2021-12-03,21:10:49,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 2,604 Of Sangamo Therapeutics Inc >SGMO",FULL-ARTICLE,Dow Jones Newswires,"Holder Biogen Inc Sells 2,604 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2021-12-06,11:37:34,CEDFD5,Biogen Inc.,100,0.01,analyst-ratings,neutral,Biogen Initiated at Neutral by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Neutral by Goldman Sachs
BIIB,2021-12-06,11:37:34,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $271.00/Share by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $271.00/Share by Goldman Sachs
BIIB,2021-12-06,21:16:10,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 207 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 207 Of Biogen Inc >BIIB
BIIB,2021-12-07,21:10:30,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 239 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 239 Of Biogen Inc >BIIB
BIIB,2021-12-09,13:36:03,CEDFD5,Biogen Inc.,100,0.01,analyst-ratings,neutral,Biogen Initiated at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Equal-Weight by Wells Fargo
BIIB,2021-12-09,13:36:03,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $250.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $250.00/Share by Wells Fargo
BIIB,2021-12-09,21:10:10,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 127,992 Of Sangamo Therapeutics Inc >SGMO",FULL-ARTICLE,Dow Jones Newswires,"Holder Biogen Inc Sells 127,992 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2021-12-10,14:43:00,CEDFD5,Biogen Inc.,93,0.49,partnerships,,Biogen and Ginkgo Bioworks announce collaboration,PRESS-RELEASE,Business Wire,"Global Spinal Muscular Atrophy Treatment Market (2021 to 2026) - Featuring Astellas Pharma, Biogen and Cytokinetics Among Others - ResearchAndMarkets.com"
BIIB,2021-12-10,21:09:57,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 23,660 Of Sangamo Therapeutics Inc >SGMO",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Biogen Inc Sells 23,660 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and TheraPanacea Announce New Collaboration,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen will invest up to $15 million in,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.55,equity-actions,,Biogen Inc.: Spinoff of,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and TheraPanacea Announce New Collaboration,FULL-ARTICLE,Dow Jones Newswires,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen will invest up to $15 million in,FULL-ARTICLE,Dow Jones Newswires,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and TheraPanacea Announce New Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen will invest up to $15 million in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:01,CEDFD5,Biogen Inc.,100,0.55,equity-actions,,Biogen Inc.: Spinoff of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:04,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and TheraPanacea Announce New Collaboration,PRESS-RELEASE,GlobeNewswire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:04,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen will invest up to $15 million in,PRESS-RELEASE,GlobeNewswire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:04,CEDFD5,Biogen Inc.,100,0.55,equity-actions,,Biogen Inc.: Spinoff of,PRESS-RELEASE,GlobeNewswire,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and TheraPanacea Announce New Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:05,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen will invest up to $15 million in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:00:05,CEDFD5,Biogen Inc.,100,0.55,equity-actions,,Biogen Inc.: Spinoff of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
BIIB,2021-12-14,12:02:47,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen to Invest Up to $15 Million in,NEWS-FLASH,Dow Jones Newswires,"Biogen, TheraPanacea: Biogen to Invest Up to $15 Million in Exchange for TheraPanacea Convertible Debt >BIIB"
BIIB,2021-12-16,15:07:41,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces New Trial for Alzheimer's drug Aduhelm -- Barrons.com
BIIB,2021-12-16,15:07:41,CEDFD5,Biogen Inc.,99,-0.68,revenues,down,Aduhelm sales fell,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces New Trial for Alzheimer's drug Aduhelm -- Barrons.com
BIIB,2021-12-17,11:56:54,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Agency approving aduhelm,FULL-ARTICLE,MarketWatch,MW Biogen and Eisai say EU regulatory committee adopted negative opinion for its Alzheimer's treatment
BIIB,2021-12-17,11:56:54,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Agency approving aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen And Eisai Say EU Regulatory Committee Adopted Negative Opinion For Its Alzheimer's Treatment -- MarketWatch
BIIB,2021-12-17,12:30:20,CEDFD5,Biogen Inc.,92,0.71,products-services,,The U.S. Food and Drug Administration granted accelerated approval for Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer's Treatment Gets Negative CHMP Opinion
BIIB,2021-12-17,12:30:20,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Aduhelm is also approved in the United Arab Emirates,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer's Treatment Gets Negative CHMP Opinion
BIIB,2021-12-17,12:45:20,CEDFD5,Biogen Inc.,92,0.71,products-services,,The U.S. Food and Drug Administration granted accelerated approval for Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer's Treatment Gets Negative CHMP Opinion
BIIB,2021-12-17,12:45:20,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Aduhelm is also approved in the United Arab Emirates,FULL-ARTICLE,Dow Jones Newswires,Biogen's Alzheimer's Treatment Gets Negative CHMP Opinion
BIIB,2021-12-20,09:59:42,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2021-12-20,09:59:42,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $325.00/Share From $450.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $325.00/Share From $450.00 by SVB Leerink
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The cost during the first,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The cost during the first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Reduced Price for ADUHELM(R) to -2-
BIIB,2021-12-20,12:00:01,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Reduced Price for ADUHELM(R) to -2-
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,GlobeNewswire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,GlobeNewswire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The cost during the first,PRESS-RELEASE,GlobeNewswire,Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,GlobeNewswire,Biogen Announces Reduced Price for ADUHELM(R) to -2-
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Announces Reduced Price for ADUHELM(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:00:02,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The cost during the first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Reduced Price for ADUHELM(R) to Improve Access for Patients with Early Alzheimer's Disease
BIIB,2021-12-20,12:01:00,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Cuts Aduhelm List Price in,NEWS-FLASH,Dow Jones Newswires,Biogen Cuts Aduhelm List Price in Half
BIIB,2021-12-20,12:01:00,CEDFD5,Biogen Inc.,100,-0.72,products-services,cut,Biogen Cuts Price for Alzheimer's Drug Aduhelm by Half,FULL-ARTICLE,Dow Jones Newswires,Biogen Cuts Price for Alzheimer's Drug Aduhelm by Half
BIIB,2021-12-20,12:01:24,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Cuts Price for Aduhelm,NEWS-FLASH,Dow Jones Newswires,Biogen Cuts Price for Aduhelm to Improve Access for Patients With Early Alzheimer's Disease >BIIB
BIIB,2021-12-20,12:03:10,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen to reduce price of its Alzheimer's drug aduhelm,NEWS-FLASH,MarketWatch,MW Biogen to reduce price of its Alzheimer's drug aduhelm in U.S. by 50% effective Jan. 1
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen to lower price of Alzheimer's drug,FULL-ARTICLE,MarketWatch,"MW Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year"
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,MarketWatch,"MW Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year"
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Aduhelm, which was approved by the U.S. Food and Drug Administration",FULL-ARTICLE,MarketWatch,"MW Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year"
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen To Lower Price Of Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen To Lower Price Of Alzheimer's Drug Aduhlem By 50% Starting Jan. 1 To About $28,200 A Year -- MarketWatch"
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,Dow Jones Newswires,"Biogen To Lower Price Of Alzheimer's Drug Aduhlem By 50% Starting Jan. 1 To About $28,200 A Year -- MarketWatch"
BIIB,2021-12-20,12:12:12,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Aduhelm, which was approved by the U.S. Food and Drug Administration",FULL-ARTICLE,Dow Jones Newswires,"Biogen To Lower Price Of Alzheimer's Drug Aduhlem By 50% Starting Jan. 1 To About $28,200 A Year -- MarketWatch"
BIIB,2021-12-20,12:20:03,CEDFD5,Biogen Inc.,100,-0.72,products-services,cut,Biogen Cuts Price for Alzheimer's Drug Aduhelm by Half,FULL-ARTICLE,Dow Jones Newswires,Biogen Cuts Price for Alzheimer's Drug Aduhelm by Half
BIIB,2021-12-20,12:20:17,CEDFD5,Biogen Inc.,100,0.46,products-services,raise,Biogen up 3% as company cuts Alzheimer's drug price by 50%,NEWS-FLASH,MarketWatch,MW Biogen up 3% as company cuts Alzheimer's drug price by 50% starting Jan. 1
BIIB,2021-12-20,13:40:03,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Halves Price of Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen Halves Price of Alzheimer's Drug, Says It Will Slash Its Own Costs -- Barrons.com"
BIIB,2021-12-20,15:54:30,CEDFD5,Biogen Inc.,93,-0.44,products-services,cut,Biogen halves Aduhelm's list price,FULL-ARTICLE,Dow Jones Newswires,Biogen's Price Cut Could Be Too Little Too Late -- Market Talk
BIIB,2021-12-20,15:54:30,CEDFD5,Biogen Inc.,93,-0.44,products-services,cut,Biogen halves Aduhelm's list price,FULL-ARTICLE,Dow Jones Newswires,Biogen's Price Cut Could Be Too Little Too Late -- Market Talk
BIIB,2021-12-20,19:31:18,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,19:31:18,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,19:31:18,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,19:31:18,CEDFD5,Biogen Inc.,99,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,19:31:18,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's third-quarter earnings,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,20:58:54,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,20:58:54,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,20:58:54,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency's approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,20:58:54,CEDFD5,Biogen Inc.,99,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-20,20:58:54,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's third-quarter earnings,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,07:10:56,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Cuts Alzheimer's Drug Price,FULL-ARTICLE,Dow Jones Newswires,Biogen Cuts Alzheimer's Drug Price  ----  By Joseph Walker
BIIB,2021-12-21,07:32:11,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Cuts Alzheimer's Drug Price,FULL-ARTICLE,Wall Street Journal,Biogen Cuts Alzheimer's Drug Price -- WSJ
BIIB,2021-12-21,10:37:51,CEDFD5,Biogen Inc.,100,-0.44,products-services,cut,Biogen Slashes Alzheimer's Drug Price,FULL-ARTICLE,Dow Jones Newswires,Biogen Slashes Alzheimer's Drug Price to Improve Access and Affordability -- ESG Insight
BIIB,2021-12-21,12:01:18,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Baird
BIIB,2021-12-21,12:01:18,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $258.00/Share From $296.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $258.00/Share From $296.00 by Baird
BIIB,2021-12-21,12:32:12,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,12:32:12,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,12:32:12,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency's approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,12:32:12,CEDFD5,Biogen Inc.,99,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,12:32:12,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's third-quarter earnings,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,13:39:37,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,13:39:37,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen shelved the product.,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,13:39:37,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Agency's approving Aduhelm,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,13:39:37,CEDFD5,Biogen Inc.,99,0.0,equity-actions,,Biogen Inc.: The company is also planning to cut costs in 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,13:39:37,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's third-quarter earnings,FULL-ARTICLE,MarketWatch,"MW Biogen's decision to halve price of Alzheimer's drug is 'a day late and a dollar short,' says Raymond James"
BIIB,2021-12-21,15:11:00,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by JP Morgan
BIIB,2021-12-21,15:11:00,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $276.00/Share From $324.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $276.00/Share From $324.00 by JP Morgan
BIIB,2021-12-22,12:40:18,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Agency's approving Aduhelm,FULL-ARTICLE,MarketWatch,MW Japan regulator to continue deliberations on Biogen and Eisai's Alzheimer's drug
BIIB,2021-12-22,12:40:18,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,Agency's approving Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Japan Regulator To Continue Deliberations On Biogen And Eisai's Alzheimer's Drug -- MarketWatch
BIIB,2021-12-22,12:40:45,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2021-12-22,12:40:45,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $350.00/Share From $390.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $350.00/Share From $390.00 by Oppenheimer
BIIB,2021-12-28,13:12:24,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 81,787 Of Sangamo Therapeutics Inc >SGMO",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Biogen Inc Sells 81,787 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2021-12-29,19:55:13,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,interest,Samsung in Talks to Buy Biogen,FULL-ARTICLE,Dow Jones Newswires,"Samsung in Talks to Buy Biogen, Sources Say -Korea Economic Daily"
BIIB,2021-12-29,21:00:04,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: the Food and Drug Administration approved a medicine developed by the company,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Rise After Report Samsung in Talks to Buy
BIIB,2021-12-29,22:12:58,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,interest,Samsung Group was in talks to acquire the drugmaker,FULL-ARTICLE,Dow Jones Newswires,"Biogen Stock Jumped. Samsung Wants to Buy It, According to a Report. -- Barrons.com"
BIIB,2021-12-30,00:41:08,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,interest,Group in Talks to Buy US Drug Firm Biogen,NEWS-FLASH,Dow Jones Newswires,Samsung Biologics Shares Gain After Media Report Its Parent Group in Talks to Buy US Drug Firm Biogen
BIIB,2021-12-30,14:43:16,CEDFD5,Biogen Inc.,99,0.57,acquisitions-mergers,interest,Parent was looking to acquire Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Give Up Gains as Samsung Denies Takeover Rumor >BIIB
BIIB,2021-12-30,14:58:16,CEDFD5,Biogen Inc.,99,0.57,acquisitions-mergers,interest,Parent was looking to acquire Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Give Up Gains as Samsung Denies Takeover Rumor
BIIB,2021-12-30,16:40:03,CEDFD5,Biogen Inc.,99,0.57,acquisitions-mergers,interest,Parent was looking to acquire Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Give Up Gains as Samsung Denies Takeover Rumor
BIIB,2021-12-30,22:14:43,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 2,764 Of Sangamo Therapeutics Inc >SGMO",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Biogen Inc Sells 2,764 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2022-01-04,12:30:06,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,PR Newswire,Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:30:06,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,PR Newswire,Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:30:06,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:30:06,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:34:32,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,GlobeNewswire,Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:34:32,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,FULL-ARTICLE,Dow Jones Newswires,Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Productive collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,20:30:09,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen launched Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimer's Drug"
BIIB,2022-01-04,20:30:09,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"June 7, 2021, the FDA approved Aduhelm",FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising -2-"
BIIB,2022-01-04,20:30:09,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen said it was lowering Aduhelm's price,FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising -2-"
BIIB,2022-01-04,20:40:04,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen launched Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimer's Drug"
BIIB,2022-01-04,20:40:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"June 7, 2021, the FDA approved Aduhelm",FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising -2-"
BIIB,2022-01-04,20:40:04,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen said it was lowering Aduhelm's price,FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising -2-"
BIIB,2022-01-05,07:08:44,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen launched Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,How Biogen Fumbled  Its Alzheimer's Drug  ---  Once-promising Aduhelm is pricey and without proven efficacy  ----  By Joseph Walker and Susan Pulliam
BIIB,2022-01-05,07:08:54,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"June 7, 2021, the FDA approved Aduhelm",FULL-ARTICLE,Dow Jones Newswires,How Biogen Fumbled  Its Alzheimer's Drug  --- -2-
BIIB,2022-01-05,07:33:24,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen launched Aduhelm in June,FULL-ARTICLE,Wall Street Journal,How Biogen Fumbled Its Alzheimer's Drug -- WSJ
BIIB,2022-01-05,07:33:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"June 7, 2021, the FDA approved Aduhelm",FULL-ARTICLE,Wall Street Journal,How Biogen Fumbled Its Alzheimer's Drug -- WSJ -2-
BIIB,2022-01-05,07:33:24,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen said it was lowering Aduhelm's price,FULL-ARTICLE,Wall Street Journal,How Biogen Fumbled Its Alzheimer's Drug -- WSJ -2-
BIIB,2022-01-06,15:25:36,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-01-06,15:25:36,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $363.00/Share From $440.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $363.00/Share From $440.00 by Morgan Stanley
BIIB,2022-01-07,12:29:07,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen stock price target cut to $343 from $502,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $343 from $502 at Truist
BIIB,2022-01-11,11:58:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2022-01-11,11:58:29,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $328.00/Share From $386.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $328.00/Share From $386.00 by Needham
BIIB,2022-01-11,21:46:27,CEDFD5,Biogen Inc.,92,0.52,products-services,,Biogen initially launched the drug at,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug In Clinical-Trial Patients
BIIB,2022-01-11,21:50:04,CEDFD5,Biogen Inc.,92,0.52,products-services,,Biogen initially launched the drug at,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug In Clinical-Trial Patients
BIIB,2022-01-11,21:58:39,CEDFD5,Biogen Inc.,95,0.52,products-services,,Biogen initially launched the drug at,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- Update
BIIB,2022-01-11,21:58:39,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,The FDA cleared Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- Update
BIIB,2022-01-11,22:35:26,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen prematurely halted its studies of the drug in 2019.,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 2nd Update
BIIB,2022-01-11,22:35:26,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen initially launched the drug at,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 2nd Update
BIIB,2022-01-11,22:35:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA cleared Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 2nd Update
BIIB,2022-01-12,00:04:27,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen prematurely halted its studies of the drug in 2019.,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 3rd Update
BIIB,2022-01-12,00:04:27,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen initially launched the drug at,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 3rd Update
BIIB,2022-01-12,00:04:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA cleared Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 3rd Update
BIIB,2022-01-12,10:42:55,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Neutral From Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Neutral From Overweight by Piper Sandler
BIIB,2022-01-12,10:42:55,CEDFD5,Biogen Inc.,100,-0.86,price-targets,downgrade,Biogen Price Target Cut to $216.00/Share From $362.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $216.00/Share From $362.00 by Piper Sandler
BIIB,2022-01-12,11:00:37,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen stock price target cut to $207 from $270 at Mizuho,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $207 from $270 at Mizuho
BIIB,2022-01-12,11:24:46,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2022-01-12,11:24:46,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $292.00/Share From $328.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $292.00/Share From $328.00 by Needham
BIIB,2022-01-12,12:32:02,CEDFD5,Biogen Inc.,97,-0.58,analyst-ratings,negative,Piper Sandler downgraded Biogen shares to neutral from overweight,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Fall Premarket on Medicaid Coverage Plans for Aduhelm
BIIB,2022-01-12,12:47:03,CEDFD5,Biogen Inc.,97,-0.58,analyst-ratings,negative,Piper Sandler downgraded Biogen shares to neutral from overweight,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Fall Premarket on Medicaid Coverage Plans for Aduhelm
BIIB,2022-01-12,13:51:46,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Mizuho
BIIB,2022-01-12,13:51:46,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $207.00/Share From $270.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $207.00/Share From $270.00 by Mizuho
BIIB,2022-01-12,14:08:56,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2022-01-12,14:08:56,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $195.00/Share From $249.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $195.00/Share From $249.00 by Wedbush
BIIB,2022-01-13,12:06:43,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Neutral From Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Neutral From Buy by Guggenheim
BIIB,2022-01-13,12:06:43,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $202.00/Share From $290.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $202.00/Share From $290.00 by Guggenheim
BIIB,2022-01-13,12:16:35,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen downgraded to neutral vs. buy,NEWS-FLASH,MarketWatch,MW Biogen downgraded to neutral vs. buy at Guggenheim
BIIB,2022-01-13,12:20:56,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen stock price target cut to $202 vs. $290,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $202 vs. $290 at Guggenheim
BIIB,2022-01-13,13:02:00,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Guggenheim downgrades Biogen to neutral from buy,FULL-ARTICLE,MarketWatch,MW Guggenheim downgrades Biogen to neutral from buy after U.S. proposes limiting access to Alzheimer's drug
BIIB,2022-01-13,13:02:01,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Guggenheim Downgrades Biogen To Neutral From Buy,FULL-ARTICLE,Dow Jones Newswires,Guggenheim Downgrades Biogen To Neutral From Buy After U.S. Proposes Limiting Access To Alzheimer's Drug -- MarketWatch
BIIB,2022-01-13,21:42:02,CEDFD5,Biogen Inc.,100,-0.54,credit-ratings,downgrade,S&P Cuts Biogen Inc. Rtg To BBB+ From A-,NEWS-FLASH,Dow Jones Newswires,S&P Cuts Biogen Inc. Rtg To BBB+ From A-; Outlk Stable
BIIB,2022-01-13,21:43:23,CEDFD5,Biogen Inc.,100,-0.54,credit-ratings,downgrade,S&PGR Downgrades Biogen To 'BBB+' From 'A-,NEWS-FLASH,Dow Jones Newswires,"S&PGR Downgrades Biogen To 'BBB+' From 'A-', Outlook Stable"
BIIB,2022-01-13,21:43:30,CEDFD5,Biogen Inc.,100,-0.54,credit-ratings,downgrade,S&PGR Downgrades Biogen To 'BBB+' From 'A-,PRESS-RELEASE,Dow Jones Newswires,"Press Release: S&PGR Downgrades Biogen To 'BBB+' From 'A-', Outlook Stable"
BIIB,2022-01-13,21:43:30,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.: We project sales,PRESS-RELEASE,Dow Jones Newswires,"Press Release: S&PGR Downgrades Biogen To 'BBB+' From 'A-', Outlook Stable"
BIIB,2022-01-13,21:43:30,CEDFD5,Biogen Inc.,100,-0.11,products-services,,Spinraza have faced increasing competition,PRESS-RELEASE,Dow Jones Newswires,"Press Release: S&PGR Downgrades Biogen To 'BBB+' From 'A-', Outlook Stable"
BIIB,2022-01-13,21:43:40,CEDFD5,Biogen Inc.,100,-0.54,credit-ratings,downgrade,S&PGR Downgrades Biogen To 'BBB+,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Downgrades Biogen To 'BBB+' -2-
BIIB,2022-01-13,21:45:06,CEDFD5,Biogen Inc.,100,-0.54,credit-ratings,downgrade,S&PGR Downgrades Biogen to 'BBB+' From 'A-,NEWS-FLASH,Dow Jones Newswires,"S&PGR Downgrades Biogen to 'BBB+' From 'A-', Notes CMS Decision and Competitive Pressures for Key Products"
BIIB,2022-01-14,15:08:10,CEDFD5,Biogen Inc.,100,-0.47,credit-ratings,negative,Moody's Reviews Biogen's Baa1 Ratings For Downgrade,NEWS-FLASH,Dow Jones Newswires,Moody's Reviews Biogen's Baa1 Ratings For Downgrade
BIIB,2022-01-18,11:21:24,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2022-01-18,11:21:24,CEDFD5,Biogen Inc.,100,-0.86,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $452.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $452.00 by HC Wainwright & Co.
BIIB,2022-01-18,14:13:15,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-01-18,14:13:15,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $360.00/Share From $363.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $360.00/Share From $363.00 by Morgan Stanley
BIIB,2022-01-20,15:01:07,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-01-20,15:01:07,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $244.00/Share From $280.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $244.00/Share From $280.00 by Barclays
BIIB,2022-01-21,08:24:37,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2021 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2021 (BIIB)"
BIIB,2022-01-21,21:50:59,CEDFD5,Biogen Inc.,100,0.0,insider-trading,,Vp Alexander Gifts 523 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Gifts 523 Of Biogen Inc >BIIB
BIIB,2022-01-24,09:37:30,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2022-01-24,09:37:30,CEDFD5,Biogen Inc.,100,-0.7,price-targets,downgrade,Biogen Price Target Cut to $300.00/Share From $325.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $300.00/Share From $325.00 by SVB Leerink
BIIB,2022-01-27,23:50:14,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Samsung Biologics,PRESS-RELEASE,GlobeNewswire,Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
BIIB,2022-01-27,23:50:15,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Samsung Biologics,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
BIIB,2022-01-27,23:50:15,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
BIIB,2022-01-27,23:50:15,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Samsung Biologics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
BIIB,2022-01-27,23:50:15,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Samsung Biologics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
BIIB,2022-01-27,23:51:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement With Samsung Biologics,HOT-NEWS-FLASH,Dow Jones Newswires,Biogen Reaches Agreement With Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for Up to $2.3 B
BIIB,2022-01-27,23:51:21,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement With Samsung Biologics,NEWS-FLASH,Dow Jones Newswires,Biogen Reaches Agreement With Samsung Biologics to Sell Equity Stake in Their Biosimilar JV for Up to $2.3 B
BIIB,2022-01-27,23:52:30,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,Biogen To Sell Stake in Samsung Bioepis Venture to Samsung Biologics,HOT-NEWS-FLASH,Dow Jones Newswires,Biogen To Sell Stake in Samsung Bioepis Venture to Samsung Biologics
BIIB,2022-01-28,00:07:39,CEDFD5,Biogen Inc.,100,0.18,acquisitions-mergers,,Samsung Biologics to Buy Biogen's Stake in JV,FULL-ARTICLE,Dow Jones Newswires,Samsung Biologics to Buy Biogen's Stake in JV
BIIB,2022-01-28,00:10:03,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire full ownership of Samsung Bioepis,PRESS-RELEASE,PR Newswire,Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis
BIIB,2022-01-28,00:10:04,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire full ownership of Samsung Bioepis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis
BIIB,2022-01-28,00:20:04,CEDFD5,Biogen Inc.,100,0.18,acquisitions-mergers,,Samsung Biologics to Buy Biogen's Stake in JV,FULL-ARTICLE,Dow Jones Newswires,Samsung Biologics to Buy Biogen's Stake in JV
BIIB,2022-01-28,00:22:39,CEDFD5,Biogen Inc.,100,0.18,acquisitions-mergers,,Samsung Biologics to Buy Biogen's Stake in JV,FULL-ARTICLE,Dow Jones Newswires,Samsung Biologics to Buy Biogen's Stake in JV
BIIB,2022-01-28,01:40:04,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics
BIIB,2022-01-28,10:35:45,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,Biogen Sells Stake in Biosimilars Venture to Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,Biogen Sells Stake in Biosimilars Venture to Samsung Biologics for $2.3 Billion -- Barrons.com
BIIB,2022-01-28,10:35:45,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,interest,Was in talks to acquire drugmaker Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Sells Stake in Biosimilars Venture to Samsung Biologics for $2.3 Billion -- Barrons.com
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,Will retire from Biogen's Board of Directors,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,Will retire from Biogen's Board of Directors,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: Board and our leadership team as,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,Will retire from Biogen's Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: Board and our leadership team as,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,Will retire from Biogen's Board of Directors,PRESS-RELEASE,GlobeNewswire,Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: Board and our leadership team as,PRESS-RELEASE,GlobeNewswire,Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,Will retire from Biogen's Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: Board and our leadership team as,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:33,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,"Biogen: Nancy Leaming, Brian Posner to Retire From Board",NEWS-FLASH,Dow Jones Newswires,"Biogen: Nancy Leaming, Brian Posner to Retire From Board"
BIIB,2022-01-31,12:58:36,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,Biogen Directors Retiring From Board,FULL-ARTICLE,Dow Jones Newswires,Two Longtime Biogen Directors Retiring From Board -- Market Talk
BIIB,2022-01-31,12:58:36,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,"Biogen's chairman, also joined the board",FULL-ARTICLE,Dow Jones Newswires,Two Longtime Biogen Directors Retiring From Board -- Market Talk
BIIB,2022-01-31,12:58:36,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,Biogen Directors Retiring From Board,FULL-ARTICLE,Dow Jones Newswires,Two Longtime Biogen Directors Retiring From Board -- Market Talk
BIIB,2022-01-31,12:58:36,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,"Biogen's chairman, also joined the board",FULL-ARTICLE,Dow Jones Newswires,Two Longtime Biogen Directors Retiring From Board -- Market Talk
BIIB,2022-02-01,12:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody in development,PRESS-RELEASE,GlobeNewswire,Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
BIIB,2022-02-01,12:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody in development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
BIIB,2022-02-01,12:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody in development,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
BIIB,2022-02-01,12:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody in development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
BIIB,2022-02-01,13:53:27,CEDFD5,Biogen Inc.,93,0.49,partnerships,,Biogen expands its long-time collaboration with Roche,FULL-ARTICLE,Dow Jones Newswires,Biogen Opts in on Genentech Non-Hodgkin's Lymphoma Candidate -- Market Talk
BIIB,2022-02-01,13:53:28,CEDFD5,Biogen Inc.,93,0.49,partnerships,,Biogen expands its long-time collaboration with Roche,FULL-ARTICLE,Dow Jones Newswires,Biogen Opts in on Genentech Non-Hodgkin's Lymphoma Candidate -- Market Talk
BIIB,2022-02-03,12:04:08,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $2.50 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q EPS $2.50 >BIIB
BIIB,2022-02-03,12:04:08,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Adj EPS $3.39,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Adj EPS $3.39 >BIIB
BIIB,2022-02-03,12:04:08,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Net $368.2M,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Net $368.2M >BIIB
BIIB,2022-02-03,12:04:08,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.73B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Rev $2.73B >BIIB
BIIB,2022-02-03,12:26:13,CEDFD5,Biogen Inc.,100,0.4,earnings,up,Biogen Q4 EPS $2.50 vs. $2.32 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q4 EPS $2.50 vs. $2.32 a year ago
BIIB,2022-02-03,12:27:53,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q4 adj. EPS $3.39; FactSet consensus $3.37,NEWS-FLASH,MarketWatch,MW Biogen Q4 adj. EPS $3.39; FactSet consensus $3.37
BIIB,2022-02-03,12:28:56,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q4 revenue $2.734 bln vs. $2.853 bln a year ago; FactSet consensus $2.620 bln,NEWS-FLASH,MarketWatch,MW Biogen Q4 revenue $2.734 bln vs. $2.853 bln a year ago; FactSet consensus $2.620 bln
BIIB,2022-02-03,12:30:17,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees 2022 adj. EPS of $14.25 to $16.00,NEWS-FLASH,MarketWatch,MW Biogen now sees 2022 adj. EPS of $14.25 to $16.00; FactSet consensus $18.76
BIIB,2022-02-03,12:30:53,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen now sees 2022 revenue of $9.7 bln to $10.0 bln,NEWS-FLASH,MarketWatch,MW Biogen now sees 2022 revenue of $9.7 bln to $10.0 bln; FactSet consensus $10.3 bln
BIIB,2022-02-03,12:33:07,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen 4Q Multiple sclerosis Rev $1.79B, Down 1%",RNS-SEC8K,Dow Jones Newswires,"Biogen 4Q Multiple sclerosis Rev $1.79B, Down 1% Vs Prior Year >BIIB"
BIIB,2022-02-03,12:33:08,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen 4Q Spinraza Rev $441M, Down 12%",RNS-SEC8K,Dow Jones Newswires,"Biogen 4Q Spinraza Rev $441M, Down 12% Vs Prior Year >BIIB"
BIIB,2022-02-03,12:33:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Aduhelm Rev $1M,RNS-SEC8K,Dow Jones Newswires,Biogen 4Q Aduhelm Rev $1M >BIIB
BIIB,2022-02-03,12:34:02,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees FY22 Rev $9.7B-$10B >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY22 Rev $9.7B-$10B >BIIB
BIIB,2022-02-03,12:34:33,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY22 Adj EPS $14.25,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY22 Adj EPS $14.25-Adj EPS $16 >BIIB
BIIB,2022-02-03,12:36:22,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Expects Decreased Rev,RNS-SEC8K,Dow Jones Newswires,Biogen Expects Decreased Rev From Some High-Margin Products to Reduce Gross Margin Percentage in FY22
BIIB,2022-02-03,12:45:26,CEDFD5,Biogen Inc.,94,0.0,earnings,,Biogen 4Q adjusted earnings per share,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q OK, But 2022 Outlook Worse Than Analysts' Forecast -- Market Talk"
BIIB,2022-02-03,12:45:26,CEDFD5,Biogen Inc.,94,0.0,earnings,,Biogen Inc.: The company sees adjusted earnings per share of $15.13,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q OK, But 2022 Outlook Worse Than Analysts' Forecast -- Market Talk"
BIIB,2022-02-03,12:45:27,CEDFD5,Biogen Inc.,94,0.0,earnings,,Biogen 4Q adjusted earnings per share,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q OK, But 2022 Outlook Worse Than Analysts' Forecast -- Market Talk"
BIIB,2022-02-03,12:45:27,CEDFD5,Biogen Inc.,94,0.0,earnings,,Biogen Inc.: The company sees adjusted earnings per share of $15.13,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q OK, But 2022 Outlook Worse Than Analysts' Forecast -- Market Talk"
BIIB,2022-02-03,12:45:44,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.2 billion in the final three months,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-03,12:45:44,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-03,12:45:44,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.2 billion in the final three months,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Falls 3.7% On Earnings Miss, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-03,12:45:44,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Falls 3.7% On Earnings Miss, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc.: the company issued new guidance for 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.7 billion in the final three months,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc.: the company issued new guidance for 2022,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.7 billion in the final three months,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-03,13:00:32,CEDFD5,Biogen Inc.,98,0.0,earnings,,Biogen 4Q adjusted earnings per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Says Medicare Policy Sews Uncertainty for Aduhelm Clinics and Patients -- Market Talk
BIIB,2022-02-03,13:00:32,CEDFD5,Biogen Inc.,98,0.0,earnings,,Biogen Inc.: The company sees adjusted earnings per share of $15.13,FULL-ARTICLE,Dow Jones Newswires,Biogen Says Medicare Policy Sews Uncertainty for Aduhelm Clinics and Patients -- Market Talk
BIIB,2022-02-03,13:06:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen 4Q adjusted earnings per share,FULL-ARTICLE,Dow Jones Newswires,Biogen to Urge Medicare to Revise Aduhelm Policy -- Market Talk
BIIB,2022-02-03,13:06:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen Inc.: The company sees adjusted earnings per share of $15.13,FULL-ARTICLE,Dow Jones Newswires,Biogen to Urge Medicare to Revise Aduhelm Policy -- Market Talk
BIIB,2022-02-03,13:28:40,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company reported non-GAAP diluted earnings of $3.39 per share for the fourth quarter of 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Drops as Results Fall Short. Sales of Alzheimer's Drug Disappoint. -- Barrons.com
BIIB,2022-02-03,13:28:40,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen said it expected 2022 revenues,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Drops as Results Fall Short. Sales of Alzheimer's Drug Disappoint. -- Barrons.com
BIIB,2022-02-03,17:34:33,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q4 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q4 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2022-02-04,10:58:36,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Market Perform From Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Market Perform From Outperform by BMO Capital
BIIB,2022-02-04,10:58:36,CEDFD5,Biogen Inc.,100,-0.74,price-targets,downgrade,Biogen Price Target Cut to $238.00/Share From $260.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $238.00/Share From $260.00 by BMO Capital
BIIB,2022-02-04,11:29:26,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2022-02-04,11:29:26,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $290.00/Share From $292.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $290.00/Share From $292.00 by Needham
BIIB,2022-02-04,12:06:13,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen stock price target cut to $236 from $276 at J.P. Morgan,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $236 from $276 at J.P. Morgan
BIIB,2022-02-04,12:46:50,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen downgraded to market perform from outperform at BMO Capital,NEWS-FLASH,MarketWatch,MW Biogen downgraded to market perform from outperform at BMO Capital
BIIB,2022-02-04,13:43:17,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Wells Fargo
BIIB,2022-02-04,13:43:17,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $235.00/Share From $284.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $235.00/Share From $284.00 by Wells Fargo
BIIB,2022-02-04,15:25:37,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-02-04,15:25:37,CEDFD5,Biogen Inc.,100,-0.74,price-targets,downgrade,Biogen Price Target Cut to $330.00/Share From $360.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $330.00/Share From $360.00 by Morgan Stanley
BIIB,2022-02-05,09:13:03,CEDFD5,Biogen Inc.,100,0.4,earnings,up,Biogen Q4 EPS $2.50 vs. $2.32 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q4 EPS $2.50 vs. $2.32 a year ago
BIIB,2022-02-05,09:13:03,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q4 adj. EPS $3.39; FactSet consensus $3.37,NEWS-FLASH,MarketWatch,MW Biogen Q4 adj. EPS $3.39; FactSet consensus $3.37
BIIB,2022-02-05,09:13:03,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q4 revenue $2.734 bln vs. $2.853 bln a year ago; FactSet consensus $2.620 bln,NEWS-FLASH,MarketWatch,MW Biogen Q4 revenue $2.734 bln vs. $2.853 bln a year ago; FactSet consensus $2.620 bln
BIIB,2022-02-05,09:13:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees 2022 adj. EPS of $14.25 to $16.00,NEWS-FLASH,MarketWatch,MW Biogen now sees 2022 adj. EPS of $14.25 to $16.00; FactSet consensus $18.76
BIIB,2022-02-05,09:13:03,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen now sees 2022 revenue of $9.7 bln to $10.0 bln,NEWS-FLASH,MarketWatch,MW Biogen now sees 2022 revenue of $9.7 bln to $10.0 bln; FactSet consensus $10.3 bln
BIIB,2022-02-05,09:13:04,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.2 billion in the final three months,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-05,09:13:04,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-05,09:13:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc.: the company issued new guidance for 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-05,09:13:04,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.7 billion in the final three months,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-05,09:13:04,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-05,09:13:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.2 billion in the final three months,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Falls 3.7% On Earnings Miss, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-05,09:13:09,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Falls 3.7% On Earnings Miss, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-05,09:13:09,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc.: the company issued new guidance for 2022,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-05,09:13:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.7 billion in the final three months,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-05,09:13:09,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-05,09:13:17,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen stock price target cut to $236 from $276 at J.P. Morgan,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $236 from $276 at J.P. Morgan
BIIB,2022-02-05,09:13:18,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen downgraded to market perform from outperform at BMO Capital,NEWS-FLASH,MarketWatch,MW Biogen downgraded to market perform from outperform at BMO Capital
BIIB,2022-02-05,09:13:22,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q4 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q4 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2022-02-07,12:52:55,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2022-02-07,12:52:55,CEDFD5,Biogen Inc.,100,-0.76,price-targets,downgrade,Biogen Price Target Cut to $305.00/Share From $335.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $305.00/Share From $335.00 by Canaccord Genuity
BIIB,2022-02-07,21:05:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane Announce Commercialization and License Agreement,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA(R) (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,21:05:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane Announce Commercialization and License Agreement,FULL-ARTICLE,Dow Jones Newswires,Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA(R) (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,21:05:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane Announce Commercialization and License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA(R) (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,21:05:03,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane Announce Commercialization and License Agreement,PRESS-RELEASE,GlobeNewswire,Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA(R) (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,21:05:03,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane Announce Commercialization and License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA(R) (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,21:06:09,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane: Announce Commercialization and License Agreement,NEWS-FLASH,Dow Jones Newswires,Biogen and Xbrane: Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA With the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,23:04:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,GlobeNewswire,"Block & Leviton LLP Has Filed a Lawsuit Against Biogen, Inc. for Securities Law Violations"
BIIB,2022-02-08,16:17:42,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen, Inc. (""Biogen"") (NASDAQ:BIIB",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm"
BIIB,2022-02-08,23:09:03,CEDFD5,Biogen Inc.,100,-0.52,legal,,Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. (NASDAQ: BIIB),PRESS-RELEASE,PR Newswire,BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-02-08,23:09:03,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,PR Newswire,BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-02-08,23:37:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-08,23:37:07,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-09,00:09:15,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,(BIIB) NEWS: Did you Suffer a Substantial Loss? Contact Johnson Fistel About Leading Biogen Inc. Class Action Lawsuit
BIIB,2022-02-09,01:11:49,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,GlobeNewswire,HAGENS BERMAN BIIB ALERT: Investors in Biogen Inc. (BIIB) With Significant Losses Have Opportunity to Lead Securities Class Action
BIIB,2022-02-09,10:03:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Investors Biogen, Inc. (BIIB) is Being Sued for",PRESS-RELEASE,Business Wire,"Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-09,10:03:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,Business Wire,"Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-09,15:00:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen, Inc. (""Biogen"") (NASDAQ: BIIB",PRESS-RELEASE,PR Newswire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm"
BIIB,2022-02-09,18:37:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firms Attorneys, Securities Class Action Filed"
BIIB,2022-02-09,21:00:49,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,"Block & Leviton LLP Has Filed a Lawsuit Against Biogen, Inc. for Securities Law Violations"
BIIB,2022-02-09,21:47:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Investors Biogen, Inc. (BIIB) is Being Sued for",PRESS-RELEASE,Business Wire,"CORRECTING and REPLACING Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-09,21:47:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,Business Wire,"CORRECTING and REPLACING Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-09,23:49:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-09,23:49:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-10,02:00:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen, Inc.",PRESS-RELEASE,Business Wire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm"
BIIB,2022-02-10,17:50:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,PR Newswire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Class Action Filed"
BIIB,2022-02-10,17:50:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,Dow Jones Newswires,"Press Release: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Class Action Filed"
BIIB,2022-02-10,18:47:42,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CHGG, TALK and BIIB"
BIIB,2022-02-10,19:11:13,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ:BIIB)
BIIB,2022-02-10,20:02:10,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Gross Law Firm Announces Class Actions on Behalf of Shareholders of RDW, CLVT and BIIB"
BIIB,2022-02-10,23:50:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-10,23:50:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-11,00:30:47,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for DOCU, FSLR and BIIB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-11,05:14:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Investors Biogen, Inc. (BIIB) is Being Sued for",PRESS-RELEASE,Business Wire,"Shareholder Alert: Robbins LLP Reminds Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-11,05:14:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,Business Wire,"Shareholder Alert: Robbins LLP Reminds Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-11,14:30:59,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SNBR, MARA and BIIB"
BIIB,2022-02-11,16:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen, Inc. (""Biogen"") (NASDAQ: BIIB",PRESS-RELEASE,Business Wire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm"
BIIB,2022-02-11,16:33:58,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for OSH, BMBL and BIIB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-11,21:08:20,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Class Action Filed"
BIIB,2022-02-12,13:27:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-12,13:27:46,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-13,13:19:44,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-02-13,13:19:44,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-02-14,02:00:00,CEDFD5,Biogen Inc.,96,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec, and Astra Space and Encourages Investors to Contact the Firm"
BIIB,2022-02-14,12:31:12,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST BHG, SLI and BIIB - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS"
BIIB,2022-02-14,14:30:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-14,14:30:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-14,14:37:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,GlobeNewswire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys About Lead Plaintiff Opportunity in Securities Class Action"
BIIB,2022-02-14,15:16:54,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of STTK, ELMS and BIIB"
BIIB,2022-02-14,16:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen, Inc. (""Biogen"") (NASDAQ: BIIB",PRESS-RELEASE,Business Wire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm"
BIIB,2022-02-14,16:30:42,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: TALK BIIB FENC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
BIIB,2022-02-15,02:22:05,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FFIE, ELMS and BIIB"
BIIB,2022-02-15,14:30:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"BIIB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 8, 2022 in the Class Action Filed on Behalf of Biogen Inc. Shareholders"
BIIB,2022-02-15,14:30:03,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,Dow Jones Newswires,"Press Release: BIIB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 8, 2022 in the Class Action Filed on Behalf of Biogen Inc. Shareholders"
BIIB,2022-02-15,21:13:00,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 171 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 171 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:13:51,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Ceo Vounatsos Acquires 150 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,CEO Vounatsos Acquires 150 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:15:14,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 104 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 104 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:16:14,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 229 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 229 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:17:34,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Guindo Acquires 255 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Guindo Acquires 255 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:19:34,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Gregory Acquires 420 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Gregory Acquires 420 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:20:04,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Alexander Acquires 224 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Acquires 224 Of Biogen Inc >BIIB
BIIB,2022-02-15,22:26:16,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys About Opportunity to Lead Securities Class Action"
BIIB,2022-02-15,23:29:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-15,23:29:11,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-15,23:57:48,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: DM CLVT BIIB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
BIIB,2022-02-16,00:30:38,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for MARA, TLIS and BIIB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-16,12:18:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen See Positive Results for Depression Treatment,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen See Positive Results for Depression Treatment"
BIIB,2022-02-16,12:33:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen See Positive Results for Depression Treatment,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen See Positive Results for Depression Treatment"
BIIB,2022-02-16,23:49:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-16,14:30:07,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 8, 2022 - (NASDAQ: BIIB)"
BIIB,2022-02-16,20:20:37,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Class Action Filed"
BIIB,2022-02-16,20:52:10,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ARVL, SLI and BIIB"
BIIB,2022-02-16,23:49:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-17,02:00:59,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Lawsuits FILED AGAINST EDU, TAL and BIIB",PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST EDU, TAL and BIIB - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,02:00:59,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST EDU, TAL and BIIB - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,14:15:55,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: INSD TLS BIIB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
BIIB,2022-02-17,14:30:07,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2022-02-17,21:02:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firms Attorneys, Securities Class Action Filed"
BIIB,2022-02-17,21:45:52,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Lawsuits Filed Against CHGG, TLS and BIIB",PRESS-RELEASE,DJ Global Press Release Wire,"Lawsuits Filed Against CHGG, TLS and BIIB Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,21:45:52,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"Lawsuits Filed Against CHGG, TLS and BIIB Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,21:49:22,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Lawsuits Filed Against CHGG, TLS and BIIB",PRESS-RELEASE,DJ Global Press Release Wire,"Lawsuits Filed Against CHGG, TLS and BIIB Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,21:49:22,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"Lawsuits Filed Against CHGG, TLS and BIIB Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,23:46:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-17,23:46:29,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-18,00:20:34,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FCFS, FSLR and BIIB"
BIIB,2022-02-18,14:30:06,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,"Who purchased Biogen between June 7, 2021",PRESS-RELEASE,PR Newswire,"BIIB SHAREHOLDER ALERT: Jakubowitz Law Reminds Biogen Shareholders of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-18,14:30:06,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"BIIB SHAREHOLDER ALERT: Jakubowitz Law Reminds Biogen Shareholders of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-18,14:57:13,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,GlobeNewswire,"BIOGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Biogen, Inc. in the United States District Court for the District of Massachusetts"
BIIB,2022-02-18,15:40:11,CEDFD5,Biogen Inc.,98,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FCFS, FFIE and BIIB"
BIIB,2022-02-18,17:42:05,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Fraud Case Pending"
BIIB,2022-02-18,19:15:34,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for FSLR, STTK and BIIB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-19,02:00:01,CEDFD5,Biogen Inc.,93,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against Electric Last Mile, TAL Education, New Oriental, and Biogen",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Electric Last Mile, TAL Education, New Oriental, and Biogen and Encourages Investors to Contact the Firm"
BIIB,2022-02-19,13:27:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-19,13:27:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-19,13:54:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $200,000 In Biogen To Contact Him Directly To Discuss Their Options"
BIIB,2022-02-19,13:54:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,GlobeNewswire,"BIOGEN DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $200,000 In Biogen To Contact Him Directly To Discuss Their Options"
BIIB,2022-02-20,13:19:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-20,13:19:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-21,12:15:39,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for DOCU, CLVT and BIIB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-22,11:00:14,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-22,11:00:14,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-22,14:33:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,GlobeNewswire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Class Action Filed"
BIIB,2022-02-22,14:55:33,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Lawsuits FILED AGAINST TLIS, BMBL and BIIB",PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST TLIS, BMBL and BIIB - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-22,14:55:33,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST TLIS, BMBL and BIIB - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-22,16:43:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-02-22,17:40:10,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TALK, BIIB and SPWR"
BIIB,2022-02-22,23:28:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-02-22,23:28:54,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-02-23,00:10:47,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FCFS, BIIB and FENC"
BIIB,2022-02-23,02:04:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for TLIS, BIIB and FENC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-23,11:00:08,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 8, 2022 - (NASDAQ: BIIB)"
BIIB,2022-02-23,21:18:40,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Alexander Acquires 826 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Acquires 826 Of Biogen Inc >BIIB
BIIB,2022-02-23,21:19:10,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Gregory Acquires 771 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Gregory Acquires 771 Of Biogen Inc >BIIB
BIIB,2022-02-23,21:20:30,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Guindo Acquires 1,102 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Guindo Acquires 1,102 Of Biogen Inc >BIIB"
BIIB,2022-02-23,21:26:11,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 419 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 419 Of Biogen Inc >BIIB
BIIB,2022-02-23,21:27:13,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 261 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 261 Of Biogen Inc >BIIB
BIIB,2022-02-23,21:27:49,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 279 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 279 Of Biogen Inc >BIIB
BIIB,2022-02-23,21:28:00,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 1,004 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 1,004 Of Biogen Inc >BIIB"
BIIB,2022-02-23,21:31:03,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Ceo Vounatsos Acquires 3,445 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CEO Vounatsos Acquires 3,445 Of Biogen Inc >BIIB"
BIIB,2022-02-24,00:06:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-24,00:06:43,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-24,01:41:10,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: FSLR SLI BIIB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
BIIB,2022-02-24,02:00:01,CEDFD5,Biogen Inc.,95,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against New Oriental Education, Biogen, Telos",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against New Oriental Education, Biogen, Telos, and Fennec and Encourages Investors to Contact the Firm"
BIIB,2022-02-24,03:25:30,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INSD, TALK and BIIB"
BIIB,2022-02-24,03:25:34,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INSD, TALK and BIIB"
BIIB,2022-02-24,11:00:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2022-02-24,18:00:19,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: TLIS TALK BIIB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
BIIB,2022-02-25,00:26:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-25,00:26:09,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-26,13:27:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-26,13:27:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-27,13:19:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-27,13:19:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-28,18:30:38,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Alert: Robbins LLP Reminds Investors of Class Action Against Biogen, Inc. (BIIB)"
BIIB,2022-03-01,02:00:01,CEDFD5,Biogen Inc.,95,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec, and Astra Space and Encourages Investors to Contact the Firm"
BIIB,2022-03-01,13:57:29,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-03-01,23:13:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-01,23:13:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-03,00:08:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-03,00:08:19,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-03,11:29:31,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Outperform From Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Sector Perform by RBC Capital
BIIB,2022-03-03,11:29:31,CEDFD5,Biogen Inc.,100,0.74,price-targets,upgrade,Biogen Price Target Raised to $248.00/Share From $227.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $248.00/Share From $227.00 by RBC Capital
BIIB,2022-03-03,14:07:27,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,"Abrahams upgraded Biogen (ticker: BIIB) to Outperform, from Sector Perform",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Has Fallen 50%. One Analyst Says It's Time to Buy. -- Barrons.com
BIIB,2022-03-03,14:07:27,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported Aduhelm revenue of $1 million for the fourth quarter of 2020,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Has Fallen 50%. One Analyst Says It's Time to Buy. -- Barrons.com
BIIB,2022-03-03,17:17:38,CEDFD5,Biogen Inc.,99,-0.51,labor-issues,,"Biogen Inc.: the company plans to cut 1,000 jobs",FULL-ARTICLE,MarketWatch,MW Biogen to lay off some U.S. employees
BIIB,2022-03-03,17:17:38,CEDFD5,Biogen Inc.,99,-0.51,labor-issues,,"Biogen Inc.: the company plans to cut 1,000 jobs",FULL-ARTICLE,Dow Jones Newswires,Biogen To Lay Off Some U.S. Employees -- MarketWatch
BIIB,2022-03-03,17:31:32,CEDFD5,Biogen Inc.,99,-0.51,labor-issues,,Biogen's job cuts,FULL-ARTICLE,Dow Jones Newswires,Biogen Makes Layoffs Amid Stalled Aduhelm Launch
BIIB,2022-03-03,17:46:32,CEDFD5,Biogen Inc.,99,-0.51,labor-issues,,Biogen's job cuts,FULL-ARTICLE,Dow Jones Newswires,Biogen Makes Layoffs Amid Stalled Aduhelm Launch
BIIB,2022-03-03,19:20:36,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,"Block & Leviton LLP Has Filed a Lawsuit Against Biogen, Inc. for Securities Law Violations"
BIIB,2022-03-03,21:00:45,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Biogen announced that the FDA had approved Aduhelm,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (BIIB); Lead Plaintiff Deadline is April 8, 2022"
BIIB,2022-03-04,00:14:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-04,00:14:54,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-04,01:57:03,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Biogen announced that the FDA had approved Aduhelm,PRESS-RELEASE,PR Newswire,"Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (NASDAQ: BIIB); Lead Plaintiff Deadline is April 8, 2022"
BIIB,2022-03-04,01:57:03,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Biogen announced that the FDA had approved Aduhelm,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (NASDAQ: BIIB); Lead Plaintiff Deadline is April 8, 2022"
BIIB,2022-03-05,13:27:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-05,13:27:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-06,13:19:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-06,13:19:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-07,02:00:01,CEDFD5,Biogen Inc.,93,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against Electric Last Mile, TAL, New Oriental Education, and Biogen",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Electric Last Mile, TAL, New Oriental Education, and Biogen and Encourages Investors to Contact the Firm"
BIIB,2022-03-08,11:22:32,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Hold From Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Hold From Buy by Stifel
BIIB,2022-03-08,11:22:32,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $223.00/Share From $304.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $223.00/Share From $304.00 by Stifel
BIIB,2022-03-08,11:57:20,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen downgraded to hold from buy at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Biogen downgraded to hold from buy at Stifel Nicolaus
BIIB,2022-03-08,15:26:37,CEDFD5,Biogen Inc.,99,0.0,products-services,,"Biogen, called lecanemab, a late-stage trial of",FULL-ARTICLE,Dow Jones Newswires,"Betting on Biogen Stock Isn't Worth the Risk, Analyst Says -- Barrons.com"
BIIB,2022-03-08,23:13:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-08,23:13:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-09,15:04:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-03-09,23:49:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-09,23:49:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-10,12:00:03,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11),PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:03,CEDFD5,Biogen Inc.,100,0.39,products-services,,"In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc.",PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:03,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:03,CEDFD5,Biogen Inc.,100,0.39,products-services,,"In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:04,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11),PRESS-RELEASE,GlobeNewswire,"Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:04,CEDFD5,Biogen Inc.,100,0.39,products-services,,"In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:15,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ (SB11,PRESS-RELEASE,Canadian News Wire,"Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ (SB11), LUCENTIS Biosimilar (Ranibizumab)"
BIIB,2022-03-10,12:00:15,CEDFD5,Biogen Inc.,100,0.39,products-services,,"In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc.",PRESS-RELEASE,Canadian News Wire,"Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ (SB11), LUCENTIS Biosimilar (Ranibizumab)"
BIIB,2022-03-10,12:08:53,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:08:53,CEDFD5,Biogen Inc.,100,0.39,products-services,,"In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-11,00:07:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-11,00:07:40,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-11,15:47:05,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Biogen announced that the FDA had approved Aduhelm,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (BIIB); Lead Plaintiff Deadline is April 8, 2022"
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the company will present new Alzheimer's disease research, as well as data for ADUHELM(R) (aducanumab-avwa) injection",FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the company will present new Alzheimer's disease research, as well as data for ADUHELM(R) (aducanumab-avwa) injection",PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the company will present new Alzheimer's disease research, as well as data for ADUHELM(R) (aducanumab-avwa) injection",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the company will present new Alzheimer's disease research, as well as data for ADUHELM(R) (aducanumab-avwa) injection",PRESS-RELEASE,GlobeNewswire,Biogen to Present New Research at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,GlobeNewswire,Biogen to Present New Research at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,23:16:24,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the company will present new Alzheimer's disease research, as well as data for ADUHELM(R) (aducanumab-avwa) injection",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Research at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,23:16:24,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Research at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-12,02:00:00,CEDFD5,Biogen Inc.,94,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against New Oriental, Biogen, Telos",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against New Oriental, Biogen, Telos, and Fennec and Encourages Investors to Contact the Firm"
BIIB,2022-03-12,13:27:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-12,13:27:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-13,12:29:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-13,12:29:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-14,11:30:00,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen Announces New Updates Across its SMA Research Program,PRESS-RELEASE,GlobeNewswire,Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Baseline Characteristics and Initial Safety Results in RESPOND: A Phase 4 Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen Announces New Updates Across its SMA Research Program,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Baseline Characteristics and Initial Safety Results in RESPOND: A Phase 4 Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen Announces New Updates Across its SMA Research Program,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen Announces New Updates Across its SMA Research Program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Baseline Characteristics and Initial Safety Results in RESPOND: A Phase 4 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,23:00:00,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen and Eisai said on Monday that they amended their collaboration agreement,FULL-ARTICLE,Dow Jones Newswires,Biogen And Eisai Rewrite Alzheimer's Drug Marketing Pact -- WSJ
BIIB,2022-03-14,23:00:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen to manufacture the drug,FULL-ARTICLE,Dow Jones Newswires,Biogen And Eisai Rewrite Alzheimer's Drug Marketing Pact -- WSJ
BIIB,2022-03-14,23:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's financial outlook for 2022,FULL-ARTICLE,Dow Jones Newswires,Biogen And Eisai Rewrite Alzheimer's Drug Marketing Pact -- WSJ
BIIB,2022-03-14,23:00:00,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: our agreement with Eisai through,PRESS-RELEASE,GlobeNewswire,Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments
BIIB,2022-03-14,23:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: our agreement with Eisai through,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments
BIIB,2022-03-14,23:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: our agreement with Eisai through,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments
BIIB,2022-03-14,23:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: our agreement with Eisai through,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments
BIIB,2022-03-14,23:00:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Eisai: Aducanumab Collaboration to,NEWS-FLASH,Dow Jones Newswires,"Biogen and Eisai: Aducanumab Collaboration to Convert From Eisai Sharing of Global Profits and Losses to Global Royalty Arrangement, Effective Jan 1, 2023 >BIIB"
BIIB,2022-03-15,00:33:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Stock News: Robbins LLP Reminds Investors of Class Action Against Biogen, Inc. (BIIB)"
BIIB,2022-03-15,22:17:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-15,22:17:51,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-16,15:12:48,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Biogen announced that the FDA had approved Aduhelm,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (BIIB); Lead Plaintiff Deadline is April 8, 2022"
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration (FDA) granted accelerated approval for ADUHELM,PRESS-RELEASE,GlobeNewswire,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,GlobeNewswire,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration (FDA) granted accelerated approval for ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration (FDA) granted accelerated approval for ADUHELM,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:53,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration (FDA) granted accelerated approval for ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:53,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:53,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration (FDA) granted accelerated approval for ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:53,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,22:49:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-16,22:49:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-17,01:00:01,CEDFD5,Biogen Inc.,95,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec, and Astra and Encourages Investors to Contact the Firm"
BIIB,2022-03-17,14:20:13,CEDFD5,Biogen Inc.,99,-0.58,analyst-ratings,negative,Downgraded Biogen to Hold from Buy,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Aduhelm Credibility Problem Deepens, and Investors Are Paying the Price -- Barrons.com"
BIIB,2022-03-17,22:46:30,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-17,22:46:30,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-19,12:27:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-19,12:27:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-20,12:30:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-20,12:30:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-22,01:00:01,CEDFD5,Biogen Inc.,93,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen and Encourages Investors to Contact the Firm"
BIIB,2022-03-22,13:08:01,CEDFD5,Biogen Inc.,92,-0.57,labor-issues,,Former chief medical officer at Biogen; he left that company,FULL-ARTICLE,MarketWatch,MW Voyager names former Biogen executive Alfred Sandrock as CEO
BIIB,2022-03-22,13:08:01,CEDFD5,Biogen Inc.,92,-0.57,labor-issues,,Former chief medical officer at Biogen; he left that company,FULL-ARTICLE,Dow Jones Newswires,Voyager Names Former Biogen Executive Alfred Sandrock As CEO -- MarketWatch
BIIB,2022-03-22,22:13:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-22,22:13:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-23,15:43:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,PR Newswire,BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-03-23,22:49:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-23,22:49:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-24,22:49:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-24,22:49:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-26,12:27:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-26,12:27:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-27,12:30:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-27,12:30:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-28,01:00:00,CEDFD5,Biogen Inc.,93,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen and Encourages Investors to Contact the Firm"
BIIB,2022-03-28,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen and Ionis Announce Topline Phase 1 Study,PRESS-RELEASE,GlobeNewswire,Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
BIIB,2022-03-28,11:30:02,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen and Ionis Announce Topline Phase 1 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
BIIB,2022-03-28,11:30:13,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen and Ionis Announce Topline Phase 1 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
BIIB,2022-03-28,14:08:54,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by B of A Securities
BIIB,2022-03-28,14:08:54,CEDFD5,Biogen Inc.,100,-0.4,price-targets,downgrade,Biogen Price Target Cut to $225.00/Share From $230.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $225.00/Share From $230.00 by B of A Securities
BIIB,2022-03-29,13:36:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,GlobeNewswire,"BIIB 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Deadline Approaching in Securities Class Action"
BIIB,2022-03-29,22:13:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Update
BIIB,2022-03-29,22:13:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Update
BIIB,2022-03-30,11:29:34,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm last June,FULL-ARTICLE,Dow Jones Newswires,Biogen Files the Final Design for Aduhelm's Post-Approval Study -- Barrons.com
BIIB,2022-03-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
BIIB,2022-03-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,FULL-ARTICLE,Dow Jones Newswires,Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
BIIB,2022-03-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
BIIB,2022-03-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,GlobeNewswire,Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
BIIB,2022-03-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
BIIB,2022-03-30,22:06:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-30,22:06:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-31,16:40:37,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB 8-DAY INVESTOR DEADLINE: Hagens Berman, National Trial Attorneys, Reminds Biogen Inc. (BIIB) Investors of April 8th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact Firms Attorneys"
BIIB,2022-03-31,22:49:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-31,22:49:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-04-01,22:52:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-04-01,22:52:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-04-03,12:19:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-04-03,12:19:32,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-04-04,19:11:10,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,GlobeNewswire,"BIIB 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Deadline Approaching in Securities Class Action"
BIIB,2022-04-04,20:06:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Real-World and Clinical Trial Data,PRESS-RELEASE,GlobeNewswire,New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression
BIIB,2022-04-04,20:06:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Real-World and Clinical Trial Data,PRESS-RELEASE,DJ Global Press Release Wire,New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression
BIIB,2022-04-04,20:06:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Real-World and Clinical Trial Data,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression
BIIB,2022-04-04,20:11:42,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Real-World and Clinical Trial Data,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression
BIIB,2022-04-05,21:46:07,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 155 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 155 Of Biogen Inc >BIIB
BIIB,2022-04-05,22:13:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-04-05,22:13:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-04-05,22:53:07,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB 8-DAY INVESTOR DEADLINE: Hagens Berman, National Trial Attorneys, Reminds Biogen Inc. (BIIB) Investors of April 8th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact Firm's Attorneys"
BIIB,2022-04-06,17:29:30,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firms Attorneys Before April 8th Deadline in Securities Class Action"
BIIB,2022-04-06,22:49:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-04-06,22:49:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-04-07,21:26:38,CEDFD5,Biogen Inc.,98,0.71,products-services,,The Food and Drug Administration granted accelerated approval to Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare Limits Payments for Biogen's Alzheimer's Drug -- Update
BIIB,2022-04-07,22:04:04,CEDFD5,Biogen Inc.,98,0.71,products-services,,The Food and Drug Administration granted accelerated approval to Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare Limits Payments for Biogen's Alzheimer's Drug -- 2nd Update
BIIB,2022-04-07,22:06:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-04-07,22:06:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-04-07,22:21:26,CEDFD5,Biogen Inc.,95,0.0,products-services,,"Biogen initially priced Aduhelm at $56,000",FULL-ARTICLE,Dow Jones Newswires,Medicare Will Limit Coverage of Biogen's Alzheimer's Drug -- Barrons.com
BIIB,2022-04-07,23:26:00,CEDFD5,Biogen Inc.,99,0.71,products-services,,The Food and Drug Administration granted accelerated approval to Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare Limits Payments for Biogen's Alzheimer's Drug -- 3rd Update
BIIB,2022-04-08,10:51:10,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2022-04-08,10:51:10,CEDFD5,Biogen Inc.,100,-0.78,price-targets,downgrade,Biogen Price Target Cut to $262.00/Share From $290.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $262.00/Share From $290.00 by Needham
BIIB,2022-04-08,11:55:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2022-04-08,11:55:01,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $240.00/Share From $285.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $240.00/Share From $285.00 by Oppenheimer
BIIB,2022-04-08,12:58:38,CEDFD5,Biogen Inc.,92,-0.57,price-targets,downgrade,Are cutting their price targets on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Seen Hurting From CMS Alzheimer's Drug Decision -- Market Talk
BIIB,2022-04-08,12:58:38,CEDFD5,Biogen Inc.,92,-0.57,price-targets,downgrade,Are cutting their price targets on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Seen Hurting From CMS Alzheimer's Drug Decision -- Market Talk
BIIB,2022-04-08,15:15:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Aduhelm, the first Alzheimer's drug approved by the Food and Drug Administration",FULL-ARTICLE,Dow Jones Newswires,It's Lights Out for Biogen's Aduhelm. But There's Some Hope for Other Alzheimer's Drugs. -- Barrons.com
BIIB,2022-04-08,22:32:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-04-08,22:32:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-04-11,19:35:32,CEDFD5,Biogen Inc.,100,-0.58,credit-ratings,downgrade,Moody's Downgrades Biogen To Baa2,NEWS-FLASH,Dow Jones Newswires,Moody's Downgrades Biogen To Baa2; Negative Outlook
BIIB,2022-04-12,12:18:56,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-04-12,12:18:56,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $219.00/Share From $235.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $219.00/Share From $235.00 by Barclays
BIIB,2022-04-12,13:14:16,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-04-12,13:14:16,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $283.00/Share From $330.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $283.00/Share From $330.00 by Morgan Stanley
BIIB,2022-04-18,11:00:03,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Overweight From Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Overweight From Equal-Weight by Wells Fargo
BIIB,2022-04-18,11:00:03,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $265.00/Share From $235.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $265.00/Share From $235.00 by Wells Fargo
BIIB,2022-04-21,07:28:59,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 1Q 2022 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 1Q 2022 (BIIB)"
BIIB,2022-04-21,14:01:43,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2022-04-21,14:01:43,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $300.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $300.00 by SVB Leerink
BIIB,2022-04-22,14:37:13,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen: Notifies EMA of Decision to Withdraw Its Marketing Authorization Application for Aducanumab for Treatment of Early Stages of Alzheimer,NEWS-FLASH,Dow Jones Newswires,Biogen: Notifies EMA of Decision to Withdraw Its Marketing Authorization Application for Aducanumab for Treatment of Early Stages of Alzheimer's >BIIB
BIIB,2022-04-22,15:00:40,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Pulls European Application for Approval of Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Pulls European Application for Approval of Alzheimer's Drug Aduhelm
BIIB,2022-04-22,15:15:40,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Pulls European Application for Approval of Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Pulls European Application for Approval of Alzheimer's Drug Aduhelm
BIIB,2022-05-02,14:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Expands Collaboration With Biogen to,PRESS-RELEASE,Business Wire,Scribe Therapeutics Expands Collaboration With Biogen to Second Target
BIIB,2022-05-03,11:07:29,CEDFD5,Biogen Inc.,100,-0.42,earnings,down,Biogen Q1 EPS $2.06 vs. $2.69 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q1 EPS $2.06 vs. $2.69 a year ago
BIIB,2022-05-03,11:07:49,CEDFD5,Biogen Inc.,100,-0.34,earnings,below-expectations,Biogen Q1 adj. EPS $3.62; FactSet consensus $4.34,NEWS-FLASH,MarketWatch,MW Biogen Q1 adj. EPS $3.62; FactSet consensus $4.34
BIIB,2022-05-03,11:08:21,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen Q1 revenue $2.532 bln down 6%,NEWS-FLASH,MarketWatch,MW Biogen Q1 revenue $2.532 bln down 6% vs. year-ago; FactSet consensus $2.500 bln
BIIB,2022-05-03,11:12:05,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen still sees full-year adj. EPS of $14.25 to $16.00,NEWS-FLASH,MarketWatch,MW Biogen still sees full-year adj. EPS of $14.25 to $16.00
BIIB,2022-05-03,11:12:17,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen still sees full-year revenue of $9.7 bln to $10.0 bln,NEWS-FLASH,MarketWatch,MW Biogen still sees full-year revenue of $9.7 bln to $10.0 bln
BIIB,2022-05-03,11:12:20,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $2.06 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $2.06 >BIIB
BIIB,2022-05-03,11:12:20,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $3.62,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Adj EPS $3.62 >BIIB
BIIB,2022-05-03,11:12:20,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Net $303.8M,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Net $303.8M >BIIB
BIIB,2022-05-03,11:12:20,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.53B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.53B >BIIB
BIIB,2022-05-03,11:23:20,CEDFD5,Biogen Inc.,94,0.49,labor-issues,,Biogen (ticker: BIIB) also said it had begun to look for a new chief executive officer,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Eliminate Alzheimer's Drug Infrastructure, Search for New CEO -- Barrons.com"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen misses on earnings,FULL-ARTICLE,MarketWatch,"MW Biogen misses on earnings in the first quarter, citing write-offs for its Alzheimer's disease drug"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed Wall Street's expectations for revenue,FULL-ARTICLE,MarketWatch,"MW Biogen misses on earnings in the first quarter, citing write-offs for its Alzheimer's disease drug"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,MarketWatch,"MW Biogen misses on earnings in the first quarter, citing write-offs for its Alzheimer's disease drug"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen Misses On Earnings,FULL-ARTICLE,Dow Jones Newswires,"Biogen Misses On Earnings In The First Quarter, Citing Write-offs For Its Alzheimer's Disease Drug -- MarketWatch"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed Wall Street's expectations for revenue,FULL-ARTICLE,Dow Jones Newswires,"Biogen Misses On Earnings In The First Quarter, Citing Write-offs For Its Alzheimer's Disease Drug -- MarketWatch"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,Dow Jones Newswires,"Biogen Misses On Earnings In The First Quarter, Citing Write-offs For Its Alzheimer's Disease Drug -- MarketWatch"
BIIB,2022-05-03,11:35:19,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen'a Q1 profit and revenue lag estimates,FULL-ARTICLE,MarketWatch,"MW Biogen'a Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug"
BIIB,2022-05-03,11:35:19,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,MarketWatch,"MW Biogen'a Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug"
BIIB,2022-05-03,11:35:19,CEDFD5,Biogen Inc.,97,-0.75,revenues,below-expectations,Biogen Inc.: the company missed Wall Street's expectations for revenue,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen'a Q1 Profit And Revenue Lag Estimates, Weighed Down By Alzheimer's Drug -- MarketWatch"
BIIB,2022-05-03,11:35:19,CEDFD5,Biogen Inc.,97,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen'a Q1 Profit And Revenue Lag Estimates, Weighed Down By Alzheimer's Drug -- MarketWatch"
BIIB,2022-05-03,11:41:13,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen Inc.: Biogen CEO Michel Vounatsos is leaving the company,NEWS-FLASH,MarketWatch,MW Biogen CEO Michel Vounatsos is leaving the company as soon as successor has been found
BIIB,2022-05-03,11:45:33,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos to step down,FULL-ARTICLE,MarketWatch,MW Biogen CEO Michel Vounatsos to step down
BIIB,2022-05-03,11:45:33,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,"Biogen Inc.: the company's first-quarter earnings, which saw Biogen missing Wall Street's expectations",FULL-ARTICLE,MarketWatch,MW Biogen CEO Michel Vounatsos to step down
BIIB,2022-05-03,11:45:33,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos To Step Down,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos To Step Down -- MarketWatch
BIIB,2022-05-03,11:45:33,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,"Biogen Inc.: the company's first-quarter earnings, which saw Biogen missing Wall Street's expectations",FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos To Step Down -- MarketWatch
BIIB,2022-05-03,11:48:19,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos to step down,NEWS-FLASH,MarketWatch,MW Biogen CEO Michel Vounatsos to step down
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen's Q1 profit and revenue lag estimates,FULL-ARTICLE,MarketWatch,"MW Biogen's Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug"
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed Wall Street's expectations for revenue,FULL-ARTICLE,MarketWatch,"MW Biogen's Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug"
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,MarketWatch,"MW Biogen's Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug"
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen's Q1 Profit And Revenue Lag Estimates,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Q1 Profit And Revenue Lag Estimates, Weighed Down By Alzheimer's Drug -- MarketWatch"
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed Wall Street's expectations for revenue,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Q1 Profit And Revenue Lag Estimates, Weighed Down By Alzheimer's Drug -- MarketWatch"
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Q1 Profit And Revenue Lag Estimates, Weighed Down By Alzheimer's Drug -- MarketWatch"
BIIB,2022-05-03,12:21:12,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos to Resign,NEWS-FLASH,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Resign; Will Stay on Until New CEO Search Finds Successor -- WSJ
BIIB,2022-05-03,12:21:12,CEDFD5,Biogen Inc.,100,0.58,equity-actions,down,Biogen Targets Cost-Cutting,NEWS-FLASH,Dow Jones Newswires,Biogen Targets Cost-Cutting of an Additional $500 Million on Top of $500 Million Announced in December -- WSJ
BIIB,2022-05-03,12:21:12,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen Inc.: Chief Executive Michel Vounatsos will resign from the company,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO to Step Aside After Alzheimer's Drug Struggles -- WSJ
BIIB,2022-05-03,12:51:22,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos to Step Aside After,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- Update
BIIB,2022-05-03,14:00:03,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen Inc.: Chief Executive Michel Vounatsos will resign from the company,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO to Step Aside After Alzheimer's Drug Struggles
BIIB,2022-05-03,14:00:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen also reported its first-quarter financial results on Tuesday,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO to Step Aside After Alzheimer's Drug Struggles
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos to Step Aside After,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen said Aduhelm sales were $2.8 million in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen's launch of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen had expected its sales,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen also reported its first-quarter financial results on Tuesday,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and its partner Eisai Co. are collaborating on lecanemab,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,16:47:55,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm last June,FULL-ARTICLE,MarketWatch,"MW Beset by challenges with its Alzheimer's disease drug, Biogen pivots"
BIIB,2022-05-03,17:34:05,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q1 2022 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q1 2022 Results -- Earnings Call Transcript >BIIB
BIIB,2022-05-03,17:34:05,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen-inc-biib-ceo-michel-vounatsos-on-q1-2022-results-earnings,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q1 2022 Results -- Earnings Call Transcript >BIIB
BIIB,2022-05-03,19:04:41,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-03,20:53:09,CEDFD5,Biogen Inc.,96,0.0,revenues,,Biogen has reported only $5.8 million in sales,FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Patients Now Less Likely to Receive Biogen's Aduhelm Treatment -- WSJ
BIIB,2022-05-04,06:12:52,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen said Aduhelm sales were $2.8 million in the first quarter,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Abandon  Alzheimer's Drug,  Part With CEO  ----  By Joseph Walker"
BIIB,2022-05-04,06:12:52,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen's launch of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Abandon  Alzheimer's Drug,  Part With CEO  ----  By Joseph Walker"
BIIB,2022-05-04,06:12:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen also reported its first-quarter results Tuesday,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Abandon  Alzheimer's Drug,  Part With CEO  ----  By Joseph Walker"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,-0.6,labor-issues,,Biogen Inc. is shedding Chief Executive,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen said Aduhelm sales were $2.8 million in the first quarter,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen's launch of Aduhelm,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen had expected its sales,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen also reported its first-quarter financial results on Tuesday,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and its partner Eisai Co. are collaborating on lecanemab,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,11:24:23,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-05-04,11:24:23,CEDFD5,Biogen Inc.,100,-0.52,price-targets,downgrade,Biogen Price Target Cut to $210.00/Share From $219.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $210.00/Share From $219.00 by Barclays
BIIB,2022-05-04,11:36:39,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm last June,FULL-ARTICLE,MarketWatch,"MW Beset by challenges with its Alzheimer's disease drug, Biogen pivots"
BIIB,2022-05-04,11:47:44,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-04,11:54:53,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2022-05-04,11:54:53,CEDFD5,Biogen Inc.,100,0.44,price-targets,upgrade,Biogen Price Target Raised to $251.00/Share From $244.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $251.00/Share From $244.00 by RBC Capital
BIIB,2022-05-04,12:00:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"2013, regulators approved Tecfidera",FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Casting Off Its Troubled Alzheimer's Drug -- WSJ
BIIB,2022-05-04,12:00:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Able to win FDA approval for Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Casting Off Its Troubled Alzheimer's Drug -- WSJ
BIIB,2022-05-04,12:00:00,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen slashed the price in half,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Casting Off Its Troubled Alzheimer's Drug -- WSJ
BIIB,2022-05-04,12:04:43,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2022-05-04,12:04:43,CEDFD5,Biogen Inc.,100,-0.66,price-targets,downgrade,Biogen Price Target Cut to $225.00/Share From $240.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $225.00/Share From $240.00 by Oppenheimer
BIIB,2022-05-04,12:10:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"2013, regulators approved Tecfidera",FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Ditching Troubled Alzheimer's Drug
BIIB,2022-05-04,12:10:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Able to win FDA approval for Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Ditching Troubled Alzheimer's Drug
BIIB,2022-05-04,12:10:04,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen slashed the price in half,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Ditching Troubled Alzheimer's Drug
BIIB,2022-05-04,12:23:20,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-04,12:25:51,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm last June,FULL-ARTICLE,MarketWatch,"MW Beset by challenges with its Alzheimer's disease drug, Biogen pivots"
BIIB,2022-05-04,13:43:02,CEDFD5,Biogen Inc.,100,-0.5,labor-issues,,Biogen's CEO Leaves Amid Alzheimer,FULL-ARTICLE,Dow Jones Newswires,Biogen's CEO Leaves Amid Alzheimer's Drug Failure -- ESG Insight
BIIB,2022-05-04,14:06:24,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-05-04,14:06:24,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $285.00/Share From $283.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $285.00/Share From $283.00 by Morgan Stanley
BIIB,2022-05-04,18:34:59,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-05,06:07:32,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,"Biogen Inc.: the Food and Drug Administration approved the company's Alzheimer's monoclonal antibody, Aduhelm",FULL-ARTICLE,Dow Jones Newswires,Biogen's CEO Becomes a Political Sacrifice  ----  By Allysia Finley
BIIB,2022-05-05,06:07:32,CEDFD5,Biogen Inc.,96,0.71,products-services,,Aduhelm and future Alzheimer's amyloid drugs receiving accelerated FDA approval,FULL-ARTICLE,Dow Jones Newswires,Biogen's CEO Becomes a Political Sacrifice  ----  By Allysia Finley
BIIB,2022-05-05,06:10:12,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"2013, regulators approved Tecfidera",FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Job After Pulling Drug  ----  By Joseph Walker
BIIB,2022-05-05,06:10:12,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Able to win FDA approval for Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Job After Pulling Drug  ----  By Joseph Walker
BIIB,2022-05-05,06:10:12,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen slashed the price in half,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Job After Pulling Drug  ----  By Joseph Walker
BIIB,2022-05-05,06:32:31,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"2013, regulators approved Tecfidera",FULL-ARTICLE,Wall Street Journal,Biogen Faces Tough Job After Pulling Drug -- WSJ
BIIB,2022-05-05,06:32:31,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Able to win FDA approval for Aduhelm,FULL-ARTICLE,Wall Street Journal,Biogen Faces Tough Job After Pulling Drug -- WSJ
BIIB,2022-05-05,06:32:31,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen slashed the price in half,FULL-ARTICLE,Wall Street Journal,Biogen Faces Tough Job After Pulling Drug -- WSJ
BIIB,2022-05-05,10:53:19,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-05,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,Business Wire,(BW) Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,GlobeNewswire,Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:30:25,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:38:19,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm last June,FULL-ARTICLE,MarketWatch,"MW Beset by challenges with its Alzheimer's drug, Biogen pivots"
BIIB,2022-05-06,11:18:17,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-06,17:07:12,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-09,15:57:37,CEDFD5,Biogen Inc.,99,-0.52,legal,,Pllc announces that a class action complaint has been filed against Biogen,PRESS-RELEASE,GlobeNewswire,"Lifshitz Law PLLC. Announces Investigations of Astra Space, Inc. (NASDAQ: ASTR), Biogen Inc, (NASDAQ: BIIB), Fennec Pharmaceuticals Inc. (NASDAQ: FENC), and Telos Corporation (NASDAQ: TLS)"
BIIB,2022-05-10,15:41:55,CEDFD5,Biogen Inc.,100,0.58,products-services,,Biogen Partner Eisai Files for Accelerated Approval,FULL-ARTICLE,Dow Jones Newswires,Biogen Partner Eisai Files for Accelerated Approval of Alzheimer's Drug -- Barrons.com
BIIB,2022-05-31,12:00:04,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study,PRESS-RELEASE,GlobeNewswire,Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
BIIB,2022-05-31,12:00:04,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,GlobeNewswire,Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
BIIB,2022-05-31,12:00:05,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
BIIB,2022-05-31,12:00:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
BIIB,2022-05-31,12:02:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Denali Therapeutics and Biogen: Initiation of Phase 2b Study of LRRK2 Inhibitor,NEWS-FLASH,Dow Jones Newswires,Denali Therapeutics and Biogen: Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
BIIB,2022-06-01,10:34:19,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Plan to Complete MDD NDA Filing in,NEWS-FLASH,Dow Jones Newswires,"Sage, Biogen Plan to Complete MDD NDA Filing in 2H >SAGE"
BIIB,2022-06-03,09:20:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen announces that results from Phase 3 VALOR study,PRESS-RELEASE,PR Newswire,Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
BIIB,2022-06-03,09:20:03,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Tofersen showed clinical benefit,PRESS-RELEASE,PR Newswire,Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
BIIB,2022-06-03,09:20:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen announces that results from Phase 3 VALOR study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
BIIB,2022-06-03,09:20:03,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Tofersen showed clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
BIIB,2022-06-03,12:00:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",FULL-ARTICLE,Dow Jones Newswires,Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
BIIB,2022-06-03,12:00:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
BIIB,2022-06-03,12:00:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
BIIB,2022-06-03,12:00:03,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,GlobeNewswire,Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
BIIB,2022-06-03,12:08:07,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,GlobeNewswire,"Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,GlobeNewswire,"Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:34:39,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-22,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Happify Health Collaborate to,PRESS-RELEASE,Business Wire,Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
BIIB,2022-06-22,13:00:17,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Happify Health Collaborate to,NEWS-FLASH,Dow Jones Newswires,Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
BIIB,2022-06-22,13:05:09,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen is collaborating with Happify,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
BIIB,2022-06-24,12:12:17,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen stops clinical trial,FULL-ARTICLE,MarketWatch,MW Biogen stops clinical trial tracking Aduhelm
BIIB,2022-06-24,12:12:17,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The Food and Drug Administration approved Aduhelm,FULL-ARTICLE,MarketWatch,MW Biogen stops clinical trial tracking Aduhelm
BIIB,2022-06-24,12:12:17,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen Stops Clinical Trial,FULL-ARTICLE,Dow Jones Newswires,Biogen Stops Clinical Trial Tracking Aduhelm -- MarketWatch
BIIB,2022-06-24,12:12:17,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The Food and Drug Administration approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Stops Clinical Trial Tracking Aduhelm -- MarketWatch
BIIB,2022-07-06,13:04:47,CEDFD5,Biogen Inc.,96,0.0,products-services,,Biogen led development of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,"Alzheimer's Drug Is Up for Accelerated Approval. Outlook for Biogen, Eisai Is Uncertain. -- Barrons.com"
BIIB,2022-07-06,23:29:39,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 356 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 356 Of Biogen Inc >BIIB
BIIB,2022-07-06,23:34:23,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 178 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 178 Of Biogen Inc >BIIB
BIIB,2022-07-13,18:51:04,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Dir Posner Registers 388 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,Dir Posner Registers 388 Of Biogen Inc >BIIB
BIIB,2022-07-14,11:00:05,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Fda approval of Biogen/Eisai's Aduhelm,PRESS-RELEASE,PR Newswire,"New Spherix Data in Alzheimer's Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk's Semaglutide"
BIIB,2022-07-18,14:59:52,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2022-07-18,14:59:52,CEDFD5,Biogen Inc.,100,0.4,price-targets,upgrade,Biogen Price Target Raised to $230.00/Share From $225.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $230.00/Share From $225.00 by Oppenheimer
BIIB,2022-07-20,11:05:53,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $7.24 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q EPS $7.24 >BIIB
BIIB,2022-07-20,11:05:53,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Adj EPS $5.25,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Adj EPS $5.25 >BIIB
BIIB,2022-07-20,11:05:53,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Net $1.06B,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Net $1.06B >BIIB
BIIB,2022-07-20,11:05:53,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 2Q Rev $2.59B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Rev $2.59B >BIIB
BIIB,2022-07-20,11:07:03,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 2Q Rev $2.59B >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 2Q Rev $2.59B >BIIB
BIIB,2022-07-20,11:07:19,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $7.24 >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 2Q EPS $7.24 >BIIB
BIIB,2022-07-20,11:07:31,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Adj EPS $5.25,RNS-SEC8K,Dow Jones Newswires,Biogen 2Q Adj EPS $5.25 >BIIB
BIIB,2022-07-20,11:09:09,CEDFD5,Biogen Inc.,100,0.82,earnings,up,Biogen Q2 EPS $7.24 vs. $2.99 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q2 EPS $7.24 vs. $2.99 a year ago
BIIB,2022-07-20,11:09:31,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees FY22 Rev $9.9B-$10.1B >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY22 Rev $9.9B-$10.1B >BIIB
BIIB,2022-07-20,11:09:35,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q2 adj. EPS $5.25; FactSet consensus $4.06,NEWS-FLASH,MarketWatch,MW Biogen Q2 adj. EPS $5.25; FactSet consensus $4.06
BIIB,2022-07-20,11:09:53,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY22 Adj EPS $15.25,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY22 Adj EPS $15.25-Adj EPS $16.75 >BIIB
BIIB,2022-07-20,11:10:00,CEDFD5,Biogen Inc.,100,-0.34,revenues,below-expectations,Biogen Q2 revenue $2.055 bln vs. $2.236 bln a year ago; FactSet consensus $2.474 bln,NEWS-FLASH,MarketWatch,MW Biogen Q2 revenue $2.055 bln vs. $2.236 bln a year ago; FactSet consensus $2.474 bln
BIIB,2022-07-20,11:10:31,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raises full-year guidance,NEWS-FLASH,MarketWatch,MW Biogen raises full-year guidance
BIIB,2022-07-20,11:11:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees full-year EPS of $15.25 to $16.75,NEWS-FLASH,MarketWatch,MW Biogen now sees full-year EPS of $15.25 to $16.75 vs. prior $14.25 to $16.00
BIIB,2022-07-20,11:11:19,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen now sees full-year revenue of $9.9 bln to $10.1 bln,NEWS-FLASH,MarketWatch,MW Biogen now sees full-year revenue of $9.9 bln to $10.1 bln vs. prior $9.7 bln to $10.0 bln
BIIB,2022-07-20,11:18:01,CEDFD5,Biogen Inc.,92,0.0,earnings,,Biogen (BIIB) posted second-quarter earnings,FULL-ARTICLE,Dow Jones Newswires,"Netflix, Tesla, Biogen, and More of Wednesday's Stock Market Movers -- Barrons.com"
BIIB,2022-07-20,11:18:01,CEDFD5,Biogen Inc.,92,0.64,earnings,up,Biogen Inc.: the company raised its earnings,FULL-ARTICLE,Dow Jones Newswires,"Netflix, Tesla, Biogen, and More of Wednesday's Stock Market Movers -- Barrons.com"
BIIB,2022-07-20,11:45:58,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed on revenue in the second quarter,FULL-ARTICLE,MarketWatch,MW Biogen's stock is down 2.8% after missing on revenue in the second quarter
BIIB,2022-07-20,11:45:58,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported earnings of $1.0 billion,FULL-ARTICLE,MarketWatch,MW Biogen's stock is down 2.8% after missing on revenue in the second quarter
BIIB,2022-07-20,11:45:58,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed on revenue in the second quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Is Down 2.8% After Missing On Revenue In The Second Quarter -- MarketWatch
BIIB,2022-07-20,11:45:58,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported earnings of $1.0 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Is Down 2.8% After Missing On Revenue In The Second Quarter -- MarketWatch
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.64,earnings,up,Biogen 2Q Profit Lifted by,FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen beats 2Q analyst estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.72,revenues,up,"Biogen slightly raised its full-year outlook, increasing its revenue guidance",FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.64,earnings,up,Biogen 2Q Profit Lifted by,FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen beats 2Q analyst estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.72,revenues,up,"Biogen slightly raised its full-year outlook, increasing its revenue guidance",FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,12:19:27,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Ticker: BIIB) said adjusted earnings were $5.25 per share for the second quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Despite an Upbeat Outlook. Here's Why. -- Barrons.com
BIIB,2022-07-20,12:19:27,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported $2.78 billion in revenue,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Despite an Upbeat Outlook. Here's Why. -- Barrons.com
BIIB,2022-07-20,15:00:25,CEDFD5,Biogen Inc.,99,0.7,earnings,above-expectations,Biogen beats 2Q analyst estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Pulls the Plug on Neuropsychiatry Candidate -- Market Talk
BIIB,2022-07-20,15:00:25,CEDFD5,Biogen Inc.,99,0.72,revenues,up,"Biogen slightly raised its full-year outlook, increasing its revenue guidance",FULL-ARTICLE,Dow Jones Newswires,Biogen Pulls the Plug on Neuropsychiatry Candidate -- Market Talk
BIIB,2022-07-20,16:45:02,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen INC. AGREES TO PAY $900 MILLION TO RESOLVE,PRESS-RELEASE,PR Newswire,BIOGEN INC. AGREES TO PAY $900 MILLION TO RESOLVE WHISTLEBLOWER CLAIM REGARDING PAYMENT OF UNLAWFUL KICKBACKS
BIIB,2022-07-20,16:45:02,CEDFD5,Biogen Inc.,100,-0.56,products-services,loss,"Biogen, to prevent its multiple sclerosis drugs from losing market share",PRESS-RELEASE,PR Newswire,BIOGEN INC. AGREES TO PAY $900 MILLION TO RESOLVE WHISTLEBLOWER CLAIM REGARDING PAYMENT OF UNLAWFUL KICKBACKS
BIIB,2022-07-20,17:10:04,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Ticker: BIIB) said adjusted earnings were $5.25 per share for the second quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Despite an Upbeat Outlook. Here's Why.
BIIB,2022-07-20,17:10:04,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported $2.78 billion in revenue,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Despite an Upbeat Outlook. Here's Why.
BIIB,2022-07-20,17:12:04,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q2 2022 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q2 2022 Results -- Earnings Call Transcript >BIIB
BIIB,2022-07-21,07:32:32,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 2Q 2022 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 2Q 2022 (BIIB)"
BIIB,2022-07-21,10:43:10,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2022-07-21,10:43:10,CEDFD5,Biogen Inc.,100,-0.56,price-targets,downgrade,Biogen Price Target Cut to $250.00/Share From $262.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $250.00/Share From $262.00 by Needham
BIIB,2022-07-21,12:39:30,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen stock price target cut to $270 from $320,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $270 from $320 at Truist
BIIB,2022-07-21,13:00:50,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-07-21,13:00:50,CEDFD5,Biogen Inc.,100,-0.56,price-targets,downgrade,Biogen Price Target Cut to $200.00/Share From $210.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $200.00/Share From $210.00 by Barclays
BIIB,2022-07-21,13:59:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2022-07-21,13:59:01,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $320.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $320.00 by Truist Securities
BIIB,2022-07-21,14:32:21,CEDFD5,Biogen Inc.,100,0.2,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Cowen & Co.
BIIB,2022-07-21,14:32:21,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $285.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $285.00 by Cowen & Co.
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.65,products-services,,Fda Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen,PRESS-RELEASE,DJ Global Press Release Wire,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: The tofersen NDA included results from a Phase 1 study,PRESS-RELEASE,DJ Global Press Release Wire,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.65,products-services,,Fda Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen,FULL-ARTICLE,Dow Jones Newswires,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen is seeking approval of tofersen,FULL-ARTICLE,Dow Jones Newswires,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.65,products-services,,Fda Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: The tofersen NDA included results from a Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,100,0.65,products-services,,Fda Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen,PRESS-RELEASE,GlobeNewswire,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: The tofersen NDA included results from a Phase 1 study,PRESS-RELEASE,GlobeNewswire,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results in early stage clinical trials,PRESS-RELEASE,GlobeNewswire,FDA Accepts Biogen's New Drug Application and -2-
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,100,0.65,products-services,,Fda Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: The tofersen NDA included results from a Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results in early stage clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Biogen's New Drug -2-
BIIB,2022-07-26,11:34:47,CEDFD5,Biogen Inc.,100,0.65,products-services,,Biogen Gets FDA Priority Review of Tofersen,NEWS-FLASH,Dow Jones Newswires,"Biogen Gets FDA Priority Review of Tofersen for a Rare, Genetic Form of ALS >BIIB"
BIIB,2022-07-26,12:02:52,CEDFD5,Biogen Inc.,100,0.65,products-services,,Biogen Gets FDA Priority Review of Tofersen,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS >BIIB
BIIB,2022-07-26,12:02:52,CEDFD5,Biogen Inc.,100,0.65,products-services,,Biogen Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS >BIIB
BIIB,2022-07-26,12:17:52,CEDFD5,Biogen Inc.,100,0.65,products-services,,Biogen Gets FDA Priority Review of Tofersen,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS
BIIB,2022-07-26,12:17:52,CEDFD5,Biogen Inc.,100,0.65,products-services,,Biogen Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS
BIIB,2022-07-26,13:41:36,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: the company disclosed disappointing results of the Phase 3 trial of the drug,FULL-ARTICLE,Dow Jones Newswires,Biogen's ALS Drug Will Get FDA Review. It's a Long Shot for the Stock. -- Barrons.com
BIIB,2022-07-26,13:41:36,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Biogen's Alzheimer's drug Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen's ALS Drug Will Get FDA Review. It's a Long Shot for the Stock. -- Barrons.com
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059,FULL-ARTICLE,Dow Jones Newswires,The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059,PRESS-RELEASE,DJ Global Press Release Wire,The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Results from Phase 2 LILAC study,PRESS-RELEASE,DJ Global Press Release Wire,The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059,PRESS-RELEASE,Dow Jones Newswires,Press Release: The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Results from Phase 2 LILAC study,PRESS-RELEASE,Dow Jones Newswires,Press Release: The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059,PRESS-RELEASE,GlobeNewswire,The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Results from Phase 2 LILAC study,PRESS-RELEASE,GlobeNewswire,The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:02,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059,PRESS-RELEASE,Dow Jones Newswires,Press Release: The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:02,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Results from Phase 2 LILAC study,PRESS-RELEASE,Dow Jones Newswires,Press Release: The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-08-03,21:41:42,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 761 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 761 Of Biogen Inc >BIIB
BIIB,2022-08-31,23:04:55,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 500,000 Of Sangamo Therapeutics Inc >SGMO",FULL-ARTICLE,Dow Jones Newswires,"Holder Biogen Inc Sells 500,000 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2022-09-06,23:33:11,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 2,318 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 2,318 Of Biogen Inc >BIIB"
BIIB,2022-09-12,11:21:32,CEDFD5,Biogen Inc.,100,-0.44,price-targets,downgrade,Biogen price target lowered to $223 from $230 at Stifel,NEWS-FLASH,MarketWatch,MW Biogen price target lowered to $223 from $230 at Stifel
BIIB,2022-09-12,13:40:56,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Hold by Stifel
BIIB,2022-09-12,13:40:56,CEDFD5,Biogen Inc.,100,-0.44,price-targets,downgrade,Biogen Price Target Cut to $223.00/Share From $230.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $223.00/Share From $230.00 by Stifel
BIIB,2022-09-13,13:30:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Biogen is also being sued by Humana Inc. for,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm
BIIB,2022-09-13,13:30:05,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen resolved similar claims with,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm
BIIB,2022-09-22,07:59:31,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The Food and Drug Administration's approval of Aduhelm in June 2021,FULL-ARTICLE,Dow Jones Newswires,Can We Beat Alzheimer's? Biogen's Latest Drug Trial Will Offer Clues. -- Barrons.com
BIIB,2022-09-22,11:44:48,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2022-09-22,11:44:48,CEDFD5,Biogen Inc.,100,-0.36,price-targets,downgrade,Biogen Price Target Cut to $265.00/Share From $270.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $265.00/Share From $270.00 by Truist Securities
BIIB,2022-09-26,21:23:17,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen Inc. Agrees to Pay $900M in Settlement,HOT-NEWS-FLASH,Dow Jones Newswires,DOJ: Biogen Inc. Agrees to Pay $900M in Settlement Realted to Alleged Kickbacks
BIIB,2022-09-26,21:24:29,CEDFD5,Biogen Inc.,100,0.46,legal,,Doj: Biogen Settlement,HOT-NEWS-FLASH,Dow Jones Newswires,DOJ: Biogen Settlement Related to Alleged Submission of False Claims to Medicare and Medicaid
BIIB,2022-09-26,21:59:45,CEDFD5,Biogen Inc.,95,0.46,legal,,Biogen Inc. agreed to pay $900 million to resolve allegations,FULL-ARTICLE,Dow Jones Newswires,DOJ Says Biogen in Settlement; Agreement-in-Principle Previously Disclosed
BIIB,2022-09-26,22:14:45,CEDFD5,Biogen Inc.,95,0.46,legal,,Biogen Inc. agreed to pay $900 million to resolve allegations,FULL-ARTICLE,Dow Jones Newswires,DOJ Says Biogen in Settlement; Agreement-in-Principle Previously Disclosed
BIIB,2022-09-26,22:37:35,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen Inc. agreed to pay $900 million to settle allegations,FULL-ARTICLE,Dow Jones Newswires,Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments -- WSJ
BIIB,2022-09-26,22:45:59,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen Inc. agreed to pay $900 million to settle allegations,FULL-ARTICLE,Dow Jones Newswires,Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments -- update -- WSJ
BIIB,2022-09-26,23:19:20,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen Inc. agreed to pay $900 million to settle allegations,FULL-ARTICLE,Dow Jones Newswires,Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments -- 2nd Update
BIIB,2022-09-26,23:19:20,CEDFD5,Biogen Inc.,99,0.72,revenues,up,Biogen Inc.: The company had hoped to bolster sales,FULL-ARTICLE,Dow Jones Newswires,Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments -- 2nd Update
BIIB,2022-09-27,06:08:23,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen Inc. agreed to pay $900 million to settle allegations,FULL-ARTICLE,Dow Jones Newswires,Biogen  Settles  Kickback  Probe  ----  By Joseph Walker
BIIB,2022-09-27,06:08:23,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Inc.: The company had hoped to bolster sales,FULL-ARTICLE,Dow Jones Newswires,Biogen  Settles  Kickback  Probe  ----  By Joseph Walker
BIIB,2022-09-27,06:32:06,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen Inc. agreed to pay $900 million to settle allegations,FULL-ARTICLE,Wall Street Journal,Biogen Settles Kickback Probe -- WSJ
BIIB,2022-09-27,06:32:06,CEDFD5,Biogen Inc.,99,0.72,revenues,up,Biogen Inc.: The company had hoped to bolster sales,FULL-ARTICLE,Wall Street Journal,Biogen Settles Kickback Probe -- WSJ
BIIB,2022-09-27,09:22:08,CEDFD5,Biogen Inc.,96,0.46,legal,,Biogen agreed to pay $900 million to settle allegations,FULL-ARTICLE,Dow Jones Newswires,Biogen Kickbacks Settlement Could Place Focus on Business-Ethics Profile -- ESG Insight
BIIB,2022-09-27,23:25:08,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2022-09-28,00:04:46,CEDFD5,Biogen Inc.,91,0.57,products-services,granted,"Aduhelm, got approval from the Food and Drug Administration",FULL-ARTICLE,Dow Jones Newswires,Pharmaceutical Makers Eisai and Biogen Claim Success in Latest Alzheimer's Drug Trial -- Barrons.com
BIIB,2022-09-28,06:45:19,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Mizuho lifts Biogen to buy,FULL-ARTICLE,MarketWatch,MW Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug success
BIIB,2022-09-28,08:20:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2022-09-28,09:05:12,CEDFD5,Biogen Inc.,100,0.0,stock-picks,,"Stocks to Watch: Biogen, Apple",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: Biogen, Apple, Alcoa -- WSJ"
BIIB,2022-09-28,09:39:28,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Neutral by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Neutral by Mizuho
BIIB,2022-09-28,09:39:28,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $270.00/Share From $207.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $270.00/Share From $207.00 by Mizuho
BIIB,2022-09-28,10:33:28,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Outperform From Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Market Perform by BMO Capital
BIIB,2022-09-28,10:33:28,CEDFD5,Biogen Inc.,100,0.88,price-targets,upgrade,Biogen Price Target Raised to $360.00/Share From $217.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $360.00/Share From $217.00 by BMO Capital
BIIB,2022-09-28,10:34:48,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Outperform From Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Neutral by Baird
BIIB,2022-09-28,10:34:48,CEDFD5,Biogen Inc.,100,0.84,price-targets,upgrade,Biogen Price Target Raised to $340.00/Share From $224.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $340.00/Share From $224.00 by Baird
BIIB,2022-09-28,10:44:08,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Piper Sandler
BIIB,2022-09-28,10:44:08,CEDFD5,Biogen Inc.,100,0.82,price-targets,upgrade,Biogen Price Target Raised to $280.00/Share From $200.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $280.00/Share From $200.00 by Piper Sandler
BIIB,2022-09-28,11:11:25,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen stock price target raised to $217 from $183 at Wedbush,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $217 from $183 at Wedbush
BIIB,2022-09-28,11:11:40,CEDFD5,Biogen Inc.,93,0.94,analyst-ratings,positive,Mizuho's Salim Syed upgrades Biogen to buy from neutral,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Update Wins Back Wall Street Fans -- Market Talk
BIIB,2022-09-28,11:11:40,CEDFD5,Biogen Inc.,93,0.57,products-services,granted,Last June after the FDA approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Update Wins Back Wall Street Fans -- Market Talk
BIIB,2022-09-28,11:11:40,CEDFD5,Biogen Inc.,96,0.94,analyst-ratings,positive,Mizuho's Salim Syed upgrades Biogen to buy from neutral,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Update Wins Back Wall Street Fans -- Market Talk
BIIB,2022-09-28,11:11:40,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Last June after the FDA approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Update Wins Back Wall Street Fans -- Market Talk
BIIB,2022-09-28,11:27:09,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Mizuho lifts Biogen to buy,FULL-ARTICLE,MarketWatch,MW Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug success as shares soar
BIIB,2022-09-28,11:54:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2022-09-28,11:54:29,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $321.00/Share From $251.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $321.00/Share From $251.00 by RBC Capital
BIIB,2022-09-28,12:32:49,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Wells Fargo
BIIB,2022-09-28,12:32:49,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $265.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $265.00 by Wells Fargo
BIIB,2022-09-28,14:03:49,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2022-09-28,14:03:49,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $217.00/Share From $183.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $217.00/Share From $183.00 by Wedbush
BIIB,2022-09-28,14:10:24,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen upgraded to outperform at BMO Capital,NEWS-FLASH,MarketWatch,MW Biogen upgraded to outperform at BMO Capital
BIIB,2022-09-28,14:41:27,CEDFD5,Biogen Inc.,96,-0.52,products-services,,Biogen halted the development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW Medicare coverage of Eisai and Biogen's promising new Alzheimer's therapy is 'another bridge to cross'
BIIB,2022-09-28,14:41:27,CEDFD5,Biogen Inc.,96,0.94,analyst-ratings,positive,Mizuho Securities upgraded Biogen's stock to buy from neutral,FULL-ARTICLE,MarketWatch,MW Medicare coverage of Eisai and Biogen's promising new Alzheimer's therapy is 'another bridge to cross'
BIIB,2022-09-28,15:11:48,CEDFD5,Biogen Inc.,96,-0.52,products-services,,Biogen halted the development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW Getting Medicare to cover Eisai and Biogen's promising new Alzheimer's therapy is 'another bridge to cross'
BIIB,2022-09-28,15:11:48,CEDFD5,Biogen Inc.,96,0.94,analyst-ratings,positive,Mizuho Securities upgraded Biogen's stock to buy from neutral,FULL-ARTICLE,MarketWatch,MW Getting Medicare to cover Eisai and Biogen's promising new Alzheimer's therapy is 'another bridge to cross'
BIIB,2022-09-28,18:16:17,CEDFD5,Biogen Inc.,96,-0.52,products-services,,Biogen halted the development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?
BIIB,2022-09-28,18:16:17,CEDFD5,Biogen Inc.,96,0.94,analyst-ratings,positive,Mizuho Securities upgraded Biogen's stock to buy from neutral,FULL-ARTICLE,MarketWatch,MW Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?
BIIB,2022-09-29,06:04:03,CEDFD5,Biogen Inc.,96,0.71,products-services,,The Food and Drug Administration will grant Biogen accelerated approval,FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street:  Alzheimer's Drug Raises Hopes, Costs  ---  Results of Biogen's treatment breathe new life into anti-amyloid drugs that were partially written off  ----  By David Wainer"
BIIB,2022-09-29,06:04:03,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,"Aduhelm, received the FDA nod",FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street:  Alzheimer's Drug Raises Hopes, Costs  ---  Results of Biogen's treatment breathe new life into anti-amyloid drugs that were partially written off  ----  By David Wainer"
BIIB,2022-09-29,06:04:03,CEDFD5,Biogen Inc.,96,0.0,products-services,,"Aduhelm launch at $56,000 a year",FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street:  Alzheimer's Drug Raises Hopes, Costs  ---  Results of Biogen's treatment breathe new life into anti-amyloid drugs that were partially written off  ----  By David Wainer"
BIIB,2022-09-29,12:40:03,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen stock price target raised to $300 from $230 at Oppenheimer,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $300 from $230 at Oppenheimer
BIIB,2022-09-29,12:49:49,CEDFD5,Biogen Inc.,96,-0.52,products-services,,Biogen halted the development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?
BIIB,2022-09-29,12:49:49,CEDFD5,Biogen Inc.,96,0.94,analyst-ratings,positive,Mizuho Securities upgraded Biogen's stock to buy from neutral,FULL-ARTICLE,MarketWatch,MW Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?
BIIB,2022-09-30,10:13:36,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen stock price target raised to $275 from $221 at J.P. Morgan,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $275 from $221 at J.P. Morgan
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The Phase 3 data from the comparative clinical trial,PRESS-RELEASE,GlobeNewswire,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,GlobeNewswire,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The Phase 3 data from the comparative clinical trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The Phase 3 data from the comparative clinical trial,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",FULL-ARTICLE,Dow Jones Newswires,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:04,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The Phase 3 data from the comparative clinical trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:04,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:27:29,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by JP Morgan
BIIB,2022-09-30,11:27:29,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $275.00/Share From $221.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $275.00/Share From $221.00 by JP Morgan
BIIB,2022-10-03,12:02:16,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Denali Therapeutics, Biogen Initiate Phase 3 Study of BIIB122",NEWS-FLASH,Dow Jones Newswires,"Denali Therapeutics, Biogen Initiate Phase 3 Study of BIIB122 in a Type of Parkinson's Disease >DNLI"
BIIB,2022-10-06,13:09:40,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by UBS
BIIB,2022-10-06,13:09:40,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $309.00/Share From $238.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $309.00/Share From $238.00 by UBS
BIIB,2022-10-06,13:31:26,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen stock price target raised to $309 from $238 at UBS,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $309 from $238 at UBS
BIIB,2022-10-07,11:02:25,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-10-07,11:02:25,CEDFD5,Biogen Inc.,100,0.82,price-targets,upgrade,Biogen Price Target Raised to $275.00/Share From $200.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $275.00/Share From $200.00 by Barclays
BIIB,2022-10-07,12:42:25,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Hold by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Hold by Argus Research
BIIB,2022-10-13,09:52:05,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Hold by Stifel
BIIB,2022-10-13,09:52:05,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $299.00/Share by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $299.00/Share by Stifel
BIIB,2022-10-13,10:43:17,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen upgraded to buy from hold at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Biogen upgraded to buy from hold at Stifel Nicolaus
BIIB,2022-10-13,12:16:06,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-10-13,12:16:06,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $321.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $321.00/Share From $285.00 by Morgan Stanley
BIIB,2022-10-13,13:00:06,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Goodrx and Biogen Collaborate to Help,PRESS-RELEASE,Business Wire,GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY(R)
BIIB,2022-10-13,13:00:06,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Goodrx and Biogen Collaborate to Help,PRESS-RELEASE,Business Wire,GoodRx and Biogen Collaborate to Help Enhance -2-
BIIB,2022-10-13,13:00:36,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Goodrx and Biogen Collaborate to Help,NEWS-FLASH,Dow Jones Newswires,GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY
BIIB,2022-10-13,13:06:41,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Goodrx and Biogen Collaborate to Help,PRESS-RELEASE,Dow Jones Newswires,Press Release: GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY(R)
BIIB,2022-10-13,13:06:41,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Goodrx and Biogen Collaborate to,PRESS-RELEASE,Dow Jones Newswires,Press Release: GoodRx and Biogen Collaborate to -2-
BIIB,2022-10-13,13:30:02,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm
BIIB,2022-10-17,11:49:05,CEDFD5,Biogen Inc.,95,0.65,products-services,,Fda granted priority review to Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen: FDA Extends Review of Tofersen in Rare Form of ALS >BIIB
BIIB,2022-10-17,12:04:05,CEDFD5,Biogen Inc.,94,0.65,products-services,,Fda granted priority review to Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen: FDA Extends Review of Tofersen in Rare Form of ALS
BIIB,2022-10-21,07:52:24,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 3Q 2022 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 3Q 2022 (BIIB)"
BIIB,2022-10-24,14:20:33,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Jefferies
BIIB,2022-10-24,14:20:33,CEDFD5,Biogen Inc.,100,0.72,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $300.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $300.00 by Jefferies
BIIB,2022-10-25,11:09:09,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,3Q EPS $7.84 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q EPS $7.84 >BIIB
BIIB,2022-10-25,11:09:09,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $4.77,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $4.77 >BIIB
BIIB,2022-10-25,11:09:09,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Net $1.13B,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Net $1.13B >BIIB
BIIB,2022-10-25,11:09:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.51B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.51B >BIIB
BIIB,2022-10-25,11:15:07,CEDFD5,Biogen Inc.,100,0.86,earnings,up,Biogen Q3 EPS $7.84 vs. $2.22 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q3 EPS $7.84 vs. $2.22 a year ago
BIIB,2022-10-25,11:15:27,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q3 adj. EPS $4.77; FactSet consensus $4.13,NEWS-FLASH,MarketWatch,MW Biogen Q3 adj. EPS $4.77; FactSet consensus $4.13
BIIB,2022-10-25,11:16:52,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q3 revenue $2.51 bln vs. $2.78 bln a year ago; FactSet consensus $2.47 bln,NEWS-FLASH,MarketWatch,MW Biogen Q3 revenue $2.51 bln vs. $2.78 bln a year ago; FactSet consensus $2.47 bln
BIIB,2022-10-25,11:17:27,CEDFD5,Biogen Inc.,100,0.46,earnings,up,Biogen raised 2022 adj. EPS outlook to $16.50-$17.15 from $15.25-$16.75,NEWS-FLASH,MarketWatch,MW Biogen raised 2022 adj. EPS outlook to $16.50-$17.15 from $15.25-$16.75
BIIB,2022-10-25,11:17:58,CEDFD5,Biogen Inc.,100,0.48,revenues,up,Biogen raised 2022 revenue outlook to $10.0 bln-$10.15 bln from $9.9 bln-$10.1 bln,NEWS-FLASH,MarketWatch,MW Biogen raised 2022 revenue outlook to $10.0 bln-$10.15 bln from $9.9 bln-$10.1 bln
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,0.72,revenues,above-expectations,Biogen beats revenue expectations in the third quarter,FULL-ARTICLE,MarketWatch,MW Biogen beats revenue expectations in the third quarter
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen said revenue was $2.5 billion for the quarter,FULL-ARTICLE,MarketWatch,MW Biogen beats revenue expectations in the third quarter
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Tecfidera revenue fell,FULL-ARTICLE,MarketWatch,MW Biogen beats revenue expectations in the third quarter
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,0.72,revenues,above-expectations,Biogen Beats Revenue Expectations In The Third Quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Beats Revenue Expectations In The Third Quarter -- MarketWatch
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen said revenue was $2.5 billion for the quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Beats Revenue Expectations In The Third Quarter -- MarketWatch
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Tecfidera revenue fell,FULL-ARTICLE,Dow Jones Newswires,Biogen Beats Revenue Expectations In The Third Quarter -- MarketWatch
BIIB,2022-10-25,12:40:04,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Lifts Profit Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. Stock Rises. -- Barrons.com
BIIB,2022-10-25,12:40:04,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) last month said the Phase 3 trial of lecanemab,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. Stock Rises. -- Barrons.com
BIIB,2022-10-25,12:40:04,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported its third-quarter adjusted profits of $4.77 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. Stock Rises. -- Barrons.com
BIIB,2022-10-25,12:40:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen said full-year adjusted earnings,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. Stock Rises. -- Barrons.com
BIIB,2022-10-25,12:50:04,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Lifts Profit Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. The Stock Rises.
BIIB,2022-10-25,12:50:04,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) last month said the Phase 3 trial of lecanemab,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. The Stock Rises.
BIIB,2022-10-25,12:50:04,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported its third-quarter adjusted profits of $4.77 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. The Stock Rises.
BIIB,2022-10-25,12:50:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen said full-year adjusted earnings,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. The Stock Rises.
BIIB,2022-10-26,08:52:52,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2022-10-26,08:52:52,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $310.00/Share From $270.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $310.00/Share From $270.00 by SVB Leerink
BIIB,2022-10-26,08:54:22,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Atlantic Equities
BIIB,2022-10-26,08:54:22,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $220.00/Share From $200.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $220.00/Share From $200.00 by Atlantic Equities
BIIB,2022-10-26,10:02:00,CEDFD5,Biogen Inc.,98,0.0,products-services,,Biogen Inc.: In the first interim analysis,PRESS-RELEASE,GlobeNewswire,New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:00,CEDFD5,Biogen Inc.,98,0.4,products-services,start,Biogen Inc.: ARISE enrolled 87 patients,PRESS-RELEASE,GlobeNewswire,New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Combined post-marketing data based on prescriptions and clinical trials,PRESS-RELEASE,GlobeNewswire,New Data at ECTRIMS 2022 Highlight Biogen's -4-
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,98,0.0,products-services,,Biogen Inc.: In the first interim analysis,PRESS-RELEASE,DJ Global Press Release Wire,New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,98,0.4,products-services,start,Biogen Inc.: ARISE enrolled 87 patients,PRESS-RELEASE,DJ Global Press Release Wire,New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,90,0.57,products-services,granted,Tysabri is approved in the U.S.,FULL-ARTICLE,Dow Jones Newswires,New Data at ECTRIMS 2022 Highlight Biogen's -2-
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Combined post-marketing data based on prescriptions and clinical trials,PRESS-RELEASE,DJ Global Press Release Wire,New Data at ECTRIMS 2022 Highlight Biogen's -4-
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,98,0.0,products-services,,Biogen Inc.: In the first interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,98,0.4,products-services,start,Biogen Inc.: ARISE enrolled 87 patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:03,CEDFD5,Biogen Inc.,98,0.0,products-services,,Biogen Inc.: In the first interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:03,CEDFD5,Biogen Inc.,98,0.4,products-services,start,Biogen Inc.: ARISE enrolled 87 patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:05:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen's collaboration with TheraPanacea, which aims to develop computer",PRESS-RELEASE,GlobeNewswire,Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
BIIB,2022-10-26,10:05:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen's collaboration with TheraPanacea, which aims to develop computer",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
BIIB,2022-10-26,10:05:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen's collaboration with TheraPanacea, which aims to develop computer",FULL-ARTICLE,Dow Jones Newswires,Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
BIIB,2022-10-26,10:05:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen's collaboration with TheraPanacea, which aims to develop computer",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
BIIB,2022-10-26,10:16:03,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2022-10-26,10:16:03,CEDFD5,Biogen Inc.,100,0.82,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $240.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $240.00 by HC Wainwright & Co.
BIIB,2022-10-26,12:25:53,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2022-10-26,12:25:53,CEDFD5,Biogen Inc.,100,0.66,price-targets,upgrade,Biogen Price Target Raised to $331.00/Share From $310.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $331.00/Share From $310.00 by RBC Capital
BIIB,2022-10-26,14:01:03,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Neutral by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Neutral by Goldman Sachs
BIIB,2022-10-26,14:01:03,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $370.00/Share by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $370.00/Share by Goldman Sachs
BIIB,2022-10-26,14:06:53,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-10-26,14:06:53,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $321.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $321.00 by Morgan Stanley
BIIB,2022-10-28,17:52:02,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Vp Alexander Registers 5,532 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"VP Alexander Registers 5,532 Of Biogen Inc >BIIB"
BIIB,2022-10-28,19:29:20,CEDFD5,Biogen Inc.,95,0.0,products-services,,Eisai is developing the drug with partner Biogen Inc.,FULL-ARTICLE,Dow Jones Newswires,Volunteer Dies Testing Eisai-Biogen Alzheimer's Drug During Study -- WSJ
BIIB,2022-10-28,23:20:20,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Alexander Sells 5,532 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Alexander Sells 5,532 Of Biogen Inc >BIIB"
BIIB,2022-11-01,11:07:55,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Mizuho
BIIB,2022-11-01,11:07:55,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $270.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $270.00 by Mizuho
BIIB,2022-11-01,12:23:30,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen stock price target raised to $325 from $270 at Mizuho,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $325 from $270 at Mizuho
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:02,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,GlobeNewswire,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:02,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,GlobeNewswire,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:05,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:05,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher Pres and CEO,NEWS-FLASH,Dow Jones Newswires,Biogen Names Christopher Viehbacher Pres and CEO
BIIB,2022-11-10,12:30:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher Pres and CEO,NEWS-FLASH,Dow Jones Newswires,Biogen Names Christopher Viehbacher Pres and CEO
BIIB,2022-11-10,12:58:30,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Former Sanofi Chief Christopher Viehbacher President,FULL-ARTICLE,Dow Jones Newswires,"Biogen Names Former Sanofi Chief Christopher Viehbacher President, CEO >BIIB"
BIIB,2022-11-10,13:08:28,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen names former Sanofi chief as new CEO,FULL-ARTICLE,MarketWatch,"MW Biogen names former Sanofi chief as new CEO, shares rise"
BIIB,2022-11-10,13:08:28,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Former Sanofi Chief As New CEO,FULL-ARTICLE,Dow Jones Newswires,"Biogen Names Former Sanofi Chief As New CEO, Shares Rise -- MarketWatch"
BIIB,2022-11-10,14:34:40,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher New CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher New CEO -- WSJ
BIIB,2022-11-10,14:40:03,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Viehbacher New CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Viehbacher New CEO
BIIB,2022-11-10,15:19:59,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher New CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher New CEO -- Update
BIIB,2022-11-10,16:06:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher New CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher New CEO -- 2nd Update
BIIB,2022-11-10,16:34:46,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm that could receive accelerated approval from the Food and Drug Administration,FULL-ARTICLE,Dow Jones Newswires,Biogen's Surprise CEO Pick Raises Questions About Post-Aduhelm Path -- Barrons.com
BIIB,2022-11-10,16:34:46,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm in June 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen's Surprise CEO Pick Raises Questions About Post-Aduhelm Path -- Barrons.com
BIIB,2022-11-10,16:34:46,CEDFD5,Biogen Inc.,99,0.47,labor-issues,,Over appointments to Biogen's board,FULL-ARTICLE,Dow Jones Newswires,Biogen's Surprise CEO Pick Raises Questions About Post-Aduhelm Path -- Barrons.com
BIIB,2022-11-10,17:35:59,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher New CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher New CEO -- 3rd Update
BIIB,2022-11-10,17:35:59,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen halted two Phase 3 studies of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher New CEO -- 3rd Update
BIIB,2022-11-11,07:05:12,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Ex-Sanofi Chief as CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Ex-Sanofi Chief as CEO  ----  By Joseph Walker and Colin Kellaher
BIIB,2022-11-11,07:05:12,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen halted two Phase 3 studies of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Ex-Sanofi Chief as CEO  ----  By Joseph Walker and Colin Kellaher
BIIB,2022-11-11,07:32:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher New CEO,FULL-ARTICLE,Wall Street Journal,Biogen Names Christopher Viehbacher New CEO -- WSJ
BIIB,2022-11-11,07:32:08,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen halted two Phase 3 studies of Aduhelm,FULL-ARTICLE,Wall Street Journal,Biogen Names Christopher Viehbacher New CEO -- WSJ
BIIB,2022-11-11,12:02:11,CEDFD5,Biogen Inc.,100,0.36,price-targets,upgrade,Biogen price target raised to $270 from $265 at Guggenheim,NEWS-FLASH,MarketWatch,MW Biogen price target raised to $270 from $265 at Guggenheim
BIIB,2022-11-11,13:59:19,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Guggenheim
BIIB,2022-11-11,13:59:19,CEDFD5,Biogen Inc.,100,0.36,price-targets,upgrade,Biogen Price Target Raised to $270.00/Share From $265.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $270.00/Share From $265.00 by Guggenheim
BIIB,2022-11-14,13:16:45,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2022-11-14,13:16:45,CEDFD5,Biogen Inc.,100,0.58,price-targets,upgrade,Biogen Price Target Raised to $315.00/Share From $300.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $315.00/Share From $300.00 by Oppenheimer
BIIB,2022-11-15,12:28:10,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen stock price target raised to $350 from $265,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $350 from $265 at Truist
BIIB,2022-11-15,14:40:06,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2022-11-15,14:40:06,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $265.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $265.00 by Truist Securities
BIIB,2022-11-15,21:22:21,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Vp Gregory Registers 5,610 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"VP Gregory Registers 5,610 Of Biogen Inc >BIIB"
BIIB,2022-11-16,07:04:02,CEDFD5,Biogen Inc.,99,0.53,labor-issues,,Biogen Inc.: the company hired former Sanofi CEO Chris Viehbacher,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street:  Alzheimer's Drug's Potential Buoys Biogen  ----  By David Wainer
BIIB,2022-11-23,19:45:20,CEDFD5,Biogen Inc.,99,0.84,products-services,positive,Biogen Inc.: the company announced positive clinical trial results for their Alzheimer's drug lecanemab,PRESS-RELEASE,DGAP News,EQS-News: CBOE's Weekly Market Recap: Nov.14-18 - Biogen's Alzheimer's Drug Captures Investors' Attention
BIIB,2022-11-23,19:45:20,CEDFD5,Biogen Inc.,99,0.84,products-services,positive,Biogen Inc.: the company announced positive clinical trial results for their Alzheimer's drug lecanemab,PRESS-RELEASE,Dow Jones Newswires,EQS-News: CBOE's Weekly Market Recap: Nov.14-18 - Biogen's Alzheimer's Drug Captures Investors' Attention
BIIB,2022-11-30,00:45:01,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2022-11-30,00:50:00,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Release New Details From Lecanemab,NEWS-FLASH,Dow Jones Newswires,Eisai and Biogen Release New Details From Lecanemab Alzheimer's Study -- WSJ
BIIB,2022-11-30,09:20:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2022-11-30,11:35:08,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-11-30,11:35:08,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $313.00/Share From $275.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $313.00/Share From $275.00 by Barclays
BIIB,2022-11-30,11:48:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Stifel analyst Paul Matteis reiterated his buy rating on Biogen,FULL-ARTICLE,MarketWatch,MW Biogen stock up 3% premarket after update on Alzheimer's treatment; Stifel reiterates buy rating
BIIB,2022-11-30,11:48:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Stifel analyst Paul Matteis reiterated his buy rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Up 3% Premarket After Update On Alzheimer's Treatment; Stifel Reiterates Buy Rating -- MarketWatch
BIIB,2022-11-30,14:44:59,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2022-11-30,14:44:59,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $247.00/Share From $218.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $247.00/Share From $218.00 by Wedbush
BIIB,2022-11-30,15:04:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Jefferies
BIIB,2022-11-30,15:04:29,CEDFD5,Biogen Inc.,100,0.68,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $325.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $325.00 by Jefferies
BIIB,2022-12-01,10:09:53,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Atlantic Equities
BIIB,2022-12-01,10:09:53,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $295.00/Share From $220.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $295.00/Share From $220.00 by Atlantic Equities
BIIB,2022-12-05,12:55:53,CEDFD5,Biogen Inc.,95,0.65,products-services,,The U.S. Food and Drug Administration granted priority review to tofersen,FULL-ARTICLE,Dow Jones Newswires,Biogen: EMA to Review Tofersen in Rare Form of ALS >BIIB
BIIB,2022-12-06,23:34:58,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 92 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 92 Of Biogen Inc >BIIB
BIIB,2022-12-06,23:39:13,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 951 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 951 Of Biogen Inc >BIIB
BIIB,2022-12-07,15:26:59,CEDFD5,Biogen Inc.,95,0.46,legal,,Biogen has agreed to pay $900 million to settle,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholder Alert: Grabar Law Office Investigates Claims on Behalf of Shareholders of Biogen, Inc. (BIIB) After It Agrees to Pay $900 Million for Improper Kickbacks"
BIIB,2022-12-09,12:30:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB800 clinical program,PRESS-RELEASE,DJ Global Press Release Wire,"FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA(R) (tocilizumab)"
BIIB,2022-12-09,12:30:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB800 clinical program,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA(R) (tocilizumab)"
BIIB,2022-12-09,12:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB800 clinical program,PRESS-RELEASE,GlobeNewswire,"FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA(R) (tocilizumab)"
BIIB,2022-12-09,12:30:04,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB800 clinical program,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA(R) (tocilizumab)"
BIIB,2022-12-09,19:34:21,CEDFD5,Biogen Inc.,95,0.0,products-services,,Biogen previously reported data from a Phase 3 trial,FULL-ARTICLE,Dow Jones Newswires,Trending: Biogen Application for Actemra Biosimilar Accepted for Review
BIIB,2022-12-09,19:49:21,CEDFD5,Biogen Inc.,95,0.0,products-services,,Biogen previously reported data from a Phase 3 trial,FULL-ARTICLE,Dow Jones Newswires,Trending: Biogen Application for Actemra Biosimilar Accepted for Review
BIIB,2022-12-12,14:00:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Frontage Partners with Eisai and Biogen to,PRESS-RELEASE,PR Newswire,"Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer's Drug, Lecanemab"
BIIB,2022-12-12,14:00:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Frontage Partners with Eisai and Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer's Drug, Lecanemab"
BIIB,2022-12-12,14:04:38,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Frontage Partners With Eisai , Biogen to",NEWS-FLASH,Dow Jones Newswires,"Frontage Partners With Eisai , Biogen to Complete the Clarity AD Study for Alzheimer's Drug Lecanemab"
BIIB,2022-12-12,23:06:48,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 194 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 194 Of Biogen Inc >BIIB
BIIB,2022-12-13,01:03:49,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Gregory Sells 5,610 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Sells 5,610 Of Biogen Inc >BIIB"
BIIB,2022-12-19,12:30:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Genentech,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-19,12:30:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Genentech,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-19,12:30:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Genentech,FULL-ARTICLE,Dow Jones Newswires,Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-19,12:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Genentech,PRESS-RELEASE,GlobeNewswire,Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-19,12:30:04,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Genentech,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-19,12:30:33,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement With Genentech,NEWS-FLASH,Dow Jones Newswires,Biogen Reaches Agreement With Genentech to Receive Royalties on Potential Commercialization of Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-29,18:00:18,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Inappropriately"" collaborated with Biogen Inc. before",FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug -- WSJ
BIIB,2022-12-29,18:00:18,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen later slashed its price in half,FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug -- WSJ
BIIB,2022-12-29,18:04:03,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Inappropriately"" collaborated with Biogen Inc. before",FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug -- Update
BIIB,2022-12-29,18:04:03,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen later slashed its price in half,FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug -- Update
BIIB,2022-12-29,18:10:11,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Inappropriately"" collaborated with Biogen Inc. before",FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug
BIIB,2022-12-29,18:10:11,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen later slashed its price in half,FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug
BIIB,2022-01-04,12:30:06,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,PR Newswire,Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:30:06,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,PR Newswire,Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:30:06,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:30:06,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:34:32,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,GlobeNewswire,Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:34:32,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,FULL-ARTICLE,Dow Jones Newswires,Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Productive collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and CommercializeInvestigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.41,products-services,start,Biogen plans to advance BIIB115 to clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,12:34:33,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our productive collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB,2022-01-04,20:30:09,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen launched Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimer's Drug"
BIIB,2022-01-04,20:30:09,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"June 7, 2021, the FDA approved Aduhelm",FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising -2-"
BIIB,2022-01-04,20:30:09,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen said it was lowering Aduhelm's price,FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising -2-"
BIIB,2022-01-04,20:40:04,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen launched Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimer's Drug"
BIIB,2022-01-04,20:40:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"June 7, 2021, the FDA approved Aduhelm",FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising -2-"
BIIB,2022-01-04,20:40:04,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen said it was lowering Aduhelm's price,FULL-ARTICLE,Dow Jones Newswires,"How Biogen Fumbled Aduhelm, Its Once-Promising -2-"
BIIB,2022-01-05,07:08:44,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen launched Aduhelm in June,FULL-ARTICLE,Dow Jones Newswires,How Biogen Fumbled  Its Alzheimer's Drug  ---  Once-promising Aduhelm is pricey and without proven efficacy  ----  By Joseph Walker and Susan Pulliam
BIIB,2022-01-05,07:08:54,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"June 7, 2021, the FDA approved Aduhelm",FULL-ARTICLE,Dow Jones Newswires,How Biogen Fumbled  Its Alzheimer's Drug  --- -2-
BIIB,2022-01-05,07:33:24,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen launched Aduhelm in June,FULL-ARTICLE,Wall Street Journal,How Biogen Fumbled Its Alzheimer's Drug -- WSJ
BIIB,2022-01-05,07:33:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"June 7, 2021, the FDA approved Aduhelm",FULL-ARTICLE,Wall Street Journal,How Biogen Fumbled Its Alzheimer's Drug -- WSJ -2-
BIIB,2022-01-05,07:33:24,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen said it was lowering Aduhelm's price,FULL-ARTICLE,Wall Street Journal,How Biogen Fumbled Its Alzheimer's Drug -- WSJ -2-
BIIB,2022-01-06,15:25:36,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-01-06,15:25:36,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $363.00/Share From $440.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $363.00/Share From $440.00 by Morgan Stanley
BIIB,2022-01-07,12:29:07,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen stock price target cut to $343 from $502,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $343 from $502 at Truist
BIIB,2022-01-11,11:58:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2022-01-11,11:58:29,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $328.00/Share From $386.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $328.00/Share From $386.00 by Needham
BIIB,2022-01-11,21:46:27,CEDFD5,Biogen Inc.,92,0.52,products-services,,Biogen initially launched the drug at,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug In Clinical-Trial Patients
BIIB,2022-01-11,21:50:04,CEDFD5,Biogen Inc.,92,0.52,products-services,,Biogen initially launched the drug at,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug In Clinical-Trial Patients
BIIB,2022-01-11,21:58:39,CEDFD5,Biogen Inc.,95,0.52,products-services,,Biogen initially launched the drug at,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- Update
BIIB,2022-01-11,21:58:39,CEDFD5,Biogen Inc.,95,0.57,products-services,granted,The FDA cleared Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- Update
BIIB,2022-01-11,22:35:26,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen prematurely halted its studies of the drug in 2019.,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 2nd Update
BIIB,2022-01-11,22:35:26,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen initially launched the drug at,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 2nd Update
BIIB,2022-01-11,22:35:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA cleared Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 2nd Update
BIIB,2022-01-12,00:04:27,CEDFD5,Biogen Inc.,99,-0.45,products-services,,Biogen prematurely halted its studies of the drug in 2019.,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 3rd Update
BIIB,2022-01-12,00:04:27,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen initially launched the drug at,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 3rd Update
BIIB,2022-01-12,00:04:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA cleared Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare to Pay for Biogen's New Alzheimer's Drug in Clinical-Trial Patients -- 3rd Update
BIIB,2022-01-12,10:42:55,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Neutral From Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Neutral From Overweight by Piper Sandler
BIIB,2022-01-12,10:42:55,CEDFD5,Biogen Inc.,100,-0.86,price-targets,downgrade,Biogen Price Target Cut to $216.00/Share From $362.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $216.00/Share From $362.00 by Piper Sandler
BIIB,2022-01-12,11:00:37,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen stock price target cut to $207 from $270 at Mizuho,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $207 from $270 at Mizuho
BIIB,2022-01-12,11:24:46,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2022-01-12,11:24:46,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $292.00/Share From $328.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $292.00/Share From $328.00 by Needham
BIIB,2022-01-12,12:32:02,CEDFD5,Biogen Inc.,97,-0.58,analyst-ratings,negative,Piper Sandler downgraded Biogen shares to neutral from overweight,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Fall Premarket on Medicaid Coverage Plans for Aduhelm
BIIB,2022-01-12,12:47:03,CEDFD5,Biogen Inc.,97,-0.58,analyst-ratings,negative,Piper Sandler downgraded Biogen shares to neutral from overweight,FULL-ARTICLE,Dow Jones Newswires,Biogen Shares Fall Premarket on Medicaid Coverage Plans for Aduhelm
BIIB,2022-01-12,13:51:46,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Mizuho
BIIB,2022-01-12,13:51:46,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $207.00/Share From $270.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $207.00/Share From $270.00 by Mizuho
BIIB,2022-01-12,14:08:56,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2022-01-12,14:08:56,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $195.00/Share From $249.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $195.00/Share From $249.00 by Wedbush
BIIB,2022-01-13,12:06:43,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Neutral From Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Neutral From Buy by Guggenheim
BIIB,2022-01-13,12:06:43,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $202.00/Share From $290.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $202.00/Share From $290.00 by Guggenheim
BIIB,2022-01-13,12:16:35,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen downgraded to neutral vs. buy,NEWS-FLASH,MarketWatch,MW Biogen downgraded to neutral vs. buy at Guggenheim
BIIB,2022-01-13,12:20:56,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen stock price target cut to $202 vs. $290,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $202 vs. $290 at Guggenheim
BIIB,2022-01-13,13:02:00,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Guggenheim downgrades Biogen to neutral from buy,FULL-ARTICLE,MarketWatch,MW Guggenheim downgrades Biogen to neutral from buy after U.S. proposes limiting access to Alzheimer's drug
BIIB,2022-01-13,13:02:01,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Guggenheim Downgrades Biogen To Neutral From Buy,FULL-ARTICLE,Dow Jones Newswires,Guggenheim Downgrades Biogen To Neutral From Buy After U.S. Proposes Limiting Access To Alzheimer's Drug -- MarketWatch
BIIB,2022-01-13,21:42:02,CEDFD5,Biogen Inc.,100,-0.54,credit-ratings,downgrade,S&P Cuts Biogen Inc. Rtg To BBB+ From A-,NEWS-FLASH,Dow Jones Newswires,S&P Cuts Biogen Inc. Rtg To BBB+ From A-; Outlk Stable
BIIB,2022-01-13,21:43:23,CEDFD5,Biogen Inc.,100,-0.54,credit-ratings,downgrade,S&PGR Downgrades Biogen To 'BBB+' From 'A-,NEWS-FLASH,Dow Jones Newswires,"S&PGR Downgrades Biogen To 'BBB+' From 'A-', Outlook Stable"
BIIB,2022-01-13,21:43:30,CEDFD5,Biogen Inc.,100,-0.54,credit-ratings,downgrade,S&PGR Downgrades Biogen To 'BBB+' From 'A-,PRESS-RELEASE,Dow Jones Newswires,"Press Release: S&PGR Downgrades Biogen To 'BBB+' From 'A-', Outlook Stable"
BIIB,2022-01-13,21:43:30,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Inc.: We project sales,PRESS-RELEASE,Dow Jones Newswires,"Press Release: S&PGR Downgrades Biogen To 'BBB+' From 'A-', Outlook Stable"
BIIB,2022-01-13,21:43:30,CEDFD5,Biogen Inc.,100,-0.11,products-services,,Spinraza have faced increasing competition,PRESS-RELEASE,Dow Jones Newswires,"Press Release: S&PGR Downgrades Biogen To 'BBB+' From 'A-', Outlook Stable"
BIIB,2022-01-13,21:43:40,CEDFD5,Biogen Inc.,100,-0.54,credit-ratings,downgrade,S&PGR Downgrades Biogen To 'BBB+,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Downgrades Biogen To 'BBB+' -2-
BIIB,2022-01-13,21:45:06,CEDFD5,Biogen Inc.,100,-0.54,credit-ratings,downgrade,S&PGR Downgrades Biogen to 'BBB+' From 'A-,NEWS-FLASH,Dow Jones Newswires,"S&PGR Downgrades Biogen to 'BBB+' From 'A-', Notes CMS Decision and Competitive Pressures for Key Products"
BIIB,2022-01-14,15:08:10,CEDFD5,Biogen Inc.,100,-0.47,credit-ratings,negative,Moody's Reviews Biogen's Baa1 Ratings For Downgrade,NEWS-FLASH,Dow Jones Newswires,Moody's Reviews Biogen's Baa1 Ratings For Downgrade
BIIB,2022-01-18,11:21:24,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2022-01-18,11:21:24,CEDFD5,Biogen Inc.,100,-0.86,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $452.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $452.00 by HC Wainwright & Co.
BIIB,2022-01-18,14:13:15,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-01-18,14:13:15,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $360.00/Share From $363.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $360.00/Share From $363.00 by Morgan Stanley
BIIB,2022-01-20,15:01:07,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-01-20,15:01:07,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $244.00/Share From $280.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $244.00/Share From $280.00 by Barclays
BIIB,2022-01-21,08:24:37,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2021 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2021 (BIIB)"
BIIB,2022-01-21,21:50:59,CEDFD5,Biogen Inc.,100,0.0,insider-trading,,Vp Alexander Gifts 523 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Gifts 523 Of Biogen Inc >BIIB
BIIB,2022-01-24,09:37:30,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2022-01-24,09:37:30,CEDFD5,Biogen Inc.,100,-0.7,price-targets,downgrade,Biogen Price Target Cut to $300.00/Share From $325.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $300.00/Share From $325.00 by SVB Leerink
BIIB,2022-01-27,23:50:14,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Samsung Biologics,PRESS-RELEASE,GlobeNewswire,Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
BIIB,2022-01-27,23:50:15,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Samsung Biologics,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
BIIB,2022-01-27,23:50:15,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
BIIB,2022-01-27,23:50:15,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Samsung Biologics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
BIIB,2022-01-27,23:50:15,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Samsung Biologics,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
BIIB,2022-01-27,23:51:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement With Samsung Biologics,HOT-NEWS-FLASH,Dow Jones Newswires,Biogen Reaches Agreement With Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for Up to $2.3 B
BIIB,2022-01-27,23:51:21,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement With Samsung Biologics,NEWS-FLASH,Dow Jones Newswires,Biogen Reaches Agreement With Samsung Biologics to Sell Equity Stake in Their Biosimilar JV for Up to $2.3 B
BIIB,2022-01-27,23:52:30,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,Biogen To Sell Stake in Samsung Bioepis Venture to Samsung Biologics,HOT-NEWS-FLASH,Dow Jones Newswires,Biogen To Sell Stake in Samsung Bioepis Venture to Samsung Biologics
BIIB,2022-01-28,00:07:39,CEDFD5,Biogen Inc.,100,0.18,acquisitions-mergers,,Samsung Biologics to Buy Biogen's Stake in JV,FULL-ARTICLE,Dow Jones Newswires,Samsung Biologics to Buy Biogen's Stake in JV
BIIB,2022-01-28,00:10:03,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire full ownership of Samsung Bioepis,PRESS-RELEASE,PR Newswire,Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis
BIIB,2022-01-28,00:10:04,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire full ownership of Samsung Bioepis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis
BIIB,2022-01-28,00:20:04,CEDFD5,Biogen Inc.,100,0.18,acquisitions-mergers,,Samsung Biologics to Buy Biogen's Stake in JV,FULL-ARTICLE,Dow Jones Newswires,Samsung Biologics to Buy Biogen's Stake in JV
BIIB,2022-01-28,00:22:39,CEDFD5,Biogen Inc.,100,0.18,acquisitions-mergers,,Samsung Biologics to Buy Biogen's Stake in JV,FULL-ARTICLE,Dow Jones Newswires,Samsung Biologics to Buy Biogen's Stake in JV
BIIB,2022-01-28,01:40:04,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics
BIIB,2022-01-28,10:35:45,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,Biogen Sells Stake in Biosimilars Venture to Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,Biogen Sells Stake in Biosimilars Venture to Samsung Biologics for $2.3 Billion -- Barrons.com
BIIB,2022-01-28,10:35:45,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,interest,Was in talks to acquire drugmaker Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Sells Stake in Biosimilars Venture to Samsung Biologics for $2.3 Billion -- Barrons.com
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,Will retire from Biogen's Board of Directors,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,Will retire from Biogen's Board of Directors,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: Board and our leadership team as,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,Will retire from Biogen's Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: Board and our leadership team as,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,Will retire from Biogen's Board of Directors,PRESS-RELEASE,GlobeNewswire,Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: Board and our leadership team as,PRESS-RELEASE,GlobeNewswire,Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,Will retire from Biogen's Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: Board and our leadership team as,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
BIIB,2022-01-31,12:30:33,CEDFD5,Biogen Inc.,100,-0.43,labor-issues,,"Biogen: Nancy Leaming, Brian Posner to Retire From Board",NEWS-FLASH,Dow Jones Newswires,"Biogen: Nancy Leaming, Brian Posner to Retire From Board"
BIIB,2022-01-31,12:58:36,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,Biogen Directors Retiring From Board,FULL-ARTICLE,Dow Jones Newswires,Two Longtime Biogen Directors Retiring From Board -- Market Talk
BIIB,2022-01-31,12:58:36,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,"Biogen's chairman, also joined the board",FULL-ARTICLE,Dow Jones Newswires,Two Longtime Biogen Directors Retiring From Board -- Market Talk
BIIB,2022-01-31,12:58:36,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,Biogen Directors Retiring From Board,FULL-ARTICLE,Dow Jones Newswires,Two Longtime Biogen Directors Retiring From Board -- Market Talk
BIIB,2022-01-31,12:58:36,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,"Biogen's chairman, also joined the board",FULL-ARTICLE,Dow Jones Newswires,Two Longtime Biogen Directors Retiring From Board -- Market Talk
BIIB,2022-02-01,12:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody in development,PRESS-RELEASE,GlobeNewswire,Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
BIIB,2022-02-01,12:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody in development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
BIIB,2022-02-01,12:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody in development,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
BIIB,2022-02-01,12:30:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody in development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
BIIB,2022-02-01,13:53:27,CEDFD5,Biogen Inc.,93,0.49,partnerships,,Biogen expands its long-time collaboration with Roche,FULL-ARTICLE,Dow Jones Newswires,Biogen Opts in on Genentech Non-Hodgkin's Lymphoma Candidate -- Market Talk
BIIB,2022-02-01,13:53:28,CEDFD5,Biogen Inc.,93,0.49,partnerships,,Biogen expands its long-time collaboration with Roche,FULL-ARTICLE,Dow Jones Newswires,Biogen Opts in on Genentech Non-Hodgkin's Lymphoma Candidate -- Market Talk
BIIB,2022-02-03,12:04:08,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $2.50 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q EPS $2.50 >BIIB
BIIB,2022-02-03,12:04:08,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Adj EPS $3.39,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Adj EPS $3.39 >BIIB
BIIB,2022-02-03,12:04:08,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Net $368.2M,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Net $368.2M >BIIB
BIIB,2022-02-03,12:04:08,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.73B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Rev $2.73B >BIIB
BIIB,2022-02-03,12:26:13,CEDFD5,Biogen Inc.,100,0.4,earnings,up,Biogen Q4 EPS $2.50 vs. $2.32 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q4 EPS $2.50 vs. $2.32 a year ago
BIIB,2022-02-03,12:27:53,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q4 adj. EPS $3.39; FactSet consensus $3.37,NEWS-FLASH,MarketWatch,MW Biogen Q4 adj. EPS $3.39; FactSet consensus $3.37
BIIB,2022-02-03,12:28:56,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q4 revenue $2.734 bln vs. $2.853 bln a year ago; FactSet consensus $2.620 bln,NEWS-FLASH,MarketWatch,MW Biogen Q4 revenue $2.734 bln vs. $2.853 bln a year ago; FactSet consensus $2.620 bln
BIIB,2022-02-03,12:30:17,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees 2022 adj. EPS of $14.25 to $16.00,NEWS-FLASH,MarketWatch,MW Biogen now sees 2022 adj. EPS of $14.25 to $16.00; FactSet consensus $18.76
BIIB,2022-02-03,12:30:53,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen now sees 2022 revenue of $9.7 bln to $10.0 bln,NEWS-FLASH,MarketWatch,MW Biogen now sees 2022 revenue of $9.7 bln to $10.0 bln; FactSet consensus $10.3 bln
BIIB,2022-02-03,12:33:07,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen 4Q Multiple sclerosis Rev $1.79B, Down 1%",RNS-SEC8K,Dow Jones Newswires,"Biogen 4Q Multiple sclerosis Rev $1.79B, Down 1% Vs Prior Year >BIIB"
BIIB,2022-02-03,12:33:08,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen 4Q Spinraza Rev $441M, Down 12%",RNS-SEC8K,Dow Jones Newswires,"Biogen 4Q Spinraza Rev $441M, Down 12% Vs Prior Year >BIIB"
BIIB,2022-02-03,12:33:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Aduhelm Rev $1M,RNS-SEC8K,Dow Jones Newswires,Biogen 4Q Aduhelm Rev $1M >BIIB
BIIB,2022-02-03,12:34:02,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees FY22 Rev $9.7B-$10B >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY22 Rev $9.7B-$10B >BIIB
BIIB,2022-02-03,12:34:33,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY22 Adj EPS $14.25,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY22 Adj EPS $14.25-Adj EPS $16 >BIIB
BIIB,2022-02-03,12:36:22,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Expects Decreased Rev,RNS-SEC8K,Dow Jones Newswires,Biogen Expects Decreased Rev From Some High-Margin Products to Reduce Gross Margin Percentage in FY22
BIIB,2022-02-03,12:45:26,CEDFD5,Biogen Inc.,94,0.0,earnings,,Biogen 4Q adjusted earnings per share,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q OK, But 2022 Outlook Worse Than Analysts' Forecast -- Market Talk"
BIIB,2022-02-03,12:45:26,CEDFD5,Biogen Inc.,94,0.0,earnings,,Biogen Inc.: The company sees adjusted earnings per share of $15.13,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q OK, But 2022 Outlook Worse Than Analysts' Forecast -- Market Talk"
BIIB,2022-02-03,12:45:27,CEDFD5,Biogen Inc.,94,0.0,earnings,,Biogen 4Q adjusted earnings per share,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q OK, But 2022 Outlook Worse Than Analysts' Forecast -- Market Talk"
BIIB,2022-02-03,12:45:27,CEDFD5,Biogen Inc.,94,0.0,earnings,,Biogen Inc.: The company sees adjusted earnings per share of $15.13,FULL-ARTICLE,Dow Jones Newswires,"Biogen 4Q OK, But 2022 Outlook Worse Than Analysts' Forecast -- Market Talk"
BIIB,2022-02-03,12:45:44,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.2 billion in the final three months,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-03,12:45:44,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-03,12:45:44,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.2 billion in the final three months,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Falls 3.7% On Earnings Miss, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-03,12:45:44,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Falls 3.7% On Earnings Miss, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc.: the company issued new guidance for 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.7 billion in the final three months,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc.: the company issued new guidance for 2022,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.7 billion in the final three months,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-03,12:55:58,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-03,13:00:32,CEDFD5,Biogen Inc.,98,0.0,earnings,,Biogen 4Q adjusted earnings per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Says Medicare Policy Sews Uncertainty for Aduhelm Clinics and Patients -- Market Talk
BIIB,2022-02-03,13:00:32,CEDFD5,Biogen Inc.,98,0.0,earnings,,Biogen Inc.: The company sees adjusted earnings per share of $15.13,FULL-ARTICLE,Dow Jones Newswires,Biogen Says Medicare Policy Sews Uncertainty for Aduhelm Clinics and Patients -- Market Talk
BIIB,2022-02-03,13:06:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen 4Q adjusted earnings per share,FULL-ARTICLE,Dow Jones Newswires,Biogen to Urge Medicare to Revise Aduhelm Policy -- Market Talk
BIIB,2022-02-03,13:06:33,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen Inc.: The company sees adjusted earnings per share of $15.13,FULL-ARTICLE,Dow Jones Newswires,Biogen to Urge Medicare to Revise Aduhelm Policy -- Market Talk
BIIB,2022-02-03,13:28:40,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company reported non-GAAP diluted earnings of $3.39 per share for the fourth quarter of 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Drops as Results Fall Short. Sales of Alzheimer's Drug Disappoint. -- Barrons.com
BIIB,2022-02-03,13:28:40,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen said it expected 2022 revenues,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Drops as Results Fall Short. Sales of Alzheimer's Drug Disappoint. -- Barrons.com
BIIB,2022-02-03,17:34:33,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q4 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q4 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2022-02-04,10:58:36,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Market Perform From Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Market Perform From Outperform by BMO Capital
BIIB,2022-02-04,10:58:36,CEDFD5,Biogen Inc.,100,-0.74,price-targets,downgrade,Biogen Price Target Cut to $238.00/Share From $260.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $238.00/Share From $260.00 by BMO Capital
BIIB,2022-02-04,11:29:26,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2022-02-04,11:29:26,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $290.00/Share From $292.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $290.00/Share From $292.00 by Needham
BIIB,2022-02-04,12:06:13,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen stock price target cut to $236 from $276 at J.P. Morgan,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $236 from $276 at J.P. Morgan
BIIB,2022-02-04,12:46:50,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen downgraded to market perform from outperform at BMO Capital,NEWS-FLASH,MarketWatch,MW Biogen downgraded to market perform from outperform at BMO Capital
BIIB,2022-02-04,13:43:17,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Wells Fargo
BIIB,2022-02-04,13:43:17,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $235.00/Share From $284.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $235.00/Share From $284.00 by Wells Fargo
BIIB,2022-02-04,15:25:37,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-02-04,15:25:37,CEDFD5,Biogen Inc.,100,-0.74,price-targets,downgrade,Biogen Price Target Cut to $330.00/Share From $360.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $330.00/Share From $360.00 by Morgan Stanley
BIIB,2022-02-05,09:13:03,CEDFD5,Biogen Inc.,100,0.4,earnings,up,Biogen Q4 EPS $2.50 vs. $2.32 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q4 EPS $2.50 vs. $2.32 a year ago
BIIB,2022-02-05,09:13:03,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q4 adj. EPS $3.39; FactSet consensus $3.37,NEWS-FLASH,MarketWatch,MW Biogen Q4 adj. EPS $3.39; FactSet consensus $3.37
BIIB,2022-02-05,09:13:03,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q4 revenue $2.734 bln vs. $2.853 bln a year ago; FactSet consensus $2.620 bln,NEWS-FLASH,MarketWatch,MW Biogen Q4 revenue $2.734 bln vs. $2.853 bln a year ago; FactSet consensus $2.620 bln
BIIB,2022-02-05,09:13:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees 2022 adj. EPS of $14.25 to $16.00,NEWS-FLASH,MarketWatch,MW Biogen now sees 2022 adj. EPS of $14.25 to $16.00; FactSet consensus $18.76
BIIB,2022-02-05,09:13:03,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen now sees 2022 revenue of $9.7 bln to $10.0 bln,NEWS-FLASH,MarketWatch,MW Biogen now sees 2022 revenue of $9.7 bln to $10.0 bln; FactSet consensus $10.3 bln
BIIB,2022-02-05,09:13:04,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.2 billion in the final three months,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-05,09:13:04,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-05,09:13:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc.: the company issued new guidance for 2022,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-05,09:13:04,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.7 billion in the final three months,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-05,09:13:04,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,MarketWatch,"MW Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter"
BIIB,2022-02-05,09:13:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.2 billion in the final three months,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Falls 3.7% On Earnings Miss, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-05,09:13:09,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Stock Falls 3.7% On Earnings Miss, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-05,09:13:09,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc.: the company issued new guidance for 2022,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-05,09:13:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported revenue of $2.7 billion in the final three months,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-05,09:13:09,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen also said it expects a recently announced deal with Samsung Biologics,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Stock Falls 3.7% After Announcing Earnings, Says It Brought In $1 Million In Sales Of Alzheimer's Drug In The Fourth Quarter -- MarketWatch"
BIIB,2022-02-05,09:13:17,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen stock price target cut to $236 from $276 at J.P. Morgan,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $236 from $276 at J.P. Morgan
BIIB,2022-02-05,09:13:18,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen downgraded to market perform from outperform at BMO Capital,NEWS-FLASH,MarketWatch,MW Biogen downgraded to market perform from outperform at BMO Capital
BIIB,2022-02-05,09:13:22,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q4 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q4 2021 Results -- Earnings Call Transcript >BIIB
BIIB,2022-02-07,12:52:55,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2022-02-07,12:52:55,CEDFD5,Biogen Inc.,100,-0.76,price-targets,downgrade,Biogen Price Target Cut to $305.00/Share From $335.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $305.00/Share From $335.00 by Canaccord Genuity
BIIB,2022-02-07,21:05:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane Announce Commercialization and License Agreement,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA(R) (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,21:05:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane Announce Commercialization and License Agreement,FULL-ARTICLE,Dow Jones Newswires,Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA(R) (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,21:05:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane Announce Commercialization and License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA(R) (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,21:05:03,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane Announce Commercialization and License Agreement,PRESS-RELEASE,GlobeNewswire,Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA(R) (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,21:05:03,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane Announce Commercialization and License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA(R) (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,21:06:09,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen and Xbrane: Announce Commercialization and License Agreement,NEWS-FLASH,Dow Jones Newswires,Biogen and Xbrane: Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA With the Potential to Treat Rheumatoid Arthritis
BIIB,2022-02-07,23:04:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,GlobeNewswire,"Block & Leviton LLP Has Filed a Lawsuit Against Biogen, Inc. for Securities Law Violations"
BIIB,2022-02-08,16:17:42,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen, Inc. (""Biogen"") (NASDAQ:BIIB",PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm"
BIIB,2022-02-08,23:09:03,CEDFD5,Biogen Inc.,100,-0.52,legal,,Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. (NASDAQ: BIIB),PRESS-RELEASE,PR Newswire,BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-02-08,23:09:03,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,PR Newswire,BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-02-08,23:37:07,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-08,23:37:07,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-09,00:09:15,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,(BIIB) NEWS: Did you Suffer a Substantial Loss? Contact Johnson Fistel About Leading Biogen Inc. Class Action Lawsuit
BIIB,2022-02-09,01:11:49,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,GlobeNewswire,HAGENS BERMAN BIIB ALERT: Investors in Biogen Inc. (BIIB) With Significant Losses Have Opportunity to Lead Securities Class Action
BIIB,2022-02-09,10:03:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Investors Biogen, Inc. (BIIB) is Being Sued for",PRESS-RELEASE,Business Wire,"Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-09,10:03:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,Business Wire,"Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-09,15:00:04,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen, Inc. (""Biogen"") (NASDAQ: BIIB",PRESS-RELEASE,PR Newswire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm"
BIIB,2022-02-09,18:37:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firms Attorneys, Securities Class Action Filed"
BIIB,2022-02-09,21:00:49,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,"Block & Leviton LLP Has Filed a Lawsuit Against Biogen, Inc. for Securities Law Violations"
BIIB,2022-02-09,21:47:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Investors Biogen, Inc. (BIIB) is Being Sued for",PRESS-RELEASE,Business Wire,"CORRECTING and REPLACING Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-09,21:47:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,Business Wire,"CORRECTING and REPLACING Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-09,23:49:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-09,23:49:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-10,02:00:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen, Inc.",PRESS-RELEASE,Business Wire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm"
BIIB,2022-02-10,17:50:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,PR Newswire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Class Action Filed"
BIIB,2022-02-10,17:50:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,Dow Jones Newswires,"Press Release: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Class Action Filed"
BIIB,2022-02-10,18:47:42,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CHGG, TALK and BIIB"
BIIB,2022-02-10,19:11:13,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ:BIIB)
BIIB,2022-02-10,20:02:10,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Gross Law Firm Announces Class Actions on Behalf of Shareholders of RDW, CLVT and BIIB"
BIIB,2022-02-10,23:50:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-10,23:50:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-11,00:30:47,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for DOCU, FSLR and BIIB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-11,05:14:00,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Investors Biogen, Inc. (BIIB) is Being Sued for",PRESS-RELEASE,Business Wire,"Shareholder Alert: Robbins LLP Reminds Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-11,05:14:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,Business Wire,"Shareholder Alert: Robbins LLP Reminds Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders"
BIIB,2022-02-11,14:30:59,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SNBR, MARA and BIIB"
BIIB,2022-02-11,16:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen, Inc. (""Biogen"") (NASDAQ: BIIB",PRESS-RELEASE,Business Wire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm"
BIIB,2022-02-11,16:33:58,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for OSH, BMBL and BIIB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-11,21:08:20,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Class Action Filed"
BIIB,2022-02-12,13:27:46,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-12,13:27:46,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-13,13:19:44,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-02-13,13:19:44,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-02-14,02:00:00,CEDFD5,Biogen Inc.,96,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec, and Astra Space and Encourages Investors to Contact the Firm"
BIIB,2022-02-14,12:31:12,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST BHG, SLI and BIIB - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS"
BIIB,2022-02-14,14:30:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-14,14:30:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-14,14:37:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,GlobeNewswire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys About Lead Plaintiff Opportunity in Securities Class Action"
BIIB,2022-02-14,15:16:54,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of STTK, ELMS and BIIB"
BIIB,2022-02-14,16:00:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Class action lawsuit has been filed against Biogen, Inc. (""Biogen"") (NASDAQ: BIIB",PRESS-RELEASE,Business Wire,"BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm"
BIIB,2022-02-14,16:30:42,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: TALK BIIB FENC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
BIIB,2022-02-15,02:22:05,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FFIE, ELMS and BIIB"
BIIB,2022-02-15,14:30:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"BIIB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 8, 2022 in the Class Action Filed on Behalf of Biogen Inc. Shareholders"
BIIB,2022-02-15,14:30:03,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,Dow Jones Newswires,"Press Release: BIIB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 8, 2022 in the Class Action Filed on Behalf of Biogen Inc. Shareholders"
BIIB,2022-02-15,21:13:00,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 171 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 171 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:13:51,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Ceo Vounatsos Acquires 150 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,CEO Vounatsos Acquires 150 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:15:14,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 104 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 104 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:16:14,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 229 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 229 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:17:34,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Guindo Acquires 255 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Guindo Acquires 255 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:19:34,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Gregory Acquires 420 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Gregory Acquires 420 Of Biogen Inc >BIIB
BIIB,2022-02-15,21:20:04,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Alexander Acquires 224 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Acquires 224 Of Biogen Inc >BIIB
BIIB,2022-02-15,22:26:16,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys About Opportunity to Lead Securities Class Action"
BIIB,2022-02-15,23:29:11,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-15,23:29:11,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-15,23:57:48,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: DM CLVT BIIB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
BIIB,2022-02-16,00:30:38,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for MARA, TLIS and BIIB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-16,12:18:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen See Positive Results for Depression Treatment,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen See Positive Results for Depression Treatment"
BIIB,2022-02-16,12:33:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen See Positive Results for Depression Treatment,FULL-ARTICLE,Dow Jones Newswires,"Sage Therapeutics, Biogen See Positive Results for Depression Treatment"
BIIB,2022-02-16,23:49:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-16,14:30:07,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 8, 2022 - (NASDAQ: BIIB)"
BIIB,2022-02-16,20:20:37,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Class Action Filed"
BIIB,2022-02-16,20:52:10,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ARVL, SLI and BIIB"
BIIB,2022-02-16,23:49:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-17,02:00:59,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Lawsuits FILED AGAINST EDU, TAL and BIIB",PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST EDU, TAL and BIIB - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,02:00:59,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST EDU, TAL and BIIB - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,14:15:55,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: INSD TLS BIIB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
BIIB,2022-02-17,14:30:07,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2022-02-17,21:02:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firms Attorneys, Securities Class Action Filed"
BIIB,2022-02-17,21:45:52,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Lawsuits Filed Against CHGG, TLS and BIIB",PRESS-RELEASE,DJ Global Press Release Wire,"Lawsuits Filed Against CHGG, TLS and BIIB Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,21:45:52,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"Lawsuits Filed Against CHGG, TLS and BIIB Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,21:49:22,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Lawsuits Filed Against CHGG, TLS and BIIB",PRESS-RELEASE,DJ Global Press Release Wire,"Lawsuits Filed Against CHGG, TLS and BIIB Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,21:49:22,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"Lawsuits Filed Against CHGG, TLS and BIIB Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-17,23:46:29,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-17,23:46:29,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-18,00:20:34,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FCFS, FSLR and BIIB"
BIIB,2022-02-18,14:30:06,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,"Who purchased Biogen between June 7, 2021",PRESS-RELEASE,PR Newswire,"BIIB SHAREHOLDER ALERT: Jakubowitz Law Reminds Biogen Shareholders of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-18,14:30:06,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"BIIB SHAREHOLDER ALERT: Jakubowitz Law Reminds Biogen Shareholders of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-18,14:57:13,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,GlobeNewswire,"BIOGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Biogen, Inc. in the United States District Court for the District of Massachusetts"
BIIB,2022-02-18,15:40:11,CEDFD5,Biogen Inc.,98,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FCFS, FFIE and BIIB"
BIIB,2022-02-18,17:42:05,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Fraud Case Pending"
BIIB,2022-02-18,19:15:34,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for FSLR, STTK and BIIB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-19,02:00:01,CEDFD5,Biogen Inc.,93,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against Electric Last Mile, TAL Education, New Oriental, and Biogen",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Electric Last Mile, TAL Education, New Oriental, and Biogen and Encourages Investors to Contact the Firm"
BIIB,2022-02-19,13:27:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-19,13:27:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-19,13:54:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,GlobeNewswire,"BIOGEN DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $200,000 In Biogen To Contact Him Directly To Discuss Their Options"
BIIB,2022-02-19,13:54:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,GlobeNewswire,"BIOGEN DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $200,000 In Biogen To Contact Him Directly To Discuss Their Options"
BIIB,2022-02-20,13:19:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-20,13:19:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-02-21,12:15:39,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for DOCU, CLVT and BIIB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-22,11:00:14,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-22,11:00:14,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022"
BIIB,2022-02-22,14:33:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,GlobeNewswire,"HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Securities Class Action Filed"
BIIB,2022-02-22,14:55:33,CEDFD5,Biogen Inc.,100,-0.52,legal,,"Lawsuits FILED AGAINST TLIS, BMBL and BIIB",PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST TLIS, BMBL and BIIB - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-22,14:55:33,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"LAWSUITS FILED AGAINST TLIS, BMBL and BIIB - Jakubowitz Law Pursues Shareholders Claims"
BIIB,2022-02-22,16:43:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-02-22,17:40:10,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TALK, BIIB and SPWR"
BIIB,2022-02-22,23:28:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-02-22,23:28:54,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-02-23,00:10:47,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FCFS, BIIB and FENC"
BIIB,2022-02-23,02:04:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"CLASS ACTION UPDATE for TLIS, BIIB and FENC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders"
BIIB,2022-02-23,11:00:08,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 8, 2022 - (NASDAQ: BIIB)"
BIIB,2022-02-23,21:18:40,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Alexander Acquires 826 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Acquires 826 Of Biogen Inc >BIIB
BIIB,2022-02-23,21:19:10,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Gregory Acquires 771 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Gregory Acquires 771 Of Biogen Inc >BIIB
BIIB,2022-02-23,21:20:30,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Guindo Acquires 1,102 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Guindo Acquires 1,102 Of Biogen Inc >BIIB"
BIIB,2022-02-23,21:26:11,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 419 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 419 Of Biogen Inc >BIIB
BIIB,2022-02-23,21:27:13,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 261 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 261 Of Biogen Inc >BIIB
BIIB,2022-02-23,21:27:49,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 279 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 279 Of Biogen Inc >BIIB
BIIB,2022-02-23,21:28:00,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 1,004 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 1,004 Of Biogen Inc >BIIB"
BIIB,2022-02-23,21:31:03,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Ceo Vounatsos Acquires 3,445 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CEO Vounatsos Acquires 3,445 Of Biogen Inc >BIIB"
BIIB,2022-02-24,00:06:43,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-24,00:06:43,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-02-24,01:41:10,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: FSLR SLI BIIB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
BIIB,2022-02-24,02:00:01,CEDFD5,Biogen Inc.,95,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against New Oriental Education, Biogen, Telos",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against New Oriental Education, Biogen, Telos, and Fennec and Encourages Investors to Contact the Firm"
BIIB,2022-02-24,03:25:30,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INSD, TALK and BIIB"
BIIB,2022-02-24,03:25:34,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,"The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INSD, TALK and BIIB"
BIIB,2022-02-24,11:00:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,PR Newswire,BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB,2022-02-24,18:00:19,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Fda approval for Aduhelm in 2019,PRESS-RELEASE,DJ Global Press Release Wire,SHAREHOLDER ALERT: TLIS TALK BIIB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
BIIB,2022-02-25,00:26:09,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-25,00:26:09,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-02-26,13:27:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-26,13:27:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-27,13:19:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-27,13:19:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-02-28,18:30:38,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,"Class Action Alert: Robbins LLP Reminds Investors of Class Action Against Biogen, Inc. (BIIB)"
BIIB,2022-03-01,02:00:01,CEDFD5,Biogen Inc.,95,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec, and Astra Space and Encourages Investors to Contact the Firm"
BIIB,2022-03-01,13:57:29,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-03-01,23:13:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-01,23:13:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-03,00:08:19,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-03,00:08:19,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-03,11:29:31,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Outperform From Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Sector Perform by RBC Capital
BIIB,2022-03-03,11:29:31,CEDFD5,Biogen Inc.,100,0.74,price-targets,upgrade,Biogen Price Target Raised to $248.00/Share From $227.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $248.00/Share From $227.00 by RBC Capital
BIIB,2022-03-03,14:07:27,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,"Abrahams upgraded Biogen (ticker: BIIB) to Outperform, from Sector Perform",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Has Fallen 50%. One Analyst Says It's Time to Buy. -- Barrons.com
BIIB,2022-03-03,14:07:27,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported Aduhelm revenue of $1 million for the fourth quarter of 2020,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Has Fallen 50%. One Analyst Says It's Time to Buy. -- Barrons.com
BIIB,2022-03-03,17:17:38,CEDFD5,Biogen Inc.,99,-0.51,labor-issues,,"Biogen Inc.: the company plans to cut 1,000 jobs",FULL-ARTICLE,MarketWatch,MW Biogen to lay off some U.S. employees
BIIB,2022-03-03,17:17:38,CEDFD5,Biogen Inc.,99,-0.51,labor-issues,,"Biogen Inc.: the company plans to cut 1,000 jobs",FULL-ARTICLE,Dow Jones Newswires,Biogen To Lay Off Some U.S. Employees -- MarketWatch
BIIB,2022-03-03,17:31:32,CEDFD5,Biogen Inc.,99,-0.51,labor-issues,,Biogen's job cuts,FULL-ARTICLE,Dow Jones Newswires,Biogen Makes Layoffs Amid Stalled Aduhelm Launch
BIIB,2022-03-03,17:46:32,CEDFD5,Biogen Inc.,99,-0.51,labor-issues,,Biogen's job cuts,FULL-ARTICLE,Dow Jones Newswires,Biogen Makes Layoffs Amid Stalled Aduhelm Launch
BIIB,2022-03-03,19:20:36,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,"Block & Leviton LLP Has Filed a Lawsuit Against Biogen, Inc. for Securities Law Violations"
BIIB,2022-03-03,21:00:45,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Biogen announced that the FDA had approved Aduhelm,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (BIIB); Lead Plaintiff Deadline is April 8, 2022"
BIIB,2022-03-04,00:14:54,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-04,00:14:54,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-04,01:57:03,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Biogen announced that the FDA had approved Aduhelm,PRESS-RELEASE,PR Newswire,"Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (NASDAQ: BIIB); Lead Plaintiff Deadline is April 8, 2022"
BIIB,2022-03-04,01:57:03,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Biogen announced that the FDA had approved Aduhelm,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (NASDAQ: BIIB); Lead Plaintiff Deadline is April 8, 2022"
BIIB,2022-03-05,13:27:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-05,13:27:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-06,13:19:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-06,13:19:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-07,02:00:01,CEDFD5,Biogen Inc.,93,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against Electric Last Mile, TAL, New Oriental Education, and Biogen",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Electric Last Mile, TAL, New Oriental Education, and Biogen and Encourages Investors to Contact the Firm"
BIIB,2022-03-08,11:22:32,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Hold From Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Hold From Buy by Stifel
BIIB,2022-03-08,11:22:32,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $223.00/Share From $304.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $223.00/Share From $304.00 by Stifel
BIIB,2022-03-08,11:57:20,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen downgraded to hold from buy at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Biogen downgraded to hold from buy at Stifel Nicolaus
BIIB,2022-03-08,15:26:37,CEDFD5,Biogen Inc.,99,0.0,products-services,,"Biogen, called lecanemab, a late-stage trial of",FULL-ARTICLE,Dow Jones Newswires,"Betting on Biogen Stock Isn't Worth the Risk, Analyst Says -- Barrons.com"
BIIB,2022-03-08,23:13:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-08,23:13:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-09,15:04:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,BIOGEN INC. (NASDAQ:BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-03-09,23:49:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-09,23:49:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-10,12:00:03,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11),PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:03,CEDFD5,Biogen Inc.,100,0.39,products-services,,"In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc.",PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:03,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:03,CEDFD5,Biogen Inc.,100,0.39,products-services,,"In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:04,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11),PRESS-RELEASE,GlobeNewswire,"Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:04,CEDFD5,Biogen Inc.,100,0.39,products-services,,"In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc.",PRESS-RELEASE,GlobeNewswire,"Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:00:15,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ (SB11,PRESS-RELEASE,Canadian News Wire,"Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ (SB11), LUCENTIS Biosimilar (Ranibizumab)"
BIIB,2022-03-10,12:00:15,CEDFD5,Biogen Inc.,100,0.39,products-services,,"In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc.",PRESS-RELEASE,Canadian News Wire,"Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ (SB11), LUCENTIS Biosimilar (Ranibizumab)"
BIIB,2022-03-10,12:08:53,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-10,12:08:53,CEDFD5,Biogen Inc.,100,0.39,products-services,,"In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc.",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ(TM) (SB11), LUCENTIS(R) Biosimilar (ranibizumab)"
BIIB,2022-03-11,00:07:40,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-11,00:07:40,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-11,15:47:05,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Biogen announced that the FDA had approved Aduhelm,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (BIIB); Lead Plaintiff Deadline is April 8, 2022"
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the company will present new Alzheimer's disease research, as well as data for ADUHELM(R) (aducanumab-avwa) injection",FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the company will present new Alzheimer's disease research, as well as data for ADUHELM(R) (aducanumab-avwa) injection",PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the company will present new Alzheimer's disease research, as well as data for ADUHELM(R) (aducanumab-avwa) injection",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Research at theInternational Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the company will present new Alzheimer's disease research, as well as data for ADUHELM(R) (aducanumab-avwa) injection",PRESS-RELEASE,GlobeNewswire,Biogen to Present New Research at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,21:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,GlobeNewswire,Biogen to Present New Research at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,23:16:24,CEDFD5,Biogen Inc.,99,0.52,products-services,,"Biogen Inc.: the company will present new Alzheimer's disease research, as well as data for ADUHELM(R) (aducanumab-avwa) injection",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Research at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-11,23:16:24,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen and Eisai Co., Ltd. are collaborating on",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Research at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
BIIB,2022-03-12,02:00:00,CEDFD5,Biogen Inc.,94,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against New Oriental, Biogen, Telos",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against New Oriental, Biogen, Telos, and Fennec and Encourages Investors to Contact the Firm"
BIIB,2022-03-12,13:27:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-12,13:27:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-13,12:29:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-13,12:29:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-14,11:30:00,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen Announces New Updates Across its SMA Research Program,PRESS-RELEASE,GlobeNewswire,Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:00,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Baseline Characteristics and Initial Safety Results in RESPOND: A Phase 4 Study,PRESS-RELEASE,GlobeNewswire,Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen Announces New Updates Across its SMA Research Program,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Baseline Characteristics and Initial Safety Results in RESPOND: A Phase 4 Study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen Announces New Updates Across its SMA Research Program,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.44,products-services,,Biogen Announces New Updates Across its SMA Research Program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Baseline Characteristics and Initial Safety Results in RESPOND: A Phase 4 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
BIIB,2022-03-14,23:00:00,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen and Eisai said on Monday that they amended their collaboration agreement,FULL-ARTICLE,Dow Jones Newswires,Biogen And Eisai Rewrite Alzheimer's Drug Marketing Pact -- WSJ
BIIB,2022-03-14,23:00:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen to manufacture the drug,FULL-ARTICLE,Dow Jones Newswires,Biogen And Eisai Rewrite Alzheimer's Drug Marketing Pact -- WSJ
BIIB,2022-03-14,23:00:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's financial outlook for 2022,FULL-ARTICLE,Dow Jones Newswires,Biogen And Eisai Rewrite Alzheimer's Drug Marketing Pact -- WSJ
BIIB,2022-03-14,23:00:00,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: our agreement with Eisai through,PRESS-RELEASE,GlobeNewswire,Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments
BIIB,2022-03-14,23:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: our agreement with Eisai through,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments
BIIB,2022-03-14,23:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: our agreement with Eisai through,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments
BIIB,2022-03-14,23:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,Biogen Inc.: our agreement with Eisai through,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Eisai amend collaboration agreements on Alzheimer's disease treatments
BIIB,2022-03-14,23:00:52,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Eisai: Aducanumab Collaboration to,NEWS-FLASH,Dow Jones Newswires,"Biogen and Eisai: Aducanumab Collaboration to Convert From Eisai Sharing of Global Profits and Losses to Global Royalty Arrangement, Effective Jan 1, 2023 >BIIB"
BIIB,2022-03-15,00:33:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB Stock News: Robbins LLP Reminds Investors of Class Action Against Biogen, Inc. (BIIB)"
BIIB,2022-03-15,22:17:51,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-15,22:17:51,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-16,15:12:48,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Biogen announced that the FDA had approved Aduhelm,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (BIIB); Lead Plaintiff Deadline is April 8, 2022"
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration (FDA) granted accelerated approval for ADUHELM,PRESS-RELEASE,GlobeNewswire,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,GlobeNewswire,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration (FDA) granted accelerated approval for ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration (FDA) granted accelerated approval for ADUHELM,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:52,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:53,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration (FDA) granted accelerated approval for ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:53,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:53,CEDFD5,Biogen Inc.,99,0.71,products-services,,The U.S. Food and Drug Administration (FDA) granted accelerated approval for ADUHELM,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,15:54:53,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Peer-Reviewed Publication of ADUHELM(R) Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease
BIIB,2022-03-16,22:49:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-16,22:49:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-17,01:00:01,CEDFD5,Biogen Inc.,95,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec, and Astra and Encourages Investors to Contact the Firm"
BIIB,2022-03-17,14:20:13,CEDFD5,Biogen Inc.,99,-0.58,analyst-ratings,negative,Downgraded Biogen to Hold from Buy,FULL-ARTICLE,Dow Jones Newswires,"Biogen's Aduhelm Credibility Problem Deepens, and Investors Are Paying the Price -- Barrons.com"
BIIB,2022-03-17,22:46:30,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-17,22:46:30,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-19,12:27:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-19,12:27:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-20,12:30:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-20,12:30:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-22,01:00:01,CEDFD5,Biogen Inc.,93,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen and Encourages Investors to Contact the Firm"
BIIB,2022-03-22,13:08:01,CEDFD5,Biogen Inc.,92,-0.57,labor-issues,,Former chief medical officer at Biogen; he left that company,FULL-ARTICLE,MarketWatch,MW Voyager names former Biogen executive Alfred Sandrock as CEO
BIIB,2022-03-22,13:08:01,CEDFD5,Biogen Inc.,92,-0.57,labor-issues,,Former chief medical officer at Biogen; he left that company,FULL-ARTICLE,Dow Jones Newswires,Voyager Names Former Biogen Executive Alfred Sandrock As CEO -- MarketWatch
BIIB,2022-03-22,22:13:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-22,22:13:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-03-23,15:43:02,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,PR Newswire,BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ: BIIB)
BIIB,2022-03-23,22:49:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-23,22:49:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-24,22:49:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-24,22:49:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-26,12:27:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-26,12:27:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-03-27,12:30:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-27,12:30:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-03-28,01:00:00,CEDFD5,Biogen Inc.,93,-0.52,legal,,"Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen",PRESS-RELEASE,GlobeNewswire,"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen and Encourages Investors to Contact the Firm"
BIIB,2022-03-28,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen and Ionis Announce Topline Phase 1 Study,PRESS-RELEASE,GlobeNewswire,Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
BIIB,2022-03-28,11:30:02,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen and Ionis Announce Topline Phase 1 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
BIIB,2022-03-28,11:30:13,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen and Ionis Announce Topline Phase 1 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
BIIB,2022-03-28,14:08:54,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by B of A Securities
BIIB,2022-03-28,14:08:54,CEDFD5,Biogen Inc.,100,-0.4,price-targets,downgrade,Biogen Price Target Cut to $225.00/Share From $230.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $225.00/Share From $230.00 by B of A Securities
BIIB,2022-03-29,13:36:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,GlobeNewswire,"BIIB 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Deadline Approaching in Securities Class Action"
BIIB,2022-03-29,22:13:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Update
BIIB,2022-03-29,22:13:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Update
BIIB,2022-03-30,11:29:34,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm last June,FULL-ARTICLE,Dow Jones Newswires,Biogen Files the Final Design for Aduhelm's Post-Approval Study -- Barrons.com
BIIB,2022-03-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
BIIB,2022-03-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,FULL-ARTICLE,Dow Jones Newswires,Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
BIIB,2022-03-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
BIIB,2022-03-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,GlobeNewswire,Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
BIIB,2022-03-30,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Eisai jointly collaborated on the development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Submits Final Protocol for ADUHELM(R) (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
BIIB,2022-03-30,22:06:22,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-30,22:06:22,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-03-31,16:40:37,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB 8-DAY INVESTOR DEADLINE: Hagens Berman, National Trial Attorneys, Reminds Biogen Inc. (BIIB) Investors of April 8th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact Firms Attorneys"
BIIB,2022-03-31,22:49:25,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-03-31,22:49:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-04-01,22:52:24,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-04-01,22:52:24,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-04-03,12:19:32,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-04-03,12:19:32,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Notice
BIIB,2022-04-04,19:11:10,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,GlobeNewswire,"BIIB 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm's Attorneys, Deadline Approaching in Securities Class Action"
BIIB,2022-04-04,20:06:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Real-World and Clinical Trial Data,PRESS-RELEASE,GlobeNewswire,New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression
BIIB,2022-04-04,20:06:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Real-World and Clinical Trial Data,PRESS-RELEASE,DJ Global Press Release Wire,New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression
BIIB,2022-04-04,20:06:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Real-World and Clinical Trial Data,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression
BIIB,2022-04-04,20:11:42,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Real-World and Clinical Trial Data,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression
BIIB,2022-04-05,21:46:07,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 155 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 155 Of Biogen Inc >BIIB
BIIB,2022-04-05,22:13:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-04-05,22:13:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Class Action Reminder
BIIB,2022-04-05,22:53:07,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB 8-DAY INVESTOR DEADLINE: Hagens Berman, National Trial Attorneys, Reminds Biogen Inc. (BIIB) Investors of April 8th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact Firm's Attorneys"
BIIB,2022-04-06,17:29:30,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The FDA approved Biogen's ADUHELM,PRESS-RELEASE,DJ Global Press Release Wire,"BIIB 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firms Attorneys Before April 8th Deadline in Securities Class Action"
BIIB,2022-04-06,22:49:26,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-04-06,22:49:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Update
BIIB,2022-04-07,21:26:38,CEDFD5,Biogen Inc.,98,0.71,products-services,,The Food and Drug Administration granted accelerated approval to Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare Limits Payments for Biogen's Alzheimer's Drug -- Update
BIIB,2022-04-07,22:04:04,CEDFD5,Biogen Inc.,98,0.71,products-services,,The Food and Drug Administration granted accelerated approval to Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare Limits Payments for Biogen's Alzheimer's Drug -- 2nd Update
BIIB,2022-04-07,22:06:27,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-04-07,22:06:27,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Deadline Alert
BIIB,2022-04-07,22:21:26,CEDFD5,Biogen Inc.,95,0.0,products-services,,"Biogen initially priced Aduhelm at $56,000",FULL-ARTICLE,Dow Jones Newswires,Medicare Will Limit Coverage of Biogen's Alzheimer's Drug -- Barrons.com
BIIB,2022-04-07,23:26:00,CEDFD5,Biogen Inc.,99,0.71,products-services,,The Food and Drug Administration granted accelerated approval to Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Medicare Limits Payments for Biogen's Alzheimer's Drug -- 3rd Update
BIIB,2022-04-08,10:51:10,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2022-04-08,10:51:10,CEDFD5,Biogen Inc.,100,-0.78,price-targets,downgrade,Biogen Price Target Cut to $262.00/Share From $290.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $262.00/Share From $290.00 by Needham
BIIB,2022-04-08,11:55:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2022-04-08,11:55:01,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $240.00/Share From $285.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $240.00/Share From $285.00 by Oppenheimer
BIIB,2022-04-08,12:58:38,CEDFD5,Biogen Inc.,92,-0.57,price-targets,downgrade,Are cutting their price targets on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Seen Hurting From CMS Alzheimer's Drug Decision -- Market Talk
BIIB,2022-04-08,12:58:38,CEDFD5,Biogen Inc.,92,-0.57,price-targets,downgrade,Are cutting their price targets on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Seen Hurting From CMS Alzheimer's Drug Decision -- Market Talk
BIIB,2022-04-08,15:15:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Aduhelm, the first Alzheimer's drug approved by the Food and Drug Administration",FULL-ARTICLE,Dow Jones Newswires,It's Lights Out for Biogen's Aduhelm. But There's Some Hope for Other Alzheimer's Drugs. -- Barrons.com
BIIB,2022-04-08,22:32:23,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen, Inc.",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-04-08,22:32:23,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Aduhelm was approved through the FDA,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Shareholder Alert
BIIB,2022-04-11,19:35:32,CEDFD5,Biogen Inc.,100,-0.58,credit-ratings,downgrade,Moody's Downgrades Biogen To Baa2,NEWS-FLASH,Dow Jones Newswires,Moody's Downgrades Biogen To Baa2; Negative Outlook
BIIB,2022-04-12,12:18:56,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-04-12,12:18:56,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $219.00/Share From $235.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $219.00/Share From $235.00 by Barclays
BIIB,2022-04-12,13:14:16,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-04-12,13:14:16,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $283.00/Share From $330.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $283.00/Share From $330.00 by Morgan Stanley
BIIB,2022-04-18,11:00:03,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Overweight From Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Overweight From Equal-Weight by Wells Fargo
BIIB,2022-04-18,11:00:03,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $265.00/Share From $235.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $265.00/Share From $235.00 by Wells Fargo
BIIB,2022-04-21,07:28:59,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 1Q 2022 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 1Q 2022 (BIIB)"
BIIB,2022-04-21,14:01:43,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2022-04-21,14:01:43,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $300.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $300.00 by SVB Leerink
BIIB,2022-04-22,14:37:13,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen: Notifies EMA of Decision to Withdraw Its Marketing Authorization Application for Aducanumab for Treatment of Early Stages of Alzheimer,NEWS-FLASH,Dow Jones Newswires,Biogen: Notifies EMA of Decision to Withdraw Its Marketing Authorization Application for Aducanumab for Treatment of Early Stages of Alzheimer's >BIIB
BIIB,2022-04-22,15:00:40,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Pulls European Application for Approval of Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Pulls European Application for Approval of Alzheimer's Drug Aduhelm
BIIB,2022-04-22,15:15:40,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Pulls European Application for Approval of Alzheimer's Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Pulls European Application for Approval of Alzheimer's Drug Aduhelm
BIIB,2022-05-02,14:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Expands Collaboration With Biogen to,PRESS-RELEASE,Business Wire,Scribe Therapeutics Expands Collaboration With Biogen to Second Target
BIIB,2022-05-03,11:07:29,CEDFD5,Biogen Inc.,100,-0.42,earnings,down,Biogen Q1 EPS $2.06 vs. $2.69 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q1 EPS $2.06 vs. $2.69 a year ago
BIIB,2022-05-03,11:07:49,CEDFD5,Biogen Inc.,100,-0.34,earnings,below-expectations,Biogen Q1 adj. EPS $3.62; FactSet consensus $4.34,NEWS-FLASH,MarketWatch,MW Biogen Q1 adj. EPS $3.62; FactSet consensus $4.34
BIIB,2022-05-03,11:08:21,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen Q1 revenue $2.532 bln down 6%,NEWS-FLASH,MarketWatch,MW Biogen Q1 revenue $2.532 bln down 6% vs. year-ago; FactSet consensus $2.500 bln
BIIB,2022-05-03,11:12:05,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen still sees full-year adj. EPS of $14.25 to $16.00,NEWS-FLASH,MarketWatch,MW Biogen still sees full-year adj. EPS of $14.25 to $16.00
BIIB,2022-05-03,11:12:17,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen still sees full-year revenue of $9.7 bln to $10.0 bln,NEWS-FLASH,MarketWatch,MW Biogen still sees full-year revenue of $9.7 bln to $10.0 bln
BIIB,2022-05-03,11:12:20,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $2.06 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $2.06 >BIIB
BIIB,2022-05-03,11:12:20,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $3.62,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Adj EPS $3.62 >BIIB
BIIB,2022-05-03,11:12:20,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Net $303.8M,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Net $303.8M >BIIB
BIIB,2022-05-03,11:12:20,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.53B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.53B >BIIB
BIIB,2022-05-03,11:23:20,CEDFD5,Biogen Inc.,94,0.49,labor-issues,,Biogen (ticker: BIIB) also said it had begun to look for a new chief executive officer,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Eliminate Alzheimer's Drug Infrastructure, Search for New CEO -- Barrons.com"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen misses on earnings,FULL-ARTICLE,MarketWatch,"MW Biogen misses on earnings in the first quarter, citing write-offs for its Alzheimer's disease drug"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed Wall Street's expectations for revenue,FULL-ARTICLE,MarketWatch,"MW Biogen misses on earnings in the first quarter, citing write-offs for its Alzheimer's disease drug"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,MarketWatch,"MW Biogen misses on earnings in the first quarter, citing write-offs for its Alzheimer's disease drug"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen Misses On Earnings,FULL-ARTICLE,Dow Jones Newswires,"Biogen Misses On Earnings In The First Quarter, Citing Write-offs For Its Alzheimer's Disease Drug -- MarketWatch"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed Wall Street's expectations for revenue,FULL-ARTICLE,Dow Jones Newswires,"Biogen Misses On Earnings In The First Quarter, Citing Write-offs For Its Alzheimer's Disease Drug -- MarketWatch"
BIIB,2022-05-03,11:34:51,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,Dow Jones Newswires,"Biogen Misses On Earnings In The First Quarter, Citing Write-offs For Its Alzheimer's Disease Drug -- MarketWatch"
BIIB,2022-05-03,11:35:19,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen'a Q1 profit and revenue lag estimates,FULL-ARTICLE,MarketWatch,"MW Biogen'a Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug"
BIIB,2022-05-03,11:35:19,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,MarketWatch,"MW Biogen'a Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug"
BIIB,2022-05-03,11:35:19,CEDFD5,Biogen Inc.,97,-0.75,revenues,below-expectations,Biogen Inc.: the company missed Wall Street's expectations for revenue,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen'a Q1 Profit And Revenue Lag Estimates, Weighed Down By Alzheimer's Drug -- MarketWatch"
BIIB,2022-05-03,11:35:19,CEDFD5,Biogen Inc.,97,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen'a Q1 Profit And Revenue Lag Estimates, Weighed Down By Alzheimer's Drug -- MarketWatch"
BIIB,2022-05-03,11:41:13,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen Inc.: Biogen CEO Michel Vounatsos is leaving the company,NEWS-FLASH,MarketWatch,MW Biogen CEO Michel Vounatsos is leaving the company as soon as successor has been found
BIIB,2022-05-03,11:45:33,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos to step down,FULL-ARTICLE,MarketWatch,MW Biogen CEO Michel Vounatsos to step down
BIIB,2022-05-03,11:45:33,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,"Biogen Inc.: the company's first-quarter earnings, which saw Biogen missing Wall Street's expectations",FULL-ARTICLE,MarketWatch,MW Biogen CEO Michel Vounatsos to step down
BIIB,2022-05-03,11:45:33,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos To Step Down,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos To Step Down -- MarketWatch
BIIB,2022-05-03,11:45:33,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,"Biogen Inc.: the company's first-quarter earnings, which saw Biogen missing Wall Street's expectations",FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos To Step Down -- MarketWatch
BIIB,2022-05-03,11:48:19,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos to step down,NEWS-FLASH,MarketWatch,MW Biogen CEO Michel Vounatsos to step down
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen's Q1 profit and revenue lag estimates,FULL-ARTICLE,MarketWatch,"MW Biogen's Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug"
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed Wall Street's expectations for revenue,FULL-ARTICLE,MarketWatch,"MW Biogen's Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug"
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,MarketWatch,"MW Biogen's Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug"
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.74,earnings,below-expectations,Biogen's Q1 Profit And Revenue Lag Estimates,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Q1 Profit And Revenue Lag Estimates, Weighed Down By Alzheimer's Drug -- MarketWatch"
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed Wall Street's expectations for revenue,FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Q1 Profit And Revenue Lag Estimates, Weighed Down By Alzheimer's Drug -- MarketWatch"
BIIB,2022-05-03,12:10:57,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,"Biogen reported revenue of $2.5 billion in the first quarter, down from $2.7 billion in the same three months",FULL-ARTICLE,Dow Jones Newswires,"Update: Biogen's Q1 Profit And Revenue Lag Estimates, Weighed Down By Alzheimer's Drug -- MarketWatch"
BIIB,2022-05-03,12:21:12,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos to Resign,NEWS-FLASH,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Resign; Will Stay on Until New CEO Search Finds Successor -- WSJ
BIIB,2022-05-03,12:21:12,CEDFD5,Biogen Inc.,100,0.58,equity-actions,down,Biogen Targets Cost-Cutting,NEWS-FLASH,Dow Jones Newswires,Biogen Targets Cost-Cutting of an Additional $500 Million on Top of $500 Million Announced in December -- WSJ
BIIB,2022-05-03,12:21:12,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen Inc.: Chief Executive Michel Vounatsos will resign from the company,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO to Step Aside After Alzheimer's Drug Struggles -- WSJ
BIIB,2022-05-03,12:51:22,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos to Step Aside After,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- Update
BIIB,2022-05-03,14:00:03,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen Inc.: Chief Executive Michel Vounatsos will resign from the company,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO to Step Aside After Alzheimer's Drug Struggles
BIIB,2022-05-03,14:00:03,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen also reported its first-quarter financial results on Tuesday,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO to Step Aside After Alzheimer's Drug Struggles
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,-0.57,labor-issues,,Biogen CEO Michel Vounatsos to Step Aside After,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen said Aduhelm sales were $2.8 million in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen's launch of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen had expected its sales,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen also reported its first-quarter financial results on Tuesday,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,14:53:45,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and its partner Eisai Co. are collaborating on lecanemab,FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Michel Vounatsos to Step Aside After Alzheimer's Drug Struggles -- 2nd Update
BIIB,2022-05-03,16:47:55,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm last June,FULL-ARTICLE,MarketWatch,"MW Beset by challenges with its Alzheimer's disease drug, Biogen pivots"
BIIB,2022-05-03,17:34:05,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q1 2022 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q1 2022 Results -- Earnings Call Transcript >BIIB
BIIB,2022-05-03,17:34:05,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen-inc-biib-ceo-michel-vounatsos-on-q1-2022-results-earnings,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q1 2022 Results -- Earnings Call Transcript >BIIB
BIIB,2022-05-03,19:04:41,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-03,20:53:09,CEDFD5,Biogen Inc.,96,0.0,revenues,,Biogen has reported only $5.8 million in sales,FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Patients Now Less Likely to Receive Biogen's Aduhelm Treatment -- WSJ
BIIB,2022-05-04,06:12:52,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen said Aduhelm sales were $2.8 million in the first quarter,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Abandon  Alzheimer's Drug,  Part With CEO  ----  By Joseph Walker"
BIIB,2022-05-04,06:12:52,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen's launch of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Abandon  Alzheimer's Drug,  Part With CEO  ----  By Joseph Walker"
BIIB,2022-05-04,06:12:52,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen also reported its first-quarter results Tuesday,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Abandon  Alzheimer's Drug,  Part With CEO  ----  By Joseph Walker"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,-0.6,labor-issues,,Biogen Inc. is shedding Chief Executive,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen said Aduhelm sales were $2.8 million in the first quarter,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen's launch of Aduhelm,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen had expected its sales,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen also reported its first-quarter financial results on Tuesday,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,06:33:05,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and its partner Eisai Co. are collaborating on lecanemab,FULL-ARTICLE,Wall Street Journal,"Biogen to Abandon Alzheimer's Drug, Part With CEO -- WSJ"
BIIB,2022-05-04,11:24:23,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-05-04,11:24:23,CEDFD5,Biogen Inc.,100,-0.52,price-targets,downgrade,Biogen Price Target Cut to $210.00/Share From $219.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $210.00/Share From $219.00 by Barclays
BIIB,2022-05-04,11:36:39,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm last June,FULL-ARTICLE,MarketWatch,"MW Beset by challenges with its Alzheimer's disease drug, Biogen pivots"
BIIB,2022-05-04,11:47:44,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-04,11:54:53,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2022-05-04,11:54:53,CEDFD5,Biogen Inc.,100,0.44,price-targets,upgrade,Biogen Price Target Raised to $251.00/Share From $244.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $251.00/Share From $244.00 by RBC Capital
BIIB,2022-05-04,12:00:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"2013, regulators approved Tecfidera",FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Casting Off Its Troubled Alzheimer's Drug -- WSJ
BIIB,2022-05-04,12:00:00,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Able to win FDA approval for Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Casting Off Its Troubled Alzheimer's Drug -- WSJ
BIIB,2022-05-04,12:00:00,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen slashed the price in half,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Casting Off Its Troubled Alzheimer's Drug -- WSJ
BIIB,2022-05-04,12:04:43,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2022-05-04,12:04:43,CEDFD5,Biogen Inc.,100,-0.66,price-targets,downgrade,Biogen Price Target Cut to $225.00/Share From $240.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $225.00/Share From $240.00 by Oppenheimer
BIIB,2022-05-04,12:10:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"2013, regulators approved Tecfidera",FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Ditching Troubled Alzheimer's Drug
BIIB,2022-05-04,12:10:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Able to win FDA approval for Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Ditching Troubled Alzheimer's Drug
BIIB,2022-05-04,12:10:04,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen slashed the price in half,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Rebuild After Ditching Troubled Alzheimer's Drug
BIIB,2022-05-04,12:23:20,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-04,12:25:51,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm last June,FULL-ARTICLE,MarketWatch,"MW Beset by challenges with its Alzheimer's disease drug, Biogen pivots"
BIIB,2022-05-04,13:43:02,CEDFD5,Biogen Inc.,100,-0.5,labor-issues,,Biogen's CEO Leaves Amid Alzheimer,FULL-ARTICLE,Dow Jones Newswires,Biogen's CEO Leaves Amid Alzheimer's Drug Failure -- ESG Insight
BIIB,2022-05-04,14:06:24,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-05-04,14:06:24,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $285.00/Share From $283.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $285.00/Share From $283.00 by Morgan Stanley
BIIB,2022-05-04,18:34:59,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-05,06:07:32,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,"Biogen Inc.: the Food and Drug Administration approved the company's Alzheimer's monoclonal antibody, Aduhelm",FULL-ARTICLE,Dow Jones Newswires,Biogen's CEO Becomes a Political Sacrifice  ----  By Allysia Finley
BIIB,2022-05-05,06:07:32,CEDFD5,Biogen Inc.,96,0.71,products-services,,Aduhelm and future Alzheimer's amyloid drugs receiving accelerated FDA approval,FULL-ARTICLE,Dow Jones Newswires,Biogen's CEO Becomes a Political Sacrifice  ----  By Allysia Finley
BIIB,2022-05-05,06:10:12,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"2013, regulators approved Tecfidera",FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Job After Pulling Drug  ----  By Joseph Walker
BIIB,2022-05-05,06:10:12,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Able to win FDA approval for Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Job After Pulling Drug  ----  By Joseph Walker
BIIB,2022-05-05,06:10:12,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen slashed the price in half,FULL-ARTICLE,Dow Jones Newswires,Biogen Faces Tough Job After Pulling Drug  ----  By Joseph Walker
BIIB,2022-05-05,06:32:31,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"2013, regulators approved Tecfidera",FULL-ARTICLE,Wall Street Journal,Biogen Faces Tough Job After Pulling Drug -- WSJ
BIIB,2022-05-05,06:32:31,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Able to win FDA approval for Aduhelm,FULL-ARTICLE,Wall Street Journal,Biogen Faces Tough Job After Pulling Drug -- WSJ
BIIB,2022-05-05,06:32:31,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen slashed the price in half,FULL-ARTICLE,Wall Street Journal,Biogen Faces Tough Job After Pulling Drug -- WSJ
BIIB,2022-05-05,10:53:19,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-05,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,Business Wire,(BW) Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,GlobeNewswire,Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:30:25,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
BIIB,2022-05-05,11:38:19,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm last June,FULL-ARTICLE,MarketWatch,"MW Beset by challenges with its Alzheimer's drug, Biogen pivots"
BIIB,2022-05-06,11:18:17,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-06,17:07:12,CEDFD5,Biogen Inc.,96,-0.58,acquisitions-mergers,scrutiny,Sec questioned Biogen's exclusion of upfront and premium payments paid for the acquisition,FULL-ARTICLE,MarketWatch,MW Drug companies are making an accounting change after the SEC cracked down on Biogen
BIIB,2022-05-09,15:57:37,CEDFD5,Biogen Inc.,99,-0.52,legal,,Pllc announces that a class action complaint has been filed against Biogen,PRESS-RELEASE,GlobeNewswire,"Lifshitz Law PLLC. Announces Investigations of Astra Space, Inc. (NASDAQ: ASTR), Biogen Inc, (NASDAQ: BIIB), Fennec Pharmaceuticals Inc. (NASDAQ: FENC), and Telos Corporation (NASDAQ: TLS)"
BIIB,2022-05-10,15:41:55,CEDFD5,Biogen Inc.,100,0.58,products-services,,Biogen Partner Eisai Files for Accelerated Approval,FULL-ARTICLE,Dow Jones Newswires,Biogen Partner Eisai Files for Accelerated Approval of Alzheimer's Drug -- Barrons.com
BIIB,2022-05-31,12:00:04,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study,PRESS-RELEASE,GlobeNewswire,Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
BIIB,2022-05-31,12:00:04,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,GlobeNewswire,Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
BIIB,2022-05-31,12:00:05,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
BIIB,2022-05-31,12:00:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen Inc.: our collaboration with Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
BIIB,2022-05-31,12:02:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Denali Therapeutics and Biogen: Initiation of Phase 2b Study of LRRK2 Inhibitor,NEWS-FLASH,Dow Jones Newswires,Denali Therapeutics and Biogen: Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
BIIB,2022-06-01,10:34:19,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Plan to Complete MDD NDA Filing in,NEWS-FLASH,Dow Jones Newswires,"Sage, Biogen Plan to Complete MDD NDA Filing in 2H >SAGE"
BIIB,2022-06-03,09:20:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen announces that results from Phase 3 VALOR study,PRESS-RELEASE,PR Newswire,Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
BIIB,2022-06-03,09:20:03,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Tofersen showed clinical benefit,PRESS-RELEASE,PR Newswire,Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
BIIB,2022-06-03,09:20:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen announces that results from Phase 3 VALOR study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
BIIB,2022-06-03,09:20:03,CEDFD5,Biogen Inc.,100,0.62,products-services,positive,Tofersen showed clinical benefit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
BIIB,2022-06-03,12:00:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",FULL-ARTICLE,Dow Jones Newswires,Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
BIIB,2022-06-03,12:00:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
BIIB,2022-06-03,12:00:02,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
BIIB,2022-06-03,12:00:03,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,GlobeNewswire,Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
BIIB,2022-06-03,12:08:07,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,GlobeNewswire,"Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,GlobeNewswire,"Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-06,11:34:39,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen and Alectos Therapeutics have entered into a license and collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson's Disease"
BIIB,2022-06-22,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Happify Health Collaborate to,PRESS-RELEASE,Business Wire,Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
BIIB,2022-06-22,13:00:17,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Happify Health Collaborate to,NEWS-FLASH,Dow Jones Newswires,Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
BIIB,2022-06-22,13:05:09,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen is collaborating with Happify,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
BIIB,2022-06-24,12:12:17,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen stops clinical trial,FULL-ARTICLE,MarketWatch,MW Biogen stops clinical trial tracking Aduhelm
BIIB,2022-06-24,12:12:17,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The Food and Drug Administration approved Aduhelm,FULL-ARTICLE,MarketWatch,MW Biogen stops clinical trial tracking Aduhelm
BIIB,2022-06-24,12:12:17,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen Stops Clinical Trial,FULL-ARTICLE,Dow Jones Newswires,Biogen Stops Clinical Trial Tracking Aduhelm -- MarketWatch
BIIB,2022-06-24,12:12:17,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,The Food and Drug Administration approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Stops Clinical Trial Tracking Aduhelm -- MarketWatch
BIIB,2022-07-06,13:04:47,CEDFD5,Biogen Inc.,96,0.0,products-services,,Biogen led development of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,"Alzheimer's Drug Is Up for Accelerated Approval. Outlook for Biogen, Eisai Is Uncertain. -- Barrons.com"
BIIB,2022-07-06,23:29:39,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 356 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 356 Of Biogen Inc >BIIB
BIIB,2022-07-06,23:34:23,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 178 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 178 Of Biogen Inc >BIIB
BIIB,2022-07-13,18:51:04,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Dir Posner Registers 388 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,Dir Posner Registers 388 Of Biogen Inc >BIIB
BIIB,2022-07-14,11:00:05,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Fda approval of Biogen/Eisai's Aduhelm,PRESS-RELEASE,PR Newswire,"New Spherix Data in Alzheimer's Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk's Semaglutide"
BIIB,2022-07-18,14:59:52,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2022-07-18,14:59:52,CEDFD5,Biogen Inc.,100,0.4,price-targets,upgrade,Biogen Price Target Raised to $230.00/Share From $225.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $230.00/Share From $225.00 by Oppenheimer
BIIB,2022-07-20,11:05:53,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $7.24 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q EPS $7.24 >BIIB
BIIB,2022-07-20,11:05:53,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Adj EPS $5.25,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Adj EPS $5.25 >BIIB
BIIB,2022-07-20,11:05:53,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Net $1.06B,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Net $1.06B >BIIB
BIIB,2022-07-20,11:05:53,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 2Q Rev $2.59B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Rev $2.59B >BIIB
BIIB,2022-07-20,11:07:03,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 2Q Rev $2.59B >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 2Q Rev $2.59B >BIIB
BIIB,2022-07-20,11:07:19,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $7.24 >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 2Q EPS $7.24 >BIIB
BIIB,2022-07-20,11:07:31,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Adj EPS $5.25,RNS-SEC8K,Dow Jones Newswires,Biogen 2Q Adj EPS $5.25 >BIIB
BIIB,2022-07-20,11:09:09,CEDFD5,Biogen Inc.,100,0.82,earnings,up,Biogen Q2 EPS $7.24 vs. $2.99 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q2 EPS $7.24 vs. $2.99 a year ago
BIIB,2022-07-20,11:09:31,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees FY22 Rev $9.9B-$10.1B >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY22 Rev $9.9B-$10.1B >BIIB
BIIB,2022-07-20,11:09:35,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q2 adj. EPS $5.25; FactSet consensus $4.06,NEWS-FLASH,MarketWatch,MW Biogen Q2 adj. EPS $5.25; FactSet consensus $4.06
BIIB,2022-07-20,11:09:53,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY22 Adj EPS $15.25,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY22 Adj EPS $15.25-Adj EPS $16.75 >BIIB
BIIB,2022-07-20,11:10:00,CEDFD5,Biogen Inc.,100,-0.34,revenues,below-expectations,Biogen Q2 revenue $2.055 bln vs. $2.236 bln a year ago; FactSet consensus $2.474 bln,NEWS-FLASH,MarketWatch,MW Biogen Q2 revenue $2.055 bln vs. $2.236 bln a year ago; FactSet consensus $2.474 bln
BIIB,2022-07-20,11:10:31,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raises full-year guidance,NEWS-FLASH,MarketWatch,MW Biogen raises full-year guidance
BIIB,2022-07-20,11:11:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees full-year EPS of $15.25 to $16.75,NEWS-FLASH,MarketWatch,MW Biogen now sees full-year EPS of $15.25 to $16.75 vs. prior $14.25 to $16.00
BIIB,2022-07-20,11:11:19,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen now sees full-year revenue of $9.9 bln to $10.1 bln,NEWS-FLASH,MarketWatch,MW Biogen now sees full-year revenue of $9.9 bln to $10.1 bln vs. prior $9.7 bln to $10.0 bln
BIIB,2022-07-20,11:18:01,CEDFD5,Biogen Inc.,92,0.0,earnings,,Biogen (BIIB) posted second-quarter earnings,FULL-ARTICLE,Dow Jones Newswires,"Netflix, Tesla, Biogen, and More of Wednesday's Stock Market Movers -- Barrons.com"
BIIB,2022-07-20,11:18:01,CEDFD5,Biogen Inc.,92,0.64,earnings,up,Biogen Inc.: the company raised its earnings,FULL-ARTICLE,Dow Jones Newswires,"Netflix, Tesla, Biogen, and More of Wednesday's Stock Market Movers -- Barrons.com"
BIIB,2022-07-20,11:45:58,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed on revenue in the second quarter,FULL-ARTICLE,MarketWatch,MW Biogen's stock is down 2.8% after missing on revenue in the second quarter
BIIB,2022-07-20,11:45:58,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported earnings of $1.0 billion,FULL-ARTICLE,MarketWatch,MW Biogen's stock is down 2.8% after missing on revenue in the second quarter
BIIB,2022-07-20,11:45:58,CEDFD5,Biogen Inc.,100,-0.75,revenues,below-expectations,Biogen Inc.: the company missed on revenue in the second quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Is Down 2.8% After Missing On Revenue In The Second Quarter -- MarketWatch
BIIB,2022-07-20,11:45:58,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported earnings of $1.0 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Is Down 2.8% After Missing On Revenue In The Second Quarter -- MarketWatch
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.64,earnings,up,Biogen 2Q Profit Lifted by,FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen beats 2Q analyst estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.72,revenues,up,"Biogen slightly raised its full-year outlook, increasing its revenue guidance",FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.64,earnings,up,Biogen 2Q Profit Lifted by,FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen beats 2Q analyst estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,11:47:15,CEDFD5,Biogen Inc.,100,0.72,revenues,up,"Biogen slightly raised its full-year outlook, increasing its revenue guidance",FULL-ARTICLE,Dow Jones Newswires,Biogen 2Q Profit Lifted by $1.5B Gain on Samsung Bioepis Sale -- Market Talk
BIIB,2022-07-20,12:19:27,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Ticker: BIIB) said adjusted earnings were $5.25 per share for the second quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Despite an Upbeat Outlook. Here's Why. -- Barrons.com
BIIB,2022-07-20,12:19:27,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported $2.78 billion in revenue,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Despite an Upbeat Outlook. Here's Why. -- Barrons.com
BIIB,2022-07-20,15:00:25,CEDFD5,Biogen Inc.,99,0.7,earnings,above-expectations,Biogen beats 2Q analyst estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Pulls the Plug on Neuropsychiatry Candidate -- Market Talk
BIIB,2022-07-20,15:00:25,CEDFD5,Biogen Inc.,99,0.72,revenues,up,"Biogen slightly raised its full-year outlook, increasing its revenue guidance",FULL-ARTICLE,Dow Jones Newswires,Biogen Pulls the Plug on Neuropsychiatry Candidate -- Market Talk
BIIB,2022-07-20,16:45:02,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen INC. AGREES TO PAY $900 MILLION TO RESOLVE,PRESS-RELEASE,PR Newswire,BIOGEN INC. AGREES TO PAY $900 MILLION TO RESOLVE WHISTLEBLOWER CLAIM REGARDING PAYMENT OF UNLAWFUL KICKBACKS
BIIB,2022-07-20,16:45:02,CEDFD5,Biogen Inc.,100,-0.56,products-services,loss,"Biogen, to prevent its multiple sclerosis drugs from losing market share",PRESS-RELEASE,PR Newswire,BIOGEN INC. AGREES TO PAY $900 MILLION TO RESOLVE WHISTLEBLOWER CLAIM REGARDING PAYMENT OF UNLAWFUL KICKBACKS
BIIB,2022-07-20,17:10:04,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Ticker: BIIB) said adjusted earnings were $5.25 per share for the second quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Despite an Upbeat Outlook. Here's Why.
BIIB,2022-07-20,17:10:04,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen reported $2.78 billion in revenue,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Is Falling Despite an Upbeat Outlook. Here's Why.
BIIB,2022-07-20,17:12:04,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,Biogen Inc. CEO Michel Vounatsos on Q2 2022 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. CEO Michel Vounatsos on Q2 2022 Results -- Earnings Call Transcript >BIIB
BIIB,2022-07-21,07:32:32,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 2Q 2022 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 2Q 2022 (BIIB)"
BIIB,2022-07-21,10:43:10,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2022-07-21,10:43:10,CEDFD5,Biogen Inc.,100,-0.56,price-targets,downgrade,Biogen Price Target Cut to $250.00/Share From $262.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $250.00/Share From $262.00 by Needham
BIIB,2022-07-21,12:39:30,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen stock price target cut to $270 from $320,NEWS-FLASH,MarketWatch,MW Biogen stock price target cut to $270 from $320 at Truist
BIIB,2022-07-21,13:00:50,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-07-21,13:00:50,CEDFD5,Biogen Inc.,100,-0.56,price-targets,downgrade,Biogen Price Target Cut to $200.00/Share From $210.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $200.00/Share From $210.00 by Barclays
BIIB,2022-07-21,13:59:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2022-07-21,13:59:01,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $320.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $320.00 by Truist Securities
BIIB,2022-07-21,14:32:21,CEDFD5,Biogen Inc.,100,0.2,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Cowen & Co.
BIIB,2022-07-21,14:32:21,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $270.00/Share From $285.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $270.00/Share From $285.00 by Cowen & Co.
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.65,products-services,,Fda Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen,PRESS-RELEASE,DJ Global Press Release Wire,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: The tofersen NDA included results from a Phase 1 study,PRESS-RELEASE,DJ Global Press Release Wire,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.65,products-services,,Fda Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen,FULL-ARTICLE,Dow Jones Newswires,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen is seeking approval of tofersen,FULL-ARTICLE,Dow Jones Newswires,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.65,products-services,,Fda Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:30:02,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: The tofersen NDA included results from a Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,100,0.65,products-services,,Fda Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen,PRESS-RELEASE,GlobeNewswire,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: The tofersen NDA included results from a Phase 1 study,PRESS-RELEASE,GlobeNewswire,"FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results in early stage clinical trials,PRESS-RELEASE,GlobeNewswire,FDA Accepts Biogen's New Drug Application and -2-
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,100,0.65,products-services,,Fda Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: The tofersen NDA included results from a Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS"
BIIB,2022-07-26,11:31:35,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results in early stage clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Accepts Biogen's New Drug -2-
BIIB,2022-07-26,11:34:47,CEDFD5,Biogen Inc.,100,0.65,products-services,,Biogen Gets FDA Priority Review of Tofersen,NEWS-FLASH,Dow Jones Newswires,"Biogen Gets FDA Priority Review of Tofersen for a Rare, Genetic Form of ALS >BIIB"
BIIB,2022-07-26,12:02:52,CEDFD5,Biogen Inc.,100,0.65,products-services,,Biogen Gets FDA Priority Review of Tofersen,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS >BIIB
BIIB,2022-07-26,12:02:52,CEDFD5,Biogen Inc.,100,0.65,products-services,,Biogen Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS >BIIB
BIIB,2022-07-26,12:17:52,CEDFD5,Biogen Inc.,100,0.65,products-services,,Biogen Gets FDA Priority Review of Tofersen,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS
BIIB,2022-07-26,12:17:52,CEDFD5,Biogen Inc.,100,0.65,products-services,,Biogen Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS
BIIB,2022-07-26,13:41:36,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: the company disclosed disappointing results of the Phase 3 trial of the drug,FULL-ARTICLE,Dow Jones Newswires,Biogen's ALS Drug Will Get FDA Review. It's a Long Shot for the Stock. -- Barrons.com
BIIB,2022-07-26,13:41:36,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Biogen's Alzheimer's drug Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen's ALS Drug Will Get FDA Review. It's a Long Shot for the Stock. -- Barrons.com
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059,FULL-ARTICLE,Dow Jones Newswires,The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059,PRESS-RELEASE,DJ Global Press Release Wire,The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Results from Phase 2 LILAC study,PRESS-RELEASE,DJ Global Press Release Wire,The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059,PRESS-RELEASE,Dow Jones Newswires,Press Release: The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Results from Phase 2 LILAC study,PRESS-RELEASE,Dow Jones Newswires,Press Release: The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059,PRESS-RELEASE,GlobeNewswire,The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Results from Phase 2 LILAC study,PRESS-RELEASE,GlobeNewswire,The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:02,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059,PRESS-RELEASE,Dow Jones Newswires,Press Release: The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-07-28,11:30:02,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: Results from Phase 2 LILAC study,PRESS-RELEASE,Dow Jones Newswires,Press Release: The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
BIIB,2022-08-03,21:41:42,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 761 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 761 Of Biogen Inc >BIIB
BIIB,2022-08-31,23:04:55,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 500,000 Of Sangamo Therapeutics Inc >SGMO",FULL-ARTICLE,Dow Jones Newswires,"Holder Biogen Inc Sells 500,000 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2022-09-06,23:33:11,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 2,318 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 2,318 Of Biogen Inc >BIIB"
BIIB,2022-09-12,11:21:32,CEDFD5,Biogen Inc.,100,-0.44,price-targets,downgrade,Biogen price target lowered to $223 from $230 at Stifel,NEWS-FLASH,MarketWatch,MW Biogen price target lowered to $223 from $230 at Stifel
BIIB,2022-09-12,13:40:56,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Hold by Stifel
BIIB,2022-09-12,13:40:56,CEDFD5,Biogen Inc.,100,-0.44,price-targets,downgrade,Biogen Price Target Cut to $223.00/Share From $230.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $223.00/Share From $230.00 by Stifel
BIIB,2022-09-13,13:30:05,CEDFD5,Biogen Inc.,99,-0.52,legal,,Biogen is also being sued by Humana Inc. for,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm
BIIB,2022-09-13,13:30:05,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen resolved similar claims with,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm
BIIB,2022-09-22,07:59:31,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,The Food and Drug Administration's approval of Aduhelm in June 2021,FULL-ARTICLE,Dow Jones Newswires,Can We Beat Alzheimer's? Biogen's Latest Drug Trial Will Offer Clues. -- Barrons.com
BIIB,2022-09-22,11:44:48,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2022-09-22,11:44:48,CEDFD5,Biogen Inc.,100,-0.36,price-targets,downgrade,Biogen Price Target Cut to $265.00/Share From $270.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $265.00/Share From $270.00 by Truist Securities
BIIB,2022-09-26,21:23:17,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen Inc. Agrees to Pay $900M in Settlement,HOT-NEWS-FLASH,Dow Jones Newswires,DOJ: Biogen Inc. Agrees to Pay $900M in Settlement Realted to Alleged Kickbacks
BIIB,2022-09-26,21:24:29,CEDFD5,Biogen Inc.,100,0.46,legal,,Doj: Biogen Settlement,HOT-NEWS-FLASH,Dow Jones Newswires,DOJ: Biogen Settlement Related to Alleged Submission of False Claims to Medicare and Medicaid
BIIB,2022-09-26,21:59:45,CEDFD5,Biogen Inc.,95,0.46,legal,,Biogen Inc. agreed to pay $900 million to resolve allegations,FULL-ARTICLE,Dow Jones Newswires,DOJ Says Biogen in Settlement; Agreement-in-Principle Previously Disclosed
BIIB,2022-09-26,22:14:45,CEDFD5,Biogen Inc.,95,0.46,legal,,Biogen Inc. agreed to pay $900 million to resolve allegations,FULL-ARTICLE,Dow Jones Newswires,DOJ Says Biogen in Settlement; Agreement-in-Principle Previously Disclosed
BIIB,2022-09-26,22:37:35,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen Inc. agreed to pay $900 million to settle allegations,FULL-ARTICLE,Dow Jones Newswires,Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments -- WSJ
BIIB,2022-09-26,22:45:59,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen Inc. agreed to pay $900 million to settle allegations,FULL-ARTICLE,Dow Jones Newswires,Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments -- update -- WSJ
BIIB,2022-09-26,23:19:20,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen Inc. agreed to pay $900 million to settle allegations,FULL-ARTICLE,Dow Jones Newswires,Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments -- 2nd Update
BIIB,2022-09-26,23:19:20,CEDFD5,Biogen Inc.,99,0.72,revenues,up,Biogen Inc.: The company had hoped to bolster sales,FULL-ARTICLE,Dow Jones Newswires,Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments -- 2nd Update
BIIB,2022-09-27,06:08:23,CEDFD5,Biogen Inc.,100,0.46,legal,,Biogen Inc. agreed to pay $900 million to settle allegations,FULL-ARTICLE,Dow Jones Newswires,Biogen  Settles  Kickback  Probe  ----  By Joseph Walker
BIIB,2022-09-27,06:08:23,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Inc.: The company had hoped to bolster sales,FULL-ARTICLE,Dow Jones Newswires,Biogen  Settles  Kickback  Probe  ----  By Joseph Walker
BIIB,2022-09-27,06:32:06,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen Inc. agreed to pay $900 million to settle allegations,FULL-ARTICLE,Wall Street Journal,Biogen Settles Kickback Probe -- WSJ
BIIB,2022-09-27,06:32:06,CEDFD5,Biogen Inc.,99,0.72,revenues,up,Biogen Inc.: The company had hoped to bolster sales,FULL-ARTICLE,Wall Street Journal,Biogen Settles Kickback Probe -- WSJ
BIIB,2022-09-27,09:22:08,CEDFD5,Biogen Inc.,96,0.46,legal,,Biogen agreed to pay $900 million to settle allegations,FULL-ARTICLE,Dow Jones Newswires,Biogen Kickbacks Settlement Could Place Focus on Business-Ethics Profile -- ESG Insight
BIIB,2022-09-27,23:25:08,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2022-09-28,00:04:46,CEDFD5,Biogen Inc.,91,0.57,products-services,granted,"Aduhelm, got approval from the Food and Drug Administration",FULL-ARTICLE,Dow Jones Newswires,Pharmaceutical Makers Eisai and Biogen Claim Success in Latest Alzheimer's Drug Trial -- Barrons.com
BIIB,2022-09-28,06:45:19,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Mizuho lifts Biogen to buy,FULL-ARTICLE,MarketWatch,MW Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug success
BIIB,2022-09-28,08:20:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2022-09-28,09:05:12,CEDFD5,Biogen Inc.,100,0.0,stock-picks,,"Stocks to Watch: Biogen, Apple",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: Biogen, Apple, Alcoa -- WSJ"
BIIB,2022-09-28,09:39:28,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Neutral by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Neutral by Mizuho
BIIB,2022-09-28,09:39:28,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $270.00/Share From $207.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $270.00/Share From $207.00 by Mizuho
BIIB,2022-09-28,10:33:28,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Outperform From Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Market Perform by BMO Capital
BIIB,2022-09-28,10:33:28,CEDFD5,Biogen Inc.,100,0.88,price-targets,upgrade,Biogen Price Target Raised to $360.00/Share From $217.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $360.00/Share From $217.00 by BMO Capital
BIIB,2022-09-28,10:34:48,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Outperform From Neutral by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Neutral by Baird
BIIB,2022-09-28,10:34:48,CEDFD5,Biogen Inc.,100,0.84,price-targets,upgrade,Biogen Price Target Raised to $340.00/Share From $224.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $340.00/Share From $224.00 by Baird
BIIB,2022-09-28,10:44:08,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Piper Sandler
BIIB,2022-09-28,10:44:08,CEDFD5,Biogen Inc.,100,0.82,price-targets,upgrade,Biogen Price Target Raised to $280.00/Share From $200.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $280.00/Share From $200.00 by Piper Sandler
BIIB,2022-09-28,11:11:25,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen stock price target raised to $217 from $183 at Wedbush,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $217 from $183 at Wedbush
BIIB,2022-09-28,11:11:40,CEDFD5,Biogen Inc.,93,0.94,analyst-ratings,positive,Mizuho's Salim Syed upgrades Biogen to buy from neutral,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Update Wins Back Wall Street Fans -- Market Talk
BIIB,2022-09-28,11:11:40,CEDFD5,Biogen Inc.,93,0.57,products-services,granted,Last June after the FDA approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Update Wins Back Wall Street Fans -- Market Talk
BIIB,2022-09-28,11:11:40,CEDFD5,Biogen Inc.,96,0.94,analyst-ratings,positive,Mizuho's Salim Syed upgrades Biogen to buy from neutral,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Update Wins Back Wall Street Fans -- Market Talk
BIIB,2022-09-28,11:11:40,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,Last June after the FDA approved Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Update Wins Back Wall Street Fans -- Market Talk
BIIB,2022-09-28,11:27:09,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Mizuho lifts Biogen to buy,FULL-ARTICLE,MarketWatch,MW Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug success as shares soar
BIIB,2022-09-28,11:54:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2022-09-28,11:54:29,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $321.00/Share From $251.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $321.00/Share From $251.00 by RBC Capital
BIIB,2022-09-28,12:32:49,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Wells Fargo
BIIB,2022-09-28,12:32:49,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $265.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $265.00 by Wells Fargo
BIIB,2022-09-28,14:03:49,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2022-09-28,14:03:49,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $217.00/Share From $183.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $217.00/Share From $183.00 by Wedbush
BIIB,2022-09-28,14:10:24,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen upgraded to outperform at BMO Capital,NEWS-FLASH,MarketWatch,MW Biogen upgraded to outperform at BMO Capital
BIIB,2022-09-28,14:41:27,CEDFD5,Biogen Inc.,96,-0.52,products-services,,Biogen halted the development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW Medicare coverage of Eisai and Biogen's promising new Alzheimer's therapy is 'another bridge to cross'
BIIB,2022-09-28,14:41:27,CEDFD5,Biogen Inc.,96,0.94,analyst-ratings,positive,Mizuho Securities upgraded Biogen's stock to buy from neutral,FULL-ARTICLE,MarketWatch,MW Medicare coverage of Eisai and Biogen's promising new Alzheimer's therapy is 'another bridge to cross'
BIIB,2022-09-28,15:11:48,CEDFD5,Biogen Inc.,96,-0.52,products-services,,Biogen halted the development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW Getting Medicare to cover Eisai and Biogen's promising new Alzheimer's therapy is 'another bridge to cross'
BIIB,2022-09-28,15:11:48,CEDFD5,Biogen Inc.,96,0.94,analyst-ratings,positive,Mizuho Securities upgraded Biogen's stock to buy from neutral,FULL-ARTICLE,MarketWatch,MW Getting Medicare to cover Eisai and Biogen's promising new Alzheimer's therapy is 'another bridge to cross'
BIIB,2022-09-28,18:16:17,CEDFD5,Biogen Inc.,96,-0.52,products-services,,Biogen halted the development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?
BIIB,2022-09-28,18:16:17,CEDFD5,Biogen Inc.,96,0.94,analyst-ratings,positive,Mizuho Securities upgraded Biogen's stock to buy from neutral,FULL-ARTICLE,MarketWatch,MW Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?
BIIB,2022-09-29,06:04:03,CEDFD5,Biogen Inc.,96,0.71,products-services,,The Food and Drug Administration will grant Biogen accelerated approval,FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street:  Alzheimer's Drug Raises Hopes, Costs  ---  Results of Biogen's treatment breathe new life into anti-amyloid drugs that were partially written off  ----  By David Wainer"
BIIB,2022-09-29,06:04:03,CEDFD5,Biogen Inc.,96,0.57,products-services,granted,"Aduhelm, received the FDA nod",FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street:  Alzheimer's Drug Raises Hopes, Costs  ---  Results of Biogen's treatment breathe new life into anti-amyloid drugs that were partially written off  ----  By David Wainer"
BIIB,2022-09-29,06:04:03,CEDFD5,Biogen Inc.,96,0.0,products-services,,"Aduhelm launch at $56,000 a year",FULL-ARTICLE,Dow Jones Newswires,"Heard on the Street:  Alzheimer's Drug Raises Hopes, Costs  ---  Results of Biogen's treatment breathe new life into anti-amyloid drugs that were partially written off  ----  By David Wainer"
BIIB,2022-09-29,12:40:03,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen stock price target raised to $300 from $230 at Oppenheimer,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $300 from $230 at Oppenheimer
BIIB,2022-09-29,12:49:49,CEDFD5,Biogen Inc.,96,-0.52,products-services,,Biogen halted the development of the drug back in 2019,FULL-ARTICLE,MarketWatch,MW Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?
BIIB,2022-09-29,12:49:49,CEDFD5,Biogen Inc.,96,0.94,analyst-ratings,positive,Mizuho Securities upgraded Biogen's stock to buy from neutral,FULL-ARTICLE,MarketWatch,MW Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?
BIIB,2022-09-30,10:13:36,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen stock price target raised to $275 from $221 at J.P. Morgan,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $275 from $221 at J.P. Morgan
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The Phase 3 data from the comparative clinical trial,PRESS-RELEASE,GlobeNewswire,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,GlobeNewswire,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The Phase 3 data from the comparative clinical trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The Phase 3 data from the comparative clinical trial,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:01,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",FULL-ARTICLE,Dow Jones Newswires,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:04,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The Phase 3 data from the comparative clinical trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:00:04,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen and Bio-Thera Solutions, Ltd. entered into a commercialization and license agreement",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA(R) (tocilizumab)"
BIIB,2022-09-30,11:27:29,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by JP Morgan
BIIB,2022-09-30,11:27:29,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $275.00/Share From $221.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $275.00/Share From $221.00 by JP Morgan
BIIB,2022-10-03,12:02:16,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Denali Therapeutics, Biogen Initiate Phase 3 Study of BIIB122",NEWS-FLASH,Dow Jones Newswires,"Denali Therapeutics, Biogen Initiate Phase 3 Study of BIIB122 in a Type of Parkinson's Disease >DNLI"
BIIB,2022-10-06,13:09:40,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by UBS
BIIB,2022-10-06,13:09:40,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $309.00/Share From $238.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $309.00/Share From $238.00 by UBS
BIIB,2022-10-06,13:31:26,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen stock price target raised to $309 from $238 at UBS,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $309 from $238 at UBS
BIIB,2022-10-07,11:02:25,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-10-07,11:02:25,CEDFD5,Biogen Inc.,100,0.82,price-targets,upgrade,Biogen Price Target Raised to $275.00/Share From $200.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $275.00/Share From $200.00 by Barclays
BIIB,2022-10-07,12:42:25,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Hold by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Hold by Argus Research
BIIB,2022-10-13,09:52:05,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Hold by Stifel
BIIB,2022-10-13,09:52:05,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $299.00/Share by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $299.00/Share by Stifel
BIIB,2022-10-13,10:43:17,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen upgraded to buy from hold at Stifel Nicolaus,NEWS-FLASH,MarketWatch,MW Biogen upgraded to buy from hold at Stifel Nicolaus
BIIB,2022-10-13,12:16:06,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-10-13,12:16:06,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $321.00/Share From $285.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $321.00/Share From $285.00 by Morgan Stanley
BIIB,2022-10-13,13:00:06,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Goodrx and Biogen Collaborate to Help,PRESS-RELEASE,Business Wire,GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY(R)
BIIB,2022-10-13,13:00:06,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Goodrx and Biogen Collaborate to Help,PRESS-RELEASE,Business Wire,GoodRx and Biogen Collaborate to Help Enhance -2-
BIIB,2022-10-13,13:00:36,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Goodrx and Biogen Collaborate to Help,NEWS-FLASH,Dow Jones Newswires,GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY
BIIB,2022-10-13,13:06:41,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Goodrx and Biogen Collaborate to Help,PRESS-RELEASE,Dow Jones Newswires,Press Release: GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY(R)
BIIB,2022-10-13,13:06:41,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Goodrx and Biogen Collaborate to,PRESS-RELEASE,Dow Jones Newswires,Press Release: GoodRx and Biogen Collaborate to -2-
BIIB,2022-10-13,13:30:02,CEDFD5,Biogen Inc.,99,0.46,legal,,Biogen agreed to pay $900 million to settle allegations,PRESS-RELEASE,PR Newswire,SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm
BIIB,2022-10-17,11:49:05,CEDFD5,Biogen Inc.,95,0.65,products-services,,Fda granted priority review to Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen: FDA Extends Review of Tofersen in Rare Form of ALS >BIIB
BIIB,2022-10-17,12:04:05,CEDFD5,Biogen Inc.,94,0.65,products-services,,Fda granted priority review to Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen: FDA Extends Review of Tofersen in Rare Form of ALS
BIIB,2022-10-21,07:52:24,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 3Q 2022 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 3Q 2022 (BIIB)"
BIIB,2022-10-24,14:20:33,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Jefferies
BIIB,2022-10-24,14:20:33,CEDFD5,Biogen Inc.,100,0.72,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $300.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $300.00 by Jefferies
BIIB,2022-10-25,11:09:09,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,3Q EPS $7.84 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q EPS $7.84 >BIIB
BIIB,2022-10-25,11:09:09,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $4.77,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $4.77 >BIIB
BIIB,2022-10-25,11:09:09,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Net $1.13B,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Net $1.13B >BIIB
BIIB,2022-10-25,11:09:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.51B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.51B >BIIB
BIIB,2022-10-25,11:15:07,CEDFD5,Biogen Inc.,100,0.86,earnings,up,Biogen Q3 EPS $7.84 vs. $2.22 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q3 EPS $7.84 vs. $2.22 a year ago
BIIB,2022-10-25,11:15:27,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q3 adj. EPS $4.77; FactSet consensus $4.13,NEWS-FLASH,MarketWatch,MW Biogen Q3 adj. EPS $4.77; FactSet consensus $4.13
BIIB,2022-10-25,11:16:52,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q3 revenue $2.51 bln vs. $2.78 bln a year ago; FactSet consensus $2.47 bln,NEWS-FLASH,MarketWatch,MW Biogen Q3 revenue $2.51 bln vs. $2.78 bln a year ago; FactSet consensus $2.47 bln
BIIB,2022-10-25,11:17:27,CEDFD5,Biogen Inc.,100,0.46,earnings,up,Biogen raised 2022 adj. EPS outlook to $16.50-$17.15 from $15.25-$16.75,NEWS-FLASH,MarketWatch,MW Biogen raised 2022 adj. EPS outlook to $16.50-$17.15 from $15.25-$16.75
BIIB,2022-10-25,11:17:58,CEDFD5,Biogen Inc.,100,0.48,revenues,up,Biogen raised 2022 revenue outlook to $10.0 bln-$10.15 bln from $9.9 bln-$10.1 bln,NEWS-FLASH,MarketWatch,MW Biogen raised 2022 revenue outlook to $10.0 bln-$10.15 bln from $9.9 bln-$10.1 bln
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,0.72,revenues,above-expectations,Biogen beats revenue expectations in the third quarter,FULL-ARTICLE,MarketWatch,MW Biogen beats revenue expectations in the third quarter
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen said revenue was $2.5 billion for the quarter,FULL-ARTICLE,MarketWatch,MW Biogen beats revenue expectations in the third quarter
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Tecfidera revenue fell,FULL-ARTICLE,MarketWatch,MW Biogen beats revenue expectations in the third quarter
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,0.72,revenues,above-expectations,Biogen Beats Revenue Expectations In The Third Quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Beats Revenue Expectations In The Third Quarter -- MarketWatch
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen said revenue was $2.5 billion for the quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Beats Revenue Expectations In The Third Quarter -- MarketWatch
BIIB,2022-10-25,11:36:35,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Tecfidera revenue fell,FULL-ARTICLE,Dow Jones Newswires,Biogen Beats Revenue Expectations In The Third Quarter -- MarketWatch
BIIB,2022-10-25,12:40:04,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Lifts Profit Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. Stock Rises. -- Barrons.com
BIIB,2022-10-25,12:40:04,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) last month said the Phase 3 trial of lecanemab,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. Stock Rises. -- Barrons.com
BIIB,2022-10-25,12:40:04,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported its third-quarter adjusted profits of $4.77 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. Stock Rises. -- Barrons.com
BIIB,2022-10-25,12:40:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen said full-year adjusted earnings,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. Stock Rises. -- Barrons.com
BIIB,2022-10-25,12:50:04,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Lifts Profit Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. The Stock Rises.
BIIB,2022-10-25,12:50:04,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) last month said the Phase 3 trial of lecanemab,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. The Stock Rises.
BIIB,2022-10-25,12:50:04,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen reported its third-quarter adjusted profits of $4.77 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. The Stock Rises.
BIIB,2022-10-25,12:50:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen said full-year adjusted earnings,FULL-ARTICLE,Dow Jones Newswires,Biogen Lifts Profit Estimates. The Stock Rises.
BIIB,2022-10-26,08:52:52,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by SVB Leerink
BIIB,2022-10-26,08:52:52,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $310.00/Share From $270.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $310.00/Share From $270.00 by SVB Leerink
BIIB,2022-10-26,08:54:22,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Atlantic Equities
BIIB,2022-10-26,08:54:22,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $220.00/Share From $200.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $220.00/Share From $200.00 by Atlantic Equities
BIIB,2022-10-26,10:02:00,CEDFD5,Biogen Inc.,98,0.0,products-services,,Biogen Inc.: In the first interim analysis,PRESS-RELEASE,GlobeNewswire,New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:00,CEDFD5,Biogen Inc.,98,0.4,products-services,start,Biogen Inc.: ARISE enrolled 87 patients,PRESS-RELEASE,GlobeNewswire,New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Combined post-marketing data based on prescriptions and clinical trials,PRESS-RELEASE,GlobeNewswire,New Data at ECTRIMS 2022 Highlight Biogen's -4-
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,98,0.0,products-services,,Biogen Inc.: In the first interim analysis,PRESS-RELEASE,DJ Global Press Release Wire,New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,98,0.4,products-services,start,Biogen Inc.: ARISE enrolled 87 patients,PRESS-RELEASE,DJ Global Press Release Wire,New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,90,0.57,products-services,granted,Tysabri is approved in the U.S.,FULL-ARTICLE,Dow Jones Newswires,New Data at ECTRIMS 2022 Highlight Biogen's -2-
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Combined post-marketing data based on prescriptions and clinical trials,PRESS-RELEASE,DJ Global Press Release Wire,New Data at ECTRIMS 2022 Highlight Biogen's -4-
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,98,0.0,products-services,,Biogen Inc.: In the first interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:01,CEDFD5,Biogen Inc.,98,0.4,products-services,start,Biogen Inc.: ARISE enrolled 87 patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:03,CEDFD5,Biogen Inc.,98,0.0,products-services,,Biogen Inc.: In the first interim analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:02:03,CEDFD5,Biogen Inc.,98,0.4,products-services,start,Biogen Inc.: ARISE enrolled 87 patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
BIIB,2022-10-26,10:05:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen's collaboration with TheraPanacea, which aims to develop computer",PRESS-RELEASE,GlobeNewswire,Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
BIIB,2022-10-26,10:05:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen's collaboration with TheraPanacea, which aims to develop computer",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
BIIB,2022-10-26,10:05:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen's collaboration with TheraPanacea, which aims to develop computer",FULL-ARTICLE,Dow Jones Newswires,Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
BIIB,2022-10-26,10:05:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen's collaboration with TheraPanacea, which aims to develop computer",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
BIIB,2022-10-26,10:16:03,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2022-10-26,10:16:03,CEDFD5,Biogen Inc.,100,0.82,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $240.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $240.00 by HC Wainwright & Co.
BIIB,2022-10-26,12:25:53,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2022-10-26,12:25:53,CEDFD5,Biogen Inc.,100,0.66,price-targets,upgrade,Biogen Price Target Raised to $331.00/Share From $310.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $331.00/Share From $310.00 by RBC Capital
BIIB,2022-10-26,14:01:03,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Neutral by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Neutral by Goldman Sachs
BIIB,2022-10-26,14:01:03,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $370.00/Share by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $370.00/Share by Goldman Sachs
BIIB,2022-10-26,14:06:53,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2022-10-26,14:06:53,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $321.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $321.00 by Morgan Stanley
BIIB,2022-10-28,17:52:02,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Vp Alexander Registers 5,532 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"VP Alexander Registers 5,532 Of Biogen Inc >BIIB"
BIIB,2022-10-28,19:29:20,CEDFD5,Biogen Inc.,95,0.0,products-services,,Eisai is developing the drug with partner Biogen Inc.,FULL-ARTICLE,Dow Jones Newswires,Volunteer Dies Testing Eisai-Biogen Alzheimer's Drug During Study -- WSJ
BIIB,2022-10-28,23:20:20,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Alexander Sells 5,532 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Alexander Sells 5,532 Of Biogen Inc >BIIB"
BIIB,2022-11-01,11:07:55,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Mizuho
BIIB,2022-11-01,11:07:55,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $270.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $270.00 by Mizuho
BIIB,2022-11-01,12:23:30,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen stock price target raised to $325 from $270 at Mizuho,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $325 from $270 at Mizuho
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:02,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,GlobeNewswire,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:02,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,GlobeNewswire,Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:05,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:05,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher President and Chief Executive Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Names Christopher Viehbacher President and Chief Executive Officer
BIIB,2022-11-10,12:30:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher Pres and CEO,NEWS-FLASH,Dow Jones Newswires,Biogen Names Christopher Viehbacher Pres and CEO
BIIB,2022-11-10,12:30:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher Pres and CEO,NEWS-FLASH,Dow Jones Newswires,Biogen Names Christopher Viehbacher Pres and CEO
BIIB,2022-11-10,12:58:30,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Former Sanofi Chief Christopher Viehbacher President,FULL-ARTICLE,Dow Jones Newswires,"Biogen Names Former Sanofi Chief Christopher Viehbacher President, CEO >BIIB"
BIIB,2022-11-10,13:08:28,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen names former Sanofi chief as new CEO,FULL-ARTICLE,MarketWatch,"MW Biogen names former Sanofi chief as new CEO, shares rise"
BIIB,2022-11-10,13:08:28,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Former Sanofi Chief As New CEO,FULL-ARTICLE,Dow Jones Newswires,"Biogen Names Former Sanofi Chief As New CEO, Shares Rise -- MarketWatch"
BIIB,2022-11-10,14:34:40,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher New CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher New CEO -- WSJ
BIIB,2022-11-10,14:40:03,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Viehbacher New CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Viehbacher New CEO
BIIB,2022-11-10,15:19:59,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher New CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher New CEO -- Update
BIIB,2022-11-10,16:06:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher New CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher New CEO -- 2nd Update
BIIB,2022-11-10,16:34:46,CEDFD5,Biogen Inc.,99,0.71,products-services,,Aduhelm that could receive accelerated approval from the Food and Drug Administration,FULL-ARTICLE,Dow Jones Newswires,Biogen's Surprise CEO Pick Raises Questions About Post-Aduhelm Path -- Barrons.com
BIIB,2022-11-10,16:34:46,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda approved Aduhelm in June 2021,FULL-ARTICLE,Dow Jones Newswires,Biogen's Surprise CEO Pick Raises Questions About Post-Aduhelm Path -- Barrons.com
BIIB,2022-11-10,16:34:46,CEDFD5,Biogen Inc.,99,0.47,labor-issues,,Over appointments to Biogen's board,FULL-ARTICLE,Dow Jones Newswires,Biogen's Surprise CEO Pick Raises Questions About Post-Aduhelm Path -- Barrons.com
BIIB,2022-11-10,17:35:59,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher New CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher New CEO -- 3rd Update
BIIB,2022-11-10,17:35:59,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen halted two Phase 3 studies of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Christopher Viehbacher New CEO -- 3rd Update
BIIB,2022-11-11,07:05:12,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Ex-Sanofi Chief as CEO,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Ex-Sanofi Chief as CEO  ----  By Joseph Walker and Colin Kellaher
BIIB,2022-11-11,07:05:12,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen halted two Phase 3 studies of Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Ex-Sanofi Chief as CEO  ----  By Joseph Walker and Colin Kellaher
BIIB,2022-11-11,07:32:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Christopher Viehbacher New CEO,FULL-ARTICLE,Wall Street Journal,Biogen Names Christopher Viehbacher New CEO -- WSJ
BIIB,2022-11-11,07:32:08,CEDFD5,Biogen Inc.,100,-0.54,products-services,suspended,Biogen halted two Phase 3 studies of Aduhelm,FULL-ARTICLE,Wall Street Journal,Biogen Names Christopher Viehbacher New CEO -- WSJ
BIIB,2022-11-11,12:02:11,CEDFD5,Biogen Inc.,100,0.36,price-targets,upgrade,Biogen price target raised to $270 from $265 at Guggenheim,NEWS-FLASH,MarketWatch,MW Biogen price target raised to $270 from $265 at Guggenheim
BIIB,2022-11-11,13:59:19,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Guggenheim
BIIB,2022-11-11,13:59:19,CEDFD5,Biogen Inc.,100,0.36,price-targets,upgrade,Biogen Price Target Raised to $270.00/Share From $265.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $270.00/Share From $265.00 by Guggenheim
BIIB,2022-11-14,13:16:45,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2022-11-14,13:16:45,CEDFD5,Biogen Inc.,100,0.58,price-targets,upgrade,Biogen Price Target Raised to $315.00/Share From $300.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $315.00/Share From $300.00 by Oppenheimer
BIIB,2022-11-15,12:28:10,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen stock price target raised to $350 from $265,NEWS-FLASH,MarketWatch,MW Biogen stock price target raised to $350 from $265 at Truist
BIIB,2022-11-15,14:40:06,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2022-11-15,14:40:06,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $265.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $265.00 by Truist Securities
BIIB,2022-11-15,21:22:21,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Vp Gregory Registers 5,610 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"VP Gregory Registers 5,610 Of Biogen Inc >BIIB"
BIIB,2022-11-16,07:04:02,CEDFD5,Biogen Inc.,99,0.53,labor-issues,,Biogen Inc.: the company hired former Sanofi CEO Chris Viehbacher,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street:  Alzheimer's Drug's Potential Buoys Biogen  ----  By David Wainer
BIIB,2022-11-23,19:45:20,CEDFD5,Biogen Inc.,99,0.84,products-services,positive,Biogen Inc.: the company announced positive clinical trial results for their Alzheimer's drug lecanemab,PRESS-RELEASE,DGAP News,EQS-News: CBOE's Weekly Market Recap: Nov.14-18 - Biogen's Alzheimer's Drug Captures Investors' Attention
BIIB,2022-11-23,19:45:20,CEDFD5,Biogen Inc.,99,0.84,products-services,positive,Biogen Inc.: the company announced positive clinical trial results for their Alzheimer's drug lecanemab,PRESS-RELEASE,Dow Jones Newswires,EQS-News: CBOE's Weekly Market Recap: Nov.14-18 - Biogen's Alzheimer's Drug Captures Investors' Attention
BIIB,2022-11-30,00:45:01,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2022-11-30,00:50:00,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Release New Details From Lecanemab,NEWS-FLASH,Dow Jones Newswires,Eisai and Biogen Release New Details From Lecanemab Alzheimer's Study -- WSJ
BIIB,2022-11-30,09:20:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2022-11-30,11:35:08,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2022-11-30,11:35:08,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $313.00/Share From $275.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $313.00/Share From $275.00 by Barclays
BIIB,2022-11-30,11:48:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Stifel analyst Paul Matteis reiterated his buy rating on Biogen,FULL-ARTICLE,MarketWatch,MW Biogen stock up 3% premarket after update on Alzheimer's treatment; Stifel reiterates buy rating
BIIB,2022-11-30,11:48:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Stifel analyst Paul Matteis reiterated his buy rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Up 3% Premarket After Update On Alzheimer's Treatment; Stifel Reiterates Buy Rating -- MarketWatch
BIIB,2022-11-30,14:44:59,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2022-11-30,14:44:59,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $247.00/Share From $218.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $247.00/Share From $218.00 by Wedbush
BIIB,2022-11-30,15:04:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Jefferies
BIIB,2022-11-30,15:04:29,CEDFD5,Biogen Inc.,100,0.68,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $325.00 by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $325.00 by Jefferies
BIIB,2022-12-01,10:09:53,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Atlantic Equities
BIIB,2022-12-01,10:09:53,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $295.00/Share From $220.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $295.00/Share From $220.00 by Atlantic Equities
BIIB,2022-12-05,12:55:53,CEDFD5,Biogen Inc.,95,0.65,products-services,,The U.S. Food and Drug Administration granted priority review to tofersen,FULL-ARTICLE,Dow Jones Newswires,Biogen: EMA to Review Tofersen in Rare Form of ALS >BIIB
BIIB,2022-12-06,23:34:58,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 92 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 92 Of Biogen Inc >BIIB
BIIB,2022-12-06,23:39:13,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 951 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 951 Of Biogen Inc >BIIB
BIIB,2022-12-07,15:26:59,CEDFD5,Biogen Inc.,95,0.46,legal,,Biogen has agreed to pay $900 million to settle,PRESS-RELEASE,DJ Global Press Release Wire,"Shareholder Alert: Grabar Law Office Investigates Claims on Behalf of Shareholders of Biogen, Inc. (BIIB) After It Agrees to Pay $900 Million for Improper Kickbacks"
BIIB,2022-12-09,12:30:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB800 clinical program,PRESS-RELEASE,DJ Global Press Release Wire,"FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA(R) (tocilizumab)"
BIIB,2022-12-09,12:30:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB800 clinical program,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA(R) (tocilizumab)"
BIIB,2022-12-09,12:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB800 clinical program,PRESS-RELEASE,GlobeNewswire,"FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA(R) (tocilizumab)"
BIIB,2022-12-09,12:30:04,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB800 clinical program,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA(R) (tocilizumab)"
BIIB,2022-12-09,19:34:21,CEDFD5,Biogen Inc.,95,0.0,products-services,,Biogen previously reported data from a Phase 3 trial,FULL-ARTICLE,Dow Jones Newswires,Trending: Biogen Application for Actemra Biosimilar Accepted for Review
BIIB,2022-12-09,19:49:21,CEDFD5,Biogen Inc.,95,0.0,products-services,,Biogen previously reported data from a Phase 3 trial,FULL-ARTICLE,Dow Jones Newswires,Trending: Biogen Application for Actemra Biosimilar Accepted for Review
BIIB,2022-12-12,14:00:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Frontage Partners with Eisai and Biogen to,PRESS-RELEASE,PR Newswire,"Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer's Drug, Lecanemab"
BIIB,2022-12-12,14:00:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Frontage Partners with Eisai and Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer's Drug, Lecanemab"
BIIB,2022-12-12,14:04:38,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Frontage Partners With Eisai , Biogen to",NEWS-FLASH,Dow Jones Newswires,"Frontage Partners With Eisai , Biogen to Complete the Clarity AD Study for Alzheimer's Drug Lecanemab"
BIIB,2022-12-12,23:06:48,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 194 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 194 Of Biogen Inc >BIIB
BIIB,2022-12-13,01:03:49,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Gregory Sells 5,610 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Sells 5,610 Of Biogen Inc >BIIB"
BIIB,2022-12-19,12:30:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Genentech,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-19,12:30:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Genentech,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-19,12:30:00,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Genentech,FULL-ARTICLE,Dow Jones Newswires,Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-19,12:30:01,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Genentech,PRESS-RELEASE,GlobeNewswire,Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-19,12:30:04,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement with Genentech,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-19,12:30:33,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen Reaches Agreement With Genentech,NEWS-FLASH,Dow Jones Newswires,Biogen Reaches Agreement With Genentech to Receive Royalties on Potential Commercialization of Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
BIIB,2022-12-29,18:00:18,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Inappropriately"" collaborated with Biogen Inc. before",FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug -- WSJ
BIIB,2022-12-29,18:00:18,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen later slashed its price in half,FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug -- WSJ
BIIB,2022-12-29,18:04:03,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Inappropriately"" collaborated with Biogen Inc. before",FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug -- Update
BIIB,2022-12-29,18:04:03,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen later slashed its price in half,FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug -- Update
BIIB,2022-12-29,18:10:11,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Inappropriately"" collaborated with Biogen Inc. before",FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug
BIIB,2022-12-29,18:10:11,CEDFD5,Biogen Inc.,99,-0.44,products-services,cut,Biogen later slashed its price in half,FULL-ARTICLE,Dow Jones Newswires,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer's Drug
BIIB,2023-01-04,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
BIIB,2023-01-04,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration,FULL-ARTICLE,Dow Jones Newswires,Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
BIIB,2023-01-04,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
BIIB,2023-01-04,12:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration,PRESS-RELEASE,GlobeNewswire,Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
BIIB,2023-01-04,12:30:05,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen has initiated a search for a new Executive Vice President,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",FULL-ARTICLE,Dow Jones Newswires,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",FULL-ARTICLE,Dow Jones Newswires,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen has initiated a search for a new Executive Vice President,FULL-ARTICLE,Dow Jones Newswires,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen has initiated a search for a new Executive Vice President,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:02,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Priya Singhal as Executive Vice President,PRESS-RELEASE,GlobeNewswire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:02,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,GlobeNewswire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:02,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen has initiated a search for a new Executive Vice President,PRESS-RELEASE,GlobeNewswire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:05,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Priya Singhal as Executive Vice President,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:05,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:05,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen has initiated a search for a new Executive Vice President,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice Pres, Head",NEWS-FLASH,Dow Jones Newswires,"Biogen Names Priya Singhal as Executive Vice Pres, Head of Development"
BIIB,2023-01-05,12:30:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice Pres, Head",NEWS-FLASH,Dow Jones Newswires,"Biogen Names Priya Singhal as Executive Vice Pres, Head of Development"
BIIB,2023-01-05,12:33:00,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen Initiates Search for New Executive VP,NEWS-FLASH,Dow Jones Newswires,"Biogen Initiates Search for New Executive VP, Head of Research >BIIB"
BIIB,2023-01-05,13:00:02,CEDFD5,Biogen Inc.,99,0.47,labor-issues,,Biogen Inc.: The appointment of Maha as a board member,PRESS-RELEASE,GlobeNewswire,"Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member"
BIIB,2023-01-05,13:00:02,CEDFD5,Biogen Inc.,99,0.47,labor-issues,,Biogen Inc.: The appointment of Maha as a board member,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member"
BIIB,2023-01-05,13:00:02,CEDFD5,Biogen Inc.,99,0.47,labor-issues,,Biogen Inc.: The appointment of Maha as a board member,PRESS-RELEASE,DJ Global Press Release Wire,"Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member"
BIIB,2023-01-06,19:00:01,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2023-01-06,19:03:49,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock halted,NEWS-FLASH,MarketWatch,MW Biogen stock halted for news pending
BIIB,2023-01-06,19:03:49,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock halted,NEWS-FLASH,MarketWatch,MW Biogen stock halted for news pending
BIIB,2023-01-06,19:18:59,CEDFD5,Biogen Inc.,91,0.57,products-services,granted,The Food and Drug Administration approved Biogen and Eisai's Alzheimer's disease therapy lecanemab,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Eisai and Biogen's New Alzheimer's Therapy -- Barrons.com
BIIB,2023-01-06,20:05:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2023-01-09,14:28:06,CEDFD5,Biogen Inc.,96,0.46,legal,,Biogen has agreed to pay $900 million to settle,PRESS-RELEASE,DJ Global Press Release Wire,"Grabar Law Office Investigates Claims on Behalf of Shareholders of Biogen, Inc. (BIIB) After It Agrees to Pay $900 Million for Improper Kickbacks"
BIIB,2023-01-10,21:48:45,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda granted preliminary approval to Aduhelm,FULL-ARTICLE,Dow Jones Newswires,FDA Commissioner Denies Wrongdoing in Approval Process for Biogen Alzheimer's Drug Aduhelm -- WSJ
BIIB,2023-01-10,23:34:18,CEDFD5,Biogen Inc.,100,0.44,products-services,conditional,Biogen Drug Received Conditional FDA Approval,NEWS-FLASH,Dow Jones Newswires,Eisai and Biogen Drug Received Conditional FDA Approval on Friday
BIIB,2023-01-21,08:27:29,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2022 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2022 (BIIB)"
BIIB,2023-01-23,17:58:07,CEDFD5,Biogen Inc.,93,0.65,products-services,,Fda last July granted priority review to the tofersen,FULL-ARTICLE,Dow Jones Newswires,FDA Sets AdCom Meeting to Review Biogen/Ionis ALS Drug -- Market Talk
BIIB,2023-01-23,17:58:08,CEDFD5,Biogen Inc.,93,0.65,products-services,,Fda last July granted priority review to the tofersen,FULL-ARTICLE,Dow Jones Newswires,FDA Sets AdCom Meeting to Review Biogen/Ionis ALS Drug -- Market Talk
BIIB,2023-01-24,13:27:54,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-01-24,13:27:54,CEDFD5,Biogen Inc.,100,0.62,price-targets,upgrade,Biogen Price Target Raised to $345.00/Share From $325.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $345.00/Share From $325.00 by Morgan Stanley
BIIB,2023-01-26,23:56:16,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization
BIIB,2023-01-27,00:11:16,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization
BIIB,2023-01-27,23:29:35,CEDFD5,Biogen Inc.,100,0.0,insider-trading,,Dir Sherwin Gifts 695 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Dir Sherwin Gifts 695 Of Biogen Inc >BIIB
BIIB,2023-01-27,23:33:31,CEDFD5,Biogen Inc.,100,0.0,insider-trading,,Dir Posner Gifts 150 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Dir Posner Gifts 150 Of Biogen Inc >BIIB
BIIB,2023-01-29,23:30:01,CEDFD5,Biogen Inc.,100,0.65,products-services,,Lecanemab Receives Priority Review Status in Japan,PRESS-RELEASE,GlobeNewswire,Lecanemab Receives Priority Review Status in Japan -2-
BIIB,2023-01-29,23:30:01,CEDFD5,Biogen Inc.,100,0.65,products-services,,Lecanemab Receives Priority Review Status in Japan,FULL-ARTICLE,Dow Jones Newswires,Lecanemab Receives Priority Review Status in Japan -2-
BIIB,2023-01-29,23:30:01,CEDFD5,Biogen Inc.,100,0.65,products-services,,Lecanemab Receives Priority Review Status in Japan,PRESS-RELEASE,DJ Global Press Release Wire,Lecanemab Receives Priority Review Status in Japan -2-
BIIB,2023-02-06,11:48:53,CEDFD5,Biogen Inc.,100,0.65,products-services,,"Biogen, Sage Get FDA Priority Review of Zuranolone",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Sage Get FDA Priority Review of Zuranolone >BIIB SAGE"
BIIB,2023-02-06,12:03:53,CEDFD5,Biogen Inc.,100,0.65,products-services,,"Biogen, Sage Get FDA Priority Review of Zuranolone",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Sage Get FDA Priority Review of Zuranolone"
BIIB,2023-02-14,21:18:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen reports its financial results for the fourth quarter on Wednesday,FULL-ARTICLE,Dow Jones Newswires,"Drugs for Alzheimer's, Depression, Are in Focus as Biogen Reports Earnings -- Barrons.com"
BIIB,2023-02-14,21:18:51,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Which Biogen has partnered on Leqembi,FULL-ARTICLE,Dow Jones Newswires,"Drugs for Alzheimer's, Depression, Are in Focus as Biogen Reports Earnings -- Barrons.com"
BIIB,2023-02-14,21:18:51,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen is partnered with Sage Therapeutics (SAGE), could launch",FULL-ARTICLE,Dow Jones Newswires,"Drugs for Alzheimer's, Depression, Are in Focus as Biogen Reports Earnings -- Barrons.com"
BIIB,2023-02-14,21:18:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Analysts expect Biogen to report fourth-quarter earnings of $3.48 a share,FULL-ARTICLE,Dow Jones Newswires,"Drugs for Alzheimer's, Depression, Are in Focus as Biogen Reports Earnings -- Barrons.com"
BIIB,2023-02-15,02:24:46,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Singhal Acquires 839 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Singhal Acquires 839 Of Biogen Inc >BIIB
BIIB,2023-02-15,02:25:19,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Murphy Acquires 1,224 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Murphy Acquires 1,224 Of Biogen Inc >BIIB"
BIIB,2023-02-15,02:26:54,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 2,151 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 2,151 Of Biogen Inc >BIIB"
BIIB,2023-02-15,02:39:19,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 471 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 471 Of Biogen Inc >BIIB
BIIB,2023-02-15,02:42:59,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 644 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 644 Of Biogen Inc >BIIB
BIIB,2023-02-15,02:45:37,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Gregory Disposes 16 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Gregory Disposes 16 Of Biogen Inc >BIIB
BIIB,2023-02-15,02:48:09,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Alexander Disposes 179 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Disposes 179 Of Biogen Inc >BIIB
BIIB,2023-02-15,12:06:18,CEDFD5,Biogen Inc.,100,0.62,earnings,up,Biogen Q4 EPS $3.79 vs. $2.50 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q4 EPS $3.79 vs. $2.50 a year ago
BIIB,2023-02-15,12:06:18,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q4 adj. EPS $4.05; FactSet consensus $3.49,NEWS-FLASH,MarketWatch,MW Biogen Q4 adj. EPS $4.05; FactSet consensus $3.49
BIIB,2023-02-15,12:07:18,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q4 revenue $2.544 bln vs. $2.734 bln a year ago; FactSet consensus $2.444 bln,NEWS-FLASH,MarketWatch,MW Biogen Q4 revenue $2.544 bln vs. $2.734 bln a year ago; FactSet consensus $2.444 bln
BIIB,2023-02-15,12:08:18,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees 2023 adj. EPS of $15 to $16,NEWS-FLASH,MarketWatch,MW Biogen now sees 2023 adj. EPS of $15 to $16; FactSet consensus $15.80
BIIB,2023-02-15,12:09:18,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen now sees 2023 revenue down,NEWS-FLASH,MarketWatch,MW Biogen now sees 2023 revenue down in mid-single digits
BIIB,2023-02-15,12:11:39,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,"Biogen Inc.: Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Says Company Will Look Beyond Neuroscience -- Market Talk
BIIB,2023-02-15,12:11:40,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,"Biogen Inc.: Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Says Company Will Look Beyond Neuroscience -- Market Talk
BIIB,2023-02-15,12:12:09,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $3.79 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q EPS $3.79 >BIIB
BIIB,2023-02-15,12:12:12,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.54B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Rev $2.54B >BIIB
BIIB,2023-02-15,12:12:17,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Net $550.4M,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Net $550.4M >BIIB
BIIB,2023-02-15,12:12:37,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Adj EPS $4.05,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Adj EPS $4.05 >BIIB
BIIB,2023-02-15,12:13:17,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees 2023 Adj EPS $15.00,NEWS-FLASH,Dow Jones Newswires,Biogen Sees 2023 Adj EPS $15.00-Adj EPS $16.00 >BIIB
BIIB,2023-02-15,12:13:37,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Sees Mid-Single-Digit Revenue Decline in 2023,NEWS-FLASH,Dow Jones Newswires,Biogen Sees Mid-Single-Digit Revenue Decline in 2023 >BIIB
BIIB,2023-02-15,12:16:32,CEDFD5,Biogen Inc.,100,-0.43,products-services,terminated,"Biogen Terminating License, Collaboration Agreement With InnoCare",NEWS-FLASH,Dow Jones Newswires,"Biogen Terminating License, Collaboration Agreement With InnoCare for Orelabrutinib >BIIB"
BIIB,2023-02-15,12:25:19,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen expects EPS of $15.00 to $16.00 in 2023,FULL-ARTICLE,MarketWatch,MW Biogen's stock gains after company beats Q4 revenue and earnings expectations
BIIB,2023-02-15,12:25:19,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen expects EPS of $15.00 to $16.00 in 2023,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Gains After Company Beats Q4 Revenue And Earnings Expectations -- MarketWatch
BIIB,2023-02-15,12:27:27,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,"Biogen Inc.: Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,"Biogen Has Lost Its Way In Recent Years, New CEO Says -- Market Talk"
BIIB,2023-02-15,12:45:31,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,"Biogen Inc.: Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen Throws in Towel on InnoCare MS Collaboration -- Market Talk
BIIB,2023-02-15,13:55:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Factset expected Biogen to earn $3.48 per share,FULL-ARTICLE,Dow Jones Newswires,"Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales -- IBD"
BIIB,2023-02-15,13:55:49,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: the company reported $2.73 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales -- IBD"
BIIB,2023-02-15,13:55:49,CEDFD5,Biogen Inc.,99,0.36,revenues,,"Biogen Inc.: The company projected ""modest in-market revenue",FULL-ARTICLE,Dow Jones Newswires,"Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales -- IBD"
BIIB,2023-02-15,15:49:33,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,"Biogen expects ""modest in-market revenue",FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,15:49:33,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen's sales fell 7% to $2.54 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,15:49:33,CEDFD5,Biogen Inc.,100,-0.8,earnings,below-expectations,Biogen's profit outlook missed,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,15:49:33,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Abrahams has an outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,18:16:05,CEDFD5,Biogen Inc.,99,-0.24,revenues,down,Biogen said on Wednesday revenue fell 7% to $10.2 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Boss Turns Corner on Alzheimer's Miscues -- Heard on the Street -- WSJ
BIIB,2023-02-15,21:04:54,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,"Biogen expects ""modest in-market revenue",FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,21:04:54,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen's sales fell 7% to $2.54 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,21:04:54,CEDFD5,Biogen Inc.,100,-0.8,earnings,below-expectations,Biogen's profit outlook missed,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,21:04:54,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Abrahams has an outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-16,07:02:42,CEDFD5,Biogen Inc.,99,-0.24,revenues,down,Biogen said on Wednesday that revenue fell 7%,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street:  Biogen Boss Aims to Turn a Corner  ---  Biotech company needs to embark on new growth path as former Sanofi CEO takes the helm  ----  By David Wainer
BIIB,2023-02-16,07:33:41,CEDFD5,Biogen Inc.,99,-0.24,revenues,down,Biogen said on Wednesday revenue fell 7% to $10.2 billion,FULL-ARTICLE,Wall Street Journal,Heard on the Street: Biogen Boss Aims to Turn a Corner -- WSJ
BIIB,2023-02-16,13:08:30,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-02-16,13:08:30,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $333.00/Share From $359.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $333.00/Share From $359.00 by RBC Capital
BIIB,2023-02-16,13:26:20,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-02-16,13:26:20,CEDFD5,Biogen Inc.,100,0.32,price-targets,upgrade,Biogen Price Target Raised to $351.00/Share From $345.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $351.00/Share From $345.00 by Morgan Stanley
BIIB,2023-02-16,13:57:10,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by UBS
BIIB,2023-02-16,13:57:11,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $340.00/Share From $337.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $340.00/Share From $337.00 by UBS
BIIB,2023-02-16,14:04:21,CEDFD5,Biogen Inc.,100,0.2,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Cowen & Co.
BIIB,2023-02-16,14:04:21,CEDFD5,Biogen Inc.,100,0.58,price-targets,upgrade,Biogen Price Target Raised to $315.00/Share From $300.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $315.00/Share From $300.00 by Cowen & Co.
BIIB,2023-02-17,17:30:06,CEDFD5,Biogen Inc.,97,0.0,investor-relations,,Biogen's earnings call on Wednesday,PRESS-RELEASE,PR Newswire,Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights
BIIB,2023-02-22,21:57:25,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Alexander Acquires 991 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Acquires 991 Of Biogen Inc >BIIB
BIIB,2023-02-22,22:04:40,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Gregory Acquires 925 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Gregory Acquires 925 Of Biogen Inc >BIIB
BIIB,2023-02-22,22:10:49,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 396 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 396 Of Biogen Inc >BIIB
BIIB,2023-02-22,22:12:57,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Singhal Acquires 309 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Singhal Acquires 309 Of Biogen Inc >BIIB
BIIB,2023-02-22,22:16:09,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 1,251 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 1,251 Of Biogen Inc >BIIB"
BIIB,2023-02-22,22:17:49,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 274 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 274 Of Biogen Inc >BIIB
BIIB,2023-02-22,22:27:39,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 247 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 247 Of Biogen Inc >BIIB
BIIB,2023-03-06,16:38:47,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen is developing in partnership with Sage Therapeutics (SAGE),FULL-ARTICLE,Dow Jones Newswires,FDA Will Weigh Full Approval for Alzheimer's Drug. Why It Matters for Biogen Stock. -- Barrons.com
BIIB,2023-03-06,23:14:56,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Officer Singhal Disposes 390 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,Officer Singhal Disposes 390 Of Biogen Inc >BIIB
BIIB,2023-03-08,12:33:10,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Names Caroline Dorsa Chairman,NEWS-FLASH,Dow Jones Newswires,"Biogen Names Caroline Dorsa Chairman, Effective at June 14 Annual Meeting >BIIB"
BIIB,2023-03-08,13:00:05,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Names Dorsa to Succeed Papadopoulos as Chairman,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Dorsa to Succeed Papadopoulos as Chairman >BIIB
BIIB,2023-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Chuck Triano as Head of Investor Relations,PRESS-RELEASE,GlobeNewswire,Biogen Appoints Chuck Triano as Head of Investor Relations
BIIB,2023-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Chuck Triano as Head of Investor Relations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Chuck Triano as Head of Investor Relations
BIIB,2023-03-14,14:52:13,CEDFD5,Biogen Inc.,99,0.0,products-services,,Aduhelm could cost Medicare $57 billion,FULL-ARTICLE,Dow Jones Newswires,The VA Will Pay for Leqembi. It's a Step in Right Direction for Biogen. -- Barrons.com
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.53,legal,,Court of Justice of the European Union decided in favor of Biogen,PRESS-RELEASE,GlobeNewswire,Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Full Year 2023 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.53,legal,,Court of Justice of the European Union decided in favor of Biogen,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Full Year 2023 Financial Guidance,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.53,legal,,Court of Justice of the European Union decided in favor of Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Full Year 2023 Financial Guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.53,legal,,Court of Justice of the European Union decided in favor of Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:15,CEDFD5,Biogen Inc.,99,0.53,legal,,Court of Justice of the European Union decided in favor of Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:37:05,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen: 2023 Guidance,NEWS-FLASH,Dow Jones Newswires,Biogen: 2023 Guidance Issued on Feb. 15 Assumed Favorable Decision >BIIB
BIIB,2023-03-17,22:45:33,CEDFD5,Biogen Inc.,100,-0.46,partnerships,terminated,"Novartis, Biogen End Collaborations",FULL-ARTICLE,Dow Jones Newswires,"Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations"
BIIB,2023-03-17,23:00:33,CEDFD5,Biogen Inc.,100,-0.46,partnerships,terminated,"Novartis, Biogen End Collaborations",FULL-ARTICLE,Dow Jones Newswires,"Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations"
BIIB,2023-03-23,00:31:57,CEDFD5,Biogen Inc.,99,0.0,products-services,filed,Biogen Inc.: The New Drug Application for tofersen,PRESS-RELEASE,GlobeNewswire,Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
BIIB,2023-03-23,00:31:57,CEDFD5,Biogen Inc.,99,0.0,products-services,filed,Biogen Inc.: The New Drug Application for tofersen,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
BIIB,2023-03-23,00:31:57,CEDFD5,Biogen Inc.,99,0.0,products-services,filed,Biogen Inc.: The New Drug Application for tofersen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
BIIB,2023-03-23,00:31:58,CEDFD5,Biogen Inc.,99,0.0,products-services,filed,Biogen Inc.: The New Drug Application for tofersen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
BIIB,2023-03-23,13:25:44,CEDFD5,Biogen Inc.,94,0.0,products-services,,Biogen and Ionis Pharmaceuticals tested tofersen,FULL-ARTICLE,Dow Jones Newswires,Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement -- IBD
BIIB,2023-03-28,14:39:26,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Officer Singhal Registers 568 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,Officer Singhal Registers 568 Of Biogen Inc >BIIB
BIIB,2023-03-29,12:45:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB080 Phase 1b clinical study,PRESS-RELEASE,DJ Global Press Release Wire,New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Phase 1b Study of BIIB080,PRESS-RELEASE,DJ Global Press Release Wire,New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB080 Phase 1b clinical study,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Phase 1b Study of BIIB080,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB080 Phase 1b clinical study,PRESS-RELEASE,GlobeNewswire,New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Phase 1b Study of BIIB080,PRESS-RELEASE,GlobeNewswire,New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB080 Phase 1b clinical study,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Phase 1b Study of BIIB080,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:02,CEDFD5,Biogen Inc.,97,0.0,products-services,,Partner Biogen presented new Phase 1b clinical data,PRESS-RELEASE,PR Newswire,New data presented at AD/PD(TM)2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
BIIB,2023-03-29,12:45:31,CEDFD5,Biogen Inc.,97,0.0,products-services,,Partner Biogen presented new Phase 1b clinical data,PRESS-RELEASE,Dow Jones Newswires,Press Release: New data presented at AD/PD(TM)2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
BIIB,2023-03-29,12:46:50,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen: Phase 1b Study of BIIB080 Showed,NEWS-FLASH,Dow Jones Newswires,Biogen: Phase 1b Study of BIIB080 Showed Dose-Dependent and Sustained Reduction of Tau Protein in Cerebral Spinal Fluid Throughout the Open-Label Long-Term Extension >BIIB
BIIB,2023-03-30,22:33:11,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Officer Singhal Sells 568 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,Officer Singhal Sells 568 Of Biogen Inc >BIIB
BIIB,2023-04-04,11:30:00,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Adam Keeney as Head of,PRESS-RELEASE,GlobeNewswire,Biogen Appoints Adam Keeney as Head of Corporate Development
BIIB,2023-04-04,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Adam Keeney as Head of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Adam Keeney as Head of Corporate Development
BIIB,2023-04-04,16:24:34,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 91 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 91 Of Biogen Inc >BIIB
BIIB,2023-04-04,21:26:42,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 123 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 123 Of Biogen Inc >BIIB
BIIB,2023-04-06,22:38:33,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 91 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 91 Of Biogen Inc >BIIB
BIIB,2023-04-12,14:56:41,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-04-12,14:56:41,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $349.00/Share From $351.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $349.00/Share From $351.00 by Morgan Stanley
BIIB,2023-04-17,09:37:17,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Overweight From Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Overweight From Neutral by Piper Sandler
BIIB,2023-04-17,09:37:17,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $346.00/Share From $280.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $346.00/Share From $280.00 by Piper Sandler
BIIB,2023-04-17,12:47:28,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2023-04-17,12:47:28,CEDFD5,Biogen Inc.,100,0.6,price-targets,upgrade,Biogen Price Target Raised to $263.00/Share From $249.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $263.00/Share From $249.00 by Wedbush
BIIB,2023-04-17,15:47:59,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Argus Research
BIIB,2023-04-17,15:47:59,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $320.00/Share From $315.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $320.00/Share From $315.00 by Argus Research
BIIB,2023-04-17,20:02:09,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Of Appointment as Chair of Biogen,NEWS-FLASH,Dow Jones Newswires,Intellia Therapeutics: Dorsa Retiring From Board as Result of Appointment as Chair of Biogen's Board
BIIB,2023-04-21,07:27:56,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 1Q 2023 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 1Q 2023 (BIIB)"
BIIB,2023-04-21,14:19:21,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by B of A Securities
BIIB,2023-04-21,14:19:21,CEDFD5,Biogen Inc.,100,0.32,price-targets,upgrade,Biogen Price Target Raised to $300.00/Share From $295.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $300.00/Share From $295.00 by B of A Securities
BIIB,2023-04-24,20:21:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen reports its quarterly earnings on Tuesday morning,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports Earnings Tuesday. Watch for Alzheimer's Drug Updates -- Barrons.com
BIIB,2023-04-24,20:21:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Analysts expect Biogen to report earnings of $3.28 a share for the first quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports Earnings Tuesday. Watch for Alzheimer's Drug Updates -- Barrons.com
BIIB,2023-04-25,11:02:53,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $2.67 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $2.67 >BIIB
BIIB,2023-04-25,11:02:53,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Net $387.9M,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Net $387.9M >BIIB
BIIB,2023-04-25,11:02:53,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.46B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.46B >BIIB
BIIB,2023-04-25,11:12:40,CEDFD5,Biogen Inc.,100,0.46,earnings,up,Biogen Q1 EPS $2.67 vs. $2.06 a year ago,FULL-ARTICLE,MarketWatch,MW Biogen Q1 EPS $2.67 vs. $2.06 a year ago
BIIB,2023-04-25,11:12:40,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q1 adj. EPS $3.40; FactSet consensus $3.28,FULL-ARTICLE,MarketWatch,MW Biogen Q1 adj. EPS $3.40; FactSet consensus $3.28
BIIB,2023-04-25,11:13:40,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q1 revenue $2.463 bln vs. $2.532 bln a year ago; FactSet consensus $2.342 bln,FULL-ARTICLE,MarketWatch,MW Biogen Q1 revenue $2.463 bln vs. $2.532 bln a year ago; FactSet consensus $2.342 bln
BIIB,2023-04-25,11:14:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen still sees full-year adj. EPS of $15 to $16,FULL-ARTICLE,MarketWatch,MW Biogen still sees full-year adj. EPS of $15 to $16
BIIB,2023-04-25,11:25:40,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen tops estimates as revenue slides 3% from a year ago,FULL-ARTICLE,MarketWatch,MW Biogen tops estimates as revenue slides 3% from a year ago
BIIB,2023-04-25,11:25:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen is still expecting full-year adjusted EPS of $15 to $16,FULL-ARTICLE,MarketWatch,MW Biogen tops estimates as revenue slides 3% from a year ago
BIIB,2023-04-25,11:25:40,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen Tops Estimates As Revenue Slides 3% From A Year Ago,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Estimates As Revenue Slides 3% From A Year Ago -- MarketWatch
BIIB,2023-04-25,11:25:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen is still expecting full-year adjusted EPS of $15 to $16,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Estimates As Revenue Slides 3% From A Year Ago -- MarketWatch
BIIB,2023-04-25,11:30:37,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $3.40,RNS-SEC8K,Dow Jones Newswires,Biogen 1Q Adj EPS $3.40 >BIIB
BIIB,2023-04-25,11:31:47,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen 1Q Capital Expenditures $67M >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 1Q Capital Expenditures $67M >BIIB
BIIB,2023-04-25,11:33:17,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Sees FY23 Revenue Down,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY23 Revenue Down Mid-Single Digits Vs FY22 >BIIB
BIIB,2023-04-25,11:33:37,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY23 Adj EPS $15,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY23 Adj EPS $15-Adj EPS $16 >BIIB
BIIB,2023-04-25,12:59:23,CEDFD5,Biogen Inc.,99,-0.65,earnings,negative,Biogen lost nearly $19 billion during the quarter,FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Drugs Still Aren't Biogen's Saving Grace -- But The Company Is Hopeful -- IBD
BIIB,2023-04-25,12:59:23,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen earned $3.62 per share,FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Drugs Still Aren't Biogen's Saving Grace -- But The Company Is Hopeful -- IBD
BIIB,2023-04-25,14:14:12,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen's Launch of Alzheimer's Drug Leqembi,FULL-ARTICLE,Dow Jones Newswires,Biogen's Launch of Alzheimer's Drug Leqembi Faces Challenges -- Market Talk
BIIB,2023-04-25,14:14:12,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen's Launch of Alzheimer's Drug Leqembi,FULL-ARTICLE,Dow Jones Newswires,Biogen's Launch of Alzheimer's Drug Leqembi Faces Challenges -- Market Talk
BIIB,2023-04-25,14:36:23,CEDFD5,Biogen Inc.,99,0.0,earnings,unchanged,Biogen reiterated its full-year outlook,FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Drugs Still Aren't Biogen's Saving Grace -- But The Company Is Hopeful -- IBD
BIIB,2023-04-25,14:36:23,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"During the March quarter, Biogen lost $18.9 billion in its collaboration with Japan's Eisai",FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Drugs Still Aren't Biogen's Saving Grace -- But The Company Is Hopeful -- IBD
BIIB,2023-04-25,14:36:23,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Drugs Still Aren't Biogen's Saving Grace -- But The Company Is Hopeful -- IBD
BIIB,2023-04-25,14:38:54,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen Reports $18.9M 1Q Loss,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports $18.9M 1Q Loss on Leqembi -- Market Talk
BIIB,2023-04-25,14:38:54,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen Reports $18.9M 1Q Loss,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports $18.9M 1Q Loss on Leqembi -- Market Talk
BIIB,2023-04-25,17:25:26,CEDFD5,Biogen Inc.,99,0.0,earnings,unchanged,Biogen reiterated its full-year outlook,FULL-ARTICLE,Dow Jones Newswires,Biogen's Transformation Remains 'A Work In Progress' With Alzheimer's On Deck -- IBD
BIIB,2023-04-25,17:25:26,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"During the March quarter, Biogen lost $18.9 billion in its collaboration with Japan's Eisai",FULL-ARTICLE,Dow Jones Newswires,Biogen's Transformation Remains 'A Work In Progress' With Alzheimer's On Deck -- IBD
BIIB,2023-04-25,17:25:26,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen is soon hoping to launch a new depression treatment,FULL-ARTICLE,Dow Jones Newswires,Biogen's Transformation Remains 'A Work In Progress' With Alzheimer's On Deck -- IBD
BIIB,2023-04-25,17:25:26,CEDFD5,Biogen Inc.,99,0.34,analyst-ratings,neutral,He has an overweight rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen's Transformation Remains 'A Work In Progress' With Alzheimer's On Deck -- IBD
BIIB,2023-04-25,17:25:26,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen's Transformation Remains 'A Work In Progress' With Alzheimer's On Deck -- IBD
BIIB,2023-04-25,17:40:47,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approves Biogen's torferson treatment,FULL-ARTICLE,MarketWatch,MW FDA approves Biogen's torferson treatment for rare form of ALS
BIIB,2023-04-25,17:52:46,CEDFD5,Biogen Inc.,100,0.71,products-services,,Fda grants accelerated approval to Biogen's treatment,FULL-ARTICLE,MarketWatch,MW FDA grants accelerated approval to Biogen's treatment for rare form of ALS
BIIB,2023-04-25,17:52:46,CEDFD5,Biogen Inc.,100,0.71,products-services,,Fda Grants Accelerated Approval To Biogen's Treatment,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Accelerated Approval To Biogen's Treatment For Rare Form Of ALS -- MarketWatch
BIIB,2023-04-25,18:21:40,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen Wins Speedy Approval For ALS Drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,18:21:40,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ionis Pharmaceuticals partnered to,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,18:21:40,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,18:21:40,CEDFD5,Biogen Inc.,100,0.0,earnings,unchanged,Biogen reiterated its forecast for full-year,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,18:33:47,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda grants accelerated approval of Biogen's treatment,FULL-ARTICLE,MarketWatch,MW FDA grants accelerated approval of Biogen's treatment for a rare form of ALS
BIIB,2023-04-25,18:48:47,CEDFD5,Biogen Inc.,100,0.71,products-services,,Fda grants accelerated approval to Biogen treatment,FULL-ARTICLE,MarketWatch,MW FDA grants accelerated approval to Biogen treatment for rare form of ALS
BIIB,2023-04-25,18:48:47,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) is developing the treatment with partner Ionis Pharmaceuticals Inc. (IONS),FULL-ARTICLE,MarketWatch,MW FDA grants accelerated approval to Biogen treatment for rare form of ALS
BIIB,2023-04-25,18:48:56,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,1448 ET - FDA approves Biogen's tofersen,FULL-ARTICLE,Dow Jones Newswires,Biogen's ALS Drug Won't Be a Big Seller -- Market Talk
BIIB,2023-04-25,18:48:56,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,1448 ET - FDA approves Biogen's tofersen,FULL-ARTICLE,Dow Jones Newswires,Biogen's ALS Drug Won't Be a Big Seller -- Market Talk
BIIB,2023-04-25,19:52:50,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approval of Biogen's Qalsody for Treatment,PRESS-RELEASE,GlobeNewswire,Muscular Dystrophy Association Celebrates FDA Approval of Biogen's Qalsody for Treatment of SOD1-ALS
BIIB,2023-04-25,19:52:50,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Inc.: Clinical trials support,PRESS-RELEASE,GlobeNewswire,Muscular Dystrophy Association Celebrates FDA Approval of Biogen's Qalsody for Treatment of SOD1-ALS
BIIB,2023-04-25,20:03:29,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen Wins Speedy Approval For ALS Drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,20:03:29,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ionis Pharmaceuticals partnered to,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,20:03:29,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,20:03:29,CEDFD5,Biogen Inc.,100,0.0,earnings,unchanged,Biogen reiterated its forecast for full-year,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-26,09:23:08,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Atlantic Equities
BIIB,2023-04-26,09:23:08,CEDFD5,Biogen Inc.,100,-0.54,price-targets,downgrade,Biogen Price Target Cut to $282.00/Share From $295.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $282.00/Share From $295.00 by Atlantic Equities
BIIB,2023-04-26,09:44:18,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-04-26,09:44:18,CEDFD5,Biogen Inc.,100,0.64,price-targets,upgrade,Biogen Price Target Raised to $371.00/Share From $349.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $371.00/Share From $349.00 by Morgan Stanley
BIIB,2023-04-26,09:59:38,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2023-04-26,09:59:38,CEDFD5,Biogen Inc.,100,-0.24,price-targets,downgrade,Biogen Price Target Cut to $321.00/Share From $325.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $321.00/Share From $325.00 by Needham
BIIB,2023-04-26,10:12:58,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2023-04-26,10:12:58,CEDFD5,Biogen Inc.,100,-0.32,price-targets,downgrade,Biogen Price Target Cut to $302.00/Share From $307.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $302.00/Share From $307.00 by Barclays
BIIB,2023-04-26,10:24:01,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen wins accelerated FDA approval,FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-26,10:24:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) is developing the treatment with partner Ionis Pharmaceuticals Inc. (IONS),FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-26,11:06:58,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2023-04-26,11:06:58,CEDFD5,Biogen Inc.,100,0.56,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $310.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $310.00 by Oppenheimer
BIIB,2023-04-26,12:25:03,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen wins accelerated FDA approval,FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-26,12:25:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) is developing the treatment with partner Ionis Pharmaceuticals Inc. (IONS),FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-26,13:20:09,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-04-26,13:20:09,CEDFD5,Biogen Inc.,100,-0.24,price-targets,downgrade,Biogen Price Target Cut to $340.00/Share From $344.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $340.00/Share From $344.00 by RBC Capital
BIIB,2023-04-26,15:49:19,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2023-04-26,15:49:19,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $330.00/Share From $325.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $330.00/Share From $325.00 by Canaccord Genuity
BIIB,2023-04-26,15:51:07,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen wins accelerated FDA approval,FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-26,15:51:07,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) is developing the treatment with partner Ionis Pharmaceuticals Inc. (IONS),FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-28,17:12:32,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Vp Gregory Registers 2,681 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"VP Gregory Registers 2,681 Of Biogen Inc >BIIB"
BIIB,2023-05-01,11:10:46,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Neutral by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Neutral by Guggenheim
BIIB,2023-05-01,11:10:46,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $270.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $270.00 by Guggenheim
BIIB,2023-05-02,16:15:06,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Biogen prices new ALS treatment at $14,230",FULL-ARTICLE,MarketWatch,"MW Biogen prices new ALS treatment at $14,230 per vial"
BIIB,2023-05-02,16:15:06,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Tofersen, was granted accelerated approval by the U.S. Food and Drug Administration",FULL-ARTICLE,MarketWatch,"MW Biogen prices new ALS treatment at $14,230 per vial"
BIIB,2023-05-02,16:15:06,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Biogen Prices New ALS Treatment At $14,230",FULL-ARTICLE,Dow Jones Newswires,"Biogen Prices New ALS Treatment At $14,230 Per Vial -- MarketWatch"
BIIB,2023-05-02,16:15:06,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Tofersen, was granted accelerated approval by the U.S. Food and Drug Administration",FULL-ARTICLE,Dow Jones Newswires,"Biogen Prices New ALS Treatment At $14,230 Per Vial -- MarketWatch"
BIIB,2023-05-03,00:07:12,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Gregory Sells 2,681 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Sells 2,681 Of Biogen Inc >BIIB"
BIIB,2023-05-03,16:02:48,CEDFD5,Biogen Inc.,99,0.34,analyst-ratings,neutral,Raymond has an overweight rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Eli Lilly Surges On 'Best-Case Scenario' For Alzheimer's Drug. Biogen Claws Back. -- IBD
BIIB,2023-05-04,13:46:39,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by B of A Securities
BIIB,2023-05-04,13:46:40,CEDFD5,Biogen Inc.,100,0.64,price-targets,upgrade,Biogen Price Target Raised to $320.00/Share From $300.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $320.00/Share From $300.00 by B of A Securities
BIIB,2023-05-11,13:22:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Argus Research
BIIB,2023-05-11,13:22:29,CEDFD5,Biogen Inc.,100,0.76,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $320.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $320.00 by Argus Research
BIIB,2023-06-01,13:28:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Piper Sandler
BIIB,2023-06-01,13:28:13,CEDFD5,Biogen Inc.,100,0.5,price-targets,upgrade,Biogen Price Target Raised to $360.00/Share From $346.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $360.00/Share From $346.00 by Piper Sandler
BIIB,2023-06-07,17:37:44,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen's expected declining revenue growth,FULL-ARTICLE,Dow Jones Newswires,Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near -- IBD
BIIB,2023-06-07,20:02:57,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen's expected declining revenue growth,FULL-ARTICLE,Dow Jones Newswires,Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near -- IBD
BIIB,2023-06-08,16:28:14,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Barclays
BIIB,2023-06-09,10:55:02,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2023-06-09,11:03:27,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock halted,FULL-ARTICLE,MarketWatch,MW Biogen stock halted for news pending
BIIB,2023-06-09,16:09:26,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock was halted Friday,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment -- IBD
BIIB,2023-06-09,18:30:48,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock was halted Friday,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment -- IBD
BIIB,2023-06-09,20:16:02,CEDFD5,Biogen Inc.,99,-0.65,equity-actions,halt,Biogen stock remained halted Friday,FULL-ARTICLE,Dow Jones Newswires,Biogen Halted After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug -- IBD
BIIB,2023-06-09,21:13:38,CEDFD5,Biogen Inc.,93,-0.65,equity-actions,halt,Biib) stock trading was halted,FULL-ARTICLE,MarketWatch,MW FDA advisers vote in favor of Biogen and Eisai's collaborative Alzheimer's treatment
BIIB,2023-06-09,23:05:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2023-06-12,11:54:50,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2023-06-12,11:54:50,CEDFD5,Biogen Inc.,100,0.62,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $330.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $330.00 by Canaccord Genuity
BIIB,2023-06-12,12:39:50,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2023-06-12,12:39:50,CEDFD5,Biogen Inc.,100,0.44,price-targets,upgrade,Biogen Price Target Raised to $360.00/Share From $350.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $360.00/Share From $350.00 by Oppenheimer
BIIB,2023-06-12,13:30:30,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,"Biogen stock, which was halted during Friday",FULL-ARTICLE,Dow Jones Newswires,Biogen Jumps After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug -- IBD
BIIB,2023-06-12,21:14:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Announces Changes to Its Board of Directors,PRESS-RELEASE,GlobeNewswire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:01,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023",PRESS-RELEASE,GlobeNewswire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:01,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: As previously announced, Board Chair Stelios Papadopoulos will step down from the Board",PRESS-RELEASE,GlobeNewswire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Announces Changes to Its Board of Directors,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: As previously announced, Board Chair Stelios Papadopoulos will step down from the Board",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Announces Changes to Its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: As previously announced, Board Chair Stelios Papadopoulos will step down from the Board",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Announces Changes to Its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: As previously announced, Board Chair Stelios Papadopoulos will step down from the Board",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Announces Changes to Its Board of Directors,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023",FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:16:08,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen: Announces Changes to Its Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Biogen: Announces Changes to Its Bd of Directors
BIIB,2023-07-03,19:39:29,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 81 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 81 Of Biogen Inc >BIIB
BIIB,2023-07-05,21:35:33,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 81 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 81 Of Biogen Inc >BIIB
BIIB,2023-07-05,21:37:18,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 130 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 130 Of Biogen Inc >BIIB
BIIB,2023-07-05,21:38:21,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 260 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 260 Of Biogen Inc >BIIB
BIIB,2023-07-06,14:28:07,CEDFD5,Biogen Inc.,99,0.71,products-services,,"Aduhelm, gained accelerated approval in 2021",FULL-ARTICLE,Dow Jones Newswires,Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment -- IBD
BIIB,2023-07-06,14:28:07,CEDFD5,Biogen Inc.,99,0.5,stock-picks,buy,Analysts are more bullish on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment -- IBD
BIIB,2023-07-06,20:13:21,CEDFD5,Biogen Inc.,99,0.71,products-services,,"Aduhelm, gained accelerated approval in 2021",FULL-ARTICLE,Dow Jones Newswires,Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment -- IBD
BIIB,2023-07-06,20:13:21,CEDFD5,Biogen Inc.,99,0.5,stock-picks,buy,Analysts are more bullish on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment -- IBD
BIIB,2023-07-06,20:22:54,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2023-07-06,20:56:15,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approves Biogen and Eisai Alzheimer's treatment Leqembi,FULL-ARTICLE,MarketWatch,MW FDA approves Biogen and Eisai Alzheimer's treatment Leqembi
BIIB,2023-07-06,20:56:15,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,"Biogen stock, which was halted",FULL-ARTICLE,MarketWatch,MW FDA approves Biogen and Eisai Alzheimer's treatment Leqembi
BIIB,2023-07-06,20:56:15,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen And Eisai Alzheimer's Treatment Leqembi,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Biogen And Eisai Alzheimer's Treatment Leqembi -- MarketWatch
BIIB,2023-07-06,20:56:15,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,"Biogen stock, which was halted",FULL-ARTICLE,Dow Jones Newswires,FDA Approves Biogen And Eisai Alzheimer's Treatment Leqembi -- MarketWatch
BIIB,2023-07-06,20:59:17,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approves Biogen and Eisai Alzheimer's treatment Leqembi,FULL-ARTICLE,MarketWatch,MW FDA approves Biogen and Eisai Alzheimer's treatment Leqembi
BIIB,2023-07-06,21:04:20,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Snags Full Approval For Alzheimer's Treatment,FULL-ARTICLE,Dow Jones Newswires,Biogen Snags Full Approval For Alzheimer's Treatment; Shares Halted -- IBD
BIIB,2023-07-06,21:04:20,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock was halted,FULL-ARTICLE,Dow Jones Newswires,Biogen Snags Full Approval For Alzheimer's Treatment; Shares Halted -- IBD
BIIB,2023-07-06,21:04:20,CEDFD5,Biogen Inc.,100,0.71,products-services,,"Aduhelm, gained accelerated approval in 2021",FULL-ARTICLE,Dow Jones Newswires,Biogen Snags Full Approval For Alzheimer's Treatment; Shares Halted -- IBD
BIIB,2023-07-06,21:04:20,CEDFD5,Biogen Inc.,100,0.5,stock-picks,buy,Analysts are more bullish on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Snags Full Approval For Alzheimer's Treatment; Shares Halted -- IBD
BIIB,2023-07-06,21:44:48,CEDFD5,Biogen Inc.,100,0.0,products-services,,Leqembi Was Developed by Eisai and Biogen,NEWS-FLASH,Dow Jones Newswires,Leqembi Was Developed by Eisai and Biogen
BIIB,2023-07-07,11:10:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2023-07-07,11:30:27,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,"Tone, reiterating its neutral rating on Biogen",FULL-ARTICLE,MarketWatch,MW Biogen's stock slides premarket as analysts take mixed view of Alzheimer's disease drug approval
BIIB,2023-07-07,11:30:27,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,"Tone, reiterating its neutral rating on Biogen",FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Slides Premarket As Analysts Take Mixed View Of Alzheimer's Disease Drug Approval -- MarketWatch
BIIB,2023-07-07,14:50:30,CEDFD5,Biogen Inc.,99,0.0,analyst-ratings,neutral,"Thursday, reiterating their neutral rating on Biogen",FULL-ARTICLE,MarketWatch,MW Biogen's big Alzheimer's drug win fails to boost the stock as analysts see slow Leqembi rollout
BIIB,2023-07-07,14:50:30,CEDFD5,Biogen Inc.,99,0.34,analyst-ratings,neutral,"Friday, reiterating their outperform rating on Biogen",FULL-ARTICLE,MarketWatch,MW Biogen's big Alzheimer's drug win fails to boost the stock as analysts see slow Leqembi rollout
BIIB,2023-07-11,12:33:15,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-07-11,12:33:15,CEDFD5,Biogen Inc.,100,0.42,price-targets,upgrade,Biogen Price Target Raised to $341.00/Share From $332.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $341.00/Share From $332.00 by RBC Capital
BIIB,2023-07-11,13:08:45,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-07-11,13:08:45,CEDFD5,Biogen Inc.,100,-0.54,price-targets,downgrade,Biogen Price Target Cut to $355.00/Share From $371.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $355.00/Share From $371.00 by Morgan Stanley
BIIB,2023-07-24,21:47:21,CEDFD5,Biogen Inc.,99,0.34,analyst-ratings,neutral,Seigerman maintained an outperform rating on BIIB,FULL-ARTICLE,Dow Jones Newswires,"All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings -- IBD"
BIIB,2023-07-24,21:47:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,"All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings -- IBD"
BIIB,2023-07-24,21:47:21,CEDFD5,Biogen Inc.,99,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,"All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings -- IBD"
BIIB,2023-07-24,21:47:21,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,"All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings -- IBD"
BIIB,2023-07-24,21:47:21,CEDFD5,Biogen Inc.,99,0.0,earnings,unchanged,Biogen reiterated its forecast for full-year,FULL-ARTICLE,Dow Jones Newswires,"All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings -- IBD"
BIIB,2023-07-25,11:04:31,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $4.07 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q EPS $4.07 >BIIB
BIIB,2023-07-25,11:04:31,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Adj EPS $4.02,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Adj EPS $4.02 >BIIB
BIIB,2023-07-25,11:04:31,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Net $591.6M,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Net $591.6M >BIIB
BIIB,2023-07-25,11:04:31,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 2Q Rev $2.46B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Rev $2.46B >BIIB
BIIB,2023-07-25,11:08:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY23 Adj EPS $15,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY23 Adj EPS $15-Adj EPS $16 >BIIB
BIIB,2023-07-25,11:24:40,CEDFD5,Biogen Inc.,100,-0.56,earnings,down,Biogen Q2 EPS $4.07 vs. $7.24 a year ago,FULL-ARTICLE,MarketWatch,MW Biogen Q2 EPS $4.07 vs. $7.24 a year ago
BIIB,2023-07-25,11:24:40,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q2 adj. EPS $4.20; FactSet consensus $3.77,FULL-ARTICLE,MarketWatch,MW Biogen Q2 adj. EPS $4.20; FactSet consensus $3.77
BIIB,2023-07-25,11:24:40,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q2 revenue $2.456 bln vs. $2.589 bln a year ago; FactSet consensus $2.365 bln,FULL-ARTICLE,MarketWatch,MW Biogen Q2 revenue $2.456 bln vs. $2.589 bln a year ago; FactSet consensus $2.365 bln
BIIB,2023-07-25,11:25:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen still sees full-year adj. EPS of $15 to $16,FULL-ARTICLE,MarketWatch,MW Biogen still sees full-year adj. EPS of $15 to $16
BIIB,2023-07-25,11:26:40,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen still sees full-year revenue down,FULL-ARTICLE,MarketWatch,MW Biogen still sees full-year revenue down by mid-single digit percentages vs. 2022
BIIB,2023-07-25,11:37:40,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen tops earnings estimates,FULL-ARTICLE,MarketWatch,MW Biogen tops earnings estimates and says it will shift resources to higher value areas
BIIB,2023-07-25,11:37:40,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company posted net income of $591.6 million,FULL-ARTICLE,MarketWatch,MW Biogen tops earnings estimates and says it will shift resources to higher value areas
BIIB,2023-07-25,11:37:40,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Tops Earnings Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Earnings Estimates And Says It Will Shift Resources To Higher Value Areas -- MarketWatch
BIIB,2023-07-25,11:37:40,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company posted net income of $591.6 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Earnings Estimates And Says It Will Shift Resources To Higher Value Areas -- MarketWatch
BIIB,2023-07-25,12:44:53,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Is Cutting 1,000 Jobs",FULL-ARTICLE,Dow Jones Newswires,"Biogen Is Cutting 1,000 Jobs In Revamp -- Market Talk"
BIIB,2023-07-25,12:44:54,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Is Cutting 1,000 Jobs",FULL-ARTICLE,Dow Jones Newswires,"Biogen Is Cutting 1,000 Jobs In Revamp -- Market Talk"
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Tops Second-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,0.0,earnings,unchanged,Biogen also reaffirmed its full-year guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:25:59,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Tops Second-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:25:59,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:25:59,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:25:59,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:25:59,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:26:19,CEDFD5,Biogen Inc.,100,-0.74,labor-issues,,Biogen to Cut Roughly 11% of Workforce,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,13:26:19,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen plans to invest about $300 million,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,13:26:19,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,"Biogen Inc.: Chris Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,13:27:04,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Tops Second-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:04,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:04,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:04,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:39,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Tops Second-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:39,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:39,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:39,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:39,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:40:04,CEDFD5,Biogen Inc.,100,-0.74,labor-issues,,Biogen to Cut Roughly 11% of Workforce,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce
BIIB,2023-07-25,13:40:04,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen plans to invest about $300 million,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce
BIIB,2023-07-25,13:40:04,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,"Biogen Inc.: Chris Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce
BIIB,2023-07-25,13:51:51,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,Biogen is cutting its staff,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Drops Despite News of Layoffs as Company Rolls Out Alzheimer's Drug -- Barrons.com
BIIB,2023-07-25,14:21:34,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: the company said it plans to cut about 1,000 jobs",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:21:34,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:21:34,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:21:34,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:21:34,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:26:49,CEDFD5,Biogen Inc.,100,-0.74,labor-issues,,Biogen to Cut Roughly 11% of Workforce,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,14:26:49,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen plans to invest about $300 million,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,14:26:49,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,"Biogen Inc.: Chris Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,14:26:49,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Aduhelm, which was cleared by U.S. regulators in 2021",FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,14:26:49,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen said second-quarter sales declined 5% from a year,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,14:44:43,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen to slash 1,000 jobs",FULL-ARTICLE,MarketWatch,"MW Biogen to slash 1,000 jobs as it looks to save $700 million"
BIIB,2023-07-25,14:44:43,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen released second-quarter results that topped analysts' estimates,FULL-ARTICLE,MarketWatch,"MW Biogen to slash 1,000 jobs as it looks to save $700 million"
BIIB,2023-07-25,14:44:43,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,"Biogen Inc.: The company posted second-quarter net income of $591.6 million, or $4.07 per share",FULL-ARTICLE,MarketWatch,"MW Biogen to slash 1,000 jobs as it looks to save $700 million"
BIIB,2023-07-25,14:44:43,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between Biogen and Sage Therapeutics Inc. (SAGE),FULL-ARTICLE,MarketWatch,"MW Biogen to slash 1,000 jobs as it looks to save $700 million"
BIIB,2023-07-25,14:46:43,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen slashing 1,000 jobs",FULL-ARTICLE,MarketWatch,"MW Biogen slashing 1,000 jobs"
BIIB,2023-07-25,14:48:47,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: the company said it plans to cut about 1,000 jobs",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:48:47,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:48:47,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:48:47,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:48:47,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,16:46:30,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Stifel
BIIB,2023-07-25,16:46:30,CEDFD5,Biogen Inc.,100,-0.24,price-targets,downgrade,Biogen Price Target Cut to $320.00/Share From $324.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $320.00/Share From $324.00 by Stifel
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: the company said it plans to cut about 1,000 jobs",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,0.55,products-services,increase,Biogen and partner Eisai can ramp up production,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-26,06:09:13,CEDFD5,Biogen Inc.,100,-0.74,labor-issues,,Biogen to Reduce Its Workforce by About 11%,FULL-ARTICLE,Dow Jones Newswires,Biogen to Reduce Its Workforce by About 11%  ----  By Peter Loftus
BIIB,2023-07-26,06:09:13,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen plans to invest about $300 million,FULL-ARTICLE,Dow Jones Newswires,Biogen to Reduce Its Workforce by About 11%  ----  By Peter Loftus
BIIB,2023-07-26,06:09:13,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,"Biogen Inc.: Chris Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen to Reduce Its Workforce by About 11%  ----  By Peter Loftus
BIIB,2023-07-26,06:09:13,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Biogen has seen revenue decline in recent years,FULL-ARTICLE,Dow Jones Newswires,Biogen to Reduce Its Workforce by About 11%  ----  By Peter Loftus
BIIB,2023-07-26,06:09:13,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen said second-quarter sales fell 5% from a year,FULL-ARTICLE,Dow Jones Newswires,Biogen to Reduce Its Workforce by About 11%  ----  By Peter Loftus
BIIB,2023-07-26,06:32:07,CEDFD5,Biogen Inc.,100,-0.74,labor-issues,,Biogen to Reduce Its Workforce by About 11%,FULL-ARTICLE,Wall Street Journal,Biogen to Reduce Its Workforce by About 11% -- WSJ
BIIB,2023-07-26,06:32:07,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen plans to invest about $300 million,FULL-ARTICLE,Wall Street Journal,Biogen to Reduce Its Workforce by About 11% -- WSJ
BIIB,2023-07-26,06:32:07,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,"Biogen Inc.: Chris Viehbacher, who took over the company in November",FULL-ARTICLE,Wall Street Journal,Biogen to Reduce Its Workforce by About 11% -- WSJ
BIIB,2023-07-26,06:32:07,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Aduhelm, which was cleared by U.S. regulators in 2021",FULL-ARTICLE,Wall Street Journal,Biogen to Reduce Its Workforce by About 11% -- WSJ
BIIB,2023-07-26,06:32:07,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen said second-quarter sales fell 5% from a year,FULL-ARTICLE,Wall Street Journal,Biogen to Reduce Its Workforce by About 11% -- WSJ
BIIB,2023-07-26,12:18:12,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by BMO Capital
BIIB,2023-07-26,12:18:12,CEDFD5,Biogen Inc.,100,-0.44,price-targets,downgrade,Biogen Price Target Cut to $347.00/Share From $357.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $347.00/Share From $357.00 by BMO Capital
BIIB,2023-07-26,14:06:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-07-26,14:06:13,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $379.00/Share From $341.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $379.00/Share From $341.00 by RBC Capital
BIIB,2023-07-26,14:53:23,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-07-26,14:53:23,CEDFD5,Biogen Inc.,100,0.4,price-targets,upgrade,Biogen Price Target Raised to $363.00/Share From $355.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $363.00/Share From $355.00 by Morgan Stanley
BIIB,2023-07-27,13:51:36,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Biogen Initiated at Sector Outperform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Sector Outperform by Scotiabank
BIIB,2023-07-27,13:51:36,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $327.00/Share by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $327.00/Share by Scotiabank
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen To Acquire Reata Pharmaceuticals >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen To Acquire Reata Pharmaceuticals >BIIB
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,PRESS-RELEASE,GlobeNewswire,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.0,marketing,,Biogen to host investor conference call today at 9:00 a.m. ET,PRESS-RELEASE,GlobeNewswire,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,PRESS-RELEASE,GlobeNewswire,Biogen to Acquire Reata Pharmaceuticals -2-
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen has agreed to acquire Reata for $172.50 per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.0,marketing,,Biogen to host investor conference call today at 9:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.0,marketing,,Biogen to host investor conference call today at 9:00 a.m. ET,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Press Release: Biogen to Acquire Reata,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata -2-
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Acquire Reata Pharmaceuticals -2-
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen has agreed to acquire Reata for $172.50 per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.0,marketing,,Biogen to host investor conference call today at 9:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Press Release: Biogen to Acquire Reata,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata -2-
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.0,marketing,,Biogen to host investor conference call today at 9:00 a.m. ET,FULL-ARTICLE,Dow Jones Newswires,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Biogen to Acquire Reata Pharmaceuticals -2-
BIIB,2023-07-28,11:06:34,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Reata Pharmaceuticals for $172.50/Share,NEWS-FLASH,Dow Jones Newswires,Biogen to Buy Reata Pharmaceuticals for $172.50/Share >BIIB RETA
BIIB,2023-07-28,11:10:50,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire Reata Pharmaceuticals for $7.3 bln in cash,FULL-ARTICLE,MarketWatch,MW Biogen to acquire Reata Pharmaceuticals for $7.3 bln in cash
BIIB,2023-07-28,11:11:50,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen expects deal to close,FULL-ARTICLE,MarketWatch,MW Biogen expects deal to close in Q4
BIIB,2023-07-28,11:17:51,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Inc. (BIIB) said Friday it has agreed to acquire Reata Pharmaceuticals Inc. (RETA) for $7.3 billion,FULL-ARTICLE,MarketWatch,MW Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion in cash
BIIB,2023-07-28,11:17:51,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Inc. (BIIB) said Friday it has agreed to acquire Reata Pharmaceuticals Inc. (RETA) for $7.3 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Agrees To Acquire Reata Pharmaceuticals For $7.3 Billion In Cash -- MarketWatch
BIIB,2023-07-28,11:20:47,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Reata Pharmaceuticals in $7.3 Billion Deal,FULL-ARTICLE,Dow Jones Newswires,Biogen to Buy Reata Pharmaceuticals in $7.3 Billion Deal
BIIB,2023-07-28,12:02:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Is Buying It for $7.3 Billion,FULL-ARTICLE,Dow Jones Newswires,Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash. -- Barrons.com
BIIB,2023-07-28,12:10:04,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Reata in $7.3 Billion Deal,FULL-ARTICLE,Dow Jones Newswires,Biogen to Buy Reata in $7.3 Billion Deal
BIIB,2023-07-28,12:14:51,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Inc. said Friday it has agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion,FULL-ARTICLE,MarketWatch,MW Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
BIIB,2023-07-28,12:14:51,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen to slash 1,000 jobs",FULL-ARTICLE,MarketWatch,MW Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
BIIB,2023-07-28,12:43:24,CEDFD5,Biogen Inc.,91,0.62,acquisitions-mergers,,Biogen announced it plans to acquire Reata for $172.50 per share,FULL-ARTICLE,Dow Jones Newswires,Will Biogen's Deal Splash Give Biotech a Lift? -- WSJ
BIIB,2023-07-28,13:35:23,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals -- IBD
BIIB,2023-07-28,14:51:25,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen announced Friday it has agreed to acquire Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce -- IBD
BIIB,2023-07-28,14:51:25,CEDFD5,Biogen Inc.,99,-0.74,labor-issues,,Biogen also outlined plans to cut around 11% of its workforce,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce -- IBD
BIIB,2023-07-28,14:51:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen SECOND-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce -- IBD
BIIB,2023-07-28,14:52:59,CEDFD5,Biogen Inc.,94,0.62,acquisitions-mergers,,Biogen's $7.3B acquisition of Reata,FULL-ARTICLE,Dow Jones Newswires,Reata Deal Fits the Bill for Biogen's Strategy -- Market Talk
BIIB,2023-07-28,16:29:26,CEDFD5,Biogen Inc.,100,0.01,credit-ratings,affirmation,Moody's Affirms Biogen's Baa2 Rating,NEWS-FLASH,Dow Jones Newswires,Moody's Affirms Biogen's Baa2 Rating; Outlook Remains Negative
BIIB,2023-07-28,18:12:56,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Inc. said Friday it has agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion,FULL-ARTICLE,MarketWatch,MW Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
BIIB,2023-07-28,18:12:56,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen to slash 1,000 jobs",FULL-ARTICLE,MarketWatch,MW Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
BIIB,2023-07-28,20:33:20,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Reata for $7.3B,FULL-ARTICLE,Dow Jones Newswires,"Top News Today: Stocks Rise as Traders Digest Data; Exxon, Chevron Report Earnings; Biogen to Buy Reata for $7.3B"
BIIB,2023-07-29,06:18:03,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen will pay $172.50 a share for Reata,FULL-ARTICLE,Dow Jones Newswires,EXCHANGE  ---  Business News:  Biogen to Buy Maker of Rare-Disease Drug  ---  The $7.3 Billion deal  for Reata is a fresh  sign of company's  turnaround efforts  ----  By Joseph Walker and Colin Kellaher
BIIB,2023-07-29,06:32:09,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Maker of Rare-Disease Drug -- WSJ,FULL-ARTICLE,Wall Street Journal,Biogen to Buy Maker of Rare-Disease Drug -- WSJ
BIIB,2023-07-29,06:32:09,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen will pay $7.3 billion in cash to acquire Reata Pharmaceuticals,FULL-ARTICLE,Wall Street Journal,Biogen to Buy Maker of Rare-Disease Drug -- WSJ
BIIB,2023-07-31,14:29:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-07-31,14:29:01,CEDFD5,Biogen Inc.,100,-0.26,price-targets,downgrade,Biogen Price Target Cut to $374.00/Share From $379.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $374.00/Share From $379.00 by RBC Capital
BIIB,2023-08-04,22:38:04,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2023-08-04,23:01:10,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Sage and Biogen's Zuranolone,NEWS-FLASH,Dow Jones Newswires,FDA Approves Sage and Biogen's Zuranolone for Postpartum Depression -- WSJ
BIIB,2023-08-04,23:01:10,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Plan to Start Sales in Late 2023,NEWS-FLASH,Dow Jones Newswires,Sage and Biogen Plan to Start Sales in Late 2023 After DEA Scheduling Review -- WSJ
BIIB,2023-08-07,11:10:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2023-08-07,12:15:35,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Wells Fargo
BIIB,2023-08-07,12:15:35,CEDFD5,Biogen Inc.,100,-0.38,price-targets,downgrade,Biogen Price Target Cut to $343.00/Share From $350.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $343.00/Share From $350.00 by Wells Fargo
BIIB,2023-08-07,14:07:06,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2023-08-07,14:07:06,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $290.00/Share From $360.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $290.00/Share From $360.00 by Oppenheimer
BIIB,2023-08-07,16:35:26,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-08-07,16:35:26,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $354.00/Share From $374.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $354.00/Share From $374.00 by RBC Capital
BIIB,2023-08-08,08:55:08,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Atlantic Equities
BIIB,2023-08-08,08:55:08,CEDFD5,Biogen Inc.,100,-0.42,price-targets,downgrade,Biogen Price Target Cut to $275.00/Share From $282.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $275.00/Share From $282.00 by Atlantic Equities
BIIB,2023-08-08,09:44:19,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2023-08-08,09:44:19,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $305.00/Share From $323.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $305.00/Share From $323.00 by Needham
BIIB,2023-08-08,10:49:49,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2023-08-08,10:49:49,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $294.00/Share From $311.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $294.00/Share From $311.00 by Barclays
BIIB,2023-08-08,12:34:09,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by BMO Capital
BIIB,2023-08-08,12:34:09,CEDFD5,Biogen Inc.,100,-0.46,price-targets,downgrade,Biogen Price Target Cut to $336.00/Share From $347.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $336.00/Share From $347.00 by BMO Capital
BIIB,2023-08-08,16:18:19,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2023-08-08,16:18:20,CEDFD5,Biogen Inc.,100,-0.44,price-targets,downgrade,Biogen Price Target Cut to $340.00/Share From $350.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $340.00/Share From $350.00 by Truist Securities
BIIB,2023-08-14,11:18:19,CEDFD5,Biogen Inc.,100,-0.3,price-targets,downgrade,Biogen price target cut to $335 from $340 at Mizuho Securities,FULL-ARTICLE,MarketWatch,MW Biogen price target cut to $335 from $340 at Mizuho Securities
BIIB,2023-08-14,13:21:49,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Mizuho
BIIB,2023-08-14,13:21:49,CEDFD5,Biogen Inc.,100,-0.3,price-targets,downgrade,Biogen Price Target Cut to $335.00/Share From $340.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $335.00/Share From $340.00 by Mizuho
BIIB,2023-08-18,18:45:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Eisai's ADUHELM (aducanumab) received accelerated approval from the US FDA,PRESS-RELEASE,PR Newswire,"Insights Into the Global Alzheimer's Disease Market, 2023-2032 - Eli Lilly's Donanemab Poised as Front-Runner for 2024 Market Debut, Set to Rival Biogen and Eisai's LEQEMBI in Emerging Therapy Arena"
BIIB,2023-08-19,07:19:20,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 2Q 2023 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 2Q 2023 (BIIB)"
BIIB,2023-08-24,22:07:59,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda first granted approval to Biogen and Elan Corp. to market Tysabri,FULL-ARTICLE,MarketWatch,MW Biogen stock slips after FDA approves first biosimilar to Tysabri MS treatment
BIIB,2023-08-24,22:07:59,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda first granted approval to Biogen and Elan Corp. to market Tysabri,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Slips After FDA Approves First Biosimilar To Tysabri MS Treatment -- MarketWatch
BIIB,2023-08-29,14:18:11,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-08-29,14:18:11,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $357.00/Share From $354.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $357.00/Share From $354.00 by RBC Capital
BIIB,2023-09-05,14:52:16,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-09-05,14:52:16,CEDFD5,Biogen Inc.,100,0.58,price-targets,upgrade,Biogen Price Target Raised to $381.00/Share From $363.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $381.00/Share From $363.00 by Morgan Stanley
BIIB,2023-09-05,15:24:27,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 431 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 431 Of Biogen Inc >BIIB
BIIB,2023-09-06,09:21:09,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Biogen Initiated at Buy by HSBC,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Buy by HSBC
BIIB,2023-09-06,09:21:09,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $360.00/Share by HSBC,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $360.00/Share by HSBC
BIIB,2023-09-06,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Jane Grogan as Head of Research
BIIB,2023-09-06,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research,FULL-ARTICLE,Dow Jones Newswires,Biogen Appoints Jane Grogan as Head of Research
BIIB,2023-09-06,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Appoints Jane Grogan as Head of Research
BIIB,2023-09-06,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research,PRESS-RELEASE,GlobeNewswire,Biogen Appoints Jane Grogan as Head of Research
BIIB,2023-09-06,11:30:02,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Jane Grogan as Head of Research
BIIB,2023-09-06,11:30:18,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Appoints Jane Grogan as Head of Research >BIIB
BIIB,2023-09-06,11:30:22,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Appoints Jane Grogan as Head of Research >BIIB
BIIB,2023-09-06,11:35:00,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen names Jane Grogan head of research,FULL-ARTICLE,MarketWatch,MW Biogen names Jane Grogan head of research
BIIB,2023-09-06,11:42:00,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen names Dr. Jane Grogan head of research,FULL-ARTICLE,MarketWatch,MW Biogen names Dr. Jane Grogan head of research effective Oct. 2
BIIB,2023-09-06,11:42:00,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Dr. Jane Grogan Head Of Research,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Dr. Jane Grogan Head Of Research Effective Oct. 2 -- MarketWatch
BIIB,2023-09-06,11:51:29,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Jane Grogan Head of Research >BIIB,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Jane Grogan Head of Research >BIIB
BIIB,2023-09-06,22:07:40,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 431 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 431 Of Biogen Inc >BIIB
BIIB,2023-09-06,22:09:23,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 2,581 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 2,581 Of Biogen Inc >BIIB"
BIIB,2023-09-21,14:08:00,CEDFD5,Biogen Inc.,100,0.59,acquisitions-mergers,approved,Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.,PRESS-RELEASE,Business Wire,Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
BIIB,2023-09-21,14:08:03,CEDFD5,Biogen Inc.,100,0.59,acquisitions-mergers,approved,Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
BIIB,2023-09-21,14:08:14,CEDFD5,Biogen Inc.,100,0.59,acquisitions-mergers,approved,Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.,NEWS-FLASH,Dow Jones Newswires,Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
BIIB,2023-09-25,10:11:29,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Eisai and Biogen get Japan regulatory approval for Leqembi,FULL-ARTICLE,Dow Jones Newswires,"Eisai, Biogen Pick Up Second Leqembi Green Light -- Market Talk"
BIIB,2023-09-26,12:59:54,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Reata Pharmaceuticals,PRESS-RELEASE,GlobeNewswire,Biogen Completes Acquisition of Reata Pharmaceuticals
BIIB,2023-09-26,12:59:54,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition Of Reata Pharmaceuticals >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Completes Acquisition Of Reata Pharmaceuticals >BIIB
BIIB,2023-09-26,12:59:54,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition Of Reata Pharmaceuticals >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Completes Acquisition Of Reata Pharmaceuticals >BIIB
BIIB,2023-09-26,12:59:55,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Reata Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Reata Pharmaceuticals
BIIB,2023-09-26,12:59:55,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Reata Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Completes Acquisition of Reata Pharmaceuticals
BIIB,2023-09-26,12:59:55,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Biogen Completes Acquisition of Reata Pharmaceuticals
BIIB,2023-09-26,12:59:57,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Reata Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Reata Pharmaceuticals
BIIB,2023-09-26,13:31:04,CEDFD5,Biogen Inc.,100,0.5,stock-picks,buy,"Thinking about buying stock in Rocket Lab USA, Faraday Future Intelligent Electric, FaZe Holdings, Biogen, or Uranium Energy Corp.?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Rocket Lab USA, Faraday Future Intelligent Electric, FaZe Holdings, Biogen, or Uranium Energy Corp.?"
BIIB,2023-09-28,21:31:13,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 6,000,000 Of Sangamo Therapeutics Inc >SGMO",FULL-ARTICLE,Dow Jones Newswires,"Holder Biogen Inc Sells 6,000,000 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2023-09-29,20:06:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen's TOFIDENCE(TM) (tocilizumab,PRESS-RELEASE,GlobeNewswire,"FDA Approves Biogen's TOFIDENCE(TM) (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA(R)"
BIIB,2023-09-29,20:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen's TOFIDENCE(TM) (tocilizumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Approves Biogen's TOFIDENCE(TM) (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA(R)"
BIIB,2023-09-29,20:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen's TOFIDENCE(TM) (tocilizumab,PRESS-RELEASE,DJ Global Press Release Wire,"FDA Approves Biogen's TOFIDENCE(TM) (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA(R)"
BIIB,2023-09-29,20:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen's TOFIDENCE(TM) (tocilizumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Approves Biogen's TOFIDENCE(TM) (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA(R)"
BIIB,2023-09-29,20:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen's TOFIDENCE(TM) (tocilizumab,FULL-ARTICLE,Dow Jones Newswires,"FDA Approves Biogen's TOFIDENCE(TM) (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA(R)"
BIIB,2023-09-29,20:19:29,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen's Tofidence Intravenous Formulation Gets FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Biogen's Tofidence Intravenous Formulation Gets FDA Approval
BIIB,2023-09-29,20:25:24,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen gets FDA approval for biotech treatment similar to Roche's Actemra,FULL-ARTICLE,MarketWatch,MW Biogen gets FDA approval for biotech treatment similar to Roche's Actemra
BIIB,2023-09-29,20:25:24,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Gets FDA Approval For Biotech Treatment Similar To Roche'S Actemra,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Approval For Biotech Treatment Similar To Roche'S Actemra -- MarketWatch
BIIB,2023-09-29,20:34:30,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen's Tofidence Intravenous Formulation Gets FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Biogen's Tofidence Intravenous Formulation Gets FDA Approval
BIIB,2023-10-11,13:35:12,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-10-11,13:35:12,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $361.00/Share From $381.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $361.00/Share From $381.00 by Morgan Stanley
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials -2-
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Data at the Clinical Trials -2-
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,GlobeNewswire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,GlobeNewswire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:22,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,NEWS-FLASH,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease 2023 Meeting
BIIB,2023-10-25,14:51:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data,PRESS-RELEASE,GlobeNewswire,New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease
BIIB,2023-10-25,14:51:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) reported new Phase 1b clinical data,PRESS-RELEASE,DJ Global Press Release Wire,New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease
BIIB,2023-10-25,14:51:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) reported new Phase 1b clinical data,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease
BIIB,2023-10-25,14:51:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) reported new Phase 1b clinical data,FULL-ARTICLE,Dow Jones Newswires,New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease
BIIB,2023-10-25,14:51:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease
BIIB,2023-10-25,21:28:36,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen and Eisai release new Alzheimer's drug,FULL-ARTICLE,MarketWatch,MW Biogen and Eisai release new Alzheimer's drug data that may support wider uptake
BIIB,2023-10-25,21:29:53,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen and Eisai release new Alzheimer's drug,FULL-ARTICLE,MarketWatch,MW Biogen and Eisai release new Alzheimer's drug data that may support wider uptake
BIIB,2023-10-26,13:16:38,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2023-10-26,13:16:38,CEDFD5,Biogen Inc.,100,-0.3,price-targets,downgrade,Biogen Price Target Cut to $266.00/Share From $270.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $266.00/Share From $270.00 by Wedbush
BIIB,2023-10-26,14:35:52,CEDFD5,Biogen Inc.,97,0.34,analyst-ratings,neutral,He has an Outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Eisai's Revised Alzheimer's Drug Works, but Safety Questions Linger -- Barrons.com"
BIIB,2023-11-06,12:30:00,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board of Directors,PRESS-RELEASE,GlobeNewswire,Biogen Appoints Monish Patolawala to its Board of Directors
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Monish Patolawala to its Board of Directors
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board of Directors,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Appoints Monish Patolawala to its Board of Directors
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Appoints Monish Patolawala to its Board of -2-
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board of Directors,FULL-ARTICLE,Dow Jones Newswires,Biogen Appoints Monish Patolawala to its Board of Directors
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board,FULL-ARTICLE,Dow Jones Newswires,Biogen Appoints Monish Patolawala to its Board of -2-
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Monish Patolawala to its Board of Directors
BIIB,2023-11-06,12:31:21,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to Its Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Biogen Appoints Monish Patolawala to Its Bd of Directors
BIIB,2023-11-07,21:30:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Reports Earnings Wednesday,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports Earnings Wednesday. Here's What to Expect. -- Barrons.com
BIIB,2023-11-07,21:30:00,CEDFD5,Biogen Inc.,100,0.0,revenues,,Analysts expect Biogen to report sales of $2.4 billion for the third quarter of its fiscal year,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports Earnings Wednesday. Here's What to Expect. -- Barrons.com
BIIB,2023-11-07,21:30:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Food and Drug Administration approval of the Alzheimer's drug Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports Earnings Wednesday. Here's What to Expect. -- Barrons.com
BIIB,2023-11-08,12:01:21,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen handily beat third-quarter estimates,FULL-ARTICLE,Dow Jones Newswires,"Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount -- IBD"
BIIB,2023-11-08,12:01:21,CEDFD5,Biogen Inc.,100,0.39,products-services,,"Biogen's acquisition of Reata Pharmaceuticals, the approval of postpartum depression drug",FULL-ARTICLE,Dow Jones Newswires,"Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount -- IBD"
BIIB,2023-11-08,12:03:04,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $1.00,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $1.00 >BIIB
BIIB,2023-11-08,12:04:17,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen 3Q Loss/Shr 47c,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Loss/Shr 47c >BIIB
BIIB,2023-11-08,12:04:27,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $4.36,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $4.36 >BIIB
BIIB,2023-11-08,12:04:36,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.53B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.53B >BIIB
BIIB,2023-11-08,12:05:31,CEDFD5,Biogen Inc.,100,-0.74,earnings,down,Biogen Cuts FY23 View To Adj EPS $14.50,NEWS-FLASH,Dow Jones Newswires,Biogen Cuts FY23 View To Adj EPS $14.50-Adj EPS $15.00 >BIIB
BIIB,2023-11-08,12:10:17,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen quarterly results top estimates,FULL-ARTICLE,MarketWatch,MW Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment
BIIB,2023-11-08,12:10:17,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen recently closed its acquisition of Reata Pharmaceuticals,FULL-ARTICLE,MarketWatch,MW Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment
BIIB,2023-11-08,13:40:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees Sales,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Sales of Alzheimer's drug Leqembi Start Growing Next Year -- WSJ
BIIB,2023-11-08,13:40:09,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen expects sales of the Alzheimer's drug Leqembi to start ramping up in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Sales of Alzheimer's drug Leqembi Start Growing Next Year -- WSJ
BIIB,2023-11-08,13:51:41,CEDFD5,Biogen Inc.,94,0.0,revenues,,Biogen provided more optimistic revenue guidance for 2023,FULL-ARTICLE,Dow Jones Newswires,Biogen's Reata Acquisition Drags 2023 Earnings View -- Market Talk
BIIB,2023-11-08,14:05:46,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024 -- Market Talk
BIIB,2023-11-08,14:05:46,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen is expecting sales to start ramping up in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024 -- Market Talk
BIIB,2023-11-08,14:05:46,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024 -- Market Talk
BIIB,2023-11-08,14:05:46,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen is expecting sales to start ramping up in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024 -- Market Talk
BIIB,2023-11-08,15:14:32,CEDFD5,Biogen Inc.,99,0.72,revenues,above-expectations,Biogen's sales beat,FULL-ARTICLE,Dow Jones Newswires,"Biogen Skids On 'Low-Quality' Beat, Cuts Profit Guidance Following Reata Buyout -- IBD"
BIIB,2023-11-08,21:04:54,CEDFD5,Biogen Inc.,99,0.72,revenues,above-expectations,Biogen's sales beat,FULL-ARTICLE,Dow Jones Newswires,"Biogen Skids On 'Low-Quality' Beat, Cuts Profit Guidance Following Reata Buyout -- IBD"
BIIB,2023-11-09,15:45:50,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Wells Fargo
BIIB,2023-11-09,15:45:50,CEDFD5,Biogen Inc.,100,0.64,price-targets,upgrade,Biogen Price Target Raised to $365.00/Share From $343.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $365.00/Share From $343.00 by Wells Fargo
BIIB,2023-11-09,15:49:20,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2023-11-09,15:49:20,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $239.00/Share From $266.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $239.00/Share From $266.00 by Wedbush
BIIB,2023-11-09,18:34:40,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-11-09,18:34:40,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $363.00/Share From $351.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $363.00/Share From $351.00 by RBC Capital
BIIB,2023-11-09,19:36:20,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by BMO Capital
BIIB,2023-11-09,19:36:20,CEDFD5,Biogen Inc.,100,-0.64,price-targets,downgrade,Biogen Price Target Cut to $295.00/Share From $314.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $295.00/Share From $314.00 by BMO Capital
BIIB,2023-11-10,14:03:33,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-11-10,14:03:33,CEDFD5,Biogen Inc.,100,0.46,price-targets,upgrade,Biogen Price Target Raised to $373.00/Share From $361.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $373.00/Share From $361.00 by Morgan Stanley
BIIB,2023-11-19,08:38:07,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 3Q 2023 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 3Q 2023 (BIIB)"
BIIB,2023-11-19,08:47:24,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Reata Pharmaceuticals Inc Cl, Inst Holders, 3Q 2023 (RETA)",RNS-SEC13F,Dow Jones Newswires,"Reata Pharmaceuticals  Inc Cl, Inst Holders, 3Q 2023 (RETA)"
BIIB,2023-12-07,12:18:35,CEDFD5,Biogen Inc.,100,0.82,analyst-ratings,positive,Biogen upgraded to outperform at Raymond James,FULL-ARTICLE,MarketWatch,MW Biogen upgraded to outperform at Raymond James
BIIB,2023-12-07,12:25:34,CEDFD5,Biogen Inc.,100,0.82,analyst-ratings,positive,Biogen Raised to Outperform From Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Market Perform by Raymond James
BIIB,2023-12-07,12:25:34,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $283.00/Share by Raymond James,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $283.00/Share by Raymond James
BIIB,2023-12-11,15:09:34,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 110 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 110 Of Biogen Inc >BIIB
BIIB,2023-12-12,22:03:40,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 181 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 181 Of Biogen Inc >BIIB
BIIB,2023-12-12,22:08:07,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 110 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 110 Of Biogen Inc >BIIB
BIIB,2023-12-13,07:30:57,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen: To Launch Lecanemab Drug in Japan on Dec. 20,NEWS-FLASH,Dow Jones Newswires,"Eisai, Biogen: To Launch Lecanemab Drug in Japan on Dec. 20"
BIIB,2023-12-14,14:21:21,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Stifel
BIIB,2023-12-14,14:21:21,CEDFD5,Biogen Inc.,100,-0.76,price-targets,downgrade,Biogen Price Target Cut to $287.00/Share From $315.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $287.00/Share From $315.00 by Stifel
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS(R) (omaveloxolone),PRESS-RELEASE,GlobeNewswire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.82,products-services,positive,Biogen Inc.: The CHMP's positive opinion for SKYCLARYS,PRESS-RELEASE,GlobeNewswire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved omaveloxolone, marketed as SKYCLARYS(R)",PRESS-RELEASE,GlobeNewswire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS(R) (omaveloxolone),PRESS-RELEASE,DJ Global Press Release Wire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.82,products-services,positive,Biogen Inc.: The CHMP's positive opinion for SKYCLARYS,PRESS-RELEASE,DJ Global Press Release Wire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved omaveloxolone, marketed as SKYCLARYS(R)",PRESS-RELEASE,DJ Global Press Release Wire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS(R) (omaveloxolone),PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.82,products-services,positive,Biogen Inc.: The CHMP's positive opinion for SKYCLARYS,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved omaveloxolone, marketed as SKYCLARYS(R)",PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS(R) (omaveloxolone),FULL-ARTICLE,Dow Jones Newswires,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"The U.S. Food and Drug Administration (FDA) approved omaveloxolone, marketed as",FULL-ARTICLE,Dow Jones Newswires,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS(R) (omaveloxolone),PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:26,CEDFD5,Biogen Inc.,99,0.82,products-services,positive,Biogen Inc.: The CHMP's positive opinion for SKYCLARYS,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved omaveloxolone, marketed as SKYCLARYS(R)",PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-18,17:15:26,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2023-12-18,17:15:26,CEDFD5,Biogen Inc.,100,0.6,price-targets,upgrade,Biogen Price Target Raised to $295.00/Share From $280.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $295.00/Share From $280.00 by Oppenheimer
BIIB,2023-01-04,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
BIIB,2023-01-04,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration,FULL-ARTICLE,Dow Jones Newswires,Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
BIIB,2023-01-04,12:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
BIIB,2023-01-04,12:30:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration,PRESS-RELEASE,GlobeNewswire,Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
BIIB,2023-01-04,12:30:05,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen has initiated a search for a new Executive Vice President,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",FULL-ARTICLE,Dow Jones Newswires,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",FULL-ARTICLE,Dow Jones Newswires,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen has initiated a search for a new Executive Vice President,FULL-ARTICLE,Dow Jones Newswires,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:01,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen has initiated a search for a new Executive Vice President,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:02,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Priya Singhal as Executive Vice President,PRESS-RELEASE,GlobeNewswire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:02,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,GlobeNewswire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:02,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen has initiated a search for a new Executive Vice President,PRESS-RELEASE,GlobeNewswire,"Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:05,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Priya Singhal as Executive Vice President,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:05,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice President, Head",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:05,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen has initiated a search for a new Executive Vice President,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Names Priya Singhal as Executive Vice President, Head of Development"
BIIB,2023-01-05,12:30:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice Pres, Head",NEWS-FLASH,Dow Jones Newswires,"Biogen Names Priya Singhal as Executive Vice Pres, Head of Development"
BIIB,2023-01-05,12:30:08,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,"Biogen Names Priya Singhal as Executive Vice Pres, Head",NEWS-FLASH,Dow Jones Newswires,"Biogen Names Priya Singhal as Executive Vice Pres, Head of Development"
BIIB,2023-01-05,12:33:00,CEDFD5,Biogen Inc.,100,0.49,labor-issues,,Biogen Initiates Search for New Executive VP,NEWS-FLASH,Dow Jones Newswires,"Biogen Initiates Search for New Executive VP, Head of Research >BIIB"
BIIB,2023-01-05,13:00:02,CEDFD5,Biogen Inc.,99,0.47,labor-issues,,Biogen Inc.: The appointment of Maha as a board member,PRESS-RELEASE,GlobeNewswire,"Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member"
BIIB,2023-01-05,13:00:02,CEDFD5,Biogen Inc.,99,0.47,labor-issues,,Biogen Inc.: The appointment of Maha as a board member,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member"
BIIB,2023-01-05,13:00:02,CEDFD5,Biogen Inc.,99,0.47,labor-issues,,Biogen Inc.: The appointment of Maha as a board member,PRESS-RELEASE,DJ Global Press Release Wire,"Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member"
BIIB,2023-01-06,19:00:01,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2023-01-06,19:03:49,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock halted,NEWS-FLASH,MarketWatch,MW Biogen stock halted for news pending
BIIB,2023-01-06,19:03:49,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock halted,NEWS-FLASH,MarketWatch,MW Biogen stock halted for news pending
BIIB,2023-01-06,19:18:59,CEDFD5,Biogen Inc.,91,0.57,products-services,granted,The Food and Drug Administration approved Biogen and Eisai's Alzheimer's disease therapy lecanemab,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Eisai and Biogen's New Alzheimer's Therapy -- Barrons.com
BIIB,2023-01-06,20:05:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2023-01-09,14:28:06,CEDFD5,Biogen Inc.,96,0.46,legal,,Biogen has agreed to pay $900 million to settle,PRESS-RELEASE,DJ Global Press Release Wire,"Grabar Law Office Investigates Claims on Behalf of Shareholders of Biogen, Inc. (BIIB) After It Agrees to Pay $900 Million for Improper Kickbacks"
BIIB,2023-01-10,21:48:45,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Fda granted preliminary approval to Aduhelm,FULL-ARTICLE,Dow Jones Newswires,FDA Commissioner Denies Wrongdoing in Approval Process for Biogen Alzheimer's Drug Aduhelm -- WSJ
BIIB,2023-01-10,23:34:18,CEDFD5,Biogen Inc.,100,0.44,products-services,conditional,Biogen Drug Received Conditional FDA Approval,NEWS-FLASH,Dow Jones Newswires,Eisai and Biogen Drug Received Conditional FDA Approval on Friday
BIIB,2023-01-21,08:27:29,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2022 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2022 (BIIB)"
BIIB,2023-01-23,17:58:07,CEDFD5,Biogen Inc.,93,0.65,products-services,,Fda last July granted priority review to the tofersen,FULL-ARTICLE,Dow Jones Newswires,FDA Sets AdCom Meeting to Review Biogen/Ionis ALS Drug -- Market Talk
BIIB,2023-01-23,17:58:08,CEDFD5,Biogen Inc.,93,0.65,products-services,,Fda last July granted priority review to the tofersen,FULL-ARTICLE,Dow Jones Newswires,FDA Sets AdCom Meeting to Review Biogen/Ionis ALS Drug -- Market Talk
BIIB,2023-01-24,13:27:54,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-01-24,13:27:54,CEDFD5,Biogen Inc.,100,0.62,price-targets,upgrade,Biogen Price Target Raised to $345.00/Share From $325.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $345.00/Share From $325.00 by Morgan Stanley
BIIB,2023-01-26,23:56:16,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization
BIIB,2023-01-27,00:11:16,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization,FULL-ARTICLE,Dow Jones Newswires,Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization
BIIB,2023-01-27,23:29:35,CEDFD5,Biogen Inc.,100,0.0,insider-trading,,Dir Sherwin Gifts 695 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Dir Sherwin Gifts 695 Of Biogen Inc >BIIB
BIIB,2023-01-27,23:33:31,CEDFD5,Biogen Inc.,100,0.0,insider-trading,,Dir Posner Gifts 150 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Dir Posner Gifts 150 Of Biogen Inc >BIIB
BIIB,2023-01-29,23:30:01,CEDFD5,Biogen Inc.,100,0.65,products-services,,Lecanemab Receives Priority Review Status in Japan,PRESS-RELEASE,GlobeNewswire,Lecanemab Receives Priority Review Status in Japan -2-
BIIB,2023-01-29,23:30:01,CEDFD5,Biogen Inc.,100,0.65,products-services,,Lecanemab Receives Priority Review Status in Japan,FULL-ARTICLE,Dow Jones Newswires,Lecanemab Receives Priority Review Status in Japan -2-
BIIB,2023-01-29,23:30:01,CEDFD5,Biogen Inc.,100,0.65,products-services,,Lecanemab Receives Priority Review Status in Japan,PRESS-RELEASE,DJ Global Press Release Wire,Lecanemab Receives Priority Review Status in Japan -2-
BIIB,2023-02-06,11:48:53,CEDFD5,Biogen Inc.,100,0.65,products-services,,"Biogen, Sage Get FDA Priority Review of Zuranolone",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Sage Get FDA Priority Review of Zuranolone >BIIB SAGE"
BIIB,2023-02-06,12:03:53,CEDFD5,Biogen Inc.,100,0.65,products-services,,"Biogen, Sage Get FDA Priority Review of Zuranolone",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Sage Get FDA Priority Review of Zuranolone"
BIIB,2023-02-14,21:18:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen reports its financial results for the fourth quarter on Wednesday,FULL-ARTICLE,Dow Jones Newswires,"Drugs for Alzheimer's, Depression, Are in Focus as Biogen Reports Earnings -- Barrons.com"
BIIB,2023-02-14,21:18:51,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Which Biogen has partnered on Leqembi,FULL-ARTICLE,Dow Jones Newswires,"Drugs for Alzheimer's, Depression, Are in Focus as Biogen Reports Earnings -- Barrons.com"
BIIB,2023-02-14,21:18:51,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"Biogen is partnered with Sage Therapeutics (SAGE), could launch",FULL-ARTICLE,Dow Jones Newswires,"Drugs for Alzheimer's, Depression, Are in Focus as Biogen Reports Earnings -- Barrons.com"
BIIB,2023-02-14,21:18:51,CEDFD5,Biogen Inc.,99,0.0,earnings,,Analysts expect Biogen to report fourth-quarter earnings of $3.48 a share,FULL-ARTICLE,Dow Jones Newswires,"Drugs for Alzheimer's, Depression, Are in Focus as Biogen Reports Earnings -- Barrons.com"
BIIB,2023-02-15,02:24:46,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Singhal Acquires 839 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Singhal Acquires 839 Of Biogen Inc >BIIB
BIIB,2023-02-15,02:25:19,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Murphy Acquires 1,224 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Murphy Acquires 1,224 Of Biogen Inc >BIIB"
BIIB,2023-02-15,02:26:54,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 2,151 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 2,151 Of Biogen Inc >BIIB"
BIIB,2023-02-15,02:39:19,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 471 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 471 Of Biogen Inc >BIIB
BIIB,2023-02-15,02:42:59,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 644 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 644 Of Biogen Inc >BIIB
BIIB,2023-02-15,02:45:37,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Gregory Disposes 16 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Gregory Disposes 16 Of Biogen Inc >BIIB
BIIB,2023-02-15,02:48:09,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Alexander Disposes 179 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Disposes 179 Of Biogen Inc >BIIB
BIIB,2023-02-15,12:06:18,CEDFD5,Biogen Inc.,100,0.62,earnings,up,Biogen Q4 EPS $3.79 vs. $2.50 a year ago,NEWS-FLASH,MarketWatch,MW Biogen Q4 EPS $3.79 vs. $2.50 a year ago
BIIB,2023-02-15,12:06:18,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q4 adj. EPS $4.05; FactSet consensus $3.49,NEWS-FLASH,MarketWatch,MW Biogen Q4 adj. EPS $4.05; FactSet consensus $3.49
BIIB,2023-02-15,12:07:18,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q4 revenue $2.544 bln vs. $2.734 bln a year ago; FactSet consensus $2.444 bln,NEWS-FLASH,MarketWatch,MW Biogen Q4 revenue $2.544 bln vs. $2.734 bln a year ago; FactSet consensus $2.444 bln
BIIB,2023-02-15,12:08:18,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen now sees 2023 adj. EPS of $15 to $16,NEWS-FLASH,MarketWatch,MW Biogen now sees 2023 adj. EPS of $15 to $16; FactSet consensus $15.80
BIIB,2023-02-15,12:09:18,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen now sees 2023 revenue down,NEWS-FLASH,MarketWatch,MW Biogen now sees 2023 revenue down in mid-single digits
BIIB,2023-02-15,12:11:39,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,"Biogen Inc.: Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Says Company Will Look Beyond Neuroscience -- Market Talk
BIIB,2023-02-15,12:11:40,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,"Biogen Inc.: Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen CEO Says Company Will Look Beyond Neuroscience -- Market Talk
BIIB,2023-02-15,12:12:09,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $3.79 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q EPS $3.79 >BIIB
BIIB,2023-02-15,12:12:12,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.54B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Rev $2.54B >BIIB
BIIB,2023-02-15,12:12:17,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Net $550.4M,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Net $550.4M >BIIB
BIIB,2023-02-15,12:12:37,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Adj EPS $4.05,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Adj EPS $4.05 >BIIB
BIIB,2023-02-15,12:13:17,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees 2023 Adj EPS $15.00,NEWS-FLASH,Dow Jones Newswires,Biogen Sees 2023 Adj EPS $15.00-Adj EPS $16.00 >BIIB
BIIB,2023-02-15,12:13:37,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Sees Mid-Single-Digit Revenue Decline in 2023,NEWS-FLASH,Dow Jones Newswires,Biogen Sees Mid-Single-Digit Revenue Decline in 2023 >BIIB
BIIB,2023-02-15,12:16:32,CEDFD5,Biogen Inc.,100,-0.43,products-services,terminated,"Biogen Terminating License, Collaboration Agreement With InnoCare",NEWS-FLASH,Dow Jones Newswires,"Biogen Terminating License, Collaboration Agreement With InnoCare for Orelabrutinib >BIIB"
BIIB,2023-02-15,12:25:19,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen expects EPS of $15.00 to $16.00 in 2023,FULL-ARTICLE,MarketWatch,MW Biogen's stock gains after company beats Q4 revenue and earnings expectations
BIIB,2023-02-15,12:25:19,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen expects EPS of $15.00 to $16.00 in 2023,FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Gains After Company Beats Q4 Revenue And Earnings Expectations -- MarketWatch
BIIB,2023-02-15,12:27:27,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,"Biogen Inc.: Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,"Biogen Has Lost Its Way In Recent Years, New CEO Says -- Market Talk"
BIIB,2023-02-15,12:45:31,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,"Biogen Inc.: Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen Throws in Towel on InnoCare MS Collaboration -- Market Talk
BIIB,2023-02-15,13:55:49,CEDFD5,Biogen Inc.,99,0.0,earnings,,Factset expected Biogen to earn $3.48 per share,FULL-ARTICLE,Dow Jones Newswires,"Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales -- IBD"
BIIB,2023-02-15,13:55:49,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen Inc.: the company reported $2.73 billion in sales,FULL-ARTICLE,Dow Jones Newswires,"Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales -- IBD"
BIIB,2023-02-15,13:55:49,CEDFD5,Biogen Inc.,99,0.36,revenues,,"Biogen Inc.: The company projected ""modest in-market revenue",FULL-ARTICLE,Dow Jones Newswires,"Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales -- IBD"
BIIB,2023-02-15,15:49:33,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,"Biogen expects ""modest in-market revenue",FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,15:49:33,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen's sales fell 7% to $2.54 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,15:49:33,CEDFD5,Biogen Inc.,100,-0.8,earnings,below-expectations,Biogen's profit outlook missed,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,15:49:33,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Abrahams has an outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,18:16:05,CEDFD5,Biogen Inc.,99,-0.24,revenues,down,Biogen said on Wednesday revenue fell 7% to $10.2 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Boss Turns Corner on Alzheimer's Miscues -- Heard on the Street -- WSJ
BIIB,2023-02-15,21:04:54,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,"Biogen expects ""modest in-market revenue",FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,21:04:54,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen's sales fell 7% to $2.54 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,21:04:54,CEDFD5,Biogen Inc.,100,-0.8,earnings,below-expectations,Biogen's profit outlook missed,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-15,21:04:54,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Abrahams has an outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount -- IBD
BIIB,2023-02-16,07:02:42,CEDFD5,Biogen Inc.,99,-0.24,revenues,down,Biogen said on Wednesday that revenue fell 7%,FULL-ARTICLE,Dow Jones Newswires,Heard on the Street:  Biogen Boss Aims to Turn a Corner  ---  Biotech company needs to embark on new growth path as former Sanofi CEO takes the helm  ----  By David Wainer
BIIB,2023-02-16,07:33:41,CEDFD5,Biogen Inc.,99,-0.24,revenues,down,Biogen said on Wednesday revenue fell 7% to $10.2 billion,FULL-ARTICLE,Wall Street Journal,Heard on the Street: Biogen Boss Aims to Turn a Corner -- WSJ
BIIB,2023-02-16,13:08:30,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-02-16,13:08:30,CEDFD5,Biogen Inc.,100,-0.68,price-targets,downgrade,Biogen Price Target Cut to $333.00/Share From $359.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $333.00/Share From $359.00 by RBC Capital
BIIB,2023-02-16,13:26:20,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-02-16,13:26:20,CEDFD5,Biogen Inc.,100,0.32,price-targets,upgrade,Biogen Price Target Raised to $351.00/Share From $345.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $351.00/Share From $345.00 by Morgan Stanley
BIIB,2023-02-16,13:57:10,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by UBS
BIIB,2023-02-16,13:57:11,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $340.00/Share From $337.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $340.00/Share From $337.00 by UBS
BIIB,2023-02-16,14:04:21,CEDFD5,Biogen Inc.,100,0.2,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Cowen & Co.
BIIB,2023-02-16,14:04:21,CEDFD5,Biogen Inc.,100,0.58,price-targets,upgrade,Biogen Price Target Raised to $315.00/Share From $300.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $315.00/Share From $300.00 by Cowen & Co.
BIIB,2023-02-17,17:30:06,CEDFD5,Biogen Inc.,97,0.0,investor-relations,,Biogen's earnings call on Wednesday,PRESS-RELEASE,PR Newswire,Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights
BIIB,2023-02-22,21:57:25,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Alexander Acquires 991 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Alexander Acquires 991 Of Biogen Inc >BIIB
BIIB,2023-02-22,22:04:40,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Gregory Acquires 925 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Gregory Acquires 925 Of Biogen Inc >BIIB
BIIB,2023-02-22,22:10:49,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 396 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 396 Of Biogen Inc >BIIB
BIIB,2023-02-22,22:12:57,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Singhal Acquires 309 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Singhal Acquires 309 Of Biogen Inc >BIIB
BIIB,2023-02-22,22:16:09,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 1,251 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 1,251 Of Biogen Inc >BIIB"
BIIB,2023-02-22,22:17:49,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 274 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 274 Of Biogen Inc >BIIB
BIIB,2023-02-22,22:27:39,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 247 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 247 Of Biogen Inc >BIIB
BIIB,2023-03-06,16:38:47,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Biogen is developing in partnership with Sage Therapeutics (SAGE),FULL-ARTICLE,Dow Jones Newswires,FDA Will Weigh Full Approval for Alzheimer's Drug. Why It Matters for Biogen Stock. -- Barrons.com
BIIB,2023-03-06,23:14:56,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Officer Singhal Disposes 390 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,Officer Singhal Disposes 390 Of Biogen Inc >BIIB
BIIB,2023-03-08,12:33:10,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Names Caroline Dorsa Chairman,NEWS-FLASH,Dow Jones Newswires,"Biogen Names Caroline Dorsa Chairman, Effective at June 14 Annual Meeting >BIIB"
BIIB,2023-03-08,13:00:05,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Names Dorsa to Succeed Papadopoulos as Chairman,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Dorsa to Succeed Papadopoulos as Chairman >BIIB
BIIB,2023-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Chuck Triano as Head of Investor Relations,PRESS-RELEASE,GlobeNewswire,Biogen Appoints Chuck Triano as Head of Investor Relations
BIIB,2023-03-14,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Chuck Triano as Head of Investor Relations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Chuck Triano as Head of Investor Relations
BIIB,2023-03-14,14:52:13,CEDFD5,Biogen Inc.,99,0.0,products-services,,Aduhelm could cost Medicare $57 billion,FULL-ARTICLE,Dow Jones Newswires,The VA Will Pay for Leqembi. It's a Step in Right Direction for Biogen. -- Barrons.com
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.53,legal,,Court of Justice of the European Union decided in favor of Biogen,PRESS-RELEASE,GlobeNewswire,Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Full Year 2023 Financial Guidance,PRESS-RELEASE,GlobeNewswire,Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.53,legal,,Court of Justice of the European Union decided in favor of Biogen,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Full Year 2023 Financial Guidance,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.53,legal,,Court of Justice of the European Union decided in favor of Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Full Year 2023 Financial Guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.53,legal,,Court of Justice of the European Union decided in favor of Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:14,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives Favorable Decision from Court of Justice of the European UnionRelating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:15,CEDFD5,Biogen Inc.,99,0.53,legal,,Court of Justice of the European Union decided in favor of Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:30:15,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's Full Year 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA(R) (dimethyl fumarate) Regulatory Data and Marketing Protection
BIIB,2023-03-16,10:37:05,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen: 2023 Guidance,NEWS-FLASH,Dow Jones Newswires,Biogen: 2023 Guidance Issued on Feb. 15 Assumed Favorable Decision >BIIB
BIIB,2023-03-17,22:45:33,CEDFD5,Biogen Inc.,100,-0.46,partnerships,terminated,"Novartis, Biogen End Collaborations",FULL-ARTICLE,Dow Jones Newswires,"Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations"
BIIB,2023-03-17,23:00:33,CEDFD5,Biogen Inc.,100,-0.46,partnerships,terminated,"Novartis, Biogen End Collaborations",FULL-ARTICLE,Dow Jones Newswires,"Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations"
BIIB,2023-03-23,00:31:57,CEDFD5,Biogen Inc.,99,0.0,products-services,filed,Biogen Inc.: The New Drug Application for tofersen,PRESS-RELEASE,GlobeNewswire,Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
BIIB,2023-03-23,00:31:57,CEDFD5,Biogen Inc.,99,0.0,products-services,filed,Biogen Inc.: The New Drug Application for tofersen,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
BIIB,2023-03-23,00:31:57,CEDFD5,Biogen Inc.,99,0.0,products-services,filed,Biogen Inc.: The New Drug Application for tofersen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
BIIB,2023-03-23,00:31:58,CEDFD5,Biogen Inc.,99,0.0,products-services,filed,Biogen Inc.: The New Drug Application for tofersen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
BIIB,2023-03-23,13:25:44,CEDFD5,Biogen Inc.,94,0.0,products-services,,Biogen and Ionis Pharmaceuticals tested tofersen,FULL-ARTICLE,Dow Jones Newswires,Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement -- IBD
BIIB,2023-03-28,14:39:26,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Officer Singhal Registers 568 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,Officer Singhal Registers 568 Of Biogen Inc >BIIB
BIIB,2023-03-29,12:45:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB080 Phase 1b clinical study,PRESS-RELEASE,DJ Global Press Release Wire,New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Phase 1b Study of BIIB080,PRESS-RELEASE,DJ Global Press Release Wire,New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB080 Phase 1b clinical study,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Phase 1b Study of BIIB080,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB080 Phase 1b clinical study,PRESS-RELEASE,GlobeNewswire,New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Phase 1b Study of BIIB080,PRESS-RELEASE,GlobeNewswire,New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: The BIIB080 Phase 1b clinical study,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Phase 1b Study of BIIB080,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data Presented at AD/PD(TM) 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
BIIB,2023-03-29,12:45:02,CEDFD5,Biogen Inc.,97,0.0,products-services,,Partner Biogen presented new Phase 1b clinical data,PRESS-RELEASE,PR Newswire,New data presented at AD/PD(TM)2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
BIIB,2023-03-29,12:45:31,CEDFD5,Biogen Inc.,97,0.0,products-services,,Partner Biogen presented new Phase 1b clinical data,PRESS-RELEASE,Dow Jones Newswires,Press Release: New data presented at AD/PD(TM)2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
BIIB,2023-03-29,12:46:50,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen: Phase 1b Study of BIIB080 Showed,NEWS-FLASH,Dow Jones Newswires,Biogen: Phase 1b Study of BIIB080 Showed Dose-Dependent and Sustained Reduction of Tau Protein in Cerebral Spinal Fluid Throughout the Open-Label Long-Term Extension >BIIB
BIIB,2023-03-30,22:33:11,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Officer Singhal Sells 568 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,Officer Singhal Sells 568 Of Biogen Inc >BIIB
BIIB,2023-04-04,11:30:00,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Adam Keeney as Head of,PRESS-RELEASE,GlobeNewswire,Biogen Appoints Adam Keeney as Head of Corporate Development
BIIB,2023-04-04,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Adam Keeney as Head of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Adam Keeney as Head of Corporate Development
BIIB,2023-04-04,16:24:34,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 91 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 91 Of Biogen Inc >BIIB
BIIB,2023-04-04,21:26:42,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Murphy Acquires 123 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Murphy Acquires 123 Of Biogen Inc >BIIB
BIIB,2023-04-06,22:38:33,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 91 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 91 Of Biogen Inc >BIIB
BIIB,2023-04-12,14:56:41,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-04-12,14:56:41,CEDFD5,Biogen Inc.,100,-0.17,price-targets,downgrade,Biogen Price Target Cut to $349.00/Share From $351.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $349.00/Share From $351.00 by Morgan Stanley
BIIB,2023-04-17,09:37:17,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Overweight From Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Overweight From Neutral by Piper Sandler
BIIB,2023-04-17,09:37:17,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $346.00/Share From $280.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $346.00/Share From $280.00 by Piper Sandler
BIIB,2023-04-17,12:47:28,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2023-04-17,12:47:28,CEDFD5,Biogen Inc.,100,0.6,price-targets,upgrade,Biogen Price Target Raised to $263.00/Share From $249.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $263.00/Share From $249.00 by Wedbush
BIIB,2023-04-17,15:47:59,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Argus Research
BIIB,2023-04-17,15:47:59,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $320.00/Share From $315.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $320.00/Share From $315.00 by Argus Research
BIIB,2023-04-17,20:02:09,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Of Appointment as Chair of Biogen,NEWS-FLASH,Dow Jones Newswires,Intellia Therapeutics: Dorsa Retiring From Board as Result of Appointment as Chair of Biogen's Board
BIIB,2023-04-21,07:27:56,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 1Q 2023 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 1Q 2023 (BIIB)"
BIIB,2023-04-21,14:19:21,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by B of A Securities
BIIB,2023-04-21,14:19:21,CEDFD5,Biogen Inc.,100,0.32,price-targets,upgrade,Biogen Price Target Raised to $300.00/Share From $295.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $300.00/Share From $295.00 by B of A Securities
BIIB,2023-04-24,20:21:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen reports its quarterly earnings on Tuesday morning,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports Earnings Tuesday. Watch for Alzheimer's Drug Updates -- Barrons.com
BIIB,2023-04-24,20:21:56,CEDFD5,Biogen Inc.,100,0.0,earnings,,Analysts expect Biogen to report earnings of $3.28 a share for the first quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports Earnings Tuesday. Watch for Alzheimer's Drug Updates -- Barrons.com
BIIB,2023-04-25,11:02:53,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $2.67 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $2.67 >BIIB
BIIB,2023-04-25,11:02:53,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Net $387.9M,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Net $387.9M >BIIB
BIIB,2023-04-25,11:02:53,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.46B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.46B >BIIB
BIIB,2023-04-25,11:12:40,CEDFD5,Biogen Inc.,100,0.46,earnings,up,Biogen Q1 EPS $2.67 vs. $2.06 a year ago,FULL-ARTICLE,MarketWatch,MW Biogen Q1 EPS $2.67 vs. $2.06 a year ago
BIIB,2023-04-25,11:12:40,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q1 adj. EPS $3.40; FactSet consensus $3.28,FULL-ARTICLE,MarketWatch,MW Biogen Q1 adj. EPS $3.40; FactSet consensus $3.28
BIIB,2023-04-25,11:13:40,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q1 revenue $2.463 bln vs. $2.532 bln a year ago; FactSet consensus $2.342 bln,FULL-ARTICLE,MarketWatch,MW Biogen Q1 revenue $2.463 bln vs. $2.532 bln a year ago; FactSet consensus $2.342 bln
BIIB,2023-04-25,11:14:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen still sees full-year adj. EPS of $15 to $16,FULL-ARTICLE,MarketWatch,MW Biogen still sees full-year adj. EPS of $15 to $16
BIIB,2023-04-25,11:25:40,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen tops estimates as revenue slides 3% from a year ago,FULL-ARTICLE,MarketWatch,MW Biogen tops estimates as revenue slides 3% from a year ago
BIIB,2023-04-25,11:25:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen is still expecting full-year adjusted EPS of $15 to $16,FULL-ARTICLE,MarketWatch,MW Biogen tops estimates as revenue slides 3% from a year ago
BIIB,2023-04-25,11:25:40,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen Tops Estimates As Revenue Slides 3% From A Year Ago,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Estimates As Revenue Slides 3% From A Year Ago -- MarketWatch
BIIB,2023-04-25,11:25:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen is still expecting full-year adjusted EPS of $15 to $16,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Estimates As Revenue Slides 3% From A Year Ago -- MarketWatch
BIIB,2023-04-25,11:30:37,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $3.40,RNS-SEC8K,Dow Jones Newswires,Biogen 1Q Adj EPS $3.40 >BIIB
BIIB,2023-04-25,11:31:47,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen 1Q Capital Expenditures $67M >BIIB,RNS-SEC8K,Dow Jones Newswires,Biogen 1Q Capital Expenditures $67M >BIIB
BIIB,2023-04-25,11:33:17,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Sees FY23 Revenue Down,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY23 Revenue Down Mid-Single Digits Vs FY22 >BIIB
BIIB,2023-04-25,11:33:37,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY23 Adj EPS $15,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY23 Adj EPS $15-Adj EPS $16 >BIIB
BIIB,2023-04-25,12:59:23,CEDFD5,Biogen Inc.,99,-0.65,earnings,negative,Biogen lost nearly $19 billion during the quarter,FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Drugs Still Aren't Biogen's Saving Grace -- But The Company Is Hopeful -- IBD
BIIB,2023-04-25,12:59:23,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen earned $3.62 per share,FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Drugs Still Aren't Biogen's Saving Grace -- But The Company Is Hopeful -- IBD
BIIB,2023-04-25,14:14:12,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen's Launch of Alzheimer's Drug Leqembi,FULL-ARTICLE,Dow Jones Newswires,Biogen's Launch of Alzheimer's Drug Leqembi Faces Challenges -- Market Talk
BIIB,2023-04-25,14:14:12,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen's Launch of Alzheimer's Drug Leqembi,FULL-ARTICLE,Dow Jones Newswires,Biogen's Launch of Alzheimer's Drug Leqembi Faces Challenges -- Market Talk
BIIB,2023-04-25,14:36:23,CEDFD5,Biogen Inc.,99,0.0,earnings,unchanged,Biogen reiterated its full-year outlook,FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Drugs Still Aren't Biogen's Saving Grace -- But The Company Is Hopeful -- IBD
BIIB,2023-04-25,14:36:23,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"During the March quarter, Biogen lost $18.9 billion in its collaboration with Japan's Eisai",FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Drugs Still Aren't Biogen's Saving Grace -- But The Company Is Hopeful -- IBD
BIIB,2023-04-25,14:36:23,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Alzheimer's Drugs Still Aren't Biogen's Saving Grace -- But The Company Is Hopeful -- IBD
BIIB,2023-04-25,14:38:54,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen Reports $18.9M 1Q Loss,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports $18.9M 1Q Loss on Leqembi -- Market Talk
BIIB,2023-04-25,14:38:54,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen Reports $18.9M 1Q Loss,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports $18.9M 1Q Loss on Leqembi -- Market Talk
BIIB,2023-04-25,17:25:26,CEDFD5,Biogen Inc.,99,0.0,earnings,unchanged,Biogen reiterated its full-year outlook,FULL-ARTICLE,Dow Jones Newswires,Biogen's Transformation Remains 'A Work In Progress' With Alzheimer's On Deck -- IBD
BIIB,2023-04-25,17:25:26,CEDFD5,Biogen Inc.,99,0.49,partnerships,,"During the March quarter, Biogen lost $18.9 billion in its collaboration with Japan's Eisai",FULL-ARTICLE,Dow Jones Newswires,Biogen's Transformation Remains 'A Work In Progress' With Alzheimer's On Deck -- IBD
BIIB,2023-04-25,17:25:26,CEDFD5,Biogen Inc.,99,0.52,products-services,,Biogen is soon hoping to launch a new depression treatment,FULL-ARTICLE,Dow Jones Newswires,Biogen's Transformation Remains 'A Work In Progress' With Alzheimer's On Deck -- IBD
BIIB,2023-04-25,17:25:26,CEDFD5,Biogen Inc.,99,0.34,analyst-ratings,neutral,He has an overweight rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen's Transformation Remains 'A Work In Progress' With Alzheimer's On Deck -- IBD
BIIB,2023-04-25,17:25:26,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen's Transformation Remains 'A Work In Progress' With Alzheimer's On Deck -- IBD
BIIB,2023-04-25,17:40:47,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approves Biogen's torferson treatment,FULL-ARTICLE,MarketWatch,MW FDA approves Biogen's torferson treatment for rare form of ALS
BIIB,2023-04-25,17:52:46,CEDFD5,Biogen Inc.,100,0.71,products-services,,Fda grants accelerated approval to Biogen's treatment,FULL-ARTICLE,MarketWatch,MW FDA grants accelerated approval to Biogen's treatment for rare form of ALS
BIIB,2023-04-25,17:52:46,CEDFD5,Biogen Inc.,100,0.71,products-services,,Fda Grants Accelerated Approval To Biogen's Treatment,FULL-ARTICLE,Dow Jones Newswires,FDA Grants Accelerated Approval To Biogen's Treatment For Rare Form Of ALS -- MarketWatch
BIIB,2023-04-25,18:21:40,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen Wins Speedy Approval For ALS Drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,18:21:40,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ionis Pharmaceuticals partnered to,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,18:21:40,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,18:21:40,CEDFD5,Biogen Inc.,100,0.0,earnings,unchanged,Biogen reiterated its forecast for full-year,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,18:33:47,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda grants accelerated approval of Biogen's treatment,FULL-ARTICLE,MarketWatch,MW FDA grants accelerated approval of Biogen's treatment for a rare form of ALS
BIIB,2023-04-25,18:48:47,CEDFD5,Biogen Inc.,100,0.71,products-services,,Fda grants accelerated approval to Biogen treatment,FULL-ARTICLE,MarketWatch,MW FDA grants accelerated approval to Biogen treatment for rare form of ALS
BIIB,2023-04-25,18:48:47,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) is developing the treatment with partner Ionis Pharmaceuticals Inc. (IONS),FULL-ARTICLE,MarketWatch,MW FDA grants accelerated approval to Biogen treatment for rare form of ALS
BIIB,2023-04-25,18:48:56,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,1448 ET - FDA approves Biogen's tofersen,FULL-ARTICLE,Dow Jones Newswires,Biogen's ALS Drug Won't Be a Big Seller -- Market Talk
BIIB,2023-04-25,18:48:56,CEDFD5,Biogen Inc.,97,0.57,products-services,granted,1448 ET - FDA approves Biogen's tofersen,FULL-ARTICLE,Dow Jones Newswires,Biogen's ALS Drug Won't Be a Big Seller -- Market Talk
BIIB,2023-04-25,19:52:50,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approval of Biogen's Qalsody for Treatment,PRESS-RELEASE,GlobeNewswire,Muscular Dystrophy Association Celebrates FDA Approval of Biogen's Qalsody for Treatment of SOD1-ALS
BIIB,2023-04-25,19:52:50,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Inc.: Clinical trials support,PRESS-RELEASE,GlobeNewswire,Muscular Dystrophy Association Celebrates FDA Approval of Biogen's Qalsody for Treatment of SOD1-ALS
BIIB,2023-04-25,20:03:29,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen Wins Speedy Approval For ALS Drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,20:03:29,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Ionis Pharmaceuticals partnered to,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,20:03:29,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-25,20:03:29,CEDFD5,Biogen Inc.,100,0.0,earnings,unchanged,Biogen reiterated its forecast for full-year,FULL-ARTICLE,Dow Jones Newswires,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat -- IBD"
BIIB,2023-04-26,09:23:08,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Atlantic Equities
BIIB,2023-04-26,09:23:08,CEDFD5,Biogen Inc.,100,-0.54,price-targets,downgrade,Biogen Price Target Cut to $282.00/Share From $295.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $282.00/Share From $295.00 by Atlantic Equities
BIIB,2023-04-26,09:44:18,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-04-26,09:44:18,CEDFD5,Biogen Inc.,100,0.64,price-targets,upgrade,Biogen Price Target Raised to $371.00/Share From $349.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $371.00/Share From $349.00 by Morgan Stanley
BIIB,2023-04-26,09:59:38,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2023-04-26,09:59:38,CEDFD5,Biogen Inc.,100,-0.24,price-targets,downgrade,Biogen Price Target Cut to $321.00/Share From $325.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $321.00/Share From $325.00 by Needham
BIIB,2023-04-26,10:12:58,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2023-04-26,10:12:58,CEDFD5,Biogen Inc.,100,-0.32,price-targets,downgrade,Biogen Price Target Cut to $302.00/Share From $307.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $302.00/Share From $307.00 by Barclays
BIIB,2023-04-26,10:24:01,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen wins accelerated FDA approval,FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-26,10:24:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) is developing the treatment with partner Ionis Pharmaceuticals Inc. (IONS),FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-26,11:06:58,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2023-04-26,11:06:58,CEDFD5,Biogen Inc.,100,0.56,price-targets,upgrade,Biogen Price Target Raised to $325.00/Share From $310.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $325.00/Share From $310.00 by Oppenheimer
BIIB,2023-04-26,12:25:03,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen wins accelerated FDA approval,FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-26,12:25:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) is developing the treatment with partner Ionis Pharmaceuticals Inc. (IONS),FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-26,13:20:09,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-04-26,13:20:09,CEDFD5,Biogen Inc.,100,-0.24,price-targets,downgrade,Biogen Price Target Cut to $340.00/Share From $344.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $340.00/Share From $344.00 by RBC Capital
BIIB,2023-04-26,15:49:19,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2023-04-26,15:49:19,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $330.00/Share From $325.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $330.00/Share From $325.00 by Canaccord Genuity
BIIB,2023-04-26,15:51:07,CEDFD5,Biogen Inc.,100,0.71,products-services,,Biogen wins accelerated FDA approval,FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-26,15:51:07,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen (BIIB) is developing the treatment with partner Ionis Pharmaceuticals Inc. (IONS),FULL-ARTICLE,MarketWatch,MW Biogen wins accelerated FDA approval for treatment for rare form of ALS
BIIB,2023-04-28,17:12:32,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Vp Gregory Registers 2,681 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"VP Gregory Registers 2,681 Of Biogen Inc >BIIB"
BIIB,2023-05-01,11:10:46,CEDFD5,Biogen Inc.,100,0.94,analyst-ratings,positive,Biogen Raised to Buy From Neutral by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Buy From Neutral by Guggenheim
BIIB,2023-05-01,11:10:46,CEDFD5,Biogen Inc.,100,0.8,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $270.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $270.00 by Guggenheim
BIIB,2023-05-02,16:15:06,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Biogen prices new ALS treatment at $14,230",FULL-ARTICLE,MarketWatch,"MW Biogen prices new ALS treatment at $14,230 per vial"
BIIB,2023-05-02,16:15:06,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Tofersen, was granted accelerated approval by the U.S. Food and Drug Administration",FULL-ARTICLE,MarketWatch,"MW Biogen prices new ALS treatment at $14,230 per vial"
BIIB,2023-05-02,16:15:06,CEDFD5,Biogen Inc.,100,0.0,products-services,,"Biogen Prices New ALS Treatment At $14,230",FULL-ARTICLE,Dow Jones Newswires,"Biogen Prices New ALS Treatment At $14,230 Per Vial -- MarketWatch"
BIIB,2023-05-02,16:15:06,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Tofersen, was granted accelerated approval by the U.S. Food and Drug Administration",FULL-ARTICLE,Dow Jones Newswires,"Biogen Prices New ALS Treatment At $14,230 Per Vial -- MarketWatch"
BIIB,2023-05-03,00:07:12,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Gregory Sells 2,681 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Sells 2,681 Of Biogen Inc >BIIB"
BIIB,2023-05-03,16:02:48,CEDFD5,Biogen Inc.,99,0.34,analyst-ratings,neutral,Raymond has an overweight rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,Eli Lilly Surges On 'Best-Case Scenario' For Alzheimer's Drug. Biogen Claws Back. -- IBD
BIIB,2023-05-04,13:46:39,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by B of A Securities
BIIB,2023-05-04,13:46:40,CEDFD5,Biogen Inc.,100,0.64,price-targets,upgrade,Biogen Price Target Raised to $320.00/Share From $300.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $320.00/Share From $300.00 by B of A Securities
BIIB,2023-05-11,13:22:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Argus Research
BIIB,2023-05-11,13:22:29,CEDFD5,Biogen Inc.,100,0.76,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $320.00 by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $320.00 by Argus Research
BIIB,2023-06-01,13:28:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Piper Sandler
BIIB,2023-06-01,13:28:13,CEDFD5,Biogen Inc.,100,0.5,price-targets,upgrade,Biogen Price Target Raised to $360.00/Share From $346.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $360.00/Share From $346.00 by Piper Sandler
BIIB,2023-06-07,17:37:44,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen's expected declining revenue growth,FULL-ARTICLE,Dow Jones Newswires,Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near -- IBD
BIIB,2023-06-07,20:02:57,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen's expected declining revenue growth,FULL-ARTICLE,Dow Jones Newswires,Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near -- IBD
BIIB,2023-06-08,16:28:14,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Barclays
BIIB,2023-06-09,10:55:02,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2023-06-09,11:03:27,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock halted,FULL-ARTICLE,MarketWatch,MW Biogen stock halted for news pending
BIIB,2023-06-09,16:09:26,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock was halted Friday,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment -- IBD
BIIB,2023-06-09,18:30:48,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock was halted Friday,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment -- IBD
BIIB,2023-06-09,20:16:02,CEDFD5,Biogen Inc.,99,-0.65,equity-actions,halt,Biogen stock remained halted Friday,FULL-ARTICLE,Dow Jones Newswires,Biogen Halted After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug -- IBD
BIIB,2023-06-09,21:13:38,CEDFD5,Biogen Inc.,93,-0.65,equity-actions,halt,Biib) stock trading was halted,FULL-ARTICLE,MarketWatch,MW FDA advisers vote in favor of Biogen and Eisai's collaborative Alzheimer's treatment
BIIB,2023-06-09,23:05:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2023-06-12,11:54:50,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2023-06-12,11:54:50,CEDFD5,Biogen Inc.,100,0.62,price-targets,upgrade,Biogen Price Target Raised to $350.00/Share From $330.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $350.00/Share From $330.00 by Canaccord Genuity
BIIB,2023-06-12,12:39:50,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2023-06-12,12:39:50,CEDFD5,Biogen Inc.,100,0.44,price-targets,upgrade,Biogen Price Target Raised to $360.00/Share From $350.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $360.00/Share From $350.00 by Oppenheimer
BIIB,2023-06-12,13:30:30,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,"Biogen stock, which was halted during Friday",FULL-ARTICLE,Dow Jones Newswires,Biogen Jumps After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug -- IBD
BIIB,2023-06-12,21:14:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Announces Changes to Its Board of Directors,PRESS-RELEASE,GlobeNewswire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:01,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023",PRESS-RELEASE,GlobeNewswire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:01,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: As previously announced, Board Chair Stelios Papadopoulos will step down from the Board",PRESS-RELEASE,GlobeNewswire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Announces Changes to Its Board of Directors,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: As previously announced, Board Chair Stelios Papadopoulos will step down from the Board",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Announces Changes to Its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: As previously announced, Board Chair Stelios Papadopoulos will step down from the Board",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Announces Changes to Its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: As previously announced, Board Chair Stelios Papadopoulos will step down from the Board",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Announces Changes to Its Board of Directors,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:14:02,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023",FULL-ARTICLE,Dow Jones Newswires,Biogen Announces Changes to Its Board of Directors
BIIB,2023-06-12,21:16:08,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen: Announces Changes to Its Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Biogen: Announces Changes to Its Bd of Directors
BIIB,2023-07-03,19:39:29,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 81 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 81 Of Biogen Inc >BIIB
BIIB,2023-07-05,21:35:33,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 81 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 81 Of Biogen Inc >BIIB
BIIB,2023-07-05,21:37:18,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 130 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 130 Of Biogen Inc >BIIB
BIIB,2023-07-05,21:38:21,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Izzar Acquires 260 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Izzar Acquires 260 Of Biogen Inc >BIIB
BIIB,2023-07-06,14:28:07,CEDFD5,Biogen Inc.,99,0.71,products-services,,"Aduhelm, gained accelerated approval in 2021",FULL-ARTICLE,Dow Jones Newswires,Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment -- IBD
BIIB,2023-07-06,14:28:07,CEDFD5,Biogen Inc.,99,0.5,stock-picks,buy,Analysts are more bullish on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment -- IBD
BIIB,2023-07-06,20:13:21,CEDFD5,Biogen Inc.,99,0.71,products-services,,"Aduhelm, gained accelerated approval in 2021",FULL-ARTICLE,Dow Jones Newswires,Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment -- IBD
BIIB,2023-07-06,20:13:21,CEDFD5,Biogen Inc.,99,0.5,stock-picks,buy,Analysts are more bullish on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment -- IBD
BIIB,2023-07-06,20:22:54,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2023-07-06,20:56:15,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approves Biogen and Eisai Alzheimer's treatment Leqembi,FULL-ARTICLE,MarketWatch,MW FDA approves Biogen and Eisai Alzheimer's treatment Leqembi
BIIB,2023-07-06,20:56:15,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,"Biogen stock, which was halted",FULL-ARTICLE,MarketWatch,MW FDA approves Biogen and Eisai Alzheimer's treatment Leqembi
BIIB,2023-07-06,20:56:15,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen And Eisai Alzheimer's Treatment Leqembi,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Biogen And Eisai Alzheimer's Treatment Leqembi -- MarketWatch
BIIB,2023-07-06,20:56:15,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,"Biogen stock, which was halted",FULL-ARTICLE,Dow Jones Newswires,FDA Approves Biogen And Eisai Alzheimer's Treatment Leqembi -- MarketWatch
BIIB,2023-07-06,20:59:17,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda approves Biogen and Eisai Alzheimer's treatment Leqembi,FULL-ARTICLE,MarketWatch,MW FDA approves Biogen and Eisai Alzheimer's treatment Leqembi
BIIB,2023-07-06,21:04:20,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Snags Full Approval For Alzheimer's Treatment,FULL-ARTICLE,Dow Jones Newswires,Biogen Snags Full Approval For Alzheimer's Treatment; Shares Halted -- IBD
BIIB,2023-07-06,21:04:20,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen stock was halted,FULL-ARTICLE,Dow Jones Newswires,Biogen Snags Full Approval For Alzheimer's Treatment; Shares Halted -- IBD
BIIB,2023-07-06,21:04:20,CEDFD5,Biogen Inc.,100,0.71,products-services,,"Aduhelm, gained accelerated approval in 2021",FULL-ARTICLE,Dow Jones Newswires,Biogen Snags Full Approval For Alzheimer's Treatment; Shares Halted -- IBD
BIIB,2023-07-06,21:04:20,CEDFD5,Biogen Inc.,100,0.5,stock-picks,buy,Analysts are more bullish on Biogen,FULL-ARTICLE,Dow Jones Newswires,Biogen Snags Full Approval For Alzheimer's Treatment; Shares Halted -- IBD
BIIB,2023-07-06,21:44:48,CEDFD5,Biogen Inc.,100,0.0,products-services,,Leqembi Was Developed by Eisai and Biogen,NEWS-FLASH,Dow Jones Newswires,Leqembi Was Developed by Eisai and Biogen
BIIB,2023-07-07,11:10:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2023-07-07,11:30:27,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,"Tone, reiterating its neutral rating on Biogen",FULL-ARTICLE,MarketWatch,MW Biogen's stock slides premarket as analysts take mixed view of Alzheimer's disease drug approval
BIIB,2023-07-07,11:30:27,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,"Tone, reiterating its neutral rating on Biogen",FULL-ARTICLE,Dow Jones Newswires,Biogen's Stock Slides Premarket As Analysts Take Mixed View Of Alzheimer's Disease Drug Approval -- MarketWatch
BIIB,2023-07-07,14:50:30,CEDFD5,Biogen Inc.,99,0.0,analyst-ratings,neutral,"Thursday, reiterating their neutral rating on Biogen",FULL-ARTICLE,MarketWatch,MW Biogen's big Alzheimer's drug win fails to boost the stock as analysts see slow Leqembi rollout
BIIB,2023-07-07,14:50:30,CEDFD5,Biogen Inc.,99,0.34,analyst-ratings,neutral,"Friday, reiterating their outperform rating on Biogen",FULL-ARTICLE,MarketWatch,MW Biogen's big Alzheimer's drug win fails to boost the stock as analysts see slow Leqembi rollout
BIIB,2023-07-11,12:33:15,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-07-11,12:33:15,CEDFD5,Biogen Inc.,100,0.42,price-targets,upgrade,Biogen Price Target Raised to $341.00/Share From $332.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $341.00/Share From $332.00 by RBC Capital
BIIB,2023-07-11,13:08:45,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-07-11,13:08:45,CEDFD5,Biogen Inc.,100,-0.54,price-targets,downgrade,Biogen Price Target Cut to $355.00/Share From $371.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $355.00/Share From $371.00 by Morgan Stanley
BIIB,2023-07-24,21:47:21,CEDFD5,Biogen Inc.,99,0.34,analyst-ratings,neutral,Seigerman maintained an outperform rating on BIIB,FULL-ARTICLE,Dow Jones Newswires,"All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings -- IBD"
BIIB,2023-07-24,21:47:21,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,"All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings -- IBD"
BIIB,2023-07-24,21:47:21,CEDFD5,Biogen Inc.,99,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,"All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings -- IBD"
BIIB,2023-07-24,21:47:21,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,"All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings -- IBD"
BIIB,2023-07-24,21:47:21,CEDFD5,Biogen Inc.,99,0.0,earnings,unchanged,Biogen reiterated its forecast for full-year,FULL-ARTICLE,Dow Jones Newswires,"All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings -- IBD"
BIIB,2023-07-25,11:04:31,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $4.07 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q EPS $4.07 >BIIB
BIIB,2023-07-25,11:04:31,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Adj EPS $4.02,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Adj EPS $4.02 >BIIB
BIIB,2023-07-25,11:04:31,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Net $591.6M,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Net $591.6M >BIIB
BIIB,2023-07-25,11:04:31,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 2Q Rev $2.46B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Rev $2.46B >BIIB
BIIB,2023-07-25,11:08:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees FY23 Adj EPS $15,RNS-SEC8K,Dow Jones Newswires,Biogen Sees FY23 Adj EPS $15-Adj EPS $16 >BIIB
BIIB,2023-07-25,11:24:40,CEDFD5,Biogen Inc.,100,-0.56,earnings,down,Biogen Q2 EPS $4.07 vs. $7.24 a year ago,FULL-ARTICLE,MarketWatch,MW Biogen Q2 EPS $4.07 vs. $7.24 a year ago
BIIB,2023-07-25,11:24:40,CEDFD5,Biogen Inc.,100,0.46,earnings,above-expectations,Biogen Q2 adj. EPS $4.20; FactSet consensus $3.77,FULL-ARTICLE,MarketWatch,MW Biogen Q2 adj. EPS $4.20; FactSet consensus $3.77
BIIB,2023-07-25,11:24:40,CEDFD5,Biogen Inc.,100,0.48,revenues,above-expectations,Biogen Q2 revenue $2.456 bln vs. $2.589 bln a year ago; FactSet consensus $2.365 bln,FULL-ARTICLE,MarketWatch,MW Biogen Q2 revenue $2.456 bln vs. $2.589 bln a year ago; FactSet consensus $2.365 bln
BIIB,2023-07-25,11:25:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen still sees full-year adj. EPS of $15 to $16,FULL-ARTICLE,MarketWatch,MW Biogen still sees full-year adj. EPS of $15 to $16
BIIB,2023-07-25,11:26:40,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen still sees full-year revenue down,FULL-ARTICLE,MarketWatch,MW Biogen still sees full-year revenue down by mid-single digit percentages vs. 2022
BIIB,2023-07-25,11:37:40,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen tops earnings estimates,FULL-ARTICLE,MarketWatch,MW Biogen tops earnings estimates and says it will shift resources to higher value areas
BIIB,2023-07-25,11:37:40,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company posted net income of $591.6 million,FULL-ARTICLE,MarketWatch,MW Biogen tops earnings estimates and says it will shift resources to higher value areas
BIIB,2023-07-25,11:37:40,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Tops Earnings Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Earnings Estimates And Says It Will Shift Resources To Higher Value Areas -- MarketWatch
BIIB,2023-07-25,11:37:40,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company posted net income of $591.6 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Earnings Estimates And Says It Will Shift Resources To Higher Value Areas -- MarketWatch
BIIB,2023-07-25,12:44:53,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Is Cutting 1,000 Jobs",FULL-ARTICLE,Dow Jones Newswires,"Biogen Is Cutting 1,000 Jobs In Revamp -- Market Talk"
BIIB,2023-07-25,12:44:54,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Is Cutting 1,000 Jobs",FULL-ARTICLE,Dow Jones Newswires,"Biogen Is Cutting 1,000 Jobs In Revamp -- Market Talk"
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Tops Second-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,0.0,earnings,unchanged,Biogen also reaffirmed its full-year guidance,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:02:07,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:25:59,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Tops Second-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:25:59,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:25:59,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:25:59,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:25:59,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:26:19,CEDFD5,Biogen Inc.,100,-0.74,labor-issues,,Biogen to Cut Roughly 11% of Workforce,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,13:26:19,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen plans to invest about $300 million,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,13:26:19,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,"Biogen Inc.: Chris Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,13:27:04,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Tops Second-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:04,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:04,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:04,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:04,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:39,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Tops Second-Quarter Estimates,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:39,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:39,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:39,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:27:39,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD
BIIB,2023-07-25,13:40:04,CEDFD5,Biogen Inc.,100,-0.74,labor-issues,,Biogen to Cut Roughly 11% of Workforce,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce
BIIB,2023-07-25,13:40:04,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen plans to invest about $300 million,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce
BIIB,2023-07-25,13:40:04,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,"Biogen Inc.: Chris Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce
BIIB,2023-07-25,13:51:51,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,Biogen is cutting its staff,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Drops Despite News of Layoffs as Company Rolls Out Alzheimer's Drug -- Barrons.com
BIIB,2023-07-25,14:21:34,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: the company said it plans to cut about 1,000 jobs",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:21:34,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:21:34,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:21:34,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:21:34,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:26:49,CEDFD5,Biogen Inc.,100,-0.74,labor-issues,,Biogen to Cut Roughly 11% of Workforce,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,14:26:49,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen plans to invest about $300 million,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,14:26:49,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,"Biogen Inc.: Chris Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,14:26:49,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Aduhelm, which was cleared by U.S. regulators in 2021",FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,14:26:49,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen said second-quarter sales declined 5% from a year,FULL-ARTICLE,Dow Jones Newswires,Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs -- WSJ
BIIB,2023-07-25,14:44:43,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen to slash 1,000 jobs",FULL-ARTICLE,MarketWatch,"MW Biogen to slash 1,000 jobs as it looks to save $700 million"
BIIB,2023-07-25,14:44:43,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen released second-quarter results that topped analysts' estimates,FULL-ARTICLE,MarketWatch,"MW Biogen to slash 1,000 jobs as it looks to save $700 million"
BIIB,2023-07-25,14:44:43,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,"Biogen Inc.: The company posted second-quarter net income of $591.6 million, or $4.07 per share",FULL-ARTICLE,MarketWatch,"MW Biogen to slash 1,000 jobs as it looks to save $700 million"
BIIB,2023-07-25,14:44:43,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between Biogen and Sage Therapeutics Inc. (SAGE),FULL-ARTICLE,MarketWatch,"MW Biogen to slash 1,000 jobs as it looks to save $700 million"
BIIB,2023-07-25,14:46:43,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen slashing 1,000 jobs",FULL-ARTICLE,MarketWatch,"MW Biogen slashing 1,000 jobs"
BIIB,2023-07-25,14:48:47,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: the company said it plans to cut about 1,000 jobs",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:48:47,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:48:47,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:48:47,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,14:48:47,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,16:46:30,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Stifel
BIIB,2023-07-25,16:46:30,CEDFD5,Biogen Inc.,100,-0.24,price-targets,downgrade,Biogen Price Target Cut to $320.00/Share From $324.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $320.00/Share From $324.00 by Stifel
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen Inc.: the company said it plans to cut about 1,000 jobs",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen also reported a loss of $20.7 million,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,0.55,products-services,increase,Biogen and partner Eisai can ramp up production,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen STOCK: FIRST-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,-0.26,earnings,down,Biogen's full-year earnings to fall 13% to $15.42,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-25,20:03:28,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen Inc.: The company earned $3.40 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD
BIIB,2023-07-26,06:09:13,CEDFD5,Biogen Inc.,100,-0.74,labor-issues,,Biogen to Reduce Its Workforce by About 11%,FULL-ARTICLE,Dow Jones Newswires,Biogen to Reduce Its Workforce by About 11%  ----  By Peter Loftus
BIIB,2023-07-26,06:09:13,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen plans to invest about $300 million,FULL-ARTICLE,Dow Jones Newswires,Biogen to Reduce Its Workforce by About 11%  ----  By Peter Loftus
BIIB,2023-07-26,06:09:13,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,"Biogen Inc.: Chris Viehbacher, who took over the company in November",FULL-ARTICLE,Dow Jones Newswires,Biogen to Reduce Its Workforce by About 11%  ----  By Peter Loftus
BIIB,2023-07-26,06:09:13,CEDFD5,Biogen Inc.,100,-0.68,revenues,down,Biogen has seen revenue decline in recent years,FULL-ARTICLE,Dow Jones Newswires,Biogen to Reduce Its Workforce by About 11%  ----  By Peter Loftus
BIIB,2023-07-26,06:09:13,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen said second-quarter sales fell 5% from a year,FULL-ARTICLE,Dow Jones Newswires,Biogen to Reduce Its Workforce by About 11%  ----  By Peter Loftus
BIIB,2023-07-26,06:32:07,CEDFD5,Biogen Inc.,100,-0.74,labor-issues,,Biogen to Reduce Its Workforce by About 11%,FULL-ARTICLE,Wall Street Journal,Biogen to Reduce Its Workforce by About 11% -- WSJ
BIIB,2023-07-26,06:32:07,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen plans to invest about $300 million,FULL-ARTICLE,Wall Street Journal,Biogen to Reduce Its Workforce by About 11% -- WSJ
BIIB,2023-07-26,06:32:07,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,"Biogen Inc.: Chris Viehbacher, who took over the company in November",FULL-ARTICLE,Wall Street Journal,Biogen to Reduce Its Workforce by About 11% -- WSJ
BIIB,2023-07-26,06:32:07,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Aduhelm, which was cleared by U.S. regulators in 2021",FULL-ARTICLE,Wall Street Journal,Biogen to Reduce Its Workforce by About 11% -- WSJ
BIIB,2023-07-26,06:32:07,CEDFD5,Biogen Inc.,100,-0.24,revenues,down,Biogen said second-quarter sales fell 5% from a year,FULL-ARTICLE,Wall Street Journal,Biogen to Reduce Its Workforce by About 11% -- WSJ
BIIB,2023-07-26,12:18:12,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by BMO Capital
BIIB,2023-07-26,12:18:12,CEDFD5,Biogen Inc.,100,-0.44,price-targets,downgrade,Biogen Price Target Cut to $347.00/Share From $357.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $347.00/Share From $357.00 by BMO Capital
BIIB,2023-07-26,14:06:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-07-26,14:06:13,CEDFD5,Biogen Inc.,100,0.78,price-targets,upgrade,Biogen Price Target Raised to $379.00/Share From $341.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $379.00/Share From $341.00 by RBC Capital
BIIB,2023-07-26,14:53:23,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-07-26,14:53:23,CEDFD5,Biogen Inc.,100,0.4,price-targets,upgrade,Biogen Price Target Raised to $363.00/Share From $355.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $363.00/Share From $355.00 by Morgan Stanley
BIIB,2023-07-27,13:51:36,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Biogen Initiated at Sector Outperform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Sector Outperform by Scotiabank
BIIB,2023-07-27,13:51:36,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $327.00/Share by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $327.00/Share by Scotiabank
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen To Acquire Reata Pharmaceuticals >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen To Acquire Reata Pharmaceuticals >BIIB
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,PRESS-RELEASE,GlobeNewswire,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.0,marketing,,Biogen to host investor conference call today at 9:00 a.m. ET,PRESS-RELEASE,GlobeNewswire,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,PRESS-RELEASE,GlobeNewswire,Biogen to Acquire Reata Pharmaceuticals -2-
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen has agreed to acquire Reata for $172.50 per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.0,marketing,,Biogen to host investor conference call today at 9:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.0,marketing,,Biogen to host investor conference call today at 9:00 a.m. ET,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Press Release: Biogen to Acquire Reata,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata -2-
BIIB,2023-07-28,11:05:44,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Acquire Reata Pharmaceuticals -2-
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen has agreed to acquire Reata for $172.50 per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.0,marketing,,Biogen to host investor conference call today at 9:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Press Release: Biogen to Acquire Reata,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Reata -2-
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.0,marketing,,Biogen to host investor conference call today at 9:00 a.m. ET,FULL-ARTICLE,Dow Jones Newswires,Biogen to Acquire Reata Pharmaceuticals
BIIB,2023-07-28,11:05:45,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Biogen to Acquire Reata Pharmaceuticals -2-
BIIB,2023-07-28,11:06:34,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Reata Pharmaceuticals for $172.50/Share,NEWS-FLASH,Dow Jones Newswires,Biogen to Buy Reata Pharmaceuticals for $172.50/Share >BIIB RETA
BIIB,2023-07-28,11:10:50,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to acquire Reata Pharmaceuticals for $7.3 bln in cash,FULL-ARTICLE,MarketWatch,MW Biogen to acquire Reata Pharmaceuticals for $7.3 bln in cash
BIIB,2023-07-28,11:11:50,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen expects deal to close,FULL-ARTICLE,MarketWatch,MW Biogen expects deal to close in Q4
BIIB,2023-07-28,11:17:51,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Inc. (BIIB) said Friday it has agreed to acquire Reata Pharmaceuticals Inc. (RETA) for $7.3 billion,FULL-ARTICLE,MarketWatch,MW Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion in cash
BIIB,2023-07-28,11:17:51,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Inc. (BIIB) said Friday it has agreed to acquire Reata Pharmaceuticals Inc. (RETA) for $7.3 billion,FULL-ARTICLE,Dow Jones Newswires,Biogen Agrees To Acquire Reata Pharmaceuticals For $7.3 Billion In Cash -- MarketWatch
BIIB,2023-07-28,11:20:47,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Reata Pharmaceuticals in $7.3 Billion Deal,FULL-ARTICLE,Dow Jones Newswires,Biogen to Buy Reata Pharmaceuticals in $7.3 Billion Deal
BIIB,2023-07-28,12:02:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Is Buying It for $7.3 Billion,FULL-ARTICLE,Dow Jones Newswires,Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash. -- Barrons.com
BIIB,2023-07-28,12:10:04,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Reata in $7.3 Billion Deal,FULL-ARTICLE,Dow Jones Newswires,Biogen to Buy Reata in $7.3 Billion Deal
BIIB,2023-07-28,12:14:51,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Inc. said Friday it has agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion,FULL-ARTICLE,MarketWatch,MW Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
BIIB,2023-07-28,12:14:51,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen to slash 1,000 jobs",FULL-ARTICLE,MarketWatch,MW Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
BIIB,2023-07-28,12:43:24,CEDFD5,Biogen Inc.,91,0.62,acquisitions-mergers,,Biogen announced it plans to acquire Reata for $172.50 per share,FULL-ARTICLE,Dow Jones Newswires,Will Biogen's Deal Splash Give Biotech a Lift? -- WSJ
BIIB,2023-07-28,13:35:23,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals -- IBD
BIIB,2023-07-28,14:51:25,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,Biogen announced Friday it has agreed to acquire Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce -- IBD
BIIB,2023-07-28,14:51:25,CEDFD5,Biogen Inc.,99,-0.74,labor-issues,,Biogen also outlined plans to cut around 11% of its workforce,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce -- IBD
BIIB,2023-07-28,14:51:25,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen SECOND-QUARTER RESULTS,FULL-ARTICLE,Dow Jones Newswires,Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce -- IBD
BIIB,2023-07-28,14:52:59,CEDFD5,Biogen Inc.,94,0.62,acquisitions-mergers,,Biogen's $7.3B acquisition of Reata,FULL-ARTICLE,Dow Jones Newswires,Reata Deal Fits the Bill for Biogen's Strategy -- Market Talk
BIIB,2023-07-28,16:29:26,CEDFD5,Biogen Inc.,100,0.01,credit-ratings,affirmation,Moody's Affirms Biogen's Baa2 Rating,NEWS-FLASH,Dow Jones Newswires,Moody's Affirms Biogen's Baa2 Rating; Outlook Remains Negative
BIIB,2023-07-28,18:12:56,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen Inc. said Friday it has agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion,FULL-ARTICLE,MarketWatch,MW Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
BIIB,2023-07-28,18:12:56,CEDFD5,Biogen Inc.,100,-0.51,labor-issues,,"Biogen to slash 1,000 jobs",FULL-ARTICLE,MarketWatch,MW Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
BIIB,2023-07-28,20:33:20,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Reata for $7.3B,FULL-ARTICLE,Dow Jones Newswires,"Top News Today: Stocks Rise as Traders Digest Data; Exxon, Chevron Report Earnings; Biogen to Buy Reata for $7.3B"
BIIB,2023-07-29,06:18:03,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen will pay $172.50 a share for Reata,FULL-ARTICLE,Dow Jones Newswires,EXCHANGE  ---  Business News:  Biogen to Buy Maker of Rare-Disease Drug  ---  The $7.3 Billion deal  for Reata is a fresh  sign of company's  turnaround efforts  ----  By Joseph Walker and Colin Kellaher
BIIB,2023-07-29,06:32:09,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Maker of Rare-Disease Drug -- WSJ,FULL-ARTICLE,Wall Street Journal,Biogen to Buy Maker of Rare-Disease Drug -- WSJ
BIIB,2023-07-29,06:32:09,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen will pay $7.3 billion in cash to acquire Reata Pharmaceuticals,FULL-ARTICLE,Wall Street Journal,Biogen to Buy Maker of Rare-Disease Drug -- WSJ
BIIB,2023-07-31,14:29:01,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-07-31,14:29:01,CEDFD5,Biogen Inc.,100,-0.26,price-targets,downgrade,Biogen Price Target Cut to $374.00/Share From $379.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $374.00/Share From $379.00 by RBC Capital
BIIB,2023-08-04,22:38:04,CEDFD5,Biogen Inc.,100,-0.65,equity-actions,halt,Biogen Inc. (BIIB) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Halted due to pending news
BIIB,2023-08-04,23:01:10,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Sage and Biogen's Zuranolone,NEWS-FLASH,Dow Jones Newswires,FDA Approves Sage and Biogen's Zuranolone for Postpartum Depression -- WSJ
BIIB,2023-08-04,23:01:10,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Plan to Start Sales in Late 2023,NEWS-FLASH,Dow Jones Newswires,Sage and Biogen Plan to Start Sales in Late 2023 After DEA Scheduling Review -- WSJ
BIIB,2023-08-07,11:10:00,CEDFD5,Biogen Inc.,100,0.48,equity-actions,resumed,Biogen Inc. (BIIB) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Biogen Inc. (BIIB) Resumed Trading
BIIB,2023-08-07,12:15:35,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Wells Fargo
BIIB,2023-08-07,12:15:35,CEDFD5,Biogen Inc.,100,-0.38,price-targets,downgrade,Biogen Price Target Cut to $343.00/Share From $350.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $343.00/Share From $350.00 by Wells Fargo
BIIB,2023-08-07,14:07:06,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2023-08-07,14:07:06,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $290.00/Share From $360.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $290.00/Share From $360.00 by Oppenheimer
BIIB,2023-08-07,16:35:26,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-08-07,16:35:26,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $354.00/Share From $374.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $354.00/Share From $374.00 by RBC Capital
BIIB,2023-08-08,08:55:08,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Atlantic Equities
BIIB,2023-08-08,08:55:08,CEDFD5,Biogen Inc.,100,-0.42,price-targets,downgrade,Biogen Price Target Cut to $275.00/Share From $282.00 by Atlantic Equities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $275.00/Share From $282.00 by Atlantic Equities
BIIB,2023-08-08,09:44:19,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Needham
BIIB,2023-08-08,09:44:19,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $305.00/Share From $323.00 by Needham,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $305.00/Share From $323.00 by Needham
BIIB,2023-08-08,10:49:49,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Barclays
BIIB,2023-08-08,10:49:49,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $294.00/Share From $311.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $294.00/Share From $311.00 by Barclays
BIIB,2023-08-08,12:34:09,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by BMO Capital
BIIB,2023-08-08,12:34:09,CEDFD5,Biogen Inc.,100,-0.46,price-targets,downgrade,Biogen Price Target Cut to $336.00/Share From $347.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $336.00/Share From $347.00 by BMO Capital
BIIB,2023-08-08,16:18:19,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2023-08-08,16:18:20,CEDFD5,Biogen Inc.,100,-0.44,price-targets,downgrade,Biogen Price Target Cut to $340.00/Share From $350.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $340.00/Share From $350.00 by Truist Securities
BIIB,2023-08-14,11:18:19,CEDFD5,Biogen Inc.,100,-0.3,price-targets,downgrade,Biogen price target cut to $335 from $340 at Mizuho Securities,FULL-ARTICLE,MarketWatch,MW Biogen price target cut to $335 from $340 at Mizuho Securities
BIIB,2023-08-14,13:21:49,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Mizuho
BIIB,2023-08-14,13:21:49,CEDFD5,Biogen Inc.,100,-0.3,price-targets,downgrade,Biogen Price Target Cut to $335.00/Share From $340.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $335.00/Share From $340.00 by Mizuho
BIIB,2023-08-18,18:45:04,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Eisai's ADUHELM (aducanumab) received accelerated approval from the US FDA,PRESS-RELEASE,PR Newswire,"Insights Into the Global Alzheimer's Disease Market, 2023-2032 - Eli Lilly's Donanemab Poised as Front-Runner for 2024 Market Debut, Set to Rival Biogen and Eisai's LEQEMBI in Emerging Therapy Arena"
BIIB,2023-08-19,07:19:20,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 2Q 2023 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 2Q 2023 (BIIB)"
BIIB,2023-08-24,22:07:59,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda first granted approval to Biogen and Elan Corp. to market Tysabri,FULL-ARTICLE,MarketWatch,MW Biogen stock slips after FDA approves first biosimilar to Tysabri MS treatment
BIIB,2023-08-24,22:07:59,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda first granted approval to Biogen and Elan Corp. to market Tysabri,FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Slips After FDA Approves First Biosimilar To Tysabri MS Treatment -- MarketWatch
BIIB,2023-08-29,14:18:11,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-08-29,14:18:11,CEDFD5,Biogen Inc.,100,0.3,price-targets,upgrade,Biogen Price Target Raised to $357.00/Share From $354.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $357.00/Share From $354.00 by RBC Capital
BIIB,2023-09-05,14:52:16,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-09-05,14:52:16,CEDFD5,Biogen Inc.,100,0.58,price-targets,upgrade,Biogen Price Target Raised to $381.00/Share From $363.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $381.00/Share From $363.00 by Morgan Stanley
BIIB,2023-09-05,15:24:27,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 431 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 431 Of Biogen Inc >BIIB
BIIB,2023-09-06,09:21:09,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Biogen Initiated at Buy by HSBC,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Buy by HSBC
BIIB,2023-09-06,09:21:09,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $360.00/Share by HSBC,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $360.00/Share by HSBC
BIIB,2023-09-06,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Jane Grogan as Head of Research
BIIB,2023-09-06,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research,FULL-ARTICLE,Dow Jones Newswires,Biogen Appoints Jane Grogan as Head of Research
BIIB,2023-09-06,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Appoints Jane Grogan as Head of Research
BIIB,2023-09-06,11:30:01,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research,PRESS-RELEASE,GlobeNewswire,Biogen Appoints Jane Grogan as Head of Research
BIIB,2023-09-06,11:30:02,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Jane Grogan as Head of Research
BIIB,2023-09-06,11:30:18,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Appoints Jane Grogan as Head of Research >BIIB
BIIB,2023-09-06,11:30:22,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Appoints Jane Grogan as Head of Research >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Appoints Jane Grogan as Head of Research >BIIB
BIIB,2023-09-06,11:35:00,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen names Jane Grogan head of research,FULL-ARTICLE,MarketWatch,MW Biogen names Jane Grogan head of research
BIIB,2023-09-06,11:42:00,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen names Dr. Jane Grogan head of research,FULL-ARTICLE,MarketWatch,MW Biogen names Dr. Jane Grogan head of research effective Oct. 2
BIIB,2023-09-06,11:42:00,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Dr. Jane Grogan Head Of Research,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Dr. Jane Grogan Head Of Research Effective Oct. 2 -- MarketWatch
BIIB,2023-09-06,11:51:29,CEDFD5,Biogen Inc.,100,0.53,labor-issues,,Biogen Names Jane Grogan Head of Research >BIIB,FULL-ARTICLE,Dow Jones Newswires,Biogen Names Jane Grogan Head of Research >BIIB
BIIB,2023-09-06,22:07:40,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 431 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 431 Of Biogen Inc >BIIB
BIIB,2023-09-06,22:09:23,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 2,581 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 2,581 Of Biogen Inc >BIIB"
BIIB,2023-09-21,14:08:00,CEDFD5,Biogen Inc.,100,0.59,acquisitions-mergers,approved,Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.,PRESS-RELEASE,Business Wire,Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
BIIB,2023-09-21,14:08:03,CEDFD5,Biogen Inc.,100,0.59,acquisitions-mergers,approved,Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
BIIB,2023-09-21,14:08:14,CEDFD5,Biogen Inc.,100,0.59,acquisitions-mergers,approved,Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.,NEWS-FLASH,Dow Jones Newswires,Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
BIIB,2023-09-25,10:11:29,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,Eisai and Biogen get Japan regulatory approval for Leqembi,FULL-ARTICLE,Dow Jones Newswires,"Eisai, Biogen Pick Up Second Leqembi Green Light -- Market Talk"
BIIB,2023-09-26,12:59:54,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Reata Pharmaceuticals,PRESS-RELEASE,GlobeNewswire,Biogen Completes Acquisition of Reata Pharmaceuticals
BIIB,2023-09-26,12:59:54,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition Of Reata Pharmaceuticals >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Completes Acquisition Of Reata Pharmaceuticals >BIIB
BIIB,2023-09-26,12:59:54,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition Of Reata Pharmaceuticals >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Completes Acquisition Of Reata Pharmaceuticals >BIIB
BIIB,2023-09-26,12:59:55,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Reata Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Reata Pharmaceuticals
BIIB,2023-09-26,12:59:55,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Reata Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Completes Acquisition of Reata Pharmaceuticals
BIIB,2023-09-26,12:59:55,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Biogen Completes Acquisition of Reata Pharmaceuticals
BIIB,2023-09-26,12:59:57,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen Completes Acquisition of Reata Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Completes Acquisition of Reata Pharmaceuticals
BIIB,2023-09-26,13:31:04,CEDFD5,Biogen Inc.,100,0.5,stock-picks,buy,"Thinking about buying stock in Rocket Lab USA, Faraday Future Intelligent Electric, FaZe Holdings, Biogen, or Uranium Energy Corp.?",PRESS-RELEASE,PR Newswire,"Thinking about buying stock in Rocket Lab USA, Faraday Future Intelligent Electric, FaZe Holdings, Biogen, or Uranium Energy Corp.?"
BIIB,2023-09-28,21:31:13,CEDFD5,Biogen Inc.,100,-0.1,equity-actions,decrease,"Holder Biogen Inc Sells 6,000,000 Of Sangamo Therapeutics Inc >SGMO",FULL-ARTICLE,Dow Jones Newswires,"Holder Biogen Inc Sells 6,000,000 Of Sangamo Therapeutics Inc >SGMO"
BIIB,2023-09-29,20:06:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen's TOFIDENCE(TM) (tocilizumab,PRESS-RELEASE,GlobeNewswire,"FDA Approves Biogen's TOFIDENCE(TM) (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA(R)"
BIIB,2023-09-29,20:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen's TOFIDENCE(TM) (tocilizumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Approves Biogen's TOFIDENCE(TM) (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA(R)"
BIIB,2023-09-29,20:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen's TOFIDENCE(TM) (tocilizumab,PRESS-RELEASE,DJ Global Press Release Wire,"FDA Approves Biogen's TOFIDENCE(TM) (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA(R)"
BIIB,2023-09-29,20:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen's TOFIDENCE(TM) (tocilizumab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: FDA Approves Biogen's TOFIDENCE(TM) (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA(R)"
BIIB,2023-09-29,20:06:01,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Fda Approves Biogen's TOFIDENCE(TM) (tocilizumab,FULL-ARTICLE,Dow Jones Newswires,"FDA Approves Biogen's TOFIDENCE(TM) (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA(R)"
BIIB,2023-09-29,20:19:29,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen's Tofidence Intravenous Formulation Gets FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Biogen's Tofidence Intravenous Formulation Gets FDA Approval
BIIB,2023-09-29,20:25:24,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen gets FDA approval for biotech treatment similar to Roche's Actemra,FULL-ARTICLE,MarketWatch,MW Biogen gets FDA approval for biotech treatment similar to Roche's Actemra
BIIB,2023-09-29,20:25:24,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Gets FDA Approval For Biotech Treatment Similar To Roche'S Actemra,FULL-ARTICLE,Dow Jones Newswires,Biogen Gets FDA Approval For Biotech Treatment Similar To Roche'S Actemra -- MarketWatch
BIIB,2023-09-29,20:34:30,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen's Tofidence Intravenous Formulation Gets FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Biogen's Tofidence Intravenous Formulation Gets FDA Approval
BIIB,2023-10-11,13:35:12,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-10-11,13:35:12,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $361.00/Share From $381.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $361.00/Share From $381.00 by Morgan Stanley
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials -2-
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present New Data at the Clinical Trials -2-
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,PRESS-RELEASE,GlobeNewswire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,GlobeNewswire,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting
BIIB,2023-10-19,11:30:22,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present New Data at the Clinical Trials,NEWS-FLASH,Dow Jones Newswires,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease 2023 Meeting
BIIB,2023-10-25,14:51:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data,PRESS-RELEASE,GlobeNewswire,New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease
BIIB,2023-10-25,14:51:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) reported new Phase 1b clinical data,PRESS-RELEASE,DJ Global Press Release Wire,New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease
BIIB,2023-10-25,14:51:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) reported new Phase 1b clinical data,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease
BIIB,2023-10-25,14:51:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) reported new Phase 1b clinical data,FULL-ARTICLE,Dow Jones Newswires,New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease
BIIB,2023-10-25,14:51:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease
BIIB,2023-10-25,21:28:36,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen and Eisai release new Alzheimer's drug,FULL-ARTICLE,MarketWatch,MW Biogen and Eisai release new Alzheimer's drug data that may support wider uptake
BIIB,2023-10-25,21:29:53,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen and Eisai release new Alzheimer's drug,FULL-ARTICLE,MarketWatch,MW Biogen and Eisai release new Alzheimer's drug data that may support wider uptake
BIIB,2023-10-26,13:16:38,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2023-10-26,13:16:38,CEDFD5,Biogen Inc.,100,-0.3,price-targets,downgrade,Biogen Price Target Cut to $266.00/Share From $270.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $266.00/Share From $270.00 by Wedbush
BIIB,2023-10-26,14:35:52,CEDFD5,Biogen Inc.,97,0.34,analyst-ratings,neutral,He has an Outperform rating on Biogen,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Eisai's Revised Alzheimer's Drug Works, but Safety Questions Linger -- Barrons.com"
BIIB,2023-11-06,12:30:00,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board of Directors,PRESS-RELEASE,GlobeNewswire,Biogen Appoints Monish Patolawala to its Board of Directors
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Monish Patolawala to its Board of Directors
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board of Directors,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Appoints Monish Patolawala to its Board of Directors
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Appoints Monish Patolawala to its Board of -2-
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board of Directors,FULL-ARTICLE,Dow Jones Newswires,Biogen Appoints Monish Patolawala to its Board of Directors
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board,FULL-ARTICLE,Dow Jones Newswires,Biogen Appoints Monish Patolawala to its Board of -2-
BIIB,2023-11-06,12:30:01,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Appoints Monish Patolawala to its Board of Directors
BIIB,2023-11-06,12:31:21,CEDFD5,Biogen Inc.,100,0.47,labor-issues,,Biogen Appoints Monish Patolawala to Its Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Biogen Appoints Monish Patolawala to Its Bd of Directors
BIIB,2023-11-07,21:30:00,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Reports Earnings Wednesday,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports Earnings Wednesday. Here's What to Expect. -- Barrons.com
BIIB,2023-11-07,21:30:00,CEDFD5,Biogen Inc.,100,0.0,revenues,,Analysts expect Biogen to report sales of $2.4 billion for the third quarter of its fiscal year,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports Earnings Wednesday. Here's What to Expect. -- Barrons.com
BIIB,2023-11-07,21:30:00,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Food and Drug Administration approval of the Alzheimer's drug Aduhelm,FULL-ARTICLE,Dow Jones Newswires,Biogen Reports Earnings Wednesday. Here's What to Expect. -- Barrons.com
BIIB,2023-11-08,12:01:21,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen handily beat third-quarter estimates,FULL-ARTICLE,Dow Jones Newswires,"Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount -- IBD"
BIIB,2023-11-08,12:01:21,CEDFD5,Biogen Inc.,100,0.39,products-services,,"Biogen's acquisition of Reata Pharmaceuticals, the approval of postpartum depression drug",FULL-ARTICLE,Dow Jones Newswires,"Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount -- IBD"
BIIB,2023-11-08,12:03:04,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $1.00,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $1.00 >BIIB
BIIB,2023-11-08,12:04:17,CEDFD5,Biogen Inc.,100,-0.65,earnings,negative,Biogen 3Q Loss/Shr 47c,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Loss/Shr 47c >BIIB
BIIB,2023-11-08,12:04:27,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $4.36,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $4.36 >BIIB
BIIB,2023-11-08,12:04:36,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.53B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.53B >BIIB
BIIB,2023-11-08,12:05:31,CEDFD5,Biogen Inc.,100,-0.74,earnings,down,Biogen Cuts FY23 View To Adj EPS $14.50,NEWS-FLASH,Dow Jones Newswires,Biogen Cuts FY23 View To Adj EPS $14.50-Adj EPS $15.00 >BIIB
BIIB,2023-11-08,12:10:17,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen quarterly results top estimates,FULL-ARTICLE,MarketWatch,MW Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment
BIIB,2023-11-08,12:10:17,CEDFD5,Biogen Inc.,100,0.57,acquisitions-mergers,completed,Biogen recently closed its acquisition of Reata Pharmaceuticals,FULL-ARTICLE,MarketWatch,MW Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment
BIIB,2023-11-08,13:40:09,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen Sees Sales,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Sales of Alzheimer's drug Leqembi Start Growing Next Year -- WSJ
BIIB,2023-11-08,13:40:09,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen expects sales of the Alzheimer's drug Leqembi to start ramping up in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Sales of Alzheimer's drug Leqembi Start Growing Next Year -- WSJ
BIIB,2023-11-08,13:51:41,CEDFD5,Biogen Inc.,94,0.0,revenues,,Biogen provided more optimistic revenue guidance for 2023,FULL-ARTICLE,Dow Jones Newswires,Biogen's Reata Acquisition Drags 2023 Earnings View -- Market Talk
BIIB,2023-11-08,14:05:46,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024 -- Market Talk
BIIB,2023-11-08,14:05:46,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen is expecting sales to start ramping up in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024 -- Market Talk
BIIB,2023-11-08,14:05:46,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024 -- Market Talk
BIIB,2023-11-08,14:05:46,CEDFD5,Biogen Inc.,100,0.72,revenues,up,Biogen is expecting sales to start ramping up in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Biogen Sees Leqembi Sales To Start Growing in 1Q 2024 -- Market Talk
BIIB,2023-11-08,15:14:32,CEDFD5,Biogen Inc.,99,0.72,revenues,above-expectations,Biogen's sales beat,FULL-ARTICLE,Dow Jones Newswires,"Biogen Skids On 'Low-Quality' Beat, Cuts Profit Guidance Following Reata Buyout -- IBD"
BIIB,2023-11-08,21:04:54,CEDFD5,Biogen Inc.,99,0.72,revenues,above-expectations,Biogen's sales beat,FULL-ARTICLE,Dow Jones Newswires,"Biogen Skids On 'Low-Quality' Beat, Cuts Profit Guidance Following Reata Buyout -- IBD"
BIIB,2023-11-09,15:45:50,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Wells Fargo
BIIB,2023-11-09,15:45:50,CEDFD5,Biogen Inc.,100,0.64,price-targets,upgrade,Biogen Price Target Raised to $365.00/Share From $343.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $365.00/Share From $343.00 by Wells Fargo
BIIB,2023-11-09,15:49:20,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Wedbush
BIIB,2023-11-09,15:49:20,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $239.00/Share From $266.00 by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $239.00/Share From $266.00 by Wedbush
BIIB,2023-11-09,18:34:40,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2023-11-09,18:34:40,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $363.00/Share From $351.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $363.00/Share From $351.00 by RBC Capital
BIIB,2023-11-09,19:36:20,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by BMO Capital
BIIB,2023-11-09,19:36:20,CEDFD5,Biogen Inc.,100,-0.64,price-targets,downgrade,Biogen Price Target Cut to $295.00/Share From $314.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $295.00/Share From $314.00 by BMO Capital
BIIB,2023-11-10,14:03:33,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Overweight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Overweight by Morgan Stanley
BIIB,2023-11-10,14:03:33,CEDFD5,Biogen Inc.,100,0.46,price-targets,upgrade,Biogen Price Target Raised to $373.00/Share From $361.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $373.00/Share From $361.00 by Morgan Stanley
BIIB,2023-11-19,08:38:07,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 3Q 2023 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 3Q 2023 (BIIB)"
BIIB,2023-11-19,08:47:24,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Reata Pharmaceuticals Inc Cl, Inst Holders, 3Q 2023 (RETA)",RNS-SEC13F,Dow Jones Newswires,"Reata Pharmaceuticals  Inc Cl, Inst Holders, 3Q 2023 (RETA)"
BIIB,2023-12-07,12:18:35,CEDFD5,Biogen Inc.,100,0.82,analyst-ratings,positive,Biogen upgraded to outperform at Raymond James,FULL-ARTICLE,MarketWatch,MW Biogen upgraded to outperform at Raymond James
BIIB,2023-12-07,12:25:34,CEDFD5,Biogen Inc.,100,0.82,analyst-ratings,positive,Biogen Raised to Outperform From Market Perform by Raymond James,NEWS-FLASH,Dow Jones Newswires,Biogen Raised to Outperform From Market Perform by Raymond James
BIIB,2023-12-07,12:25:34,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $283.00/Share by Raymond James,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $283.00/Share by Raymond James
BIIB,2023-12-11,15:09:34,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 110 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 110 Of Biogen Inc >BIIB
BIIB,2023-12-12,22:03:40,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 181 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 181 Of Biogen Inc >BIIB
BIIB,2023-12-12,22:08:07,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 110 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 110 Of Biogen Inc >BIIB
BIIB,2023-12-13,07:30:57,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen: To Launch Lecanemab Drug in Japan on Dec. 20,NEWS-FLASH,Dow Jones Newswires,"Eisai, Biogen: To Launch Lecanemab Drug in Japan on Dec. 20"
BIIB,2023-12-14,14:21:21,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Stifel
BIIB,2023-12-14,14:21:21,CEDFD5,Biogen Inc.,100,-0.76,price-targets,downgrade,Biogen Price Target Cut to $287.00/Share From $315.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $287.00/Share From $315.00 by Stifel
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS(R) (omaveloxolone),PRESS-RELEASE,GlobeNewswire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.82,products-services,positive,Biogen Inc.: The CHMP's positive opinion for SKYCLARYS,PRESS-RELEASE,GlobeNewswire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved omaveloxolone, marketed as SKYCLARYS(R)",PRESS-RELEASE,GlobeNewswire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS(R) (omaveloxolone),PRESS-RELEASE,DJ Global Press Release Wire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.82,products-services,positive,Biogen Inc.: The CHMP's positive opinion for SKYCLARYS,PRESS-RELEASE,DJ Global Press Release Wire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved omaveloxolone, marketed as SKYCLARYS(R)",PRESS-RELEASE,DJ Global Press Release Wire,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS(R) (omaveloxolone),PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.82,products-services,positive,Biogen Inc.: The CHMP's positive opinion for SKYCLARYS,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved omaveloxolone, marketed as SKYCLARYS(R)",PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS(R) (omaveloxolone),FULL-ARTICLE,Dow Jones Newswires,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:25,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"The U.S. Food and Drug Administration (FDA) approved omaveloxolone, marketed as",FULL-ARTICLE,Dow Jones Newswires,"CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS(R) (omaveloxolone),PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:26,CEDFD5,Biogen Inc.,99,0.82,products-services,positive,Biogen Inc.: The CHMP's positive opinion for SKYCLARYS,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-15,14:05:26,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved omaveloxolone, marketed as SKYCLARYS(R)",PRESS-RELEASE,Dow Jones Newswires,"Press Release: CHMP Issues Positive Opinion for Biogen's SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease"
BIIB,2023-12-18,17:15:26,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Oppenheimer
BIIB,2023-12-18,17:15:26,CEDFD5,Biogen Inc.,100,0.6,price-targets,upgrade,Biogen Price Target Raised to $295.00/Share From $280.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $295.00/Share From $280.00 by Oppenheimer
BIIB,2025-01-02,16:27:24,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Neutral From Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Neutral From Overweight by Piper Sandler
BIIB,2025-01-02,16:27:24,CEDFD5,Biogen Inc.,100,-0.9,price-targets,downgrade,Biogen Price Target Cut to $138.00/Share From $315.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $138.00/Share From $315.00 by Piper Sandler
BIIB,2025-01-07,13:00:01,CEDFD5,Biogen Inc.,100,0.63,products-services,,Alivegen Receives FDA Orphan Drug Designation for ALG-801,PRESS-RELEASE,Business Wire,AliveGen Receives FDA Orphan Drug Designation for ALG-801 for Pulmonary Arterial Hypertension
BIIB,2025-01-08,11:54:37,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2025-01-08,11:54:37,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $220.00/Share From $302.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $220.00/Share From $302.00 by Truist Securities
BIIB,2025-01-10,14:21:12,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Wells Fargo
BIIB,2025-01-10,14:21:12,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $165.00/Share From $190.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $165.00/Share From $190.00 by Wells Fargo
BIIB,2025-01-10,23:49:00,CEDFD5,Biogen Inc.,96,0.55,acquisitions-mergers,interest,Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen,PRESS-RELEASE,Business Wire,Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
BIIB,2025-01-10,23:49:00,CEDFD5,Biogen Inc.,96,0.55,acquisitions-mergers,interest,Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
BIIB,2025-01-13,11:39:01,CEDFD5,Biogen Inc.,100,0.55,acquisitions-mergers,interest,Biogen Proposes Takeover,FULL-ARTICLE,Dow Jones Newswires,Sage Shares Surge Premarket After Biogen Proposes Takeover
BIIB,2025-01-13,14:56:04,CEDFD5,Biogen Inc.,100,0.55,acquisitions-mergers,interest,Biogen Wants to Buy Its Partner Sage,FULL-ARTICLE,Dow Jones Newswires,Biogen Wants to Buy Its Partner Sage for Almost No Premium -- Barrons.com
BIIB,2025-01-13,14:56:04,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Sage have been working together since,FULL-ARTICLE,Dow Jones Newswires,Biogen Wants to Buy Its Partner Sage for Almost No Premium -- Barrons.com
BIIB,2025-01-15,13:00:53,CEDFD5,Biogen Inc.,99,0.53,labor-issues,,"Biogen Inc.: On January 13, 2025, Biogen Inc. (the ""Company"") appointed Sean Godbout as Vice President, Chief Accounting Officer",RNS-SEC8K,Dow Jones Newswires,"Biogen Files 8K - Director, Officer or Compensation Filing >BIIB"
BIIB,2025-01-15,13:00:53,CEDFD5,Biogen Inc.,99,0.0,labor-issues,,Biogen Inc.: the Company's annual bonus plan,RNS-SEC8K,Dow Jones Newswires,"Biogen Files 8K - Director, Officer or Compensation Filing >BIIB"
BIIB,2025-01-27,11:14:46,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen, Eisai Get FDA Nod for Leqembi",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing"
BIIB,2025-01-27,11:29:46,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen, Eisai Get FDA Nod for Leqembi",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing"
BIIB,2025-01-27,14:42:57,CEDFD5,Biogen Inc.,100,-0.59,acquisitions-mergers,rejected,Sage Rejects Biogen Bid,FULL-ARTICLE,Dow Jones Newswires,"Sage Rejects Biogen Bid, Launches Review of Alternatives"
BIIB,2025-01-28,12:30:21,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Citigroup
BIIB,2025-01-28,12:30:21,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $160.00/Share From $190.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $160.00/Share From $190.00 by Citigroup
BIIB,2025-02-03,23:04:16,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Singhal Acquires 1,250 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Singhal Acquires 1,250 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:43:24,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Alexander Acquires 2,896 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Alexander Acquires 2,896 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:45:03,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Gregory Acquires 2,396 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Acquires 2,396 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:47:47,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Singhal Acquires 1,535 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Singhal Acquires 1,535 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:48:13,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Murphy Acquires 2,819 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Murphy Acquires 2,819 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:50:37,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Kramer Acquires 1,015 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Kramer Acquires 1,015 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:52:18,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Keeney Acquires 1,238 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Keeney Acquires 1,238 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:53:32,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Grogan Acquires 942 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Grogan Acquires 942 Of Biogen Inc >BIIB
BIIB,2025-02-10,23:56:59,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Ceo Viehbacher Acquires 5,807 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CEO Viehbacher Acquires 5,807 Of Biogen Inc >BIIB"
BIIB,2025-02-11,00:00:01,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 3,049 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 3,049 Of Biogen Inc >BIIB"
BIIB,2025-02-12,02:53:49,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Izzar Acquires 2,679 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Acquires 2,679 Of Biogen Inc >BIIB"
BIIB,2025-02-12,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Excited to collaborate with Biogen on,PRESS-RELEASE,GlobeNewswire,Royalty Pharma Announces R&D Funding Collaboration With Biogen
BIIB,2025-02-12,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Litifilimab is currently in Phase 3 trials,PRESS-RELEASE,GlobeNewswire,Royalty Pharma Announces R&D Funding Collaboration With Biogen
BIIB,2025-02-12,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Excited to collaborate with Biogen on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Royalty Pharma Announces R&D Funding Collaboration With Biogen
BIIB,2025-02-12,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Litifilimab is currently in Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Royalty Pharma Announces R&D Funding Collaboration With Biogen
BIIB,2025-02-12,11:45:08,CEDFD5,Biogen Inc.,99,0.7,earnings,above-expectations,Biogen beat fourth-quarter earnings and sales expectations,FULL-ARTICLE,Dow Jones Newswires,Why Investors Might Hammer Biogen Despite Its Earnings Beat -- IBD
BIIB,2025-02-12,11:45:08,CEDFD5,Biogen Inc.,99,-0.8,earnings,below-expectations,Biogen's outlook missed projections for,FULL-ARTICLE,Dow Jones Newswires,Why Investors Might Hammer Biogen Despite Its Earnings Beat -- IBD
BIIB,2025-02-12,11:45:08,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen noted U.S. sales,FULL-ARTICLE,Dow Jones Newswires,Why Investors Might Hammer Biogen Despite Its Earnings Beat -- IBD
BIIB,2025-02-12,11:58:31,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.5B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Rev $2.5B >BIIB
BIIB,2025-02-12,11:58:54,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $1.83 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q EPS $1.83 >BIIB
BIIB,2025-02-12,11:59:05,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Adj EPS $3.44,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Adj EPS $3.44 >BIIB
BIIB,2025-02-12,12:00:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees 2025 Adj EPS $15.25,NEWS-FLASH,Dow Jones Newswires,Biogen Sees 2025 Adj EPS $15.25-Adj EPS $16.25 >BIIB
BIIB,2025-02-12,12:01:13,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Expects 2025 Revenue to Decline,NEWS-FLASH,Dow Jones Newswires,Biogen Expects 2025 Revenue to Decline By Mid-Single Digit Percentage Vs 2024 >BIIB
BIIB,2025-02-12,12:06:59,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $1.83 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q EPS $1.83 >BIIB
BIIB,2025-02-12,12:06:59,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Net $266.8M,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Net $266.8M >BIIB
BIIB,2025-02-12,12:06:59,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.45B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Rev $2.45B >BIIB
BIIB,2025-02-12,12:23:20,CEDFD5,Biogen Inc.,100,0.72,revenues,above-expectations,Biogen 4Q Revenue Tops Wall Street,FULL-ARTICLE,Dow Jones Newswires,Biogen 4Q Revenue Tops Wall Street's Estimates
BIIB,2025-02-12,12:23:20,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen also guided for full-year adjusted earnings per share,FULL-ARTICLE,Dow Jones Newswires,Biogen 4Q Revenue Tops Wall Street's Estimates
BIIB,2025-02-12,15:22:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,"For 2025, Biogen expects adjusted earnings of $15.25 to $16.25 a share",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Falls After Company Gives Weaker-Than-Expected Financial Outlook -- WSJ
BIIB,2025-02-12,16:43:22,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Early Wednesday, Royalty Pharma (RPRX) unveiled a new partnership with Biogen",FULL-ARTICLE,MarketWatch,MW Biogen's stock slides on soft guidance and a decline in sales of MS drugs
BIIB,2025-02-12,21:19:39,CEDFD5,Biogen Inc.,99,-0.8,earnings,below-expectations,Biogen's outlook missed projections for,FULL-ARTICLE,Dow Jones Newswires,Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat -- IBD
BIIB,2025-02-12,21:19:39,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen noted U.S. sales,FULL-ARTICLE,Dow Jones Newswires,Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat -- IBD
BIIB,2025-02-12,22:40:51,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Izzar Acquires 1,070 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Acquires 1,070 Of Biogen Inc >BIIB"
BIIB,2025-02-12,22:46:12,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Alexander Acquires 1,768 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Alexander Acquires 1,768 Of Biogen Inc >BIIB"
BIIB,2025-02-12,22:46:35,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Gregory Acquires 1,525 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Acquires 1,525 Of Biogen Inc >BIIB"
BIIB,2025-02-12,22:49:09,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 589 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 589 Of Biogen Inc >BIIB
BIIB,2025-02-12,22:49:21,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 1,886 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 1,886 Of Biogen Inc >BIIB"
BIIB,2025-02-12,22:49:32,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Murphy Acquires 1,602 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Murphy Acquires 1,602 Of Biogen Inc >BIIB"
BIIB,2025-02-12,22:49:56,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Singhal Acquires 855 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Acquires 855 Of Biogen Inc >BIIB
BIIB,2025-02-13,07:04:43,CEDFD5,Biogen Inc.,94,-0.75,revenues,down,Biogen forecast lower-than-expected revenue,FULL-ARTICLE,Dow Jones Newswires,Technology: Biogen's Outlook Hurt by Slower Sales And Competition ---- By Joseph Walker
BIIB,2025-02-13,07:04:43,CEDFD5,Biogen Inc.,94,0.0,earnings,,"For 2025, Biogen expects adjusted earnings of $15.25 to $16.25 a share",FULL-ARTICLE,Dow Jones Newswires,Technology: Biogen's Outlook Hurt by Slower Sales And Competition ---- By Joseph Walker
BIIB,2025-02-13,12:02:27,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2025-02-13,12:02:27,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $265.00/Share From $298.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $265.00/Share From $298.00 by Canaccord Genuity
BIIB,2025-02-13,13:48:18,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2025-02-13,13:48:18,CEDFD5,Biogen Inc.,100,-0.56,price-targets,downgrade,Biogen Price Target Cut to $210.00/Share From $220.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $210.00/Share From $220.00 by Truist Securities
BIIB,2025-02-13,14:02:47,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2025-02-13,14:02:47,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $241.00/Share From $300.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $241.00/Share From $300.00 by HC Wainwright & Co.
BIIB,2025-02-13,15:28:38,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Wells Fargo
BIIB,2025-02-13,15:28:38,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $140.00/Share From $165.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $140.00/Share From $165.00 by Wells Fargo
BIIB,2025-02-13,16:45:38,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Citigroup
BIIB,2025-02-13,16:45:38,CEDFD5,Biogen Inc.,100,-0.78,price-targets,downgrade,Biogen Price Target Cut to $145.00/Share From $160.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $145.00/Share From $160.00 by Citigroup
BIIB,2025-02-13,16:55:38,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-02-13,16:55:38,CEDFD5,Biogen Inc.,100,-0.42,price-targets,downgrade,Biogen Price Target Cut to $225.00/Share From $231.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $225.00/Share From $231.00 by RBC Capital
BIIB,2025-02-13,17:13:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Goldman Sachs
BIIB,2025-02-13,17:13:29,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $245.00/Share From $281.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $245.00/Share From $281.00 by Goldman Sachs
BIIB,2025-02-13,17:50:18,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Morgan Stanley
BIIB,2025-02-13,17:50:18,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $157.00/Share From $192.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $157.00/Share From $192.00 by Morgan Stanley
BIIB,2025-02-13,17:57:18,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Market Perform by BMO Capital
BIIB,2025-02-13,17:57:18,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $139.00/Share From $156.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $139.00/Share From $156.00 by BMO Capital
BIIB,2025-02-13,19:00:18,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Sector Outperform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Outperform by Scotiabank
BIIB,2025-02-13,19:00:18,CEDFD5,Biogen Inc.,100,-0.72,price-targets,downgrade,Biogen Price Target Cut to $224.00/Share From $244.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $224.00/Share From $244.00 by Scotiabank
BIIB,2025-02-18,13:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,Business Wire,"Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for",PRESS-RELEASE,Business Wire,"Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,GlobeNewswire,"(PMZN) Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration",PRESS-RELEASE,GlobeNewswire,"(PMZN) Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:07,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter Into Collaboration to Develop and Commercialize Zorevunersen,NEWS-FLASH,Dow Jones Newswires,"Biogen and Stoke Therapeutics Enter Into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated With Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:14:32,CEDFD5,Biogen Inc.,100,0.39,products-services,,Stoke Therapeutics And Biogen In Pact,FULL-ARTICLE,Dow Jones Newswires,Stoke Therapeutics And Biogen In Pact For Treatment For Severe Form Of Epilepsy -- MarketWatch
BIIB,2025-02-18,13:14:32,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Stoke Therapeutics Inc.: the company and Biogen Inc. announced a collaboration,FULL-ARTICLE,Dow Jones Newswires,Stoke Therapeutics And Biogen In Pact For Treatment For Severe Form Of Epilepsy -- MarketWatch
BIIB,2025-02-18,13:14:32,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen in pact for treatment,FULL-ARTICLE,MarketWatch,MW Stoke Therapeutics and Biogen in pact for treatment for severe form of epilepsy
BIIB,2025-02-18,13:14:32,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Stoke Therapeutics Inc.: the company and Biogen Inc. announced a collaboration,FULL-ARTICLE,MarketWatch,MW Stoke Therapeutics and Biogen in pact for treatment for severe form of epilepsy
BIIB,2025-02-18,13:46:40,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen in pact for treatment,FULL-ARTICLE,MarketWatch,MW Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
BIIB,2025-02-18,13:55:18,CEDFD5,Biogen Inc.,95,0.49,partnerships,,Biogen and Stoke Therapeutics have agreed to collaborate,FULL-ARTICLE,Dow Jones Newswires,"Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration"
BIIB,2025-02-18,14:34:59,CEDFD5,Biogen Inc.,100,-0.4,price-targets,downgrade,Biogen Price Target Cut to $135.00/Share From $138.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $135.00/Share From $138.00 by Piper Sandler
BIIB,2025-02-18,14:45:29,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen in pact for treatment,FULL-ARTICLE,MarketWatch,MW Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
BIIB,2025-02-19,08:07:01,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2024 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2024 (BIIB)"
BIIB,2025-02-20,08:07:10,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2024 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2024 (BIIB)"
BIIB,2025-03-07,21:21:27,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Dir Sherwin Registers 8,760 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"Dir Sherwin Registers 8,760 Of Biogen Inc >BIIB"
BIIB,2025-03-10,20:10:54,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Dir Sherwin Sells 8,760 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"Dir Sherwin Sells 8,760 Of Biogen Inc >BIIB"
BIIB,2025-03-11,11:30:00,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Inc.: Building upon the promising results from the Phase 2 study,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:00,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Inc.: Building upon the promising results from the Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of -2-
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Nasdaq: BIIB) -- announced the initiation of dosing in the global clinical study,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,TABULAR-MATERIAL,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Inc.: Building upon the promising results from the Phase 2 study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Inc.: Building upon the promising results from the Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of -2-
BIIB,2025-03-11,11:30:11,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,NEWS-FLASH,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection in Kidney Transplant Patients >BIIB
BIIB,2025-03-17,11:00:09,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Skyclarys(TM) (omaveloxolone) Approval by Health Canada,PRESS-RELEASE,Canadian News Wire,SKYCLARYS(TM) (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich's Ataxia Treatment in Canada
BIIB,2025-03-17,11:00:09,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,Canadian News Wire,SKYCLARYS(TM) (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich's Ataxia Treatment in Canada
BIIB,2025-03-18,13:00:15,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Remedy Pharmaceuticals Secures Key U.S. Patent Allowance for CIRARA(R),PRESS-RELEASE,PR Newswire,"Remedy Pharmaceuticals Secures Key U.S. Patent Allowance for CIRARA(R) in Treating Large Hemispheric Infarction, Including Wake-Up Strokes"
BIIB,2025-04-01,11:30:00,CEDFD5,Biogen Inc.,100,0.51,products-services,,Organon Acquires TOFIDENCE(TM) -,PRESS-RELEASE,Business Wire,Organon Acquires TOFIDENCE(TM) -2-
BIIB,2025-04-02,11:30:00,CEDFD5,Biogen Inc.,99,0.69,products-services,,Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation,PRESS-RELEASE,GlobeNewswire,Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,"Biogen Inc.: As previously announced, results from the Phase 1b study",PRESS-RELEASE,GlobeNewswire,Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:01,CEDFD5,Biogen Inc.,99,0.69,products-services,,Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:01,CEDFD5,Biogen Inc.,99,0.69,products-services,,Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation,PRESS-RELEASE,DJ Global Press Release Wire,Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:01,CEDFD5,Biogen Inc.,99,0.69,products-services,,Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation,FULL-ARTICLE,Dow Jones Newswires,Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:01,CEDFD5,Biogen Inc.,99,0.69,products-services,,Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,"Biogen Inc.: As previously announced, results from the Phase 1b study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:31:58,CEDFD5,Biogen Inc.,100,0.69,products-services,,Biogen Gets FDA Fast-Track Designation for BIIB080,NEWS-FLASH,Dow Jones Newswires,Biogen Gets FDA Fast-Track Designation for BIIB080 in Alzheimer's Disease >BIIB
BIIB,2025-04-02,12:08:45,CEDFD5,Biogen Inc.,100,0.69,products-services,,Biogen's BIIB080 Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
BIIB,2025-04-02,12:08:45,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Japan's Eisai are partners on Leqembi, which the FDA approved in 2023 for",FULL-ARTICLE,Dow Jones Newswires,Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
BIIB,2025-04-02,12:23:45,CEDFD5,Biogen Inc.,100,0.69,products-services,,Biogen's BIIB080 Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
BIIB,2025-04-02,12:23:45,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Japan's Eisai are partners on Leqembi, which the FDA approved in 2023 for",FULL-ARTICLE,Dow Jones Newswires,Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
BIIB,2025-04-02,13:35:05,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Reata Pharmaceuticals, Inc. (""Reata""), which was subsequently acquired by Biogen in September 2023",PRESS-RELEASE,LSE Regulatory News Service (RNS),BioPharma Credit PLC BIOGEN SETTLEMENT
BIIB,2025-04-04,15:13:27,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Hold From Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Hold From Buy by Argus Research
BIIB,2025-04-09,14:05:59,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Morgan Stanley
BIIB,2025-04-09,14:05:59,CEDFD5,Biogen Inc.,100,-0.46,price-targets,downgrade,Biogen Price Target Cut to $152.00/Share From $157.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $152.00/Share From $157.00 by Morgan Stanley
BIIB,2025-04-15,23:01:18,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Eisai and Biogen: Leqembi Authorized in the European Union,NEWS-FLASH,Dow Jones Newswires,Eisai and Biogen: Leqembi Authorized in the European Union
BIIB,2025-04-16,17:33:19,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,European Commission approved Eisai and Biogen's drug Leqembi,FULL-ARTICLE,Dow Jones Newswires,Biogen Unlikely to Receive Boost from Leqembi Approval in EU -- Market Talk
BIIB,2025-04-16,17:33:20,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,European Commission approved Eisai and Biogen's drug Leqembi,FULL-ARTICLE,Dow Jones Newswires,Biogen Unlikely to Receive Boost from Leqembi Approval in EU -- Market Talk
BIIB,2025-04-22,14:25:44,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-04-22,14:25:44,CEDFD5,Biogen Inc.,100,0.34,price-targets,upgrade,Biogen Price Target Raised to $225.00/Share From $221.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $225.00/Share From $221.00 by RBC Capital
BIIB,2025-04-23,14:54:35,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Goldman Sachs
BIIB,2025-04-23,14:54:35,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $197.00/Share From $219.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $197.00/Share From $219.00 by Goldman Sachs
BIIB,2025-04-29,14:40:39,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Piper Sandler
BIIB,2025-04-29,14:40:39,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $115.00/Share From $135.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $115.00/Share From $135.00 by Piper Sandler
BIIB,2025-04-29,16:36:38,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2025-04-29,16:36:38,CEDFD5,Biogen Inc.,100,-0.6,price-targets,downgrade,Biogen Price Target Cut to $199.00/Share From $210.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $199.00/Share From $210.00 by Truist Securities
BIIB,2025-05-01,10:46:36,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Easily Tops Earnings Forecasts,FULL-ARTICLE,Dow Jones Newswires,"Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar -- IBD"
BIIB,2025-05-01,10:46:36,CEDFD5,Biogen Inc.,100,0.65,revenues,up,Skyclarys Sales Soar,FULL-ARTICLE,Dow Jones Newswires,"Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar -- IBD"
BIIB,2025-05-01,10:46:36,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,In the 2023 takeover of Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,"Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar -- IBD"
BIIB,2025-05-01,10:46:36,CEDFD5,Biogen Inc.,100,0.65,revenues,up,Spinraza sales jumped,FULL-ARTICLE,Dow Jones Newswires,"Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar -- IBD"
BIIB,2025-05-01,10:46:36,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen also expects full-year sales to decline,FULL-ARTICLE,Dow Jones Newswires,"Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar -- IBD"
BIIB,2025-05-01,10:52:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $1.64 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $1.64 >BIIB
BIIB,2025-05-01,10:52:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $3.02,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Adj EPS $3.02 >BIIB
BIIB,2025-05-01,10:52:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Net $240.5M,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Net $240.5M >BIIB
BIIB,2025-05-01,10:52:36,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.43B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.43B >BIIB
BIIB,2025-05-01,13:30:03,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,In the 2023 takeover of Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-01,13:30:03,CEDFD5,Biogen Inc.,99,0.65,revenues,up,Spinraza sales jumped,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-01,13:30:03,CEDFD5,Biogen Inc.,99,-0.75,revenues,down,Biogen also expects full-year sales to decline,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-01,13:31:07,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,In the 2023 takeover of Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-01,13:31:07,CEDFD5,Biogen Inc.,99,0.65,revenues,up,Spinraza sales jumped,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-01,13:31:07,CEDFD5,Biogen Inc.,99,-0.75,revenues,down,Biogen also expects full-year sales to decline,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-02,12:37:05,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Baird
BIIB,2025-05-02,12:37:05,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $255.00/Share From $300.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $255.00/Share From $300.00 by Baird
BIIB,2025-05-02,13:25:15,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2025-05-02,13:25:15,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $187.00/Share From $241.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $187.00/Share From $241.00 by HC Wainwright & Co.
BIIB,2025-05-02,15:49:15,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2025-05-02,15:49:15,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $220.00/Share From $265.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $220.00/Share From $265.00 by Canaccord Genuity
BIIB,2025-05-02,18:50:25,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-05-02,18:50:25,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $205.00/Share From $217.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $205.00/Share From $217.00 by RBC Capital
BIIB,2025-05-05,14:40:49,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by JP Morgan
BIIB,2025-05-05,14:40:49,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $175.00/Share From $185.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $175.00/Share From $185.00 by JP Morgan
BIIB,2025-05-05,20:18:26,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Dir Dorsa Buys 1,235 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Dir Dorsa Buys 1,235 Of Biogen Inc >BIIB"
BIIB,2025-05-05,20:24:27,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Keeney Acquires 484 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Keeney Acquires 484 Of Biogen Inc >BIIB
BIIB,2025-05-06,14:08:59,CEDFD5,Biogen Inc.,100,0.06,credit-ratings,set,S&PGR Rates Biogen Inc.'s Senior Unsecured Notes 'BBB+,NEWS-FLASH,Dow Jones Newswires,S&PGR Rates Biogen Inc.'s Senior Unsecured Notes 'BBB+'
BIIB,2025-05-06,14:08:59,CEDFD5,Biogen Inc.,100,0.06,credit-ratings,set,S&PGR Rates Biogen Inc.'s Senior Unsecured Notes 'BBB+,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Rates Biogen Inc.'s Senior Unsecured Notes 'BBB+'
BIIB,2025-05-06,14:14:06,CEDFD5,Biogen Inc.,100,0.01,credit-ratings,stable,Moody's Ratings Assigns Baa2 Rating To Biogen's Notes; Stable Outlook,NEWS-FLASH,Dow Jones Newswires,Moody's Ratings Assigns Baa2 Rating To Biogen's Notes; Stable Outlook
BIIB,2025-05-07,13:26:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Mizuho
BIIB,2025-05-07,13:26:13,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $169.00/Share From $207.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $169.00/Share From $207.00 by Mizuho
BIIB,2025-05-12,20:45:39,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen Inc.: On May 6, 2025, Biogen Inc. (the ""Company"") entered into an Underwriting Agreement (the ""Underwriting Agreement"") with BofA Securities, Inc., Citigroup Global Markets Inc.",RNS-SEC8K,Dow Jones Newswires,Biogen Files 8K - Other Events >BIIB
BIIB,2025-05-12,21:41:07,CEDFD5,Biogen Inc.,100,0.0,credit,,Biogen Sells $1.75B of Notes,RNS-SEC8K,Dow Jones Newswires,"Biogen Sells $1.75B of Notes, Including $400M of 5.05% Senior Notes Due 2031, and Notes Due in 2035 and 2055"
BIIB,2025-05-19,07:06:56,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 1Q 2025 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 1Q 2025 (BIIB)"
BIIB,2025-05-19,15:27:32,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Vp Singhal Registers 3,806 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"VP Singhal Registers 3,806 Of Biogen Inc >BIIB"
BIIB,2025-05-20,20:09:21,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Singhal Sells 3,806 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Singhal Sells 3,806 Of Biogen Inc >BIIB"
BIIB,2025-05-27,11:30:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and City Therapeutics Announce Strategic Research Collaboration to,PRESS-RELEASE,GlobeNewswire,Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB,2025-05-27,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and City Therapeutics Announce Strategic Research Collaboration to,FULL-ARTICLE,Dow Jones Newswires,Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB,2025-05-27,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and City Therapeutics Announce Strategic Research Collaboration to,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB,2025-05-27,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and City Therapeutics Announce Strategic Research Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB,2025-05-27,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and City Therapeutics Announce Strategic Research Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB,2025-05-27,11:32:05,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen to Invest $30 Million for,NEWS-FLASH,Dow Jones Newswires,Biogen to Invest $30 Million for City Therapeutics Convertible Note >BIIB
BIIB,2025-06-05,11:00:08,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Skyclarys was approved in March 2025 under Health Canada,PRESS-RELEASE,Canadian News Wire,Biogen Disappointed by INESSS Recommendation on SKYCLARYS(TM) and its Impact on Quebec Patients with Friedreich Ataxia
BIIB,2025-06-05,11:00:08,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,Canadian News Wire,Biogen Disappointed by INESSS Recommendation on SKYCLARYS(TM) and its Impact on Quebec Patients with Friedreich Ataxia
BIIB,2025-06-12,14:23:38,CEDFD5,Biogen Inc.,100,0.0,price-targets,unchanged,Biogen Price Target Maintained With a $121.00/Share by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Maintained With a $121.00/Share by Wedbush
BIIB,2025-06-12,17:09:58,CEDFD5,Biogen Inc.,100,0.0,price-targets,unchanged,Biogen Price Target Maintained With a $115.00/Share by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Maintained With a $115.00/Share by Piper Sandler
BIIB,2025-06-18,11:30:27,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:27,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial",PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:27,CEDFD5,Biogen Inc.,100,0.41,assets,open,Biogen Inc.: we plan to open BRAVE study sites,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,assets,open,Biogen Inc.: we plan to open BRAVE study sites,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,assets,open,Biogen Inc.: we plan to open BRAVE study sites,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial",FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,assets,open,Biogen Inc.: we plan to open BRAVE study sites,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:41,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,NEWS-FLASH,Dow Jones Newswires,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-25,11:30:37,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115,PRESS-RELEASE,GlobeNewswire,Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:37,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: An interim analysis of,PRESS-RELEASE,GlobeNewswire,Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:37,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:37,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: An interim analysis of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:38,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115,FULL-ARTICLE,Dow Jones Newswires,Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:38,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:38,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: An interim analysis of,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:38,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:38,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: An interim analysis of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:31:00,CEDFD5,Biogen Inc.,99,0.84,products-services,positive,"Biogen, shared positive topline results from the Phase 1 study",PRESS-RELEASE,Business Wire,Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
BIIB,2025-06-25,11:31:01,CEDFD5,Biogen Inc.,99,0.84,products-services,positive,"Biogen, shared positive topline results from the Phase 1 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
BIIB,2025-06-25,11:31:34,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen MOVES INTO PHASE 3 TESTING,FULL-ARTICLE,Dow Jones Newswires,Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? -- IBD
BIIB,2025-06-25,11:57:05,CEDFD5,Biogen Inc.,95,0.49,partnerships,,Biogen and Ionis are also partners on Spinraza,FULL-ARTICLE,Dow Jones Newswires,Biogen to Advance SMA Treatment Into Registrational Studies
BIIB,2025-06-25,14:08:48,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-06-25,14:08:48,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $213.00/Share From $205.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $213.00/Share From $205.00 by RBC Capital
BIIB,2025-06-25,20:19:35,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen MOVES INTO PHASE 3 TESTING,FULL-ARTICLE,Dow Jones Newswires,Can Biogen Save Even More Kids With This New Drug? -- IBD
BIIB,2025-06-26,11:55:40,CEDFD5,Biogen Inc.,100,0.0,price-targets,unchanged,Biogen Price Target Maintained With a $187.00/Share by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Maintained With a $187.00/Share by HC Wainwright & Co.
BIIB,2025-06-27,13:10:02,CEDFD5,Biogen Inc.,100,0.0,price-targets,unchanged,Biogen Price Target Maintained With a $213.00/Share by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Maintained With a $213.00/Share by RBC Capital
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Inc.: announced the initiation of dosing in the global clinical study,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Inc.: announced the initiation of dosing in the global clinical study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of -2-
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Nasdaq: BIIB) -- announced the initiation of dosing in the global clinical study,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Inc.: announced the initiation of dosing in the global clinical study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Inc.: announced the initiation of dosing in the global clinical study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of -2-
BIIB,2025-06-30,11:30:22,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,NEWS-FLASH,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for Treatment of Primary Membranous Nephropathy >BIIB
BIIB,2025-06-30,11:53:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Launches Phase 3 Study of Felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Launches Phase 3 Study of Felzartamab in Rare Kidney Disease PMN
BIIB,2025-06-30,11:53:28,CEDFD5,Biogen Inc.,100,0.34,products-services,,Biogen acquired the rights to felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Launches Phase 3 Study of Felzartamab in Rare Kidney Disease PMN
BIIB,2025-07-07,20:36:02,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Expects $46M 2Q Expense,FULL-ARTICLE,Dow Jones Newswires,Biogen Expects $46M 2Q Expense From In-Process Research and Development
BIIB,2025-07-07,20:36:02,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's second quarter results,FULL-ARTICLE,Dow Jones Newswires,Biogen Expects $46M 2Q Expense From In-Process Research and Development
BIIB,2025-07-08,19:27:26,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Officer Izzar Registers 2,223 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"Officer Izzar Registers 2,223 Of Biogen Inc >BIIB"
BIIB,2025-07-10,11:00:01,CEDFD5,Biogen Inc.,97,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:01,CEDFD5,Biogen Inc.,97,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:01,CEDFD5,Biogen Inc.,96,0.49,partnerships,,A strategic collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Business Wire,"Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,"(PMZN) Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-16,21:56:32,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Officer Izzar Sells 2,223 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Sells 2,223 Of Biogen Inc >BIIB"
BIIB,2025-07-21,11:30:00,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen Announces $2 Billion Manufacturing Investment in North Carolina,PRESS-RELEASE,GlobeNewswire,Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary
BIIB,2025-07-21,11:30:01,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen Announces $2 Billion Manufacturing Investment in North Carolina,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary
BIIB,2025-07-21,11:30:13,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen Announces $2 B Manufacturing Investment in North Carolina,NEWS-FLASH,Dow Jones Newswires,Biogen Announces $2 B Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction With Its 30th Anniversary
BIIB,2025-07-21,11:58:12,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen to Invest Additional $2 Billion in North Carolina,FULL-ARTICLE,Dow Jones Newswires,Biogen to Invest Additional $2 Billion in North Carolina Research Hub
BIIB,2025-07-21,23:30:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: our Phase 2 study of BIIB080,PRESS-RELEASE,GlobeNewswire,Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,GlobeNewswire,Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen have been collaborating on,FULL-ARTICLE,Dow Jones Newswires,Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: our Phase 2 study of BIIB080,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: results in a clinical trial,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Highlight Scientific Progress Across -2-
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: our Phase 2 study of BIIB080,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: results in a clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Highlight Scientific -2-
BIIB,2025-07-25,11:21:06,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen: Zurzuvae Gets CHMP Positive Opinion,NEWS-FLASH,Dow Jones Newswires,Biogen: Zurzuvae Gets CHMP Positive Opinion for Treatment of Women With Postpartum Depression >BIIB
BIIB,2025-07-31,10:14:16,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $4.33 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q EPS $4.33 >BIIB
BIIB,2025-07-31,10:14:16,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Adj EPS $5.47,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Adj EPS $5.47 >BIIB
BIIB,2025-07-31,10:14:16,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Net $634.8M,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Net $634.8M >BIIB
BIIB,2025-07-31,10:14:16,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 2Q Rev $2.65B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Rev $2.65B >BIIB
BIIB,2025-07-31,10:18:58,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Increases Full-Year 2025 Guidance >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Increases Full-Year 2025 Guidance >BIIB
BIIB,2025-07-31,10:19:27,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises 2025 View To Adj EPS $15.50,NEWS-FLASH,Dow Jones Newswires,Biogen Raises 2025 View To Adj EPS $15.50-Adj EPS $16.00 >BIIB
BIIB,2025-07-31,10:19:41,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Had Seen 2025 Adjusted EPS $14.50-$15.50,NEWS-FLASH,Dow Jones Newswires,Biogen Had Seen 2025 Adjusted EPS $14.50-$15.50 >BIIB
BIIB,2025-07-31,10:20:38,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Had Seen 2025 Revenue Down,NEWS-FLASH,Dow Jones Newswires,Biogen Had Seen 2025 Revenue Down Mid-Single Digits Constant-Currency >BIIB
BIIB,2025-07-31,10:51:36,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises 2025 Outlook After,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises 2025 Outlook After Momentum in 1H
BIIB,2025-07-31,10:51:36,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raised its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises 2025 Outlook After Momentum in 1H
BIIB,2025-07-31,10:51:36,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc.: The company also expects adjusted earnings per-share to be between $15.50 to $16,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises 2025 Outlook After Momentum in 1H
BIIB,2025-08-01,10:47:42,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2025-08-01,10:47:42,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $194.00/Share From $187.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $194.00/Share From $187.00 by HC Wainwright & Co.
BIIB,2025-08-01,14:22:02,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Morgan Stanley
BIIB,2025-08-01,14:22:02,CEDFD5,Biogen Inc.,100,-0.28,price-targets,downgrade,Biogen Price Target Cut to $144.00/Share From $146.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $144.00/Share From $146.00 by Morgan Stanley
BIIB,2025-08-01,15:36:23,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-08-01,15:36:23,CEDFD5,Biogen Inc.,100,0.6,price-targets,upgrade,Biogen Price Target Raised to $219.00/Share From $208.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $219.00/Share From $208.00 by RBC Capital
BIIB,2025-08-01,20:25:47,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Citigroup
BIIB,2025-08-01,20:25:47,CEDFD5,Biogen Inc.,100,0.7,price-targets,upgrade,Biogen Price Target Raised to $135.00/Share From $125.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $135.00/Share From $125.00 by Citigroup
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen,PRESS-RELEASE,Business Wire,"Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Business Wire,"Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,96,0.49,partnerships,,A strategic collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,"(PMZN) Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:04,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen,NEWS-FLASH,Dow Jones Newswires,"Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-13,23:20:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc. (NASDAQ:BIIB)",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2025-08-13,23:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2025-08-13,23:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2025-08-14,15:39:02,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Piper Sandler
BIIB,2025-08-14,15:39:02,CEDFD5,Biogen Inc.,100,0.42,price-targets,upgrade,Biogen Price Target Raised to $118.00/Share From $115.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $118.00/Share From $115.00 by Piper Sandler
BIIB,2025-08-19,07:06:53,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 2Q 2025 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 2Q 2025 (BIIB)"
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,95,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Business Wire,Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,95,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,97,0.49,partnerships,,A strategic collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-09-02,11:00:01,CEDFD5,Biogen Inc.,93,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-09-02,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Stoke Therapeutics Present Data at the -2-
BIIB,2025-09-02,11:00:01,CEDFD5,Biogen Inc.,97,0.49,partnerships,,A strategic collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,Biogen and Stoke Therapeutics Present Data at the -2-
BIIB,2025-09-02,11:00:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Stoke Therapeutics -2-
BIIB,2025-09-02,11:00:02,CEDFD5,Biogen Inc.,93,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-09-02,11:00:02,CEDFD5,Biogen Inc.,93,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Business Wire,Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-09-02,16:57:31,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 517 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 517 Of Biogen Inc >BIIB
BIIB,2025-09-02,21:57:19,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 517 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 517 Of Biogen Inc >BIIB
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First",PRESS-RELEASE,GlobeNewswire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved ZURZUVAE,PRESS-RELEASE,GlobeNewswire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,In 2020 Biogen and Sage Therapeutics entered into a collaboration,PRESS-RELEASE,GlobeNewswire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved ZURZUVAE,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,In 2020 Biogen and Sage Therapeutics entered into a collaboration,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved ZURZUVAE,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,In 2020 Biogen and Sage Therapeutics entered into a collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved ZURZUVAE,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,In 2020 Biogen and Sage Therapeutics entered into a collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:06,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First",FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:06,CEDFD5,Biogen Inc.,100,0.49,partnerships,,In 2020 Biogen and Sage Therapeutics entered into a collaboration,FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:34:23,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE, First",NEWS-FLASH,Dow Jones Newswires,"Biogen Receives European Commission Approval for ZURZUVAE, First and Only Treatment Approved for Women With Postpartum Depression in Europe"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,GlobeNewswire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Alcyone Therapeutics have collaborated since,PRESS-RELEASE,GlobeNewswire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen plans to introduce the new drug,PRESS-RELEASE,GlobeNewswire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,GlobeNewswire,"Biogen to Acquire Alcyone Therapeutics, Expanding -2-"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Press Release: Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Alcyone Therapeutics have collaborated since,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen plans to introduce the new drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results in early-stage clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Alcyone -2-
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Alcyone Therapeutics have collaborated since,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen plans to introduce the new drug,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Press Release: Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Alcyone Therapeutics have collaborated since,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen plans to introduce the new drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Press Release: Biogen to Acquire Alcyone,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Alcyone -2-
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen to Acquire Alcyone Therapeutics, Expanding -2-"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen to Acquire Alcyone Therapeutics, Expanding -3-"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Alcyone Therapeutics have collaborated since,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen plans to introduce the new drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Acquire Alcyone Therapeutics, Expanding -2-"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Acquire Alcyone Therapeutics, Expanding -3-"
BIIB,2025-09-18,11:40:10,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen to Acquire Alcyone Therapeutics >BIIB
BIIB,2025-09-18,11:41:48,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen To Buy Alcyone Therapeutics for,NEWS-FLASH,Dow Jones Newswires,Biogen To Buy Alcyone Therapeutics for Upfront Cash Payment of $85 Million >BIIB
BIIB,2025-09-18,12:59:40,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Alcyone Therapeutics for Initial $85 Million,FULL-ARTICLE,Dow Jones Newswires,Biogen to Buy Alcyone Therapeutics for Initial $85 Million
BIIB,2025-09-23,06:00:16,CEDFD5,Biogen Inc.,97,0.62,acquisitions-mergers,,Biogen to acquire Alcyone Therapeutics,PRESS-RELEASE,LSE Regulatory News Service (RNS),RTW Biotech Opportunities Ltd Biogen to acquire Alcyone Therapeutics
BIIB,2025-09-23,06:00:16,CEDFD5,Biogen Inc.,97,0.49,partnerships,,Biogen and Alcyone have collaborated since,PRESS-RELEASE,LSE Regulatory News Service (RNS),RTW Biotech Opportunities Ltd Biogen to acquire Alcyone Therapeutics
BIIB,2025-09-23,20:30:00,CEDFD5,Biogen Inc.,99,-0.58,products-services,denied,Biogen Inc.: the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug,PRESS-RELEASE,GlobeNewswire,Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
BIIB,2025-09-23,20:30:01,CEDFD5,Biogen Inc.,99,-0.58,products-services,denied,Biogen Inc.: the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
BIIB,2025-09-23,20:30:01,CEDFD5,Biogen Inc.,99,-0.58,products-services,denied,Biogen Inc.: the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
BIIB,2025-09-23,20:30:01,CEDFD5,Biogen Inc.,99,-0.58,products-services,denied,Biogen Inc.: the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
BIIB,2025-09-23,20:30:01,CEDFD5,Biogen Inc.,99,-0.58,products-services,denied,Biogen Inc.: the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
BIIB,2025-09-25,11:14:38,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Biogen Initiated at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Buy by Jefferies
BIIB,2025-09-25,11:14:38,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $190.00/Share by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $190.00/Share by Jefferies
BIIB,2025-09-25,12:00:13,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Foundation Partners with Biogen to,PRESS-RELEASE,PR Newswire,"National Ataxia Foundation Partners with Biogen to Bring Bill Nye ""the Science Guy"" Back To the Lab With New Series About Friedreich Ataxia"
BIIB,2025-10-06,17:02:13,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Godbout Acquires 18 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Godbout Acquires 18 Of Biogen Inc >BIIB
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),FULL-ARTICLE,Dow Jones Newswires,Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,DJ Global Press Release Wire,Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Collaboration between Eisai and Biogen,FULL-ARTICLE,Dow Jones Newswires,Eisai and Biogen Announce U.S. Availability of -3-
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Collaboration between Eisai and Biogen,PRESS-RELEASE,DJ Global Press Release Wire,Eisai and Biogen Announce U.S. Availability of -3-
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Collaboration between Eisai and Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Biogen Announce U.S. -3-
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,GlobeNewswire,(PMZN) Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Collaboration between Eisai and Biogen,PRESS-RELEASE,GlobeNewswire,(PMZN) Eisai and Biogen Announce U.S. -3-
BIIB,2025-10-06,20:30:05,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:05,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Collaboration between Eisai and Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Biogen Announce U.S. -3-
BIIB,2025-10-06,20:30:10,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,PR Newswire,(PR) Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:13,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:31:20,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI,NEWS-FLASH,Dow Jones Newswires,"Eisai, Biogen Announce U.S. Availability of LEQEMBI IQLIK Subcutaneous Injection Maintenance Dose to Treat Early Alzheimer's Disease"
BIIB,2025-10-09,20:30:01,CEDFD5,Biogen Inc.,96,0.49,partnerships,,A strategic collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-10-09,20:30:04,CEDFD5,Biogen Inc.,98,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Business Wire,Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-10-09,20:30:04,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-10-09,20:30:06,CEDFD5,Biogen Inc.,98,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-10-09,20:30:06,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-10-10,17:47:15,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Morgan Stanley
BIIB,2025-10-10,17:47:15,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $149.00/Share From $144.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $149.00/Share From $144.00 by Morgan Stanley
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: A second Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between Biogen and UCB,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,"Biogen Inc.: Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present Additional -2-
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between Biogen and UCB,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: A second Phase 3 study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between Biogen and UCB,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,"Biogen Inc.: Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients",PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present Additional Results from Phase 3 -2-
BIIB,2025-10-22,11:30:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: A second Phase 3 study,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between Biogen and UCB,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:03,CEDFD5,Biogen Inc.,98,0.0,products-services,,"Biogen Inc.: Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients",PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present Additional Results from -2-
BIIB,2025-10-22,11:30:14,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present Additional Results From Phase 3 Study of Dapirolizumab Pegol,NEWS-FLASH,Dow Jones Newswires,Biogen to Present Additional Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
BIIB,2025-10-30,10:14:33,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,3Q EPS $3.17 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q EPS $3.17 >BIIB
BIIB,2025-10-30,10:14:33,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $4.81,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $4.81 >BIIB
BIIB,2025-10-30,10:14:33,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Net $466.5M,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Net $466.5M >BIIB
BIIB,2025-10-30,10:14:33,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.53B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.53B >BIIB
BIIB,2025-10-30,10:25:32,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees 2025 Adj EPS $14.50,RNS-SEC8K,Dow Jones Newswires,Biogen Sees 2025 Adj EPS $14.50-Adj EPS $15 >BIIB
BIIB,2025-10-30,10:25:58,CEDFD5,Biogen Inc.,100,0.48,revenues,up,Biogen Sees 2025 Revenue Flat to 1% Higher,RNS-SEC8K,Dow Jones Newswires,Biogen Sees 2025 Revenue Flat to 1% Higher >BIIB
BIIB,2025-10-30,11:24:43,CEDFD5,Biogen Inc.,100,-0.74,earnings,down,"Biogen Cuts FY Earnings Guidance, Despite",FULL-ARTICLE,Dow Jones Newswires,"Biogen Cuts FY Earnings Guidance, Despite 3Q Profit Rise"
BIIB,2025-10-30,11:24:43,CEDFD5,Biogen Inc.,100,0.0,earnings,,"For the full year, Biogen now expects adjusted earnings of $14.50 to $15 a share",FULL-ARTICLE,Dow Jones Newswires,"Biogen Cuts FY Earnings Guidance, Despite 3Q Profit Rise"
BIIB,2025-10-30,11:24:43,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen on Thursday said it was raising its full-year revenue guidance and now sees growth to be roughly flat,FULL-ARTICLE,Dow Jones Newswires,"Biogen Cuts FY Earnings Guidance, Despite 3Q Profit Rise"
BIIB,2025-10-30,11:40:41,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.54B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.54B >BIIB
BIIB,2025-10-30,20:07:08,CEDFD5,Biogen Inc.,99,0.72,revenues,above-expectations,Biogen BEATS SALES,FULL-ARTICLE,Dow Jones Newswires,Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem -- IBD
BIIB,2025-10-30,20:07:08,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen earned $4.81 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem -- IBD
BIIB,2025-10-30,20:07:08,CEDFD5,Biogen Inc.,99,0.41,revenues,up,Tysabri sales rose 6%,FULL-ARTICLE,Dow Jones Newswires,Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem -- IBD
BIIB,2025-10-30,20:07:08,CEDFD5,Biogen Inc.,99,-0.24,revenues,down,Spinraza sales fell 2%,FULL-ARTICLE,Dow Jones Newswires,Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem -- IBD
BIIB,2025-10-30,20:07:08,CEDFD5,Biogen Inc.,99,0.72,revenues,up,Biogen raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem -- IBD
BIIB,2025-10-31,14:44:02,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-10-31,14:44:02,CEDFD5,Biogen Inc.,100,-0.46,price-targets,downgrade,Biogen Price Target Cut to $210.00/Share From $217.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $210.00/Share From $217.00 by RBC Capital
BIIB,2025-01-02,16:27:24,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Neutral From Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Neutral From Overweight by Piper Sandler
BIIB,2025-01-02,16:27:24,CEDFD5,Biogen Inc.,100,-0.9,price-targets,downgrade,Biogen Price Target Cut to $138.00/Share From $315.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $138.00/Share From $315.00 by Piper Sandler
BIIB,2025-01-07,13:00:01,CEDFD5,Biogen Inc.,100,0.63,products-services,,Alivegen Receives FDA Orphan Drug Designation for ALG-801,PRESS-RELEASE,Business Wire,AliveGen Receives FDA Orphan Drug Designation for ALG-801 for Pulmonary Arterial Hypertension
BIIB,2025-01-08,11:54:37,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2025-01-08,11:54:37,CEDFD5,Biogen Inc.,100,-0.84,price-targets,downgrade,Biogen Price Target Cut to $220.00/Share From $302.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $220.00/Share From $302.00 by Truist Securities
BIIB,2025-01-10,14:21:12,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Wells Fargo
BIIB,2025-01-10,14:21:12,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $165.00/Share From $190.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $165.00/Share From $190.00 by Wells Fargo
BIIB,2025-01-10,23:49:00,CEDFD5,Biogen Inc.,96,0.55,acquisitions-mergers,interest,Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen,PRESS-RELEASE,Business Wire,Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
BIIB,2025-01-10,23:49:00,CEDFD5,Biogen Inc.,96,0.55,acquisitions-mergers,interest,Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
BIIB,2025-01-13,11:39:01,CEDFD5,Biogen Inc.,100,0.55,acquisitions-mergers,interest,Biogen Proposes Takeover,FULL-ARTICLE,Dow Jones Newswires,Sage Shares Surge Premarket After Biogen Proposes Takeover
BIIB,2025-01-13,14:56:04,CEDFD5,Biogen Inc.,100,0.55,acquisitions-mergers,interest,Biogen Wants to Buy Its Partner Sage,FULL-ARTICLE,Dow Jones Newswires,Biogen Wants to Buy Its Partner Sage for Almost No Premium -- Barrons.com
BIIB,2025-01-13,14:56:04,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Sage have been working together since,FULL-ARTICLE,Dow Jones Newswires,Biogen Wants to Buy Its Partner Sage for Almost No Premium -- Barrons.com
BIIB,2025-01-15,13:00:53,CEDFD5,Biogen Inc.,99,0.53,labor-issues,,"Biogen Inc.: On January 13, 2025, Biogen Inc. (the ""Company"") appointed Sean Godbout as Vice President, Chief Accounting Officer",RNS-SEC8K,Dow Jones Newswires,"Biogen Files 8K - Director, Officer or Compensation Filing >BIIB"
BIIB,2025-01-15,13:00:53,CEDFD5,Biogen Inc.,99,0.0,labor-issues,,Biogen Inc.: the Company's annual bonus plan,RNS-SEC8K,Dow Jones Newswires,"Biogen Files 8K - Director, Officer or Compensation Filing >BIIB"
BIIB,2025-01-27,11:14:46,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen, Eisai Get FDA Nod for Leqembi",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing"
BIIB,2025-01-27,11:29:46,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen, Eisai Get FDA Nod for Leqembi",FULL-ARTICLE,Dow Jones Newswires,"Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing"
BIIB,2025-01-27,14:42:57,CEDFD5,Biogen Inc.,100,-0.59,acquisitions-mergers,rejected,Sage Rejects Biogen Bid,FULL-ARTICLE,Dow Jones Newswires,"Sage Rejects Biogen Bid, Launches Review of Alternatives"
BIIB,2025-01-28,12:30:21,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Citigroup
BIIB,2025-01-28,12:30:21,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $160.00/Share From $190.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $160.00/Share From $190.00 by Citigroup
BIIB,2025-02-03,23:04:16,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Singhal Acquires 1,250 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Singhal Acquires 1,250 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:43:24,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Alexander Acquires 2,896 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Alexander Acquires 2,896 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:45:03,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Gregory Acquires 2,396 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Acquires 2,396 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:47:47,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Singhal Acquires 1,535 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Singhal Acquires 1,535 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:48:13,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Murphy Acquires 2,819 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Murphy Acquires 2,819 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:50:37,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Kramer Acquires 1,015 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Kramer Acquires 1,015 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:52:18,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Keeney Acquires 1,238 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Keeney Acquires 1,238 Of Biogen Inc >BIIB"
BIIB,2025-02-10,23:53:32,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Grogan Acquires 942 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Grogan Acquires 942 Of Biogen Inc >BIIB
BIIB,2025-02-10,23:56:59,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Ceo Viehbacher Acquires 5,807 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CEO Viehbacher Acquires 5,807 Of Biogen Inc >BIIB"
BIIB,2025-02-11,00:00:01,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 3,049 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 3,049 Of Biogen Inc >BIIB"
BIIB,2025-02-12,02:53:49,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Izzar Acquires 2,679 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Acquires 2,679 Of Biogen Inc >BIIB"
BIIB,2025-02-12,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Excited to collaborate with Biogen on,PRESS-RELEASE,GlobeNewswire,Royalty Pharma Announces R&D Funding Collaboration With Biogen
BIIB,2025-02-12,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Litifilimab is currently in Phase 3 trials,PRESS-RELEASE,GlobeNewswire,Royalty Pharma Announces R&D Funding Collaboration With Biogen
BIIB,2025-02-12,11:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Excited to collaborate with Biogen on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Royalty Pharma Announces R&D Funding Collaboration With Biogen
BIIB,2025-02-12,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Litifilimab is currently in Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Royalty Pharma Announces R&D Funding Collaboration With Biogen
BIIB,2025-02-12,11:45:08,CEDFD5,Biogen Inc.,99,0.7,earnings,above-expectations,Biogen beat fourth-quarter earnings and sales expectations,FULL-ARTICLE,Dow Jones Newswires,Why Investors Might Hammer Biogen Despite Its Earnings Beat -- IBD
BIIB,2025-02-12,11:45:08,CEDFD5,Biogen Inc.,99,-0.8,earnings,below-expectations,Biogen's outlook missed projections for,FULL-ARTICLE,Dow Jones Newswires,Why Investors Might Hammer Biogen Despite Its Earnings Beat -- IBD
BIIB,2025-02-12,11:45:08,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen noted U.S. sales,FULL-ARTICLE,Dow Jones Newswires,Why Investors Might Hammer Biogen Despite Its Earnings Beat -- IBD
BIIB,2025-02-12,11:58:31,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.5B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Rev $2.5B >BIIB
BIIB,2025-02-12,11:58:54,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $1.83 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q EPS $1.83 >BIIB
BIIB,2025-02-12,11:59:05,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Adj EPS $3.44,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Adj EPS $3.44 >BIIB
BIIB,2025-02-12,12:00:40,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees 2025 Adj EPS $15.25,NEWS-FLASH,Dow Jones Newswires,Biogen Sees 2025 Adj EPS $15.25-Adj EPS $16.25 >BIIB
BIIB,2025-02-12,12:01:13,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Expects 2025 Revenue to Decline,NEWS-FLASH,Dow Jones Newswires,Biogen Expects 2025 Revenue to Decline By Mid-Single Digit Percentage Vs 2024 >BIIB
BIIB,2025-02-12,12:06:59,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,4Q EPS $1.83 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q EPS $1.83 >BIIB
BIIB,2025-02-12,12:06:59,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 4Q Net $266.8M,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Net $266.8M >BIIB
BIIB,2025-02-12,12:06:59,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 4Q Rev $2.45B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 4Q Rev $2.45B >BIIB
BIIB,2025-02-12,12:23:20,CEDFD5,Biogen Inc.,100,0.72,revenues,above-expectations,Biogen 4Q Revenue Tops Wall Street,FULL-ARTICLE,Dow Jones Newswires,Biogen 4Q Revenue Tops Wall Street's Estimates
BIIB,2025-02-12,12:23:20,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen also guided for full-year adjusted earnings per share,FULL-ARTICLE,Dow Jones Newswires,Biogen 4Q Revenue Tops Wall Street's Estimates
BIIB,2025-02-12,15:22:01,CEDFD5,Biogen Inc.,100,0.0,earnings,,"For 2025, Biogen expects adjusted earnings of $15.25 to $16.25 a share",FULL-ARTICLE,Dow Jones Newswires,Biogen Stock Falls After Company Gives Weaker-Than-Expected Financial Outlook -- WSJ
BIIB,2025-02-12,16:43:22,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Early Wednesday, Royalty Pharma (RPRX) unveiled a new partnership with Biogen",FULL-ARTICLE,MarketWatch,MW Biogen's stock slides on soft guidance and a decline in sales of MS drugs
BIIB,2025-02-12,21:19:39,CEDFD5,Biogen Inc.,99,-0.8,earnings,below-expectations,Biogen's outlook missed projections for,FULL-ARTICLE,Dow Jones Newswires,Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat -- IBD
BIIB,2025-02-12,21:19:39,CEDFD5,Biogen Inc.,99,0.0,revenues,,Biogen noted U.S. sales,FULL-ARTICLE,Dow Jones Newswires,Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat -- IBD
BIIB,2025-02-12,22:40:51,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Izzar Acquires 1,070 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Acquires 1,070 Of Biogen Inc >BIIB"
BIIB,2025-02-12,22:46:12,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Alexander Acquires 1,768 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Alexander Acquires 1,768 Of Biogen Inc >BIIB"
BIIB,2025-02-12,22:46:35,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Vp Gregory Acquires 1,525 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"VP Gregory Acquires 1,525 Of Biogen Inc >BIIB"
BIIB,2025-02-12,22:49:09,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Kramer Acquires 589 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Kramer Acquires 589 Of Biogen Inc >BIIB
BIIB,2025-02-12,22:49:21,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Cfo McDonnell Acquires 1,886 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"CFO McDonnell Acquires 1,886 Of Biogen Inc >BIIB"
BIIB,2025-02-12,22:49:32,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Officer Murphy Acquires 1,602 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Officer Murphy Acquires 1,602 Of Biogen Inc >BIIB"
BIIB,2025-02-12,22:49:56,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Vp Singhal Acquires 855 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Acquires 855 Of Biogen Inc >BIIB
BIIB,2025-02-13,07:04:43,CEDFD5,Biogen Inc.,94,-0.75,revenues,down,Biogen forecast lower-than-expected revenue,FULL-ARTICLE,Dow Jones Newswires,Technology: Biogen's Outlook Hurt by Slower Sales And Competition ---- By Joseph Walker
BIIB,2025-02-13,07:04:43,CEDFD5,Biogen Inc.,94,0.0,earnings,,"For 2025, Biogen expects adjusted earnings of $15.25 to $16.25 a share",FULL-ARTICLE,Dow Jones Newswires,Technology: Biogen's Outlook Hurt by Slower Sales And Competition ---- By Joseph Walker
BIIB,2025-02-13,12:02:27,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2025-02-13,12:02:27,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $265.00/Share From $298.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $265.00/Share From $298.00 by Canaccord Genuity
BIIB,2025-02-13,13:48:18,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2025-02-13,13:48:18,CEDFD5,Biogen Inc.,100,-0.56,price-targets,downgrade,Biogen Price Target Cut to $210.00/Share From $220.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $210.00/Share From $220.00 by Truist Securities
BIIB,2025-02-13,14:02:47,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2025-02-13,14:02:47,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $241.00/Share From $300.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $241.00/Share From $300.00 by HC Wainwright & Co.
BIIB,2025-02-13,15:28:38,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Wells Fargo
BIIB,2025-02-13,15:28:38,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $140.00/Share From $165.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $140.00/Share From $165.00 by Wells Fargo
BIIB,2025-02-13,16:45:38,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Citigroup
BIIB,2025-02-13,16:45:38,CEDFD5,Biogen Inc.,100,-0.78,price-targets,downgrade,Biogen Price Target Cut to $145.00/Share From $160.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $145.00/Share From $160.00 by Citigroup
BIIB,2025-02-13,16:55:38,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-02-13,16:55:38,CEDFD5,Biogen Inc.,100,-0.42,price-targets,downgrade,Biogen Price Target Cut to $225.00/Share From $231.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $225.00/Share From $231.00 by RBC Capital
BIIB,2025-02-13,17:13:29,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Goldman Sachs
BIIB,2025-02-13,17:13:29,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $245.00/Share From $281.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $245.00/Share From $281.00 by Goldman Sachs
BIIB,2025-02-13,17:50:18,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Morgan Stanley
BIIB,2025-02-13,17:50:18,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $157.00/Share From $192.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $157.00/Share From $192.00 by Morgan Stanley
BIIB,2025-02-13,17:57:18,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Market Perform by BMO Capital
BIIB,2025-02-13,17:57:18,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $139.00/Share From $156.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $139.00/Share From $156.00 by BMO Capital
BIIB,2025-02-13,19:00:18,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Sector Outperform by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Sector Outperform by Scotiabank
BIIB,2025-02-13,19:00:18,CEDFD5,Biogen Inc.,100,-0.72,price-targets,downgrade,Biogen Price Target Cut to $224.00/Share From $244.00 by Scotiabank,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $224.00/Share From $244.00 by Scotiabank
BIIB,2025-02-18,13:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,Business Wire,"Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for",PRESS-RELEASE,Business Wire,"Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen,PRESS-RELEASE,GlobeNewswire,"(PMZN) Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration",PRESS-RELEASE,GlobeNewswire,"(PMZN) Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:00:07,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Stoke Therapeutics Enter Into Collaboration to Develop and Commercialize Zorevunersen,NEWS-FLASH,Dow Jones Newswires,"Biogen and Stoke Therapeutics Enter Into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated With Refractory Seizures and Neurodevelopmental Impairments"
BIIB,2025-02-18,13:14:32,CEDFD5,Biogen Inc.,100,0.39,products-services,,Stoke Therapeutics And Biogen In Pact,FULL-ARTICLE,Dow Jones Newswires,Stoke Therapeutics And Biogen In Pact For Treatment For Severe Form Of Epilepsy -- MarketWatch
BIIB,2025-02-18,13:14:32,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Stoke Therapeutics Inc.: the company and Biogen Inc. announced a collaboration,FULL-ARTICLE,Dow Jones Newswires,Stoke Therapeutics And Biogen In Pact For Treatment For Severe Form Of Epilepsy -- MarketWatch
BIIB,2025-02-18,13:14:32,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen in pact for treatment,FULL-ARTICLE,MarketWatch,MW Stoke Therapeutics and Biogen in pact for treatment for severe form of epilepsy
BIIB,2025-02-18,13:14:32,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Stoke Therapeutics Inc.: the company and Biogen Inc. announced a collaboration,FULL-ARTICLE,MarketWatch,MW Stoke Therapeutics and Biogen in pact for treatment for severe form of epilepsy
BIIB,2025-02-18,13:46:40,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen in pact for treatment,FULL-ARTICLE,MarketWatch,MW Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
BIIB,2025-02-18,13:55:18,CEDFD5,Biogen Inc.,95,0.49,partnerships,,Biogen and Stoke Therapeutics have agreed to collaborate,FULL-ARTICLE,Dow Jones Newswires,"Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration"
BIIB,2025-02-18,14:34:59,CEDFD5,Biogen Inc.,100,-0.4,price-targets,downgrade,Biogen Price Target Cut to $135.00/Share From $138.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $135.00/Share From $138.00 by Piper Sandler
BIIB,2025-02-18,14:45:29,CEDFD5,Biogen Inc.,100,0.39,products-services,,Biogen in pact for treatment,FULL-ARTICLE,MarketWatch,MW Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
BIIB,2025-02-19,08:07:01,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2024 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2024 (BIIB)"
BIIB,2025-02-20,08:07:10,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 4Q 2024 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 4Q 2024 (BIIB)"
BIIB,2025-03-07,21:21:27,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Dir Sherwin Registers 8,760 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"Dir Sherwin Registers 8,760 Of Biogen Inc >BIIB"
BIIB,2025-03-10,20:10:54,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Dir Sherwin Sells 8,760 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"Dir Sherwin Sells 8,760 Of Biogen Inc >BIIB"
BIIB,2025-03-11,11:30:00,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:00,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Inc.: Building upon the promising results from the Phase 2 study,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:00,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:00,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Inc.: Building upon the promising results from the Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of -2-
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Nasdaq: BIIB) -- announced the initiation of dosing in the global clinical study,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,TABULAR-MATERIAL,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Inc.: Building upon the promising results from the Phase 2 study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.84,products-services,positive,Biogen Inc.: Building upon the promising results from the Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
BIIB,2025-03-11,11:30:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of -2-
BIIB,2025-03-11,11:30:11,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,NEWS-FLASH,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection in Kidney Transplant Patients >BIIB
BIIB,2025-03-17,11:00:09,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Skyclarys(TM) (omaveloxolone) Approval by Health Canada,PRESS-RELEASE,Canadian News Wire,SKYCLARYS(TM) (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich's Ataxia Treatment in Canada
BIIB,2025-03-17,11:00:09,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,Canadian News Wire,SKYCLARYS(TM) (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich's Ataxia Treatment in Canada
BIIB,2025-03-18,13:00:15,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Remedy Pharmaceuticals Secures Key U.S. Patent Allowance for CIRARA(R),PRESS-RELEASE,PR Newswire,"Remedy Pharmaceuticals Secures Key U.S. Patent Allowance for CIRARA(R) in Treating Large Hemispheric Infarction, Including Wake-Up Strokes"
BIIB,2025-04-01,11:30:00,CEDFD5,Biogen Inc.,100,0.51,products-services,,Organon Acquires TOFIDENCE(TM) -,PRESS-RELEASE,Business Wire,Organon Acquires TOFIDENCE(TM) -2-
BIIB,2025-04-02,11:30:00,CEDFD5,Biogen Inc.,99,0.69,products-services,,Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation,PRESS-RELEASE,GlobeNewswire,Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,"Biogen Inc.: As previously announced, results from the Phase 1b study",PRESS-RELEASE,GlobeNewswire,Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:01,CEDFD5,Biogen Inc.,99,0.69,products-services,,Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:01,CEDFD5,Biogen Inc.,99,0.69,products-services,,Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation,PRESS-RELEASE,DJ Global Press Release Wire,Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:01,CEDFD5,Biogen Inc.,99,0.69,products-services,,Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation,FULL-ARTICLE,Dow Jones Newswires,Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:01,CEDFD5,Biogen Inc.,99,0.69,products-services,,Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,"Biogen Inc.: As previously announced, results from the Phase 1b study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
BIIB,2025-04-02,11:31:58,CEDFD5,Biogen Inc.,100,0.69,products-services,,Biogen Gets FDA Fast-Track Designation for BIIB080,NEWS-FLASH,Dow Jones Newswires,Biogen Gets FDA Fast-Track Designation for BIIB080 in Alzheimer's Disease >BIIB
BIIB,2025-04-02,12:08:45,CEDFD5,Biogen Inc.,100,0.69,products-services,,Biogen's BIIB080 Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
BIIB,2025-04-02,12:08:45,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Japan's Eisai are partners on Leqembi, which the FDA approved in 2023 for",FULL-ARTICLE,Dow Jones Newswires,Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
BIIB,2025-04-02,12:23:45,CEDFD5,Biogen Inc.,100,0.69,products-services,,Biogen's BIIB080 Gets FDA Fast-Track Designation,FULL-ARTICLE,Dow Jones Newswires,Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
BIIB,2025-04-02,12:23:45,CEDFD5,Biogen Inc.,100,0.49,partnerships,,"Biogen and Japan's Eisai are partners on Leqembi, which the FDA approved in 2023 for",FULL-ARTICLE,Dow Jones Newswires,Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
BIIB,2025-04-02,13:35:05,CEDFD5,Biogen Inc.,99,0.62,acquisitions-mergers,,"Reata Pharmaceuticals, Inc. (""Reata""), which was subsequently acquired by Biogen in September 2023",PRESS-RELEASE,LSE Regulatory News Service (RNS),BioPharma Credit PLC BIOGEN SETTLEMENT
BIIB,2025-04-04,15:13:27,CEDFD5,Biogen Inc.,100,-0.58,analyst-ratings,negative,Biogen Cut to Hold From Buy by Argus Research,NEWS-FLASH,Dow Jones Newswires,Biogen Cut to Hold From Buy by Argus Research
BIIB,2025-04-09,14:05:59,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Morgan Stanley
BIIB,2025-04-09,14:05:59,CEDFD5,Biogen Inc.,100,-0.46,price-targets,downgrade,Biogen Price Target Cut to $152.00/Share From $157.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $152.00/Share From $157.00 by Morgan Stanley
BIIB,2025-04-15,23:01:18,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Eisai and Biogen: Leqembi Authorized in the European Union,NEWS-FLASH,Dow Jones Newswires,Eisai and Biogen: Leqembi Authorized in the European Union
BIIB,2025-04-16,17:33:19,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,European Commission approved Eisai and Biogen's drug Leqembi,FULL-ARTICLE,Dow Jones Newswires,Biogen Unlikely to Receive Boost from Leqembi Approval in EU -- Market Talk
BIIB,2025-04-16,17:33:20,CEDFD5,Biogen Inc.,92,0.57,products-services,granted,European Commission approved Eisai and Biogen's drug Leqembi,FULL-ARTICLE,Dow Jones Newswires,Biogen Unlikely to Receive Boost from Leqembi Approval in EU -- Market Talk
BIIB,2025-04-22,14:25:44,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-04-22,14:25:44,CEDFD5,Biogen Inc.,100,0.34,price-targets,upgrade,Biogen Price Target Raised to $225.00/Share From $221.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $225.00/Share From $221.00 by RBC Capital
BIIB,2025-04-23,14:54:35,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Goldman Sachs
BIIB,2025-04-23,14:54:35,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $197.00/Share From $219.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $197.00/Share From $219.00 by Goldman Sachs
BIIB,2025-04-29,14:40:39,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Piper Sandler
BIIB,2025-04-29,14:40:39,CEDFD5,Biogen Inc.,100,-0.8,price-targets,downgrade,Biogen Price Target Cut to $115.00/Share From $135.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $115.00/Share From $135.00 by Piper Sandler
BIIB,2025-04-29,16:36:38,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Truist Securities
BIIB,2025-04-29,16:36:38,CEDFD5,Biogen Inc.,100,-0.6,price-targets,downgrade,Biogen Price Target Cut to $199.00/Share From $210.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $199.00/Share From $210.00 by Truist Securities
BIIB,2025-05-01,10:46:36,CEDFD5,Biogen Inc.,100,0.7,earnings,above-expectations,Biogen Easily Tops Earnings Forecasts,FULL-ARTICLE,Dow Jones Newswires,"Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar -- IBD"
BIIB,2025-05-01,10:46:36,CEDFD5,Biogen Inc.,100,0.65,revenues,up,Skyclarys Sales Soar,FULL-ARTICLE,Dow Jones Newswires,"Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar -- IBD"
BIIB,2025-05-01,10:46:36,CEDFD5,Biogen Inc.,100,0.65,acquisitions-mergers,,In the 2023 takeover of Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,"Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar -- IBD"
BIIB,2025-05-01,10:46:36,CEDFD5,Biogen Inc.,100,0.65,revenues,up,Spinraza sales jumped,FULL-ARTICLE,Dow Jones Newswires,"Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar -- IBD"
BIIB,2025-05-01,10:46:36,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen also expects full-year sales to decline,FULL-ARTICLE,Dow Jones Newswires,"Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar -- IBD"
BIIB,2025-05-01,10:52:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,1Q EPS $1.64 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q EPS $1.64 >BIIB
BIIB,2025-05-01,10:52:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Adj EPS $3.02,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Adj EPS $3.02 >BIIB
BIIB,2025-05-01,10:52:36,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 1Q Net $240.5M,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Net $240.5M >BIIB
BIIB,2025-05-01,10:52:36,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 1Q Rev $2.43B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 1Q Rev $2.43B >BIIB
BIIB,2025-05-01,13:30:03,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,In the 2023 takeover of Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-01,13:30:03,CEDFD5,Biogen Inc.,99,0.65,revenues,up,Spinraza sales jumped,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-01,13:30:03,CEDFD5,Biogen Inc.,99,-0.75,revenues,down,Biogen also expects full-year sales to decline,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-01,13:31:07,CEDFD5,Biogen Inc.,99,0.65,acquisitions-mergers,,In the 2023 takeover of Reata Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-01,13:31:07,CEDFD5,Biogen Inc.,99,0.65,revenues,up,Spinraza sales jumped,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-01,13:31:07,CEDFD5,Biogen Inc.,99,-0.75,revenues,down,Biogen also expects full-year sales to decline,FULL-ARTICLE,Dow Jones Newswires,Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? -- IBD
BIIB,2025-05-02,12:37:05,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Baird
BIIB,2025-05-02,12:37:05,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $255.00/Share From $300.00 by Baird,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $255.00/Share From $300.00 by Baird
BIIB,2025-05-02,13:25:15,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2025-05-02,13:25:15,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $187.00/Share From $241.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $187.00/Share From $241.00 by HC Wainwright & Co.
BIIB,2025-05-02,15:49:15,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by Canaccord Genuity
BIIB,2025-05-02,15:49:15,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $220.00/Share From $265.00 by Canaccord Genuity,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $220.00/Share From $265.00 by Canaccord Genuity
BIIB,2025-05-02,18:50:25,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-05-02,18:50:25,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $205.00/Share From $217.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $205.00/Share From $217.00 by RBC Capital
BIIB,2025-05-05,14:40:49,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by JP Morgan
BIIB,2025-05-05,14:40:49,CEDFD5,Biogen Inc.,100,-0.62,price-targets,downgrade,Biogen Price Target Cut to $175.00/Share From $185.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $175.00/Share From $185.00 by JP Morgan
BIIB,2025-05-05,20:18:26,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,"Dir Dorsa Buys 1,235 Of Biogen Inc >BIIB",FULL-ARTICLE,Dow Jones Newswires,"Dir Dorsa Buys 1,235 Of Biogen Inc >BIIB"
BIIB,2025-05-05,20:24:27,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Keeney Acquires 484 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Keeney Acquires 484 Of Biogen Inc >BIIB
BIIB,2025-05-06,14:08:59,CEDFD5,Biogen Inc.,100,0.06,credit-ratings,set,S&PGR Rates Biogen Inc.'s Senior Unsecured Notes 'BBB+,NEWS-FLASH,Dow Jones Newswires,S&PGR Rates Biogen Inc.'s Senior Unsecured Notes 'BBB+'
BIIB,2025-05-06,14:08:59,CEDFD5,Biogen Inc.,100,0.06,credit-ratings,set,S&PGR Rates Biogen Inc.'s Senior Unsecured Notes 'BBB+,PRESS-RELEASE,Dow Jones Newswires,Press Release: S&PGR Rates Biogen Inc.'s Senior Unsecured Notes 'BBB+'
BIIB,2025-05-06,14:14:06,CEDFD5,Biogen Inc.,100,0.01,credit-ratings,stable,Moody's Ratings Assigns Baa2 Rating To Biogen's Notes; Stable Outlook,NEWS-FLASH,Dow Jones Newswires,Moody's Ratings Assigns Baa2 Rating To Biogen's Notes; Stable Outlook
BIIB,2025-05-07,13:26:13,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by Mizuho
BIIB,2025-05-07,13:26:13,CEDFD5,Biogen Inc.,100,-0.82,price-targets,downgrade,Biogen Price Target Cut to $169.00/Share From $207.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $169.00/Share From $207.00 by Mizuho
BIIB,2025-05-12,20:45:39,CEDFD5,Biogen Inc.,99,0.39,products-services,,"Biogen Inc.: On May 6, 2025, Biogen Inc. (the ""Company"") entered into an Underwriting Agreement (the ""Underwriting Agreement"") with BofA Securities, Inc., Citigroup Global Markets Inc.",RNS-SEC8K,Dow Jones Newswires,Biogen Files 8K - Other Events >BIIB
BIIB,2025-05-12,21:41:07,CEDFD5,Biogen Inc.,100,0.0,credit,,Biogen Sells $1.75B of Notes,RNS-SEC8K,Dow Jones Newswires,"Biogen Sells $1.75B of Notes, Including $400M of 5.05% Senior Notes Due 2031, and Notes Due in 2035 and 2055"
BIIB,2025-05-19,07:06:56,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 1Q 2025 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 1Q 2025 (BIIB)"
BIIB,2025-05-19,15:27:32,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Vp Singhal Registers 3,806 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"VP Singhal Registers 3,806 Of Biogen Inc >BIIB"
BIIB,2025-05-20,20:09:21,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Vp Singhal Sells 3,806 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"VP Singhal Sells 3,806 Of Biogen Inc >BIIB"
BIIB,2025-05-27,11:30:00,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and City Therapeutics Announce Strategic Research Collaboration to,PRESS-RELEASE,GlobeNewswire,Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB,2025-05-27,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and City Therapeutics Announce Strategic Research Collaboration to,FULL-ARTICLE,Dow Jones Newswires,Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB,2025-05-27,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and City Therapeutics Announce Strategic Research Collaboration to,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB,2025-05-27,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and City Therapeutics Announce Strategic Research Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB,2025-05-27,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and City Therapeutics Announce Strategic Research Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB,2025-05-27,11:32:05,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen to Invest $30 Million for,NEWS-FLASH,Dow Jones Newswires,Biogen to Invest $30 Million for City Therapeutics Convertible Note >BIIB
BIIB,2025-06-05,11:00:08,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,Skyclarys was approved in March 2025 under Health Canada,PRESS-RELEASE,Canadian News Wire,Biogen Disappointed by INESSS Recommendation on SKYCLARYS(TM) and its Impact on Quebec Patients with Friedreich Ataxia
BIIB,2025-06-05,11:00:08,CEDFD5,Biogen Inc.,99,0.57,products-services,granted,"Biogen Received European Commission Approval for SKYCLARYS(R) (omaveloxolone), the First",PRESS-RELEASE,Canadian News Wire,Biogen Disappointed by INESSS Recommendation on SKYCLARYS(TM) and its Impact on Quebec Patients with Friedreich Ataxia
BIIB,2025-06-12,14:23:38,CEDFD5,Biogen Inc.,100,0.0,price-targets,unchanged,Biogen Price Target Maintained With a $121.00/Share by Wedbush,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Maintained With a $121.00/Share by Wedbush
BIIB,2025-06-12,17:09:58,CEDFD5,Biogen Inc.,100,0.0,price-targets,unchanged,Biogen Price Target Maintained With a $115.00/Share by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Maintained With a $115.00/Share by Piper Sandler
BIIB,2025-06-18,11:30:27,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:27,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial",PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:27,CEDFD5,Biogen Inc.,100,0.41,assets,open,Biogen Inc.: we plan to open BRAVE study sites,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,assets,open,Biogen Inc.: we plan to open BRAVE study sites,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial",PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,assets,open,Biogen Inc.: we plan to open BRAVE study sites,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial",FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,"Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:28,CEDFD5,Biogen Inc.,100,0.41,assets,open,Biogen Inc.: we plan to open BRAVE study sites,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-18,11:30:41,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone,NEWS-FLASH,Dow Jones Newswires,Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
BIIB,2025-06-25,11:30:37,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115,PRESS-RELEASE,GlobeNewswire,Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:37,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: An interim analysis of,PRESS-RELEASE,GlobeNewswire,Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:37,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:37,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: An interim analysis of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:38,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115,FULL-ARTICLE,Dow Jones Newswires,Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:38,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:38,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: An interim analysis of,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:38,CEDFD5,Biogen Inc.,99,0.0,products-services,,Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:30:38,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: An interim analysis of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
BIIB,2025-06-25,11:31:00,CEDFD5,Biogen Inc.,99,0.84,products-services,positive,"Biogen, shared positive topline results from the Phase 1 study",PRESS-RELEASE,Business Wire,Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
BIIB,2025-06-25,11:31:01,CEDFD5,Biogen Inc.,99,0.84,products-services,positive,"Biogen, shared positive topline results from the Phase 1 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
BIIB,2025-06-25,11:31:34,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen MOVES INTO PHASE 3 TESTING,FULL-ARTICLE,Dow Jones Newswires,Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? -- IBD
BIIB,2025-06-25,11:57:05,CEDFD5,Biogen Inc.,95,0.49,partnerships,,Biogen and Ionis are also partners on Spinraza,FULL-ARTICLE,Dow Jones Newswires,Biogen to Advance SMA Treatment Into Registrational Studies
BIIB,2025-06-25,14:08:48,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-06-25,14:08:48,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $213.00/Share From $205.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $213.00/Share From $205.00 by RBC Capital
BIIB,2025-06-25,20:19:35,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen MOVES INTO PHASE 3 TESTING,FULL-ARTICLE,Dow Jones Newswires,Can Biogen Save Even More Kids With This New Drug? -- IBD
BIIB,2025-06-26,11:55:40,CEDFD5,Biogen Inc.,100,0.0,price-targets,unchanged,Biogen Price Target Maintained With a $187.00/Share by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Maintained With a $187.00/Share by HC Wainwright & Co.
BIIB,2025-06-27,13:10:02,CEDFD5,Biogen Inc.,100,0.0,price-targets,unchanged,Biogen Price Target Maintained With a $213.00/Share by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Maintained With a $213.00/Share by RBC Capital
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Inc.: announced the initiation of dosing in the global clinical study,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,GlobeNewswire,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Inc.: announced the initiation of dosing in the global clinical study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:12,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of -2-
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Nasdaq: BIIB) -- announced the initiation of dosing in the global clinical study,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Inc.: announced the initiation of dosing in the global clinical study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Initiates Phase 3 Study of Felzartamab for -2-
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Inc.: announced the initiation of dosing in the global clinical study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen acquired HI-Bio in July 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
BIIB,2025-06-30,11:30:13,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Initiates Phase 3 Study of -2-
BIIB,2025-06-30,11:30:22,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Initiates Phase 3 Study of Felzartamab,NEWS-FLASH,Dow Jones Newswires,Biogen Initiates Phase 3 Study of Felzartamab for Treatment of Primary Membranous Nephropathy >BIIB
BIIB,2025-06-30,11:53:28,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Launches Phase 3 Study of Felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Launches Phase 3 Study of Felzartamab in Rare Kidney Disease PMN
BIIB,2025-06-30,11:53:28,CEDFD5,Biogen Inc.,100,0.34,products-services,,Biogen acquired the rights to felzartamab,FULL-ARTICLE,Dow Jones Newswires,Biogen Launches Phase 3 Study of Felzartamab in Rare Kidney Disease PMN
BIIB,2025-07-07,20:36:02,CEDFD5,Biogen Inc.,100,0.0,equity-actions,,Biogen Expects $46M 2Q Expense,FULL-ARTICLE,Dow Jones Newswires,Biogen Expects $46M 2Q Expense From In-Process Research and Development
BIIB,2025-07-07,20:36:02,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen's second quarter results,FULL-ARTICLE,Dow Jones Newswires,Biogen Expects $46M 2Q Expense From In-Process Research and Development
BIIB,2025-07-08,19:27:26,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,"Officer Izzar Registers 2,223 Of Biogen Inc >BIIB",RNS-SEC144,Dow Jones Newswires,"Officer Izzar Registers 2,223 Of Biogen Inc >BIIB"
BIIB,2025-07-10,11:00:01,CEDFD5,Biogen Inc.,97,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:01,CEDFD5,Biogen Inc.,97,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:01,CEDFD5,Biogen Inc.,96,0.49,partnerships,,A strategic collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Business Wire,"Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,"(PMZN) Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-10,11:00:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress"
BIIB,2025-07-16,21:56:32,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,"Officer Izzar Sells 2,223 Of Biogen Inc",FULL-ARTICLE,Dow Jones Newswires,"Officer Izzar Sells 2,223 Of Biogen Inc >BIIB"
BIIB,2025-07-21,11:30:00,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen Announces $2 Billion Manufacturing Investment in North Carolina,PRESS-RELEASE,GlobeNewswire,Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary
BIIB,2025-07-21,11:30:01,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen Announces $2 Billion Manufacturing Investment in North Carolina,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary
BIIB,2025-07-21,11:30:13,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen Announces $2 B Manufacturing Investment in North Carolina,NEWS-FLASH,Dow Jones Newswires,Biogen Announces $2 B Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction With Its 30th Anniversary
BIIB,2025-07-21,11:58:12,CEDFD5,Biogen Inc.,100,0.46,equity-actions,,Biogen to Invest Additional $2 Billion in North Carolina,FULL-ARTICLE,Dow Jones Newswires,Biogen to Invest Additional $2 Billion in North Carolina Research Hub
BIIB,2025-07-21,23:30:00,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: our Phase 2 study of BIIB080,PRESS-RELEASE,GlobeNewswire,Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:00,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,GlobeNewswire,Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen have been collaborating on,FULL-ARTICLE,Dow Jones Newswires,Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: our Phase 2 study of BIIB080,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: results in a clinical trial,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Highlight Scientific Progress Across -2-
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: our Phase 2 study of BIIB080,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Eisai and Biogen have been collaborating on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
BIIB,2025-07-21,23:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: results in a clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Highlight Scientific -2-
BIIB,2025-07-25,11:21:06,CEDFD5,Biogen Inc.,100,0.82,products-services,positive,Biogen: Zurzuvae Gets CHMP Positive Opinion,NEWS-FLASH,Dow Jones Newswires,Biogen: Zurzuvae Gets CHMP Positive Opinion for Treatment of Women With Postpartum Depression >BIIB
BIIB,2025-07-31,10:14:16,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,2Q EPS $4.33 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q EPS $4.33 >BIIB
BIIB,2025-07-31,10:14:16,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Adj EPS $5.47,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Adj EPS $5.47 >BIIB
BIIB,2025-07-31,10:14:16,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 2Q Net $634.8M,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Net $634.8M >BIIB
BIIB,2025-07-31,10:14:16,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 2Q Rev $2.65B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 2Q Rev $2.65B >BIIB
BIIB,2025-07-31,10:18:58,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Increases Full-Year 2025 Guidance >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen Increases Full-Year 2025 Guidance >BIIB
BIIB,2025-07-31,10:19:27,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises 2025 View To Adj EPS $15.50,NEWS-FLASH,Dow Jones Newswires,Biogen Raises 2025 View To Adj EPS $15.50-Adj EPS $16.00 >BIIB
BIIB,2025-07-31,10:19:41,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Had Seen 2025 Adjusted EPS $14.50-$15.50,NEWS-FLASH,Dow Jones Newswires,Biogen Had Seen 2025 Adjusted EPS $14.50-$15.50 >BIIB
BIIB,2025-07-31,10:20:38,CEDFD5,Biogen Inc.,100,-0.75,revenues,down,Biogen Had Seen 2025 Revenue Down,NEWS-FLASH,Dow Jones Newswires,Biogen Had Seen 2025 Revenue Down Mid-Single Digits Constant-Currency >BIIB
BIIB,2025-07-31,10:51:36,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen Raises 2025 Outlook After,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises 2025 Outlook After Momentum in 1H
BIIB,2025-07-31,10:51:36,CEDFD5,Biogen Inc.,100,0.7,earnings,up,Biogen raised its outlook for the year,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises 2025 Outlook After Momentum in 1H
BIIB,2025-07-31,10:51:36,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Inc.: The company also expects adjusted earnings per-share to be between $15.50 to $16,FULL-ARTICLE,Dow Jones Newswires,Biogen Raises 2025 Outlook After Momentum in 1H
BIIB,2025-08-01,10:47:42,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Buy by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Buy by HC Wainwright & Co.
BIIB,2025-08-01,10:47:42,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $194.00/Share From $187.00 by HC Wainwright & Co.,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $194.00/Share From $187.00 by HC Wainwright & Co.
BIIB,2025-08-01,14:22:02,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Morgan Stanley
BIIB,2025-08-01,14:22:02,CEDFD5,Biogen Inc.,100,-0.28,price-targets,downgrade,Biogen Price Target Cut to $144.00/Share From $146.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $144.00/Share From $146.00 by Morgan Stanley
BIIB,2025-08-01,15:36:23,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-08-01,15:36:23,CEDFD5,Biogen Inc.,100,0.6,price-targets,upgrade,Biogen Price Target Raised to $219.00/Share From $208.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $219.00/Share From $208.00 by RBC Capital
BIIB,2025-08-01,20:25:47,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Citigroup
BIIB,2025-08-01,20:25:47,CEDFD5,Biogen Inc.,100,0.7,price-targets,upgrade,Biogen Price Target Raised to $135.00/Share From $125.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $135.00/Share From $125.00 by Citigroup
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen,PRESS-RELEASE,Business Wire,"Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Business Wire,"Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,96,0.49,partnerships,,A strategic collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,"Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,"(PMZN) Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-11,11:00:04,CEDFD5,Biogen Inc.,100,0.41,products-services,start,Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen,NEWS-FLASH,Dow Jones Newswires,"Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome"
BIIB,2025-08-13,23:20:00,CEDFD5,Biogen Inc.,99,-0.52,legal,,"Firm, is investigating potential claims against Biogen Inc. (NASDAQ:BIIB)",PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2025-08-13,23:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen's 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2025-08-13,23:20:00,CEDFD5,Biogen Inc.,99,0.0,earnings,,Biogen announced its third quarter 2023 results,PRESS-RELEASE,GlobeNewswire,"BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm"
BIIB,2025-08-14,15:39:02,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Neutral by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Neutral by Piper Sandler
BIIB,2025-08-14,15:39:02,CEDFD5,Biogen Inc.,100,0.42,price-targets,upgrade,Biogen Price Target Raised to $118.00/Share From $115.00 by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $118.00/Share From $115.00 by Piper Sandler
BIIB,2025-08-19,07:06:53,CEDFD5,Biogen Inc.,100,0.0,investor-relations,,"Biogen Inc, Inst Holders, 2Q 2025 (BIIB)",RNS-SEC13F,Dow Jones Newswires,"Biogen Inc, Inst Holders, 2Q 2025 (BIIB)"
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,95,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Business Wire,Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,95,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-08-25,11:00:01,CEDFD5,Biogen Inc.,97,0.49,partnerships,,A strategic collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BIIB,2025-09-02,11:00:01,CEDFD5,Biogen Inc.,93,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-09-02,11:00:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,DJ Global Press Release Wire,Biogen and Stoke Therapeutics Present Data at the -2-
BIIB,2025-09-02,11:00:01,CEDFD5,Biogen Inc.,97,0.49,partnerships,,A strategic collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,Biogen and Stoke Therapeutics Present Data at the -2-
BIIB,2025-09-02,11:00:02,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Stoke Therapeutics -2-
BIIB,2025-09-02,11:00:02,CEDFD5,Biogen Inc.,93,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-09-02,11:00:02,CEDFD5,Biogen Inc.,93,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Business Wire,Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-09-02,16:57:31,CEDFD5,Biogen Inc.,100,-0.48,insider-trading,,Vp Singhal Registers 517 Of Biogen Inc >BIIB,RNS-SEC144,Dow Jones Newswires,VP Singhal Registers 517 Of Biogen Inc >BIIB
BIIB,2025-09-02,21:57:19,CEDFD5,Biogen Inc.,100,-0.49,insider-trading,,Vp Singhal Sells 517 Of Biogen Inc,FULL-ARTICLE,Dow Jones Newswires,VP Singhal Sells 517 Of Biogen Inc >BIIB
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First",PRESS-RELEASE,GlobeNewswire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved ZURZUVAE,PRESS-RELEASE,GlobeNewswire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,In 2020 Biogen and Sage Therapeutics entered into a collaboration,PRESS-RELEASE,GlobeNewswire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First",PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved ZURZUVAE,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,In 2020 Biogen and Sage Therapeutics entered into a collaboration,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved ZURZUVAE,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,In 2020 Biogen and Sage Therapeutics entered into a collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,Biogen Inc.: The U.S. Food and Drug Administration (FDA) approved ZURZUVAE,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:05,CEDFD5,Biogen Inc.,100,0.49,partnerships,,In 2020 Biogen and Sage Therapeutics entered into a collaboration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:06,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First",FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:30:06,CEDFD5,Biogen Inc.,100,0.49,partnerships,,In 2020 Biogen and Sage Therapeutics entered into a collaboration,FULL-ARTICLE,Dow Jones Newswires,"Biogen Receives European Commission Approval for ZURZUVAE(R) (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe"
BIIB,2025-09-17,20:34:23,CEDFD5,Biogen Inc.,100,0.57,products-services,granted,"Biogen Receives European Commission Approval for ZURZUVAE, First",NEWS-FLASH,Dow Jones Newswires,"Biogen Receives European Commission Approval for ZURZUVAE, First and Only Treatment Approved for Women With Postpartum Depression in Europe"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,GlobeNewswire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Alcyone Therapeutics have collaborated since,PRESS-RELEASE,GlobeNewswire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen plans to introduce the new drug,PRESS-RELEASE,GlobeNewswire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,GlobeNewswire,"Biogen to Acquire Alcyone Therapeutics, Expanding -2-"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Press Release: Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Alcyone Therapeutics have collaborated since,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen plans to introduce the new drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,Biogen Inc.: Results in early-stage clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Alcyone -2-
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Alcyone Therapeutics have collaborated since,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen plans to introduce the new drug,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Press Release: Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Alcyone Therapeutics have collaborated since,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen plans to introduce the new drug,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Press Release: Biogen to Acquire Alcyone,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Acquire Alcyone -2-
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen to Acquire Alcyone Therapeutics, Expanding -2-"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,PRESS-RELEASE,DJ Global Press Release Wire,"Biogen to Acquire Alcyone Therapeutics, Expanding -3-"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Biogen and Alcyone Therapeutics have collaborated since,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen plans to introduce the new drug,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Acquire Alcyone Therapeutics, Expanding -2-"
BIIB,2025-09-18,11:40:02,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics,FULL-ARTICLE,Dow Jones Newswires,"Biogen to Acquire Alcyone Therapeutics, Expanding -3-"
BIIB,2025-09-18,11:40:10,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Acquire Alcyone Therapeutics >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen to Acquire Alcyone Therapeutics >BIIB
BIIB,2025-09-18,11:41:48,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen To Buy Alcyone Therapeutics for,NEWS-FLASH,Dow Jones Newswires,Biogen To Buy Alcyone Therapeutics for Upfront Cash Payment of $85 Million >BIIB
BIIB,2025-09-18,12:59:40,CEDFD5,Biogen Inc.,100,0.62,acquisitions-mergers,,Biogen to Buy Alcyone Therapeutics for Initial $85 Million,FULL-ARTICLE,Dow Jones Newswires,Biogen to Buy Alcyone Therapeutics for Initial $85 Million
BIIB,2025-09-23,06:00:16,CEDFD5,Biogen Inc.,97,0.62,acquisitions-mergers,,Biogen to acquire Alcyone Therapeutics,PRESS-RELEASE,LSE Regulatory News Service (RNS),RTW Biotech Opportunities Ltd Biogen to acquire Alcyone Therapeutics
BIIB,2025-09-23,06:00:16,CEDFD5,Biogen Inc.,97,0.49,partnerships,,Biogen and Alcyone have collaborated since,PRESS-RELEASE,LSE Regulatory News Service (RNS),RTW Biotech Opportunities Ltd Biogen to acquire Alcyone Therapeutics
BIIB,2025-09-23,20:30:00,CEDFD5,Biogen Inc.,99,-0.58,products-services,denied,Biogen Inc.: the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug,PRESS-RELEASE,GlobeNewswire,Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
BIIB,2025-09-23,20:30:01,CEDFD5,Biogen Inc.,99,-0.58,products-services,denied,Biogen Inc.: the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
BIIB,2025-09-23,20:30:01,CEDFD5,Biogen Inc.,99,-0.58,products-services,denied,Biogen Inc.: the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug,PRESS-RELEASE,DJ Global Press Release Wire,Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
BIIB,2025-09-23,20:30:01,CEDFD5,Biogen Inc.,99,-0.58,products-services,denied,Biogen Inc.: the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug,FULL-ARTICLE,Dow Jones Newswires,Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
BIIB,2025-09-23,20:30:01,CEDFD5,Biogen Inc.,99,-0.58,products-services,denied,Biogen Inc.: the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
BIIB,2025-09-25,11:14:38,CEDFD5,Biogen Inc.,100,0.95,analyst-ratings,positive,Biogen Initiated at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Initiated at Buy by Jefferies
BIIB,2025-09-25,11:14:38,CEDFD5,Biogen Inc.,100,0.0,price-targets,set,Biogen Price Target Announced at $190.00/Share by Jefferies,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Announced at $190.00/Share by Jefferies
BIIB,2025-09-25,12:00:13,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Foundation Partners with Biogen to,PRESS-RELEASE,PR Newswire,"National Ataxia Foundation Partners with Biogen to Bring Bill Nye ""the Science Guy"" Back To the Lab With New Series About Friedreich Ataxia"
BIIB,2025-10-06,17:02:13,CEDFD5,Biogen Inc.,100,0.52,insider-trading,,Officer Godbout Acquires 18 Of Biogen Inc >BIIB,FULL-ARTICLE,Dow Jones Newswires,Officer Godbout Acquires 18 Of Biogen Inc >BIIB
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),FULL-ARTICLE,Dow Jones Newswires,Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,DJ Global Press Release Wire,Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Collaboration between Eisai and Biogen,FULL-ARTICLE,Dow Jones Newswires,Eisai and Biogen Announce U.S. Availability of -3-
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Collaboration between Eisai and Biogen,PRESS-RELEASE,DJ Global Press Release Wire,Eisai and Biogen Announce U.S. Availability of -3-
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Collaboration between Eisai and Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Biogen Announce U.S. -3-
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,GlobeNewswire,(PMZN) Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:01,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Collaboration between Eisai and Biogen,PRESS-RELEASE,GlobeNewswire,(PMZN) Eisai and Biogen Announce U.S. -3-
BIIB,2025-10-06,20:30:05,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:05,CEDFD5,Biogen Inc.,99,0.49,partnerships,,Collaboration between Eisai and Biogen,PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Biogen Announce U.S. -3-
BIIB,2025-10-06,20:30:10,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,PR Newswire,(PR) Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:30:13,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
BIIB,2025-10-06,20:31:20,CEDFD5,Biogen Inc.,100,0.52,products-services,,Biogen Announce U.S. Availability of LEQEMBI,NEWS-FLASH,Dow Jones Newswires,"Eisai, Biogen Announce U.S. Availability of LEQEMBI IQLIK Subcutaneous Injection Maintenance Dose to Treat Early Alzheimer's Disease"
BIIB,2025-10-09,20:30:01,CEDFD5,Biogen Inc.,96,0.49,partnerships,,A strategic collaboration with Biogen to,FULL-ARTICLE,Dow Jones Newswires,Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-10-09,20:30:04,CEDFD5,Biogen Inc.,98,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Business Wire,Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-10-09,20:30:04,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-10-09,20:30:06,CEDFD5,Biogen Inc.,98,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-10-09,20:30:06,CEDFD5,Biogen Inc.,99,0.49,partnerships,,A strategic collaboration with Biogen to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BIIB,2025-10-10,17:47:15,CEDFD5,Biogen Inc.,100,0.0,analyst-ratings,neutral,Biogen Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Equal-Weight by Morgan Stanley
BIIB,2025-10-10,17:47:15,CEDFD5,Biogen Inc.,100,0.48,price-targets,upgrade,Biogen Price Target Raised to $149.00/Share From $144.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Raised to $149.00/Share From $144.00 by Morgan Stanley
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: A second Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between Biogen and UCB,PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,"Biogen Inc.: Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients",PRESS-RELEASE,Dow Jones Newswires,Press Release: Biogen to Present Additional -2-
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between Biogen and UCB,FULL-ARTICLE,Dow Jones Newswires,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: A second Phase 3 study,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between Biogen and UCB,PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:01,CEDFD5,Biogen Inc.,99,0.0,products-services,,"Biogen Inc.: Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients",PRESS-RELEASE,DJ Global Press Release Wire,Biogen to Present Additional Results from Phase 3 -2-
BIIB,2025-10-22,11:30:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:03,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen Inc.: A second Phase 3 study,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:03,CEDFD5,Biogen Inc.,100,0.49,partnerships,,Collaboration between Biogen and UCB,PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
BIIB,2025-10-22,11:30:03,CEDFD5,Biogen Inc.,98,0.0,products-services,,"Biogen Inc.: Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients",PRESS-RELEASE,GlobeNewswire,(PMZN) Biogen to Present Additional Results from -2-
BIIB,2025-10-22,11:30:14,CEDFD5,Biogen Inc.,100,0.0,products-services,,Biogen to Present Additional Results From Phase 3 Study of Dapirolizumab Pegol,NEWS-FLASH,Dow Jones Newswires,Biogen to Present Additional Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
BIIB,2025-10-30,10:14:33,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,3Q EPS $3.17 >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q EPS $3.17 >BIIB
BIIB,2025-10-30,10:14:33,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Adj EPS $4.81,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Adj EPS $4.81 >BIIB
BIIB,2025-10-30,10:14:33,CEDFD5,Biogen Inc.,100,0.61,earnings,positive,Biogen 3Q Net $466.5M,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Net $466.5M >BIIB
BIIB,2025-10-30,10:14:33,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.53B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.53B >BIIB
BIIB,2025-10-30,10:25:32,CEDFD5,Biogen Inc.,100,0.0,earnings,,Biogen Sees 2025 Adj EPS $14.50,RNS-SEC8K,Dow Jones Newswires,Biogen Sees 2025 Adj EPS $14.50-Adj EPS $15 >BIIB
BIIB,2025-10-30,10:25:58,CEDFD5,Biogen Inc.,100,0.48,revenues,up,Biogen Sees 2025 Revenue Flat to 1% Higher,RNS-SEC8K,Dow Jones Newswires,Biogen Sees 2025 Revenue Flat to 1% Higher >BIIB
BIIB,2025-10-30,11:24:43,CEDFD5,Biogen Inc.,100,-0.74,earnings,down,"Biogen Cuts FY Earnings Guidance, Despite",FULL-ARTICLE,Dow Jones Newswires,"Biogen Cuts FY Earnings Guidance, Despite 3Q Profit Rise"
BIIB,2025-10-30,11:24:43,CEDFD5,Biogen Inc.,100,0.0,earnings,,"For the full year, Biogen now expects adjusted earnings of $14.50 to $15 a share",FULL-ARTICLE,Dow Jones Newswires,"Biogen Cuts FY Earnings Guidance, Despite 3Q Profit Rise"
BIIB,2025-10-30,11:24:43,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen on Thursday said it was raising its full-year revenue guidance and now sees growth to be roughly flat,FULL-ARTICLE,Dow Jones Newswires,"Biogen Cuts FY Earnings Guidance, Despite 3Q Profit Rise"
BIIB,2025-10-30,11:40:41,CEDFD5,Biogen Inc.,100,0.0,revenues,,Biogen 3Q Rev $2.54B >BIIB,NEWS-FLASH,Dow Jones Newswires,Biogen 3Q Rev $2.54B >BIIB
BIIB,2025-10-30,20:07:08,CEDFD5,Biogen Inc.,99,0.72,revenues,above-expectations,Biogen BEATS SALES,FULL-ARTICLE,Dow Jones Newswires,Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem -- IBD
BIIB,2025-10-30,20:07:08,CEDFD5,Biogen Inc.,99,0.61,earnings,positive,Biogen earned $4.81 per share,FULL-ARTICLE,Dow Jones Newswires,Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem -- IBD
BIIB,2025-10-30,20:07:08,CEDFD5,Biogen Inc.,99,0.41,revenues,up,Tysabri sales rose 6%,FULL-ARTICLE,Dow Jones Newswires,Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem -- IBD
BIIB,2025-10-30,20:07:08,CEDFD5,Biogen Inc.,99,-0.24,revenues,down,Spinraza sales fell 2%,FULL-ARTICLE,Dow Jones Newswires,Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem -- IBD
BIIB,2025-10-30,20:07:08,CEDFD5,Biogen Inc.,99,0.72,revenues,up,Biogen raised its sales outlook,FULL-ARTICLE,Dow Jones Newswires,Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem -- IBD
BIIB,2025-10-31,14:44:02,CEDFD5,Biogen Inc.,100,0.34,analyst-ratings,neutral,Biogen Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Is Maintained at Outperform by RBC Capital
BIIB,2025-10-31,14:44:02,CEDFD5,Biogen Inc.,100,-0.46,price-targets,downgrade,Biogen Price Target Cut to $210.00/Share From $217.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Biogen Price Target Cut to $210.00/Share From $217.00 by RBC Capital
